<SEC-DOCUMENT>0000939767-22-000058.txt : 20220510
<SEC-HEADER>0000939767-22-000058.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510161009
ACCESSION NUMBER:		0000939767-22-000058
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20220401
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		22909676

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel-20220401.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:73bfe3ae-0c1e-4ba4-a72f-9891e89b0476,g:eb76abd8-9ed1-48d1-b6dc-c6870e560f34,d:8de248c3265649ac8d88b7bfb8f42ed9--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:exel="http://www.exelixis.com/20220401" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20220401</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV8yLTEtMS0xLTQ4NzI5_77be437c-e305-424c-9b61-d335284044b5">false</ix:nonNumeric><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV80LTEtMS0xLTQ4NzI5_dfdd4d1c-ce8d-44f0-97d4-1210dd86199d">2022</ix:nonNumeric><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV81LTEtMS0xLTQ4NzI5_8fa051e5-c51f-47e1-9ac7-2424cf2aa422">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV82LTEtMS0xLTQ4NzI5_ae5eb290-0ed4-4061-a1f7-49b1724a8d13">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV83LTEtMS0xLTQ4NzI5_4943e273-7b86-4bbe-b000-c70250a37d1f">December 31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20220401.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icceeeac4473d4c3e9581cd8f8a7b5119_I20220502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i07e399f10aef4b259d2c54579c871e1a_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i07d2fa3b35a449daad65b440257d44b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idef460046aca49f3a2753fad35f32387_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1f98ab028c4075b3c5959b7f157dc9_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d496fb0cfe4be9ab5f4af2e1a705bd_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d9a170e7200455d9d99fa4118712bb7_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf02010d20b45d38532755c0e8242ff_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f8de81af7714dbc880d1340b695ef37_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c02a85ca1984c97bac05b5150b1f317_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id30a451f1ae3428baafdcfb79ecdf5c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d32bfc908c4aea8558c37289a11f4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68602b8c374e4c99bad4ffbcbe010108_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i881cc8f9bcd1476592152fb7be160129_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c24d1e3dc4c4181ac01f37d0cb06d20_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib66100d961d94fc796a1669816ba4936_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0754265633149458c5c6423485e11cc_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a0f7014d644e399cd7787b3ea5c2f1_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667c3bfce7ba4ae99e9ae889d6f2a909_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5290c3943d846a0881409e0cf707dc8_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cce372e8cd44b4b8d65b809a8e7b49a_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32215b9047b046b18b950af503dc8257_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2daa23ebb2ce4921b71a755a66326784_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i907cde9d0d3842e9a97643cb4ed9e659_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b6a0c1e8f84451bda05b7283d51453_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bba33a166db4495b501a3f2b8852f3c_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9933b35b4354750bab2c5139b42078a_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3afdd1736f3c44988bdbd68e0e8b99e2_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc4d5467005e45d985299ab2ab1495fc_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a10b6811c84b769705e56f58585a71_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae18b65c34724d73aab497d548fc2f19_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if48023ef0a6d49198622a6d1d8e4809a_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic91d1ea7f73646298e060832ddc685eb_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48eb912406143e587ee2129a748a248_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3de2311ad9f4eaa86a15e6ff586a051_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i008e83363bc848538e1a5dcbff4c3ac6_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>exel:country</xbrli:measure></xbrli:unit><xbrli:context id="i00814bc003494d9bb50fd207cefbb476_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="iab56d00962654960b416e521404e7025_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b1dfc7877944b6bf20d7065aa99c7f_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a078295ea354ce7aeb0547546b5bb8f_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c0408a82aa46779a73c11dcfa75a56_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i551086107bad4e84b1d3ac16ad914e4d_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8513f10a32ca4e5abd8caeb8ce075aa8_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i398655de202c44728712889a41d779af_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i74a2013f8a16433e81293adc6ea5aa4d_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e90932b0d54d7da6e98d7fb3f07a50_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35254c0fd6f2407a89472d5432f6dacb_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7194cce6e63646fc9583d308abcef753_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib194841422484f7ba4a2b5e11ae924ce_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b84ad3f0ce4c27bd1d8097e8ef9797_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285a461c2de24898a0698ba0e074b002_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd800703a0a47a2a1821615e0313ebf_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83adfa8283634307bba32f1f4f54be14_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idce044eac78b4541ab6f56af1a43efe3_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica5f788e45c34e62807c3bba9ae992de_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961f155c52124473a01a4b5c400a76c2_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ec26770cc04919bd55ec958f5914f9_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbff6ceb5ce44bd99cb97c1b5bf4d24_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7546b59743254d7abf29b3243ae24052_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ea966d46c44ecb89ce18913d688c79_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90cb5dcefc15490d8098cf331b8ea9e1_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5766b5f0fc6649db9a9ece11f5731c2e_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa84da93f4a441758b16037d47ea6de1_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09eb26b2a404183be3cabe74831a09a_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a440e479bdb4fd5bf6b77258180697f_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e249821f56b45859aadda9d9a17870c_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7134fedfc494cc3aa6a8ae4190620d4_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if112a05a2b34404190a5729507b01b3b_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic274dc535ec045c5a329dc95ebae978d_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if44863bdae614924beec29fc65467290_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3767f6dbcf4f4d6cb11379d61c886681_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c698e49d45749dd946feaceac85ad90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15e0ac305444b18b2693bb09e7e1d35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib578158f471a4e36ad81dc312a12517d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35b4b3ffc9844993a92bbc43161faf68_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47fd97f14ad845a9bc98e017beac244a_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e948ebc35043fc8774b5ae38d6c32e_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20581f34d4d4396b415e4232596769d_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4951c1e73e874036b22ef0fa4b27bb5d_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3fd33fa71724f02a5838171f02316d9_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie18ac2c818d84341a05b5734a270a492_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exel:TakedaAndIspenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb9a5aa7f23e407aa788942742f46640_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39de048fc1144bb9be6ca20c5cacab33_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa98a70e1323433694d00cfce4b2b09e_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c62f456465404387850b8211c219f4_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a69ed17a5c74d79b446ce43b6eaf688_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifafb6fd490eb48bb9c8638ac3fc3247c_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca89d95ab5f4f82898ebc804c7d67c3_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id880f02651a04201866bb497ae9e96c0_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia992f174fe4c4a2c942a413095955ad3_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1561bb88d7f84399858e3575701cc3ad_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082deb7d649f464697d7bfcd0ecc9862_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064bf749eb654609b6626219640cc568_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8004462b3a4394be38cbda3e7571cc_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8688f6af6d944b5d9a869f64d77e207b_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0401aaeb66fd4321aaf94500fb43ff2d_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f8d2d0983748df85b871e2e1598f45_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b815ad748341c0a26d4fa1bcd0c7ea_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9dca35b8b24f119a51c3af9f3582fc_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i538440738be741a491a5c13daa06b6ed_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1bd21583b04c1198ee03ae25c583c5_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867c322cc2874132b092bc2a3ff658c9_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:AssetPurchaseAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65909c185a5f44b1a3af13f2646e6415_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i216f029a7d3140eda781b2bd89f45d1a_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e0a785551d4eb5b700653888c4db8d_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3a51673cab54c2c99014b6a758949cd_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ce553376d14a1e9bbcaf23624a1e75_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb28bbb730bd440b8dd81392fd62926d_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib35610c2f2f64e28b729777490e05b5a_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba307933d72242f293a72ee9fda21f66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f302f2dfc743a7baa51a5301f9feb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca5786fb2a340c09e8c451543dcf63d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i432f85dd8d664eee9a0730a69f1e1b48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if26e7aaf62fb4dfd93a135a62c26622d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:context id="i39a97239c0614813a9bcdb47d5079585_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5947ed8d61374685906f19d9a2843814_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae72b8862524ed3bc2b8076fccf13b7_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f27864b6b9f4932ab380c795945d7bf_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8f75092b0242e1ae826f92f356d80d_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077a405a4ad640958488bbaf28a3f902_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie91f2d21f92d443c8661271beebb3543_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708e1024f4b043f5b3ca5956a7e0b0f3_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib739bb13678f47dfafa308d8f18febb0_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361a4fd0426d441c8c588a99db99da57_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb018c27cf90423abecc6191d113e300_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b1eef055e9241f1bb4210e3898693e9_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecade2a3f84649a985b16aa9c12ad66e_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad8a4c467cd646c8baca4f7b23ef5df5_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ec798216a747d2a34f9808d6def632_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47ba248b6ca34c99b5dca94a7a314c11_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebc722e878a2424da9fcbea991b54c27_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d3eadd8ce14ffe8c19bfbb349b6627_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff127cda51a421eafdfdfc142c594bc_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53790e7d78b6449e828c39355b724f3e_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1dcd1471658475dab1dc78d180aeb5d_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib276f1befb584f2eb0d3d8400a5211c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aae95b2dad1408b92e286980170dfc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf6386ba6236456c9cb250e103fddfb3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ec7c9bfa1446a2aa2e7e77616f7444_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00701b0060ff40e3bf9e67174a926ca5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c6db7d27ba346c7a74173cedc687715_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id642b16c75c042b8b4f0872704ddeb4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9732c24ef7d4030924d2fffc47a71c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9f4cd6591c4439e807a82ca409c8519_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f55b03203d14b7199c525ee8fb9a037_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e31300c13f4b42b4ccc7397381d5c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98e51bc0ba15407f9467b03b370593c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9317c7dece422d8d017470956ef4c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee8761f5b144743b68bf5786e2cb23f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41dfb8c579ab4f9bb95a37a5d8e40b2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6962f24fdd4732b9aea4dfba7aeb43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22e357e289d4e58b700f917e7b65f71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0be18ed8e8ba449981c62abecf9bf6ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7406990966249758acd778bc8008496_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b1c0ac24664ff79ea2d1b0020ed617_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50204c4c28b948cb80f20f78f4be649e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4e846c084c4559b6a9595a6687fd2f_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="forward_contract"><xbrli:measure>exel:forward_contract</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ic881e9f145a74a479a9c7527b88c7852_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7b2f0fe2cf41038946282cc39c3653_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia939647731704dcda59a54bb06e17828_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b94af5f9c714b06876549ec2d63eef9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6ac444fe974dedb4a9b7fe83af78ce_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a2837ce514e4359abcc29c595fb4d0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae08cfc122445338953c327341f7d67_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0817dc61f16c4beb874045356c0ac962_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6664829ae3ae483fa02b63376c5628fa_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1a0fc30e914cd38e29d4ce13c7080f_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422c757fd8504d8d9bd061c6daee9c01_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac399c1a21047abb423228840492006_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4258bed58c6048f58584c4e2f94d0ee9_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c08f7404ff4eb485860a6fd51e4b73_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14bb8ff89fac4afabb3b6fe4dc3cf4e5_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7ff6b6e16e434293d751847fe852e9_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f50fb2bc0e46d39335240d888c8205_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc02918e98774e5ab327c89a0477cfcc_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied00e348414944e896116d415bab3625_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia195c1f38ea54879b3d52bd17362ea4e_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c24c63c06b046a89283ea6c11d9a730_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5757437e306d438b96edc7549e66fa17_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i277d7677672b42a28307cdefe84dc555_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if01316baae344a38a3c7cf53ddd5d7b4_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5850614cec8549968a33dfef9671139c_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2c5399d43b4b588fd04c0afca7e0f6_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086d58fc90a14a97898df45878c69671_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic64a47c5e8ba4d3db3fd89a64b034421_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6c8e9889ae843dc8773c941eac343d0_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8602446ff3b94e92b5b78b0fb780866b_D20220402-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6ZTY4NjJlZjdjMDVlNGMzZmJiZjk0NWE5NzUwMmNkNWEvdGFibGVyYW5nZTplNjg2MmVmN2MwNWU0YzNmYmJmOTQ1YTk3NTAyY2Q1YV8wLTEtMS0xLTQ4NzI5_c3af508b-c241-4a52-a7ee-f2967354dcfd">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6ZDAzZTViOGNiYmJlNGU2MWFlYWQxZDA2OWFmMmU0YjAvdGFibGVyYW5nZTpkMDNlNWI4Y2JiYmU0ZTYxYWVhZDFkMDY5YWYyZTRiMF8wLTAtMS0xLTQ4NzI5_c13927f4-b173-4023-a148-bba91b983a84">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the quarterly period ended <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV83Njk2NTgxMzk2NDQx_63ea5015-e743-44a2-a4c3-738a26533676">April 1, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6ZmM0YmNlZmQzYTY4NDQ5MWI3MTdkYWRjNDIwMDQ0ZTEvdGFibGVyYW5nZTpmYzRiY2VmZDNhNjg0NDkxYjcxN2RhZGM0MjAwNDRlMV8wLTAtMS0xLTQ4NzI5_d9673190-a413-4e66-9d5f-6d3b19e9e6e3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODcy_5e925627-c978-4bac-a2ca-3d787bbf926e">000-30235</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-top:9pt;text-align:center"><img src="exel-20220401_g1.jpg" alt="exel-20220401_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:188px"/></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6YWVlZGRjMGNlMjU1NDgxNjhlMmJkYmMzZTczOGIxZmYvdGFibGVyYW5nZTphZWVkZGMwY2UyNTU0ODE2OGUyYmRiYzNlNzM4YjFmZl8xLTAtMS0xLTQ4NzI5_8581c13f-f5fa-4481-a279-3b6b9a86bc4e">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6NDJmMzE5MzBjODU1NDhkMGJhNTYxMTQ1YzU3NGJjOWUvdGFibGVyYW5nZTo0MmYzMTkzMGM4NTU0OGQwYmE1NjExNDVjNTc0YmM5ZV8wLTAtMS0xLTQ4NzI5_2ad9d8ed-9b1d-4074-a942-c35a78864826">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6NDJmMzE5MzBjODU1NDhkMGJhNTYxMTQ1YzU3NGJjOWUvdGFibGVyYW5nZTo0MmYzMTkzMGM4NTU0OGQwYmE1NjExNDVjNTc0YmM5ZV8wLTEtMS0xLTQ4NzI5_585ad83f-85aa-47fa-9cb9-ec311dc8f714">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODcz_84336e6f-9279-4d55-8576-cfe2c9d282dc">1851 Harbor Bay Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc0_ccf6e4b5-ea7b-484e-a63d-ca638cbbba68">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc1_3b33e3c7-6000-4d9f-844e-90497c5c8641">CA</ix:nonNumeric> <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc4_41723fd8-76c1-4f8d-a8fd-fdbfb6900d45">94502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc5_645b9c98-2be4-4166-af24-3728b50378e2">650</ix:nonNumeric>) <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODgw_9d98fff0-b5ba-46e9-9ff7-360b88c21d8b">837-7000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6OGZjMzcxOGJmNjBkNDFmZWI2OTY4YzIwNWU0ZjNhZDIvdGFibGVyYW5nZTo4ZmMzNzE4YmY2MGQ0MWZlYjY5NjhjMjA1ZTRmM2FkMl8xLTAtMS0xLTQ4NzI5_6e33b1bd-622d-4a7a-8c42-fa6789d51d2c">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6OGZjMzcxOGJmNjBkNDFmZWI2OTY4YzIwNWU0ZjNhZDIvdGFibGVyYW5nZTo4ZmMzNzE4YmY2MGQ0MWZlYjY5NjhjMjA1ZTRmM2FkMl8xLTEtMS0xLTQ4NzI5_9c18205d-93a9-4bc8-84a0-c856b35066e9">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6OGZjMzcxOGJmNjBkNDFmZWI2OTY4YzIwNWU0ZjNhZDIvdGFibGVyYW5nZTo4ZmMzNzE4YmY2MGQ0MWZlYjY5NjhjMjA1ZTRmM2FkMl8xLTItMS0xLTQ4NzI5_7f9da0b1-4b7b-45f1-8de5-a74bbfa7c024">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODgx_ce79c767-d0bc-4c77-9988-1942c92b5a43">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc2_c48156ff-b69d-4ea9-9ad0-6ebce12b899f">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.208%"><tr><td style="width:1.0%"></td><td style="width:31.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6YzFkMjBlNGY4ZTNkNGI3N2IyMmE0NWUyYThhYzk1MjIvdGFibGVyYW5nZTpjMWQyMGU0ZjhlM2Q0Yjc3YjIyYTQ1ZTJhOGFjOTUyMl8wLTAtMS0xLTQ4NzI5_d25b2a08-43f4-49ed-b7c5-31afeaad4441">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6YzFkMjBlNGY4ZTNkNGI3N2IyMmE0NWUyYThhYzk1MjIvdGFibGVyYW5nZTpjMWQyMGU0ZjhlM2Q0Yjc3YjIyYTQ1ZTJhOGFjOTUyMl8xLTQtMS0xLTQ4NzI5_7207feaa-3975-422d-b582-e59c755619de">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6YzFkMjBlNGY4ZTNkNGI3N2IyMmE0NWUyYThhYzk1MjIvdGFibGVyYW5nZTpjMWQyMGU0ZjhlM2Q0Yjc3YjIyYTQ1ZTJhOGFjOTUyMl8yLTQtMS0xLTY1NTIw_8a613469-1dfc-4546-9a39-7de49f7f4f4c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc3_517109c0-0fee-4238-8320-165bb7861bcb">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of May&#160;2, 2022, there were <ix:nonFraction unitRef="shares" contextRef="icceeeac4473d4c3e9581cd8f8a7b5119_I20220502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODE3_96f757f2-e1c9-4cf9-9b81-c241c4ac4917">320,740,721</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_16">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_19">Condensed Consolidated Statements of Income </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_19">(Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_22">Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_28">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_31">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_64">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_64">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_79">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_79">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_82">34</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_85">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_88">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_88">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_91">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_91">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_94">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_94">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_97">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_97">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_100">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_103">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_103">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_106">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_106">56</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_109">SIGNATURES</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_13"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 1. Financial Statements</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_16"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNy0xLTEtMS00ODcyOQ_84d881c9-dcc2-47c5-90ea-c6fa81cf60e6">723,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNy0zLTEtMS00ODcyOQ_6fe56791-5341-4dd5-85e0-508c4ce2b828">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfOC0xLTEtMS00ODcyOQ_06c100d1-33e4-48d3-8f2f-674a1727e195">847,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfOC0zLTEtMS00ODcyOQ_b92f486a-6359-41f2-b04a-0e7910baa903">819,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfOS0xLTEtMS00ODcyOQ_f44c770b-4fa8-483b-b95e-c4f6d76e95ad">190,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfOS0zLTEtMS00ODcyOQ_51e88db1-8af7-41bf-806e-079f5207b9fd">282,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTAtMS0xLTEtNDg3Mjk_5e3c62f2-91d3-4d88-bcbc-73b4205aa5cd">28,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTAtMy0xLTEtNDg3Mjk_910f857b-e340-4f13-96ed-e2ca6b2a0140">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTItMS0xLTEtNDg3Mjk_8238b078-4a8d-44b4-bde6-40f871ac7d8e">53,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTItMy0xLTEtNDg3Mjk_5b1f889a-cc83-46aa-b2ee-e83e5be2e607">57,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTMtMS0xLTEtNDg3Mjk_519b3fdb-4749-44d9-8a40-d4e3570f8cf6">1,842,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTMtMy0xLTEtNDg3Mjk_3b84710f-4cf8-41d9-ae60-d11777ce219a">1,834,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTQtMS0xLTEtNDg3Mjk_baaec21c-ca7e-4e0b-88ba-a625ba42899a">404,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTQtMy0xLTEtNDg3Mjk_159d36b6-4fc8-4e55-8d98-25302f94a974">371,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTUtMS0xLTEtNDg3Mjk_89877b0b-21d7-4c17-aa1f-76b996e6b9b4">106,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTUtMy0xLTEtNDg3Mjk_48299ac3-2c80-4940-976a-809d64992090">104,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTYtMS0xLTEtNDg3Mjk_810716ae-9455-4e0c-8a79-c9835607af29">98,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTYtMy0xLTEtNDg3Mjk_5f989a80-5bf7-48e4-8870-81a0371830f2">111,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTctMS0xLTEtNDg3Mjk_8aea7a8e-a1e8-4397-90dd-bbe34f4e3aef">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTctMy0xLTEtNDg3Mjk_b7ed051f-a95e-4d44-9d2e-a070ec676cc8">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTgtMS0xLTEtNDg3Mjk_003773d6-e728-4569-a997-32a24febcc6f">138,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTgtMy0xLTEtNDg3Mjk_e9059be3-5f24-4744-9780-1771d7392436">131,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTktMS0xLTEtNDg3Mjk_473b038a-9282-43d0-855d-4132c010e40f">2,654,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTktMy0xLTEtNDg3Mjk_fdfca540-5aea-4473-b2d5-90a829dd1240">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjItMS0xLTEtNDg3Mjk_f06b7bac-c806-4b15-93d5-bf96d1f94f4e">17,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjItMy0xLTEtNDg3Mjk_f76397cf-57c9-4565-9fbe-f7345da009dc">24,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjMtMS0xLTEtNDg3Mjk_b5c0c6f5-891a-4d4f-9403-e81ff3a8ab88">42,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjMtMy0xLTEtNDg3Mjk_f5225b49-8180-4e84-9401-1f5111e715ee">61,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjQtMS0xLTEtNDg3Mjk_ee3091e5-7d4b-4d54-bff2-602d34145425">82,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjQtMy0xLTEtNDg3Mjk_47a59992-c54d-49dd-aba8-e750664a13ea">77,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjUtMS0xLTEtNDg3Mjk_1af33c90-e582-49e6-8e90-f4f6ea9bdaed">49,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjUtMy0xLTEtNDg3Mjk_0e70d701-2290-4b13-830b-8579202db6b7">33,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjYtMS0xLTEtNDg3Mjk_3cc9deb2-854a-4932-aa86-ab6205a8f419">32,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjYtMy0xLTEtNDg3Mjk_e5336a7c-85ff-4af5-a88b-e930386772f5">86,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjgtMS0xLTEtNDg3Mjk_ba90ff91-258a-4ee9-9932-51222050f31e">63,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjgtMy0xLTEtNDg3Mjk_ca4ddf4d-2431-4f17-b1e6-207a6f7a277e">53,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjktMS0xLTEtNDg3Mjk_3398d898-2050-4f18-90d5-4fefe8114e8d">289,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjktMy0xLTEtNDg3Mjk_265ae230-ec0a-4128-9ea0-77f0aaf6e157">337,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzAtMS0xLTEtNDg3Mjk_d664a941-68c0-4c5b-b8ef-e9a2db50a2b1">8,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzAtMy0xLTEtNDg3Mjk_884d4120-b86c-41de-aefe-c47ae9121443">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzEtMS0xLTEtNDg3Mjk_77060fce-d07b-4af8-a587-d5f1e1e6d3df">50,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzEtMy0xLTEtNDg3Mjk_c82e2956-6cd9-40e2-8c47-4a6c1af071e0">51,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzItMS0xLTEtNDg3Mjk_6dab6e25-2393-4fcd-b055-67e7feae23bd">12,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzItMy0xLTEtNDg3Mjk_33953114-ce1c-47f0-83e9-4ee918bb690b">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzMtMS0xLTEtNDg3Mjk_b00bae51-26ca-445a-9742-01fa0bc12220">360,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzMtMy0xLTEtNDg3Mjk_eff60537-d53b-4f08-abc9-982bf23e0244">405,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzQtMS0xLTEtNDg3Mjk_0bd42c32-6b7f-4217-9c98-9904c00b4cf6"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzQtMy0xLTEtNDg3Mjk_ecb71d50-b644-4f29-adf6-3d2500b54c2a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV8yMQ_0a056031-2fc8-4ad4-9a09-f4e2e0ad4955"><ix:nonFraction unitRef="usdPerShare" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV8yMQ_62f3f3d1-0d69-4641-851b-b220a848073e">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV8zNQ_259cb5fd-33a2-48fc-861c-b5e4556ea78d"><ix:nonFraction unitRef="shares" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV8zNQ_a5bbfc2b-9d16-48f2-ab41-b9cab70ce6bb">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV82MA_02fca04b-c0fd-4e81-ad43-acd50d0ccc34"><ix:nonFraction unitRef="shares" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV82MA_48d6f7c1-5c0d-458e-84df-b7ada57fa95a">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMS0xLTEtNDg3Mjk_72693d63-7f07-4793-a054-4475626fa8af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMy0xLTEtNDg3Mjk_4e29cd15-19b3-4b78-afdd-d1a30694c1bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxOTAy_150d442b-62dd-4e3f-92b9-6bfccf3e60ee"><ix:nonFraction unitRef="usdPerShare" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxOTAy_63396fd0-62ab-4938-a974-ec7131a5e507">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODg4_d45c5073-7e2d-44b9-bba4-bf2550cea120"><ix:nonFraction unitRef="shares" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODg4_eacc4ef8-d7bb-4ee6-af48-15ebbcc45fee">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODY4_0716d809-3ae1-4c9f-b565-895f40989641"><ix:nonFraction unitRef="shares" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODY4_83e53606-9d86-4840-b5eb-e776ded39c71">320,268</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODc4_cf6dd3db-2272-4cf7-9abe-b475d65463f6"><ix:nonFraction unitRef="shares" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODc4_f88239d3-fcfc-4f43-ac55-529b8cf3f06c">318,842</ix:nonFraction></ix:nonFraction> at March&#160;31, 2022, and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMS0xLTEtNDg3Mjk_c1bb91f6-10b7-4795-aa9f-54101461582f">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMy0xLTEtNDg3Mjk_097303b5-f800-488b-b397-a3f2984d0064">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzgtMS0xLTEtNDg3Mjk_47ff829f-83a9-4f34-8b1d-0f0d39d817c2">2,448,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzgtMy0xLTEtNDg3Mjk_42af1c41-f354-4a88-9c7e-b77f39782e0c">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzktMS0xLTEtNDg3Mjk_036a3902-e5c8-471f-aeb3-e8bd7137420e">6,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzktMy0xLTEtNDg3Mjk_864698ab-1a21-4aaf-bc24-e7197e7ecde6">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDAtMS0xLTEtNDg3Mjk_b91c6ecc-8a82-429b-8bc1-71286e12ca42">147,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDAtMy0xLTEtNDg3Mjk_81b04179-27cf-49b7-9dd3-656ac9403b4e">216,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDEtMS0xLTEtNDg3Mjk_81383fb1-05d4-48be-a50a-58bc6fc5e25b">2,293,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDEtMy0xLTEtNDg3Mjk_5d086165-ef79-4b8b-b14d-6081f0126ae1">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDItMS0xLTEtNDg3Mjk_46fc2f17-084d-4cf3-8fa0-8eda5a526d58">2,654,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDItMy0xLTEtNDg3Mjk_0dd5ad0f-5ba3-4628-9c69-ded93853077a">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef460046aca49f3a2753fad35f32387_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMy0xLTEtMS00ODcyOQ_fad99c1c-9bde-463b-8b2e-a5a35753679f">310,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1f98ab028c4075b3c5959b7f157dc9_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMy0zLTEtMS00ODcyOQ_051c3bc3-9bcf-498b-a792-59862ae5363f">227,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d496fb0cfe4be9ab5f4af2e1a705bd_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNC0xLTEtMS00ODcyOQ_85878222-8838-41d4-ba0a-75fc5801e059">32,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9a170e7200455d9d99fa4118712bb7_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNC0zLTEtMS00ODcyOQ_08049445-0cf7-4fca-80e0-fdb4bd80a5ac">27,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf02010d20b45d38532755c0e8242ff_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNS0xLTEtMS00ODcyOQ_47f29c8f-dca5-45c4-b9a4-f6233c031d5f">13,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8de81af7714dbc880d1340b695ef37_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNS0zLTEtMS00ODcyOQ_91346705-f5c9-4254-ad5a-d80ca09466ca">15,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNi0xLTEtMS00ODcyOQ_b751ee23-3bb9-48cd-8d70-e0030bcab6fe">355,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNi0zLTEtMS00ODcyOQ_dd51d12e-8876-48c3-b7e2-a3a2d38aa8ff">270,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfOC0xLTEtMS00ODcyOQ_4c3cbe99-2b22-443b-b4f7-f326ff27ed58">13,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfOC0zLTEtMS00ODcyOQ_1bffb3b4-6429-415d-add5-93ea9b04dc85">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfOS0xLTEtMS00ODcyOQ_c3068cc8-fba1-4481-8d40-271d52d6b668">156,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfOS0zLTEtMS00ODcyOQ_31c03312-c972-49ff-aa07-3e615921de4c">159,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTAtMS0xLTEtNDg3Mjk_20375019-af1f-4264-9605-d0240ee6fa96">102,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTAtMy0xLTEtNDg3Mjk_c4fff2be-e562-473e-b820-fd44191e3d20">102,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTEtMS0xLTEtNDg3Mjk_b1aa5548-195f-470d-aa1e-fbfc35ceb843">272,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTEtMy0xLTEtNDg3Mjk_da772141-461e-41fe-bf73-dea366571194">274,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTItMS0xLTEtNDg3Mjk_e6b72206-98fe-4bfd-a62c-1dce5abd44b3">83,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTItMy0xLTEtNDg3Mjk_321214cd-4f74-4d05-827d-68b3a6631820">4,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTMtMS0xLTEtNDg3Mjk_c2cba2d3-731f-4431-929d-61e8b598edef">1,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTMtMy0xLTEtNDg3Mjk_2a4ffd8f-7d18-4707-aabc-88f7d34ba929">2,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTQtMS0xLTEtNDg3Mjk_8f62bc68-7a4d-4d8f-9f9c-b00af633b54b">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTQtMy0xLTEtNDg3Mjk_728702a5-68e3-45f0-971c-84f77aeb1c93">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTUtMS0xLTEtNDg3Mjk_83c821ca-8b87-40c9-ac83-fc1e2df1068e">85,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTUtMy0xLTEtNDg3Mjk_1b208926-6e87-4ca9-a19d-e8d92ef1163f">2,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTYtMS0xLTEtNDg3Mjk_d63254f1-5564-4998-95dd-d17b4d62112a">16,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTYtMy0xLTEtNDg3Mjk_03833372-78b3-48cd-9a6d-33d1552a0fda">3,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTctMS0xLTEtNDg3Mjk_e6f12bd3-6737-4a26-84ba-ede00144975d">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTctMy0xLTEtNDg3Mjk_bdfd9e7d-a56e-4eeb-941e-e7cf5aeddfce">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTktMS0xLTEtNDg3Mjk_824b75e3-22d1-4e4a-be41-1ba3c7788008">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTktMy0xLTEtNDg3Mjk_cfcf81ef-1e5b-49ad-a6d4-83269d9871cc">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjAtMS0xLTEtNDg3Mjk_76b8bfa9-3cd7-4ed2-a86b-589323385452">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjAtMy0xLTEtNDg3Mjk_5e1b60f9-95e9-4bc0-9e61-217fb633c67e">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjItMS0xLTEtNDg3Mjk_adf748de-649b-493e-9e17-bee327546154">319,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjItMy0xLTEtNDg3Mjk_85ef594e-7e6d-4789-ade5-824c0519b471">312,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjMtMS0xLTEtNDg3Mjk_859d8612-136c-445d-a550-cc8f2c238ea1"><ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjMtMS0xLTEtNDg3Mjk_c784476d-b3b8-43e6-8974-8bccf524ab2d">323,289</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjMtMy0xLTEtNDg3Mjk_d78abe91-086f-4351-986f-38242cdeb39c">321,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_22"></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfMi0xLTEtMS00ODcyOQ_e6f12bd3-6737-4a26-84ba-ede00144975d">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfMi0zLTEtMS00ODcyOQ_bdfd9e7d-a56e-4eeb-941e-e7cf5aeddfce">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses on available-for-sale debt securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNC0wLTEtMS00ODcyOS90ZXh0cmVnaW9uOjQxNTg2YmMwNWJhMTQ2Y2M4Y2M4YTQ1MTA3ODRhYzUwXzE2NDkyNjc0NDI2Njk_99e3b20f-e909-4a3e-8cb3-bcda00e7b18f">1,656</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNC0wLTEtMS00ODcyOS90ZXh0cmVnaW9uOjQxNTg2YmMwNWJhMTQ2Y2M4Y2M4YTQ1MTA3ODRhYzUwXzE2NDkyNjc0NDI2ODI_0efb6c43-3282-47bc-84cd-bea35c18c990">499</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNC0xLTEtMS00ODcyOQ_03ba9a52-10ed-4aad-a821-1d24d4e2f145">5,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNC0zLTEtMS00ODcyOQ_4428b0a4-5913-4762-adb2-146d56c134cc">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNi0xLTEtMS00ODcyOQ_a48b5c0a-93d8-4581-a249-1cf543ef6a78">62,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNi0zLTEtMS00ODcyOQ_b1902ba6-2206-4019-9a33-d2261f3c2c07">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c02a85ca1984c97bac05b5150b1f317_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtMS0xLTEtNDg3Mjk_eddbe3eb-f3ec-429d-840e-e58095b18b46">318,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c02a85ca1984c97bac05b5150b1f317_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtMy0xLTEtNDg3Mjk_e8b5b2ba-b33c-4b45-98d6-566e585cf59a">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30a451f1ae3428baafdcfb79ecdf5c9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtNS0xLTEtNDg3Mjk_b4b753b8-f4c0-405d-8e01-2b2dd409b04c">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9d32bfc908c4aea8558c37289a11f4d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtNy0xLTEtNDg3Mjk_283bebeb-bcf8-458b-8175-24a9612b744d">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68602b8c374e4c99bad4ffbcbe010108_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtOS0xLTEtNDg3Mjk_663de2ae-2ceb-42d9-bf86-b42cbec4cd4f">216,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtMTEtMS0xLTQ4NzI5_5826933d-366a-4dda-8f13-8c4a194e7f4b">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881cc8f9bcd1476592152fb7be160129_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjQtOS0xLTEtNDg3Mjk_00074c72-db14-429c-9110-4ad327d45c15">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjQtMTEtMS0xLTQ4NzI5_c7f87aea-b4c8-48b4-acfc-30e38327454d">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24d1e3dc4c4181ac01f37d0cb06d20_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjUtNy0xLTEtNDg3Mjk_71f71ba1-aa44-424d-bce5-12327e1fd95e">5,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjUtMTEtMS0xLTQ4NzI5_8c1aac23-2042-4826-8777-3e5b0247c1ee">5,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib66100d961d94fc796a1669816ba4936_D20220101-20220401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjYtMS0xLTEtNDg3Mjk_c5b9ecf2-dfe5-4b5f-8272-a8d8bc7bae81">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66100d961d94fc796a1669816ba4936_D20220101-20220401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjYtMy0xLTEtNDg3Mjk_3b94f5a6-8add-4b64-bce8-b4c6cc3d5b1a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0754265633149458c5c6423485e11cc_D20220101-20220401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjYtNS0xLTEtNDg3Mjk_38b21a42-38a9-4f2a-a081-690d15a2f490">5,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjYtMTEtMS0xLTQ4NzI5_7ea756ab-7470-4745-a0e2-c61840b31145">5,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0754265633149458c5c6423485e11cc_D20220101-20220401" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjctNS0xLTEtNDg3Mjk_8aab69bb-625d-4cc8-af3c-9c90f0e9ce45">4,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjctMTEtMS0xLTQ4NzI5_b8f31ed6-0be1-4b38-b800-4945a704efdb">4,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib0754265633149458c5c6423485e11cc_D20220101-20220401" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjgtNS0xLTEtNDg3Mjk_79c5ff32-a3f4-4312-b491-99fc155519f6">20,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjgtMTEtMS0xLTQ4NzI5_07f2f316-da5c-4f9d-9e43-9ed067229177">20,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6a0f7014d644e399cd7787b3ea5c2f1_I20220401" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktMS0xLTEtNDg3Mjk_2edf4f06-e36b-4669-bc66-d9b5acce4f81">320,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a0f7014d644e399cd7787b3ea5c2f1_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktMy0xLTEtNDg3Mjk_abc96399-2462-406a-b23a-25da8f5bbfa2">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667c3bfce7ba4ae99e9ae889d6f2a909_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktNS0xLTEtNDg3Mjk_5d160677-d7d5-426e-8053-ae4cc9015a44">2,448,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5290c3943d846a0881409e0cf707dc8_I20220401" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktNy0xLTEtNDg3Mjk_092571fa-357e-457c-8bc3-e796b2b9ef19">6,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cce372e8cd44b4b8d65b809a8e7b49a_I20220401" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktOS0xLTEtNDg3Mjk_81182240-9304-45b0-b5af-a26c770a8f36">147,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktMTEtMS0xLTQ4NzI5_83bc26a3-83bd-463e-a3bf-a5d63ce0cc0f">2,293,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32215b9047b046b18b950af503dc8257_I20210101" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtMS0xLTEtNDg3Mjk_acb8bc7c-90a3-43da-abb3-bcfb8e54df74">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32215b9047b046b18b950af503dc8257_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtMy0xLTEtNDg3Mjk_b8e8f891-6916-4863-ba3f-e1f79b9860e4">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2daa23ebb2ce4921b71a755a66326784_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtNS0xLTEtNDg3Mjk_669c7d03-d7af-44a8-a3a9-d83f6315dab9">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i907cde9d0d3842e9a97643cb4ed9e659_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtNy0xLTEtNDg3Mjk_cdcedccc-33ba-479d-bdda-8010f8ad777f">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b6a0c1e8f84451bda05b7283d51453_I20210101" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtOS0xLTEtNDg3Mjk_7446a1f7-90f1-41ea-9fdc-d6b4acbcbfa3">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bba33a166db4495b501a3f2b8852f3c_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtMTEtMS0xLTQ4NzI5_f41bb4f0-550a-46d4-8566-b6fcb044a534">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9933b35b4354750bab2c5139b42078a_D20210102-20210402" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjQtOS0xLTEtNDg3Mjk_b8492745-0c1e-48dc-bf89-c2fe0351b45a">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjQtMTEtMS0xLTQ4NzI5_2330185b-eb15-4e32-a1fe-731750f6e8c3">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3afdd1736f3c44988bdbd68e0e8b99e2_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjUtNy0xLTEtNDg3Mjk_3a426d67-8998-41a9-a3bc-2ee308494a48">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjUtMTEtMS0xLTQ4NzI5_434fae62-a68f-4958-9da8-fe91aef3f668">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc4d5467005e45d985299ab2ab1495fc_D20210102-20210402" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjYtMS0xLTEtNDg3Mjk_c8f12aca-6bbf-4a14-a249-512b69aaa7a8">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4d5467005e45d985299ab2ab1495fc_D20210102-20210402" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjYtMy0xLTEtNDg3Mjk_a353ad4f-0d3b-499b-8bda-9fda0b654903">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61a10b6811c84b769705e56f58585a71_D20210102-20210402" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjYtNS0xLTEtNDg3Mjk_522bbcd4-4da5-4f48-8c20-b10678cadbf0">4,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjYtMTEtMS0xLTQ4NzI5_d0cd07fe-e197-408c-9ee5-8969725eec0c">4,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61a10b6811c84b769705e56f58585a71_D20210102-20210402" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjctNS0xLTEtNDg3Mjk_708989eb-9efe-4639-a291-fe713b971cec">6,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjctMTEtMS0xLTQ4NzI5_fa58e6cf-6caa-48b1-b29a-e0bad941fe64">6,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i61a10b6811c84b769705e56f58585a71_D20210102-20210402" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjgtNS0xLTEtNDg3Mjk_9be091ea-dc47-42ec-b3fb-3801b0783bcf">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjgtMTEtMS0xLTQ4NzI5_a0b07118-d795-44a7-9db5-bfc105a539c8">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae18b65c34724d73aab497d548fc2f19_I20210402" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktMS0xLTEtNDg3Mjk_7efc7fb9-9a1e-4b65-b830-fb91cfea9b7b">313,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae18b65c34724d73aab497d548fc2f19_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktMy0xLTEtNDg3Mjk_30ab6ec1-c79b-4234-b32f-fb4a89cd6bf0">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48023ef0a6d49198622a6d1d8e4809a_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktNS0xLTEtNDg3Mjk_caa7baca-df3f-42e4-b494-ff59bd7cbb88">2,354,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91d1ea7f73646298e060832ddc685eb_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktNy0xLTEtNDg3Mjk_ebef5416-8c2c-4f15-9330-f3e5c1176f45">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic48eb912406143e587ee2129a748a248_I20210402" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktOS0xLTEtNDg3Mjk_b8fb118b-4d5f-41bf-be72-ef353e4afc14">445,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3de2311ad9f4eaa86a15e6ff586a051_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktMTEtMS0xLTQ4NzI5_54ebef0d-01e3-41bb-8649-66dfa99e7b08">1,911,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMi0xLTEtMS00ODcyOQ_e6f12bd3-6737-4a26-84ba-ede00144975d">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMi0zLTEtMS00ODcyOQ_bdfd9e7d-a56e-4eeb-941e-e7cf5aeddfce">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNC0xLTEtMS00ODcyOQ_9225e05d-9121-44d2-a423-b0fe19a5c11a">4,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNC0zLTEtMS00ODcyOQ_9730c840-e24e-4617-bf45-2441c08a51de">3,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNS0xLTEtMS00ODcyOQ_e963cf48-7222-41c3-82b1-843e9d4467a8">19,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNS0zLTEtMS00ODcyOQ_e5ad5b4f-9a19-465d-b93f-b392901558df">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNi0xLTEtMS00ODcyOQ_0844e6cc-0a51-4449-b65c-496b435d86e7">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNi0zLTEtMS00ODcyOQ_e6d87f0f-f147-4684-bdc6-4a5ade183b34">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNy0xLTEtMS00ODcyOQ_202061cb-0b74-4445-9d31-d45cde45bafd">15,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNy0zLTEtMS00ODcyOQ_c7ba68ac-6c6d-4443-8ede-52b847d98109">3,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfOC0xLTEtMS00ODcyOQ_f72f941d-cb34-4c1d-a0df-a234492992fc">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfOC0zLTEtMS00ODcyOQ_15cb72b0-e2cc-45e2-8d64-ef758ecbcc20">6,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTAtMS0xLTEtNDg3Mjk_8dd47285-29f5-415b-9b73-220fd2e48b62">91,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTAtMy0xLTEtNDg3Mjk_d219bdac-511d-456b-bfc0-21bfd7a7b68d">17,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTEtMS0xLTEtNDg3Mjk_9d5bd72f-9e17-4ec6-a218-525c6afe2a1e">3,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTEtMy0xLTEtNDg3Mjk_35f8e652-beb4-494f-b277-efa70e457f57">2,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTMtMS0xLTEtNDg3Mjk_f71a64da-e89d-42aa-a829-7213f79a7420">3,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTMtMy0xLTEtNDg3Mjk_a674a60e-cf1c-4db0-9f88-a4b00ef1affd">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTUtMS0xLTEtNDg3Mjk_30903743-e21d-4139-a13a-472f84b9832e">1,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTUtMy0xLTEtNDg3Mjk_529b10df-be7f-4ddb-932d-364496576b2f">13,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTYtMS0xLTEtNTkyOTU_bb5637b5-ab70-4b31-89d7-877dd19315a0">54,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTYtMy0xLTEtNTkzMDQ_c0b4ac35-b820-4c9d-9c09-7cb0e13f7e6a">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTYtMS0xLTEtNDg3Mjk_c4f51823-ea43-468c-a2d1-267ddab09b20">7,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTYtMy0xLTEtNDg3Mjk_afceabac-50bf-4cd6-9b92-147e66ed07d9">867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTctMS0xLTEtNDg3Mjk_781cea10-005a-49bc-8ebf-8a7eddb6253a">147,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTctMy0xLTEtNDg3Mjk_c208ff77-0dcb-4f74-8a89-f6480121187a">39,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTktMS0xLTEtNDg3Mjk_4f0dc952-e6b7-4cef-9dd9-96348cb41bef">5,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTktMy0xLTEtNDg3Mjk_39841b7d-1502-46cd-b44e-2b7340818dd2">13,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjEtMS0xLTEtNDg3Mjk_decdb4fb-52c4-43ef-aa66-9f5340afdf6d">336,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjEtMy0xLTEtNDg3Mjk_b2d78b40-d7ba-4961-bd93-4adb19bb075d">331,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjItMS0xLTEtNDg3Mjk_42b68759-4f69-4169-bc7c-4bb65bb5bb67">267,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjItMy0xLTEtNDg3Mjk_7dbe7e42-49f6-41e3-98e3-9a940e1ea7df">407,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjMtMS0xLTEtNDg3Mjk_eb90d2fc-b4bf-4ab0-84f7-4cf65d9fb1c9">74,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjMtMy0xLTEtNDg3Mjk_535405a7-8d1e-46ad-ac05-7fbab6965f30">62,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjUtMS0xLTEtNDg3Mjk_dc564d37-6644-43be-8d74-3b91eccac769">4,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjUtMy0xLTEtNDg3Mjk_43aa0a47-6a1d-4796-97ee-4c3b3342a161">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjYtMS0xLTEtNDg3Mjk_cbef72f6-fa31-4dbd-9ca5-4f6d5f920578">4,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjYtMy0xLTEtNDg3Mjk_88977c1e-6cda-4af3-95a8-e60fc47584c4">5,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjktMS0xLTEtNDg3Mjk_1a9db026-9070-49b2-9c6d-2e4d996682c8">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjktMy0xLTEtNDg3Mjk_ae46595f-bbca-4511-a02e-14c464a6fce0">2,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzAtMS0xLTEtNDg3Mjk_e5c53f20-5c3f-49e0-ae6b-194dcc4b654a">73,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzAtMy0xLTEtNDg3Mjk_f39c5235-a3ec-4cec-84f9-a551e53d2f78">99,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzEtMS0xLTEtNDg3Mjk_d19f90e8-162c-4eca-8da7-e897d1f1abba">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bba33a166db4495b501a3f2b8852f3c_I20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzEtMy0xLTEtNDg3Mjk_d362e055-dc6e-4737-b79f-58e06936181a">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzItMS0xLTEtNDg3Mjk_8f8ecf54-8a9f-40cd-9323-0897bd4ccdaf">737,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3de2311ad9f4eaa86a15e6ff586a051_I20210402" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzItMy0xLTEtNDg3Mjk_1eb638ea-cd72-4578-9c15-b9ae7750447a">419,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODY5OQ_0bd03951-4381-4ba2-81ee-094062d215f0" continuedAt="ia81770b4fd434da29696031382b11aaf" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ia81770b4fd434da29696031382b11aaf" continuedAt="iebf51d8e6ff5426eabb46135799d7dd2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, <ix:nonFraction unitRef="product" contextRef="i008e83363bc848538e1a5dcbff4c3ac6_D20220101-20220401" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfNjI3_a38038db-97d4-42d5-baa6-02f3ca965532">four</ix:nonFraction> products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in <ix:nonFraction unitRef="country" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="INF" name="exel:NumberOfCountriesWithDrugApprovalExcludingTheUS" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfMTY0OTI2NzQ1MjUzOA_210949dd-c8af-4fa3-91e9-b8aa5ab9199f">61</ix:nonFraction> other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and the European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="i00814bc003494d9bb50fd207cefbb476_D20220101-20220401" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfMTYyNw_5c4bc52c-4456-477b-b626-4d70d172ef88">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODY5MA_3160969e-8d6b-4a09-87cc-aab0994e817c" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODczNQ_309480e0-b57a-4bdd-9f05-c7475a99f0e2" escape="true">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021, included in Part II, Item 8 of our Annual Report on Form 10-K filed with the SEC on February&#160;18, 2022.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODY5NQ_5819be72-e269-4d7c-a3f5-c516332400bc" continuedAt="i802237fe2724405f8c5907bb38d1a1c1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i802237fe2724405f8c5907bb38d1a1c1">. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the three months ended April 1, 2022 and April 2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the three months ended March 31, 2022 and March 31, 2021, and the year ending December 31, 2022, respectively.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="iebf51d8e6ff5426eabb46135799d7dd2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODcwMQ_8f75dcff-b17e-4699-affc-0fac6f195a4c" escape="true">We operate in <ix:nonFraction unitRef="segment" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfMTY0OTI2NzQ1NTg5OQ_1ea8aaf3-ce35-4fbb-92c7-f6cefed31713">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODcyMw_a0d15c5c-651c-48bb-a01f-34a784ce15d6" escape="true">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfNzY5NjU4MTQxMTg3Ng_5d101737-a26d-4c24-ac24-3d9031610e04" escape="true">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies during the three months ended March 31, 2022, compared to the significant accounting policies disclosed in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODY4Nw_80164468-1891-483d-85f7-643e93a9a70f" escape="true"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNTAwNA_535f3349-acd6-4f28-9116-95e990f34e8c" continuedAt="i61b304ce241e48b0ad947cea6a2a5f5b" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i61b304ce241e48b0ad947cea6a2a5f5b" continuedAt="ia175e1d1c8e74702b41afe443156a5f3"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNTAwNw_f0fa3403-63b4-42e6-9c9c-101e15736986" continuedAt="i370df1105f47432382854023c3110a86" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab56d00962654960b416e521404e7025_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfMy0xLTEtMS00ODcyOQ_c379bfa4-2337-4cc0-a439-a1db49b76fea">448,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b1dfc7877944b6bf20d7065aa99c7f_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfMy0zLTEtMS00ODcyOQ_d20f3fba-1f50-42e2-89a8-f04481a942c1">314,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a078295ea354ce7aeb0547546b5bb8f_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNC0xLTEtMS00ODcyOQ_c3a480ba-e133-4ee5-ad16-4ecb7c66fd1b">137,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39c0408a82aa46779a73c11dcfa75a56_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNC0zLTEtMS00ODcyOQ_7758d72a-d000-413c-b2fa-fa390c7bb863">86,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef460046aca49f3a2753fad35f32387_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNS0xLTEtMS00ODcyOQ_fad99c1c-9bde-463b-8b2e-a5a35753679f">310,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1f98ab028c4075b3c5959b7f157dc9_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNS0zLTEtMS00ODcyOQ_051c3bc3-9bcf-498b-a792-59862ae5363f">227,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d496fb0cfe4be9ab5f4af2e1a705bd_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNy0xLTEtMS00ODcyOQ_85878222-8838-41d4-ba0a-75fc5801e059">32,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9a170e7200455d9d99fa4118712bb7_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNy0zLTEtMS00ODcyOQ_08049445-0cf7-4fca-80e0-fdb4bd80a5ac">27,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf02010d20b45d38532755c0e8242ff_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfOC0xLTEtMS00ODcyOQ_47f29c8f-dca5-45c4-b9a4-f6233c031d5f">13,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8de81af7714dbc880d1340b695ef37_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfOC0zLTEtMS00ODcyOQ_91346705-f5c9-4254-ad5a-d80ca09466ca">15,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551086107bad4e84b1d3ac16ad914e4d_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfOS0xLTEtMS00ODcyOQ_d008b15d-bd65-4f26-b711-0c669e80932f">45,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8513f10a32ca4e5abd8caeb8ce075aa8_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfOS0zLTEtMS00ODcyOQ_a9c40117-8ebe-4da1-824b-d75d54fed042">43,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfMTAtMS0xLTEtNDg3Mjk_6ea1fa7a-e058-4863-a33d-70e5c066c8f7">355,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfMTAtMy0xLTEtNDg3Mjk_79bf974b-1897-40c6-86fa-0fa57764429b">270,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNDk5Nw_53045bdb-82ee-4e1b-b873-c3834195dfe3" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i398655de202c44728712889a41d779af_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfMy0xLTEtMS00ODcyOQ_9dd9d317-eaf5-4189-9239-a932ef034f16">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74a2013f8a16433e81293adc6ea5aa4d_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfMy0zLTEtMS00ODcyOQ_e8650a0c-519e-44a3-aa1f-9dd73aec733a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3e90932b0d54d7da6e98d7fb3f07a50_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNC0xLTEtMS00ODcyOQ_b624218e-9b37-49fb-b63d-a310f021f447">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35254c0fd6f2407a89472d5432f6dacb_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNC0zLTEtMS00ODcyOQ_df7ee974-ec3a-44e1-af19-7a0fd66a3f7f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7194cce6e63646fc9583d308abcef753_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNS0xLTEtMS00ODcyOQ_eaa61dfc-889b-4e14-8725-fa92af31cdb0">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib194841422484f7ba4a2b5e11ae924ce_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNS0zLTEtMS00ODcyOQ_a4dbf36b-3932-44d2-b3f9-991b422e97c3">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8b84ad3f0ce4c27bd1d8097e8ef9797_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNi0xLTEtMS02MTk4OA_e26bd026-55b9-4f50-a476-f738209843df">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i285a461c2de24898a0698ba0e074b002_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNi0zLTEtMS02MTk4OA_8b548a93-b88e-4df1-ab2e-8fcd1caeb698">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1cd800703a0a47a2a1821615e0313ebf_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNi0xLTEtMS00ODcyOQ_32817c5f-138e-417c-ad0e-04408b107f2b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i83adfa8283634307bba32f1f4f54be14_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNi0zLTEtMS00ODcyOQ_607d1345-dea7-4083-b92a-f7acf456c4cf">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idce044eac78b4541ab6f56af1a43efe3_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMS0xLTEtMS02MjA3NA_fec8283b-b627-4bca-a6bb-5fd57df4f0dc">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica5f788e45c34e62807c3bba9ae992de_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMS0zLTEtMS02MjA3NA_c02a8ec4-62bb-4632-a1d3-82bfd5f00db0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i961f155c52124473a01a4b5c400a76c2_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMS0xLTEtMS00ODcyOQ_511467bd-accb-431b-951d-3a570c749d19">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6ec26770cc04919bd55ec958f5914f9_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMS0zLTEtMS00ODcyOQ_204a5a56-63d1-4433-b4a6-7152fe86c694">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebbff6ceb5ce44bd99cb97c1b5bf4d24_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMy0xLTEtMS00ODcyOQ_ac395170-2592-45d3-ab4c-a6f760cc9c48">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7546b59743254d7abf29b3243ae24052_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMy0zLTEtMS00ODcyOQ_80ce8bd2-1e63-4ab7-a51c-6381242a8e68">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5ea966d46c44ecb89ce18913d688c79_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfNC0xLTEtMS00ODcyOQ_9b9ddbee-9769-4433-8a11-6c70ee3f80b9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90cb5dcefc15490d8098cf331b8ea9e1_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfNC0zLTEtMS00ODcyOQ_732cee55-728d-4d4c-9eec-cf5f73fa5922">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNTAwOA_4b485786-2474-4b51-abb8-f90e559ba725" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5766b5f0fc6649db9a9ece11f5731c2e_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfMi0xLTEtMS00ODcyOQ_9af1ace9-b77d-4406-83d6-85306fdb96a7">314,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa84da93f4a441758b16037d47ea6de1_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfMi0zLTEtMS00ODcyOQ_45a4c0db-d5dc-441d-92ed-5a094bbd1eb7">229,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09eb26b2a404183be3cabe74831a09a_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfMy0xLTEtMS00ODcyOQ_73efaf76-da7c-4699-97ab-adc311503663">34,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a440e479bdb4fd5bf6b77258180697f_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfMy0zLTEtMS00ODcyOQ_c3c312bf-19e9-45bd-84ad-d8739945fb1c">33,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e249821f56b45859aadda9d9a17870c_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfNC0xLTEtMS00ODcyOQ_e0e31c5d-1835-4d70-8ae9-f8874c000841">7,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7134fedfc494cc3aa6a8ae4190620d4_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfNC0zLTEtMS00ODcyOQ_1e2a7e2c-741b-457e-b22d-7d06f804c33e">6,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfNS0xLTEtMS00ODcyOQ_af5dec76-acfb-4296-9a7d-66cc3dd57d9b">355,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfNS0zLTEtMS00ODcyOQ_14754cbe-89e2-455f-bc2f-b34a05306d45">270,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNDk5MQ_05d5544b-8575-4f3f-8c95-6ada318841f2" continuedAt="ibbfad48acffb4ac0b02e1a63c906666d" escape="true">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="ia175e1d1c8e74702b41afe443156a5f3" continuedAt="i46ad286947ac404d83857cd7ec842f9a"><div style="margin-top:9pt;text-indent:36pt"><ix:continuation id="ibbfad48acffb4ac0b02e1a63c906666d" continuedAt="ieed8dedfe165434fafd9d71b520c8949"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></ix:continuation></div><ix:continuation id="i370df1105f47432382854023c3110a86"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if112a05a2b34404190a5729507b01b3b_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfMi0xLTEtMS00ODcyOQ_64d0f7cc-8bae-487c-9ff5-b3b312e2a208">302,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic274dc535ec045c5a329dc95ebae978d_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfMi0zLTEtMS00ODcyOQ_861d94de-4b6b-47ee-a673-2915dfc44955">223,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if44863bdae614924beec29fc65467290_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfMy0xLTEtMS00ODcyOQ_ceb5c5c1-688a-4c23-b526-21b3507d42d5">7,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3767f6dbcf4f4d6cb11379d61c886681_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfMy0zLTEtMS00ODcyOQ_245df61b-da5a-4d76-ba66-8bf7895ee5a2">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef460046aca49f3a2753fad35f32387_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfNC0xLTEtMS00ODcyOQ_253b05a2-e8c3-4788-a84b-8ad167b5d9a3">310,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1f98ab028c4075b3c5959b7f157dc9_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfNC0zLTEtMS00ODcyOQ_4c33fbe2-9b99-4240-8411-3bcab9e5f4d2">227,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNTAwOQ_0120fdb3-690a-45e5-b7a1-9bf3701b7855" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:41.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c698e49d45749dd946feaceac85ad90_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMS0xLTEtMS00ODcyOQ_075a5fd8-b5b0-48c5-aef6-a73ab0ba9016">14,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15e0ac305444b18b2693bb09e7e1d35_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMS0zLTEtMS00ODcyOQ_7425cb01-37b2-4e07-9f34-fe5e173c9363">8,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib578158f471a4e36ad81dc312a12517d_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMS01LTEtMS00ODcyOQ_c093a07d-dff3-436d-8fa8-d129c21f2a61">24,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMS05LTEtMS00ODcyOQ_75f17a83-bec0-43da-81fc-6d3cac27c1e9">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b4b3ffc9844993a92bbc43161faf68_D20220101-20220401" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMy0xLTEtMS00ODcyOQ_7316e744-1fe2-4750-af6d-f8e48f514f74">86,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47fd97f14ad845a9bc98e017beac244a_D20220101-20220401" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMy0zLTEtMS00ODcyOQ_df57e1ea-65b4-4226-a033-61916e0a222b">12,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e948ebc35043fc8774b5ae38d6c32e_D20220101-20220401" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMy01LTEtMS00ODcyOQ_1695e332-06c4-42c0-9ba6-cdffbaa14bb9">38,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMy05LTEtMS00ODcyOQ_0fd1c003-09a3-47f1-ba6f-6a881db66091">137,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b4b3ffc9844993a92bbc43161faf68_D20220101-20220401" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNC0xLTEtMS00ODcyOQ_cc1fbb52-668e-4291-b266-2b208ca85127">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47fd97f14ad845a9bc98e017beac244a_D20220101-20220401" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNC0zLTEtMS00ODcyOQ_f79a84a8-9baf-4e35-991f-c3b99fc688a4">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e948ebc35043fc8774b5ae38d6c32e_D20220101-20220401" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNC01LTEtMS00ODcyOQ_46b1fe31-922a-4c83-8d62-36ef1396ef69">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNC05LTEtMS00ODcyOQ_312215cf-9049-4484-b0a3-bfa7a425a916">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35b4b3ffc9844993a92bbc43161faf68_D20220101-20220401" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNS0xLTEtMS00ODcyOQ_a667b90b-ef96-4b71-b2b1-d256d71b015b">83,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47fd97f14ad845a9bc98e017beac244a_D20220101-20220401" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNS0zLTEtMS00ODcyOQ_08fba883-34d5-4c5d-9502-71b66426f9f0">10,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e948ebc35043fc8774b5ae38d6c32e_D20220101-20220401" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNS01LTEtMS00ODcyOQ_11c6c884-52fc-4ffc-bbe9-7160648123d2">24,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNS05LTEtMS00ODcyOQ_ebf076b2-a459-4311-9700-7d157dd86995">117,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20581f34d4d4396b415e4232596769d_I20220401" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNi0xLTEtMS00ODcyOQ_61d0fc8e-1dff-4bef-9405-5c1281a5f78d">18,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4951c1e73e874036b22ef0fa4b27bb5d_I20220401" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNi0zLTEtMS00ODcyOQ_c74d967b-8ba9-45e7-b6ed-e0f9a4905a93">10,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3fd33fa71724f02a5838171f02316d9_I20220401" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNi01LTEtMS00ODcyOQ_e2450a5b-d40c-428a-82aa-8fb467604379">39,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNi05LTEtMS00ODcyOQ_7857988a-a390-4b8a-a726-51654d87be9c">68,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="ieed8dedfe165434fafd9d71b520c8949"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="i46ad286947ac404d83857cd7ec842f9a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNDk4OQ_a64fc74f-2807-447a-a9cb-e32b453d4fca" continuedAt="i7a7df93b639240e28eef27468be61989" escape="true">Contract assets and liabilities were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i7a7df93b639240e28eef27468be61989" continuedAt="ic50ce66f06814b9bbb300d8ecc7118b2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfNC0xLTEtMS01Nzg4Mw_97d9e1bc-9d11-480f-985a-f747a3bcb8a7">3,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfNC0zLTEtMS00ODcyOQ_027b37ee-7767-4d7e-b39d-eefdb2781127">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfNy0xLTEtMS00ODcyOQ_34eaa71c-8309-435e-a260-e39b9fec2163">7,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfNy0zLTEtMS00ODcyOQ_e17f141b-6eb9-453d-840f-148123f5fb53">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfOC0xLTEtMS00ODcyOQ_e62978f8-af7b-49b8-9ebe-02771db400f7">8,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfOC0zLTEtMS00ODcyOQ_163d87eb-00a9-419d-ad38-87b72a0d9898">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfOS0xLTEtMS00ODcyOQ_0f306490-b579-42e9-9a40-4d66df785f93">15,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfOS0zLTEtMS00ODcyOQ_3f39e5ab-dee2-466a-b204-5c04df363299">16,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:continuation id="ic50ce66f06814b9bbb300d8ecc7118b2"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI1Ng_374df11a-50d7-4168-98ea-7b8780f087e0">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI2MA_7300048e-8587-4de2-b19b-8dbb787b98c8">2.5</ix:nonFraction>&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI1Nw_bcf6abdb-9ff3-400e-9744-2f81d3342f5c">31.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI3NA_b07e0872-1fbb-4fe5-acc7-aaa50bafadb0">27.8</ix:nonFraction>&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ie18ac2c818d84341a05b5734a270a492_I20220401" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI1OA_8fce6b01-ea4d-4e38-88ea-f31933656986">87.4</ix:nonFraction>&#160;million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 for information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfODQ0MQ_423e4933-00b0-46b1-9138-a92d8b4855ca" continuedAt="i4777d6468f5246ae8913688b0d3b99cd" escape="true">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i4777d6468f5246ae8913688b0d3b99cd" continuedAt="ica6995ab92764daa938885781894b519"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; to our Consolidated Financial Statements included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, or as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="ica6995ab92764daa938885781894b519" continuedAt="iadd3c6f5aa634431bef87917f0e7947e"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfODQyOA_4a94c1cf-9d2a-4dee-9e09-013c0c3ca64c" continuedAt="i3bf81f7dfe5746b0b7367bb6221919bf" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9a5aa7f23e407aa788942742f46640_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfMi0xLTEtMS00ODcyOQ_d261a0cf-a6ce-4ef9-9b63-486c5c4a9613">24,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39de048fc1144bb9be6ca20c5cacab33_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfMi0zLTEtMS00ODcyOQ_cb7980a5-bc2a-4cd1-918b-79de6855a7cb">22,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa98a70e1323433694d00cfce4b2b09e_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfMy0xLTEtMS00ODcyOQ_d21cfaca-4ff9-4ae6-88b2-7e48ea185679">9,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c62f456465404387850b8211c219f4_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfMy0zLTEtMS00ODcyOQ_c3a5f474-9500-4594-b66c-3ea8b98cd478">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a69ed17a5c74d79b446ce43b6eaf688_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfNC0xLTEtMS00ODcyOQ_87f307ac-7c24-4643-aa2b-306c46f8ef84">34,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifafb6fd490eb48bb9c8638ac3fc3247c_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfNC0zLTEtMS00ODcyOQ_8e9be06e-4ea7-4a3a-ad75-79f9ec90e239">33,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ibca89d95ab5f4f82898ebc804c7d67c3_I20220401" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTU4NA_cb672ed6-d02d-40cb-b719-902deb08a922">46.7</ix:nonFraction>&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><ix:continuation id="i3bf81f7dfe5746b0b7367bb6221919bf" continuedAt="i6cd822cf1fba43f086c311f6a8d24a79"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id880f02651a04201866bb497ae9e96c0_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfMi0xLTEtMS00ODcyOQ_6c16ea4c-3891-415e-a824-58dc6ee111d9">2,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia992f174fe4c4a2c942a413095955ad3_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfMi0zLTEtMS00ODcyOQ_d21dd604-78c2-4d19-8fd5-ae563a88bb8f">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1561bb88d7f84399858e3575701cc3ad_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfMy0xLTEtMS00ODcyOQ_1e9e09f8-38a5-45a6-803a-72d15131ee90">3,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082deb7d649f464697d7bfcd0ecc9862_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfMy0zLTEtMS00ODcyOQ_a26cbb41-8bda-4941-909b-b8f72425a1e4">4,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064bf749eb654609b6626219640cc568_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfNC0xLTEtMS00ODcyOQ_ff7440fd-f9be-49b7-b2f0-a7c7a41fe251">6,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8004462b3a4394be38cbda3e7571cc_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfNC0zLTEtMS00ODcyOQ_540deb12-a309-4f1b-b619-df048537b526">5,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i8688f6af6d944b5d9a869f64d77e207b_I20220401" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTU4NQ_5265d788-3e33-4168-917c-8b2caad3e56a">40.6</ix:nonFraction>&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a <ix:nonFraction unitRef="number" contextRef="i0401aaeb66fd4321aaf94500fb43ff2d_D20220101-20220401" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNDc5Mg_47f353c3-68c2-4d80-8be9-550f157a8df4">3</ix:nonFraction>% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royal Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $<ix:nonFraction unitRef="usd" contextRef="i72f8d2d0983748df85b871e2e1598f45_D20220101-20220401" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQxMDI5MQ_c952b955-5a7d-4c6a-a3a3-a66f74fc0dbf">13.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i81b815ad748341c0a26d4fa1bcd0c7ea_D20210102-20210402" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTU3MA_2fe5e646-be76-42e4-bd73-22cfdac13093">10.1</ix:nonFraction>&#160;million during the three months ended March 31, 2022, and 2021, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="iadd3c6f5aa634431bef87917f0e7947e"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:continuation id="i6cd822cf1fba43f086c311f6a8d24a79" continuedAt="iea7a69f24ca84c9b92388922d9216311">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</ix:continuation></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="iea7a69f24ca84c9b92388922d9216311"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9dca35b8b24f119a51c3af9f3582fc_D20220101-20220401" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOmM4YjUxYzk5NTZmODQxNDQ4OWQyNjU4ZDY4MWU3YWY2L3RhYmxlcmFuZ2U6YzhiNTFjOTk1NmY4NDE0NDg5ZDI2NThkNjgxZTdhZjZfMi0xLTEtMS00ODcyOQ_1b38862d-9ceb-4511-9b50-7dc75686a1d1">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538440738be741a491a5c13daa06b6ed_D20210102-20210402" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOmM4YjUxYzk5NTZmODQxNDQ4OWQyNjU4ZDY4MWU3YWY2L3RhYmxlcmFuZ2U6YzhiNTFjOTk1NmY4NDE0NDg5ZDI2NThkNjgxZTdhZjZfMi0zLTEtMS00ODcyOQ_9fb6193a-b4e9-40ea-90b2-209fd1d66a83">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9dca35b8b24f119a51c3af9f3582fc_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOmM4YjUxYzk5NTZmODQxNDQ4OWQyNjU4ZDY4MWU3YWY2L3RhYmxlcmFuZ2U6YzhiNTFjOTk1NmY4NDE0NDg5ZDI2NThkNjgxZTdhZjZfMy0xLTEtMS00ODcyOQ_079445e6-7a3b-41c1-b4e4-b7d88b8af2d2">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538440738be741a491a5c13daa06b6ed_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOmM4YjUxYzk5NTZmODQxNDQ4OWQyNjU4ZDY4MWU3YWY2L3RhYmxlcmFuZ2U6YzhiNTFjOTk1NmY4NDE0NDg5ZDI2NThkNjgxZTdhZjZfMy0zLTEtMS00ODcyOQ_6b42bdad-7efd-4835-ba69-5d97904ac0ff">951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i8c1bd21583b04c1198ee03ae25c583c5_I20220401" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTQ2MA_f967768d-7607-47ea-907b-b71af8dbbe7c">254.3</ix:nonFraction>&#160;million, regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i8c1bd21583b04c1198ee03ae25c583c5_I20220401" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTQ3Ng_9916a287-94d7-41fb-80b0-dc402fd88655">426.5</ix:nonFraction>&#160;million and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i8c1bd21583b04c1198ee03ae25c583c5_I20220401" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTQ5Mg_60dc2f36-4d47-4139-9150-5b31c7f39e8f">1,911.5</ix:nonFraction>&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In conjunction with an asset purchase agreement entered into in 2021, we will make a $<ix:nonFraction unitRef="usd" contextRef="i867c322cc2874132b092bc2a3ff658c9_I20220401" decimals="-5" name="exel:AssetAcquisitionPaymentUponClosingOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTUxMA_4503b204-c53a-4c3a-82a6-4c5060e92cd5">4.0</ix:nonFraction>&#160;million payment upon the completion of the technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i867c322cc2874132b092bc2a3ff658c9_I20220401" decimals="-5" name="exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTUzOQ_5d132ca2-396b-4de5-9d5a-ad75d1da3ce1">42.0</ix:nonFraction>&#160;million and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i867c322cc2874132b092bc2a3ff658c9_I20220401" decimals="-5" name="exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTU1NA_f2bb0941-6d91-4126-b762-8305a4a709af">22.5</ix:nonFraction>&#160;million, per product.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNzY5NjU4MTM5NzgwNA_16abe05d-9458-4515-a618-2560cd53bc5c" continuedAt="i3fb037b028c74bb4a4ca95dd6ed0fe64" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i3fb037b028c74bb4a4ca95dd6ed0fe64" continuedAt="ie687631aa68f48d5aaac928a7ff5478f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjczMQ_85e17fb6-68a6-4dde-b0f9-de470229767f" continuedAt="i961f5326fce84588a5f1acc0d34e9b7c" escape="true"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjc1OA_4caae4b0-e85b-4afc-a7fb-e6b790035a54" continuedAt="i8fad526f21a54f89b6804ab5f6ec3067" escape="true">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i961f5326fce84588a5f1acc0d34e9b7c"><ix:continuation id="i8fad526f21a54f89b6804ab5f6ec3067"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfMS0xLTEtMS00ODcyOQ_84d881c9-dcc2-47c5-90ea-c6fa81cf60e6">723,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfMS0zLTEtMS00ODcyOQ_6fe56791-5341-4dd5-85e0-508c4ce2b828">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfMy0xLTEtMS00ODcyOQ_6afb4dd5-0a09-4801-806f-b2e1954cf013">14,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfMy0zLTEtMS00ODcyOQ_9cfea315-2a2a-4531-b259-5865fb3ce819">16,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfNC0xLTEtMS00ODcyOQ_6aca1d83-cffa-4b77-b58b-f7c8404d02c6">737,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfNC0zLTEtMS00ODcyOQ_d19f90e8-162c-4eca-8da7-e897d1f1abba">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, restricted cash equivalents included $<ix:nonFraction unitRef="usd" contextRef="i65909c185a5f44b1a3af13f2646e6415_I20220401" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNDM5ODA0NjUxNDUyOA_d436b1be-25a0-4f0d-8d8b-25b18b66de1d">12.5</ix:nonFraction> million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our January 2021 standby letter of credit will remain effective through June 30, 2022.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="ie687631aa68f48d5aaac928a7ff5478f" continuedAt="i399f2b7b37b746578f83462c536faf01"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjcyNw_7542b1ec-9f67-4454-8e22-acbefea7097e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMy0xLTEtMS00ODcyOQ_455fa6c7-b856-4906-9e34-146749199cde">954,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMy0zLTEtMS00ODcyOQ_2bab3cbf-3a10-4094-82d1-5cd30c5a7397">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMy01LTEtMS00ODcyOQ_f70b071c-3f61-4091-8087-1ae4cb7e33ce">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMy03LTEtMS00ODcyOQ_f2e19870-df7a-4e34-b4ce-4e24343a3ff6">954,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNC0xLTEtMS00ODcyOQ_c00893e1-2522-4dc4-8325-3dbb4bccf31e">529,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNC0zLTEtMS00ODcyOQ_977f320e-e39c-49e9-91aa-51ac3a792a3f">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNC01LTEtMS00ODcyOQ_ee215aa9-5323-4873-b2a1-1d75236abfbb">7,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNC03LTEtMS00ODcyOQ_9b0ef0b9-30dd-4734-b5d9-39fe7457ff7f">522,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNS0xLTEtMS00ODcyOQ_c2ed243e-dd73-4fca-a6c8-19669e474304">197,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNS0zLTEtMS00ODcyOQ_28db3bb3-1693-4117-94b1-92539ee9584c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNS01LTEtMS00ODcyOQ_cf2de0ba-124d-439c-93f6-d54c9394d340">1,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNS03LTEtMS00ODcyOQ_f0c97bcf-bfe2-49f1-8ef4-57591fe58f8d">196,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNi0xLTEtMS00ODcyOQ_b6beb090-6775-4884-936a-058740ff3a34">13,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNi0zLTEtMS00ODcyOQ_35bf5068-2c08-40a6-836b-4c1f0fb7a83b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNi01LTEtMS00ODcyOQ_f0e910da-390e-480d-9926-26cb052890fa">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNi03LTEtMS00ODcyOQ_b8d91988-2a28-45c5-b2ac-573af4681b15">13,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNy0xLTEtMS00ODcyOQ_46420d25-b938-4f17-8043-927f0840faa9">1,694,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNy0zLTEtMS00ODcyOQ_9c5babbe-3894-4310-811e-fea88a709a17">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNy01LTEtMS00ODcyOQ_e52cecaa-a367-4b44-9732-1aabce0690b1">8,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNy03LTEtMS00ODcyOQ_72f9b708-8937-4c6d-bacc-8b5e3cbf852f">1,686,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb28bbb730bd440b8dd81392fd62926d_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOC0xLTEtMS00ODcyOQ_d5f7fb3d-bc52-45b5-b180-ad2bef5a42cf">97,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb28bbb730bd440b8dd81392fd62926d_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOC0zLTEtMS00ODcyOQ_7be87e42-7eb3-406f-92fa-623054ddfdc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb28bbb730bd440b8dd81392fd62926d_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOC01LTEtMS00ODcyOQ_fc6aab31-83ee-4281-934c-824d6dfb763c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb28bbb730bd440b8dd81392fd62926d_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOC03LTEtMS00ODcyOQ_c1031373-88ce-419f-9925-085428c9d483">97,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35610c2f2f64e28b729777490e05b5a_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOS0xLTEtMS00ODcyOQ_731070a7-cbe9-44d6-807a-7b642b355526">87,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35610c2f2f64e28b729777490e05b5a_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOS0zLTEtMS00ODcyOQ_bc289b40-ac40-4724-b738-6cc1924f035a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35610c2f2f64e28b729777490e05b5a_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOS01LTEtMS00ODcyOQ_205d80a6-a2e0-4889-be5d-09395b077674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35610c2f2f64e28b729777490e05b5a_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOS03LTEtMS00ODcyOQ_37f8655c-097f-42d8-9072-2eb57874317b">87,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTAtMS0xLTEtNDg3Mjk_1d7c6ba0-69d9-4c4b-b4aa-00e832fdc66a">117,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTAtMy0xLTEtNDg3Mjk_103e0e44-614c-43b4-ab8c-c9c91fb1d359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTAtNS0xLTEtNDg3Mjk_bb23d083-be0f-4651-bd66-32ee80c6dc82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTAtNy0xLTEtNDg3Mjk_4d149367-6c43-4b46-a69e-3b5e5723e962">117,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTEtMS0xLTEtNDg3Mjk_311d36c7-a40a-47f6-a811-55d3c24dc346">1,997,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTEtMy0xLTEtNDg3Mjk_d08799c3-44af-4296-baa3-a964d5376a1d">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTEtNS0xLTEtNDg3Mjk_9f331f23-8361-43b6-a590-e6b580e904ab">8,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTEtNy0xLTEtNDg3Mjk_3b58a7b0-d7e2-48ee-8801-3d466dfee861">1,988,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba307933d72242f293a72ee9fda21f66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMy0xLTEtMS00ODcyOQ_48104bc4-14a3-4e42-b833-5f54ea6cd0e6">945,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba307933d72242f293a72ee9fda21f66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMy0zLTEtMS00ODcyOQ_ac57b6e8-b9f8-4b3b-8d6f-a312927daf4d">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba307933d72242f293a72ee9fda21f66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMy01LTEtMS00ODcyOQ_7de05d5c-c54b-43b0-a6c5-c97eb86b9a47">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba307933d72242f293a72ee9fda21f66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMy03LTEtMS00ODcyOQ_89ae4858-8909-499a-8461-66cc44c09b51">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNC0xLTEtMS00ODcyOQ_cc9ddc60-eab1-4861-a8a5-27d346be39b2">541,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNC0zLTEtMS00ODcyOQ_fcd904a7-955b-41f6-9413-9e83248232f2">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNC01LTEtMS00ODcyOQ_b51b9166-d0c5-4345-8a4f-26c238ced998">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNC03LTEtMS00ODcyOQ_0b837448-8b18-447b-a41d-a43259d299cb">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNS0xLTEtMS00ODcyOQ_b6a7e0f8-a6b6-41f4-a589-f5e8fad56ecb">33,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNS0zLTEtMS00ODcyOQ_c6250079-8c8c-4566-becf-8b9b38d967c0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNS01LTEtMS00ODcyOQ_1650d70f-fd7d-4975-9ab0-e87d08aed754">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNS03LTEtMS00ODcyOQ_c04c7a6d-b9d1-4519-af33-0f4d5fe820fb">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNi0xLTEtMS00ODcyOQ_8ea59c7d-e63c-40b4-b2ea-017cd06dbda3">12,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNi0zLTEtMS00ODcyOQ_9d87a5da-e1cc-4add-a28b-c00f5edfc127">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNi01LTEtMS00ODcyOQ_7413192e-3fd5-43e1-836b-337457fb4a8d">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNi03LTEtMS00ODcyOQ_3ac3e7b7-1cd1-4567-8812-28736c1df9c9">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNy0xLTEtMS00ODcyOQ_649b78e3-4cc4-4ce2-8bfa-60bf0c54f174">1,534,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNy0zLTEtMS00ODcyOQ_e0df490c-a0f3-408d-a6d8-9e230f2acd06">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNy01LTEtMS00ODcyOQ_dfd44c31-dfa0-4588-9e2d-0cf5892d8403">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNy03LTEtMS00ODcyOQ_c714f4eb-1a6b-413e-b6c5-391ef57fb087">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOC0xLTEtMS00ODcyOQ_d77f52d6-120e-4722-9d48-bba01ef2f860">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOC0zLTEtMS00ODcyOQ_e3e7e1e2-7228-43dc-9005-1ecf8828e404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOC01LTEtMS00ODcyOQ_c03be479-84e0-4fdd-b0ca-88b22c21c375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOC03LTEtMS00ODcyOQ_bdb99d56-41f9-4c68-b367-d963b7bf0ec2">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i432f85dd8d664eee9a0730a69f1e1b48_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOS0xLTEtMS00ODcyOQ_57d21a5b-a285-4c69-ac32-0cf24302f5fa">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i432f85dd8d664eee9a0730a69f1e1b48_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOS0zLTEtMS00ODcyOQ_84810118-7c43-47b4-9bd1-659feeb3541c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i432f85dd8d664eee9a0730a69f1e1b48_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOS01LTEtMS00ODcyOQ_42c05fe4-aacc-4032-88bc-182569e030f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i432f85dd8d664eee9a0730a69f1e1b48_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOS03LTEtMS00ODcyOQ_7a98bac5-1b95-4ff7-a228-85ecf43e5b7d">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26e7aaf62fb4dfd93a135a62c26622d_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTAtMS0xLTEtNDg3Mjk_82494048-c92c-433c-b2b1-631e86febd3b">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26e7aaf62fb4dfd93a135a62c26622d_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTAtMy0xLTEtNDg3Mjk_deb815db-52fc-434b-ab69-455e5f827b9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26e7aaf62fb4dfd93a135a62c26622d_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTAtNS0xLTEtNDg3Mjk_d3d9908c-16fd-468c-ae61-0dae9eba4b7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26e7aaf62fb4dfd93a135a62c26622d_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTAtNy0xLTEtNDg3Mjk_3876bffa-a1d8-4012-ae6e-ef18bfbb8c95">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTEtMS0xLTEtNDg3Mjk_4b9aa7bd-a635-4a88-a512-96c5a8b44fac">1,855,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTEtMy0xLTEtNDg3Mjk_8ee335b1-133e-4c67-867a-80022bdb35dc">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTEtNS0xLTEtNDg3Mjk_42711c23-f2dd-4ae0-add8-56595bcd3052">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTEtNy0xLTEtNDg3Mjk_fdd4a0a6-3ab8-4c6a-baa3-1f6d4d40a0e2">1,854,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMTY0OTI2NzQ0NDQ0Mw_8e10e5c0-e878-4cfd-9b20-7108ca85c925">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNDM5ODA0NjUxNDUwNQ_096e2ad5-aaf0-4436-9a1b-fd8b91600b9e">2.9</ix:nonFraction> million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three months ended March 31, 2022, and 2021.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="i399f2b7b37b746578f83462c536faf01"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjc0MQ_04da046e-36c1-4e48-8e24-c31080d84390" continuedAt="i09d79c9ec0484a1f9499d9e6092e7de4" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i09d79c9ec0484a1f9499d9e6092e7de4"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfMy05LTEtMS00ODcyOQ_bf2200e1-3dfd-434c-b15e-6fed7cd24acb">456,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfMy0xMS0xLTEtNDg3Mjk_792387c0-f1ca-4636-b459-43f9b9f1d1a6">7,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC05LTEtMS02MTMxMw_c25d5ad6-6483-49ba-9575-48cde989c8b8">196,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC0xMS0xLTEtNjEzMTM_56f86c36-3c77-4503-a050-b20a2ab3aeb3">1,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC05LTEtMS01Nzc1Nw_a3fd500f-ba54-4ff8-addb-254ddbc034e6">32,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC0xMS0xLTEtNTc3NTk_40456152-25a4-4a94-bb95-2b9a8cd2d443">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC05LTEtMS00ODcyOQ_da02de75-d277-454f-88a4-53532ac722d6">13,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC0xMS0xLTEtNDg3Mjk_96286249-de41-4f72-ba98-0782d64a9ce3">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNi05LTEtMS00ODcyOQ_c48e8de9-1c29-480b-b527-fbbe37eecffd">698,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNi0xMS0xLTEtNDg3Mjk_e2248b51-bd53-4a7e-bc8b-4a37d2055df9">8,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMi05LTEtMS00ODcyOQ_d58d45d8-b8b0-43a5-9d19-5ff64e29c9f7">385,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMi0xMS0xLTEtNDg3Mjk_ebba859e-1f91-48c2-9fe8-ff485a66ec8d">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba307933d72242f293a72ee9fda21f66_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMy05LTEtMS01Nzc2MQ_8d70e852-7301-44f6-b75e-ac70acc5a6b6">43,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba307933d72242f293a72ee9fda21f66_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMy0xMS0xLTEtNTc3NjM_ebb7dac4-4a1e-4d55-adfe-878b496f4046">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMy05LTEtMS00ODcyOQ_e5269bd4-fc04-4ac9-83d1-bb02b77a84ed">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMy0xMS0xLTEtNDg3Mjk_b4939bf5-5170-4d4b-a3b9-68a547ea8175">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfNC05LTEtMS00ODcyOQ_c718c1dc-9f9c-4514-8407-8b3da7143ff4">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfNC0xMS0xLTEtNDg3Mjk_d8552c59-102e-48ad-8331-585b990b7df8">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfNS05LTEtMS00ODcyOQ_137159aa-1a8c-487b-8494-3aad198265ab">454,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfNS0xMS0xLTEtNDg3Mjk_0b4a3005-e917-49cb-b6ae-db9c37eab085">1,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="investment" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMTY0OTI2NzQ0NDQ4Nw_b3aac9de-8f1a-453c-9dca-16553e15cb3a">197</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNDM5ODA0NjUxNDUzNg_40ab2374-e6c7-4c3e-a982-69033c57088d">133</ix:nonFraction> investments in an unrealized loss position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for <ix:nonFraction unitRef="investment" contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNzE0NjgyNTU4NDkzOQ_c79eb969-4464-4e8a-853e-e9fbe8717859">two</ix:nonFraction> corporate bond securities with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfODc5NjA5MzAyNjUzNw_4207ead9-4cba-45c6-b88c-2c3310e0841d">6.3</ix:nonFraction>&#160;million and an aggregate immaterial unrealized loss as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three months ended March 31, 2022, and 2021, we did <ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjEwNA_9438711e-7606-41b4-aab6-3e42a4ad73e5"><ix:nonFraction unitRef="usd" contextRef="ib3de2311ad9f4eaa86a15e6ff586a051_I20210402" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjEwNA_b4b3233f-fa86-4de6-bdea-451655bbe3c1">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjc1NQ_3983714f-e87d-43b2-9362-1488e4c9ecc5" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMS0xLTEtMS00ODcyOQ_3d774bcb-2afb-4b9f-8db9-1500fb62e1cd">1,290,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMS0zLTEtMS00ODcyOQ_e5c06287-f2b2-401a-a089-677f64f9dd28">1,168,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMi0xLTEtMS00ODcyOQ_8cdfb80c-b815-4ae6-b837-0bc518b0310f">395,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMi0zLTEtMS00ODcyOQ_0d8c4de9-a1e9-4f37-afd8-de00099fc6e6">365,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMy0xLTEtMS00ODcyOQ_10ce49f6-2df3-4992-899d-09c5d18b2c54">1,686,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMy0zLTEtMS00ODcyOQ_d42e07a0-280c-4be4-99f2-1873b88d42e2">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8de248c3265649ac8d88b7bfb8f42ed9_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfMjQ4Nw_e2faf20b-f563-4ec7-a915-66bbef0567db" continuedAt="if58bf529b94d439ebe481fee444874e2" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="if58bf529b94d439ebe481fee444874e2" continuedAt="if0391859f5194438b0a7523012e3e3a4"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="if0391859f5194438b0a7523012e3e3a4"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfMjQ4OA_666219fa-6741-40c8-af56-c601b4a8e06b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a97239c0614813a9bcdb47d5079585_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMi0xLTEtMS00ODcyOQ_1f34e742-b613-43fc-8c48-b5567ea9e9e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5947ed8d61374685906f19d9a2843814_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMi0zLTEtMS00ODcyOQ_25d60948-daf5-4a32-a8f2-8492f28c763b">954,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae72b8862524ed3bc2b8076fccf13b7_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMi01LTEtMS00ODcyOQ_232cd6e8-e3bd-45e8-a3f1-97531df06576">954,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f27864b6b9f4932ab380c795945d7bf_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMy0xLTEtMS00ODcyOQ_3c79bdb5-8a14-4d75-9bee-d145b0f34f4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8f75092b0242e1ae826f92f356d80d_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMy0zLTEtMS00ODcyOQ_6ccfd7c3-12a8-4f3d-8b89-c053bf9e1a94">522,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077a405a4ad640958488bbaf28a3f902_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMy01LTEtMS00ODcyOQ_33fad2fd-2537-4211-af23-4541e5f57b1d">522,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie91f2d21f92d443c8661271beebb3543_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNC0xLTEtMS00ODcyOQ_facd50c5-e28b-47c5-a8d2-de9cba08060a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708e1024f4b043f5b3ca5956a7e0b0f3_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNC0zLTEtMS00ODcyOQ_c4e7a74e-9969-4c9d-8200-c80f62b49790">196,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib739bb13678f47dfafa308d8f18febb0_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNC01LTEtMS00ODcyOQ_545c59bc-5cf7-4911-b36d-05978aa56155">196,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361a4fd0426d441c8c588a99db99da57_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNS0xLTEtMS00ODcyOQ_eea8232e-ec53-4859-bde8-328ff36ca5b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb018c27cf90423abecc6191d113e300_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNS0zLTEtMS00ODcyOQ_aa5c2ce7-1092-4a31-95ed-a78f56309c81">13,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1eef055e9241f1bb4210e3898693e9_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNS01LTEtMS00ODcyOQ_55e0b8df-955d-489e-977c-2b180cb57a61">13,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecade2a3f84649a985b16aa9c12ad66e_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNi0xLTEtMS00ODcyOQ_0d5b6a64-e675-44f6-a2d8-cd7ffce16912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8a4c467cd646c8baca4f7b23ef5df5_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNi0zLTEtMS00ODcyOQ_31370249-5fa7-43e3-8143-b0ed68a3b4a8">1,686,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ec798216a747d2a34f9808d6def632_I20220401" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNi01LTEtMS00ODcyOQ_58a1466c-45d5-417f-a63d-8cd365fdc978">1,686,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47ba248b6ca34c99b5dca94a7a314c11_I20220401" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNy0xLTEtMS00ODcyOQ_f500deed-b480-4477-bada-b9d7fee67991">87,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc722e878a2424da9fcbea991b54c27_I20220401" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNy0zLTEtMS00ODcyOQ_33cdb383-29cc-4c08-a980-0279ce548a15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d3eadd8ce14ffe8c19bfbb349b6627_I20220401" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNy01LTEtMS00ODcyOQ_7fe38200-4f16-43b3-8a6f-280c286ab7ea">87,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff127cda51a421eafdfdfc142c594bc_I20220401" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOC0xLTEtMS00ODcyOQ_4b0ead3f-c5af-4700-92ce-6c03114506c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53790e7d78b6449e828c39355b724f3e_I20220401" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOC0zLTEtMS00ODcyOQ_7b3ad962-6306-43c9-baaf-3295242c9435">117,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1dcd1471658475dab1dc78d180aeb5d_I20220401" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOC01LTEtMS00ODcyOQ_ed606402-64af-4762-8b2e-5f5ef4bbad91">117,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecade2a3f84649a985b16aa9c12ad66e_I20220401" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOS0xLTEtMS00ODcyOQ_92ead3ec-315b-48ab-950e-82ea6844767d">87,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8a4c467cd646c8baca4f7b23ef5df5_I20220401" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOS0zLTEtMS00ODcyOQ_6a130e11-15c9-47f6-81ad-077288e0fb5d">1,804,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ec798216a747d2a34f9808d6def632_I20220401" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOS01LTEtMS00ODcyOQ_80aa8f01-cb77-467e-bd4a-d776e6d9921e">1,891,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib276f1befb584f2eb0d3d8400a5211c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMi0xLTEtMS00ODcyOQ_118ae192-3005-4ea2-a74d-85386e0f7367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aae95b2dad1408b92e286980170dfc9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMi0zLTEtMS00ODcyOQ_a6805990-abb7-4089-88ac-16c7ff67e5bf">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6386ba6236456c9cb250e103fddfb3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMi01LTEtMS00ODcyOQ_b93ae13d-4d7b-47aa-be4e-eb80695487c3">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ec7c9bfa1446a2aa2e7e77616f7444_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMy0xLTEtMS00ODcyOQ_0dcd45c6-1135-4eef-96e9-8e7958516cd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00701b0060ff40e3bf9e67174a926ca5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMy0zLTEtMS00ODcyOQ_d9c8636d-7207-44c1-849c-4c674c35da24">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6db7d27ba346c7a74173cedc687715_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMy01LTEtMS00ODcyOQ_918b83b9-d755-4785-af30-b3c4616b078c">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id642b16c75c042b8b4f0872704ddeb4b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNC0xLTEtMS00ODcyOQ_4dc04853-c4a5-4d31-a8d5-685564347893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9732c24ef7d4030924d2fffc47a71c7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNC0zLTEtMS00ODcyOQ_38c2e5c0-f294-48cf-b9cb-3e2db38ae6e3">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9f4cd6591c4439e807a82ca409c8519_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNC01LTEtMS00ODcyOQ_80dff479-032b-4b6e-a24e-41b9fc45c6c5">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f55b03203d14b7199c525ee8fb9a037_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNS0xLTEtMS00ODcyOQ_a6233941-3e60-41a5-80b4-68ff2c442fde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e31300c13f4b42b4ccc7397381d5c8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNS0zLTEtMS00ODcyOQ_de2d09e1-c2d0-4841-8a53-36b1f801cc50">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e51bc0ba15407f9467b03b370593c0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNS01LTEtMS00ODcyOQ_c83ae993-4d90-4521-af8f-f98aaadb17df">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9317c7dece422d8d017470956ef4c5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNi0xLTEtMS00ODcyOQ_d3fcb379-c348-41ac-9c02-87dd41909e37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee8761f5b144743b68bf5786e2cb23f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNi0zLTEtMS00ODcyOQ_ebdacb2d-51a5-4c53-97fd-39f4c30dad9c">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41dfb8c579ab4f9bb95a37a5d8e40b2d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNi01LTEtMS00ODcyOQ_f3e17275-aca4-4ece-a716-ff94e5573159">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6962f24fdd4732b9aea4dfba7aeb43_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNy0xLTEtMS00ODcyOQ_ffb2ac3d-9973-4fce-930e-0c6bb266dba1">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22e357e289d4e58b700f917e7b65f71_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNy0zLTEtMS00ODcyOQ_9dc119a1-0cf1-4c52-80e1-db1877078518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be18ed8e8ba449981c62abecf9bf6ba_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNy01LTEtMS00ODcyOQ_40bd725f-54f5-47ae-aac8-cddafd832d56">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7406990966249758acd778bc8008496_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOC0xLTEtMS00ODcyOQ_7803674b-9532-4313-8dc8-7e55cfe5555f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b1c0ac24664ff79ea2d1b0020ed617_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOC0zLTEtMS00ODcyOQ_c1d5d897-6490-4ba2-905c-ae9fb81bbc9c">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50204c4c28b948cb80f20f78f4be649e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOC01LTEtMS00ODcyOQ_c88af359-e2f8-4f49-8c8f-c9bdbe26721b">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9317c7dece422d8d017470956ef4c5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOS0xLTEtMS00ODcyOQ_9bd11443-5b74-4392-bd66-a2a054883556">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee8761f5b144743b68bf5786e2cb23f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOS0zLTEtMS00ODcyOQ_8275948a-e226-47d5-92fe-57eb8484559f">1,652,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41dfb8c579ab4f9bb95a37a5d8e40b2d_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOS01LTEtMS00ODcyOQ_3c9181aa-0569-466a-96e6-59230e4260b1">1,719,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had <ix:nonFraction unitRef="forward_contract" contextRef="i1e4e846c084c4559b6a9595a6687fd2f_I20220401" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfMTg3Mw_ef06c52a-1d73-4582-8cb6-ebcc5778e716">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="i1e4e846c084c4559b6a9595a6687fd2f_I20220401" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfNzY5NjU4MTM5NzIyNw_6a337588-bfc1-4324-befe-3cd50adba656">7.5</ix:nonFraction>&#160;million. The forward contract with a maturity of <ix:nonNumeric contextRef="ic881e9f145a74a479a9c7527b88c7852_D20220101-20220401" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfMTk1Nw_e2174219-05ec-4506-98ca-e83f058c4820">three months</ix:nonNumeric> is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the three months ended March 31, 2022, and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="ic881e9f145a74a479a9c7527b88c7852_D20220101-20220401" decimals="-5" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfNzY5NjU4MTM5NzIyOA_b85d670f-d809-412d-ac90-835b6b67b60d">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3f7b2f0fe2cf41038946282cc39c3653_D20210102-20210402" decimals="-5" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfNzY5NjU4MTM5NzIzMQ_5e297723-80f5-4e24-a55f-7f545a0be5f0">0.4</ix:nonFraction>&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RleHRyZWdpb246YTc3YmIwMjk4MjFmNDhjOGFiMDljMTZiNmMwYmM2NWFfNzY_c410bcf2-7b3a-4e3f-918c-5c33ae28966f" continuedAt="i881dfc9a7abb42be8f7d478684fe7eb1" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i881dfc9a7abb42be8f7d478684fe7eb1"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RleHRyZWdpb246YTc3YmIwMjk4MjFmNDhjOGFiMDljMTZiNmMwYmM2NWFfODQ_31a83ab4-5ad7-48c0-a704-2bb428ef989a" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:64.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMS0xLTEtMS00ODcyOQ_a69762a8-48df-4bcc-b93a-0beb5080fa26">10,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMS0zLTEtMS00ODcyOQ_b2706a81-f1f6-4940-98fd-6429cae7cab5">8,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMi0xLTEtMS00ODcyOQ_11c15e10-cba8-4148-b60f-f6d14b16b1da">27,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMi0zLTEtMS00ODcyOQ_a006081a-d7e6-48a8-a318-f6397f060795">27,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMy0xLTEtMS00ODcyOQ_5e7de3b3-d764-496c-972a-185f4c8d9719">14,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMy0zLTEtMS00ODcyOQ_86e084cc-d3f4-455d-baf9-60374bcc16cc">12,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfNC0xLTEtMS00ODcyOQ_082412f0-b7ce-494d-bea7-fc04ea58e5bf">53,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfNC0zLTEtMS00ODcyOQ_e1039833-7287-4c65-a72a-f9392ba7d2d7">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia939647731704dcda59a54bb06e17828_I20220401" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfNy0xLTEtMS00ODcyOQ_742b20f8-dde5-4856-8412-b7c0ea256eb0">28,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b94af5f9c714b06876549ec2d63eef9_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfNy0zLTEtMS00ODcyOQ_936bd88f-0336-460e-8c89-aa0cbc6281ee">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6ac444fe974dedb4a9b7fe83af78ce_I20220401" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOC0xLTEtMS00ODcyOQ_e69d4dc0-6445-49f6-86bc-0fefde8e4e40">24,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a2837ce514e4359abcc29c595fb4d0c_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOC0zLTEtMS00ODcyOQ_842c8b95-6ca7-4792-96c9-7761aae602e7"><ix:nonFraction unitRef="usd" contextRef="i3a2837ce514e4359abcc29c595fb4d0c_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOC0zLTEtMS00ODcyOQ_ba12034c-761e-4cf3-84dc-760df55080cf">22,018</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOS0xLTEtMS00ODcyOQ_7eaaa341-e0c8-4a44-9668-be6c09691db7">53,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOS0zLTEtMS00ODcyOQ_dbd8a603-84e0-46bc-8b4b-c5e6f90eeca4">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8de248c3265649ac8d88b7bfb8f42ed9_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfMzg1Ng_e7e51f82-bcab-4171-bfb1-9ab6807219ad" continuedAt="idfb4d3feb435453abfbd82c4292d7b1f" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="idfb4d3feb435453abfbd82c4292d7b1f" continuedAt="i4fea2bf27b45463b8c7750bb69a8023d"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfMzgxOQ_d6d8545c-9437-494c-a5f2-83498607f3fb" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae08cfc122445338953c327341f7d67_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfMy0xLTEtMS00ODcyOQ_c3718395-685f-4b82-b257-954b1da90266">8,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0817dc61f16c4beb874045356c0ac962_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfMy0zLTEtMS00ODcyOQ_4e118eba-c375-45f1-a780-f6c09ee47394">12,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6664829ae3ae483fa02b63376c5628fa_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfNC0xLTEtMS00ODcyOQ_faf6b385-bbd1-4cda-aa30-cec0cb272a6f">10,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1a0fc30e914cd38e29d4ce13c7080f_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfNC0zLTEtMS00ODcyOQ_f1dd49fd-a933-4231-b70a-763e75657ecb">22,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfNS0xLTEtMS00ODcyOQ_05e6ca8c-41b9-45bb-a44e-a107885cef5a">19,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfNS0zLTEtMS00ODcyOQ_5cb43e31-c979-48ea-a878-953c0e3f2b81">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422c757fd8504d8d9bd061c6daee9c01_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfMi0xLTEtMS00ODcyOQ_eaf61bcc-2f84-458a-857d-ecdfb589f37f">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac399c1a21047abb423228840492006_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfMi0zLTEtMS00ODcyOQ_7a776354-ec53-42a8-8c50-e8301bae06b8">4,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4258bed58c6048f58584c4e2f94d0ee9_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfMy0xLTEtMS00ODcyOQ_84068630-e5f4-4c65-89e2-d9de33b3ef19">13,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c08f7404ff4eb485860a6fd51e4b73_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfMy0zLTEtMS00ODcyOQ_84b0614a-dc74-494e-9ee4-d01b72147939">11,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14bb8ff89fac4afabb3b6fe4dc3cf4e5_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNC0xLTEtMS00ODcyOQ_6c346e96-924e-4e28-bd0f-c611d57b36e1">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7ff6b6e16e434293d751847fe852e9_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNC0zLTEtMS00ODcyOQ_a65a2aa2-9843-4af4-a666-c9d956236845">17,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f50fb2bc0e46d39335240d888c8205_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNS0xLTEtMS00ODcyOQ_f3c62813-b054-4de4-9848-98c3a04e39b8">1,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02918e98774e5ab327c89a0477cfcc_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNS0zLTEtMS00ODcyOQ_0b5b2ebc-888b-42a6-9e02-9d5cffdef057">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNi0xLTEtMS00ODcyOQ_0405065d-d79c-4a35-9c39-df4225b6333a">19,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNi0zLTEtMS00ODcyOQ_5d0ce3f3-7e30-413c-9149-c3ca6514a0b7">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDQ3MA_ccbd68bf-331e-419b-842b-64e730237d82">4,152,901</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNDg3_922b4819-0f97-412a-818c-4b768939f65a">1</ix:nonFraction> share for each share issued pursuant to a stock option and <ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNTQ5_379e592e-dcbf-4523-a11d-3ce54edd7142">1.5</ix:nonFraction> shares for full value awards granted in the form of restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we granted <ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDQ4Mg_51f31b8c-6bbe-478a-8ecc-9ce6e74fbc54">233,476</ix:nonFraction> stock options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDUyMA_498cd965-0d61-4848-b0b9-6e029437a7b2">19.02</ix:nonFraction> per share and a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNTQ5NzU1ODE1NTI4OQ_3cdb0210-ba09-4513-879e-32b4d23cfe2d">7.51</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="shares" contextRef="ied00e348414944e896116d415bab3625_I20220401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDUwOA_bc5c5c3e-d799-4d0d-9bac-eeb515f63523">12,635,435</ix:nonFraction> stock options outstanding and $<ix:nonFraction unitRef="usd" contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDQ5Mg_3e1fc9a4-657e-4ed0-8b25-5b8e7d412c9e">24.8</ix:nonFraction>&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we awarded to certain employees an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia195c1f38ea54879b3d52bd17362ea4e_D20220301-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQwNzA2Mg_3669fc52-0e3a-4694-85e8-a99720e77523">1,003,482</ix:nonFraction> (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to <ix:nonFraction unitRef="number" contextRef="i3c24c63c06b046a89283ea6c11d9a730_D20220301-20220331" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQwNzA3NQ_51e86d78-1c8d-4ac3-b97d-834eb8dc86f4">175</ix:nonFraction>% of the target amount of shares. <ix:nonFraction unitRef="number" contextRef="i5757437e306d438b96edc7549e66fa17_D20220301-20220331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5MzI2Mw_0ead5d3e-462a-44ce-8d74-d8d4d18b34e6">50</ix:nonFraction>% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately <ix:nonNumeric contextRef="i5757437e306d438b96edc7549e66fa17_D20220301-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5MzI0MA_7564368d-1613-44b3-839c-ff0944012054">one year</ix:nonNumeric> later, subject to employee&#8217;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="i4fea2bf27b45463b8c7750bb69a8023d"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfMzgzNg_0c65eb49-40ff-4258-80ba-86273b59d867" continuedAt="i5ba39b9ac66a4f54acfc58f03419aa89" escape="true">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i277d7677672b42a28307cdefe84dc555_D20220101-20220401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDQ2MQ_3040a717-f9f1-4b3f-a445-38a1e542c3a4">33.17</ix:nonFraction> per share for the TSR-based RSUs:</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i5ba39b9ac66a4f54acfc58f03419aa89"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:90.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="if01316baae344a38a3c7cf53ddd5d7b4_I20220401" decimals="2" name="us-gaap:SharePrice" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmE4MzlhNDUzMWJkMjQ1NGJhOGRlM2EyMGZjODg1Y2JhL3RhYmxlcmFuZ2U6YTgzOWE0NTMxYmQyNDU0YmE4ZGUzYTIwZmM4ODVjYmFfMC0xLTEtMS00ODcyOQ_819f2fe6-fb64-42da-9e38-ab83226a59b8">20.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i277d7677672b42a28307cdefe84dc555_D20220101-20220401" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmE4MzlhNDUzMWJkMjQ1NGJhOGRlM2EyMGZjODg1Y2JhL3RhYmxlcmFuZ2U6YTgzOWE0NTMxYmQyNDU0YmE4ZGUzYTIwZmM4ODVjYmFfMS0xLTEtMS00ODcyOQ_5243be91-cf9a-472b-a600-7ffc7d3fe8cd">46.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i277d7677672b42a28307cdefe84dc555_D20220101-20220401" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmE4MzlhNDUzMWJkMjQ1NGJhOGRlM2EyMGZjODg1Y2JhL3RhYmxlcmFuZ2U6YTgzOWE0NTMxYmQyNDU0YmE4ZGUzYTIwZmM4ODVjYmFfMi0xLTEtMS00ODcyOQ_b0521528-4d4a-4343-816c-24755034123e">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i277d7677672b42a28307cdefe84dc555_D20220101-20220401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmE4MzlhNDUzMWJkMjQ1NGJhOGRlM2EyMGZjODg1Y2JhL3RhYmxlcmFuZ2U6YTgzOWE0NTMxYmQyNDU0YmE4ZGUzYTIwZmM4ODVjYmFfMy0xLTEtMS00ODcyOQ_2276e2c1-a999-41af-bbb1-f84db41c4e91">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we granted <ix:nonFraction unitRef="shares" contextRef="i4258bed58c6048f58584c4e2f94d0ee9_D20220101-20220401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5NjgzMQ_d7b5fa0c-183d-4e9a-89f0-b1f7b20c6504">3,549,973</ix:nonFraction> service-based RSUs with a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4258bed58c6048f58584c4e2f94d0ee9_D20220101-20220401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg0Mw_bdd20949-93c8-4ab4-b11d-f9a90c0df5bc">20.51</ix:nonFraction> per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="shares" contextRef="i5850614cec8549968a33dfef9671139c_I20220401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg1Mg_ca55d92d-6e1b-49ea-8b86-7e8842374ad4">11,635,329</ix:nonFraction> RSUs outstanding, including the TSR-based RSUs, and $<ix:nonFraction unitRef="usd" contextRef="i5850614cec8549968a33dfef9671139c_I20220401" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg2NQ_9780497c-0fec-4ed1-b759-6bd3b2f63630">209.6</ix:nonFraction>&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and service-based RSUs granted to employees during the three months ended March 31, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were&#160;<ix:nonFraction unitRef="shares" contextRef="i7b2c5399d43b4b588fd04c0afca7e0f6_I20220401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg4Mg_b480c3d1-f9ce-4b10-810f-15b2ba7a9024">5,698,281</ix:nonFraction> performance-based restricted stock units (PSUs) outstanding and $<ix:nonFraction unitRef="usd" contextRef="i7b2c5399d43b4b588fd04c0afca7e0f6_I20220401" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg5NA_b5ae1cac-d343-4f5c-8222-e9357b5b591b">116.0</ix:nonFraction>&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81NS9mcmFnOjNlNTMyMWQyZjA0NzQ4OTA4MzQ4YjhkNGJhZTY0YzVmL3RleHRyZWdpb246M2U1MzIxZDJmMDQ3NDg5MDgzNDhiOGQ0YmFlNjRjNWZfNzg1_7bd1a272-25f4-48fb-922d-6cdf0b51b189" continuedAt="ie322bfc4b3614e82abc2b29c64aa2396" escape="true">PROVISION FOR (BENEFIT FROM) INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie322bfc4b3614e82abc2b29c64aa2396">The effective tax rate for the three months ended March 31, 2022 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits, partially offset by state taxes. The effective rate for the three months ended March 31, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, in relation to the generation of a small pre-tax loss during the period.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RleHRyZWdpb246MDM5NTA2ZTM0M2U5NGI3YmFhN2RkMDk1MDdhMGE4MzBfNzU0_b1b5c9d7-1343-4b83-a054-23bfa3df41bc" continuedAt="i6bfcc2aaa62b445da4ff42f6a1be91e6" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i6bfcc2aaa62b445da4ff42f6a1be91e6" continuedAt="i0d2ceb9dc615463391615c67228d097c"><ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RleHRyZWdpb246MDM5NTA2ZTM0M2U5NGI3YmFhN2RkMDk1MDdhMGE4MzBfNzYw_227c5378-b87f-4f03-99f2-582e96310e29" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfMy0xLTEtMS00ODcyOQ_e6f12bd3-6737-4a26-84ba-ede00144975d">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfMy0zLTEtMS00ODcyOQ_bdfd9e7d-a56e-4eeb-941e-e7cf5aeddfce">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNS0xLTEtMS00ODcyOQ_adf748de-649b-493e-9e17-bee327546154">319,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNS0zLTEtMS00ODcyOQ_0b9bb511-1737-424d-90ba-74bd27a0b784">312,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNi0xLTEtMS00ODcyOQ_2015175b-9278-4701-b2e0-68e93057471b">3,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNi0zLTEtMS00ODcyOQ_dbc7fc62-cb1a-492f-bcd9-e3b3393b247d">8,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNy0xLTEtMS00ODcyOQ_548822e8-b00d-40e9-866a-373d68d2756f">323,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNy0zLTEtMS00ODcyOQ_a3e3f2e7-99d4-4b2f-b8c5-d0a99a1e18f6">321,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfOS0xLTEtMS00ODcyOQ_47c83310-40fc-4cd7-88ee-c57b9426d241">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfOS0zLTEtMS00ODcyOQ_934db787-9eb4-45f7-9ac3-b4f755e6cba0">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfMTAtMS0xLTEtNDg3Mjk_2c640796-78f4-4e43-8046-13f03bfb59c5">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfMTAtMy0xLTEtNDg3Mjk_8132283d-36a8-4ac6-b0ec-6f8bf5a2c55c">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="i0d2ceb9dc615463391615c67228d097c"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RleHRyZWdpb246MDM5NTA2ZTM0M2U5NGI3YmFhN2RkMDk1MDdhMGE4MzBfNzU4_4a3b5011-aa41-48fd-9e3f-011a32a16c6b" continuedAt="i36bc4ba3141643d4bb3ef3c10660dc86" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i36bc4ba3141643d4bb3ef3c10660dc86"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.419%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i086d58fc90a14a97898df45878c69671_D20220101-20220401" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOmRiOWFkNTA4ODhjOTRjY2M5NzJjOTU0NzgyNDdkNDVlL3RhYmxlcmFuZ2U6ZGI5YWQ1MDg4OGM5NGNjYzk3MmM5NTQ3ODI0N2Q0NWVfMi0xLTEtMS00ODcyOQ_0f0a388f-6ad7-4bc1-9f05-8274da756c5c">16,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic64a47c5e8ba4d3db3fd89a64b034421_D20210102-20210402" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOmRiOWFkNTA4ODhjOTRjY2M5NzJjOTU0NzgyNDdkNDVlL3RhYmxlcmFuZ2U6ZGI5YWQ1MDg4OGM5NGNjYzk3MmM5NTQ3ODI0N2Q0NWVfMi0zLTEtMS00ODcyOQ_009d9e1e-570e-4dee-b3b3-350903fec43b">10,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV82MS9mcmFnOjU5YjNkNzU1MWYzMzQzNWE4N2I1ZjVkYmM3OTcwMTY3L3RleHRyZWdpb246NTliM2Q3NTUxZjMzNDM1YTg3YjVmNWRiYzc5NzAxNjdfNjU2Mw_fff8124b-dc26-466b-b88b-f8901a01a94a" continuedAt="ia25972048657445cb16ec39f4cbf9895" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ia25972048657445cb16ec39f4cbf9895" continuedAt="i70cc8501db1d4d278a192b7061a69f26"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the upcoming trial will address two issues: (1) infringement of claims 1 and 2 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A three-day bench trial has been scheduled to begin on May 16, 2022.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><ix:continuation id="i70cc8501db1d4d278a192b7061a69f26"><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (salt and polymorphic forms), 11,091,440 (formulations) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. In the 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patents identified in the 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The 2022 MSN ANDA Complaint is a new case against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-02017 and 20-00633 described above. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. A bench trial in connection with the 2022 MSN ANDA Complaint has been scheduled for May 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Limited (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Parent), asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. On February 11, 2022, this case was administratively closed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_924"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODEzOTcyMTE_74b73096-05a9-483c-ae25-44d3331aa345" continuedAt="i625ac0920e084e448f108a6379dc2003" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i625ac0920e084e448f108a6379dc2003"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Build-to-Suit Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is approximately <ix:nonFraction unitRef="sqft" contextRef="id6c8e9889ae843dc8773c941eac343d0_I20220430" decimals="INF" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNDE_f250c052-bbc3-4d70-9c19-4d3214053370">220,000</ix:nonFraction> square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is <ix:nonNumeric contextRef="id6c8e9889ae843dc8773c941eac343d0_I20220430" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNTA_19e75030-557a-4b1e-bf5d-05425b0ddc49">242</ix:nonNumeric> months, includes <ix:nonFraction unitRef="segment" contextRef="i8602446ff3b94e92b5b78b0fb780866b_D20220402-20220430" decimals="INF" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNjE_2c9a6826-cf0e-4d0b-b6a8-f7b11c180cae">two</ix:nonFraction> <ix:nonNumeric contextRef="id6c8e9889ae843dc8773c941eac343d0_I20220430" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNjY_ff13a25e-65f0-4430-8ce5-91dcac27f068">five-year</ix:nonNumeric> options to extend the term of the lease and a one-time option to terminate the lease after <ix:nonNumeric contextRef="i8602446ff3b94e92b5b78b0fb780866b_D20220402-20220430" name="exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNTU_83ccb3cb-dd76-4bd2-9b41-55bb47736ab2">180</ix:nonNumeric> months. In addition to the lease payments, we are also responsible for paying operating expenses related to the New Premises. For more information about our Build-to-Suit Lease, see &#8220;Note 11. Commitments and Contingencies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> filed with the Securities and Exchange Commission (SEC) on February&#160;18, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 61 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc., a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo, Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs. So far, these drug discovery and preclinical activities have resulted in four clinical-stage compounds: XL092, a next-generation oral tyrosine kinase inhibitor (TKI); XB002, an antibody drug conjugate (ADC) that targets tissue factor (TF); XL102, a potent, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7); and XL114, a n</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ovel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) complex</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Franchise</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA first approved CABOMETYX as a monotherapy for previously treated patients with advanced RCC in April 2016, and then for previously untreated patients with advanced RCC in December 2017. In January 2021, the CABOMETYX label was expanded to include first-line advanced RCC in combination with OPDIVO, which was the first CABOMETYX regimen approved for treatment in combination with an immune checkpoint inhibitor (ICI). In addition to RCC, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC previously treated with sorafenib, and then in September 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen and Takeda. We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU), the United Kingdom (U.K.) and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, followed by additional regulatory approvals for the combination in other territories beyond the EU. Most recently, in May 2022, we announced that Ipsen received regulatory approval from the EC for CABOMETYX as a monotherapy for the treatment of adult patients with locally advanced or metastatic, RAI-refractory or ineligible DTC and who have progressed during or after prior systemic therapy. With respect to the Japanese market, Takeda received Manufacturing and Marketing Approvals in 2020 from the Japanese Ministry of Health, Labour and Welfare (MHLW) of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. In August 2021, Takeda and Ono Pharmaceutical Co., Ltd. (Ono), BMS&#8217; development and commercialization partner in Japan, received Manufacturing and Marketing Approval from the Japanese MHLW of CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could potentially benefit from this medicine. We continue to evaluate cabozantinib, both as a single agent and in combination with ICIs, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple tumor types. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. The data from these third-party clinical trials have helped advance our development program for the cabozantinib franchise by informing subsequent label-enabling trials, including COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib in previously treated patients with RAI-refractory DTC, from which positive results served as the basis for the FDA&#8217;s and EC&#8217;s approvals of CABOMETYX for DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on preclinical and clinical observations that cabozantinib in combination with ICIs may promote a more immune-permissive tumor environment, we initiated numerous pivotal studies to further explore these combination regimens. The first of these studies to deliver results was CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of CABOMETYX and OPDIVO compared to sunitinib in previously untreated, advanced or metastatic RCC, and positive results from CheckMate -9ER served as the basis for the FDA&#8217;s, EC&#8217;s and MHLW&#8217;s approvals of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021, March 2021 and August 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. Enrollment for COSMIC-313 was completed in March 2021, and we expect to report top-line results of the event-driven analyses from the trial in July 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our exploration of combinations with ICIs, we also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd.&#8217;s (Roche) ICI, atezolizumab, beginning in 2017 with COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with a wide variety of locally advanced or metastatic solid tumors. The data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, and three phase 3 pivotal trials in collaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC) and advanced RCC, respectively. CONTACT-01 and CONTACT-03 are sponsored by Roche and co-funded by us, and we announced the completion of enrollment for the two trials in November 2021 and January 2022, respectively, with interim results from both trials expected in the second half of 2022; CONTACT-02 is sponsored by us and co-funded by Roche, with enrollment ongoing globally. In June 2021, we </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">announced that the COSMIC-312 phase 3 trial met one of the primary endpoints, demonstrating significant improvement in blinded independent radiology committee (BIRC) assessed PFS at the planned primary analysis, reducing the risk of disease progression or death by 37% compared with sorafenib. However, the final analysis for the second primary endpoint of overall survival (OS), which we announced in March 2022, showed neither improvement nor detriment in OS for cabozantinib in combination with atezolizumab versus sorafenib. Based on this outcome for OS and the rapidly evolving treatment landscape for previously untreated HCC, we do not intend to submit a supplemental New Drug Application (sNDA) to the FDA for the combination regimen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6 million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases. The first compound to enter the clinic following our re-initiation of drug discovery activities in 2017 was XL092, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining a similar target profile while improving key characteristics, including the pharmacokinetic half-life. To date, we have initiated two large phase 1b clinical trials studying XL092: STELLAR-001 and STELLAR-002. STELLAR-001 is a phase 1b clinical trial evaluating XL092, both as a monotherapy and in combination with either atezolizumab or avelumab, an ICI developed by Merck KGaA Damstadt, Germany and Pfizer Inc. We have established recommended doses for single-agent XL092 and XL092 in combination with atezolizumab and have begun enrolling expansion cohorts for patients with clear cell RCC, hormone-receptor positive breast cancer and mCRPC, and we are continuing to enroll patients into dose-escalation cohorts for XL092 in combination with avelumab; additional expansion cohorts for STELLAR-001 may include non-clear cell RCC, colorectal cancer (CRC) and urothelial carcinoma (UC). STELLAR-002 is a phase 1b clinical trial evaluating XL092 in combination with either nivolumab or with nivolumab and ipilimumab. An amendment is also underway to remove the previously included triplet combination of XL092, nivolumab and Nektar Therapeutics&#8217; bempegaldesleukin; we are also negotiating with a partner to replace that combination regimen with a different XL092 triplet combination regimen. We are enrolling patients with advanced solid tumors in dose-escalation cohorts, and depending on the dose-escalation results, STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC and UC. To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include XL092 as a single-agent in addition to the ICI combination regimens. We plan to initiate the first global phase 3 pivotal trial for the compound in the second quarter of 2022, and other phase 3 pivotal trials may follow throughout the year. This first planned global phase 3 pivotal trial, STELLAR-303, will evaluate XL092 in combination with atezolizumab versus regorafenib in patients with metastatic non-microsatellite instability-high CRC who have progressed after or are intolerant to the current standard of care. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies. The most advanced compounds to emerge from these arrangements are XL102 , the lead program targeting CDK7 under our collaboration with Aurigene Discovery Technologies Limited (Aurigene), and XL114, Aurigene&#8217;s novel anti-cancer compound that inhibits the CBM complex. Based on encouraging preclinical data, we exercised our exclusive options to license XL102 and XL114 from Aurigene and initiated phase 1 clinical trials evaluating XL102 and XL114 in January 2021 and April 2022, respectively, and we expect to provide clinical updates from the phase study of XL102 in the second half of 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond small molecules, we have also launched rigorous efforts to discover and advance various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues, and this biotherapeutic approach has been validated by multiple regulatory approvals for the commercial sale of ADCs in the past several years. To facilitate the growth of these programs, we have established multiple research collaborations and in-licensing arrangements and entered into other strategic transactions that provide us with access to antibodies or other binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or multispecific antibodies. We have already made significant progress under these arrangements and believe we will continue to do so in the remainder of 2022 and in future years: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Iconic.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We in-licensed XB002, our lead TF-targeting ADC program, from Iconic, Inc. (Iconic) in December 2020 and then initiated a phase 1 clinical trial in June 2021. We expect to provide clinical updates from the trial in the second half of 2022. In December 2021, we amended our exclusive option and license agreement with Iconic to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">WuXi Bio.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We expanded our access to antibodies through arrangements with WuXi Biologics Ireland Limited, a wholly owned subsidiary of WuXi Biologics (Cayman) Inc. (individually and collectively referred to as WuXi Bio). We are focused on leveraging WuXi Bio&#8217;s panel of monoclonal antibodies (mAbs) against an undisclosed target for the development of ADC, bispecific and certain other novel tumor-targeting biotherapeutics. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">GamaMabs. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed an asset purchase from GamaMabs Pharma SA (GamaMabs) in May 2022. In the transaction, we acquired all rights, title and interest in GamaMabs&#8217; antibody program directed at </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anti-M&#252;llerian hormone receptor 2 (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMHR2), a novel oncology target with relevance in multiple forms of cancer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Invenra</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expanded our collaboration with Invenra, Inc. (Invenra) several times since our first engagement in 2018, most recently in August 2021 to include an additional 20 oncology targets. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">NBE and Catalent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into collaborations with NBE-Therapeutics AG (NBE) and Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc. (individually and collectively referred to as Catalent) in September 2020. These platform collaborations allow us to utilize their site-specific conjugation technologies and payloads to construct ADCs using the antibodies we have sourced from our arrangements with WuXi Bio, GamaMabs and Invenra. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Adagene</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into a collaboration with Adagene Inc. (Adagene) in February 2021, focused on using Adagene&#8217;s SAFEbody&#174; technology to develop novel masked ADCs or other innovative biotherapeutics, with the potential to develop ADCs or other biotherapeutics with improved therapeutic index. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of these arrangements, we designated XB010, our first ADC advanced internally, as a development candidate in late 2021. XB010, which targets the tumor antigen 5T4, incorporates antibodies sourced from Invenra and was constructed using Catalent&#8217;s SMARTag&#174; site-specific bioconjugation platform.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report, we are currently advancing more than 10 discovery programs and expect to progress up to five new development candidates into preclinical development during 2022. In addition, we will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, the COVID-19 pandemic continues to have a modest impact on our business operations. While the pandemic has created operational difficulties and complexities, we have thus far been successful at devising solutions to mitigate its impact. We will continue to monitor new developments that could pose additional risks for us, including the spread of the Omicron and other SARS-CoV-2 variants in the U.S. and other countries and the potential emergence of new variants that may prove especially contagious or virulent. Despite our mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business, which are described in more detail in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. We recognize that this pandemic will continue to present unique challenges for us throughout 2022, and potentially into 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2022 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, we appointed Vicki L. Goodman, M.D., as Executive Vice President, Product Development &amp; Medical Affairs, and Chief Medical Officer. Dr. Goodman had previously served as Vice President, Clinical Research and Therapeutic Area Head, Late Stage Oncology at Merck &amp; Co.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, we announced the completion of enrollment for CONTACT-03, a phase 3 pivotal trial evaluating the efficacy and safety of cabozantinib in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic RCC who progressed during or following treatment with an ICI as the immediate preceding therapy. Based on current event rates, we anticipate announcing results of PFS and the first interim OS analysis in the second half of 2022. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, we announced an amendment to our exclusive option and license agreement with Iconic to acquire broad rights to use the anti-TF antibody incorporated into XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, we presented encouraging data from two early-stage studies evaluating cabozantinib in combination with ICIs in patients with previously treated CRC at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium: cohort 16 from COSMIC-021, evaluating cabozantinib in combination with atezolizumab in patients with metastatic CRC who were previously treated with fluoropyrimidine-containing chemotherapy; and cohort 2 from CAMILLA, the phase 2 IST evaluating cabozantinib in combination with durvalumab in patients with advanced mismatch repair proficient/micro satellite stable CRC patients who were chemotherapy-refractory. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, cabozantinib was the subject of multiple data presentations in forms of RCC and other genitourinary cancers at the 2022 ASCO Genitourinary Cancers Symposium.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022 , we filed a patent lawsuit in the United States District Court for the District of Delaware (the Delaware District Court) against MSN Pharmaceuticals, Inc. (MSN) asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#8217;s further amendment of its Abbreviated New Drug Application (ANDA), originally filed with the FDA in September 2019 for a generic version of CABOMETYX tablets and first amended by MSN in May 2020. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of the patents referenced in our lawsuit, the latest of which expires on January 15, 2030. This is a new case against MSN involving Exelixis patents that are different from those asserted previously in consolidated patent lawsuits that we filed in 2019 and 2020. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e announced results from the final OS analysis of COSMIC-312 trial, which showed neither improvement nor detriment in OS for cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced HCC. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this outcome for OS and the rapidly evolving treatment landscape for previously untreated HCC, we do not intend to submit an sNDA to the FDA for the combination regimen.In April 2022, we announced the initiation of a phase 1 clinical trial evaluating XL114 as a monotherapy in patients with non-Hodgkin&#8217;s Lymphoma (NHL).</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In May 2022, we announced that Ipsen received regulatory approvals from the EC and Health Canada for CABOMETYX as a monotherapy for patients with previously treated, RAI-refractory DTC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2022, cabozantinib will be the subject of multiple data presentations in NSCLC, UC, RCC, head and neck squamous cell carcinoma, and DTC at the 2022 ASCO Annual Meeting.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net product revenues for the first quarter of 2022 were $310.3 million, compared to $227.2 million for the first quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Total revenues for the first quarter of 2022 were $356.0 million, compared to $270.2 million for the first quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Research and development expenses for the first quarter of 2022, were $156.7 million, compared to $159.3 million for the first quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Selling, general and administrative expenses for the first quarter of 2022 were $102.9 million, compared to $102.4 million for the first quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Provision for (benefit from) income taxes for the first quarter of 2022 was $16.7 million, compared to $(3.6) million for the first quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net income for the first quarter of 2022 was $68.6 million, or $0.21 per share, basic and diluted, compared to net income of $1.6 million, or $0.01 per share, basic and $0.00 per share, diluted, for the first quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook, Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to face a number of challenges and risks that may impact our ability to execute on our 2022 business objectives. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at expanding access to, and restricting the prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our 2022 business objectives will also depend on our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy for the treatment of cancer, which we may not be able to do. While we have had success in adapting our development strategy for the cabozantinib franchise and other product candidates to address the competitive landscape, including through evaluation of therapies that combine ICIs with other targeted agents, it is uncertain whether current and future clinical trials will lead to regulatory approvals, or whether physicians will prescribe regimens containing our products instead of competing product combinations in approved indications. Moreover, the complexities of this development strategy have required and are likely to continue to require collaboration with some of our competitors. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN and Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva), and the approval of either MSN&#8217;s or Teva&#8217;s ANDA could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, and others are common to companies in the biopharmaceutical industry with development and commercial operations. For a more detailed discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Convention</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the three months ended April 1, 2022 and April 2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the three months ended March 31, 2022 and March 31, 2021, and the year ending December 31, 2022, respectively.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net product revenues for the three months ended March 31, 2022, as compared to the corresponding prior year period, was primarily related to a 33% increase in the number of units sold following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021, in part due to the longer duration of therapy for this combination and, to a lesser extent, a 2% increase in the average net selling price of CABOMETYX.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our net product revenues for the remainder of 2022 may increase, as compared to the corresponding prior year period, for similar reasons noted above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in discounts and allowances for the three months ended March 31, 2022,as compared to the corresponding prior year period, was primarily from higher utilization by covered entities in the 340B Drug Pricing Program, an increase in Medicaid utilization and an increase in co-pay assistance for commercially insured patients. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and allowances as a percentage of gross revenues have increased over time as the number of patients participating in government programs has increased and as the discounts given and rebates paid to government payers also increased. We project this trend will continue and that our discounts and allowances as a percentage of gross revenues may increase during the remainder of 2022, as compared to the corresponding prior year period.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues generally include: (a) the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur; (b) royalty revenues; and (c) the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues increased primarily as a result of increases in Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $24.6 million for the three months ended March 31, 2022 compared to $22.5 million for the corresponding prior year period. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, primarily due to regulatory approval in new territories, including regulatory approval in the EU for the combination therapy of CABOMETYX and OPDIVO received in March 2021. Royalty revenues for the three months ended March 31, 2022 also included $2.4 million, compared to $1.3 million for the corresponding prior year period, related to Takeda&#8217;s net sales of CABOMETYX which have continued to grow since their first commercial sale of product in Japan in 2020. Additionally, Takeda royalty revenues have increased due to the August 2021 regulatory approval in Japan for the combination therapy of CABOMETYX and OPDIVO. As of March 31, 2022, CABOMETYX is approved and is commercially available in 61 countries outside the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $2.1 million for the three months ended March 31, 2022, as compared to $1.8 million for the corresponding prior year period. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of $1.6 million for the three months ended March 31, 2022, compared to $1.0 million for the corresponding prior year period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and milestones can vary significantly from period to period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, and product supply revenues, which are net of product supply costs and the royalties we pay on sales by Ipsen and Takeda of products containing cabozantinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $17.3 million for the three months ended March 31, 2022, compared to $18.3 million for the corresponding prior year period. The decrease in development cost reimbursements for the three months ended March 31, 2022, as compared to the corresponding prior year period, is primarily attributable to a decrease in spending on the COSMIC-312 and COSMIC-021 studies, partially offset by an increase in spending on CONTACT-02 and development cost reimbursements related to Ipsen&#8217;s decision to opt in and co-fund COSMIC-311 development costs in the second quarter of 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $3.8 million for the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib for the three months ended March 31, 2022, compared to $3.3 million for the corresponding prior year period. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may decrease for the remainder of 2022, as compared to the corresponding prior year period, primarily as a result of decreased development cost reimbursements related to Ipsen&#8217;s opt in and co-funding of COSMIC-311 and the related cumulative catch-up in development cost reimbursements recognized in 2021 for which no similar event is projected to occur in 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring, excess and obsolete inventory, and other third-party logistics costs. Cost of goods sold for the three months ended March 31, 2022, as compared to the corresponding prior year period was consistent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in r</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oyalties as a result of increased U.S. CABOMETYX sales was offset by lower period costs. We project our gross margin will not change significantly during the remainder of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds and biologics such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.970%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes upfront license fees, development milestone payments, program initiation fees, and research funding commitments associated with programs in preclinical development stage</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the allocation of general corporate costs to research and development services, and development cost reimbursements in connection with our collaboration arrangement with Roche executed in December 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he decrease in research </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development expenses for the three months ended March 31, 2022, as compared to the corresponding prior year period, was primarily related to decreases in license and other collaboration costs, stock-based compensation and clinical trial costs, which were partially offset by increases in personnel expenses, other drug discovery and other research and development costs. License and other collaboration costs decreased as compared to the corresponding prior year period primarily due to decreases in upfront license fees and program initiation fees related to business development activities. Stock-based compensation expense decreased as compared to the corresponding prior year period due primarily to higher expense related to performance-based restricted stock units (PSUs) granted in 2019 that became probable of achievement in the first quarter of 2021. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, decreased as compared to the corresponding prior year period primarily due to lower costs associated with the COSMIC-312, COSMIC-313, and COSMIC-021 studies which were partially offset by increases in costs associated with XL092, CONTACT-02, XB002 and CONTACT-03 studies. Personnel expenses increased primarily due to an increase in headcount to support our expanding discovery and development organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing a significant amount of our development efforts on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a substantial portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable ongoing company-sponsored studies resulting from this program include: COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge and CONTACT-02 for which Roche is sharing the development costs and providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. In this regard, we conduct drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. In addition, we will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may increase for the remainder of 2022, as compared to the corresponding prior year period, primarily driven by our ongoing clinical evaluation of cabozantinib, the initiation of new clinical trials and expansion of ongoing clinical trials evaluating other product candidates in our pipeline, including current early-stage trials evaluating XL092, XB002, XL102 and XL114 and anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of the risks and uncertainties with respect to our research and development activities and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the three months ended March 31, 2022, as compared to the corresponding prior year period, remained relatively constant as increases in personnel expenses and marketing costs were </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offset by a decrease in stock-based compensation expense. Personnel expenses increased as compared to the corresponding prior year period, primarily due to increases in administrative headcount to support our commercial and research and development organizations. Marketing costs increased as compared to the corresponding prior year period in support of the commercialization of</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the combination therapy of CABOMETYX and OPDIVO for the treatment of advanced RCC following approval by the FDA in January 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in stock-based compensation expense for the three months ended March 31, 2022, as compared to the corresponding prior year period was primarily due to higher compensation expense associated with the PSUs granted in 2019 that became probable of achievement in the first quarter of 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may continue to increase for the remainder of 2022 as compared to the corresponding prior year period primarily driven by our continuing commercial investment in CABOMETYX and the growth of the broader organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in non-operating income for the three months ended March 31, 2022, as compared to the corresponding prior year period was primarily the result of a decrease in interest income due to lower interest rates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for (Benefit From) Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,616)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits, partially offset by state taxes. We recorded a benefit from income taxes for the three months ended March 31, 2021 as a result of the reported pre-tax loss. The effective tax rate for the three months ended March 31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, in relation to the generation of a small pre-tax loss during the period.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had $2.0 billion in cash, cash equivalents, restricted cash equivalents and investments, compared to $1.9 billion as of December&#160;31, 2021. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary cash requirements for operating activities, which we project will increase for the remainder of 2022, compared to the corresponding period in 2021, are for: employee related expenditures; costs related to our development programs including payments to third party contract research organizations that conduct and manage global clinical trials; drug discovery programs, including payments made to collaboration partners for in-licensing arrangements relative to upfront and option exercise fees, research and development funding, and development, regulatory and commercial milestones; income tax payments, royalty payments on our net product sales; and costs of inventory and our leased facilities. Our primary source of operating cash is cash collections from customers related to net product sales which we project will increase for the remainder of 2022 compared to the corresponding period in 2021 and cash collections from our commercial collaboration arrangements with Ipsen, Takeda and others related to royalties earned, the achievement of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain development, regulatory and commercial milestones as well as cash payments to us for cost reimbursements under certain of our development programs. The timing of cash generated from commercial collaborations and cash payments required for in-licensing collaborations relative to upfront payments, initiation fees, milestone payments and cost reimbursements may vary from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have cash requirements related to capital expenditures to support the planned growth of our business including investments in laboratory facilities and equipment. We project that we may continue to spend significant amounts of cash to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, and regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity based on market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $14.0&#160;million and $16.7&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a standby letter of credit as guarantee of our obligation to fund our portion of the tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and presented in other long-term assets in our Condensed Consolidated Balance Sheets and will be reduced as we fund our portion of the tenant improvements. As of March&#160;31, 2022, restricted cash equivalents included $12.5 million of short-term investments as collateral under our standby letter of credit for our portion of the tenant improvements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,553,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash equivalents, and investments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working capital</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The increase in working capital as of March&#160;31, 2022, as compared to December&#160;31, 2021, was primarily due to the favorable impacts to our net current assets resulting from our net income during the first quarter of 2022 and the reclassification of certain investments from long-term to short term assets. In the future, our working capital may be impacted by one or both of these factors or other factors, the amounts and timing of which are variable.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents primarily consist of cash deposits held at major banks, commercial paper and other securities with original maturities 90 days or less. Restricted cash equivalents and investments relate to our letter of credit agreements and are invested in short-term marketable securities. For additional information regarding our cash, cash equivalents, restricted cash equivalents and investments, see &#8220;Note 4. Cash and Investments,&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item 1 of this Quarterly Report on Form 10-Q. The increase in cash, cash equivalents, restricted cash equivalent and investments at March&#160;31, 2022 compared to December&#160;31, 2021, was primarily due to cash inflows generated by our operations, including collections of amounts due from customers, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collection of a $100.0 million milestone payment from Ipsen, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by operating cash payments for employee related expenditures, our development and discovery programs, and capital expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary source of operating cash flows is cash collections from customers related to our net product sales and cash collections from our commercial collaboration arrangements. Our primary uses of cash from operating activities are for employee related costs, costs related to our development and discovery programs, income tax payments, cash payments for inventory, royalty payments on our net product sales, and our leased facilities.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities is derived by adjusting our net income for non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the three months ended March 31, 2022, increased as compared to the corresponding prior year period, primarily due to an increase in cash received on sales of our products and from our commercial collaboration arrangements, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including collection of a $100.0 million milestone payment from Ipsen</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which was partially offset by an increase in cash paid for certain operating expenses resulting in net favorable changes in operating assets and liabilities.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from investing activities primarily relates to the timing of marketable securities investment activity and capital expenditures. Our capital expenditures primarily consist of investments to expand our operations and acquire assets that further our research and development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash was used in investing activities for the three months ended March 31, 2022 compared to net cash provided by investing activities in the corresponding prior year period. The increase in cash used in investing activities was primarily due to a decrease in cash proceeds from maturities and sales of investments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an increase in purchase of investments which was partially offset by a decrease in </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital expenditures.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from financing activities primarily relate to proceeds from employee stock programs and taxes paid related to net share settlement of equity awards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash was provided by financing activities for the three months ended March 31, 2021, compared to net cash used in financing activities in the corresponding prior year period. The increase in cash provided by financing activities was due to an increase in proceeds received from the issuance of common stock under our equity incentive plans, and lower withholding taxes remitted to the government related to net share settlements of equity awards.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations as of March&#160;31, 2022 from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021. In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is approximately 220,000 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the lease payments, we are also responsible for paying operating expenses related to the New Premises. For more information about our Build-to-Suit Lease, and our other contractual obligations see &#8220;Note 11. Commitments and contingencies&#8221; of the &#8220;Notes to Consolidated Financial Statements included Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_76"></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market and/or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three months ended March 31, 2022, compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_79"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of March&#160;31, 2022 have not changed significantly from those described in Item&#160;7A of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_82"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the effectiveness of controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_85"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_88"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the upcoming trial will address two issues: (1) infringement of claims 1 and 2 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A three-day bench trial has been scheduled to begin on May 16, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (salt and polymorphic forms), 11,091,440 (formulations) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. In the 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patents identified in the 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The 2022 MSN ANDA Complaint is a new case against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-02017 and 20-00633 described above. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. A bench trial in connection with the 2022 MSN ANDA Complaint has been scheduled for May 2023.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Limited (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Parent), asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. On February 11, 2022, this case was administratively closed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Parent, asserting infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. The stipulation and order were filed under seal.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_91"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Pricing for pharmaceutical products, both in the U.S. and in foreign countries, has come under increasing attention and scrutiny by federal, state and foreign national governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce the barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks. For example, we rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Data breaches, cyber attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional indications for CABOMETYX and increase the number of cancer patients who could potentially benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the number of labeled indications for which CABOMETYX is approved, or if we or our collaboration partners fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX depends upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, foreign and U.S. government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could be impacted by numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of patients in its approved indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is competitive and characterized by constant technological change and diverse offerings of products, particularly in the area of oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biopharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. While we have had success in adapting our development strategy for the cabozantinib franchise to address the competitive landscape, including through evaluation of therapies that combine ICIs with other targeted agents, it is uncertain whether current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in NSCLC and mCRPC, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations in approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving our commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biopharmaceutical companies seeking to build out and maintain their commercial organizations, as well as larger biopharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, or should we have to revert back to primarily telephonic and virtual interactions in lieu of in-person meetings with healthcare professionals for an extended period of time as a result of the COVID-19 pandemic, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including foreign and U.S. governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting, or alternatively for patients who rely on our co-pay assistance program, implement co-pay accumulators or maximizers that exempt such co-pay assistance from patient deductibles, which has increased and could further increase the costs of our co-pay assistance program or cause patients to abandon CABOMETYX or COMETRIQ therapy due to higher out-of-pocket costs. If third-party payers do not provide or increase limitations on coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations may suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended (PPACA), some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. Although such efforts have not significantly impacted our business to date, it is possible that the PPACA will be subject to additional judicial or legislative challenges in the future, which may have a material adverse impact on our business, financial condition and results of operations, and we </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannot predict how future healthcare reform measures of the Biden Administration and federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products. Furthermore, the expansion of the 340B Drug Pricing Program through the PPACA (the 340B Program) has increased the number of purchasers who are eligible for significant discounts on branded drugs, including our marketed products. Because we participate in the 340B Program to sell a portion of our marketed products, changes in the administration of the program could have a material adverse impact on our revenues, including the implementation of the program&#8217;s Administrative Dispute Resolution Process, which is in part intended to resolve claims by covered entities that manufacturers have overcharged them for covered outpatient drugs. A federal court has preliminarily enjoined the 340B Administrative Dispute Resolution Process with respect to the plaintiff manufacturer in that specific challenge, and other legal challenges are ongoing. The Office of Management and Budget initiated review of a new proposed rule titled &#8220;340B Drug Pricing Program; Administrative Dispute Resolution&#8221; in November 2021. In addition, there is ongoing litigation regarding the legality of contract pharmacy arrangements under the 340B Program, which may affect the way in which manufacturers are required to extend discounts to covered entities through contract pharmacies. Due to general uncertainty with respect to this litigation and in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we may engage may be unable to adapt to any changes implemented as a result of such measures, and we may have difficulties in sustaining profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. This may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying drug prices to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits; implement additional data collection and transparency reporting regarding drug pricing, rebates, fees and other remuneration provided by drug manufacturers; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid; eliminate the Anti-Kickback Statute (AKS) discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and revise the rebate methodology under the Medicaid Drug Rebate Program. For instance, President Biden issued an executive order in July 2021 supporting legislation to enact some of these drug pricing reforms, and in response, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices in September 2021 with specific legislative and administrative policies that Congress could enact to help improve affordability of and access to prescription drugs. While we cannot know the final form or timing of any such legislative, regulatory and/or administrative measures, some of the pending and enacted legislative proposals or executive rulemaking if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partners Ipsen and Takeda may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, cost-control initiatives, increasingly based on affordability and accessibility, as well as post-marketing assessments of the added value of CABOMETYX and COMETRIQ as compared to existing treatments, could influence the prices paid for and net revenues we realize from CABOMETYX and COMETRIQ, or the indications for which we are able to obtain reimbursement, which would result in lower license revenues to us. Upcoming legislative and policy changes in the EU are aimed at increasing cooperation between the EU Member States. Such initiatives, particularly the Regulation on Health Technology Assessment adopted in December 2021, may further impact the price and reimbursement status of CABOMETYX and COMETRIQ in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug and Cosmetic Act (FDCA), the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a New Drug Application (NDA) under section 505(b)(2) of the FDCA that relies in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Both the ANDA and 505(b)(2) NDA processes are discussed in more detail in &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8212;Abbreviated FDA Approval Pathways and Generic Products&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In either case, if an ANDA or 505(b)(2) NDA applicant submits an application referencing one of our marketed products prior to the expiry of one or more our Orange Book-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs, divert the attention of management, and could have an adverse impact on our stock price. For example, MSN and Teva have separately submitted ANDAs to the FDA requesting approval to market their respective generic versions of CABOMETYX tablets, and we have subsequently filed patent lawsuits against both companies. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q. It is possible that MSN, Teva or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic or otherwise competitor versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib would likely decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. There are also equivalent procedures in the EU permitting authorization of generic versions and biosimilars of medicinal products authorized in the EU once related data and market exclusivity periods have expired.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. Both Congress and the FDA are considering, and have enacted, various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Ensuring Innovation Act, enacted in April 2021, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amended the FDA&#8217;s statutory authority for granting new chemical entity (NCE) exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, purports to promote competition in the market for drugs and biotherapeutic products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biotherapeutic products, including by allowing ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biotherapeutic product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and the Civil Monetary Penalties Law;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, as amended; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Open Payments program of the PPACA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion, and also impact our current and future business arrangements with third parties, including various healthcare entities. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight through a Corporate Integrity Agreement or other monitoring agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation or investigation and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer patient assistance programs and donations to patient assistance foundations created by charitable organizations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The HHS Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. Moreover, in December 2020, the Centers for Medicare and Medicaid Services finalized changes to Medicaid Drug Rebate Program pricing calculations regarding the provision of co-payment assistance to patients that may be impacted by private insurer accumulator programs. Although this rule is subject to litigation, if sustained, the rule could affect the amount of rebates owed under the Medicaid program or otherwise limit our ability to support our patient co-pay assistance program. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities. Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve in the U.S. and other jurisdictions around the world. For example, the California Consumer Privacy Act of 2018 (CCPA) went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections will be expanded by the California Privacy Rights Act (CPRA), which will be operational in most key respects on January 1, 2023. Similar legislative proposals have passed or are being advanced in other states, and Congress is also considering additional federal privacy legislation. In addition, most healthcare professionals and facilities are subject to privacy and security requirements under HIPAA with respect to our clinical and commercial activities. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, in the EU, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also places restrictions on transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, CPRA and GDPR, we could be subject to sanctions or other penalties, litigation, an increase in our cost of doing business and questions concerning the validity of our data processing activities, including clinical trials.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of a product candidate or of an approved product for a new indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib in new indications or of new product candidates. These events may include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to identify and maintain a sufficient number of clinical trial sites; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additional complexities posed by clinical trials evaluating cabozantinib or our other product candidates in combination with other therapies, including extended timelines to provide for collaboration on clinical development planning, the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">reduced staffing or shortages in laboratory supplies and other resources necessary to complete the trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, variations, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing Russo-Ukrainian War could have a modest impact on our clinical development operations, particularly with respect to patient recruitment, potentially delaying our ability to complete enrollment in a timely manner. In addition, this conflict has had and may continue to have an adverse impact on the ability of clinical sites and their patients to adhere to trial protocols for in-office clinical visits and other procedures, our ability to supply clinical sites with cabozantinib or other study drugs and to pay clinical sites and investigators for work performed, as well as our ability to collect data and conduct site monitoring visits, all of which could undermine the data quality for patients enrolled at these clinical sites. The need to shift enrollment of patients away from these clinical sites, or potentially to replace a significant number of patients in affected territories should investigators be unable to continue treating and monitoring them, could further impact our anticipated timelines for completing the trials and achieving clinical endpoints. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of the cabozantinib franchise or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or otherwise may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: the characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable regulatory authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to comparable regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates. For example, the FDA launched Project Optimus in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval, and the FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates. Recently, in part due to questions raised by the process underlying the approval of the Alzheimer&#8217;s disease drug Aduhelm</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government authorities and other stakeholders have been scrutinizing the accelerated approval pathway, with some stakeholders advocating for reforms. Even prior to the Aduhelm approval, FDA has held Oncologic Drugs Advisory Committee meetings to discuss accelerated approvals for which confirmatory trials have not verified clinical benefit. Such scrutiny, among other factors, has resulted in voluntary withdrawals of certain products and indications approved on an accelerated basis. Moreover, also spurred by the Aduhelm controversy, the HHS Office of Inspector General has initiated an assessment of how the FDA implements the accelerated approval pathway. In addition, members of Congress have introduced proposed legislation to revise the statutory accelerated approval pathway, including with respect to the FDA&#8217;s ability to rapidly withdraw products and indications for which effectiveness is not confirmed in post-marketing studies. At this time, it is not clear what impact, if any, these developments may have on the statutory accelerated approval pathway or our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-marketing studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in that indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders governing FDA or foreign regulatory approval processes that may be enacted or executed could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates and technologies. However, the in-licensing and acquisition of product candidates and technologies is a highly competitive area, and many other companies are pursuing the same or similar product candidates and technologies to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional product candidates and technologies on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates and technologies, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products and technologies will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target company, or retain key personnel of the acquired business. Furthermore, we could assume unknown or contingent liabilities or otherwise incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters and Capital Requirements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $68.6 million for the three months ended March 31, 2022 and $231.1 million for the fiscal year ended December&#160;31, 2021, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our achievement of development, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive drug discovery, clinical development and business development activities, both for the cabozantinib franchise and our earlier-stage product candidates, as well as our general business expansion plans. Our expected future expenses in particular may also be increased by inflationary pressures, whether resulting from the effects of the ongoing Russo-Ukrainian War or the COVID-19 pandemic or otherwise, which could increase the costs of outside services, labor, raw materials and finished drug product. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of the cabozantinib franchise and our earlier-stage product candidates, and increasing drug discovery activities, as well as through the execution of business development transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing economic conditions and financial, business and other factors beyond our control. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their sales of CABOMETYX in their respective territories outside of the U.S., could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or other factors. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biopharmaceutical companies for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligence or other insufficient performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial, or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to comply with legal and regulatory requirements relevant to the authorization, marketing, distribution and supply of our marketed products in the territories outside the U.S. where they are approved; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our research and in-licensing partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">laws, regulations or practices imposed by countries outside the U.S. that could impact or inhibit scientific research or the development of healthcare products by foreign competitors or otherwise disadvantage healthcare products made by foreign competitors, as well as general political or economic instability in those countries, any of which could complicate, interfere with or impede our relationships with our ex-U.S. research, development and in-licensing partners; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to Good Manufacturing Practice and Good Laboratory Practice.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government, third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib beyond currently approved indications or obtain regulatory approval for our other product candidates. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to help advance our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities for chemistry, manufacturing and control development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements. Although we have not yet experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic or the ongoing Russo-Ukrainian War, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to facility closures and other hardships as a result of these types of global events, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA). If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by increased demand for such services from other companies or by other external factors, such as reduced capacity to perform services, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any future data breach and/or unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN and Teva concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets. Should MSN, Teva or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. They may also be negatively impacted by the decisions of foreign courts, which could limit the protection contemplated by the original regulatory approval and our ability to thwart the development of competing products that might otherwise have been determined to infringe our intellectual property rights. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in the EU, have compulsory licensing laws based on related EU rules, under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the Russian Federation has and may further limit protections on patents originating from &#8220;unfriendly countries&#8221; (including the U.S.) in response to sanctions relating to the ongoing Russo-Ukrainian War, and in general, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We also rely on trade secret protection for some of our confidential and proprietary information, and we are taking security measures to protect our proprietary information and trade secrets, particularly in light of recent instances of data loss and misappropriation of intellectual property in the biopharmaceutical industry. However, these measures may not provide adequate protection, and while we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, as well as maintain cybersecurity protocols within our information technology infrastructure, we cannot provide assurance that our proprietary information will not be disclosed, or that we can </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that they used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular with respect to our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. As the COVID-19 pandemic continues to have a significant presence in various parts of the world, particularly with the spread of the Omicron and other SARS-CoV-2 variants and the potential emergence of new variants that may prove especially contagious or virulent, the impact on our clinical development operations could continue or grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites, including staffing and materials shortages and the implementation of crisis management initiatives, have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could further delay some of our clinical trial plans or may require certain trials to be temporarily suspended. In addition, increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in conducting those clinical trials to increase considerably. Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in planning and conducting new clinical trials of the investigative product candidates entering and advancing through our development pipeline, which could increase the operating expenses associated with these trials and adversely affect their timelines for completion and ultimately our ability to obtain regulatory approvals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both drug discovery work in our laboratories and outsourced drug discovery activities have fully resumed following temporary suspensions during the early days of the COVID-19 pandemic; however, we may be unable to maximize the potential of these programs due to the imposition of increased safety protocols, and should the effects of the COVID-19 pandemic become more severe, we may have to again scale back or suspend activities in the future. We are also reliant on laboratory materials manufactured and distributed from areas impacted by both the COVID-19 pandemic and other natural </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disasters, for which supply has become limited. If we are unable to obtain the requisite materials to conduct our planned drug discovery activities, we may be required to redirect the focus of, or even suspend, such activities. Should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These continuing or future effects of the COVID-19 pandemic could materially and adversely affect our business, financial condition, results of operations and growth prospects, and exacerbate the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to expand the cabozantinib franchise into new indications and grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We continue to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as a result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials. Such liability may exceed our insurance coverage and our total assets, and in addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of FDA or other regulatory approval or non-approval, or delays in the FDA or other regulatory review process with respect to cabozantinib, our collaboration partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise or any of our other programs or product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other strategic transactions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of regulatory applications, such as MSN&#8217;s and Teva&#8217;s respective ANDAs, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">developments in the biopharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, policies governing foreign trade and healthcare spending and delivery, or the ongoing Russo-Ukrainian War, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been initiated. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_94"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_97"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_100"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_103"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_106"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000076/exel20210526ex31restatedce.htm">Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000028/exhibit31amendedandrestate.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210331exhibit10110q.htm">Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210331exhibit10210q.htm">Second Amendment dated May 7, 2019, to Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20220331exhibit31110q.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210331exhibit31210q.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20220331exhibit32110q.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i8de248c3265649ac8d88b7bfb8f42ed9_109"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Table of </a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8de248c3265649ac8d88b7bfb8f42ed9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:5pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher J. Senner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exel20210331exhibit10110q.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3447274f374e4c4db08d115ec9278751_1"></div><div style="min-height:125.28pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1 </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">This Collaboration and License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of January 30, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Takeda Pharmaceutical Company Limited, a Japanese corporation with principal offices located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Exelixis and Collaborator may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis, a biopharmaceutical company, is developing its proprietary compound known as cabozantinib for the treatment of cancer, and owns or controls certain patents, know-how, and other intellectual property relating to such compound&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaborator, a pharmaceutical company, possesses substantial resources and expertise in the development and commercialization of pharmaceutical products&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Collaborator and Exelixis desire to form a collaboration for the continued development and commercialization of cabozantinib, under which Exelixis will continue to have primary responsibility for the conduct of the global development program for cabozantinib, with Collaborator providing input and support&#59; and Exelixis desires to obtain Collaborator&#8217;s specific Japanese clinical development expertise in order for Exelixis and Collaborator to collaborate and pursue such development in Japan as the Parties agree&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Collaborator desires to obtain the exclusive rights to develop and commercialize cabozantinib in Japan and to have primary responsibility for the commercialization of cabozantinib in Japan&#59; and, Exelixis desires to manufacture and supply cabozantinib for Collaborator&#8217;s development and commercialization activities in Japan&#59; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties wish to establish such collaboration, all on the terms and conditions set forth below.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Exelixis and Collaborator hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Definitions</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means, subject to the final sentence of this paragraph, with respect to any party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such party, but for only so long as such control exists.  As used in this Section&#160;1.1, &#8220;control&#8221; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance&#59; or (b) direct or indirect </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.  For the avoidance of any doubt, neither &#91; * &#93; nor &#91; * &#93; shall constitute an Affiliate of Collaborator.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means cabozantinib, having the chemical structure set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the applicable provisions of any and all national, supranational, regional, state, and local laws, treaties, statutes, rules, regulations, administrative codes, guidance (including cGCP, cGLP and cGMP), ordinances, judgments, decrees, directives, orders, permits (including MAAs) of or from any court, Regulatory Authority, or governmental agency or authority having competent jurisdiction over or related to the subject item.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Monday through Friday of each week, except that a legal holiday recognized as such by the federal government of the United States and&#47;or a national holiday in Japan shall not be regarded as a Business Day.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each respective period of three (3) consecutive months ending on March&#160;31, June&#160;30, September&#160;30, and December&#160;31.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each respective period of twelve (12) consecutive months ending on December 31.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, Phase 4 Clinical Trial or Expanded Access Program as the context dictates.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">cGCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the current clinical practice as set out in (i) ICH Harmonized Guidance on current Good Clinical Practice (CPMP&#47;ICH&#47;135&#47;95), (ii) US Code of Federal Regulations, Title 21, Chapters 50, 54, 56, 58, 210, 211 and 312, as may be amended from time to time, or (iii) the equivalent law or regulation in any other applicable jurisdiction in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">cGLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S.), as they may be updated from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the current standards for systems to assure the proper design, monitoring, and control of processes and facilities to be used for the manufacture, processing, packing, or holding of a drug as specified by applicable laws of the relevant countries at the time of manufacturing conducted in accordance with this Agreement, defined under (i) 21 C.F.R. Part 210 and 211 or (ii) equivalent law or regulations in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Know-How that Collaborator or its Affiliate Controls as of the Effective Date or during the Term, including any Joint Inventions, that is used in the research, Development, manufacture, use, importation, offer for sale, sale or  Commercialization of any Compound or Product in the Field.  The Collaborator Know-How includes the Collaborator Data.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Patents that Collaborator or its Affiliate Controls as of the Effective Date or during the Term (including any Joint Patents) that would be infringed, absent a license or other right to practice granted under such Patents, by the research, Development, manufacture, use, importation, offer for sale, sale or Commercialization of any Compound or Product in the Field (considering patent applications to be issued with the then-pending claims and considering Joint Patents as if owned solely by Collaborator or its Affiliate).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Collaborator Know-How and the Collaborator Patents, including Collaborator&#8217;s interest in the Joint Inventions and Joint Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Japan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the conduct of all activities undertaken before and after Regulatory Approval relating to the promotion, sales, marketing, medical support, and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling, and delivering Products to customers) of Products in the Field in or outside of the Collaborator Territory, including sales force efforts, detailing, advertising, market research, market access (including list price and reimbursement activities), medical education and information services, publication, scientific and Medical Affairs&#59; advisory and collaborative activities with opinion leaders and professional societies including symposia, marketing, sales force training, and sales (including receiving, accepting, and filling Product orders) and distribution.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; have correlative meanings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party and its obligations under this Agreement, those commercially reasonable efforts and resources consistent with the usual practices of a similarly situated company for the development and commercialization of a pharmaceutical product originating from its own research and development department, which is at a similar stage of research, development, or commercialization, taking into account that product&#8217;s profile of efficacy and safety&#59; proprietary position, including patent and regulatory exclusivity&#59; regulatory status, including anticipated or approved labeling and anticipated or approved post-approval requirements&#59; present and future market and commercial potential, including competitive market conditions, and all other relevant factors, including technical, legal, business, scientific, and&#47;or medical factors.  Commercially Reasonable Efforts requires that a Party&#58; (i) promptly assign responsibility for each contractual obligation to specific employee(s) who are held accountable for progress and monitor such progress on an ongoing basis, (ii) set and seek to achieve specific and meaningful objectives for carrying out such obligation, and (iii) make and implement decisions and allocate resources designed to advance progress with respect to such objectives.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the JEC, JDC, JCC or any subcommittee established by the JEC, as applicable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any product or compound, other than the Compound and Products&#58; (a) for which the mechanism of action includes modulation of the kinase activities of cMET and&#47;or VEGFR2, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) which directly binds and modulates the activity of&#58; (i) VEGFR2 and&#47;or (ii) cMET, &#91; * &#93;.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competitive Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the diagnosis, treatment, or prevention of cancer indications other than&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#91; * &#93;&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#91; * &#93;&#59; provided, however, that (i) if and when &#91; * &#93;, and &#91; * &#93;&#59; and (ii) if &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means API in a form approved by the applicable Regulatory Authority in a particular jurisdiction for use in connection with the Development or Commercialization of the Product in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Confidential Disclosure Agreement between Exelixis and Collaborator dated as of &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Know-How and other proprietary scientific, marketing, financial, or commercial information or data that is generated by or on behalf of a Party or its Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs, or formulae in relation to this Agreement&#59; provided that all Exelixis Technology will be deemed Exelixis&#8217; Confidential Information, all Collaborator Technology will be deemed Collaborator&#8217;s Confidential Information, and all Joint Inventions and Joint Patents will be deemed both Parties&#8217; Confidential Information.  Confidential Information shall include&#58; (a) the terms and conditions of this Agreement, and (b) Confidential Information disclosed by either Party pursuant to the Confidentiality Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Know-How, Patents, or other intellectual property rights, the legal authority or right (whether by ownership, license, or otherwise but without taking into account any rights granted by one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license, or a sublicense of or under such Know-How, Patents, or other intellectual property rights to another Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost of Goods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the fully burdened cost to manufacture Compound or Drug Product, as applicable, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Supplied Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which means&#58; (a)&#160;&#91; * &#93;&#59; and (b)&#160;in the case of &#91; * &#93;.  Actual unit costs shall consist of &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all scientific, technical, test, marketing, or sales data pertaining to any API, Compound and&#47;or Product that is generated by or on behalf of Exelixis, Collaborator, their respective Affiliates, and, to the extent Controlled by a Party, Exelixis&#8217; other licensee(s) and Collaborator&#8217;s Sublicensees, including research data, clinical pharmacology data, pre-clinical data, CMC data, clinical data, clinical study reports, or submissions made in association with an IND or MAA with respect to any API, Compound and&#47;or Product. </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all development activities for the Compound and Product (whether alone or for use together, or in combination, with another active agent or pharmaceutical product as a combination product or combination therapy) that are directed to obtaining Regulatory Approval(s) of the Product and&#47;or lifecycle management of the Product in any country in the world, including all non-clinical, preclinical, and clinical testing and studies of the Product&#59; toxicology, pharmacokinetic, and pharmacological studies&#59; statistical analyses&#59; assay development&#59; protocol design and development&#59; the preparation, filing, and prosecution of any MAA for the Product&#59; development activities directed to label expansion and&#47;or obtaining Regulatory Approval for one or more additional indications following initial Regulatory Approval&#59; development activities conducted after receipt of Regulatory Approval, including Phase 4 Clinical Trials and Expanded Access Program&#59; and all regulatory affairs related to any of the foregoing.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; have correlative meanings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the costs incurred by a Party or for its account, during the Term and pursuant to this Agreement, that are specifically directed (or reasonably allocable) to the Development of a Product.  The Development Costs shall include amounts that a Party pays to Third Parties involved in the Development of a Product (at cost, and excluding any Third Party Royalties), and all internal costs (calculated on an FTE basis at the then-current FTE Rate) and reasonable out-of-pocket costs incurred by or on account of a Party in performing Development work in accordance with the GDP.  Development Costs shall also include &#91; * &#93;.  For clarity, &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Drug Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, for a given Product, packaged and unlabeled product comprising the Compound in its final dosage form for such Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; the Chief Executive Officer of Exelixis and the Chief Executive Officer of Collaborator (or his&#47;her designated person).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Know-How that Exelixis or its Affiliate Controls as of the Effective Date or during the Term, including any Joint Inventions, that is&#160;necessary or reasonably useful for the Development, use, importation, offer for sale, or sale of any Compound or Product in the Field in or for the Collaborator Territory.  The Exelixis Know-How includes the Exelixis Data.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Patents in the Collaborator Territory that Exelixis or its Affiliate Controls as of the Effective Date or during the Term (including any Joint Patents) that would be infringed, absent a license or other right to practice granted under such Patents, by the Development, use, importation, offer for sale, sale or Commercialization of any Compound or Product in the Field in the Collaborator Territory (considering patent applications to be issued with the then-pending claims and considering Joint Patents as if owned solely by Exelixis).  The Exelixis Patents existing as of the Effective Date are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit 1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> which shall be periodically, at least annually, updated by Exelixis or its counsel).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Exelixis Know-How and the Exelixis Patents, including Exelixis&#8217; interest in the Joint Inventions and Joint Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means worldwide, excluding the Collaborator Territory (i.e., Japan).</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Expanded Access Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the administration of the Product to named individuals who do not meet the clinical trial enrollment criteria either outside of a clinical trial or after the completion of a clinical trial.  Expanded Access Programs are also known as named patient programs, named patient supply, and temporary authorization for use (including patient request treatment pursuant to Article 63-2(4) of Japanese Act on Health Insurance).  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Export Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all applicable U.S. laws and regulations relating to (a) sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the Export Administration Act of 1979, 24 U.S.C. &#167;&#167; 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. &#167;&#167; 1701-1706, the Trading with the Enemy Act, 50 U.S.C. &#167;&#167; 1 et. seq., the Arms Export Control Act, 22 U.S.C. &#167;&#167; 2778 and 2779, and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.), as amended.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Food and Drug Administration or its successor.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all indications and uses in humans and animals, including, but not limited to, RCC and HCC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finished Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the manufacture of Finished Product from Compound or Drug Product, as the case may be.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Finished Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a given Product, (i) the applicable Compound or Drug Product, as the case may be, packaged and labeled for Development or Commercialization purposes, as applicable, in accordance with the applicable Specifications and legal requirements in the Collaborator Territory, or (ii) the Compound or Drug Product, as the case may be, along with its appropriate packaging and labeling in such other configuration as may be agreed upon by the Parties and set forth in the applicable Supply Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on a Product-by-Product basis, the first commercial sale by Collaborator or any of its Affiliates or Sublicensees to a Third Party for end use of such Product in the Collaborator Territory after Regulatory Approval has been granted with respect to such Product in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the equivalent of a full-time individual&#8217;s work for a twelve (12) month period (consisting of a total of &#91; * &#93; hours per year of dedicated effort).  Any person who devotes more or less than &#91; * &#93; hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, based upon the actual number of hours worked by such person on such activities, divided by &#91; * &#93;.  For the avoidance of any doubt, the hours spent by Exelixis temporary workers and contractors on applicable activities and the hours allocated to the work of general corporate or administrative personnel shall not be incorporated into FTE.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to Exelixis&#8217; personnel, an initial rate of &#91; * &#93; U.S. Dollars ($&#91; * &#93;) per FTE per year, which rate shall apply through December 31, 2017.  </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thereafter, the FTE Rate for Exelixis&#8217; personnel shall be changed annually on a Calendar Year basis to reflect any year-to-year percentage increase or decrease (as the case may be) in the Consumer Price Index for All Urban Consumers for the U.S., as published by the U.S. Department of Labor, Bureau of Labor Statistics (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  With respect to Collaborator&#8217;s personnel, &#8220;FTE Rate&#8221; means a reasonable rate in Japanese yen reasonably determined by Collaborator based on Collaborator&#8217;s actual, fully-burdened costs for Collaborative Work on a case-by-case basis, provided that Collaborator shall provide Exelixis with supporting documentation for each such determination.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Generic Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product, any pharmaceutical product that (a) contains the same API as such Product&#59; and (b) is approved by the Regulatory Authority in such regulatory jurisdiction as a substitutable generic for such Product (for an indication for which such Product obtained Regulatory Approval from the applicable Regulatory Authority in such jurisdiction) on an expedited or abbreviated basis based on bioequivalence or interchangeability with the Product under Article 14-4.1 of Pharmaceuticals and Medical Device Act or equivalent laws or regulations in any other jurisdiction in the Exelixis Territory. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any national, international, federal, state, provincial, or local government, or political subdivision thereof, or any multinational organization or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means hepatocellular carcinoma.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the International Conference on Harmonization (of Technical Requirements for Registration of Pharmaceuticals for Human Use).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an investigational new drug application or equivalent application filed with the applicable Regulatory Authority, which application is required to commence human clinical trials in the applicable country.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Clinical Trial, the first dosing of the first human subject in such Clinical Trial.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all inventions, whether or not patentable, discovered, made, conceived, or reduced to practice, in the course of activities contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all technical information, know-how, and data, including inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, compositions of matter, cells, cell lines, assays, animal models and other physical, biological, or chemical materials, expertise and other technology applicable to, development, registration, use, or marketing or to methods of assaying or testing them, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, and analytical, safety, nonclinical, and clinical data, regulatory documents, data and filings, instructions, processes, formulae, expertise and information, relevant to the research, development, use, importation, offering for sale or sale of, or which may be useful in studying, testing, or developing Products in </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Field.  Know-How excludes Patents and manufacturing know-how of the Compound or Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a marketing authorization application or equivalent application, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in the Collaborator Territory.  For clarity, MAA does not include any application for Pricing and Reimbursement Approval.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means approval of an MAA by the applicable Regulatory Authority for marketing and sale of a Product in the Collaborator Territory, but excluding any Pricing and Reimbursement Approval.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Medical Affairs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means activities designed to ensure or improve appropriate medical use of, conduct medical education of, or further research regarding, the Product, including by way of example&#58;  (a) activities of medical scientific liaisons who, among their other functions, may&#58; (i) conduct service-based medical activities including providing input and assistance with consultancy meetings, proposing investigators for clinical trials sponsored or co-sponsored by a Party or Affiliate, and providing input in the design of such trials and other research related activities&#59; and&#47;or (ii) deliver non-promotional communications and conduct non-promotional activities&#59; (b) grants to support continuing medical education, symposia, or Third Party research related to the Product&#59; (c) development, publication, and dissemination of publications relating to the Products&#59; (d) medical information services provided in response to inquiries communicated via sales representatives or received by letter, phone call, or email&#59; (e) conducting advisory board meetings, international advisory board activities or other consultant programs, including the engagement of key opinion leaders and health care professional in individual or group advisory and consulting arrangements&#59; and (f) conducting company-sponsored studies (CSS) and post-marketing surveillance trials or the evaluation of area of permissible scientific and medical inquiry (including, the evaluation of applications submitted to Collaborator for support of off-label or on-label investigator-initiated trials or studies).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MHLW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Japan&#8217;s Ministry of Health, Labour and Welfare, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Product, the gross amounts invoiced for sales or other dispositions of such Product by or on behalf of Collaborator and its Affiliates and Sublicensees to Third Parties in the Collaborator Territory, less the following deductions to the extent included in the gross invoiced sales price for such Product or otherwise directly paid or incurred by Collaborator or its Affiliates or Sublicensees, as applicable, with respect to the sale or other disposition of such Product&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">normal and customary trade and quantity discounts actually allowed and properly taken directly with respect to sales of such Product (provided that such discounts are not applied disproportionately to such Product when compared to the other products of Collaborator or its Affiliate or Sublicensee, as applicable)&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">credits or allowances given or made for rejection or return of previously sold Products or for retroactive price reductions and billing errors&#59;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">rebates and chargeback payments granted to managed health care organizations, pharmacy benefit managers (or equivalents thereof), national, state&#47;provincial, local, and other governments, their agencies and purchasers and reimbursers, or to trade customers&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">costs of freight, carrier insurance, and other transportation charges directly related to the distribution of such Product&#59; and&#47;or</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">taxes, duties or other governmental charges (including any tax such as a value added or similar tax, other than any taxes based on income, and annual contributions paid pursuant to the Japanese Act on Pharmaceuticals and Medical Devises Agency) directly levied on or measured by the billing amount for such Product, as adjusted for rebates and refunds. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon any sale or other disposition of any Product that should be included within Net Sales for any consideration other than exclusively monetary consideration on bona fide arms&#8217;-length terms, then for purposes of calculating Net Sales under this Agreement, such Product shall be deemed to be sold exclusively for money at the average sales price of the relevant Product in arm&#8217;s-length transactions during the applicable reporting period generally achieved for such Product in the Collaborator Territory when such Product is sold alone and not with other products (average sales price to be measured as the aggregate Product Net Sales divided by the aggregate number of units sold in the Collaborator Territory).</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In no event will any particular amount identified above be deducted more than once in calculating Net Sales.  Sales of a Product between Collaborator and its Affiliates or Sublicensees for resale shall be excluded from the computation of Net Sales, but the subsequent resale of such Product to a Third Party shall be included within the computation of Net Sales.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The supply of Product as samples, for use in non-clinical or clinical trials&#47;studies, or for use in any test or studies reasonably necessary to comply with any applicable laws, rules, or regulations or as is otherwise normal and customary in the industry (including for use in Phase 4 Clinical Trial, Expanded Access Program or any other Medical Affairs Activities) shall not be included in the computation of Net Sales, so long as Collaborator, its Affiliates, and Sublicensees do not receive payment for such Product in excess of the Cost of Goods of such Product.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) all patents, certificates of invention, applications for certificates of invention, priority patent filings, and patent applications, and (b) any renewals, divisions, continuations (in whole or in part), or requests for continued examination of any of such patents, certificates of invention and patent applications, and any all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, supplementary protection certificates, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase 1 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a clinical trial in any country conducted in a small number of human volunteers designed or intended to establish an initial safety profile, pharmacodynamics, or pharmacokinetics of a Product.  For clarity, a Phase 1 Clinical Trial may include studies conducted in oncology patients.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase 2 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a clinical trial of a Product in human patients in any country to determine initial efficacy and safety and dose range finding.  A Phase 2 Clinical Trial is typically conducted before embarking on a Phase 3 Clinical Trial, but may be registrational.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase 3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a pivotal clinical trial of a Product in human patients in any country with a defined dose or a set of defined doses of a Product designed to ascertain efficacy and safety of such Product for the purpose of submitting a MAA to the competent Regulatory Authorities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase 4 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a product support clinical trial of a Product that is commenced after receipt of MAA Approval in the country where such trial is conducted.  Phase 4 Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies and post-marketing surveillance trials.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PMDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Japan&#8217;s Pharmaceuticals and Medical Devices Agency, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product, the approval, agreement, determination, or decision of any Governmental Authority establishing the list price or level of reimbursement for such Product, as required in a given country or jurisdiction prior to sale of such Product in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical product containing the Compound as an active ingredient, in any form, presentations, dosage, or formulation.  For purposes of this Agreement, all formulations of single-agent Product containing the Compound shall be considered the same Product, and all formulations of combination products, if any, containing the same set of active agents shall be considered the same Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Public Official or Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) any officer, employee (including physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital, or (b) any candidate for political office, any political party or any official of a political party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means renal cell carcinoma.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all approvals (including MAA Approval, and Pricing and Reimbursement Approval), licenses, registrations, permits, notifications, and authorizations (or waivers) of any Regulatory Authority that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of a Product in any country or jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products in a given jurisdiction, including the FDA and </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MHLW, or any successor agency of the foregoing having regulatory jurisdiction over the manufacture, distribution, and sale of drugs in the Collaborator Territory, and any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Product other than patents, including, without limitation, rights conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity), or rights similar thereto in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications, and authorizations (or waivers) with respect to the testing, Development, manufacture, or Commercialization of any Product made to or received from any Regulatory Authority in a given country, including any INDs and MAAs.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Safety Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means Data related solely to any adverse drug experiences and serious adverse drug experience as such information is reportable to Regulatory Authorities.  Safety Data also includes &#8220;adverse events&#8221;, &#8220;adverse drug reactions&#8221;, and &#8220;unexpected adverse drug reactions&#8221; as defined in the ICH Harmonised Tripartite Guideline for Clinical Safety Data Management&#58; Definitions and Standards for Expedited Reporting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Supplied Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.24.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities and Exchange Commission, or any successor entity or its foreign equivalent in the Collaborator Territory, as applicable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Specifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all the attributes, acceptance criteria, tests, analytical methods, and&#47;or limits, and the results thereof, as applicable, for which the raw materials, bulk active, intermediates, or process of making the Drug Product must conform to in order for the Drug Product or Finished Product, as the case may be, to be acceptable for clinical use or commercial use, as applicable, as may be modified as set forth in this Agreement or the applicable Supply Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Party that takes the ultimate responsibility for the initiation, performance and management of, including financing or arranging the financing for, the appropriate Clinical Trial.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Third Party to whom Collaborator grants a sublicense to Develop, use, import, promote, offer for sale, sell or otherwise Commercialize any Product in the Field in the Collaborator Territory, beyond the mere right to purchase Products from Collaborator and its Affiliates, and excluding wholesalers, full-service distributors that do not promote the sale of the Product, and other similar physical distributors.  In no event shall Exelixis or any of its Affiliates be deemed a Sublicensee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any entity other than Exelixis or Collaborator or an Affiliate of Exelixis or Collaborator.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tier 1 Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91; * &#93;.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tier 2 Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the United States of America, including its territories and possessions (including Puerto Rico).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) a claim of an issued and unexpired patent that has not been revoked or held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal, and that has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or (b) a claim of a pending patent application that has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken and that has not been pending for more than &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Additional Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The following table identifies the location of definitions set forth in various Sections of the Agreement&#58; </font></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Defined Terms</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acquisition Transaction</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.8(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alliance Manager</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.7</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Allowable Increases</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Auditor</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Beneficial Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Budget Cap</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5(a)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Claim</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaborative Work</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaborator Data</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaborator Indemnitee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaborator Local Development Work</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commercialization Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Competing Program</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compound Invention</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1(b)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Development Budget</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Developing Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Disputed Matter</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Divest</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis Data</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis Entity</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.8(a)(i)(1)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis Indemnitee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis Local Development Work</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5(c)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Full Calendar Year</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3(b)</font></td></tr></table></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Generic Entry</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Global Development Plan or GDP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnitee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnitor</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent Work</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent Work Cost</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Injunctive Relief</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.3(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Joint Commercialization Committee or JCC </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Joint Development Committee or JDC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Joint Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Committee or JEC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Joint Inventions</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1(b)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Joint Patents</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1(b)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Local Regulatory Requirement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.5(b)(i)(2)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Losses</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Materials</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.14</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Minimum Commercial Performance</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3(b)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Minimum Commercial Performance Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3(b)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Newly-Proposed Development</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Developing Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PV Costs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pharmacovigilance Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Previously Achieved Sales Milestone</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product Infringement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.4(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product Marks</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.8(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Promotional Materials</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Proposal</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Quality Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recall</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.9</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulatory Meeting</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Remaining Royalty Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5(d)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Responding Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4(a)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalty Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rules</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.3(a)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sole Inventions</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1(b)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standstill Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.8(a)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Submitting Party</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4(a)</font></td></tr></table></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sunshine Reporting Laws</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Supply Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Supply Contacts</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.8</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unaffiliated Third Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8(a)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Withholding Tax Action</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3(c)</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Grant of Licenses</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Licenses Granted to Collaborator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, Exelixis hereby grants to Collaborator, during the Term&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">an exclusive (even as to Exelixis, except as expressly set forth in Section 2.3), royalty-bearing license, with the right to grant sublicenses solely as provided in Section 2.2, under the Exelixis Technology to use, sell, offer for sale, import, and otherwise Commercialize (but not to make or have made) the Products in the Field and in the Collaborator Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">to the extent Exelixis supplies to Collaborator Compound or Drug Product and not Finished Product, an exclusive (even as to Exelixis), royalty-bearing license, with the right to grant sublicenses as provided in Section 2.2, under the Exelixis Technology to conduct or have conducted Finished Manufacture in the Collaborator Territory for use in the Development and Commercialization of the Products in the Field in the Collaborator Territory&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">a co-exclusive license, together solely with Exelixis and its other licensee(s) of the Product, with the right to grant sublicenses solely as provided in Section 2.2, under the Exelixis Technology to Develop (but not to make or have made) the Products in the Collaborator Territory under the GDP, and to use the Products for that purpose.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Sublicensees&#47;Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall not have the right to grant sublicenses under the licenses granted in Section 2.1 without Exelixis&#8217; express prior written consent.  All sublicenses granted under the licenses granted in Section 2.1 with Exelixis&#8217; consent shall be expressed in writing and shall be subject to, and consistent with, the terms and conditions of this Agreement and shall provide that any such Sublicensee (for clarity, excluding any wholesale distributor) shall not further sublicense except with the consent of Collaborator and Exelixis.  Collaborator shall ensure that each agreement with a Sublicensee grants Exelixis all rights with respect to Data, Inventions, and Regulatory Filings made or generated by such Sublicensee as if such Data, Inventions, and Regulatory Filings were made or generated by Collaborator.  Collaborator shall be responsible for the compliance of its Affiliates involved in the Development or Commercialization of the Compound and Products and Sublicensees (for clarity, excluding any wholesale distributor) and subcontractors with the terms and conditions of this Agreement.  Within &#91; * &#93; after execution, Collaborator shall provide Exelixis with a copy of each agreement granting a sublicense under the license granted in Section 2.1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise set forth in this Agreement, Collaborator may contract with any of its Affiliates or Third Party contractors (e.g., contract research organization, contract sales organization, contract manufacturing organization, or regulatory agent) to conduct any of its activities contemplated </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereunder without the prior written consent of Exelixis&#59; provided, however, that Collaborator shall impose on each such contractor the same obligations that Collaborator undertakes hereunder and Collaborator shall remain responsible to Exelixis for the performance of such obligations by each such contractor.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Reserved Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, Exelixis hereby expressly reserves&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the right under the Exelixis Technology to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more licensees or subcontractors, including the right to Develop the Compound and Products in the Collaborator Territory under the GDP&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">subject to Section 2.8, all rights to practice, and to grant licenses under, the Exelixis Technology outside of the scope of the licenses granted in Section 2.1, including the exclusive right to make and have made the Compound and Products anywhere in the world, and the exclusive rights to practice the Exelixis Patents and Exelixis Know-How with respect to compounds and products other than Compound and Products.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Licenses Granted to Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, Collaborator hereby grants to Exelixis, during the Term&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">an exclusive (even as to Collaborator), royalty-free, fully-paid, and irrevocable license, with the right to sublicense through multiple tiers, under the Collaborator Technology to use, sell, offer for sale, import, and otherwise Commercialize the Products in the Field in the Exelixis Territory as long as such Collaborator Technology is those actually applied and&#47;or used in the Product Developed or Commercialized by Collaborator&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">a co-exclusive (with Collaborator), royalty-free, fully-paid, and irrevocable license, with the right to grant sublicenses through multiple tiers, under the Collaborator Technology to Develop the Compound and Products on a worldwide basis under the GDP as long as such Collaborator Technology is those actually applied and&#47;or used in the Product Developed or Commercialized by Collaborator&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">an exclusive (even as to Collaborator), royalty-free, fully-paid, and irrevocable license, with the right to sublicense through multiple tiers, under the Collaborator Technology to make and have made the Compound and Products anywhere in the world as long as such Collaborator Technology is those actually applied and&#47;or used in the Product Developed or Commercialized by Collaborator.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of any doubt, a scope of the license under the Collaborator Technology granted to Exelixis under this Section 2.4 shall be limited only to each purpose of license explicitly provided in the above (a) through (c), and Collaborator may reserve the rights to use or grant a license under the Collaborator Technology freely for outside of such scope of Exelixis&#8217; exclusive license set forth above. For the avoidance of any doubt, any such use by Collaborator of the Collaborator Technology outside of the scope of Exelixis&#8217; exclusive license set forth above shall be subject to the conditions under Section 2.8 (Exclusivity).</font></div><div><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">No Implied Licenses&#59; Negative Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How, or other intellectual property owned or controlled by the other Party.  Neither Party shall, nor shall it permit any of its Affiliates or sublicensees to, practice any Patents or Know-How licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement.  Without limitation of the foregoing, each Party acknowledges the restrictions on its activities set forth in Section 4.13 and Collaborator agrees that such activities are outside the scope of the licenses granted to it herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Disclosure of Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For as long as the Parties are conducting Development activities under the GDP, Exelixis shall, without additional compensation, disclose and make available to Collaborator, in electronic form where possible, all Exelixis Know-How that comes into existence after the Effective Date and that was not previously provided to Collaborator, promptly after the development, making, conception, or reduction to practice of such Exelixis Know-How.  For as long as the Parties are conducting Development activities under the GDP, Collaborator shall and shall cause its Affiliates to, without additional compensation, disclose and make available to Exelixis, in electronic form where possible, any Collaborator Know-How not previously provided to Exelixis, and promptly after the earlier of the development, making, conception, or reduction to practice of such Collaborator Know-How.  The JDC and JCC shall each establish a mechanism for the reciprocal disclosure of Know-How within its respective area of responsibility.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Third Party Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If Exelixis enters into any agreement with a Third Party after the Effective Date that includes a license from such Third Party to Exelixis under any Patents that would be infringed, absent a license or other right to practice granted under such Patents, by the Development, use, Manufacture, sales, offer for sale, import, or Commercialization of the Product in the Field and in the Collaborator Territory (including as contemplated in Section 10.5), then Exelixis shall notify Collaborator and identify for Collaborator the relevant Patents.  Such Patents, to the extent falling within the definition of Exelixis Patents, will be sublicensed to Collaborator if Collaborator provides Exelixis with written notice in which (i) Collaborator consents to adding such Patents to the definition of Exelixis Patents, (ii) Exelixis and Collaborator shall &#91; * &#93; of the payments that would be owed by Exelixis under such Third Party license agreement as a result of Exelixis granting a sublicense to Collaborator or Collaborator&#8217;s practice thereunder, including Collaborator&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; Development, use, Manufacture, sale, offer for sale, importation, and Commercialization of the Compound and Products in the Field in the Collaborator Territory, and such payments would be reasonably allocated proportionately to Collaborator Territory in the case such Third Party license agreement covers multiple countries including the Collaborator Territory, and to make all payments when due and provide all reports required under such license agreement&#59; and (iii) Collaborator acknowledges in writing that its sublicense under such license agreement is subject to the terms and conditions of such license agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Collaborator shall promptly notify Exelixis if it becomes aware of any Third Party&#8217;s Patents that are necessary or reasonably useful to Develop, make, have made, use, sell, offer for sale, import or Commercialize the Compound and Products in the Field in the Collaborator Territory, and shall give Exelixis the first right to negotiate and obtain a license </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from such Third Party under such Patents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except with the prior written consent of Exelixis, Collaborator shall not obtain a license to Third Party&#8217;s Patents that is necessary or reasonably useful to Develop, make, have made, use, sell, offer for sale, import or Commercialize the Products in either Party&#8217;s territory, unless it obtains the right to sublicense such rights to Exelixis.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to Section 2.8(b) below, (i) for the period starting from the Effective Date until the earlier of either of (1) eight (8) years after the First Commercial Sale of any Product in the Collaborator Territory or (2) the first commercial sale in the Collaborator Territory by an Unaffiliated Third Party of a Generic Product for which such Third Party has obtained National Health Insurance pricing from the MHLW (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Generic Entry</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), neither Party (nor any of its Affiliates) shall, directly or indirectly (including through a Third Party), develop &#91; * &#93; any Competing Product for any use in the Competitive Field in the Collaborator Territory (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (ii) for the period starting from the Effective Date and continuing until two (2) years following the First Generic Entry, neither Party (nor any of its Affiliates) shall, directly or indirectly (including through a Third Party), commercialize any Competing Product for any use in the Competitive Field in the Collaborator Territory.  For purposes of this Section 2.8, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Unaffiliated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Third Party that is not a Sublicensee and did not purchase the applicable Generic Product in a chain of distribution that included any of Exelixis, Collaborator, or their respective Affiliates, licensees, or sublicensees.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">In the event that a Third Party becomes an assignee of this Agreement, or an Affiliate of a Party after the Effective Date through merger, acquisition, consolidation, or other similar transaction, and such Third Party, as of the closing date of such transaction, is engaged in the development &#91; * &#93; or commercialization of a Competing Program&#58; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">if such transaction arises with respect to &#91; * &#93;, then such assignee or new Affiliate (as the case may be) shall have the right to continue the Competing Program and such continuation shall not constitute a breach of &#91; * &#93; exclusivity obligations set forth above&#59; provided that such assignee or new Affiliate (as the case may be) conducts the Competing Program independently of the activities of this Agreement and does not use any &#91; * &#93; in the conduct of the Competing Program and provided further that &#91; * &#93; shall continue to Develop &#91; * &#93; the Product for the Collaborator Territory in accordance with the terms of this Agreement &#91; * &#93; as if the Competing Program was not acquired&#59;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">if such transaction arises with respect to &#91; * &#93;, then such assignee or new Affiliate (as the case may be&#59; in either case, referred to as &#91; * &#93; for the remainder of this Section 2.8(b)(ii)) shall continue to Develop and Commercialize the Product &#91; * &#93; that assumes as if the Competing Program was not acquired, provided that, within &#91; * &#93; after the closing of such transaction, &#91; * &#93; shall either&#58; (a) Divest the Competing Program to a Third Party, or (b) discontinue the Competing Program.  For clarity, if the closing of such transaction occurs after the earlier of 2.8(a)(i)(1) or 2.8(a)(i)(2), &#91; * &#93; may continue the development of such Competing Program &#91; * &#93;, but shall in no event be permitted to commercialize such Competing Program in the Competitive Field in the Collaborator Territory until two (2) years after the First Generic Entry, as set forth in Section 2.8(a)(ii).  For the avoidance of any doubt, during such &#91; * &#93; period, &#91; * &#93; shall continue to fulfill its obligations under this Agreement in all respects, shall conduct </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Competing Program activities independently of the activities pursuant to this Agreement, shall not use any &#91; * &#93; in the conduct of the Competing Program, and shall not initiate or launch any new Competing Program activities.  Notwithstanding the foregoing, in the event that &#91; * &#93; reasonably anticipates that it will require more than &#91; * &#93; to complete any then-ongoing clinical trials or studies with respect to the Competing Program, then &#91; * &#93; shall notify Exelixis via the JEC and the JEC shall discuss and determine in good faith any necessary extension to such &#91; * &#93; period to permit &#91; * &#93; solely to complete and not to interrupt such ongoing clinical trials and studies with respect to the Competing Program, and &#91; * &#93; shall not withhold its consent to any such necessary extension.  For clarity, if &#91; * &#93; completely winds down the Competing Program within such &#91; * &#93; time period plus the period of time of the extension, if any, &#91; * &#93; shall be allowed to Divest the Competing Program later, provided that it does not restart any Competing Program activities.  For the purpose of this Section 2.8(b)(ii), an &#8220;ongoing clinical trial or study&#8221; shall be any clinical trial or study for which &#91; * &#93; as of the closing of such transaction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in this Section 2.8(b), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Divest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the sale or transfer of all rights to the Competing Program to a Third Party without receiving any contractual mechanism for Collaborator to provide involvement in or support of any diligence or performance obligations of such Third Party with respect to the Competing Program, or to perform or be involved in any development or commercial activities with respect to such Competing Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Divesture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has a correlative meaning).  For the avoidance of any doubt, &#8220;Divest&#8221; does not mean the renouncement nor waiver of any right to receive payment from the Third Party involved in the development and commercial activities with respect to the Competing Program and to the extent that &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Term of this Agreement, to the extent permitted by Applicable Law, for the legitimate and proportionate purpose and means for the protection of Confidential Information and Know-How and for the lifecycle management of the Product, neither Party (nor any of its Affiliates) shall, directly or indirectly (including through a Third Party), commercialize any Generic Product of any Product in the other Party&#8217;s territory&#59; provided, however, that the foregoing restriction shall apply to &#91; * &#93; only until &#91; * &#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Authorized Generics and Off Patent Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Authorized Generics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties acknowledge that it may become in the Parties&#8217; mutual interest to create an authorized generic of the Product either during or after the Royalty Term for such Product in the Collaborator Territory.  If and when &#91; * &#93; believes that creating such an authorized generic for commercialization in the Collaborator Territory would be mutually beneficial to the Parties, &#91; * &#93; shall notify &#91; * &#93; and the Parties shall discuss whether to create such an authorized generic for commercialization in the Collaborator Territory.  In the event that the Parties determine to create an authorized generic version of the Product, the Parties shall negotiate the commercially reasonable terms and conditions of manufacturing and commercializing such authorized generic in the Collaborator Territory and either amend this Agreement or enter into a separate agreement with respect thereto, as appropriate. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Off Patent Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties acknowledge that it may be in the Parties&#8217; mutual interest and wishes to continue to commercialize the Product for patients in the Collaborator Territory by using Exelixis supplied API, Compound, or Product even after the &#91; * &#93; for such Product.  If Collaborator desires to purchase the API, Compound, and&#47;or Product of the </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaborator Territory after the &#91; * &#93; for such Product, Collaborator shall notify Exelixis up to &#91; * &#93; prior to the expiration of the &#91; * &#93; and the Parties shall discuss in good faith with the intent to determine commercially reasonable terms and conditions for the continued supply of the API, Compound, and&#47;or Product (in the form then-currently supplied to Collaborator by Exelixis and which supply price shall include a reasonable margin) and a license under the Product Marks for use in connection with the Commercialization of the Product.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Governance</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Joint Executive Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As of the Effective Date, the Parties have established a joint executive committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Executive Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), composed of an equal number of up to &#91; * &#93; senior officers&#47;representatives of each Party, to oversee and guide the strategic direction of the collaboration of the Parties under this Agreement.  The JEC shall act as a joint consultative body and to the extent expressly provided herein, a joint decision-making body.  The JEC in particular shall&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">review the overall status of the Development and Commercialization of the Compound and Products in the Exelixis Territory and the Collaborator Territory, as presented by the JDC and JCC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">review and approve any proposed amendments to the GDP, including corresponding budgets, following recommendation by the JDC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">review and approve the Commercialization Plans for the Collaborator Territory, including proposed amendments, following recommendation by the JCC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">review and approve Minimum Commercial Performance thresholds pursuant to Section 6.3(b), following recommendation by the JCC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">review the status and strategy of manufacturing and supply, following  recommendation by the JDC or JCC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">resolve any disputed matter submitted to it by the JDC or JCC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">establish additional Committees as it deems necessary or advisable to further the purpose of this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or allocated to it by the Parties&#8217; written agreement, including providing financial oversight of the activities conducted pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For clarity, any information sharing of Commercialization matters regarding the Exelixis Territory shall be solely for purposes of the coordination of the Parties&#8217; activities, and Exelixis shall retain all decision making authority with respect to such matters without requiring any approvals except as expressly provided in Sections 13.4 and 13.5.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Joint Development Committee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As of the Effective Date, the Parties have established a joint Development, Medical Affairs, and regulatory committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), composed of up to &#91; * &#93; representatives of each Party, to monitor and coordinate the Development of, and Medical Affairs Activities connected with, the Compound and Products at the operational level.  Each JDC representative shall have knowledge and expertise in the clinical development of products similar to the Products.  The JDC shall in particular&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">coordinate and monitor the Development activities of the Parties under the GDP and oversee implementation of the GDP, and report to the JEC on all significant Development activities in the Collaborator Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">provide a forum for and facilitate communications between the Parties with respect to the Development of Products in the Collaborator Territory and the Exelixis Territory, including sharing of Development information and Data in accordance with Section 4.7&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">review and approve for the Collaborator Territory Clinical Trial protocols, including investigator-initiated and cooperative group clinical trial plans and protocols, and statistical analysis plans for Clinical Trials (and any amendments thereto)&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">define areas of permissible scientific and medical inquiry and parameters for Phase 4 Clinical Trials in the Collaborator Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">review Data resulting from Clinical Trials to determine if progression to additional Clinical Trials or submission of Regulatory Filings in the Collaborator Territory is warranted in terms of regulatory and scientific point of view&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">review and recommend amendments to the GDP (including the Development Budget) and propose the recommendation to JEC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">provide a forum for Exelixis to provide Collaborator with a status report, at each regularly-scheduled meeting of the JDC, of any significant potential or proposed change(s) in any of Exelixis&#8217; or its other Product licensee&#8217;s Development plans and activities that may result in or require an amendment to the GDP, including any global clinical trial or study of the Product in which Collaborator may wish to participate&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">review the status of Product manufacturing and supply activities and strategies associated with Development&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">provide a forum for evaluation of Japanese regulatory actions, communications and submissions for the Compound and Products under the GDP, and pharmacovigilance and safety matters worldwide&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">establish joint working groups (such as clinical, regulatory and safety working groups) as it deems necessary or appropriate to oversee the day-to-day management of different aspects of the Development work under the GDP&#59;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">oversee and coordinate the material Medical Affairs Activities for the Product in all indications, which shall be subject to a Medical Affairs portion of the GDP and may be coordinated through a Medical Affairs working group established and overseen by the JDC&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">review and coordinate decisions related to research or Development of Products for new indications, characterization, and Development of &#91; * &#93; (if any)&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Development of Products, including endeavoring to resolve any disputes between the Parties arising from the deliberations of the JDC, or as otherwise directed by the JEC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Joint Commercialization Committee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As of the Effective Date, the Parties have established a joint commercialization committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Commercialization Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), composed of up to &#91; * &#93; representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level.  Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products.  The JCC shall in particular&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">review and recommend the Commercialization Plans and related activities with respect to the Commercialization of Products in the Collaborator Territory, and report to the JEC on all significant Commercialization activities in the Collaborator Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">provide a forum for and facilitate communications and coordination between the Parties with respect to the Commercialization of Products in the Collaborator Territory and the Exelixis Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">on an annual basis, discuss and establish Collaborator&#8217;s Minimum Commercial Performance thresholds pursuant to Section 6.3(b) and propose recommendation to JEC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">review the status of material Product manufacturing and supply activities and strategies associated with Commercialization&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">review and discuss the major findings of Collaborator&#8217;s market research with respect to any Product in the Collaborator Territory, if any&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">review and oversee the branding and product positioning strategy for Products in the Collaborator Territory and evaluate Collaborator&#8217;s brand strategy for the Product in the Collaborator Territory for consistency with the then-current global brand strategy for the Product&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">discuss Product list price and status of reimbursement in the Collaborator Territory&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Commercialization of Products, including endeavoring to </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">resolve any disputes between the Parties arising from the deliberations of the JCC, or as otherwise directed by the JEC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Committee Membership and Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Committee Members.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Committee representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the applicable Committee&#8217;s responsibilities.  Each Party may replace its representatives on any Committee on written notice to the other Party, but each Party shall strive to maintain continuity in the representation of its Committee members.  The &#91; * &#93;.  &#91; * &#93;.  The chairperson shall have Alliance Manager prepare and circulate agendas and any background materials to be discussed at the Committee to Committee members at least &#91; * &#93; before each Committee meeting and shall direct the preparation of reasonably detailed minutes for each Committee meeting, which shall be approved by the chairperson and circulated to Committee members within &#91; * &#93; of such meeting.  The initial members of each of the JEC, JCC, and JDC shall be determined by the Parties promptly following the Effective Date. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Committee shall hold meetings at such times as it elects to do so, but in no event shall meetings of the JDC be held less frequently than once every &#91; * &#93; during the first &#91; * &#93; following the Effective Date&#59; meetings of the JCC be held less frequently than once every &#91; * &#93; during the &#91; * &#93; in the Collaborator Territory and &#91; * &#93;&#59; and meetings of the JEC once every &#91; * &#93; during the first &#91; * &#93; following the Effective Date and once every &#91; * &#93; during the &#91; * &#93; in the Collaborator Territory&#59; provided, the Parties may decide to reduce the frequency of the Committee meetings.  The first JEC meeting, first JDC meeting, and first JCC meeting shall be held within &#91; * &#93; after the Effective Date, at which meetings the dates for the first Calendar Year shall be set.  Meetings of any Committee may be held in person, or by audio or video teleconference&#59; provided that unless otherwise agreed, at least one (1) meeting per year of each Committee shall be held in person.  In-person Committees shall be held at locations alternately selected by the Parties and Collaborator shall select the location of the first meeting.  Each Party shall be responsible for all of its own expenses of participating in any Committee meetings.  No action taken at any meeting of a Committee shall be effective unless at least &#91; * &#93; of each Party is participating.  In addition, upon written notice to the other Party, either Party may request that a special </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">ad hoc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> meeting of the (i) JEC be convened for the purpose of resolving disputes or for the purpose of reviewing or making decisions pertaining to material subject-matter, the review or resolution of which cannot be reasonably postponed until the following scheduled JEC meeting, and (ii) JDC be convened for the purpose of addressing or resolving (on an expedited basis) any dispute with respect to any Local Regulatory Requirement.  Such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">ad hoc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than &#91; * &#93; following the notification date of request that such meeting be held.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Non-Member Attendance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend the Committee meetings in a non-voting capacity&#59; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party&#8217;s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld, delayed, or conditioned.  Such Party shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">22</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">All decisions of each Committee shall be made by unanimous vote, with each Party&#8217;s representatives collectively having one (1) vote.  If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter before a Committee, the representatives of the Parties cannot reach an agreement as to such matter within &#91; * &#93; after such matter was brought to such Committee for resolution, then, except as provided in Section 3.5(c), if such disagreement arose within the JDC or JCC, it shall be referred to the JEC for resolution.  If the JEC cannot resolve such matter within &#91; * &#93;, or if the disagreement first arose within the JEC, then either Party at any time may refer such issue to the Executive Officers for resolution.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If the Executive Officers cannot resolve such matter within &#91; * &#93; after such matter has been referred to them, then&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Exelixis shall have the final decision making authority, which shall be exercised in its reasonable discretion, with respect to Development and regulatory matters that may be reasonably expected to affect the Exelixis Territory, except for&#58;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the &#91; * &#93;, the costs of which would be &#91; * &#93;&#59;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any material modification to a &#91; * &#93;.  For clarity, the foregoing shall include any material modification to &#91; * &#93;.  As used in this clause, &#8220;material modification&#8221; means any material changes to the agreed upon &#91; * &#93;&#59;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any modification to the Development Budget, the costs of which would be &#91; * &#93;&#59; and&#47;or</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the addition or inclusion of &#91; * &#93;, whether the Parties &#91; * &#93; or not.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Notwithstanding Section 3.5(b)(i), Collaborator shall have the final decision making authority, which shall be exercised in its reasonable discretion, with respect to (1) Commercialization in the Collaborator Territory (except for &#91; * &#93;), (2) regulatory matters in the Collaborator Territory that are reasonably expected not to directly affect the Exelixis Territory (including, &#91; * &#93;), and (3) immediate treatment that is reasonably necessary to protect patient safety in any Development activities held in the Collaborator Territory&#59; in each case provided that Collaborator&#8217;s decision shall be consistent with the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Neither Party shall have the final decision making authority with respect to the matters in Sections 3.5(b)(i)(1), 3.5(b)(i)(2), 3.5(b)(i)(3), and 3.5(b)(i)(4) and the status quo shall persist with respect to such matter unless and until the Parties mutually agree&#59; provided, however, that with respect to any material modification in order to fulfill a &#91; * &#93; in Section 3.5(b)(i)(2), Exelixis&#8217; consent through the JDC shall not be unreasonably withheld, delayed, or conditioned. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding Section 3.5(a) and (b), &#91; * &#93; representative shall have the deciding vote on all tactical or strategic &#91; * &#93; matters for the Products in Collaborator Territory </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#91; * &#93;), and such matter shall not be subject to escalation to &#91; * &#93;&#59; provided that such decision is reasonably expected not to directly affect &#91; * &#93; and such decision shall be consistent with the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.6&#160;&#160;&#160;&#160;Limitations on Authority.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Committee shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.  Without limiting the generality of the foregoing, no Committee will have the power to amend this Agreement, and no decision of a Committee may be in contravention of any terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.7&#160;&#160;&#160;&#160;Alliance Managers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Promptly after the Effective Date, each Party shall appoint an individual who shall be an employee of such Party having appropriate qualification and experience to act as the alliance manager for such Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each Alliance Manager shall be responsible for coordinating and managing processes and interfacing between the Parties on a day-to-day basis throughout the Term.  The Alliance Manager will ensure communication to the JEC of all relevant matters raised at the JDC, the JCC, and at any joint subcommittees and project teams (if any).  Each Alliance Manager shall be permitted to attend meetings of the JEC and other Committees as appropriate as non-voting participants.  The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate all such activities hereunder.  Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party.  Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.  Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment within the JEC and its subcommittees.  Each Party shall bear its own costs of its Alliance Manager, which costs shall be excluded from the Parties&#8217; respective Development and manufacturing costs (i.e., Development Costs and Cost of Goods).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.8&#160;&#160;&#160;&#160;Supply Contacts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall designate one (1) qualified and experienced supply chain professional to serve as that Party&#8217;s primary supply contact regarding the supply of Compound and Products within this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Supply Contacts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and under the direction of the JCC.  Each Party may replace its Supply Contact with an alternative representative at any time with prior written notice to the other Party.  Supply Contacts shall be responsible for facilitating information exchange and discussion between the Parties regarding the supply of Compound and Products under this Agreement.  &#91; * &#93;.  Each Party shall bear its own costs of its Supply Contact, which costs shall be excluded from the Parties&#8217; respective Development and Cost of Goods.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Development</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms and conditions of this Agreement, the Parties will collaborate with respect to the Development of the Compound and Products and share the Data resulting from such collaboration to facilitate the Development of the Compound and Products throughout the Collaborator Territory and the Exelixis Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">24</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Development of the Compound and Products under this Agreement (including the development of the Compound and any Product as a combination product or combination therapy with another product and&#47;or therapy), including Independent Work and Local Development Work, shall be conducted only pursuant to a comprehensive written global Development plan which shall be updated at least &#91; * &#93; through the JDC subject to the JEC&#8217;s approval during the Term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The GDP shall be incorporated by reference as part of this Agreement.  As of the Effective Date, the Parties have agreed upon an initial GDP, including an initial Development Budget, attached to this Agreement as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   If the terms of the then-current GDP contradicts, or creates inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The GDP shall set forth the timeline and details (including line of therapy, tumor type, primary endpoints, approximate patient size, combination agents, and comparator agents) of all preclinical and clinical Development activities to be conducted by the Parties as necessary to generate Data sufficient to meet the common requirements of both the FDA and PMDA for MAA Approval of the Compound and Products for RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line and 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), HCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), and other indications agreed upon by the Parties.   The GDP shall also include (i) any other Development activities approved by the JDC, including parameters for permissible scientific inquiry in Phase 4 Clinical Trials or Expanded Access Program&#59; (ii) Clinical Trials that the Parties are committed to conducting&#59; (iii) any modification to the Clinical Trials set forth in GDP that will be decided by the JDC based on requirement from a Regulatory Authority or any local or regional IRB (Institutional Review Board)&#47;ethics committee or reasonably necessary to protect patient safety&#59; and (iv) Clinical Trials that will be decided by the JDC based on Data and results obtained after the Effective Date and the Parties&#8217; review of the future competitive landscape.  The GDP shall include a coordinated Development and regulatory strategy, including the Parties&#8217; respective roles in the Development of the registration dossier and Regulatory Filings for the Products and the countries in which Development of the Products will occur.  The GDP shall also set forth the detailed budget of the anticipated costs for such Development activities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on a study-by-study or Clinical Trial-by-Clinical Trial basis.  For clarity, the Development Budget shall not include any Development Costs associated with Collaborator Local Development Work or Exelixis Local Development Work.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If upon the determination by the JDC, any modification to the then-current GDP, including any non-clinical or Clinical Trials not included in the GDP, (i) is required in order to obtain and&#47;or maintain MAA Approval for a Product in the Collaborator Territory or in one or more of the countries of the Exelixis Territory, (ii) is otherwise recommended or suggested by the PMDA in the Collaborator Territory or the FDA or other Regulatory Authority in the Exelixis Territory, (iii) is required by any local or regional IRB&#47;ethics committee or (iv) is reasonably deemed necessary to protect patient safety, then the JDC shall prepare an amendment to the GDP reflecting such required, recommended or suggested modification, including associated Development Budget.  The costs of such additional studies shall be borne by the Parties as provided in Section 4.5(a). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Independent Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If either Party is interested in pursuing additional Development work on a Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the benefit of the Exelixis Territory (in the case of Exelixis) or the Collaborator Territory (in the case of Collaborator) beyond what is set forth in the then-current GDP, then such Party shall provide the other Party with a written detailed plan and budget for such additional work (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Within &#91; * &#93; </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">25</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of receipt of the Proposal, the JDC or delegated team shall meet to review the Proposal and to permit the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Developing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) an opportunity to ask questions and request additional information from the Developing Party related to the Proposal, including whether such Proposal is reasonably likely to have a material and adverse effect on the Product in the Non-Developing Party&#8217;s territory.  No additional Development work shall proceed without the approval of the JDC, and following each such approval such additional Development work and corresponding budget shall be incorporated into the GDP by the JDC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Newly-Proposed Development)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For any Newly-Proposed Development work, the Non-Developing Party that did not propose such work originally may elect, at its discretion, to share the Development Costs with respect to such Development work under Section 8.2(b).  For clarity, for any Newly-Proposed Development by Exelixis, if Collaborator elects to share the Development Costs with respect to such Development work in accordance with Section 8.2(b), Collaborator shall have the option to &#91; * &#93;.  If the Non-Developing Party does not decide to pursue the Newly-Proposed Development work jointly with the Developing Party or does not share the Development Costs with respect to such Newly-Proposed Development work, in which event such Development work shall be deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Independent Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the Developing Party may pursue such work in the Field in its respective territory and the Development Costs with respect thereto shall be deemed Independent Work Costs and subject to Sections 4.5(b) and 8.2(b).  Notwithstanding the foregoing, following the approval of the Independent Work by the JDC, the Party proposing the Independent Work may conduct such Independent Work, provided that&#58; (A) it shall do so in accordance with the amended GDP&#59; (B) such Independent Work shall be conducted under the oversight of the JDC&#59; and (C) neither Party shall conduct Independent Work in a manner that would have a material adverse effect on any Product(s) in either Party&#8217;s territory.  For the purpose of clarification, the Development activities conducted by Exelixis for RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line and 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line) and HCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line) before the Effective Date shall not be treated as Independent Work.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Annual Update to Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The JDC shall discuss and agree, without a casting vote by either Party with respect to costs that would be shared by the Parties, upon the subsequent year&#8217;s Development Budget on an annual basis no later than &#91; * &#93; of each year.  The JDC shall report any significant changes in the annual budgets to the JEC at the next regularly-scheduled JEC meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Collaborative Work Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Exelixis shall be responsible for eighty percent (80%) and Collaborator shall be responsible for twenty percent (20%) of all Development Costs for any Development activities (including Clinical Trials) set forth in the GDP other than Independent Work, Collaborator Local Development Work and&#47;or Exelixis Local Development Work (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of any doubt, such Development Costs with respect to the Collaborative Work shall include work performed by temporary workers and contractors on applicable activities and all Allowable Increases.  For the purpose of this Section 4.5(a), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Allowable Increases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; are defined as increased Development Costs in connection with the Collaborative Work resulting from (i) changes in study design after the Effective Date that are approved by the JDC &#91; * &#93; (up to the amount of a mutually-agreed budget increase), (ii) changes in regulatory requirements arising after the Effective Date (including changes required or recommended by Regulatory Authorities, but excluding changes required or recommended specifically by a Regulatory Authority of the Exelixis Territory solely for the benefit of the Exelixis Territory), or (iii) extensions in the duration of Clinical Trials </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">26</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">resulting from a lower than anticipated patient accrual rate, rate of clinical events, or higher rates of survival.  The Parties&#8217; foregoing Development Cost obligations with respect to the Collaborative Work (including Allowable Increases, if any) are subject to a maximum payment obligation of &#91; * &#93; of the amount specified in the Development Budget (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Budget Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  For clarification, notwithstanding Section 3.2(f), in the event that the Collaborative Work is conducted in accordance with the GDP and within the Budget Cap, no amendment of the Development Budget shall be required.  In the event that Development Costs are expected or anticipated to exceed the Budget Cap, the Party conducting the applicable Clinical Trial shall notify the other Party and the JDC shall meet to discuss amending the Development Budget.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Independent Work Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding Section 4.5(a), the Party conducting the Independent Work approved by the JDC under Section 4.3 shall be solely responsible for the Development Costs with respect to such Independent Work, subject to Section 8.2(b).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Local Development Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding Section 4.5(a), each Party shall be solely responsible for all Development Costs with respect to Development activities that are exclusively for the benefit of the country(ies) within such Party&#8217;s territory, including&#58; (i) any and all country-specific activities (e.g., a Canada only trial for Exelixis, a Japan only trial for Collaborator, or an Expanded Access Program)&#59; (ii) all Phase 4 Clinical Trials solely benefiting such Party&#8217;s territory&#59; (iii) any and all Development activities required for any pricing and&#47;or reimbursement approvals in such Party&#8217;s territory (but are not required for the MAA Approval in such territory)&#59; and (iv) any and all indirect manufacturing overhead costs solely benefiting such Party&#8217;s territory.  The Development work set forth in this Section 4.5(c) pertaining to Collaborator shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator Local Development Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the Development work set forth in this Section 4.5(c) pertaining to Exelixis shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Local Development Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.  For clarity, only studies that are exclusively for the benefit of the Collaborator Territory shall be deemed local Development activities which constitute Collaborator Local Development Work&#59; all other studies under the GDP, including studies with portions conducted in the Collaborator Territory, shall constitute global Development activities subject to Section 4.5(a).  All planned and in-process Collaborator Local Development Work and Exelixis Local Development Work shall be included in and conducted in accordance with the GDP, to be performed reasonably and subject to the oversight of the JDC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JDC shall reasonably allocate Development responsibilities of the Compound and Products under the GDP between the Parties and such allocation shall be set forth in the GDP, provided that&#58; (a) Exelixis or its designee shall be the Sponsor and have the operational responsibility for all Development work under the GDP that is ongoing as of the Effective Date&#59; (b) each Party shall have the operational responsibility for its own Independent Work in its Territory&#59; and (c) Collaborator shall be the Sponsor and have the operational responsibility for the Collaborator Local Development Work and Exelixis or its designee shall be the Sponsor and have the operational responsibility for the Exelixis Local Development Work.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Data Exchange and Use.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In addition to its adverse event and Safety Data reporting obligations pursuant to Section 5.5, each Party shall promptly provide the other Party with (i) </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">27</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93; status reports on trial recruitment and other metrics consistent with the performing Party&#8217;s internal reporting for clinical studies and Development activities, provided however that in case of unexpected events that may have any impact on safety, (such case will be elaborated and defined in Pharmacovigilance Agreement), each Party shall inform the other Party within &#91; * &#93; from knowledge of the occurrence of such event&#59; (ii) supporting documentation (e.g. protocols, case report forms, analysis plans, etc.)&#59; (iii) preliminary and final Data, and interim, preliminary, and final results and reports&#59; and (iv) output from advisory committees and investigator meetings, any and all such documentation generated by each Party (including by any Sublicensee or licensee) from its Development activities under this Agreement as such documentation could reasonably be deemed to affect the Development or Commercialization activities of the Product in each Party&#8217;s territory.  As time may be of the essence, each Party shall collaborate in good faith in the exchange of any such Data set forth in this Section within &#91; * &#93; of receipt.  The Parties shall cooperate on a secure website to facilitate the sharing of reports, Data, and other information on a routine basis.  Except as set forth in Section 4.7(b) below, each Party shall have the right to use and reference, without additional consideration, any and all Data generated by or on behalf of the other Party (including by any Sublicensee or other licensee) under this Agreement for obtaining and maintaining Regulatory Approval for the Products and otherwise Commercializing the Products in its territory in accordance with the terms of this Agreement.  For clarity, this Section 4.7(a) shall apply to any and all Data generated in the Development under the GDP, including Independent Work (but subject to Section 4.7(b) below), Exelixis Local Development Work, and Collaborator Local Development Work.  Notwithstanding the foregoing, should either Party fail to obtain such use and reference rights entirely from any Sublicensee or other licensee, such Party shall not have the right to grant use and access or rights to such Sublicensee or other licensee to any corresponding documentation for which such Party failed to obtain such right listed in this Section 4.7(a) generated by or on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Independent Work.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding the foregoing, the Party receiving Data resulting from the other Party&#8217;s Independent Work shall have the right to use such Data only to the extent reasonably necessary for the receiving Party to comply with its regulatory reporting and compliance obligations, including safety reporting obligations, but shall not have the right to use such Data to support its own Development, Regulatory Approval, or Commercialization except pursuant to Section 8.2(b).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall use Commercially Reasonable Efforts to perform the Development activities assigned to such Party under and in accordance with the GDP.  In addition, consistent with the GDP, Collaborator shall use Commercially Reasonable Efforts to perform Collaborator Local Development Work and any Collaborator Independent Work, file MAAs and seek and maintain Regulatory Approval (including Pricing and Reimbursement Approval, as applicable) for the Products in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall Develop the Compound and Products in compliance with all Applicable Laws, including good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Development Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall maintain complete, current, and accurate records of all Development activities conducted by it hereunder, and all Data and other information resulting from such activities.  Such records shall fully and properly reflect all work </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">28</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.  Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, cGCP, cGLP, and cGMP).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Development Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  At &#91; * &#93; JDC meeting, each Party shall provide the JDC with regular reports detailing its Development activities for the Products under this Agreement, and the results of such activities.  In addition, after the completion of any Clinical Trial or other study of the Products, the Party responsible for the conduct of such Clinical Trial or study shall provide the other Party with a data package consisting of, at a minimum, tables, lists, and figures, as well as any other Data specified in the GDP or otherwise agreed by the Parties, within &#91; * &#93; following the completion of such data package.  The Parties shall discuss the status, progress, and results of each Party&#8217;s Development activities under this Agreement at such JDC meetings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Use of Subcontractors.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party may perform its Development activities under this Agreement through one or more subcontractors, provided that (a) such Party will remain responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself&#59; (b) each subcontractor undertakes in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to Article 13, and (c) each subcontractor agrees in writing to assign all intellectual property developed in the course of performing any such work to such Party (or, in the event such assignment is not feasible, a license to such intellectual property with the right to sublicense to such other Party).  The Parties may also subcontract work on terms other than those set forth in this Section 4.12 with the prior written approval of the JDC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After the Effective Date and during the Term, neither Party nor any of its Affiliates or (sub)licensees shall, directly or through any Third Party, sponsor, conduct, or cause to be conducted, otherwise assist in, supply any Product for use in connection with, or otherwise fund&#58; (a) any Development of any Product outside the scope of the GDP&#59; or (b) comparative studies of its product versus the Product outside the scope of the GDP.  For clarity and without limiting the foregoing, except as expressly approved by the JDC and included in the GDP, Collaborator shall not perform or sponsor any study or test on the Compound or Products, including any pre-clinical or non-clinical study, toxicology study, or CMC-related study, or seek to modify or create the Compound or any analog thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Materials Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order to facilitate the Development activities contemplated by this Agreement, either Party may provide to the other Party certain biological materials or chemical compounds Controlled by the supplying Party (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for use by the other Party in furtherance of such Development activities.  Except as otherwise provided for under this Agreement, all such Materials delivered to the other Party will remain the sole property of the supplying Party, will be used only in furtherance of the Development activities conducted in accordance with this Agreement, will not be used or delivered to or for the benefit of any Third Party, except to subcontractors permitted in Section 4.12, without the prior written consent of the supplying Party, and will be used in compliance with all Applicable Laws.  The Materials supplied under this Agreement must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known.  Except as expressly set forth in this Agreement, THE MATERIALS ARE PROVIDED &#8220;AS IS&#8221; AND </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">29</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Regulatory Activities</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Regulatory Responsibilities.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">General.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The GDP shall set forth the regulatory strategy for seeking Regulatory Approval for the Compound and Products by the appropriate Regulatory Authorities in the Collaborator Territory and Exelixis Territory.  Unless otherwise necessary for global registration requirements, Collaborator shall apply for and hold Regulatory Filings in the Collaborator Territory with respect to the conduct of Development activities.  Subject to the direction and oversight of the JDC, each Party shall be responsible for implementing such regulatory strategy in its territory.  Except as otherwise provided herein or required by Applicable Law, each Party shall be responsible for the preparation and submission of any and all Product registrations and marketing approvals in its territory and shall own and hold all such Regulatory Filings (including Regulatory Approvals), and neither Party shall submit any application for Product registration or marketing approval in the other Party&#8217;s territory.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Each Party shall be responsible for the cost and expense of all regulatory activities in connection with obtaining or maintaining Regulatory Approval of Products in its territory.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Collaborator acknowledges that Exelixis may be required to communicate with Regulatory Authorities in the Collaborator Territory as a result of manufacturing activities for the Collaborator Territory.  Exelixis shall notify Collaborator as soon as reasonably possible of such communication with Regulatory Authorities and seek to incorporate input from Collaborator in preparation for such communication.  Exelixis shall then keep Collaborator informed of any such communications.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Transfer of Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Exelixis shall provide, promptly after the execution of this Agreement, to Collaborator a copy of all the IND for the Product for the Collaborator Territory submitted to the PMDA, which IND the Parties acknowledge is, as of the Effective Date, closed and inactive in the Collaborator Territory.  Collaborator shall have a right to use and&#47;or reference such IND in connection with Collaborator&#8217;s Development and regulatory activities under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Regulatory Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that such Regulatory Filings that relate to the activities in the requesting Party&#8217;s territory, each Party shall, upon the other Party&#8217;s reasonable request, promptly provide the other Party (but in no event more than &#91; * &#93;) with copies of Regulatory Filings prepared (including any drafts and supporting information), submitted or received by such Party in the Exelixis Territory including the U.S. and the </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">30</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaborator Territory pertaining to the Compound and Products, and such other Party shall have the right to review and comment on drafts of such Regulatory Filings, provided that such review and comment shall not delay the submission of any Regulatory Filings.  The sharing of Regulatory Filings shall include any communications&#47;correspondence with the Regulatory Authority regarding label changes, IND annual reports and cover letters, and documents related to regulatory milestones and dates (e.g., submissions and validations).  If any Regulatory Filing to be provided under this Section 5.2 was originally created in a language other than the English language, then at the receiving Party&#8217;s request and to the extent already existing and readily available, the providing Party shall provide an English translation along with the original document to the receiving Party.  The Parties acknowledge that it is their intent to collaborate in good faith in the exchange of such Regulatory communications including with any Sublicensee or other Exelixis licensee.  Each of Collaborator and Exelixis shall reasonably endeavor to grant access and rights for the other Party to use any such communications with any Regulatory Authority generated by or on behalf of any Sublicensee or other Exelixis licensee, respectively.  For clarity, a Party&#8217;s provision to the other Party of copies of Regulatory Filings prepared, submitted, or received in each Party&#8217;s territory is expressly conditioned upon the receiving Party granting to the providing Party the right to share with the providing Party&#8217;s own licensee for its territory copies of any and all Regulatory Filings prepared, submitted, or received by the receiving Party in its territory.  Should either Party fail to obtain such access and rights from any Sublicensee or Exelixis licensee, such Party shall not have the right to grant access or rights to such Sublicensee or other Exelixis licensee to any such communications with any Regulatory Authority generated by or on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Meetings with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a current and ongoing basis, each Party shall provide the other Party with a list and schedule of any significant in-person meeting or teleconference with the Regulatory Authorities (or related advisory committees) in the Collaborator Territory planned for the next &#91; * &#93; that relates to the Development of the Compound and Products under the GDP in the Collaborator Territory (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  In addition, each Party shall notify the other Party as soon as reasonably practicable if such Party becomes aware of any additional Regulatory Meetings that become scheduled for such &#91; * &#93; and will keep the other Party informed of any significant interface or communication with any Regulatory Authority which is reasonably expected to affect efforts to obtain Regulatory Approval for the Product in its respective territory.  Collaborator shall be solely responsible for any communications with the Regulatory Authorities occurring or required in connection with performing its regulatory responsibilities set forth in this Article 5 with respect to the Product in the Collaborator Territory, and Exelixis shall have the right to provide input in preparation for all Regulatory Meetings and the right, but not the obligation, to have its representatives attend (but, unless otherwise requested by Collaborator, not participate in) the Regulatory Meetings.  Collaborator shall have these same rights with respect to any such Regulatory Meetings in the Collaborator Territory before such Regulatory Filings are transferred to Collaborator under Section 5.1(b).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Regulatory Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall permit the Regulatory Authority(ies) in the Exelixis Territory to conduct inspections of Collaborator, its Affiliates, Sublicensees, or subcontractors (including Clinical Trial sites) relating to Product Development under the GDP or the Finished Manufacture of the Finished Product, and shall ensure that such Affiliates, Sublicensees, and subcontractors permit such inspections.  In addition, Collaborator shall promptly notify Exelixis of any such inspection and shall supply Exelixis with all information </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pertinent thereto.  Exelixis shall have the right, but not the obligation, to attend any such inspection with the presence of Collaborator.  Exelixis shall permit the Regulatory Authority(ies) in the Collaborator Territory to conduct inspections of Exelixis, its Affiliates, and its sublicensees or subcontractors (including Clinical Trial sites) relating to Product Development under the GDP for the Collaborator Territory, and shall ensure that such Affiliates, sublicensees, and subcontractors permit such inspections.  In addition, Exelixis shall promptly notify Collaborator of any such inspection and shall supply Collaborator with all information pertinent thereto.  Collaborator shall have the right, but not the obligation, to attend any such inspection with the presence of Exelixis.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Pharmacovigilance and Adverse Event Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91; * &#93; after the Effective Date, but in any case prior to the Initiation of a Clinical Trial for the Product in the Collaborator Territory, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for and responsibilities of the Parties with respect to the Products, such as Safety Data sharing, adverse events reporting, and safety signal and risk management (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which agreement shall be amended by the Parties &#91; * &#93; to comply with any changes in Applicable Laws or any guidance received from Regulatory Authorities.  Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Global Safety Database</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Exelixis has established and shall continue to hold, at its expense, the Product global safety database, and shall maintain such global safety database for so long as such Product is under Development and&#47;or Commercialization hereunder.  Exelixis will ensure that each Party is able to access the Safety Data, if necessary indirectly, from the global safety database in order to meet legal and regulatory obligations.  For the Collaborator Territory, the Parties will agree on data cut points for periodic aggregate safety reports, Exelixis will author such reports, including the integrated data sets, the Parties will jointly review and approve such reports, and Collaborator will generate final versions of the reports for submission in accordance with regulatory requirements in the Collaborator Territory.  If the PMDA requires any additional reports, Collaborator shall prepare such reports for submission to the PMDA, consulting with Exelixis as practicable and appropriate and, upon Exelixis&#8217; reasonable request, providing to Exelixis a copy (in English) of any such report.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">PV Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As between the Parties, Exelixis shall be responsible for the cost and expense incurred by Exelixis for establishing and maintaining such global safety database and the preparation of periodic aggregate safety reports that are specifically directed (or reasonably allocable) to the Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) prior to &#91; * &#93;.  For the period of time commencing upon &#91; * &#93; until &#91; * &#93;, Exelixis shall be responsible for &#91; * &#93; of PV Costs and Collaborator shall be responsible for &#91; * &#93; of PV Costs.  Thereafter, Exelixis shall be responsible for &#91; * &#93; of PV Costs and Collaborator shall be responsible for &#91; * &#93; of PV Costs.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">PV Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JDC shall establish a safety subcommittee and all Safety Data, including adverse event reports, shall be submitted to such safety subcommittee and Exelixis concurrently so that Exelixis may update the global safety database accordingly.  Such safety subcommittee shall coordinate with respect to any Safety Data reporting for the Product to Regulatory Authorities in the Collaborator Territory, but Collaborator shall be primarily </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsible for (i) reporting quality complaints, adverse events, and Safety Data related to the Products, and all case processing of adverse events, to applicable Regulatory Authorities in the Collaborator Territory, and (ii) responding to safety issues and to all requests of Regulatory Authorities in the Collaborator Territory related to the Products, in each case at its own expense.  Collaborator shall have the right to use, at its own expense, a safety database owned by Collaborator for the purpose of tracking and reporting quality complaints, adverse events, and Safety Data related to the Products in the Collaborator Territory&#59; provided, however, that such right shall not relieve Collaborator of its obligation to communicate all such information directly to the safety subcommittee and Exelixis.  Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees, and sublicensees to comply with such obligations.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">No Harmful Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Party believes that the other Party is taking or intends to take any action with respect to a Product that could reasonably be expected to have a material adverse impact upon the regulatory status of such Product in the first Party&#8217;s territory, then such Party may bring the matter to the attention of the JDC and the Parties shall discuss in good faith to resolve such concern.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Notification of Threatened Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall notify the other Party within &#91; * &#93; of any information it receives regarding any threatened or pending action, inspection, or communication by any Regulatory Authority, which may affect the safety or efficacy claims of any Product or the continued Development or Commercialization of any Product.  Upon receipt of such information, the Parties shall promptly consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Right of Reference to Regulatory Materials.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party hereby grants to the other Party the right of reference to all Regulatory Filings pertaining to the Compound and Products submitted by or on behalf of such Party.  The receiving Party may use such right of reference solely for the purpose of seeking, obtaining, and maintaining Regulatory Approval of the Products for use in its territory in accordance with this Agreement.  Notwithstanding the foregoing, the receiving Party has such right of reference to any Regulatory Filings based on Data resulting from the other Party&#8217;s Independent Work only to comply with its safety reporting obligations, unless the receiving Party pays the other Party for such work as set forth in Section 8.2(b).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that a recall, withdrawal, or correction (including the dissemination of relevant information) of any Product in a Party&#8217;s territory is required by a Regulatory Authority of competent jurisdiction, or if any Regulatory Authority requires or advises either Party or such Party&#8217;s Affiliates or sublicensees to distribute a &#8220;Dear Doctor&#8221; letter or its equivalent regarding use of such Product in a Party&#8217;s territory, or if a recall, withdraw, or correction of a Product in its territory is deemed advisable by such Party in its sole discretion, such Party shall so notify the other Party no later than &#91; * &#93; in advance of the earlier of (i) initiation of a recall, withdrawal, or correction&#59; or (ii) the submission of plans for such an action to a Regulatory Authority.&#160; Any such recall, withdrawal, correction, or dissemination of information (e.g., &#8220;Dear Doctor&#8221; letter) shall be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.  Promptly after being notified of a Recall, each Party shall provide the other Party with such assistance in connection with such Recall as may be reasonably requested by such other Party.&#160; All costs and expenses in connection with a Recall in a Party&#8217;s territory shall be paid by such Party, including </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">33</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without limitation the costs and expenses related to the dissemination of relevant information.&#160; Each Party shall handle exclusively the organization and implementation of all Recalls of Products in its territory.  Notwithstanding the foregoing, any Recall related to the manufacture and supply of the Product by Exelixis to Collaborator shall be governed by the terms and conditions of the Parties&#8217; applicable Supply Agreement and the Quality Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Sunshine Reporting Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party acknowledges that the other Party may be subject to federal, state, local, international, industrial and internal laws, regulations, rules and guidelines related to the tracking and reporting of payments and transfers of value provided to health care professionals, health care organizations, and other relevant individuals and entities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sunshine Reporting Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and agrees to provide the other Party with all information regarding such payments or transfers of value by such Party as necessary for such other Party to comply in a timely manner with its reporting obligations under the Sunshine Reporting Law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Commercialization</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the terms and conditions of this Article 6, Collaborator shall have the sole and exclusive responsibility, at its own expense, for all aspects of the Commercialization of the Products in the Collaborator Territory, including&#58; (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities and other payors regarding the price and reimbursement status of the Products&#59; (c) marketing and promotion&#59; (d) booking sales and distribution and performance of related services&#59; (e) handling all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">aspects of order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">processing, invoicing, and collection, inventory and receivables&#59; (f) providing customer support, including handling medical queries, and performing other related functions&#59; and (g) conforming its practices and procedures to Applicable Laws relating to the promotion, sales and marketing, access, and distribution of the Products.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Commercialization Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  No later than &#91; * &#93;, Collaborator shall prepare and present to the JCC a Commercialization plan for Products in the Collaborator Territory, including a reasonably detailed description and an anticipated timeline for Collaborator&#8217;s significant Commercialization activities for the Products for the next &#91; * &#93; the plan will include, at a minimum, a reasonably detailed description of the activities contemplated by Sections 6.4 through 6.7 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Collaborator shall update and amend the Commercialization Plan periodically (&#91; * &#93;) and shall present such updates and amendments to the JCC for review and discussion.  Without limiting the provisions of this Section&#160;6.2, through the JCC, Collaborator shall consult with and provide updates to Exelixis regarding strategy and tactics for Commercialization of Products in the Collaborator Territory.  Subject to the provisions of this Agreement and compliance with the Commercialization Plan, Collaborator shall have full control and authority with respect to the day-to-day Commercialization of the Products and implementation of the Commercialization Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, Collaborator shall use Commercially Reasonable Efforts to Commercialize the Products for all indications that have received or will receive Regulatory Approval throughout the Collaborator Territory.  In addition, and without </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">34</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limitation of the foregoing, Collaborator shall, as soon as possible following each MAA Approval(s), launch the Product for such indication and obtain all necessary Price and Reimbursement Approvals.  Thereafter, Collaborator shall utilize Commercially Reasonable Efforts in the ongoing support for the Product in the Collaborator Territory. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Minimum Commercial Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the foregoing general commitments, Collaborator shall also achieve for the first six (6) full Calendar Years following the First Commercial Sale of the Product in the Collaborator Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Minimum Commercial Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (i) a minimum annual sale volume based on the aggregate sales forecast for the Collaborator Territory, and (ii) minimum annual promotional and sales force requirements for the Collaborator Territory, for each Calendar Year as set forth in the table below ((i) and (ii) collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Minimum Commercial Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Minimum Commercial Performance for the First Full Calendar Year shall be determined by &#91; * &#93;, and set forth in the first Commercialization Plan.  Thereafter during the Minimum Commercial Performance Period, the Minimum Commercial Performance will be updated &#91; * &#93;, to reflect any changes in the timing of Regulatory Approvals and the First Commercial Sale of a Product for each approved indication in the Collaborator Territory as well as actual experience and competitive conditions then prevailing.</font></div><div style="padding-left:19.82pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"><tr><td style="width:1.0%"></td><td style="width:19.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Full Calendar Year</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales Volume Minimum</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Promotional Efforts Minimum</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td></tr></table></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;For clarity, for the &#91; * &#93;, the sales volume and promotional effort minimums set forth in the table above will be non-binding and solely for planning purposes and of no effect under this Agreement.  For the &#91; * &#93;, Collaborator shall be required to achieve either the sales volume minimum or the promotional efforts minimum, but not both.  For the &#91; * &#93;, Collaborator shall be required to achieve the sales volume minimum only.  Collaborator&#8217;s failure to achieve Minimum Commercial Performance for any &#91; * &#93; Calendar Years during the Minimum Commercial Performance Period (excluding the &#91; * &#93;) shall be considered a material breach of this Agreement, giving rise to Exelixis&#8217; right to terminate the Agreement pursuant to Section 14.2(a) as a sole and exclusive remedy for Exelixis regarding such material breach of Collaborator.  For the purpose of this Section 6.3(b), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Full Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">35</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">January 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> following the date of the First Commercial Sale of the Product in the Collaborator Territory and ending on December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of such Calendar Year.   For example, if the First Commercial Sale of the Product occurs in August 2021, the First Full Calendar Year begins on January 1, 2022 and ends on December 31, 2022.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Commercial Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall update the JCC on a &#91; * &#93; basis regarding its Commercialization activities with respect to the Products in the Collaborator Territory.  Each such update shall be in a form to be agreed by the JCC and shall summarize Collaborator&#8217;s, its Affiliates&#8217;, and Sublicensees&#8217; significant Commercialization activities with respect to the Products in the Collaborator Territory, and shall contain at least such information at such level of detail reasonably required by Exelixis to determine Collaborator&#8217;s compliance with its diligence obligations set forth herein.  Such updates shall include Collaborator&#8217;s sales activities, marketing activities, and Medical Affairs Activities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Coordination of Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties recognize that their collaboration may benefit from the coordination of certain activities in support of the Commercialization of Products in both the Collaborator Territory and the Exelixis Territory.  As such, the JCC shall review Collaborator&#8217;s Commercialization strategies for the Product in the Collaborator Territory (e.g., branding and messaging, international congresses, national- or global-level advisory boards) in order to provide input and drive consistency with those Commercialization strategies for the Product in the Exelixis Territory that have proven successful.  For clarity, (i) the foregoing sentence shall not be construed as limiting Collaborator&#8217;s rights under Section 3.5, and (ii) Exelixis shall not be obligated to seek Collaborator&#8217;s consent in connection with the establishment and&#47;or implementation of any sales, marketing, or medical affairs practices in the Exelixis Territory.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">List Price and Pricing for Combination Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall keep Exelixis timely informed on the status of any application for Pricing and Reimbursement Approval or material updates to an existing Pricing and Reimbursement Approval in the Collaborator Territory, including any discussion with a Regulatory Authority with respect thereto, via the JCC.  Collaborator and its Affiliates and Sublicensees shall not sell any Product &#91; * &#93;, as part of &#91; * &#93;, or as &#91; * &#93;, or offer &#91; * &#93; to customers that include a Product, in such a manner as to disproportionately discount the selling price of the Product &#91; * &#93;.  For clarification, should Collaborator derive direct economic benefit from the sale of another pharmaceutical product that is approved to be used in combination with the Product, &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Sharing of Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall, at its own expense, prepare, develop, produce, or otherwise obtain and utilize sales, promotional, advertising, marketing, website, educational, and training materials (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to support its Commercialization activities in the Collaborator Territory.  The Parties shall share samples of Promotional Materials (including English translation, if such materials are not in the English language) with respect to and for use in the Commercialization of the Products with one another.  Additional materials, including medical education and medical information, sales force and sales force training materials, will be made available to the other Party upon reasonable request.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">36</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Commercialization in Exelixis Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Exelixis shall have the exclusive right to Commercialize the Product in the Exelixis Territory at its own cost and expense, with or without Third Party(ies).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Detailing and Promotion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Collaborator shall have the right to engage Third Party contract sales representatives to help with the promotion of the Product in the Collaborator Territory without prior written JCC approval, provided that in no event shall the total number of such contract sales representatives exceed &#91; * &#93; of the total sales representatives provided in support of the Product in the Collaborator Territory at any given &#91; * &#93; during the Royalty Term without prior written JCC approval.  If Collaborator elects to engage Third Party contract sales representatives in accordance with this Section 6.5(a), it shall inform the JCC in reasonable detail of the number of contract sales representatives to be provided.  All Third Party contract sales representatives engaged by Collaborator shall have at least, but in no event less than, the same or similar level of experience, capabilities, and training as Collaborator&#8217;s in-house sales representatives for the Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Collaborator shall not use the same sales force to promote or detail the Product and a separate product that is &#91; * &#93; (except in the case &#91; * &#93;).  If Collaborator desires to use the same sales force to promote or detail the Product and a separate product that is &#91; * &#93;, Collaborator shall indicate such desire to Exelixis and Exelixis shall, in its sole discretion, determine whether to permit such sales force to promote or detail both the Product and such other product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Collaborator shall lead and conduct all Medical Affairs Activities for the Product in the Collaborator Territory in accordance with the medical affairs portion of the GDP, provided, however, that medical affairs publications and medical information activities shall be subject to Section 13.4.  Exelixis will not undertake any Medical Affairs Activities in the Collaborator Territory without prior coordination with and consent of Collaborator, such consent not to be unreasonably withheld.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">To the extent practicable, Collaborator shall provide Exelixis with written notice at least &#91; * &#93; in advance of any national-level advisory panel meetings with key opinion leaders regarding the Development or Commercialization of the Products in the Collaborator Territory.  If requested by Exelixis, Collaborator shall provide Exelixis with a written summary (in English) of such meetings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Diversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party hereby covenants and agrees that it and its Affiliates shall not, and it shall contractually obligate (and use Commercially Reasonable Efforts to enforce such contractual obligation) its sublicensees not to, directly or indirectly, promote, market, distribute, import, sell, or have sold any Product, including via the Internet or mail order, to any Third Party or to any address or Internet Protocol address or the like in the other Party&#8217;s territory.  Neither Party shall engage, nor permit its Affiliates and sublicensees to engage, in any advertising or promotional activities relating to any Product for use directed primarily to customers or other buyers or users of such Product located in any country or jurisdiction in the other Party&#8217;s </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">37</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">territory, or solicit orders from any prospective purchaser located in any country or jurisdiction in the other Party&#8217;s territory.  If a Party or its Affiliates or sublicensees receives any order for a Product for use from a prospective purchaser located in a country or jurisdiction in the other Party&#8217;s territory, such Party shall immediately refer that order to such other Party and shall not accept any such orders.  Neither Party shall, nor permit its Affiliates and sublicensees to, deliver or tender (or cause to be delivered or tendered) any Product for use in the other Party&#8217;s territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Manufacture and Supply.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Manufacture and Supply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Exelixis, through one or more Third Party contract manufacturers, will provide all Supplied Product for use in the Development and Commercialization of the Products under this Agreement.  All Supplied Product supplied by Exelixis to Collaborator shall be at a price equal to &#91; * &#93;. During the Term, Exelixis shall use Commercially Reasonable Efforts to &#91; * &#93;.  If &#91; * &#93; for particular Supplied Product is reasonably expected to exceed &#91; * &#93; per tablet of any dose strength, Exelixis shall inform Collaborator promptly, and discuss with Collaborator in good faith a reasonable mitigation plan to reduce &#91; * &#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis (through one or more Third Party contract manufacturers) shall be exclusively responsible for the supply of Supplied Product to Collaborator and Collaborator shall be exclusively responsible, at its expense, for the Finished Manufacture of the Finished Product.  &#91; * &#93; of the Supplied Product used in the Development work under the GDP shall be included in the Development Cost and shared by the Parties in accordance with Section 4.5.  Exelixis shall source such Supplied Product supply for both Parties either from a facility owned by Exelixis or from a reputable, qualified, and certified Third Party and, in the event that Collaborator is responsible for conducting any Clinical Studies pursuant to Section 4.2 or 4.3, Exelixis shall provide such supply to Collaborator for such Clinical Studies in accordance with the GDP.  As soon as reasonably practicable after the Effective Date, but in any event prior to the initial supply of the Supplied Product to Collaborator for use in Development work, the Parties shall enter into supply agreements for the manufacture and supply of the Supplied Product to Collaborator for use in Development or Commercialization activities (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and a Quality Agreement setting forth in detail the quality assurance arrangements and procedures for Exelixis&#8217; manufacture of Supplied Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Exelixis shall, upon Collaborator&#8217;s reasonable request, allow Collaborator to access Exelixis and&#47;or its manufacturing facility of the Supplied Product, as applicable, for the purpose of regulatory and Collaborator&#8217;s reasonable in-house auditing. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Financial Provisions</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Upfront Payment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaborator shall make a one-time, non-refundable, non-creditable upfront payment to Exelixis of fifty million U.S. dollars ($50,000,000) within five (5) Business Days after the Effective Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Sharing&#47;Reimbursements of Development Costs and PV Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Future Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No later than &#91; * &#93; after the beginning of each Calendar Quarter during which a Party will perform any Collaborative Work in such Calendar Quarter pursuant to the GDP, such Party shall submit to the other Party a statement setting forth the Development Costs incurred, including the other Party&#8217;s share (calculated in accordance with Section 4.5) of (i) estimated Development Costs for the then current quarter&#59; (ii) </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">38</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">variances from prior invoiced estimates and actual Development Costs&#59; and (iii) Development Costs incurred by or on account of such Party in the past quarter not previously invoiced.  Such invoice shall include a reasonably detailed report for such Development Costs, including supporting documents.  To the extent provided in Section 4.5, the other Party shall pay the amount invoiced within &#91; * &#93; after the receipt of the invoice.  For clarity, making such a payment does not preempt the paying Party&#8217;s audit rights under Section 9.4, which remain in full force and effect.  If both Parties will perform Development activities under the GDP in such Calendar Quarter, the Parties shall consolidate the payments for such Calendar Quarter into a single payment from one Party to the other Party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Independent Work.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to Section 4.7(b), and except as set forth below in this Section 8.2(b), each Party shall bear all the internal (calculated on an FTE basis using the then current FTE Rate) and reasonable out-of-pocket expenses incurred by or on account of such Party in performing its own Independent Work (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Independent Work Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  After the completion of such Independent Work, such Party shall provide the other Party with a report of such Independent Work Costs.  If a Party desires to submit any portion of the Data resulting from any Independent Work conducted by the other Party and related Regulatory Filings generated by the other Party to support Regulatory Approval in its territory, then such Party shall notify the other Party in writing at any time upon the completion of such Independent Work.  Within &#91; * &#93; after its receipt of such notice, the Party conducting or having conducted such Independent Work shall submit to the other Party a reasonably detailed invoice setting forth &#91; * &#93; of the Independent Work Costs that would have been incurred by or on account of such other Party in connection with the generation of such Data under Section 8.2(b) as if such Independent Work Costs were Development Costs with respect to Collaborative Work.  If the Party seeking to use such Data decides to use such Data to support Regulatory Approval in its territory, then such Party shall notify the other Party in writing and pay the amount invoiced (i.e., if Collaborator seeks to use the Data resulting from Exelixis&#8217; Independent Work, twenty percent (20%) of &#91; * &#93; of the Independent Work Costs) within &#91; * &#93; after the receipt of such invoice.  For clarity, making such a payment does not preempt the paying Party&#8217;s audit rights under Section 9.4, which remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Internal Development Cost.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party shall record and calculate its internal Development Costs with respect to Collaborative Work and&#47;or its Independent Work on an FTE basis at the FTE Rate.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Development Cost for Products in Combination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If the Parties agree to Develop a Product under this Agreement in combination with &#91; * &#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Beneficial Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), either as a combination product or combination therapy, then such Development work shall be conducted in accordance with the GDP and the Development Costs with respect to such Development shall be included in the Development Budget, provided that only &#91; * &#93; of the Development Cost with respect to such Development shall be subject to the Parties&#8217; cost sharing under Section 8.2(b) and the Beneficial Party shall be solely responsible for the other &#91; * &#93; of the Development Costs.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">PV Costs Following Initiation of Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following the Initiation of the first Clinical Trial in the Collaborator Territory, no later than &#91; * &#93; after the beginning of each Calendar Quarter, Exelixis shall submit to Collaborator a statement setting forth the PV Costs incurred, including Collaborator&#8217;s share (calculated in accordance with </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">39</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.5) of (i) estimated PV Costs for the then current quarter&#59; (ii) variances from prior invoiced estimates and actual PV Costs&#59; and (iii) PV Costs incurred by or on account of Exelixis in the past quarter not previously invoiced.  Such invoice shall include a reasonably detailed report for such PV Costs, including supporting documents.  To the extent provided in Section 5.5, Collaborator shall pay the amount invoiced within &#91; * &#93; after the receipt of the invoice.  For clarity, making such a payment does not preempt Collaborator&#8217;s audit rights under Section 9.4, which remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Development Milestones.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the remainder of this Section 8.3, Collaborator shall pay to Exelixis the non-refundable, non-creditable payment set forth in the table below upon the achievement of the applicable milestone event (whether by or on behalf of Collaborator, Exelixis, or their Affiliates, licensee(s) of Exelixis, or Sublicensees)&#58;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">40</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.724%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Milestone Event</font></td><td colspan="15" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Milestone Payments</font></td></tr><tr style="height:80pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For RCC <br>(2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For RCC <br>(1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  line)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For HCC <br>(2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 1 Indications </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 2 Indications</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Milestone #1&#58; Upon &#91; * &#93; the first Phase 3 Clinical Trial for the Product in the Collaborator Territory</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Milestone #2&#58; Upon &#91; * &#93; the first MAA for the Product in the Collaborator Territory</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Milestone #3&#58; Upon First Commercial Sales for the Product in the relevant indication in the Collaborator Territory</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">41</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">For RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), and HCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), each milestone payment shall be paid only once for the first applicable events described above for each different applicable Product.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Milestone #1 shall be deemed achieved and payable, if not already achieved, upon achievement of any of Milestone #2 and&#47;or Milestone #3 for the same indication.  Milestone #2 shall be deemed achieved and payable, if not already achieved, upon achievement of Milestone #3 for the same indication.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Without limiting the foregoing, with respect to RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line) and RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), if Milestone #3 is achieved for RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line) prior to being achieved for RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), then Milestone #3 for RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line) shall be deemed achieved and payable upon achievement of Milestone #3 for RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), except if Collaborator is, at the time of such achievement, diligently engaged in the performance of Development or regulatory activities with respect to Products for the express purpose of achieving Milestone #3 for both RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line) and RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line), in which case Milestone #3 for RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line) shall not be deemed achieved and payable unless and until achieved by a Product for RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> line).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Notice and Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party shall notify the other Party in writing within &#91; * &#93; after the achievement of any milestone set forth in this Section 8.3 by such Party, its Affiliates, licensee(s) of Exelixis, or Sublicensees.  Collaborator shall pay to Exelixis the applicable development milestone payments within &#91; * &#93; after the delivery or receipt of such notice.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Sales-Based Milestones Payments.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Sales Milestones.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Collaborator shall pay to Exelixis the one-time, non-refundable, non-creditable payments set forth in the table below when the aggregated Net Sales of all Products in the Collaborator Territory in any period of four (4) consecutive Calendar Quarters first reach the values indicated in the table below.  Once one of the values indicated in the table below is first reached and the corresponding Milestone Payment is paid by Collaborator under this Section 8.4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Previously Achieved Sales Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the period of four (4) consecutive Calendar Quarters to be applied to determine the reaching of a subsequent Net Sales amount in the table below shall only start at the Calendar Quarter immediately following the fourth (4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) Calendar Quarter which served as the period to determine the reaching of the Net Sales amount triggering the Previously Achieved Sales Milestone.  For the avoidance of any doubt, each payment in this Section 8.4(a) shall be payable once only, regardles</font><font style="color:#3d4240;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the number of times such mile</font><font style="color:#3d4240;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tone is achieved.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">42</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:69.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Aggregate Net Sales of all Products in the Collaborator Territory in any 4 consecutive Calendar Quarters</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales Milestone Payments</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equal or exceed&#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.85pt;padding-right:19.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equal or exceed&#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.85pt;padding-right:19.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equal or exceed &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.85pt;padding-right:19.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equal or exceed &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.85pt;padding-right:19.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td></tr></table></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Notice and Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As part of the report in Section 9.1, Collaborator shall provide written notice to Exelixis upon the aggregated Net Sales of all Products in the Collaborator Territory in any four (4) consecutive Calendar Quarters first reaching the values set forth in Section 8.4(a) above, and Collaborator shall pay to Exelixis the corresponding sales milestone payment within &#91; * &#93; after the end of the Calendar Quarter.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Cumulative Net Sales Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall pay to Exelixis the one-time, non-refundable, non-creditable payments set forth in the table below when the cumulative Net Sales of all Products in the Collaborator Territory first reach the values indicated in the table below. </font></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:69.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cumulative Net Sales of all Products in the Collaborator Territory</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cumulative Net Sales Milestone Payments</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exceed&#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.85pt;padding-right:19.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exceed&#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.85pt;padding-right:19.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Notice and Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As part of the report in Section 9.1, Collaborator shall provide written notice to Exelixis upon the cumulative Net Sales of all Products in the Collaborator Territory first reaching the values set forth in Section 8.4(c) above, and Collaborator shall pay to Exelixis the corresponding cumulative Net Sales milestone payment within &#91; * &#93; after the end of the Calendar Quarter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Royalty Rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the other terms of this Section 8.5, during the Royalty Term, Collaborator shall make quarterly, non-refundable, non-creditable royalty payments to Exelixis on the annual Net Sales of all Products sold in the Collaborator Territory at the applicable rate set forth in the table below.  For clarity, if the threshold in Section 8.5(b) is </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">43</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">achieved in any Calendar Year, then the Net Sales for purposes of this Section 8.5(a) will commence on the date after which such threshold is achieved.</font></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:69.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Net Sales of all Products in the <br>Collaborator Territory</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 1&#58; Portion less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20%</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 2&#58; Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;<br>and less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 3&#58; Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;<br>and less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 4&#58; Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;<br>and less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 5&#58; Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30%</font></td></tr></table></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Initial Royalty Rate Adjustment Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding Section 8.5(a), for the first three hundred million dollars ($300,000,000) of cumulative Net Sales of all Products sold in the Collaborator Territory, Collaborator shall make quarterly, non-refundable, non-creditable royalty payments to Exelixis on the Net Sales of all Products sold in the Collaborator Territory at the rates set forth in the table below.  Thereafter, the royalty rate for all Net Sales shall be at the applicable rate set forth in Section 8.5(a).</font></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:69.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cumulative Net Sales of all Products in the <br>Collaborator Territory</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 1&#58; Portion less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 2&#58; Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;<br>and less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 3&#58; Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;<br>and less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91; * &#93;%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tier 4&#58; Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;<br>and less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24%</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">44</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Royalty Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Royalties shall be paid on a Product-by-Product basis in the Collaborator Territory from the First Commercial Sale of such Product by or on behalf of Collaborator, its Affiliates, or Sublicensees, until the earlier of (i) two (2) years after the First Generic Entry with respect to such Product, and (ii) the later of (A)&#160;expiration of the last-to-expire Valid Claim of the Exelixis Patents, Joint Patents, and Collaborator Patents and (B) expiration of any Regulatory Exclusivity covering such Product in the Collaborator Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Royalty Rate Adjustment for Collaborator Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Royalty Term extends beyond the expiration of the last-to-expire Valid Claim of the &#91; * &#93; Patents, and any Regulatory Exclusivity &#91; * &#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Remaining Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the royalty rates to be paid by Collaborator to Exelixis during the Remaining Royalty Term shall be reduced by &#91; * &#93; of the amounts otherwise applicable under Section 8.5(a).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Basis of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Section 8.5 is intended to provide for royalty payments to Exelixis equal to the percentages of Net Sales set forth in this Section 8.5 for the entire duration of the Royalty Term.  In establishing this payment structure, Collaborator recognizes and acknowledges the substantial value of the various actions and investments that Exelixis has taken and will undertake under this Agreement, as well as the fact that the value of the license granted hereunder resides substantially in the Know-How.  Therefore, Collaborator agrees that the royalty payments set forth above are appropriate for the entire duration of such payment obligation.  The Parties have agreed to the payment structure set forth herein as a convenient and fair mechanism for both Parties to be compensated for the value of their actions and investments under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Exelixis Payments to Third Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Exelixis shall be solely responsible for all payments, including royalties and milestone payments, due with respect to Compound and Products pursuant to any Third Party agreement that Exelixis entered into prior to or as of the Effective Date, including any obligations &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Supply Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall pay Exelixis for Compound, Drug Product, or Finished Product, as the case may be, Exelixis supplies to Collaborator an amount equal to &#91; * &#93;, as applicable, all as provided in the applicable Supply Agreement.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Payment&#59; Records&#59; Audits</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Payment&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Royalty payments due by Collaborator to Exelixis under Section 8.5 shall be calculated and reported for each Calendar Quarter during the Royalty Term.  Within &#91; * &#93; after the end of each month during the Royalty Term, Collaborator shall provide to Exelixis a preliminary report setting forth the gross amount of sales of the Products by Collaborator and its Affiliates and Sublicensees in the Collaborator Territory during such month.  Within &#91; * &#93; after the end of each Calendar Quarter during the Royalty Term, Collaborator shall provide to Exelixis a preliminary report setting forth the estimated Net Sales of the Products by Collaborator and its Affiliates and Sublicensees in the Collaborator Territory during such Calendar Quarter.  Within &#91; * &#93; after the end of each Calendar Quarter, Collaborator shall deliver to Exelixis all royalty payments due under Section 8.5.  Each such payment shall be accompanied by a final report setting forth the Net Sales of the Products by Collaborator and its </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">45</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliates and Sublicensees in the Collaborator Territory in such Calendar Quarter in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including the number of Products sold, the gross sales and Net Sales of Products, including the deductions from gross sales to arrive at Net Sales, the royalties payable, the method used to calculate the royalties, the exchange rates used, and whether any commercial milestone under Section 8.4 has been achieved.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Collaborator shall submit a single report for all Net Sales during the Calendar Quarter, including all of Collaborator&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; Net Sales, but shall separately identify the Net Sales and other information applicable to each entity. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Exchange Rate&#59; Manner and Place of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All references to dollars and &#8220;$&#8221; herein shall refer to U.S. dollars.  All payments hereunder shall be payable in U.S. dollars.  With respect to conversion of Net Sales in Japanese yen to U.S. dollars, such conversion shall be at the exchange rate equal to the U.S. dollar conversion rate for the Japanese yen as published by &#91; * &#93;.  All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Exelixis, unless otherwise specified in writing by Exelixis.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Taxes. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Taxes on Income.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in this Section 9.3, each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Tax Cooperation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding, transfer taxes, or similar obligations with respect to milestone payments, royalty payments, and other payments made by Collaborator to Exelixis under this Agreement.  To the extent Collaborator is required by Applicable Laws to deduct and withhold taxes on any payment to Exelixis, Collaborator shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Exelixis an official tax certificate or other evidence of such payment sufficient to enable Exelixis to claim such payment of taxes.  Exelixis shall provide Collaborator any tax forms that may be reasonably necessary in order for Collaborator to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, to the extent legally able to do so.  Exelixis shall use reasonable efforts to provide any such tax forms to Collaborator in advance of the due date provided that Exelixis may direct Collaborator to temporarily hold a payment otherwise payable in order to avoid withholding taxes if Exelixis is waiting for a required tax form to be issued by a Governmental Authority.  Collaborator shall provide Exelixis with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes, transfer taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of Exelixis.  Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Taxes Resulting From Collaborator&#8217;s Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator represents and warrants that, as of the Effective Date, (i) Collaborator is not required by Applicable Law to deduct or withhold taxes on the upfront payment, milestone payments, royalty payments, and other payments payable to Exelixis under this Agreement and (ii) no transfer taxes will be </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">46</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">imposed on the foregoing payments under the laws of Japan.  If a Party takes any action of its own discretion (i.e., not required by a Regulatory Authority), including any assignment, sublicense, change of place of incorporation, or failure to comply with Applicable Laws or filing or record retention requirements, which results in a withholding or deduction obligation or a transfer tax (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Withholding Tax Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then such Party shall pay the sum associated with such Withholding Tax Action.  For clarity, if Collaborator undertakes a Withholding Tax Action, then the sum payable by Collaborator (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Exelixis receives a sum equal to the sum that it would have received had no such Withholding Tax Action occurred.  Otherwise, the sum payable by Collaborator (in respect of which such deduction or withholding is required to be made) shall be made to Exelixis after deduction of the amount required to be so withheld or deducted.  If a change in Applicable Laws results in a withholding or deduction obligation absent either Party taking a Withholding Tax Action, then the amount of such withholding or deduction obligation shall be paid by Collaborator to the applicable Governmental Authority on behalf of Exelixis in accordance with the provisions of Section 9.3(b).  The Parties shall use commercially reasonable efforts to invoke the application of any applicable bilateral income tax treaty that would reduce or eliminate otherwise applicable taxes with respect to payments payable pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Records&#59; Audit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party shall maintain complete and accurate records in sufficient detail in relation to this Agreement to permit the other Party to confirm the accuracy of the amount of Development Costs and the Cost of Goods to be reimbursed or shared, achievement of commercial milestones, and the amount of royalty and other payments under this Agreement.  Each Party will keep such books and records for &#91; * &#93; following the Calendar Year to which they pertain, or such longer period of time as may be required by Applicable Laws.&#160; Upon reasonable prior notice, such records shall be inspected during regular business hours at such place or places where such records are customarily kept by an independent certified public accountant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party pursuant to this Agreement.  Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit.  Such audits shall be limited to once each Calendar Year and once with respect to records covering any specific period of time.  Such auditor shall not disclose the audited Party&#8217;s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments to or by the audited Party under this Agreement.  In the event that the final result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within &#91; * &#93; after the Auditor&#8217;s report.  The auditing Party shall bear the full cost of such audit unless such audit reveals an underpayment of more than &#91; * &#93; by the audited Party, in which case the audited Party shall reimburse the auditing Party for the costs of such audit.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Late Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event that any payment due under this Agreement is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due at &#91; * &#93;&#59; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate.  The payment of such interest shall not limit the </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">47</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party entitled to receive payment from exercising any other rights it may have as a consequence of the lateness of any payment.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Intellectual Property  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Data.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All Data generated in connection with any Development or Commercial activities with respect to any Product conducted by or on behalf of Exelixis and its Affiliates and licensees (other than Collaborator) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be the sole and exclusive property of Exelixis or its Affiliates or licensees, as applicable.  All Data generated in connection with any Development or Commercial activities with respect to any Product conducted by or on behalf of Collaborator or its Affiliates or Sublicensees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be the sole and exclusive property of Collaborator or of its Affiliates or Sublicensees, as applicable.  For clarity, each Party shall have access to and the right to use and reference the other Party&#8217;s Data as and to the extent set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Inventions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Inventorship of any Inventions will be determined in accordance with the standards of inventorship and conception under U.S. patent laws.  The Parties will work together to resolve any issues regarding inventorship or ownership of Inventions.  Ownership of Inventions will be allocated as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Exelixis will solely own all data, Inventions, and Patents claiming such Inventions that relate to the composition, manufacture, or use of any Compound, or any improvement of any such composition, manufacture, or use, or are necessary for use in any combination therapy with the Compound produced by either Party or jointly during the Term and in the course of Development or Commercialization of the Product (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compound Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All Compound Inventions will be included in the Exelixis Know-How, and Patents in the Collaborator Territory claiming such Inventions will be included in the Exelixis Patents.  To the extent any Compound Invention is made by or on behalf of Collaborator, whether solely or jointly with Exelixis, Collaborator shall, and hereby does, transfer and assign to Exelixis, without additional consideration, all of its interest in such Compound Invention.  To effectuate the foregoing assignment by Collaborator to Exelixis, Collaborator shall ensure that its Affiliates and Sublicensees are obligated to assign all such Compound Inventions to Collaborator.  In addition, Exelixis hereby grants to Collaborator a non-exclusive, fully-paid, perpetual, and irrevocable license under such Compound Inventions in the Collaborator Territory for any purpose other than to Develop, use, manufacture, sell, offer for sale, import, or otherwise Commercialize the Compound or Product.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Except for Compound Inventions, each Party shall solely own any Inventions made solely by its and its Affiliates&#8217; employees, agents, or independent contractors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sole Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the Parties shall jointly own any Inventions that are made jointly by employees, agents, or independent contractors of one Party or its Affiliates together with employees, agents, or independent contractors of the other Party or its Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  All Patents claiming patentable Joint Inventions shall be referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;  Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice, license, assign, and </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">48</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise exploit its interest under the Joint Inventions and Joint Patents without the duty of accounting or seeking consent from the other Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Exelixis Patents. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Subject to this Section 10.2(a), Exelixis shall have the sole right, but not the obligation, to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, inter partes review, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) of the Exelixis Patents (other than Joint Patents) worldwide, using counsel of its own choice in the Exelixis Territory and counsel mutually agreed to by the Parties in the Collaborator Territory.  Collaborator shall reimburse Exelixis for all costs and expenses incurred with respect to the preparation, filing, prosecution, and maintenance of Exelixis Patents in the Collaborator Territory after the Effective Date and until the expiration or termination of this Agreement as provided in Section 14.1(a), within &#91; * &#93; from the date of invoice for such costs and expenses provided by Exelixis.  In the event that Collaborator does not reimburse Exelixis for such costs and expenses for any Exelixis Patent or notifies Exelixis in writing that it elects to cease reimbursing Exelixis for such costs and expenses for any Exelixis Patent, such Patent shall cease to be an Exelixis Patent and shall no longer be subject to the licenses and other rights granted by Exelixis to Collaborator under this Agreement.  Exelixis shall keep Collaborator informed of material progress with regard to the preparation, filing, prosecution, and maintenance of Exelixis Patents in the Collaborator Territory, sufficiently in advance for Collaborator to be able to review any material documents, including content, timing, and jurisdiction of the filing of such Exelixis Patents in the Collaborator Territory, and Exelixis shall consult with, and consider in good faith the requests and suggestions of, Collaborator with respect to strategies for filing, prosecuting, and defending, if any, Exelixis Patents in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">In the event that Exelixis desires to abandon or cease prosecution or maintenance of any Exelixis Patent in the Collaborator Territory during the Term, Exelixis shall provide reasonable prior written notice to Collaborator of such intention to abandon (which notice shall, to the extent possible, be given no later than &#91; * &#93; prior to the next deadline for any action that must be taken with respect to any such Exelixis Patent in the relevant patent office).  In such case, upon Collaborator&#8217;s written election provided no later than &#91; * &#93; after such notice from Exelixis, Exelixis shall continue prosecution and maintenance of such Exelixis Patent at Collaborator&#8217;s direction and expense.  If Collaborator does not provide such election within &#91; * &#93; after such notice from Exelixis, Exelixis may, in its sole discretion, continue prosecution and maintenance of such Exelixis Patent or discontinue prosecution and maintenance of such Exelixis Patent.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Collaborator Patents.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Subject to this Section 10.2(b), Collaborator shall have the first right, but not the obligation, to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">49</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defense of validity or enforceability challenges) of all Collaborator Patents (other than Joint Patents) worldwide, at its sole cost and expense and by counsel of its own choice in the Collaborator Territory and by counsel mutually agreed to by the Parties in the Exelixis Territory.  Collaborator shall keep Exelixis informed of the status of filing, prosecution, maintenance and defense, if any, of the Collaborator Patents, and Collaborator shall consult with, and consider in good faith the requests and suggestions of, Exelixis with respect to strategies for filing, prosecuting and defending, if any, Collaborator Patents.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">In the event that Collaborator desires to abandon or cease prosecution or maintenance of any Collaborator Patent during the Term, Collaborator shall provide reasonable prior written notice to Exelixis of such intention to abandon (which notice shall, to the extent possible, be given no later than &#91; * &#93; prior to the next deadline for any action that must be taken with respect to any such Collaborator Patent in the relevant patent office).  In such case, upon Exelixis&#8217; written election provided no later than &#91; * &#93; after such notice from Collaborator, Exelixis shall have the right to assume prosecution and maintenance of such Collaborator Patent at Exelixis&#8217; expense and Collaborator shall assign to Exelixis all of its rights, title, and interest in and to such Collaborator Patent.  If Exelixis does not provide such election within &#91; * &#93; after such notice from Collaborator, Collaborator may, in its sole discretion, continue prosecution and maintenance of such Collaborator Patent or discontinue prosecution and maintenance of such Collaborator Patent.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Joint Patents.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Subject to this Section 10.2(c), Exelixis shall have the first right, but not the obligation, to prepare, file, prosecute, and maintain (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) Joint Patents using a patent counsel selected by Exelixis in the Exelixis Territory and counsel mutually agreed to by the Parties in the Collaborator Territory.  Collaborator shall reimburse Exelixis for all costs and expenses incurred with respect to the preparation, filing, prosecution, and maintenance of Joint Patents in the Collaborator Territory, within &#91; * &#93; from the date of invoice for such costs and expenses provided by Exelixis.  In the event that Collaborator does not reimburse Exelixis for such costs and expense for any Joint Patent or notifies Exelixis in writing that it elects to cease reimbursing Exelixis for such costs and expense for any Joint Patent, Collaborator shall execute such documents and perform such acts, at Collaborator&#8217;s expense, as may be reasonably necessary to effect an assignment of Collaborator&#8217;s entire right, title, and interest in and to such Joint Patent to Exelixis, and such Patent shall cease to be either a Joint Patent or an Exelixis Patent and shall no longer be subject to the licenses and other rights granted by Exelixis to Collaborator under this Agreement.  Exelixis shall keep Collaborator informed of material progress with regard to the preparation, filing, prosecution, maintenance, and defense, if any, of Joint Patents, including content, timing, and jurisdiction of the filing of such Joint Patents, and Exelixis shall consult with, and consider in good faith the requests and suggestions of, Collaborator with respect to filing, prosecuting and defending, if any, Joint Patents in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">In the event that Exelixis desires to abandon or cease prosecution or maintenance of any Joint Patent in the Collaborator Territory, Exelixis shall provide reasonable prior written notice to Collaborator of such intention to abandon (which notice shall, </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">50</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the extent possible, be given no later than &#91; * &#93; prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office).  In such case, at Collaborator&#8217;s sole discretion, upon written notice from Collaborator to Exelixis, Collaborator may elect to continue prosecution or maintenance of any such Joint Patent at its own expense, and Exelixis shall execute such documents and perform such acts, at Collaborator&#8217;s expense, as may be reasonably necessary to allow Collaborator to continue the prosecution and maintenance of such Joint Patent in the Collaborator Territory.  Any such assignment shall be completed in a timely manner to allow Collaborator to continue prosecution and maintenance of any such Joint Patent and any such Patent so assigned shall cease to be either a Joint Patent or a Collaborator Patent and shall no longer be subject to the licenses and other rights granted by Collaborator to Exelixis under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Cooperation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party agrees to cooperate fully in the preparation, filing, prosecution, maintenance, and defense, if any, of Patents under Section 10.2 and in the obtaining and maintenance of any patent term extensions, supplementary protection certificates, and their equivalent with respect thereto, at its own cost (except as expressly set forth otherwise in this Article 10).  Such cooperation includes&#58; (i)&#160;executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as to enable the other Party to apply for and to prosecute patent applications in any country as permitted by Section 10.2&#59; and (ii)&#160;promptly informing the other Party of any matters coming to such Party&#8217;s attention that may affect the preparation, filing, prosecution, or maintenance of any such patent application and the obtaining of any patent term extensions, supplementary protection certificates, and their equivalent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Term Extensions in the Collaborator Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JEC will discuss and recommend for which, if any, of the Patents within the Exelixis Patents, Collaborator Patents, or Joint Patents the Parties should seek patent term extensions in the Collaborator Territory.  Exelixis in the case of the Exelixis Patents or any Joint Patents, and Collaborator in the case of the Collaborator Patents, shall have the final decision-making authority with respect to applying for any such patent term extension in the Collaborator Territory, and will act with reasonable promptness in light of the development stage of the Product to apply for any such patent term extension, where it so elects&#59; provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that if in the Collaborator Territory only one such Patent can obtain a patent term extension, then the Parties will consult in good faith to determine which such Patent(s) should be the subject of efforts to obtain a patent term extension.  The Party that does not apply for an extension hereunder will cooperate fully with the other Party in making such filings or actions, for example and without limitation, making available all required regulatory Data and information and executing any required authorizations to apply for such patent term extension.  All expenses incurred in connection with activities of each Party with respect to the Patent(s) for which such Party seeks patent term extensions pursuant to this Section 10.3 shall be the sole responsibility of such Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party shall notify the other within &#91; * &#93; of becoming aware of any alleged or threatened infringement by a Third Party of any of the Exelixis Patents (including Joint Patents) in the Collaborator Territory, which infringement adversely affects or is expected to adversely affect any Product, including any declaratory judgment, opposition, or </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">51</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">similar action alleging the invalidity, unenforceability, or non-infringement of any of the Exelixis Patents (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Enforcement Right.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis shall have the first right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate.  If Exelixis (i) decides not to bring such legal action against a Product Infringement (the decision of which Exelixis shall inform Collaborator promptly) or (ii) Exelixis otherwise fails to bring such legal action against a Product Infringement within &#91; * &#93; of first becoming aware of such Product Infringement, Collaborator shall have the right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate after consultation with Exelixis.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Collaboration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party&#8217;s request and expense, including to be named in such action if required by Applicable Laws to pursue such action.  The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts and shall reasonably consider the other Party&#8217;s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court.  The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Expense and Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Except as set forth in clause (ii) below, the enforcing Party shall be solely responsible for any expenses incurred by such Party as a result of such enforcement action.  If such Party recovers monetary damages in such enforcement action, such recovery shall be allocated first to the reimbursement of any expenses incurred by the enforcing Party in such enforcement action, second to the reimbursement of any expenses incurred by the other Party in such enforcement action, and any remaining amounts shall be retained by the enforcing Party. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Notwithstanding the foregoing, if Exelixis is the enforcing Party against a Product Infringement in the Collaborator Territory, Collaborator shall have the option to share &#91; * &#93; of the expense incurred by Exelixis in such enforcement action, which option may be exercised by Collaborator by providing written notice to Exelixis within &#91; * &#93; after receiving a notice from Exelixis that Exelixis decides to bring such action.  If Collaborator exercises such option, then (1) Collaborator shall reimburse Exelixis for &#91; * &#93; of all expenses incurred by Exelixis in such enforcement action, within &#91; * &#93; from the date of invoice for such expenses provided by Exelixis&#59; and (2) If Exelixis recovers any monetary damages in such enforcement action, such recovery shall be allocated &#91; * &#93; to Exelixis and &#91; * &#93; to Collaborator. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Other Infringement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except for Product Infringement as set forth above, each Party shall have the exclusive right to enforce its own Patent against any infringement anywhere in the world.  For clarity, Exelixis shall have the exclusive right to enforce (i) the Exelixis Patents against any infringement in the Collaborator Territory that is not a Product Infringement, and (ii) the Exelixis Patents and Joint Patents against any infringement in the Exelixis Territory, in each case at its own expense as it reasonably determines appropriate.  The Parties shall discuss global enforcement strategy for the Exelixis Patents and Collaborator </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">52</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patents, including the defense of validity and enforceability challenges arising from any enforcement action.    </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Infringement of Third Party Rights.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any Product used or sold by Collaborator, its Affiliates or Sublicensees becomes the subject of a Third Party&#8217;s claim or assertion of infringement of any intellectual property rights in a jurisdiction within the Collaborator Territory, Collaborator shall promptly notify Exelixis and the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a &#8220;common interest agreement&#8221; wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute.  Absent any agreement to the contrary, and subject to claims for indemnification under Article 13, each Party shall defend itself from any such Third Party claim at its own cost and expense, provided, however, that the provisions of Section 10.3 shall govern the right of Collaborator to assert a counterclaim of infringement of any Exelixis Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Marking.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Collaborator shall, and shall require its Affiliates and Sublicensees, to mark the Products sold by it hereunder (in a reasonable manner consistent with industry custom and practice) with appropriate Patent numbers or indicia to the extent permitted by Applicable Laws&#59; provided, however, that Collaborator shall only be required to so mark such Products to the extent such markings or such notices would impact recoveries of damages or equitable remedies available under Applicable Laws with respect to infringements of Patents in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patents Licensed From Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party&#8217;s rights under this Article 10 with respect to the prosecution and enforcement of any Exelixis Patent and Collaborator Patent shall be subject to the rights&#58; (a) retained by any upstream licensor to prosecute and enforce such Patent Right, if such Patent Right is subject to an upstream license agreement&#59; and (b) granted to any Third Party prior to such Patent Right becoming subject to the license grant under this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Trademarks.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Product Trademarks.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Exelixis shall develop and adopt trademarks, including trade names, trade dresses, branding, and logos, to be used for the Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Exelixis shall own the Product Marks throughout the world and all goodwill in the Product Marks shall accrue to Exelixis.  To the extent permitted by Applicable Laws, the Parties shall use CABOMETYX&#174;, or an equivalent trademark in Japanese, for all indications.  Exelixis shall be responsible for the registration, maintenance, defense, and enforcement of the Product Marks using counsel of its own choice in the Exelixis Territory and counsel mutually agreed to by the Parties in the Collaborator Territory.  Collaborator shall reimburse Exelixis for all costs and expenses incurred with respect to the registration and maintenance of the Product Marks after the Effective Date in the Collaborator Territory, within &#91; * &#93; from the date of invoice for such costs and expenses provided by Exelixis.  Exelixis shall keep Collaborator informed of material progress with regard to the registration, prosecution, maintenance, and defense, if any, of Product Marks in the Collaborator Territory, including content and timing of the filing of such Product Marks in the Collaborator Territory, sufficiently in advance for Collaborator to be able to review any material documents, and Exelixis shall consult with, and consider in good faith the </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">53</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requests and suggestions of, Collaborator with respect to strategies for filing, prosecuting, and defending, if any, the Product Marks in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Trademark License.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Collaborator shall use the Product Marks selected by Exelixis to Commercialize the Product in the Collaborator Territory.  Where use of the Product Mark is not permitted by Applicable Laws, the Parties shall agree on an alternative product trademark and such alternative product trademark shall be included as a Product Mark.  In addition, unless prohibited by Applicable Laws, Collaborator shall include Exelixis&#8217; corporate trademark on the packaging and product information (i.e., SmPC) of the Products sold in the Collaborator Territory to indicate that the Product is licensed from Exelixis.  Exelixis hereby grants to Collaborator a limited royalty-free license to use such Product Marks and Exelixis&#8217; corporate trademark solely in connection with the Commercialization of the Product in the Collaborator Territory during the Royalty Term under this Agreement.  All use of the Product Marks and Exelixis&#8217; corporate trademark shall comply with Applicable Laws and regulations and shall be subject to Exelixis&#8217; review and approval.  For clarity, Collaborator shall also include its (or its Affiliate&#8217;s or Sublicensee&#8217;s) corporate logo in the Product sold in the Collaborator Territory.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Representations and Warranties</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party represents and warrants to the other that, as of the Effective Date&#58; (a)&#160;it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof, (b)&#160;it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action, (c)&#160;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body, or administrative or other agency having jurisdiction over it, and (d)&#160;it has the right to grant the licenses granted by it under this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Employees, Consultants, and Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party covenants that it has obtained or will obtain written agreements from each of its employees, consultants, and contractors who perform Development activities pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign (or, in the case of contractor, grant a license under) Inventions in a manner consistent with the provisions of this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party represents, warrants, and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to any Product.  In the event that either </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">54</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or Sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party covenants as follows&#58; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">In the performance of its obligations under this Agreement, each Party shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all Applicable Laws. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Each Party and its Affiliates&#8217; employees and contractors shall not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise, or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or Entity or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, including such Party (and each Party represents and warrants that as of the Effective Date, such Party, and to its knowledge, its and its Affiliates&#8217; employees and contractors, have not directly or indirectly promised, offered, or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift, or hospitality or other illegal or unethical benefit to a Public Official or other entity or any other person in connection with the performance of such Party&#8217;s obligations under this Agreement, and each Party  covenants that it and its Affiliates&#8217; employees and contractors shall not, directly or indirectly, engage in any of the foregoing).   </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Each Party and its Affiliates, and their respective employees and contractors, in connection with the performance of their respective obligations under this Agreement, shall not cause its Indemnitees to be in violation of the FCPA, Export Control Laws, or any other Applicable Laws or otherwise cause any reputational harm to the other Party. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Each Party shall immediately notify the other Party if such Party has any information or suspicion that there may be a violation of the FCPA, Export Control Laws, or any other Applicable Laws in connection with the performance of this Agreement or the Development, manufacture, or Commercialization of any Product. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In connection with the performance of its obligations under this Agreement, each Party shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with such Party&#8217;s own anti-corruption and anti-bribery policy, a copy of which has been provided to the other Party prior to the Effective Date. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Each Party will have the right, upon reasonable prior written notice and during the other Party&#8217;s regular business hours, to conduct, at its own expense, inspections of and to audit the other Party&#8217;s books and records in the event of a suspected violation or to ensure compliance with the representations, warranties, or covenants of this Section 11.2(c)&#59; provided, however, that in the absence of good cause for such inspections and audits, such Party may only exercise this right on an annual basis. </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">55</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">In the event that either Party has violated or been suspected of violating any of the representations, warranties, or covenants in this Section 11.2(c), the other Party will cause its or its Affiliates&#8217; personnel or others working under its direction or control to submit to periodic training that such violating Party will provide on anti-corruption law compliance.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">Either Party will, at the other Party's request, annually certify to the other Party in writing such Party&#8217;s compliance, in connection with the performance of its obligations under this Agreement, with the representations, warranties, or covenants in this Section 11.2(c), which certification shall be issued by such Party&#8217;s commercial head of its respective territory.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Each Party shall have the right to suspend or terminate this Agreement in its entirety where there is a credible finding, after a reasonable investigation, that the other Party, its Affiliates, or its Sublicensees, in connection with performance of the other Party&#8217;s obligations under this Agreement, has violated the FCPA. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Additional Exelixis Representations, Warranties, and Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Exelixis represents, warrants, and covenants, as applicable, to Collaborator that, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exhibit 1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> lists all Patents Controlled by Exelixis in the Collaborator Territory as of the Effective Date that claim the composition of matter or use of the Compound&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Exelixis has the right to grant all rights and licenses it purports to grant to Collaborator with respect to the Exelixis Technology under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Exelixis has not granted any liens or security interests on the Exelixis Technology&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Exelixis has not received any written notice from a Third Party that the Development of any Product conducted by Exelixis prior to the Effective Date has infringed any Patents of any Third Party&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Exelixis has not as of the Effective Date, and will not during the Term, grant any right to any Third Party under the Exelixis Technology that would conflict with the rights granted to Collaborator hereunder&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">no claim or action has been brought or, to Exelixis&#8217; knowledge, threatened in writing, by any Third Party alleging that the Exelixis Patents are invalid or unenforceable, and no Exelixis Patent is the subject of any interference, opposition, cancellation or other protest proceeding&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">to Exelixis&#8217; knowledge, no Third Party is infringing or misappropriating or has infringed or misappropriated the Exelixis Technology in the Collaborator Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Exelixis has disclosed to Collaborator all clinical and non-clinical data in the Control of Exelixis that is necessary and&#47;or material to the evaluation of the safety, efficacy and manufacturing process of the Product&#59; and</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">56</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">to Exelixis&#8217; knowledge, there are no issues or information, which to Exelixis&#8217; knowledge and reasonable opinion, are reasonably likely to have a material impact on the Development of the Product that have not been fully disclosed to Collaborator in the course of Collaborator&#8217;s due diligence.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Additional Representations, Warranties and Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Collaborator represents, warrants, and covenants to Exelixis that, as of the Effective Date, Collaborator has not granted, and will not grant during the Term, any right to any Third Party under the Collaborator Technology that would conflict with the rights granted to Exelixis hereunder.  Collaborator further represents, warrants, and covenants to Exelixis that, as of the Effective Date, Collaborator does not own or control any Collaborator Patents. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Disclaimer.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as expressly set forth in this Agreement, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED &#8220;AS IS&#8221; AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.  Without limiting the foregoing, (a)&#160;neither Party represents or warrants that any data obtained from conducting Clinical Trials in one country or jurisdiction will comply with the laws and regulations of any other country or jurisdiction, and (b)&#160;neither Party represents or warrants the success of any study or test conducted by it pursuant to this Agreement, or the safety or usefulness for any purpose of the technology it provides hereunder.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Indemnification</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Indemnification by Exelixis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Exelixis hereby agrees to defend, indemnify, and hold harmless Collaborator and its Affiliates and their respective directors, officers, employees and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all liabilities, expenses, and losses, including reasonable legal expenses and attorneys&#8217; fees (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to which any Collaborator Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of&#58; (a) the manufacturing, Development, use, handling, storage, Commercialization, or other disposition of any Compound or Product by Exelixis or its Affiliates or licensees or the contractors of any of them (excluding any activities by or on behalf of Collaborator or its Affiliates or Sublicensees), (b) the  negligence or willful misconduct of any Exelixis Indemnitee, or (c)&#160;the breach by Exelixis of any warranty, representation, covenant, or agreement made by Exelixis in this Agreement&#59; except, in each case (a)-(c), to the extent such Losses arise out of any activities set forth in Sections 12.2(a)-(c) for which Collaborator is obligated to indemnify the Exelixis Indemnitee under Section 12.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Indemnification by Collaborator.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Collaborator hereby agrees to defend, indemnify, and hold harmless Exelixis, its Affiliates, and licensees and their respective directors, officers, employees, and agents (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all Losses to which any Exelixis Indemnitee may become subject as a result of any claim, demand, </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">57</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">action, or other proceeding by any Third Party to the extent such Losses arise out of&#58; (a)&#160;the manufacturing, Development, use, handling, storage, Commercialization, or other disposition of any Compound or Product by Collaborator, its Affiliates, or Sublicensees or the contractor of any of them, (b) the negligence or willful misconduct of any Collaborator Indemnitee, or (c)&#160;the breach by Collaborator of any warranty, representation, covenant, or agreement made by Collaborator in this Agreement&#59; except, in each case (a)-(c), to the extent such Losses arise out of any activities set forth in Sections 12.1(a)-(c) for which Exelixis is obligated to indemnify the Collaborator Indemnitee under Section 12.1.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Procedure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A party that intends to claim indemnification under this Article 12 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall promptly notify the indemnifying Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in writing of any Third Party claim, demand, action, or other proceeding (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense or settlement thereof.  The Indemnitee may participate, at its expense and using its own counsel, in the Indemnitor&#8217;s defense of and settlement negotiations for any Claim.  The indemnity arrangement in this Article&#160;12 shall not apply to amounts paid in settlement of any action with respect to a Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed.  The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article&#160;12 if and to the extent the Indemnitor is actually prejudiced thereby.  The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Claim covered by this indemnification.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the Term, each Party, at its own expense, shall maintain commercial general liability insurance, including public and product liability and other appropriate insurance (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement.  Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 13, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, LOST PROFIT OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER&#59; provided, however, that the foregoing limitation shall not apply with respect to any amounts that may become payable as a result of Losses arising from a Third Party Claim.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Confidentiality</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for &#91; * &#93; thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the other Party, and both Parties shall keep confidential and, subject to Sections 13.2 and 13.3 and 13.4, shall not publish or otherwise </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">58</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">disclose the terms of this Agreement.  Each Party may use the other Party&#8217;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations under this Agreement.  Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own of similar nature (but no less than reasonable care) to ensure that its officers, directors, employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the Confidential Information of the other Party.  Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Exceptions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations of confidentiality and restriction on use under Section 13.1 will not apply to any information that the receiving Party can prove by competent evidence&#58; (a)&#160;is as of the Effective Date, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public&#59; (b)&#160;is known by the receiving Party or its Affiliate at the time of receiving such information hereunder, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors&#59; (c)&#160;is hereafter furnished to the receiving Party or its Affiliate without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right&#59; or (d)&#160;is independently discovered or developed by or on behalf of the receiving Party or its Affiliate without the use of Confidential Information belonging to the disclosing Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Authorized Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">filing, prosecuting, or maintaining Patents as permitted by this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">filing Regulatory Filings for Products that such Party has a license or right to Develop and Commercialize hereunder in a given country or jurisdiction&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">prosecuting or defending litigation as permitted by this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">complying with Applicable Laws or regulations (including regulations promulgated by securities exchanges) or orders from a court having competent jurisdiction or administrative orders&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">disclosure to potential and actual investors, acquirors, licensees, and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent as those herein&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">disclosure to its and its Affiliates&#8217; officers, directors, employees, consultants, contractors, and agents, to its licensees and sublicensees, in each case on a need-to-know basis in connection with the Development, manufacture, or Commercialization of the Compound and Products in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein.  For the </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">59</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">avoidance of any doubt, Collaborator shall not be permitted to disclose, for any reason, any Confidential Information of Exelixis to &#91; * &#93; or &#91; * &#93; without Exelixis&#8217; prior written consent.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event that a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section&#160;13.3(c) or 13.3(d), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such Confidential Information at least as diligent as such Party would use to protect its own confidential information, but in no event less than reasonable efforts.  In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder.  Any information disclosed pursuant to Section 13.3(c) or 13.3(d) shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article 13.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Publications.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each Party shall have the right to review and comment on any material proposed for disclosure or publication by the other Party regarding results of and other information regarding the other Party&#8217;s Development activities with respect to the &#91; * &#93;, whether by oral presentation, manuscript, or abstract.  Before any such material is submitted for publication, or presentation of any such material is made, the Party disclosing or submitting the proposed publication (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Submitting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall deliver a complete copy of the material proposed for disclosure to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Responding Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to the extent reasonably practicable, at least &#91; * &#93; (for oral presentations or abstracts) or &#91; * &#93; (for manuscripts) prior to submitting the material to a publisher or initiating any other disclosure.  The Responding Party shall review any such material and give its comments to the Submitting Party within &#91; * &#93; (for oral presentations or abstracts) or &#91; * &#93; (for manuscripts) of the receipt of such material.  Notwithstanding the foregoing, the Parties acknowledge that each Party may require expedited review with respect to oral presentation materials, abstracts, and manuscripts&#59; accordingly, the Responding Party shall make reasonable efforts to expedite review of such materials, abstracts, and manuscripts, and shall return such items as soon as practicable to the Submitting Party with appropriate comments, if any.  Following the expiration of the applicable time period for review, the Submitting Party shall be free to submit such proposed publication for publication or otherwise disclose to the public such information, subject to the procedures set forth in Section 13.4(b). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If the Responding Party believes that the subject matter of the proposed publication or other disclosure contains Confidential Information or a patentable invention of the Responding Party, then prior to the expiration of the applicable time period for review, the Responding Party shall notify the Submitting Party in writing of its determination that such proposed publication or other disclosure, as applicable, contains such information or subject matter for which patent protection should be sought.  Upon receipt of such written notice from the Responding Party, the Submitting Party shall delay public disclosure of such information or submission of the proposed publication for an additional period of &#91; * &#93; (or such other time period mutually agreed by the Parties in writing) to permit preparation and filing of a patent application on the disclosed subject matter.  The Submitting Party shall thereafter provide the Responding Party with a copy of final version of publication materials and be free to publish or disclose such information, except that the Submitting Party may not disclose any Confidential Information of the Responding Party in violation of Section 13.1.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">60</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Publicity&#59; Public Disclosures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Parties agree to issue a joint press release substantially in a form agreed by the Parties and attached to this Agreement as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit 13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> announcing the signature of this Agreement at or shortly after the Effective Date within the time-period required by applicable securities laws.  It is understood that each Party may desire or be required to issue subsequent press releases relating to this Agreement or activities hereunder.  The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof, to the extent practicable, provided that a Party may not unreasonably withhold, condition, or delay consent to such releases by more than &#91; * &#93;, and that either Party may issue such press releases or make such disclosures to the SEC or other applicable agency as it determines, based on advice of counsel, as reasonably necessary to comply with laws or regulations or for appropriate market disclosure.  Each Party shall provide the other Party with advance notice of legally required disclosures to the extent practicable.  The Parties will consult with each other on the provisions of this Agreement to be redacted in any filings made by a Party with the SEC or as otherwise required by Applicable Laws&#59; provided that each Party shall have the right to make any such filing as it reasonably determines necessary under Applicable Laws.  In addition, following the initial joint press release announcing this Agreement, either Party shall be free to disclose, without the other Party&#8217;s prior written consent, the existence of this Agreement, the identity of the other Party, and those terms of the Agreement which have already been publicly disclosed in accordance herewith. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Equitable Relief. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use, or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 13.  In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 13.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Term and Termination</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Term.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Agreement shall commence on the Effective Date and, unless terminated earlier as provided in this Article 14 or by mutual written agreement of the Parties, shall continue until the expiration of the Royalty Term in the Collaborator Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Notwithstanding anything herein, on a Product-by-Product basis, upon the expiration of the Royalty Term (i.e., all royalty payment obligations for a Product in the Collaborator Territory), the licenses granted to Collaborator in Section 2.1 shall be deemed to be perpetual and fully paid-up with respect to such Product in the Collaborator Territory, but thereafter shall be on a non-exclusive basis.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding anything herein, on a Product-by-Product basis, upon the expiration of the Royalty Term the licenses granted to Exelixis in Section 2.4 shall become perpetual and non-exclusive.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">61</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Termination for Cause.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the other Party within &#91; * &#93; (&#91; * &#93; with respect to any payment breach) after notice of such breach from the non-breaching Party.  If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party, and such alleged breaching Party provides the other Party notice of such dispute within &#91; * &#93;, then the other Party shall not have the right to terminate this Agreement under this Section 14.2(a) unless and until an arbitral panel, in accordance with Article 15, has determined that the alleged breaching Party has materially breached the Agreement and that such Party fails to cure such breach within the applicable cure period set forth above following such decision.  In the event Exelixis commences an arbitration alleging material breach by Collaborator and Collaborator later delivers notice of voluntary termination under Section 14.3, then, at the election of Exelixis, the period of time set forth in Section 14.3 shall be reduced by an amount of time equal to the duration of time from the commencement of the arbitration to the delivery of such notice, &#91; * &#93;. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee, or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation, or any other similar proceeding for the release of financially distressed debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within &#91; * &#93; after the commencement thereof.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Exelixis shall have the right to terminate this Agreement immediately in its entirety upon written notice to Collaborator if Collaborator or any of its Affiliates or Sublicensees directly, or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Exelixis Patent.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Safety Reasons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the terminating Party reasonably determines, based upon additional information that becomes available or an analysis of the existing information at any time, that the medical risk&#47;benefit of such Product is so unfavorable that it would be incompatible with the welfare of patients to Develop or Commercialize or to continue to Develop or Commercialize such Product.  Prior to any such termination, the terminating Party shall comply with such internal review and management approval processes as it would normally follow in connection with the termination of the development and commercialization of its own products for safety reasons.  The terminating Party shall document the decisions of such committees or members of management and the basis therefor and shall make such minutes and documentation available to the other Party promptly upon written request.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">62</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Discontinuation of Clinical Trials. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Collaborator may terminate this Agreement upon &#91; * &#93; advance written notice to Exelixis, if substantially all ongoing Clinical Trials of the Product are ordered or required to be terminated by the FDA or the MHLW.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Termination without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Prior to Commercial Launch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  At any time prior to August 1, 2023, the Parties may mutually agree that the PMDA is unlikely to grant approval of the MAA for the Product in any cancer indication in the Collaborator Territory.  In such event, the Parties may agree to terminate this Agreement by mutual written agreement, such agreement to include a mutually acceptable plan to wind down and terminate the Agreement.  Commencing on August 1, 2023, Collaborator shall have the right to terminate the Agreement without cause upon &#91; * &#93; prior written notice to Exelixis if the PMDA has not granted approval of the MAA for the Product in any cancer indication in the Collaborator Territory.  For the purpose of this Section 14.3(a), if the PMDA grants such MAA Approval conditioned on the performance of additional Phase 3b or other studies, then the PMDA shall be deemed to have granted approval of such MAA. For clarification, this Section 14.3(a) shall not be construed as limiting a right of termination under Section 14.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">After Commercial Launch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall have the right to terminate this Agreement in its entirety without cause upon twelve (12) months&#8217; prior written notice after the First Commercial Sale of a Product in the Collaborator Territory&#59; provided, however, that Collaborator may not terminate this Agreement pursuant to this Section 14.3(b) prior to the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) anniversary of the First Commercial Sale of such Product in the Collaborator Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Effects of Termination (Except By Reason Of Exelixis Material Breach).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon any termination of this Agreement by either Party for any reason other than termination under Section 14.2(a) resulting from a material breach of this Agreement by Exelixis, the following will apply&#58;  For clarity, during the pendency of any dispute regarding material breach and&#47;or any termination notice period, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All licenses granted by Exelixis to Collaborator will automatically terminate, including all sublicenses granted by Collaborator to any Sublicensee.  All licenses granted by Collaborator to Exelixis shall survive such termination and shall automatically become worldwide and perpetual. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Regulatory Materials&#59; Data.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Within &#91; * &#93;  of the effective date of termination of this Agreement, Collaborator shall transfer and assign to Exelixis, at no cost to Exelixis, all Regulatory Filings and Regulatory Approvals for the Products, Data from all preclinical, non-clinical and clinical studies conducted by or on behalf of Collaborator, its Affiliates, or Sublicensees on the Products, and all pharmacovigilance data (including any adverse events database) on the Products.  In the event any Regulatory Filings and&#47;or Regulatory Approval for a Product cannot be transferred to Exelixis within such &#91; * &#93; period, Collaborator shall continue to maintain such Regulatory Fillings and&#47;or Regulatory Approval until such time as Collaborator is permitted to transfer such Regulatory Filing or Regulatory Approval to </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">63</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis.  In addition, at Exelixis&#8217; request, Collaborator shall provide Exelixis with reasonable assistance with any inquiries and correspondence with Regulatory Filings and Regulatory Authorities regarding the Product in the Collaborator Territory for a period of &#91; * &#93; after such termination.  Exelixis shall be responsible for Collaborator&#8217;s reasonable costs incurred directly in connection with any such Exelixis request.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Development Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall either, as directed by Exelixis, (i) wind-down any ongoing Development activities (including any Clinical Trials) of Collaborator and its Affiliates and Sublicensees with respect to any Product in the Collaborator Territory in an orderly fashion, or (ii) promptly transfer such Development activities to Exelixis or its designee, in compliance with all Applicable Laws.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Cost of Ongoing Trials.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If there is any ongoing Clinical Trial of the Product under the GDP for which Collaborator has committed to share the costs or be fully responsible for funding, then Collaborator shall continue to share the non-cancelable costs of or fund such Clinical Trial, as the case may be, until &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Commercial Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Collaborator shall, as directed by Exelixis, (i) continue certain ongoing Commercial activities of Collaborator and its Affiliates and Sublicensees with respect to any Product in the Collaborator Territory for a period of up to &#91; * &#93; as determined by Exelixis, and (ii) handoff such Commercial activities to Exelixis or its designee, on a timetable to be set by Exelixis, not to exceed &#91; * &#93;, and in compliance with all Applicable Laws.  During such commercial wind-down period, Collaborator shall continue to book sales and pay royalties to Exelixis in accordance with Section 8.5.  Except as necessary to conduct the foregoing activities as directed by Exelixis, Collaborator shall immediately discontinue its (and shall ensure that its Affiliates and Sublicensees immediately discontinue their) promotion, marketing, offering for sale, and servicing of the Product and its use of all Product Marks.  In addition, Collaborator shall immediately deliver to Exelixis (at Collaborator&#8217;s expense) all samples, demonstration equipment, sales materials, catalogs, and literature of Exelixis in Collaborator&#8217;s possession or control.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Transition Assistance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Collaborator shall use Commercially Reasonable Efforts to seek an orderly transition of the Development and Commercialization of the Compound and Products to Exelixis or its designee for so long as is necessary to ensure patient safety, including ensuring continuity of supply to any patients.  Collaborator shall, at no cost to Exelixis, provide reasonable consultation and assistance for a period of no more than &#91; * &#93; after termination for the purpose of transferring or transitioning to Exelixis all Collaborator Know-How not already in Exelixis&#8217; possession and, at Exelixis&#8217; request, all then-existing commercial arrangements relating to the Products that Collaborator is able, using Commercially Reasonable Efforts, to transfer or transition to Exelixis or its designee, in each case, to the extent reasonably necessary or useful for Exelixis to continue the Development and&#47;or Commercialization of the Compound and Products in the Collaborator Territory.  If any such contract between Collaborator and a Third Party is not assignable to Exelixis or its designee (whether by such contract&#8217;s terms or because such contract does not relate specifically to the Products) but is otherwise reasonably necessary or useful for Exelixis to continue the Development and&#47;or Commercialization of the Compound and Products in the Collaborator Territory, or if Collaborator is performing such work for the Compound and Product itself (and thus there is no contract to assign), then Collaborator shall reasonably cooperate with Exelixis to negotiate for </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">64</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the continuation of such services for Exelixis from such entity, or Collaborator shall continue to perform such work for Exelixis, as applicable, for a reasonable period (not to exceed &#91; * &#93;) after termination at Exelixis&#8217; cost until Exelixis establishes an alternate, validated source of such services.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Remaining Inventories. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Exelixis shall have the right, at its discretion, to purchase from Collaborator any or all of the inventory of the Products held by Collaborator as of the date of termination at a price equal to the transfer price paid by Collaborator to acquire such inventory from Exelixis.  Exelixis shall notify Collaborator within &#91; * &#93; after the date of termination whether Exelixis elects to exercise such right.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Non-Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following any termination of this Agreement by Collaborator pursuant to Section 14.3(b), or by Exelixis pursuant to Section 14.2, neither Collaborator nor any of its Affiliates shall (directly or indirectly, either with or without a bona fide Collaborator or any other Third Party) (i) develop any Competing Product in the Collaborator Territory for a period of &#91; * &#93; following the effective date of such termination, or (ii) commercialize any Competing Product in the Collaborator Territory for a period of &#91; * &#93; following the effective date of such termination. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">No Generic Product.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Following any termination of this Agreement by Collaborator pursuant to Section 14.3(b) or by Exelixis pursuant to Section 14.2, neither Collaborator nor any of its Affiliates shall (directly or indirectly, either with or without a bona fide Collaborator or any other Third Party) (i) develop any Generic Product in the Collaborator Territory for a period of &#91; * &#93; following the effective date of such termination or (ii) commercialize any Generic Product in the Collaborator Territory for a period of &#91; * &#93; following the effective date of such termination. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Effect of Termination (Material Breach by Exelixis).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon any termination of this Agreement by Collaborator pursuant to Section 14.2(a) resulting from a material breach of this Agreement by Exelixis, then all of the provisions of Section 14.4 shall apply, except that (1) Sections 14.4 (d), (h) and (i) shall have no effect, and (2) to the extent Exelixis requests Collaborator&#8217;s performance under any of the provisions of Sections 14.4 (b), (c), (e), (f) or (g), Exelixis shall reimburse Collaborator for all costs incurred by Collaborator in connection with such performance, including both its external costs plus its internal costs calculated on a reasonable FTE basis. For clarity, while Collaborator shall not be subject to Section 14.4(d) in such event, it shall remain subject to Section 14.4(c) subject to the reimbursement of costs by Exelixis.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Rights in Bankruptcy.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All rights and licenses granted under or pursuant to this Agreement by one Party to the other Party are, and otherwise will be deemed to be, for purposes of Section&#160;365(n) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, licenses of right to &#8220;intellectual property&#8221; as defined under Section&#160;101 of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws.  The Parties agree that a Party that is a licensee of such rights under this Agreement will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws.  The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party to this Agreement under the U.S. Bankruptcy Code or comparable provision of </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">65</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable bankruptcy or insolvency laws, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in its possession, will be promptly delivered to it (a)&#160;upon any such commencement of a bankruptcy or insolvency proceeding upon its written request therefor, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b)&#160;if not delivered under (a) above, following the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Confidential Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon expiration or termination of this Agreement in its entirety, except to the extent that a Party obtains or retains the right to use the other Party&#8217;s Confidential Information, each Party shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party&#8217;s possession or control containing Confidential Information of the other Party&#59; provided that a Party may keep one copy of such materials for archival purposes subject to continuing confidentiality obligations and other copies to the extent necessary for complying with Applicable Laws.  All Collaborator Data and Regulatory Filings assigned to Exelixis upon termination of this Agreement will be deemed Exelixis&#8217; Confidential Information and no longer Collaborator&#8217;s Confidential Information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Additional Remedies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In case of termination by reason of either Party&#8217;s material breach, unless otherwise expressly provided in the Agreement, the termination under this Article 14 will not be an exclusive remedy for the terminating Party, and will not preclude, limit, nor be in lieu of any other remedies available to the terminating Party under this Agreement or Applicable Laws as a result of any material breach by the other Party. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination.  Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement to the extent that the subject matter of such provision exists&#58;  Article 1 (Definitions)&#59; Article 9 (Payments, Records, Audits)&#59; Article 12 (Indemnification)&#59; Article 15 (Dispute Resolution)&#59; Article 16 (General Provisions)&#59; Section 2.5 (No Implied Licenses&#59; Negative Covenant)&#59; Section 5.10 (Sunshine Reporting Laws)&#59; Section 10.1 (IP Ownership)&#59; Section 10.2(c) (Joint Patent Prosecution)&#59; Sections 13.1, 13.2, 13.3 and 13.6 (Confidentiality)&#59; Sections 14.1(b) and (c) (Term&#59; in each case to the extent applicable)&#59; Sections 14.4 and 14.5 (Effects of Termination, in each case to the extent applicable)&#59; Section 14.6 (Rights in Bankruptcy&#59; to the extent applicable)&#59; Section 14.7 (Confidentiality)&#59; Section 14.8 (Additional Remedies)&#59; and Section 14.9 (Survival).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Dispute Resolution </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Objective.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Parties recognize that disputes as to matters arising under, in connection with or relating to this Agreement or either Party&#8217;s rights and obligations hereunder may arise from time to time.  It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient and amicable manner by mutual cooperation and without resort to litigation.  To accomplish this objective, the Parties agree to follow the procedures set forth in this Article&#160;15 to resolve any such dispute if and when it arises.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">66</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Executive Mediation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will try to settle any dispute, controversy, or claim that arises out of, in connection with or relates to, any provision of the Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disputed Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by first referring the Disputed Matter to the Parties&#8217; Executive Officers.  Either Party may initiate such informal dispute resolution by sending written notice of the Disputed Matter to the other Party, and, within &#91; * &#93; after such notice, the Executive Officers (or their respective designees having the authority to settle such Disputed Matter) of the Parties will meet for attempted resolution by good faith negotiations.  If the Executive Officers (or their respective designees) are unable to resolve such dispute within &#91; * &#93; of their first meeting for such negotiations, either Party may seek to have such dispute resolved in accordance with Section 15.3 below. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Dispute Resolution.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If the Parties are unable to resolve a Disputed Matter using the process described in Section 15.2, then a Party seeking further resolution of the Disputed Matter will submit the Disputed Matter to resolution by final and binding arbitration.  Whenever a Party will decide to institute arbitration proceedings, it will give written notice to that effect to the other Party.  Arbitration will be held in &#91; * &#93;, and administered by the International Chamber of Commerce pursuant to its ICC International Arbitration Rules then in effect (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), except as otherwise provided herein and applying the substantive law specified in Section 16.1.  The arbitration will be conducted by a panel of three (3) arbitrators appointed in accordance with the Rules&#59; provided that each Party will, within &#91; * &#93; after the institution of the arbitration proceedings, appoint an arbitrator, and such arbitrators will together, within &#91; * &#93;, select a third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) arbitrator as the chairman of the arbitration panel.  Each arbitrator must have significant business or legal experience in the pharmaceutical business.  If the two (2) initial arbitrators are unable to select a third (3rd) arbitrator within such &#91; * &#93; period, the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) arbitrator will be appointed in accordance with Rules.  In addition to the authority conferred by the Rules, the Parties hereby agree to engage in discovery of information and evidence that is or might be relevant to the claims, defenses, and issues in the dispute, including by means of discovery in the form of &#91; * &#93;, subject to &#91; * &#93; being permitted by the panel of arbitrators on a showing of good cause.&#160; The Parties further agree to the ability, right, and power to subpoena Third Party witnesses for both discovery and hearing purposes.  After conducting any hearing and taking any evidence deemed appropriate for consideration, the arbitrators will render their opinion within &#91; * &#93; of the final arbitration hearing.  The panel of arbitrators will not have the power to award damages excluded pursuant to Section 12.5 under this Agreement and any arbitral award that purports to award such damages is expressly prohibited and void ab initio.  Decisions of the panel of arbitrators that conform to the terms of this Section 15.3 will be final and binding on the Parties and judgment on the award so rendered may be entered in any court of competent jurisdiction.  The losing Party, as determined by the panel of arbitrators, will pay all of the ICC administrative costs and fees of the arbitration and the fees and costs of the arbitrators, and the arbitrators will be directed to provide for payment or reimbursement of such fees and costs by the losing Party.  If the panel of arbitrators determines that there is no losing Party, the Parties will each be responsible for one-half of those costs and fees and the arbitrators&#8217; award will so provide.  Notwithstanding the foregoing, each Party shall be responsible for its own attorneys&#8217; fees, expert or witness fees, and any other fees and costs, and no such fees or costs will be shifted to the other Party.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">67</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Notwithstanding the terms of and procedures set forth in Section 15.2 or 15.3, any applications, motions, or orders to show cause seeking temporary restraining orders, preliminary injunctions or other similar preliminary or temporary legal or equitable relief (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) concerning a Disputed Matter (including, but not limited to, Disputed Matters arising out of a potential or actual breach of the confidentiality and non-use provisions in Article 13)  may immediately be brought in the first instance and without invocation or exhaustion of the procedures set forth in subsections (a) and (b) for hearing and resolution in and by a court of competent jurisdiction.  Alternatively, a party seeking Injunctive Relief may immediately institute arbitral proceedings without invocation or exhaustion of the procedures set forth in subsections (a) and (b), and any such Injunctive Relief proceedings will be administered by the ICC pursuant to its ICC emergency arbitration procedures then in effect and applying the substantive law specified in Section 16.1.  In either event, once the Injunctive Relief proceedings have been conducted and a decision rendered thereon by the court or arbitral forum, the Parties will, if the Disputed Matter is not finally resolved by the Injunctive Relief, proceed to resolve the Disputed Matter in accordance with the terms of Section 15.2 and 15.3. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding the foregoing, this Section 15.3 shall not apply to any dispute, controversy, or claim that concerns (i)&#160;the validity, enforceability, or infringement of a patent, trademark, or copyright&#59; or (ii)&#160;any antitrust, anti-monopoly, or competition law or regulation, whether or not statutory.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">General Provisions</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Governing Law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement, and all questions regarding the existence, validity, interpretation, breach, or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, United States, without reference to its conflicts of law principles.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Entire Agreement&#59; Modification.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement, including the exhibits, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to all of its terms.  This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, concerning any and all matters contained herein.  This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Relationship Between the Parties.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors.  This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties.  Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Waiver.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.   Any waiver by a Party of a particular term or condition will be effective only if set </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">68</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Assignment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld)&#59; provided, however, that either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#8217;s consent&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">in connection with the transfer or sale of all or substantially all of the business or assets of such Party relating to the Compound and Products to a Third Party, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets, or otherwise, provided that in the event of any such transaction (whether this Agreement is actually assigned or is assumed by the acquiring Party by operation of law (e.g., in the context of a reverse triangular merger)), intellectual property rights of the acquiring Party to such transaction (if other than one of the Parties to this Agreement) shall not be included in the technology licensed hereunder&#59; or </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this Section 16.5.  Any assignment not in accordance with this Section 16.5 shall be null and void and of no legal force or effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Severability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.  The Parties will in such an instance use their best efforts to replace the invalid, unenforceable, or illegal provision(s) with valid, enforceable, and legal provision(s) that implement the purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Notices.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any notice to be given under this Agreement must be in writing and delivered either in person, by (a) overnight courier by FedEx or DHL, or (b) facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party may designate by prior written notice to the other in accordance with this Section 16.7.  Notice shall be deemed sufficiently given for all purposes upon the earliest of&#58;  (i)&#160;the date of delivery&#59; or (ii)&#160; if sent by facsimile, the date of confirmation of receipt if during the recipient&#8217;s normal business hours, otherwise the next Business Day.</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">69</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Collaborator, notices must be addressed to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited </font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12-10, Nihonbashi 2-chome, Chuo-ku</font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tokyo 103-8668, JAPAN</font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  &#91; * &#93;</font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Facsimile&#58; +&#91; * &#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;with a copy to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited </font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12-10, Nihonbashi 2-chome, Chuo-ku</font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tokyo 103-8668, JAPAN </font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  &#91; * &#93;</font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Facsimile&#58; +&#91; * &#93;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91; * &#93;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">If to Exelixis, notices must be addressed to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis, Inc.<br>210 East Grand Avenue, <br>So. San Francisco, CA 94080</font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>USA<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  General Counsel</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Facsimile&#58; +&#91; * &#93;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Standstill.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Commencing the Effective Date and expiring on the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) anniversary date of the Effective Date, unless such provision is terminated earlier by mutual written agreement of the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standstill Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), neither Collaborator nor any of its Affiliates, without the prior consent of Exelixis or except as provided for in this Agreement or in any agreement referred to herein, or in any agreement executed after the Effective Date by Exelixis with Collaborator or any of its Affiliates, will&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">make, effect, initiate, cause or participate in&#58;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any acquisition of beneficial ownership of any securities of Exelixis or any securities of any subsidiary or other Affiliate of Exelixis (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) such that following any such acquisition, Collaborator and its Affiliates then own more than &#91; * &#93; of the securities of such Exelixis Entity&#59; </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any acquisition of any assets of any Exelixis Entity&#59; </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">70</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any tender offer, exchange offer, merger, business combination, recapitalization, restructuring, liquidation, dissolution or extraordinary transaction involving an Exelixis Entity, or involving any securities or assets of a Exelixis Entity&#59; or </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any &#8220;solicitation&#8221; of &#8220;proxies&#8221; (as those terms are used in the proxy rules of the Securities and Exchange Commission) or consents with respect to any securities of an Exelixis Entity&#59;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">form, join, or participate in a &#8220;group&#8221; (as defined in the Securities Exchange Act of 1934 and the rules promulgated thereunder) with respect to the beneficial ownership of any securities of an Exelixis Entity&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">act, alone or in concert with others, to seek to control or influence the management, board of directors, or policies of an Exelixis Entity&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">take any action that might require an Exelixis Entity to make a public announcement regarding any of the types of matters set forth in clause &#8220;(i)&#8221; of this Section 16.8(a)&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">agree or offer to take, or encourage or propose (publicly or otherwise) the taking of, any action referred to in clause &#8220;(i)&#8221;, &#8220;(ii)&#8221;, &#8220;(iii)&#8221; or &#8220;(iv)&#8221; of this Section 16.8(a)&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">assist, induce or encourage any other person or entity to take any action of the type referred to in clause &#8220;(i)&#8221;, &#8220;(ii)&#8221;, &#8220;(iii)&#8221;, &#8220;(iv)&#8221; or &#8220;(v)&#8221; of this Section 16.8(a)&#59; or</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">enter into any discussions, negotiations, arrangement, or agreement with any other person or entity relating to any of the foregoing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For clarity, the expiration of the Standstill Period will not terminate or otherwise affect any of the other provisions of this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Notwithstanding the foregoing provisions, Collaborator or its Affiliates will not be subject to any of the restrictions set forth in this Section 16.8 with respect to an Exelixis Entity if either&#58; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">such Exelixis Entity publicly announces its intention to pursue a proposed Acquisition Transaction (as defined below)&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">such Exelixis Entity shall have entered into an agreement in principle or definitive agreement providing for an Acquisition Transaction&#59;   </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">the board of directors of such Exelixis Entity shall have adopted a formal plan of liquidation or dissolution&#59;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">71</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">if a Third Party commences a tender or exchange offer or bid which, if successful, would result in such Third Party beneficially owning not less than &#91; * &#93; of the voting securities or equity interest in such Exelixis Entity&#59; or</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">if a Third Party makes a public announcement of a bona fide takeover bid to acquire the outstanding voting securities or equity interest in such Exelixis Entity. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acquisition Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (A) any direct or indirect acquisition or purchase of assets of the applicable Exelixis Entity at a purchase price representing &#91; * &#93; of the voting securities of or equity interest in such Exelixis Entity by any person or &#8220;group&#8221;&#59; (B) any tender offer or exchange offer that if consummated would result in any person or &#8220;group&#8221; beneficially owning &#91; * &#93; or more of any class of equity securities of such Exelixis Entity&#59; or (C) any merger, consolidation, business combination, sale of assets, recapitalization, or similar transaction involving such Exelixis Entity representing more than &#91; * &#93; of the market capitalization of such Exelixis Entity.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding the foregoing, the Parties agree that Collaborator or its Affiliates shall not be prohibited from (i) initiating private discussions with, and submitting confidential private proposals to, the management or Chief Executive Officer of any Exelixis Entity&#59; or (ii) proposing other collaborative research agreements or other commercial license agreements to Exelixis.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Force Majeure.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement (other than failure to make payment when due) by reason of any event beyond such Party&#8217;s reasonable control, including Acts of God, fire, flood, explosion, earthquake, tsunami, pandemic flu, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of electricity, any lack or failure of supply of raw materials, or any other event similar to those enumerated above.  Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur.  Notice of a Party&#8217;s failure or delay in performance due to force majeure must be given to the other Party within &#91; * &#93; after its occurrence.  All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.  In no event shall any Party be required to prevent or settle any labor disturbance or dispute.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Interpretation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction.  All references in this Agreement to the singular shall include the plural where applicable.  Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections, and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection.  The word &#8220;including&#8221; and similar words means including without limitation.  The word &#8220;or&#8221; means &#8220;and&#47;or&#8221; unless the context dictates otherwise because the subject of the conjunction are mutually exclusive.  The words &#8220;herein&#8221;, &#8220;hereof&#8221;, and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision.  All </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">72</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:125.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">references to days in this Agreement mean calendar days, unless otherwise specified.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.  This Agreement has been prepared in the English language and the English language shall control its interpretation.  In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Counterparts&#59; Electronic or Facsimile Signatures.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#123;Signature Page Follows&#125;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">73</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><div id="i3447274f374e4c4db08d115ec9278751_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Parties hereto have caused this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration and License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to be executed and entered into by their duly authorized representatives as of the Effective Date.</font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Exelixis, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Michael M. Morrissey</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Michael M. Morrissey, Ph.D.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  President and Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">akeda </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">harmaceutical </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">ompany </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">imited</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Tsudoi Miyoshi</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Tsudoi Miyoshi</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  Head of Japan Oncology Business Unit</font></div></td></tr></table></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><div id="i3447274f374e4c4db08d115ec9278751_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">List of Exhibits&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;&#160;&#160;&#160;&#160;Chemical Structure of cabozantinib</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;&#160;&#160;&#160;&#160;Exelixis Patents</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;&#160;&#160;&#160;&#160;Initial Global Development Plan and Budget</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58; &#160;&#160;&#160;&#160;Press Release </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">75</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Chemical Structure of cabozantinib</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:156px;margin-bottom:5pt;vertical-align:text-bottom;width:297px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cabozantinib (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">)-malate salt</font></div><div style="text-align:center"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">76</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis Patents</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;Redacted content comprises approximately 4 pages&#125;</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91; * &#93;</font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">77</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>Initial Global Development Plan and Budget</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;Redacted content comprises approximately 6 pages&#125;</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91; * &#93;</font></div><div><font><br></font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">78</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 13.5</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Press Release</font></div><div style="text-align:right"><img alt="image_1.jpg" src="image_1.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><img alt="image_2.jpg" src="image_2.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:139px"></div><div><img alt="image_3.jpg" src="image_3.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:688px"></div><div><font><br></font></div><div style="padding-right:-4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXELIXIS AND TAKEDA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE AND DEVELOP NOVEL CANCER THERAPY CABOZANTINIB IN JAPAN</font></div><div><font><br></font></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Takeda&#8217;s Rights to Include all Potential Indications for Cabozantinib, which is Marketed in the U.S. and European Union for Renal Cell Carcinoma and Medullary Thyroid Carcinoma &#8211;</font></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exelixis Receives $50 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones &#8211;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">South San Francisco, Calif., Cambridge, Mass. and Osaka, Japan &#8211; January 30 (PST) and (EST&#47;JST), 2017 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exelixis, Inc. (NASDAQ&#58; EXEL) and Takeda Pharmaceutical Company Limited (TSE&#58;4502) today announced an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, Exelixis&#8217; lead oncology medicine. With the signing of the agreement, Takeda gains exclusive commercial rights for all potential future cabozantinib indications in Japan, including advanced renal cell carcinoma (RCC), for which cabozantinib is marketed in the United States and European Union as CABOMETYX&#8482; tablets. The two companies will collaborate on the future clinical development of cabozantinib in Japan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Under the terms of the agreement, Exelixis will receive a $50 million upfront payment. Exelixis is eligible to receive development, regulatory, and first-sales milestones of $95 million for the first three planned indications. In addition, Exelixis will be eligible to receive royalties on sales by Takeda.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;As an organization with a strong focus on oncology innovation, our agreement with Exelixis brings a promising and well-studied solid-tumor therapy to our pipeline that may help patients in Japan suffering from RCC and potentially other equally devastating cancers,&#8221; said Tsudoi Miyoshi, Head of Japan Oncology Business Unit of Takeda. &#8220;We intend to pursue regulatory approval for RCC indications as soon as we&#8217;re able, and look forward to commencing the local clinical trial program to further strengthen the clinical profile of cabozantinib.&#8221;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exelixis and Takeda will partner on cabozantinib&#8217;s clinical development in Japan and on translating existing and forthcoming clinical data for potential regulatory filings in the country. In the METEOR pivotal trial, cabozantinib demonstrated statistically significant improvements in overall survival, progression-free survival and objective response rate, meaningfully differentiating it from other therapies to treat advanced renal cell carcinoma following prior therapy. In addition to advanced RCC, future indications could include advanced hepatocellular cancer (HCC), the subject of the CELESTIAL global pivotal trial for which results are anticipated in 2017. Additional earlier-stage studies are under way through Exelixis&#8217; collaboration with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program, and its ongoing Investigator-Sponsored Trial program. Through these two programs, there are more than 45 ongoing or planned studies including trials in advanced RCC, bladder cancer, colorectal cancer, non-small cell lung cancer, and endometrial cancer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Takeda is the ideal partner to advance cabozantinib in Japan and deliver this important treatment option to Japanese patients with cancer,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. &#8220;Takeda is widely respected for both its clinical development and commercial expertise. We look forward to supporting our new partner as it pursues Japanese regulatory approval for cabozantinib, while simultaneously working together to plan the next steps for clinical development in the country. This agreement further propels the global progress for cabozantinib development and commercialization, which now includes the recent first commercial sale of CABOMETYX in the United Kingdom, triggering a $10 million milestone payment from Ipsen to Exelixis.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">79</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cabozantinib is not approved for use in Japan. Previously, Exelixis and its collaborators conducted early-stage clinical trials in Japan, including a phase 1 trial in advanced solid tumors. Data from this trial were presented at the European Society for Medical Oncology 2012 Congress and the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1,2</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exelixis maintains its exclusive rights to develop and commercialize cabozantinib in the United States, and its partner Ipsen maintains its exclusive commercialization rights for current and potential future cabozantinib indications outside of the United States and Japan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About CABOMETYX&#8482; (cabozantinib) Tablets</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CABOMETYX is the tablet formulation of cabozantinib. Its targets include MET, AXL, and VEGFR-1, -2 and -3. In preclinical models, cabozantinib has been shown to inhibit the activity of these receptors, which are involved in normal cellular function and pathologic processes such as tumor angiogenesis, invasiveness, metastasis, and drug resistance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CABOMETYX is available in 20 mg, 40 mg or 60 mg doses. The recommended dose is 60 mg orally, once daily.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">On April 25, 2016, the FDA approved CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. On September 9, 2016, the European Commission approved CABOMETYX tablets for the treatment of advanced renal cell carcinoma in adults who have received prior vascular endothelial growth factor (VEGF)-targeted therapy in the European Union, Norway and Iceland. On February 29, 2016, Exelixis and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib indications outside of the United States, Canada and Japan. On December 20, 2016, Exelixis and Ipsen jointly announced an amendment to their exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">U.S. Important Safety Information</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Hemorrhage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; Severe hemorrhage occurred with CABOMETYX. The incidence of Grade &#8805;3 hemorrhagic events was 2.1% in CABOMETYX-treated patients and 1.6% in everolimus-treated patients. Fatal hemorrhages also occurred in the cabozantinib clinical program. Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gastrointestinal (GI) Perforations and Fistulas&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fistulas were reported in 1.2% (including 0.6% anal fistula) of CABOMETYX-treated patients and 0% of everolimus-treated patients. GI perforations were reported in 0.9% of CABOMETYX-treated patients and 0.6% of everolimus-treated patients. Fatal perforations occurred in the cabozantinib clinical program. Monitor patients for symptoms of fistulas and perforations. Discontinue CABOMETYX in patients who experience a fistula that cannot be appropriately managed or a GI perforation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Thrombotic Events&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CABOMETYX treatment results in an increased incidence of thrombotic events. Venous thromboembolism was reported in 7.3% of CABOMETYX-treated patients and 2.5% of everolimus-treated patients. Pulmonary embolism occurred in 3.9% of CABOMETYX-treated patients and 0.3% of everolimus-treated patients. Events of arterial thromboembolism were reported in 0.9% of CABOMETYX-treated patients and 0.3% of everolimus-treated patients. Fatal thrombotic events occurred in the cabozantinib clinical program. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or any other arterial thromboembolic complication.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Hypertension and Hypertensive Crisis&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CABOMETYX treatment results in an increased incidence of treatment-emergent hypertension. Hypertension was reported in 37% (15% Grade &#8805;3) of CABOMETYX-treated patients and 7.1% (3.1% Grade &#8805;3) of everolimus-treated patients. Monitor blood pressure prior to </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Nokihara et al., Molecular profile and anti-tumor activity in non-small cell lung cancer (NSCLC) patients (pts) in a phase 1 study of cabozantinib (XL184) in Japan. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Ann Oncol.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2012&#59; 23 (suppl 9)&#58; ix152-ix174.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Nokihara et al., Final results of a phase 1 study of cabozantinib (Cabo) in Japanese patients (pts) with expansion cohorts in non-small cell lung cancer (NSCLC) with defined molecular alterations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mol Cancer Ther.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> December 1 2015 (14) (12 Supplement 2) B179.</font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">80</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">initiation and regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management&#59; when controlled, resume CABOMETYX at a reduced dose. Discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy. Discontinue CABOMETYX if there is evidence of hypertensive crisis or severe hypertension despite optimal medical management.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Diarrhea&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diarrhea occurred in 74% of patients treated with CABOMETYX and in 28% of patients treated with everolimus. Grade 3 diarrhea occurred in 11% of CABOMETYX-treated patients and in 2% of everolimus-treated patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 diarrhea or Grade 3-4 diarrhea that cannot be managed with standard antidiarrheal treatments until improvement to Grade 1&#59; resume CABOMETYX at a reduced dose. Dose modification due to diarrhea occurred in 26% of patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Palmar-Plantar Erythrodysesthesia Syndrome (PPES)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 42% of patients treated with CABOMETYX and in 6% of patients treated with everolimus. Grade 3 PPES occurred in 8.2% of CABOMETYX-treated patients and in &#60;1% of everolimus-treated patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 PPES or Grade 3 PPES until improvement to Grade 1&#59; resume CABOMETYX at a reduced dose. Dose modification due to PPES occurred in 16% of patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reversible Posterior Leukoencephalopathy Syndrome (RPLS)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in the cabozantinib clinical program. Perform an evaluation for RPLS in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Embryo-fetal Toxicity&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CABOMETYX can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Adverse Reactions&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The most commonly reported (&#8805;25%) adverse reactions are&#58; diarrhea, fatigue, nausea, decreased appetite, PPES, hypertension, vomiting, weight decreased, and constipation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Drug Interactions&#58; Strong CYP3A4 inhibitors and inducers&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reduce the dosage of CABOMETYX if concomitant use with strong CYP3A4 inhibitors cannot be avoided. Increase the dosage of CABOMETYX if concomitant use with strong CYP3A4 inducers cannot be avoided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lactation&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advise a lactating woman not to breastfeed during treatment with CABOMETYX and for 4 months after the final dose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reproductive Potential&#58; Contraception&#8213;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the final dose. Infertility &#8213;CABOMETYX may impair fertility in females and males of reproductive potential.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Hepatic Impairment&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reduce the CABOMETYX dose in patients with mild (Child-Pugh score &#91; * &#93; A) or moderate (C-P B) hepatic impairment. CABOMETYX is not recommended for use in patients with severe hepatic impairment.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Please see full Prescribing Information at</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> https&#58;&#47;&#47;cabometyx.com&#47;downloads&#47;cabometyxuspi.pdf</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Takeda Pharmaceutical Company </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&#38;D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&#38;D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees </font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">81</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http&#58;&#47;&#47;www.takeda.com&#47;news.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Exelixis</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exelixis, Inc. (Nasdaq&#58; EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines with the potential to improve care and outcomes for people with cancer. Since its founding in 1994, three medicines discovered at Exelixis have progressed through clinical development to receive regulatory approval. Currently, Exelixis is focused on advancing cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors, which has shown clinical anti-tumor activity in more than 20 forms of cancer and is the subject of a broad clinical development program. Two separate formulations of cabozantinib have received regulatory approval to treat certain forms of kidney and thyroid cancer and are marketed for those purposes as CABOMETYX&#8482; tablets (U.S. and EU) and COMETRIQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> capsules (U.S. and EU), respectively. Another Exelixis-discovered compound, COTELLIC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (cobimetinib), a selective inhibitor of MEK, has been approved in major territories including the United States and European Union, and is being evaluated for further potential indications by Roche and Genentech (a member of the Roche Group) under a collaboration with Exelixis. For more information on Exelixis, please visit www.exelixis.com or follow &#64;ExelixisInc on Twitter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; the future clinical development of cabozantinib by Exelixis and Takeda in Japan&#59; Exelixis&#8217; receipt of a $50 million upfront payment&#59; Exelixis&#8217; eligibility to receive development, regulatory and first-sales milestones of $95 million for the first three planned indications&#59; Exelixis&#8217; eligibility to receive royalties on sales of cabozantinib by Takeda&#59; the clinical and therapeutic potential of cabozantinib for patients in Japan suffering from RCC and potentially other cancers&#59; Takeda&#8217;s intent to pursue regulatory approval for cabozantinib in RCC indications and commence a local clinical trial program&#59; Exelixis&#8217; and Takeda&#8217;s plan to translate existing and forthcoming clinical data for potential regulatory filings in Japan&#59; advanced HCC as a potential future commercial indication&#59; the timing of anticipated results from CELESTIAL&#59; the continued development of cabozantinib through Exelixis&#8217; collaboration with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program, and its ongoing Investigator-Sponsored Trial program&#59; Exelixis&#8217; intent to support Takeda as it pursues Japanese regulatory approval for cabozantinib, while simultaneously working together to plan the next steps for clinical development in Japan&#59; Exelixis' commitment to the discovery, development and commercialization of new medicines with the potential to improve care and outcomes for people with cancer&#59; Exelixis&#8217; focus on advancing cabozantinib&#59; and the continued development of cobimetinib. Words such as &#8220;potential,&#8221; &#8220;further,&#8221; &#8220;will,&#8221; &#8220;eligible,&#8221; &#8220;planned,&#8221; &#8220;may,&#8221; &#8220;intend,&#8221; &#8220;look forward,&#8221; &#8220;future,&#8221; &#8220;could,&#8221; &#8220;anticipated,&#8221; &#8220;next,&#8221; &#8220;committed,&#8221; &#8220;focused,&#8221; or other similar expressions identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the complexities and challenges associated with regulatory review and approval processes&#59; Exelixis&#8217; dependence on its relationship with Takeda, including, the level of Takeda&#8217;s investment in the resources necessary to successfully commercialize cabozantinib in Japan&#59; the degree of market acceptance of CABOMETYX and the availability of coverage and reimbursement for CABOMETYX&#59; the risk that unanticipated developments could adversely affect the commercialization of CABOMETYX&#59; Exelixis&#8217; ability to conduct clinical trials of cabozantinib sufficient to achieve a positive completion&#59; risks related to the potential failure of cabozantinib to demonstrate safety and efficacy in clinical testing&#59; Exelixis&#8217; dependence on its relationship with other collaborators, including Ipsen with respect to cabozantinib in territories outside of the United States and Japan and Genentech&#47;Roche with respect to cobimetinib&#59; Exelixis&#8217; dependence on third-party vendors&#59; Exelixis&#8217; ability to protect the company&#8217;s intellectual property rights&#59; market competition&#59; changes in economic and business conditions, and other factors discussed under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; quarterly report on </font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">82</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 3, 2016, and in Exelixis&#8217; future filings with the SEC. The forward-looking statements made in this press release speak only as of the date of this press release. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis&#8217; expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exelixis Contacts</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Community&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Susan Hubbard</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">EVP, Public Affairs and </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Investor Relations</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(650) 837-8194</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000aa;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">shubbard&#64;exelixis.com</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Media&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">For Exelixis, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Hal Mackins</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(415) 994-0040</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">hal&#64;torchcomllc.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Takeda Contacts</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Japanese Media</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Tsuyoshi Tada</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Tel&#58; +81 (0) 3-3278-2417</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">tsuyoshi.tada&#64;takeda.com</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Media Outside Japan&#58; </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Amy Atwood</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">+1 (617) 444-2147</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">amy.atwood&#64;takeda.com</font></div></td></tr></table></div><div style="padding-right:-4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered U.S. trademarks,<br> and CABOMETYX is a U.S. trademark.</font></div><div style="height:79.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">83</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exel20210331exhibit10210q.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6ec65bff75a94908ac3392d7c85a3dac_1"></div><div style="min-height:110.88pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Second</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment to the Collaboration and License Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of May 7, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between Exelixis, Inc., a Delaware company having an address at 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Takeda Pharmaceutical Company Limited, a Japanese corporation with principal offices located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborator</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Exelixis and Collaborator may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font><font style="color:#2e2e2e;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Exelixis and Collaborator are parties to the Collaboration and License Agreement dated January 30, 2017, as amended on March 22, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib in Japan&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Parties desire to enter into this Amendment to modify certain reimbursement obligations and certain milestone payments payable under the License Agreement on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Now, Therefore,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Regulatory Activities</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.64pt">Section 5.5(c) of the License Agreement is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PV Costs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As between the Parties, Exelixis shall be responsible for the cost and expense incurred by Exelixis for establishing and maintaining such global safety database and the preparation of periodic aggregate safety reports that are specifically directed (or reasonably allocable) to the Product (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PV</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Costs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) prior to &#91; * &#93;.  For the period of time commencing upon &#91; * &#93; until &#91; * &#93;, Exelixis shall be responsible for &#91; * &#93; of PV Costs and Collaborator shall be responsible for &#91; * &#93; of PV Costs.  Thereafter, Exelixis shall be responsible for &#91; * &#93; of PV Costs and Collaborator shall be responsible for &#91; * &#93; of PV Costs&#59; provided, however, that in no event shall Collaborator be responsible for more than one million U.S. dollars ($1,000,000) in PV Costs in any Calendar Year during such period of time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Financial Provisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Development Milestone Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The milestone table in Section 8.3(a) of the License Agreement is hereby deleted in its entirety and replaced with the following&#58; </font></div><div><font><br></font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:110.88pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.537%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Milestone Event</font></td><td colspan="24" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Milestone Payments</font></td></tr><tr style="height:148pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For HCC <br>(2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> line)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For RCC <br>(2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> line)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For RCC <br>(1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  line) as a combination therapy (including, for clarity, the Takeda 9ER Trial Opt-In)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For RCC (1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> line) as a single agent </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tier 1 Indications </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tier 2 Indications</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tier 3 Indications&#58; Clinical Trial sponsored by Collaborator or its Affiliate</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tier 3 Indications&#58; Investigator-Initiated Clinical Trial</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone #1&#58; Upon &#91; * &#93; the first Phase 3 Clinical Trial for the Product in Collaborator Territory</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone #2&#58; Upon filing the first MAA for the Product in Collaborator Territory</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$10 million</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$16 million</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$10 million</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone #3&#58; Upon First Commercial Sale for the Product in the relevant indication in Collaborator Territory</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$15 million</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$20 million</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; * &#93;</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:108pt"><font><br></font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:110.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Cumulative Net Sales Milestones</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The milestone table in Section 8.4(c) of the License Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:35.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cumulative Net Sales of all Products in the Collaborator Territory</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cumulative Net Sales Milestone Payments</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exceed&#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.85pt;padding-right:19.85pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exceed&#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.85pt;padding-right:19.85pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91; * &#93;</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">General Provisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Effect of Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Entire Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The License Agreement as modified by this Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Severability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Counterparts&#59; Electronic or Facsimile Signatures</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> &#123;Signature Page Follows&#125;</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6ec65bff75a94908ac3392d7c85a3dac_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;In Witness Whereof</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties hereto have caused this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Second</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Exelixis, Inc.<br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Michael M. Morrissey, Ph.D.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">____</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Michael M. Morrissey, Ph.D.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  President and Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Takeda Pharmaceutical Company Limited</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Tsudoi Miyoshi</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">_______________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Tsudoi Miyoshi</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  Head of Japan Oncology Business Unit</font></div></td></tr></table></div><div><font><br></font></div><div style="height:111.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#123;Signature Page to the Second Amendment to the Collaboration and License Agreement&#125;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exel20220331exhibit31110q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2bb39515ac4e45a38c115a407bd29add_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.22pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;10, 2022 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exel20210331exhibit31210q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia6dd8543a9e546fe85e1c3287ea42bf0_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.22pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;10, 2022 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exel20220331exhibit32110q.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieca827dcf1694994a5210e811aa9306a_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.92pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended April&#160;1, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.92pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Witness Whereof, the undersigned have set their hands hereto as of the 10th day of May 2022.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>exel-20220401.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73bfe3ae-0c1e-4ba4-a72f-9891e89b0476,g:eb76abd8-9ed1-48d1-b6dc-c6870e560f34-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20220401" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20220401">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220401_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220401_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220401_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220401_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2104102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2305301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails">
        <link:definition>2407403 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivities" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities">
        <link:definition>2112103 - Disclosure - Collaboration Agreements And Business Development Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables">
        <link:definition>2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
        <link:definition>2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails">
        <link:definition>2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
        <link:definition>2419413 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails">
        <link:definition>2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>2121104 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>2322303 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>2424416 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails_1" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2128105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2329304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2430420 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativesDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails">
        <link:definition>2431421 - Disclosure - Fair Value Measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2132106 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2333305 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2434422 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2135107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2336306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2437423 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
        <link:definition>2438424 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails">
        <link:definition>2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes">
        <link:definition>2141108 - Disclosure - Provision For (Benefit From) Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2142109 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2343307 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2444427 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails">
        <link:definition>2445428 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>2146110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exelixis.com/role/SubsequentEvents">
        <link:definition>2147111 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.exelixis.com/role/SubsequentEventsDetails">
        <link:definition>2448429 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TSRBasedRestrictedStockUnitsMember" abstract="true" name="TSRBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" abstract="false" name="NumberOfCountriesWithDrugApprovalExcludingTheUS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_ProductOrServiceAxisDomain" abstract="true" name="ProductOrServiceAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_RoyalPharmaMember" abstract="true" name="RoyalPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CotellicMember" abstract="true" name="CotellicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductOrServiceAxisAxis" abstract="true" name="ProductOrServiceAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TakedaAndIspenMember" abstract="true" name="TakedaAndIspenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_AssetAcquisitionPaymentUponClosingOfTransaction" abstract="false" name="AssetAcquisitionPaymentUponClosingOfTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" abstract="false" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" abstract="true" name="ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_BuiltToSuitLeaseMember" abstract="true" name="BuiltToSuitLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AssetPurchaseAgreement2021Member" abstract="true" name="AssetPurchaseAgreement2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" abstract="false" name="LesseeOperatingLeaseOptionToTerminateAfterPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>exel-20220401_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73bfe3ae-0c1e-4ba4-a72f-9891e89b0476,g:eb76abd8-9ed1-48d1-b6dc-c6870e560f34-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1516c310-e87e-4010-aac6-dcf5e4a96403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6e9b249e-cf79-4072-8ee6-dd7cf1c2071e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1516c310-e87e-4010-aac6-dcf5e4a96403" xlink:to="loc_us-gaap_AccountsPayableCurrent_6e9b249e-cf79-4072-8ee6-dd7cf1c2071e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_01f1e70d-1be1-40ee-949a-3ef6da85838c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1516c310-e87e-4010-aac6-dcf5e4a96403" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_01f1e70d-1be1-40ee-949a-3ef6da85838c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_53aff6fc-9801-4c14-8b59-3494c7887dff" xlink:href="exel-20220401.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1516c310-e87e-4010-aac6-dcf5e4a96403" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_53aff6fc-9801-4c14-8b59-3494c7887dff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_ce07dd30-d555-4b23-8c95-e18e21fde9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1516c310-e87e-4010-aac6-dcf5e4a96403" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_ce07dd30-d555-4b23-8c95-e18e21fde9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_100e6133-26b6-4ce9-9cfa-4a37264518cf" xlink:href="exel-20220401.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1516c310-e87e-4010-aac6-dcf5e4a96403" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_100e6133-26b6-4ce9-9cfa-4a37264518cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6088ea42-591e-4b47-8598-86ed421121d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1516c310-e87e-4010-aac6-dcf5e4a96403" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6088ea42-591e-4b47-8598-86ed421121d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7eeec992-0e55-444c-a387-de0d81a50a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3bf43485-3170-40e0-a7ee-9b7ea7367364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eeec992-0e55-444c-a387-de0d81a50a17" xlink:to="loc_us-gaap_ShortTermInvestments_3bf43485-3170-40e0-a7ee-9b7ea7367364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_f3e6fa07-82a3-4357-b266-508fd6ebe546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eeec992-0e55-444c-a387-de0d81a50a17" xlink:to="loc_us-gaap_ReceivablesNetCurrent_f3e6fa07-82a3-4357-b266-508fd6ebe546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_52665aae-8cec-47ad-b342-e3e42e609346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eeec992-0e55-444c-a387-de0d81a50a17" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_52665aae-8cec-47ad-b342-e3e42e609346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_008c5b70-9878-4afe-9bad-ab37cb4bccde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eeec992-0e55-444c-a387-de0d81a50a17" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_008c5b70-9878-4afe-9bad-ab37cb4bccde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3fc03939-4aae-4e56-a5b0-09aa3b483d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eeec992-0e55-444c-a387-de0d81a50a17" xlink:to="loc_us-gaap_InventoryNet_3fc03939-4aae-4e56-a5b0-09aa3b483d74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7f62875d-ab71-4d5c-b495-42bafd62eaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a6f333a9-4435-4c54-be68-5f31c4c9f5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7f62875d-ab71-4d5c-b495-42bafd62eaae" xlink:to="loc_us-gaap_Liabilities_a6f333a9-4435-4c54-be68-5f31c4c9f5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21eac296-5f20-456a-abdb-7a3fb4e8d8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7f62875d-ab71-4d5c-b495-42bafd62eaae" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21eac296-5f20-456a-abdb-7a3fb4e8d8e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_67209332-aca4-46a1-90bc-affa1d9490e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7f62875d-ab71-4d5c-b495-42bafd62eaae" xlink:to="loc_us-gaap_StockholdersEquity_67209332-aca4-46a1-90bc-affa1d9490e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4c755d53-6d05-4a47-a716-036299290167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d999996e-5e55-4cf4-ba2f-ca486c175cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c755d53-6d05-4a47-a716-036299290167" xlink:to="loc_us-gaap_LiabilitiesCurrent_d999996e-5e55-4cf4-ba2f-ca486c175cc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0691ada7-9711-4f2a-9277-e6b7ebe2aa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c755d53-6d05-4a47-a716-036299290167" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0691ada7-9711-4f2a-9277-e6b7ebe2aa1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c81fc0cb-71a4-4db7-b973-a17b12c90630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c755d53-6d05-4a47-a716-036299290167" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c81fc0cb-71a4-4db7-b973-a17b12c90630" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d8e0a821-6f10-4d27-bf36-f9b090239431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c755d53-6d05-4a47-a716-036299290167" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d8e0a821-6f10-4d27-bf36-f9b090239431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f5becba-d408-4aa6-8ca4-271d249a529a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5dc26a17-7a84-4606-aa24-57e4d45f3fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5becba-d408-4aa6-8ca4-271d249a529a" xlink:to="loc_us-gaap_PreferredStockValue_5dc26a17-7a84-4606-aa24-57e4d45f3fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_eae1a7d5-bafd-42fc-b24c-2e08fcac6fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5becba-d408-4aa6-8ca4-271d249a529a" xlink:to="loc_us-gaap_CommonStockValue_eae1a7d5-bafd-42fc-b24c-2e08fcac6fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d82954cd-86ba-46a0-9f44-42dfac114b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5becba-d408-4aa6-8ca4-271d249a529a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d82954cd-86ba-46a0-9f44-42dfac114b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba94ce51-232b-402f-a9c4-802748f425c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5becba-d408-4aa6-8ca4-271d249a529a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba94ce51-232b-402f-a9c4-802748f425c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4b83115e-f5c7-4c31-9fc9-8faf8b7cda3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5becba-d408-4aa6-8ca4-271d249a529a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4b83115e-f5c7-4c31-9fc9-8faf8b7cda3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_789eeae0-d8a7-4949-b3e1-236ab320e4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cadedc38-e1f9-4b74-a020-47776554b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_789eeae0-d8a7-4949-b3e1-236ab320e4ce" xlink:to="loc_us-gaap_AssetsCurrent_cadedc38-e1f9-4b74-a020-47776554b3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_69d12bac-2138-471a-95f6-07aa1ab5604d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_789eeae0-d8a7-4949-b3e1-236ab320e4ce" xlink:to="loc_us-gaap_LongTermInvestments_69d12bac-2138-471a-95f6-07aa1ab5604d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2e184da2-c82f-41e0-bc23-bd712f21644f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_789eeae0-d8a7-4949-b3e1-236ab320e4ce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2e184da2-c82f-41e0-bc23-bd712f21644f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_83a0aa23-b1e1-412d-a21f-318c58ece173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_789eeae0-d8a7-4949-b3e1-236ab320e4ce" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_83a0aa23-b1e1-412d-a21f-318c58ece173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d79adb4f-71ec-4cf2-8468-644f8c532aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_789eeae0-d8a7-4949-b3e1-236ab320e4ce" xlink:to="loc_us-gaap_Goodwill_d79adb4f-71ec-4cf2-8468-644f8c532aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6a29dad0-a7f4-4976-b3b0-638e16118caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_789eeae0-d8a7-4949-b3e1-236ab320e4ce" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6a29dad0-a7f4-4976-b3b0-638e16118caa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85011693-43d2-4a66-aadb-bec930f8e6be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_dc00e9d3-7d43-4940-8b57-06785eace9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_85011693-43d2-4a66-aadb-bec930f8e6be" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_dc00e9d3-7d43-4940-8b57-06785eace9c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ae536af1-9b91-4de3-99be-c174bd9da005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_85011693-43d2-4a66-aadb-bec930f8e6be" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ae536af1-9b91-4de3-99be-c174bd9da005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c9be02b1-184c-4b97-b66f-18ff8ddf9222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1fd3f7de-4218-463f-8ccf-2e961bee3d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c9be02b1-184c-4b97-b66f-18ff8ddf9222" xlink:to="loc_us-gaap_CostsAndExpenses_1fd3f7de-4218-463f-8ccf-2e961bee3d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ccf16da3-b281-494a-84e2-9f97ddbe12fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c9be02b1-184c-4b97-b66f-18ff8ddf9222" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ccf16da3-b281-494a-84e2-9f97ddbe12fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_0246e508-05f6-45f6-9e81-01dad4b6f65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7e688cac-fede-4a94-a7c9-1918128c15c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_0246e508-05f6-45f6-9e81-01dad4b6f65e" xlink:to="loc_us-gaap_OperatingIncomeLoss_7e688cac-fede-4a94-a7c9-1918128c15c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_dc4f7732-5603-4c27-ac0c-18b56fefbe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_0246e508-05f6-45f6-9e81-01dad4b6f65e" xlink:to="loc_us-gaap_InterestIncomeOther_dc4f7732-5603-4c27-ac0c-18b56fefbe8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a0ead799-c181-4f65-afe4-a46b55660e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_0246e508-05f6-45f6-9e81-01dad4b6f65e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a0ead799-c181-4f65-afe4-a46b55660e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_09b43a2d-ca6a-46da-9369-b243b868d2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1ad21cc7-83b4-4ad9-b1e3-3a6972150408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09b43a2d-ca6a-46da-9369-b243b868d2bc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1ad21cc7-83b4-4ad9-b1e3-3a6972150408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_29fa5a9b-d9f0-4cc5-bb20-ae95608972ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09b43a2d-ca6a-46da-9369-b243b868d2bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_29fa5a9b-d9f0-4cc5-bb20-ae95608972ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_69c5b0eb-a598-4b56-bde6-3f2b7f68c747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09b43a2d-ca6a-46da-9369-b243b868d2bc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_69c5b0eb-a598-4b56-bde6-3f2b7f68c747" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c475714b-db0d-48d5-9abc-aa27b305b593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_baece981-9ad1-449c-96be-83fdaaf95e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c475714b-db0d-48d5-9abc-aa27b305b593" xlink:to="loc_us-gaap_NetIncomeLoss_baece981-9ad1-449c-96be-83fdaaf95e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9b8c977e-587b-4630-962e-e04f3a163abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c475714b-db0d-48d5-9abc-aa27b305b593" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9b8c977e-587b-4630-962e-e04f3a163abe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2d14bcb-cdcf-4d70-bbc6-b8d51143be5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_677b255c-5f4b-47dd-a03c-40bac57ed6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2d14bcb-cdcf-4d70-bbc6-b8d51143be5b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_677b255c-5f4b-47dd-a03c-40bac57ed6ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1aaf7f5a-8260-41ee-865e-b46b6009c055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2d14bcb-cdcf-4d70-bbc6-b8d51143be5b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1aaf7f5a-8260-41ee-865e-b46b6009c055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99b673f8-c432-44fe-9d47-ebb0a72159fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51c1520a-d3a4-4db7-ac9f-f59aeb121934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99b673f8-c432-44fe-9d47-ebb0a72159fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51c1520a-d3a4-4db7-ac9f-f59aeb121934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7abe0209-aac3-4c30-bb9e-b184a811c324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99b673f8-c432-44fe-9d47-ebb0a72159fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7abe0209-aac3-4c30-bb9e-b184a811c324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_39ca6b6b-edf0-4215-ba9f-4a1872ae2233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99b673f8-c432-44fe-9d47-ebb0a72159fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_39ca6b6b-edf0-4215-ba9f-4a1872ae2233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d969fbea-a9b8-4b51-9bb7-fc5d5df3c04b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_NetIncomeLoss_d969fbea-a9b8-4b51-9bb7-fc5d5df3c04b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6c5ba26a-a6be-4166-bf77-437c41e5eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6c5ba26a-a6be-4166-bf77-437c41e5eca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_be644532-a8a6-4078-8354-b29192ba7807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_ShareBasedCompensation_be644532-a8a6-4078-8354-b29192ba7807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_73b8dbbf-5aea-4eeb-bb26-7ed252e0a55c" xlink:href="exel-20220401.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_exel_NoncashLeaseExpense_73b8dbbf-5aea-4eeb-bb26-7ed252e0a55c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c217befc-26b4-4be2-8b50-58a554226d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c217befc-26b4-4be2-8b50-58a554226d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1aaacee4-b4aa-4255-be74-766e1f9f2c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1aaacee4-b4aa-4255-be74-766e1f9f2c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3d0bc94e-41a9-490a-a3e9-a37a4f5d7525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3d0bc94e-41a9-490a-a3e9-a37a4f5d7525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3a9537e-66f7-4849-9990-98d44eeeea6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3a9537e-66f7-4849-9990-98d44eeeea6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ac7637d5-d279-4d22-a525-b57c732a76e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ac7637d5-d279-4d22-a525-b57c732a76e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ab665d73-7f1f-420f-8ed7-833ef0ebff90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ab665d73-7f1f-420f-8ed7-833ef0ebff90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0f6058ad-f237-4ec2-a364-8173015da9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0f6058ad-f237-4ec2-a364-8173015da9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_32893a51-4b43-4a9c-b9b5-1753b2fc7d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb38b923-3227-45e8-a0c5-922bfe68b276" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_32893a51-4b43-4a9c-b9b5-1753b2fc7d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_232d400e-014a-4407-a7c3-29933cad921e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f009696-5016-41c0-bb33-9f5bcbd881cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_232d400e-014a-4407-a7c3-29933cad921e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f009696-5016-41c0-bb33-9f5bcbd881cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_9971ece4-4f6e-41f7-831e-2472766b2070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_232d400e-014a-4407-a7c3-29933cad921e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_9971ece4-4f6e-41f7-831e-2472766b2070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_890acc6b-95be-409b-8cc1-46e53e88885e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_232d400e-014a-4407-a7c3-29933cad921e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_890acc6b-95be-409b-8cc1-46e53e88885e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_aacc2d98-1c8f-48b8-8390-eb68e15dba92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_80bd0dec-8a21-4fd7-aca9-c809b7d65d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_aacc2d98-1c8f-48b8-8390-eb68e15dba92" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_80bd0dec-8a21-4fd7-aca9-c809b7d65d97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8b965af1-f036-42f3-ae3b-856c75fff7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_aacc2d98-1c8f-48b8-8390-eb68e15dba92" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8b965af1-f036-42f3-ae3b-856c75fff7cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_04cd76b7-3590-4d97-8bf3-bf7f7b8b711a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_1327b0e4-3bb0-459b-b7dd-8f20ee2fc113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_04cd76b7-3590-4d97-8bf3-bf7f7b8b711a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_1327b0e4-3bb0-459b-b7dd-8f20ee2fc113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5bd0039-f01c-4b7e-b1bc-43208afa390c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_04cd76b7-3590-4d97-8bf3-bf7f7b8b711a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5bd0039-f01c-4b7e-b1bc-43208afa390c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_fab2db00-c4c7-4ac9-8b09-21e1f1eed832" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e594b566-c9f7-4586-82f6-08e5f770e186" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_fab2db00-c4c7-4ac9-8b09-21e1f1eed832" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e594b566-c9f7-4586-82f6-08e5f770e186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_91a779f3-a168-4cd6-acef-41304af9785a" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_fab2db00-c4c7-4ac9-8b09-21e1f1eed832" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_91a779f3-a168-4cd6-acef-41304af9785a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_77b7d122-3c65-4aae-876b-f89341e236d7" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_fab2db00-c4c7-4ac9-8b09-21e1f1eed832" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_77b7d122-3c65-4aae-876b-f89341e236d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8aac600d-0053-4d42-85c7-42b4638a0a9b" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8bc87a68-924b-4bdb-b3f3-308ecb3775ef" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8aac600d-0053-4d42-85c7-42b4638a0a9b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8bc87a68-924b-4bdb-b3f3-308ecb3775ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22c784c2-5773-4433-b92a-caa39dc62c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8aac600d-0053-4d42-85c7-42b4638a0a9b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22c784c2-5773-4433-b92a-caa39dc62c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_691008f3-0874-4363-a594-d622b125e72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7d74ae21-2153-4530-88e2-02e7e94a1a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_691008f3-0874-4363-a594-d622b125e72b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7d74ae21-2153-4530-88e2-02e7e94a1a83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb2a9401-60f2-4faa-a106-a40babd049c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_691008f3-0874-4363-a594-d622b125e72b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb2a9401-60f2-4faa-a106-a40babd049c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_742c06b2-f2e0-4a42-af48-0cc8429108b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_691008f3-0874-4363-a594-d622b125e72b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_742c06b2-f2e0-4a42-af48-0cc8429108b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b812379e-60fd-4dc4-b57c-99141b30f235" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_d634e54b-d56b-471e-8a7b-79ffc247f108" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b812379e-60fd-4dc4-b57c-99141b30f235" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_d634e54b-d56b-471e-8a7b-79ffc247f108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b230cb00-88a5-4257-8452-806e116c5b6e" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b812379e-60fd-4dc4-b57c-99141b30f235" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b230cb00-88a5-4257-8452-806e116c5b6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e529bb16-0b0a-455b-a25a-0a49ea033277" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b812379e-60fd-4dc4-b57c-99141b30f235" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e529bb16-0b0a-455b-a25a-0a49ea033277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6a235a4a-b923-4c12-93f6-2625ae9e6d04" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7f118fd-d7d0-452d-aa6a-3564268c5b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6a235a4a-b923-4c12-93f6-2625ae9e6d04" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7f118fd-d7d0-452d-aa6a-3564268c5b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_e794c93d-7fdb-48bd-8fa0-314ee9dc3ea2" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6a235a4a-b923-4c12-93f6-2625ae9e6d04" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_e794c93d-7fdb-48bd-8fa0-314ee9dc3ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_548935b3-5e60-4e10-a55c-791e0efe952c" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_30498af0-108c-4650-a3f2-683ef26665cd" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_548935b3-5e60-4e10-a55c-791e0efe952c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_30498af0-108c-4650-a3f2-683ef26665cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d62c8c3f-8516-48b1-befe-e6fd13931286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_548935b3-5e60-4e10-a55c-791e0efe952c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d62c8c3f-8516-48b1-befe-e6fd13931286" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2892af4c-0803-40b5-a662-c2343702c184" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_180e5cf6-f9f4-4d32-a199-fd20eb8dd6e0" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2892af4c-0803-40b5-a662-c2343702c184" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_180e5cf6-f9f4-4d32-a199-fd20eb8dd6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b422dd75-784f-4139-9d8f-e5bc9f213619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2892af4c-0803-40b5-a662-c2343702c184" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b422dd75-784f-4139-9d8f-e5bc9f213619" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_25615ce2-afbc-4256-bd21-585fa9a5e939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3c5e6d1d-0e9e-478f-ac9f-ffeda6b16fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_25615ce2-afbc-4256-bd21-585fa9a5e939" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3c5e6d1d-0e9e-478f-ac9f-ffeda6b16fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_37faf77a-b5e9-46e4-85b5-09eba0dc2f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_25615ce2-afbc-4256-bd21-585fa9a5e939" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_37faf77a-b5e9-46e4-85b5-09eba0dc2f80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f5207b4e-39a8-4c7d-bfed-95a1d06ee3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6554ca47-bd5f-4bde-82c5-9e3018458334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f5207b4e-39a8-4c7d-bfed-95a1d06ee3c6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6554ca47-bd5f-4bde-82c5-9e3018458334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b558401b-061a-49fc-98ad-2f2c3c1474a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f5207b4e-39a8-4c7d-bfed-95a1d06ee3c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b558401b-061a-49fc-98ad-2f2c3c1474a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_6f33d6e4-e4f4-47e1-aed4-d760601c38d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_00437b1d-d2fd-4352-ab07-6c858d5047d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6f33d6e4-e4f4-47e1-aed4-d760601c38d0" xlink:to="loc_us-gaap_InventoryRawMaterials_00437b1d-d2fd-4352-ab07-6c858d5047d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_02590d6c-0ea3-4e0d-b649-9571cbb894ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6f33d6e4-e4f4-47e1-aed4-d760601c38d0" xlink:to="loc_us-gaap_InventoryWorkInProcess_02590d6c-0ea3-4e0d-b649-9571cbb894ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e200f0ec-8e8b-4d6d-a60a-375b16b840c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6f33d6e4-e4f4-47e1-aed4-d760601c38d0" xlink:to="loc_us-gaap_InventoryFinishedGoods_e200f0ec-8e8b-4d6d-a60a-375b16b840c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7cd07304-9617-4d77-bfb8-fdb72ff35187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6f8d0a0c-3eef-4ec9-807a-853e7dc1b23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7cd07304-9617-4d77-bfb8-fdb72ff35187" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6f8d0a0c-3eef-4ec9-807a-853e7dc1b23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1713cf78-532d-4b4d-bfac-fb7b31d901b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7cd07304-9617-4d77-bfb8-fdb72ff35187" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1713cf78-532d-4b4d-bfac-fb7b31d901b8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>exel-20220401_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73bfe3ae-0c1e-4ba4-a72f-9891e89b0476,g:eb76abd8-9ed1-48d1-b6dc-c6870e560f34-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended" id="ia01fb2460a86410485b4db57439c12cc_CondensedConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_11d51c1f-cbc9-4e20-87a3-aa0131886012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_RevenuesAbstract_11d51c1f-cbc9-4e20-87a3-aa0131886012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05da490f-23fe-417e-8cad-feb8ffbc9adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_11d51c1f-cbc9-4e20-87a3-aa0131886012" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05da490f-23fe-417e-8cad-feb8ffbc9adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_280b475e-7032-40ca-b288-0212be53fa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_280b475e-7032-40ca-b288-0212be53fa5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8316bfa8-b8a1-4cdc-a330-eb8674e31411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8316bfa8-b8a1-4cdc-a330-eb8674e31411" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9f21edd4-4bef-47d5-b190-eeff13f1e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9f21edd4-4bef-47d5-b190-eeff13f1e2f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5d6537e3-000a-4860-bfc9-70ed722cb9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:to="loc_us-gaap_CostsAndExpenses_5d6537e3-000a-4860-bfc9-70ed722cb9ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3cadd47a-6b99-4955-9678-8e0a2fdaf038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_OperatingIncomeLoss_3cadd47a-6b99-4955-9678-8e0a2fdaf038" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_efdef9d6-3c22-40b9-b178-463abae85096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_InterestIncomeOther_efdef9d6-3c22-40b9-b178-463abae85096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bc637782-aecb-4365-88ff-17f343243285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bc637782-aecb-4365-88ff-17f343243285" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9114331d-fc5a-4238-afad-129971f9dca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_9114331d-fc5a-4238-afad-129971f9dca1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_012053aa-27a4-4e16-87be-34c1ecee1421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_012053aa-27a4-4e16-87be-34c1ecee1421" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca3e9067-c1b5-490a-af29-8b8edeb927cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_NetIncomeLoss_ca3e9067-c1b5-490a-af29-8b8edeb927cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a2b86756-f5ab-4fa9-bfcd-8018101592ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a2b86756-f5ab-4fa9-bfcd-8018101592ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8b73a48b-26ca-4df2-b3bc-34e68b62aa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2b86756-f5ab-4fa9-bfcd-8018101592ea" xlink:to="loc_us-gaap_EarningsPerShareBasic_8b73a48b-26ca-4df2-b3bc-34e68b62aa9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5d31bcc0-7a5a-4cfd-a8e5-a76fb00a4488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2b86756-f5ab-4fa9-bfcd-8018101592ea" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5d31bcc0-7a5a-4cfd-a8e5-a76fb00a4488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9b503232-df57-4a13-a09b-52c4cf3c0fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9b503232-df57-4a13-a09b-52c4cf3c0fa0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ab04ab62-7870-49c0-942b-b550d3277aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9b503232-df57-4a13-a09b-52c4cf3c0fa0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ab04ab62-7870-49c0-942b-b550d3277aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_be8a5370-7246-4e39-841e-b9b1d368cd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9b503232-df57-4a13-a09b-52c4cf3c0fa0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_be8a5370-7246-4e39-841e-b9b1d368cd5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1228955d-3031-4b8b-b9bc-ec56f306d986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_StatementTable_1228955d-3031-4b8b-b9bc-ec56f306d986" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17956d70-07f5-4e36-ae11-00e3b6a5adc2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1228955d-3031-4b8b-b9bc-ec56f306d986" xlink:to="loc_srt_ProductOrServiceAxis_17956d70-07f5-4e36-ae11-00e3b6a5adc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17956d70-07f5-4e36-ae11-00e3b6a5adc2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_17956d70-07f5-4e36-ae11-00e3b6a5adc2" xlink:to="loc_srt_ProductsAndServicesDomain_17956d70-07f5-4e36-ae11-00e3b6a5adc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_17956d70-07f5-4e36-ae11-00e3b6a5adc2" xlink:to="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c8fa394e-1e87-45c9-bf64-5c263605d2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:to="loc_us-gaap_ProductMember_c8fa394e-1e87-45c9-bf64-5c263605d2b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_e079362a-e99c-46d9-ad58-4c1b569899f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:to="loc_us-gaap_LicenseMember_e079362a-e99c-46d9-ad58-4c1b569899f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_aee16e85-9201-4ac8-b260-66194a6eecfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:to="loc_us-gaap_ServiceMember_aee16e85-9201-4ac8-b260-66194a6eecfe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i045bce9d408643999f24de4bc2779516_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f4610be0-4b40-4909-81c5-10902acc7479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f4610be0-4b40-4909-81c5-10902acc7479" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d2c6b199-d33e-4007-814b-ab37de4eb34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d2c6b199-d33e-4007-814b-ab37de4eb34d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_921832b1-c9a4-40b6-9863-144a61ef22ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_StockholdersEquity_921832b1-c9a4-40b6-9863-144a61ef22ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_743a5fe5-e5e4-4423-8371-2bed7535314d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_NetIncomeLoss_743a5fe5-e5e4-4423-8371-2bed7535314d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2247dc49-f6ee-430f-91f6-fa3b994114af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2247dc49-f6ee-430f-91f6-fa3b994114af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_baa5bca1-a35c-49c8-9a11-b4dee958216e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_baa5bca1-a35c-49c8-9a11-b4dee958216e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_43a54b38-09a0-4759-a19e-0372fd121d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_43a54b38-09a0-4759-a19e-0372fd121d48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_014b8d1f-1c5a-46ef-9944-2d15f12a6a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_014b8d1f-1c5a-46ef-9944-2d15f12a6a3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc44d708-4568-47a9-b235-659b8cb55cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc44d708-4568-47a9-b235-659b8cb55cc5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_91599882-db8d-4016-afac-a80835796b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b1ee730-913d-449f-a277-4a71da93bfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ba85c6a7-577b-4104-870c-ed03ed4f7767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f4610be0-4b40-4909-81c5-10902acc7479" xlink:to="loc_us-gaap_StatementTable_ba85c6a7-577b-4104-870c-ed03ed4f7767" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eef50666-8de1-47e9-8bdc-8eadd96394d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ba85c6a7-577b-4104-870c-ed03ed4f7767" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eef50666-8de1-47e9-8bdc-8eadd96394d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eef50666-8de1-47e9-8bdc-8eadd96394d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eef50666-8de1-47e9-8bdc-8eadd96394d6" xlink:to="loc_us-gaap_EquityComponentDomain_eef50666-8de1-47e9-8bdc-8eadd96394d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eef50666-8de1-47e9-8bdc-8eadd96394d6" xlink:to="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_35a7462f-d943-49e3-95e8-62beef23736e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:to="loc_us-gaap_CommonStockMember_35a7462f-d943-49e3-95e8-62beef23736e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6dec5193-7b85-4b00-96ec-a86a359894fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6dec5193-7b85-4b00-96ec-a86a359894fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b29110ca-1a04-4049-ba05-0ac1a793f150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b29110ca-1a04-4049-ba05-0ac1a793f150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cdeac8e4-6db5-4cca-bd8d-55b53d2aea53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:to="loc_us-gaap_RetainedEarningsMember_cdeac8e4-6db5-4cca-bd8d-55b53d2aea53" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i71d1b70b5bb5451ea22049115c131e88_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:href="exel-20220401.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_195b3fe8-01fe-4eaf-a9cb-04a24bdbb989" xlink:href="exel-20220401.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:to="loc_exel_NumberofProductsinCommercialMarket_195b3fe8-01fe-4eaf-a9cb-04a24bdbb989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_5f2b39ca-b24e-41b1-8345-9dc09f0ffca9" xlink:href="exel-20220401.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_5f2b39ca-b24e-41b1-8345-9dc09f0ffca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c1970705-73ee-4214-83b5-b91a8f46d620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c1970705-73ee-4214-83b5-b91a8f46d620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_73caa9fa-22a6-4b15-82d4-6d57b43c21fa" xlink:href="exel-20220401.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_73caa9fa-22a6-4b15-82d4-6d57b43c21fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dadbd865-c34b-4603-ac68-c08d02a3f6b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_73caa9fa-22a6-4b15-82d4-6d57b43c21fa" xlink:to="loc_srt_ProductOrServiceAxis_dadbd865-c34b-4603-ac68-c08d02a3f6b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dadbd865-c34b-4603-ac68-c08d02a3f6b2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dadbd865-c34b-4603-ac68-c08d02a3f6b2" xlink:to="loc_srt_ProductsAndServicesDomain_dadbd865-c34b-4603-ac68-c08d02a3f6b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6aa7ddf0-810f-49b8-8dbb-38764369a36d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dadbd865-c34b-4603-ac68-c08d02a3f6b2" xlink:to="loc_srt_ProductsAndServicesDomain_6aa7ddf0-810f-49b8-8dbb-38764369a36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_25c63806-62d5-4ffa-b294-5830a85f9851" xlink:href="exel-20220401.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6aa7ddf0-810f-49b8-8dbb-38764369a36d" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_25c63806-62d5-4ffa-b294-5830a85f9851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_0d056562-3f9d-4bfe-8baa-628aa0c0ffd0" xlink:href="exel-20220401.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6aa7ddf0-810f-49b8-8dbb-38764369a36d" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_0d056562-3f9d-4bfe-8baa-628aa0c0ffd0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="i6b26c631fd9b44daa79d82a18ad3051d_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6df95fc5-b02b-4ba0-bd43-18950181139e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_efb4cab1-db4d-43df-ba43-d76e23e8f0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6df95fc5-b02b-4ba0-bd43-18950181139e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_efb4cab1-db4d-43df-ba43-d76e23e8f0db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_084b9842-d8e9-448b-bfa8-7fbf3a0a298e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6df95fc5-b02b-4ba0-bd43-18950181139e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_084b9842-d8e9-448b-bfa8-7fbf3a0a298e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_58bf469e-f887-4053-9016-54330ac0cba6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084b9842-d8e9-448b-bfa8-7fbf3a0a298e" xlink:to="loc_srt_ProductOrServiceAxis_58bf469e-f887-4053-9016-54330ac0cba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_58bf469e-f887-4053-9016-54330ac0cba6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_58bf469e-f887-4053-9016-54330ac0cba6" xlink:to="loc_srt_ProductsAndServicesDomain_58bf469e-f887-4053-9016-54330ac0cba6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_58bf469e-f887-4053-9016-54330ac0cba6" xlink:to="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_05575db3-608d-47f7-87c2-3d3f014a7e35" xlink:href="exel-20220401.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_exel_ProductGrossMember_05575db3-608d-47f7-87c2-3d3f014a7e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_fcdc76e1-3fab-4ceb-a6ae-c943fa95a273" xlink:href="exel-20220401.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_fcdc76e1-3fab-4ceb-a6ae-c943fa95a273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7f11deca-b4e0-40b1-bb8d-1d5438355420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_us-gaap_ProductMember_7f11deca-b4e0-40b1-bb8d-1d5438355420" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_55c68f7c-b7e5-453f-98e2-c2e8a313b95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_us-gaap_LicenseMember_55c68f7c-b7e5-453f-98e2-c2e8a313b95b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f960fc1c-63b6-4109-9045-cdb347c2a49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_us-gaap_ServiceMember_f960fc1c-63b6-4109-9045-cdb347c2a49d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_545a7e72-cfd8-4983-af20-f51e7756abb7" xlink:href="exel-20220401.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_exel_CollaborationMember_545a7e72-cfd8-4983-af20-f51e7756abb7" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="extended" id="i9fae3436174e4ff58b287b8b9ca83dfa_RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_f064f222-942d-4a22-9bf1-e4ddf4eed9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6b418615-3bbd-4ac4-ada5-0934b6bcd381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_f064f222-942d-4a22-9bf1-e4ddf4eed9da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6b418615-3bbd-4ac4-ada5-0934b6bcd381" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_f064f222-942d-4a22-9bf1-e4ddf4eed9da" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_212d122e-a19f-4078-b460-3620b307230c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:to="loc_srt_MajorCustomersAxis_212d122e-a19f-4078-b460-3620b307230c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_212d122e-a19f-4078-b460-3620b307230c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_212d122e-a19f-4078-b460-3620b307230c" xlink:to="loc_srt_NameOfMajorCustomerDomain_212d122e-a19f-4078-b460-3620b307230c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_212d122e-a19f-4078-b460-3620b307230c" xlink:to="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_2249cfbb-7a32-4ad6-b2d2-56850d772c26" xlink:href="exel-20220401.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_2249cfbb-7a32-4ad6-b2d2-56850d772c26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_8edb0c96-b7b5-457e-8ffe-7d4291098937" xlink:href="exel-20220401.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_8edb0c96-b7b5-457e-8ffe-7d4291098937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_74bba8fe-1dd2-442e-8fa1-594cb7209a45" xlink:href="exel-20220401.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_74bba8fe-1dd2-442e-8fa1-594cb7209a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_1c6b256e-a091-446d-88d7-e98c1554da1b" xlink:href="exel-20220401.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_IpsenMember_1c6b256e-a091-446d-88d7-e98c1554da1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_db8d322c-c947-4e77-b402-d2c9012ac63e" xlink:href="exel-20220401.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_db8d322c-c947-4e77-b402-d2c9012ac63e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f0b02dab-6268-46e0-8c3b-193f89c8fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f0b02dab-6268-46e0-8c3b-193f89c8fe69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0b02dab-6268-46e0-8c3b-193f89c8fe69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f0b02dab-6268-46e0-8c3b-193f89c8fe69" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0b02dab-6268-46e0-8c3b-193f89c8fe69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_004e6ad3-74b2-41f0-a197-8a5049f8053c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f0b02dab-6268-46e0-8c3b-193f89c8fe69" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_004e6ad3-74b2-41f0-a197-8a5049f8053c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1c6efaed-b107-47fc-be38-505f6e21a775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_004e6ad3-74b2-41f0-a197-8a5049f8053c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_1c6efaed-b107-47fc-be38-505f6e21a775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_551b11cc-0fa7-4572-96eb-0e65dc7103c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_004e6ad3-74b2-41f0-a197-8a5049f8053c" xlink:to="loc_us-gaap_AccountsReceivableMember_551b11cc-0fa7-4572-96eb-0e65dc7103c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d9b41785-010b-407d-a7db-17753c6ea6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d9b41785-010b-407d-a7db-17753c6ea6fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d9b41785-010b-407d-a7db-17753c6ea6fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d9b41785-010b-407d-a7db-17753c6ea6fb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d9b41785-010b-407d-a7db-17753c6ea6fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_46bc756d-bb96-4e81-9df5-5e161f32f033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d9b41785-010b-407d-a7db-17753c6ea6fb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_46bc756d-bb96-4e81-9df5-5e161f32f033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2c800fff-725d-42ce-b566-274e5ef477dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_46bc756d-bb96-4e81-9df5-5e161f32f033" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2c800fff-725d-42ce-b566-274e5ef477dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="i36cc1335105743e385a28bb65b1dce13_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_80aa6177-a60c-49c7-be89-e43ca9b1b43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7dcfe12c-1263-4414-b253-1e786a7d59e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_80aa6177-a60c-49c7-be89-e43ca9b1b43e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7dcfe12c-1263-4414-b253-1e786a7d59e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_966ca308-94cf-48ef-a5fc-95b73632490e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_80aa6177-a60c-49c7-be89-e43ca9b1b43e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_966ca308-94cf-48ef-a5fc-95b73632490e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2af3ad2e-4043-49f6-beff-d464d38b8399" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_966ca308-94cf-48ef-a5fc-95b73632490e" xlink:to="loc_srt_StatementGeographicalAxis_2af3ad2e-4043-49f6-beff-d464d38b8399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2af3ad2e-4043-49f6-beff-d464d38b8399_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2af3ad2e-4043-49f6-beff-d464d38b8399" xlink:to="loc_srt_SegmentGeographicalDomain_2af3ad2e-4043-49f6-beff-d464d38b8399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2af3ad2e-4043-49f6-beff-d464d38b8399" xlink:to="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9a5ed3a6-9d0f-4824-98df-27664063a57c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:to="loc_country_US_9a5ed3a6-9d0f-4824-98df-27664063a57c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_ddc8bc1c-9da2-4930-a062-45bb177a1a01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:to="loc_srt_EuropeMember_ddc8bc1c-9da2-4930-a062-45bb177a1a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_770e2e53-ca50-4daa-866d-fdf2fa6d71ad" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:to="loc_country_JP_770e2e53-ca50-4daa-866d-fdf2fa6d71ad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="i7ffc44ce7d4d45f89e8524518f65ae63_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d871445c-e051-493a-a40a-05b31d5f5269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fe70633-a653-484d-a7ba-11505260beb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d871445c-e051-493a-a40a-05b31d5f5269" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fe70633-a653-484d-a7ba-11505260beb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0e37c9cf-1932-47b2-8533-2e3a8fa19ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d871445c-e051-493a-a40a-05b31d5f5269" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0e37c9cf-1932-47b2-8533-2e3a8fa19ecf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d6678ee3-aa23-4268-be26-5a18fa2fee3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0e37c9cf-1932-47b2-8533-2e3a8fa19ecf" xlink:to="loc_srt_ProductOrServiceAxis_d6678ee3-aa23-4268-be26-5a18fa2fee3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6678ee3-aa23-4268-be26-5a18fa2fee3d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d6678ee3-aa23-4268-be26-5a18fa2fee3d" xlink:to="loc_srt_ProductsAndServicesDomain_d6678ee3-aa23-4268-be26-5a18fa2fee3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_40a604a6-5d2d-4bae-a70f-200407bfb528" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d6678ee3-aa23-4268-be26-5a18fa2fee3d" xlink:to="loc_srt_ProductsAndServicesDomain_40a604a6-5d2d-4bae-a70f-200407bfb528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c513e9fa-94d5-42d8-817e-bd9173af9435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_40a604a6-5d2d-4bae-a70f-200407bfb528" xlink:to="loc_us-gaap_ProductMember_c513e9fa-94d5-42d8-817e-bd9173af9435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_315790ab-8946-4644-b9ec-500f3cb69b6f" xlink:href="exel-20220401.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_c513e9fa-94d5-42d8-817e-bd9173af9435" xlink:to="loc_exel_CabometyxMember_315790ab-8946-4644-b9ec-500f3cb69b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_b0443452-12a3-4846-9efc-458593de9cdf" xlink:href="exel-20220401.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_c513e9fa-94d5-42d8-817e-bd9173af9435" xlink:to="loc_exel_CometriqMember_b0443452-12a3-4846-9efc-458593de9cdf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="ib92031beabbc4b378f1c13840cc93b62_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_96c27987-5830-4d8c-a2f2-e51181a98766" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_96c27987-5830-4d8c-a2f2-e51181a98766" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e1e915b8-e31d-44b3-bef4-c24d14938e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e1e915b8-e31d-44b3-bef4-c24d14938e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2043fa46-3405-4946-b70e-835f0ff45f57" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2043fa46-3405-4946-b70e-835f0ff45f57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_7ab9d817-d328-47c3-814b-1654d39bf122" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2043fa46-3405-4946-b70e-835f0ff45f57" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_7ab9d817-d328-47c3-814b-1654d39bf122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_c65f5633-b1fd-45b6-a7fa-0404f97111a8" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2043fa46-3405-4946-b70e-835f0ff45f57" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_c65f5633-b1fd-45b6-a7fa-0404f97111a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_aa22bfc1-3d47-47ba-ac72-262eabc9497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_aa22bfc1-3d47-47ba-ac72-262eabc9497a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8a65165a-d47d-4746-9ade-5b81682b68a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a244ef8a-4879-4396-86da-5039f0f7c8cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_96c27987-5830-4d8c-a2f2-e51181a98766" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a244ef8a-4879-4396-86da-5039f0f7c8cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a244ef8a-4879-4396-86da-5039f0f7c8cc" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_87727d9a-8888-46e2-aa1e-e866bc56fcb4" xlink:href="exel-20220401.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_87727d9a-8888-46e2-aa1e-e866bc56fcb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_e453ecf6-fc18-447f-b8b2-50aa247f7802" xlink:href="exel-20220401.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_e453ecf6-fc18-447f-b8b2-50aa247f7802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_94f277b8-8c18-4301-9fc1-b7b90b9ac541" xlink:href="exel-20220401.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:to="loc_exel_AllowanceForProductRebatesMember_94f277b8-8c18-4301-9fc1-b7b90b9ac541" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i1aeb648dcf26488cb9a7d4d5b20bb2af_RevenuesContractAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_a392191f-31c1-411b-a9e2-0756b95b2b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_a392191f-31c1-411b-a9e2-0756b95b2b99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_dca0fc5c-dc21-42d1-8320-e0704dd89815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_a392191f-31c1-411b-a9e2-0756b95b2b99" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_dca0fc5c-dc21-42d1-8320-e0704dd89815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d34d50c6-b563-47cd-9d8d-84e8e3f48826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d34d50c6-b563-47cd-9d8d-84e8e3f48826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55fb39f0-05e3-4a73-a136-a3e57f78c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55fb39f0-05e3-4a73-a136-a3e57f78c06e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5c922896-346b-4e31-98d9-b9c7920387a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5c922896-346b-4e31-98d9-b9c7920387a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_6d4d580c-c025-409f-8233-60f55a5b60c3" xlink:href="exel-20220401.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_6d4d580c-c025-409f-8233-60f55a5b60c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f15a702c-4516-41cc-8c92-b09b14cd87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f15a702c-4516-41cc-8c92-b09b14cd87c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_63211d87-b6f6-478f-a759-b61678815707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_63211d87-b6f6-478f-a759-b61678815707" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d3eaecce-21ef-4d36-adfa-86dce016a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d3eaecce-21ef-4d36-adfa-86dce016a7a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_24b5dcec-374b-4cb9-9463-1f7b636bfd1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3eaecce-21ef-4d36-adfa-86dce016a7a9" xlink:to="loc_srt_CounterpartyNameAxis_24b5dcec-374b-4cb9-9463-1f7b636bfd1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24b5dcec-374b-4cb9-9463-1f7b636bfd1e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_24b5dcec-374b-4cb9-9463-1f7b636bfd1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24b5dcec-374b-4cb9-9463-1f7b636bfd1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe59f932-423c-4403-bbc1-dec36f551496" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_24b5dcec-374b-4cb9-9463-1f7b636bfd1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe59f932-423c-4403-bbc1-dec36f551496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember_df488a25-386f-4876-85d4-87e12865a411" xlink:href="exel-20220401.xsd#exel_TakedaAndIspenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe59f932-423c-4403-bbc1-dec36f551496" xlink:to="loc_exel_TakedaAndIspenMember_df488a25-386f-4876-85d4-87e12865a411" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i478dc6323e5e42739ab419da500f3b09_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3ee5309-70b0-40d7-b258-bdf23dda5a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda9b808-e838-46c8-b2ff-fc1fe3cfd068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3ee5309-70b0-40d7-b258-bdf23dda5a46" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda9b808-e838-46c8-b2ff-fc1fe3cfd068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3ee5309-70b0-40d7-b258-bdf23dda5a46" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_438c2f53-1603-46b6-becf-aa8d2d1d1a8c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:to="loc_srt_ProductOrServiceAxis_438c2f53-1603-46b6-becf-aa8d2d1d1a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_438c2f53-1603-46b6-becf-aa8d2d1d1a8c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_438c2f53-1603-46b6-becf-aa8d2d1d1a8c" xlink:to="loc_srt_ProductsAndServicesDomain_438c2f53-1603-46b6-becf-aa8d2d1d1a8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea1d2495-8dea-4247-971a-b4e97969c60c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_438c2f53-1603-46b6-becf-aa8d2d1d1a8c" xlink:to="loc_srt_ProductsAndServicesDomain_ea1d2495-8dea-4247-971a-b4e97969c60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_cf2cf26d-616e-4abf-83e5-f0aaa6c0cf55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea1d2495-8dea-4247-971a-b4e97969c60c" xlink:to="loc_us-gaap_LicenseMember_cf2cf26d-616e-4abf-83e5-f0aaa6c0cf55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_fa32db77-5117-4131-aa96-dabc25f9b58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea1d2495-8dea-4247-971a-b4e97969c60c" xlink:to="loc_us-gaap_ServiceMember_fa32db77-5117-4131-aa96-dabc25f9b58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b52462ff-7a1f-4f81-ab76-d00d8ea09d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b52462ff-7a1f-4f81-ab76-d00d8ea09d23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b52462ff-7a1f-4f81-ab76-d00d8ea09d23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b52462ff-7a1f-4f81-ab76-d00d8ea09d23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b52462ff-7a1f-4f81-ab76-d00d8ea09d23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d9d3ca-ebf7-432d-bf19-4c4cb67890ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b52462ff-7a1f-4f81-ab76-d00d8ea09d23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d9d3ca-ebf7-432d-bf19-4c4cb67890ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_6973f3e3-2750-412d-b746-c337861dc9f8" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d9d3ca-ebf7-432d-bf19-4c4cb67890ab" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_6973f3e3-2750-412d-b746-c337861dc9f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended" id="i628a30b9009746fd996b0c31ad395b0f_CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8bd1d5-c39a-4d98-965c-9e95cb9dc217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6bca8246-934d-40c7-8289-45cd4871544a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8bd1d5-c39a-4d98-965c-9e95cb9dc217" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6bca8246-934d-40c7-8289-45cd4871544a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d595a2c5-686d-4936-be10-7c7d87f9bf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8bd1d5-c39a-4d98-965c-9e95cb9dc217" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d595a2c5-686d-4936-be10-7c7d87f9bf7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e720aa44-9709-4aff-b71c-e1e53980e5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d595a2c5-686d-4936-be10-7c7d87f9bf7e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e720aa44-9709-4aff-b71c-e1e53980e5e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e720aa44-9709-4aff-b71c-e1e53980e5e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e720aa44-9709-4aff-b71c-e1e53980e5e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e720aa44-9709-4aff-b71c-e1e53980e5e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_193ee7ae-8784-4fc1-b306-9f6e0a455b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e720aa44-9709-4aff-b71c-e1e53980e5e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_193ee7ae-8784-4fc1-b306-9f6e0a455b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_fcc535c0-1413-48f6-9b8f-0e31c14c601f" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_193ee7ae-8784-4fc1-b306-9f6e0a455b18" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_fcc535c0-1413-48f6-9b8f-0e31c14c601f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i3376fd20b35d4cefa78fc630261d3608_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f518622-b38a-4565-bc7c-58dcb368a224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5390b81c-e806-4de8-9df2-4eac8a886da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f518622-b38a-4565-bc7c-58dcb368a224" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5390b81c-e806-4de8-9df2-4eac8a886da3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f518622-b38a-4565-bc7c-58dcb368a224" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0338f753-d56e-4222-8619-71fbc1b084d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:to="loc_srt_ProductOrServiceAxis_0338f753-d56e-4222-8619-71fbc1b084d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0338f753-d56e-4222-8619-71fbc1b084d9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0338f753-d56e-4222-8619-71fbc1b084d9" xlink:to="loc_srt_ProductsAndServicesDomain_0338f753-d56e-4222-8619-71fbc1b084d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c6f9d5e6-3165-4f43-8ef1-2b7e2d006743" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0338f753-d56e-4222-8619-71fbc1b084d9" xlink:to="loc_srt_ProductsAndServicesDomain_c6f9d5e6-3165-4f43-8ef1-2b7e2d006743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b020bcde-1347-47a0-862a-5730b2abd214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c6f9d5e6-3165-4f43-8ef1-2b7e2d006743" xlink:to="loc_us-gaap_LicenseMember_b020bcde-1347-47a0-862a-5730b2abd214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_c298d411-be34-4b68-9520-174b0830e347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c6f9d5e6-3165-4f43-8ef1-2b7e2d006743" xlink:to="loc_us-gaap_ServiceMember_c298d411-be34-4b68-9520-174b0830e347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07286376-d192-42c4-a96d-8645c144eada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07286376-d192-42c4-a96d-8645c144eada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_c6a23b0c-b658-4206-8f87-bcd1b8f2db01" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07286376-d192-42c4-a96d-8645c144eada" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_c6a23b0c-b658-4206-8f87-bcd1b8f2db01" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended" id="ic2875126c17c4c5b8c35c89c105d650c_CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e311790e-2f29-41ea-8d3c-fa9dd1bcce55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d07ac075-83a8-4212-adb1-21a5a671819b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e311790e-2f29-41ea-8d3c-fa9dd1bcce55" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d07ac075-83a8-4212-adb1-21a5a671819b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c6f2d47c-e1a1-42bc-9da5-d7685968b2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e311790e-2f29-41ea-8d3c-fa9dd1bcce55" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c6f2d47c-e1a1-42bc-9da5-d7685968b2a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1c76e65d-21e1-488b-811c-87973fe7d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c6f2d47c-e1a1-42bc-9da5-d7685968b2a7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1c76e65d-21e1-488b-811c-87973fe7d0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c76e65d-21e1-488b-811c-87973fe7d0f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c76e65d-21e1-488b-811c-87973fe7d0f7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c76e65d-21e1-488b-811c-87973fe7d0f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_875001d0-6fea-40c7-aefb-dbd7cb25023d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c76e65d-21e1-488b-811c-87973fe7d0f7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_875001d0-6fea-40c7-aefb-dbd7cb25023d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_091fb599-d3ac-41a7-ae84-85d4fc0307cf" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_875001d0-6fea-40c7-aefb-dbd7cb25023d" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_091fb599-d3ac-41a7-ae84-85d4fc0307cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="extended" id="i92b6e1639053422aa8f235af62c1a368_CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c7f35f5-e39c-4e84-9b26-59e227702a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_9e855115-8ae0-49e5-b71d-a1370734b657" xlink:href="exel-20220401.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c7f35f5-e39c-4e84-9b26-59e227702a35" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_9e855115-8ae0-49e5-b71d-a1370734b657" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_f0d7dd5d-cac2-4254-8893-9542fb503240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c7f35f5-e39c-4e84-9b26-59e227702a35" xlink:to="loc_us-gaap_RoyaltyExpense_f0d7dd5d-cac2-4254-8893-9542fb503240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ece827e3-d4ef-4cdf-b5a9-586dec4d7acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c7f35f5-e39c-4e84-9b26-59e227702a35" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ece827e3-d4ef-4cdf-b5a9-586dec4d7acf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ece827e3-d4ef-4cdf-b5a9-586dec4d7acf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aef70535-2340-44e9-bec8-6586bf4a6284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aef70535-2340-44e9-bec8-6586bf4a6284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_dbdfab34-ea89-4b0b-a6df-371778c27f5e" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aef70535-2340-44e9-bec8-6586bf4a6284" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_dbdfab34-ea89-4b0b-a6df-371778c27f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember_5b827d13-2974-4bf7-baaf-6019f9855caa" xlink:href="exel-20220401.xsd#exel_RoyalPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aef70535-2340-44e9-bec8-6586bf4a6284" xlink:to="loc_exel_RoyalPharmaMember_5b827d13-2974-4bf7-baaf-6019f9855caa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended" id="ifde32b856baa4c61ae8cc145c04b1882_CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd4a4429-8237-414f-8ac2-2bab1a0cff8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_0b1a2c16-ece5-4ab9-83b0-648d99ca71cd" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd4a4429-8237-414f-8ac2-2bab1a0cff8c" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_0b1a2c16-ece5-4ab9-83b0-648d99ca71cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b5ed416-37e3-4f04-a70b-081574576892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd4a4429-8237-414f-8ac2-2bab1a0cff8c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b5ed416-37e3-4f04-a70b-081574576892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd4a4429-8237-414f-8ac2-2bab1a0cff8c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8aa85533-99b9-486e-b0fe-d68422ca0f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8aa85533-99b9-486e-b0fe-d68422ca0f49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8aa85533-99b9-486e-b0fe-d68422ca0f49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aa85533-99b9-486e-b0fe-d68422ca0f49" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8aa85533-99b9-486e-b0fe-d68422ca0f49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b3521e9-a6df-49f7-ad76-bd44133be445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aa85533-99b9-486e-b0fe-d68422ca0f49" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b3521e9-a6df-49f7-ad76-bd44133be445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_408e3e20-af86-4e7c-81d4-8708d92f8295" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b3521e9-a6df-49f7-ad76-bd44133be445" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_408e3e20-af86-4e7c-81d4-8708d92f8295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis_d57233dc-9971-4fc7-92cc-bce20bb9065f" xlink:href="exel-20220401.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:to="loc_exel_ProductOrServiceAxisAxis_d57233dc-9971-4fc7-92cc-bce20bb9065f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_d57233dc-9971-4fc7-92cc-bce20bb9065f_default" xlink:href="exel-20220401.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_ProductOrServiceAxisAxis_d57233dc-9971-4fc7-92cc-bce20bb9065f" xlink:to="loc_exel_ProductOrServiceAxisDomain_d57233dc-9971-4fc7-92cc-bce20bb9065f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_7a98a3be-7948-460e-b151-863238bcb5a6" xlink:href="exel-20220401.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_ProductOrServiceAxisAxis_d57233dc-9971-4fc7-92cc-bce20bb9065f" xlink:to="loc_exel_ProductOrServiceAxisDomain_7a98a3be-7948-460e-b151-863238bcb5a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_092207f1-b039-44f7-846e-11a49b1cb665" xlink:href="exel-20220401.xsd#exel_CotellicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProductOrServiceAxisDomain_7a98a3be-7948-460e-b151-863238bcb5a6" xlink:to="loc_exel_CotellicMember_092207f1-b039-44f7-846e-11a49b1cb665" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="extended" id="id7e8402613b54b18a861b020b4393232_CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_af55606e-5ac7-4027-acce-8709435d3636" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_af55606e-5ac7-4027-acce-8709435d3636" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_f7db9b02-669e-448c-9d80-b9634f92955b" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_f7db9b02-669e-448c-9d80-b9634f92955b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_c3636be4-04ed-40c5-9e36-625032246be9" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_c3636be4-04ed-40c5-9e36-625032246be9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_efaec324-e0c8-4ad9-bf1e-dcf1e2c1d059" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_efaec324-e0c8-4ad9-bf1e-dcf1e2c1d059" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_edfc17fb-f9dc-42af-b757-b88f5e2824b7" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_edfc17fb-f9dc-42af-b757-b88f5e2824b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_ef7c6c19-eb7b-438e-baec-e3cdbbe131c9" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_ef7c6c19-eb7b-438e-baec-e3cdbbe131c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c98da7d9-ce38-434a-a04f-8acac654bdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c98da7d9-ce38-434a-a04f-8acac654bdf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c98da7d9-ce38-434a-a04f-8acac654bdf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c98da7d9-ce38-434a-a04f-8acac654bdf3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c98da7d9-ce38-434a-a04f-8acac654bdf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_fae4cfb6-9380-4423-b35c-7519e37c70ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c98da7d9-ce38-434a-a04f-8acac654bdf3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_fae4cfb6-9380-4423-b35c-7519e37c70ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetPurchaseAgreement2021Member_5251ff1f-5dc6-4a42-af23-f5ba24a9ad8d" xlink:href="exel-20220401.xsd#exel_AssetPurchaseAgreement2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_fae4cfb6-9380-4423-b35c-7519e37c70ad" xlink:to="loc_exel_AssetPurchaseAgreement2021Member_5251ff1f-5dc6-4a42-af23-f5ba24a9ad8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_501687c7-c596-4c30-a015-992c4b60686c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:to="loc_us-gaap_TypeOfArrangementAxis_501687c7-c596-4c30-a015-992c4b60686c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_501687c7-c596-4c30-a015-992c4b60686c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_501687c7-c596-4c30-a015-992c4b60686c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_501687c7-c596-4c30-a015-992c4b60686c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8cf49d5-ed39-4de7-a4af-8fa17550961b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_501687c7-c596-4c30-a015-992c4b60686c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8cf49d5-ed39-4de7-a4af-8fa17550961b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_0011d0b8-0b98-4d2d-8fd8-a4e7d2095c02" xlink:href="exel-20220401.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8cf49d5-ed39-4de7-a4af-8fa17550961b" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_0011d0b8-0b98-4d2d-8fd8-a4e7d2095c02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended" id="i5c4bee0dcf2c4bdb9330012b212a16e0_CashandInvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_bde3ffd6-1ba0-4b92-b17d-4600fb73aa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_bde3ffd6-1ba0-4b92-b17d-4600fb73aa0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_544e0db8-974e-4637-b825-3bdb13820699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_InterestReceivable_544e0db8-974e-4637-b825-3bdb13820699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_43f621d8-e318-4126-bd46-8762e2da771d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_43f621d8-e318-4126-bd46-8762e2da771d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_6c250eb1-5598-48ec-b6b6-44d457f1b622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_6c250eb1-5598-48ec-b6b6-44d457f1b622" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0379b032-f4e3-442e-b81f-cbac44c3dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0379b032-f4e3-442e-b81f-cbac44c3dccb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_e89d6758-d22b-45e2-a438-ed23f99b4948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_e89d6758-d22b-45e2-a438-ed23f99b4948" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c6f76451-5202-4dba-864c-6433f9ceafe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c6f76451-5202-4dba-864c-6433f9ceafe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6f76451-5202-4dba-864c-6433f9ceafe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6f76451-5202-4dba-864c-6433f9ceafe5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6f76451-5202-4dba-864c-6433f9ceafe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2ec9bd0-f720-4393-b761-894c8a516a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6f76451-5202-4dba-864c-6433f9ceafe5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2ec9bd0-f720-4393-b761-894c8a516a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_af3fb7ef-15a2-4254-8f8f-6fc03f108f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2ec9bd0-f720-4393-b761-894c8a516a92" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_af3fb7ef-15a2-4254-8f8f-6fc03f108f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5166a4c0-ac9b-4e85-8ecf-82140b91cccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5166a4c0-ac9b-4e85-8ecf-82140b91cccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_2d66248d-620d-4eee-97d9-b7bbd726f976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5166a4c0-ac9b-4e85-8ecf-82140b91cccb" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_2d66248d-620d-4eee-97d9-b7bbd726f976" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="i1a9d8159c5b0442a9c1d7834a57d89c8_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_51f83a97-5046-4015-8260-b93c7e93940e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_51f83a97-5046-4015-8260-b93c7e93940e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0da0e32-41ee-4015-b701-95c723201e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0da0e32-41ee-4015-b701-95c723201e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f07c9f3d-bc13-475d-85dd-ae51691ea0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f07c9f3d-bc13-475d-85dd-ae51691ea0f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87f019eb-3c31-47eb-8b7c-7b34ffe0abee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87f019eb-3c31-47eb-8b7c-7b34ffe0abee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_2d4875e3-bdc7-4609-bc8f-b44e98e93d7c" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_2d4875e3-bdc7-4609-bc8f-b44e98e93d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_4648b361-6f6a-4514-8f4f-8b5d4befb674" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_4648b361-6f6a-4514-8f4f-8b5d4befb674" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_db156ff3-e5f9-490e-9627-7664dfc56ccb" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_db156ff3-e5f9-490e-9627-7664dfc56ccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a158ff37-7c4d-4556-ae60-ff49294e97f2" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a158ff37-7c4d-4556-ae60-ff49294e97f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2b047a86-aaad-4df9-bcb0-c9e4e9ddc932" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2b047a86-aaad-4df9-bcb0-c9e4e9ddc932" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e6675999-58a8-487a-b551-632d5935d004" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e6675999-58a8-487a-b551-632d5935d004" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_99de496f-149b-41db-8929-baae7028450a" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_99de496f-149b-41db-8929-baae7028450a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_4b91550b-b26f-4d32-a80d-966be86a2811" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_4b91550b-b26f-4d32-a80d-966be86a2811" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2fee2dc4-c560-43ef-987a-a8b5351b6056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2fee2dc4-c560-43ef-987a-a8b5351b6056" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4ad69fc5-6930-4409-a9cc-7498ef8e81fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2fee2dc4-c560-43ef-987a-a8b5351b6056" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4ad69fc5-6930-4409-a9cc-7498ef8e81fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ad69fc5-6930-4409-a9cc-7498ef8e81fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4ad69fc5-6930-4409-a9cc-7498ef8e81fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ad69fc5-6930-4409-a9cc-7498ef8e81fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4ad69fc5-6930-4409-a9cc-7498ef8e81fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_683f9dff-697a-4855-a28f-3cd34cc0e02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_CommercialPaperMember_683f9dff-697a-4855-a28f-3cd34cc0e02a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_af51d977-fa87-4d76-b065-680656fe0705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_af51d977-fa87-4d76-b065-680656fe0705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_5d8239cf-879f-4c46-8c0b-ee71bfd3bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_5d8239cf-879f-4c46-8c0b-ee71bfd3bd41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_dd97a19c-7c72-4d03-95fd-4587e2b53672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_MunicipalBondsMember_dd97a19c-7c72-4d03-95fd-4587e2b53672" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_25eeca50-c5e0-4915-9227-b9af58b305cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_CashMember_25eeca50-c5e0-4915-9227-b9af58b305cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_115a8012-4b62-4237-abdd-6cc58dfd1932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_MoneyMarketFundsMember_115a8012-4b62-4237-abdd-6cc58dfd1932" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_8dedd3db-0edc-404f-bedf-5620f68a3401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_CertificatesOfDepositMember_8dedd3db-0edc-404f-bedf-5620f68a3401" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="ic9d672247bb14e39a6e4c17a80bca97f_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ace6744-d5a6-4aad-8c4a-4fc33815e581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4b89f866-cb19-4395-a3b5-2694c2122283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ace6744-d5a6-4aad-8c4a-4fc33815e581" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4b89f866-cb19-4395-a3b5-2694c2122283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fd921f43-c635-4c26-81a7-319f55512425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4b89f866-cb19-4395-a3b5-2694c2122283" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fd921f43-c635-4c26-81a7-319f55512425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8c1d7495-a11b-4eb3-a947-0bae1a490b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4b89f866-cb19-4395-a3b5-2694c2122283" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8c1d7495-a11b-4eb3-a947-0bae1a490b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c583a0a-4a32-4812-ad2b-ce5c8b6f2e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ace6744-d5a6-4aad-8c4a-4fc33815e581" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c583a0a-4a32-4812-ad2b-ce5c8b6f2e9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e5e44749-681f-4f19-931a-51dcf6c562d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c583a0a-4a32-4812-ad2b-ce5c8b6f2e9c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e5e44749-681f-4f19-931a-51dcf6c562d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e5e44749-681f-4f19-931a-51dcf6c562d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e5e44749-681f-4f19-931a-51dcf6c562d3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e5e44749-681f-4f19-931a-51dcf6c562d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e5e44749-681f-4f19-931a-51dcf6c562d3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d689c921-6bc9-4747-9c62-4155cf0ed108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d689c921-6bc9-4747-9c62-4155cf0ed108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_31ebd1e4-788b-4caa-bd3e-982b19c78985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_31ebd1e4-788b-4caa-bd3e-982b19c78985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f817deea-c7de-4c4b-b296-5138dfed4a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:to="loc_us-gaap_CommercialPaperMember_f817deea-c7de-4c4b-b296-5138dfed4a82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_4d263437-6d31-47b2-8e26-f6a5b7ed92e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:to="loc_us-gaap_MunicipalBondsMember_4d263437-6d31-47b2-8e26-f6a5b7ed92e0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i43973f0547cc4c4d87fd38a5f2837cf5_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_97e6c91f-be9a-4f5a-ba20-36b86faa443d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_97e6c91f-be9a-4f5a-ba20-36b86faa443d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea632ced-ee56-4e2e-b2a4-79b5cf4cbe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea632ced-ee56-4e2e-b2a4-79b5cf4cbe3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8f28fedb-c4f1-4035-816f-1ea17ff5866e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8f28fedb-c4f1-4035-816f-1ea17ff5866e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_96b52678-862c-484a-bf62-ad30371c21aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_CommercialPaperMember_96b52678-862c-484a-bf62-ad30371c21aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_c70d3ace-381d-4223-a245-7a5765c33a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_c70d3ace-381d-4223-a245-7a5765c33a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_9cff1b40-0df8-46c0-9ac3-04ac1d816c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_9cff1b40-0df8-46c0-9ac3-04ac1d816c8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_3019bffd-cdbb-4c71-8201-37228516f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_MunicipalBondsMember_3019bffd-cdbb-4c71-8201-37228516f41a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cb0dbf3f-f09a-4715-b86b-5d10c6b1a6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cb0dbf3f-f09a-4715-b86b-5d10c6b1a6b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_82888ba7-953a-483f-b03a-b8eede8de8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_CertificatesOfDepositMember_82888ba7-953a-483f-b03a-b8eede8de8fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a07a70bb-1918-416c-9f73-58d57ec5699c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a07a70bb-1918-416c-9f73-58d57ec5699c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a07a70bb-1918-416c-9f73-58d57ec5699c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a07a70bb-1918-416c-9f73-58d57ec5699c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a07a70bb-1918-416c-9f73-58d57ec5699c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b9aacec-d1d3-442a-9cf9-34eb12e987e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a07a70bb-1918-416c-9f73-58d57ec5699c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b9aacec-d1d3-442a-9cf9-34eb12e987e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e82a4d5d-5a66-4b93-a53c-48c2cd1c3c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b9aacec-d1d3-442a-9cf9-34eb12e987e5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e82a4d5d-5a66-4b93-a53c-48c2cd1c3c8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4945f25c-bfd2-4454-bfb7-80ccafebc363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b9aacec-d1d3-442a-9cf9-34eb12e987e5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4945f25c-bfd2-4454-bfb7-80ccafebc363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0d77a69-5c1a-4535-9ed2-01118db4f2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0d77a69-5c1a-4535-9ed2-01118db4f2eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0d77a69-5c1a-4535-9ed2-01118db4f2eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0d77a69-5c1a-4535-9ed2-01118db4f2eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0d77a69-5c1a-4535-9ed2-01118db4f2eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7c57768-c508-4278-8413-4acff7a1da09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0d77a69-5c1a-4535-9ed2-01118db4f2eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7c57768-c508-4278-8413-4acff7a1da09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_082c81e4-abd2-4a1d-b9b2-4cbfbc2be255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7c57768-c508-4278-8413-4acff7a1da09" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_082c81e4-abd2-4a1d-b9b2-4cbfbc2be255" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended" id="i9893f4a2e94d495a86b016a746a00711_FairValueMeasurementsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_e81026ec-06ee-4f7a-b362-3a4691475967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_e81026ec-06ee-4f7a-b362-3a4691475967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_d9b10624-a8c7-4db4-915c-81aeaa6d03c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_DerivativeNotionalAmount_d9b10624-a8c7-4db4-915c-81aeaa6d03c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_d22fe3eb-ba6d-44f6-be68-4e9f15a04876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_DerivativeTermOfContract_d22fe3eb-ba6d-44f6-be68-4e9f15a04876" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_d9b618b1-0c0a-4f03-998c-36f46939cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_d9b618b1-0c0a-4f03-998c-36f46939cdf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d1dac51-b37e-432c-91b5-1345c83714e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d1dac51-b37e-432c-91b5-1345c83714e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_35cd7d93-c861-4f94-ab0c-e9089e506d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d1dac51-b37e-432c-91b5-1345c83714e2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_35cd7d93-c861-4f94-ab0c-e9089e506d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_35cd7d93-c861-4f94-ab0c-e9089e506d12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_35cd7d93-c861-4f94-ab0c-e9089e506d12" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_35cd7d93-c861-4f94-ab0c-e9089e506d12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b2fb86e2-42b7-46a9-a277-eb7e9a5693a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_35cd7d93-c861-4f94-ab0c-e9089e506d12" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b2fb86e2-42b7-46a9-a277-eb7e9a5693a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_a56328c6-34f8-4594-b7e1-3b7009ba57e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b2fb86e2-42b7-46a9-a277-eb7e9a5693a6" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_a56328c6-34f8-4594-b7e1-3b7009ba57e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="idc0e51fa160f40e781fc58fc8f092f20_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_59d0057d-f2f3-4278-b052-f1063c22e057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryRawMaterials_59d0057d-f2f3-4278-b052-f1063c22e057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_dcce8c2c-ec68-4b38-a012-ab403ceea61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryWorkInProcess_dcce8c2c-ec68-4b38-a012-ab403ceea61d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_909f4866-f3f0-4e4c-af7d-2199767e6885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryFinishedGoods_909f4866-f3f0-4e4c-af7d-2199767e6885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_5efd0778-d1fc-4893-aaf8-0842a5af9d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryGross_5efd0778-d1fc-4893-aaf8-0842a5af9d14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_23c2265e-ea8e-4a4f-a5d5-1c48895b2634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryCurrentTable_23c2265e-ea8e-4a4f-a5d5-1c48895b2634" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9132246a-3ca2-4dd9-830e-1b3551e62e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_23c2265e-ea8e-4a4f-a5d5-1c48895b2634" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9132246a-3ca2-4dd9-830e-1b3551e62e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9132246a-3ca2-4dd9-830e-1b3551e62e52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9132246a-3ca2-4dd9-830e-1b3551e62e52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9132246a-3ca2-4dd9-830e-1b3551e62e52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_082676b6-de64-441b-b545-a5c0fa10663c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9132246a-3ca2-4dd9-830e-1b3551e62e52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_082676b6-de64-441b-b545-a5c0fa10663c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_654384a2-d731-40f5-99b9-ce477b80bb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_082676b6-de64-441b-b545-a5c0fa10663c" xlink:to="loc_us-gaap_InventoriesMember_654384a2-d731-40f5-99b9-ce477b80bb91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_75c3f308-6a67-49a3-8061-e6c4685de970" xlink:href="exel-20220401.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_082676b6-de64-441b-b545-a5c0fa10663c" xlink:to="loc_exel_OtherLongtermAssetsMember_75c3f308-6a67-49a3-8061-e6c4685de970" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="idbd6d61357d749e1b6f01357a42cf1f7_StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_af9dc396-f332-4405-a6eb-5ea874e6e472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1406e64f-693e-4b27-8b0a-523d6c67d1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_af9dc396-f332-4405-a6eb-5ea874e6e472" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1406e64f-693e-4b27-8b0a-523d6c67d1ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d18ad8e6-c2a9-43d9-9357-46f118e383cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_af9dc396-f332-4405-a6eb-5ea874e6e472" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d18ad8e6-c2a9-43d9-9357-46f118e383cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fea397d7-1367-49bc-95cf-05ce80cd38b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d18ad8e6-c2a9-43d9-9357-46f118e383cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fea397d7-1367-49bc-95cf-05ce80cd38b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fea397d7-1367-49bc-95cf-05ce80cd38b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fea397d7-1367-49bc-95cf-05ce80cd38b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fea397d7-1367-49bc-95cf-05ce80cd38b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_06048ad7-81a0-495d-8ea9-2ee7f0b2a478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fea397d7-1367-49bc-95cf-05ce80cd38b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_06048ad7-81a0-495d-8ea9-2ee7f0b2a478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46bd01d2-4ba8-4af3-8a4b-a11cc8c5b731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_06048ad7-81a0-495d-8ea9-2ee7f0b2a478" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46bd01d2-4ba8-4af3-8a4b-a11cc8c5b731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_741c68c9-39a5-402f-9240-a8246238b30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_06048ad7-81a0-495d-8ea9-2ee7f0b2a478" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_741c68c9-39a5-402f-9240-a8246238b30f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended" id="i1387f5eacaf045f8a9c0941486a62d99_StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9a53a16-c426-4152-9697-1bb73025ed7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e877f985-3db0-4f68-bbb3-a461ae351841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9a53a16-c426-4152-9697-1bb73025ed7a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e877f985-3db0-4f68-bbb3-a461ae351841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508716b5-3c29-46bb-bcb1-b5d4192e6425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9a53a16-c426-4152-9697-1bb73025ed7a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508716b5-3c29-46bb-bcb1-b5d4192e6425" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508716b5-3c29-46bb-bcb1-b5d4192e6425" xlink:to="loc_us-gaap_AwardTypeAxis_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_60817473-511c-4cbd-bfb7-76a476ddf073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_60817473-511c-4cbd-bfb7-76a476ddf073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_92830d3e-4972-45e6-86cc-d5df8306fa00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_92830d3e-4972-45e6-86cc-d5df8306fa00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3a925f45-c651-4af9-94f6-65245b741991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:to="loc_us-gaap_PerformanceSharesMember_3a925f45-c651-4af9-94f6-65245b741991" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2f2d6295-61c1-4516-bab5-b277cb652065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:to="loc_us-gaap_EmployeeStockMember_2f2d6295-61c1-4516-bab5-b277cb652065" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ie2f394ccb5ff422d9c613a13c98ef0f8_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_542534fb-3f17-4643-ab86-a10238dad1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_542534fb-3f17-4643-ab86-a10238dad1b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_e2592d43-c754-4b0d-8174-0331661d137d" xlink:href="exel-20220401.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_e2592d43-c754-4b0d-8174-0331661d137d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_0cec8cb8-b704-43fe-9498-6025252c2070" xlink:href="exel-20220401.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_0cec8cb8-b704-43fe-9498-6025252c2070" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95b8d874-a8cc-4d33-941a-fc91d5b03679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95b8d874-a8cc-4d33-941a-fc91d5b03679" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e4543ebd-9e95-4939-b764-3da90a6a571d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e4543ebd-9e95-4939-b764-3da90a6a571d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_965b4bf6-1119-4062-9d2c-227b063f541a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_965b4bf6-1119-4062-9d2c-227b063f541a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90a9f449-2d68-4f25-8e81-34b3829dd61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90a9f449-2d68-4f25-8e81-34b3829dd61d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60b0f452-a868-45ff-b2ea-cbc8d4a2ce1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60b0f452-a868-45ff-b2ea-cbc8d4a2ce1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c2adec4-94c2-4e24-9ebf-15b4af3df510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c2adec4-94c2-4e24-9ebf-15b4af3df510" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_badd7bc2-2b8c-432d-96ad-2b80a5b6edff" xlink:href="exel-20220401.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_badd7bc2-2b8c-432d-96ad-2b80a5b6edff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2570415d-034b-4102-8c48-017c75faae25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2570415d-034b-4102-8c48-017c75faae25" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8c2c1479-a3be-4fb2-b4f7-3a500bb33083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8c2c1479-a3be-4fb2-b4f7-3a500bb33083" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87872fdc-6321-4552-93f1-729fe64a07c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87872fdc-6321-4552-93f1-729fe64a07c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_192247d5-ba8f-4c92-a618-9ddee737e665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_192247d5-ba8f-4c92-a618-9ddee737e665" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:to="loc_us-gaap_AwardTypeAxis_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4927997-bfe4-44d0-9181-314a56d765fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4927997-bfe4-44d0-9181-314a56d765fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_43d3643f-7058-45cd-b434-ff0d494faf2c" xlink:href="exel-20220401.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_e4927997-bfe4-44d0-9181-314a56d765fd" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_43d3643f-7058-45cd-b434-ff0d494faf2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e187d952-dbc8-4096-992e-8e3f549f337b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:to="loc_us-gaap_PerformanceSharesMember_e187d952-dbc8-4096-992e-8e3f549f337b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53712441-4831-4cfd-81f8-71f1894a4b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53712441-4831-4cfd-81f8-71f1894a4b3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d3598858-aac6-4a45-b570-477d725c3675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:to="loc_us-gaap_VestingAxis_d3598858-aac6-4a45-b570-477d725c3675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d3598858-aac6-4a45-b570-477d725c3675_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_d3598858-aac6-4a45-b570-477d725c3675" xlink:to="loc_us-gaap_VestingDomain_d3598858-aac6-4a45-b570-477d725c3675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_afd6bf87-ce7e-4719-93a9-e5dceea0afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_d3598858-aac6-4a45-b570-477d725c3675" xlink:to="loc_us-gaap_VestingDomain_afd6bf87-ce7e-4719-93a9-e5dceea0afa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8df39a14-bcbb-41cd-a623-ed38a015dc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_afd6bf87-ce7e-4719-93a9-e5dceea0afa6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8df39a14-bcbb-41cd-a623-ed38a015dc91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended" id="i2fc952e700b84ba8b4c3d4929600a0c8_StockBasedCompensationEstimateGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59e710ac-549d-47c7-8b9e-3e66d6096ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59e710ac-549d-47c7-8b9e-3e66d6096ba3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_b5d648e3-4f64-4297-a369-6424e599710c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_SharePrice_b5d648e3-4f64-4297-a369-6424e599710c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b710db67-15a6-42d0-b3a5-5f7b12940fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b710db67-15a6-42d0-b3a5-5f7b12940fb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c83ae5d6-5f86-49ce-87b2-40196b1d3519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c83ae5d6-5f86-49ce-87b2-40196b1d3519" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f7105893-c252-4fca-89ca-3348464a3b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f7105893-c252-4fca-89ca-3348464a3b05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c12c0c95-222b-4bb1-86a6-ce7f0a9ddb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c12c0c95-222b-4bb1-86a6-ce7f0a9ddb36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c12c0c95-222b-4bb1-86a6-ce7f0a9ddb36" xlink:to="loc_us-gaap_AwardTypeAxis_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59cad1ca-7a9e-499c-9ea4-28849d6ba8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59cad1ca-7a9e-499c-9ea4-28849d6ba8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_b771bec0-ca37-4a2a-9e69-5c9c9b00cb24" xlink:href="exel-20220401.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59cad1ca-7a9e-499c-9ea4-28849d6ba8f7" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_b771bec0-ca37-4a2a-9e69-5c9c9b00cb24" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="extended" id="i208d723cd7e24d6db8a45f5f9094c8a4_NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee745e2b-a587-43be-b25c-5cc4e850a0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00ee7ebb-6fc9-40b6-b3da-5bcc228e4212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee745e2b-a587-43be-b25c-5cc4e850a0c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00ee7ebb-6fc9-40b6-b3da-5bcc228e4212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_65da67a1-7b40-401c-9aa3-abf328416298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee745e2b-a587-43be-b25c-5cc4e850a0c7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_65da67a1-7b40-401c-9aa3-abf328416298" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_539fe16b-f816-456c-97ee-8f83673295cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_65da67a1-7b40-401c-9aa3-abf328416298" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_539fe16b-f816-456c-97ee-8f83673295cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_539fe16b-f816-456c-97ee-8f83673295cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_539fe16b-f816-456c-97ee-8f83673295cb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_539fe16b-f816-456c-97ee-8f83673295cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82862481-5b22-40c2-bd80-c92a0fa8a6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_539fe16b-f816-456c-97ee-8f83673295cb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82862481-5b22-40c2-bd80-c92a0fa8a6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_24d8d68f-ba15-433e-8705-d66e2e5bc8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82862481-5b22-40c2-bd80-c92a0fa8a6dc" xlink:to="loc_us-gaap_StockCompensationPlanMember_24d8d68f-ba15-433e-8705-d66e2e5bc8ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie5f3937dedb040ed81f3a91fe52182dc_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_ab79380a-1b0a-4770-a295-6e2d720069bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_ab79380a-1b0a-4770-a295-6e2d720069bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3bb5d40b-3c23-4548-b9d0-50ffa769bf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3bb5d40b-3c23-4548-b9d0-50ffa769bf61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_4de5212a-be6e-4900-89ff-67da56d205ca" xlink:href="exel-20220401.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_4de5212a-be6e-4900-89ff-67da56d205ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3f62715c-6dce-4602-b394-451e2ab933bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3f62715c-6dce-4602-b394-451e2ab933bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_040a1963-5dfd-469f-a4d3-50f0b975a5a9" xlink:href="exel-20220401.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_040a1963-5dfd-469f-a4d3-50f0b975a5a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_8f29e970-6409-4257-acd8-c5764aa3c6b3" xlink:href="exel-20220401.xsd#exel_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:to="loc_exel_LeaseArrangementsAxis_8f29e970-6409-4257-acd8-c5764aa3c6b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_8f29e970-6409-4257-acd8-c5764aa3c6b3_default" xlink:href="exel-20220401.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_LeaseArrangementsAxis_8f29e970-6409-4257-acd8-c5764aa3c6b3" xlink:to="loc_exel_LeaseArrangementsDomain_8f29e970-6409-4257-acd8-c5764aa3c6b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_0211126d-3099-43b6-a60c-f6eba9eaea21" xlink:href="exel-20220401.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_LeaseArrangementsAxis_8f29e970-6409-4257-acd8-c5764aa3c6b3" xlink:to="loc_exel_LeaseArrangementsDomain_0211126d-3099-43b6-a60c-f6eba9eaea21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember_434e7a6b-5eb0-445e-be35-85cca57ad545" xlink:href="exel-20220401.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_0211126d-3099-43b6-a60c-f6eba9eaea21" xlink:to="loc_exel_BuiltToSuitLeaseMember_434e7a6b-5eb0-445e-be35-85cca57ad545" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c30727fa-77ad-4377-9418-c246b7acd41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c30727fa-77ad-4377-9418-c246b7acd41a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c30727fa-77ad-4377-9418-c246b7acd41a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c30727fa-77ad-4377-9418-c246b7acd41a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c30727fa-77ad-4377-9418-c246b7acd41a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b45dc360-b9e5-45c9-a2b7-0c7c961d46c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c30727fa-77ad-4377-9418-c246b7acd41a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b45dc360-b9e5-45c9-a2b7-0c7c961d46c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bc4b59e3-6489-46e0-8891-fab1391f0b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b45dc360-b9e5-45c9-a2b7-0c7c961d46c1" xlink:to="loc_us-gaap_SubsequentEventMember_bc4b59e3-6489-46e0-8891-fab1391f0b53" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>exel-20220401_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73bfe3ae-0c1e-4ba4-a72f-9891e89b0476,g:eb76abd8-9ed1-48d1-b6dc-c6870e560f34-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_28a56574-8be0-4573-a674-7b2c7531fbb9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5bbb6a8c-29da-41f9-96fe-883767c552ad_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_377e8fb1-2630-419a-b807-ded71936701d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_964fd9ec-1ba9-4a93-b482-64d761d709e8_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1493c80-d7b4-4e44-b669-9a5172e1d745_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0fe264e6-218f-4243-9ac2-9b159875b499_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ebf5d207-7aeb-4f0c-9de8-9ace06a2e3e6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1a511b82-d584-47fd-a567-9b4f32cdd2ab_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6630a119-3998-4120-a82e-461d8c27e11c_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_c01ba44c-aae8-4a68-8064-b7de249a45dc_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments, pretax</link:label>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_label_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c7f4e749-3780-4bac-b2c8-5cff6e270319_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d746c314-d00b-4024-b81c-bb3c9e1a94af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ee10ba6c-ea3b-4064-ab7c-c61de74ab780_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3cb36d9a-e3f8-438d-afb8-9c3edd6709fb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_7b8c888b-d8c0-4fdc-8684-a03d355b300b_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20220401.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9c6c410e-d741-419a-bf50-f4dfae50e000_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_8c742cdc-dc6c-44e3-aecc-e96bfde5d31d_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20220401.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_cbd940dc-eb43-4597-b291-9f451ce1e56b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_34f72377-36f3-4ee5-91c5-262131e17dea_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_b1057f3f-2e8a-4230-80c8-afa229c3428c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_8007db5e-3ce6-4dbb-9f92-3d50c20e22ce_terseLabel_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Axis]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_label_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Axis]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_documentation_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis" xlink:href="exel-20220401.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductOrServiceAxisAxis" xlink:to="lab_exel_ProductOrServiceAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a67d1d76-e0cb-41ce-9f52-4e783f8a4360_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cfeaa07f-ea77-4956-95d3-a45201d3bd4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_365454eb-98f2-4cfc-91bf-7b2cc738b229_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_734fef2d-c092-4055-99e4-30099d01120e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_4611514a-7895-4801-8328-9a913dd0c038_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fef52763-db74-4fd2-a956-7c38830407fd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_c46b2f8c-4acf-4467-abb2-2ce7853337e5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3de726a9-b952-4f5b-98b3-f1dd45028913_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b40adbe5-6bd3-49bf-ac3f-6f99d1c7cb34_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8e2fd54a-3c82-47c6-8ae7-9ade712b81ec_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_db88f0bb-1ff1-494c-81eb-3d1f5c078738_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_84f4c3d6-7b0e-487d-a64b-72c25ada2a38_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_8e195ec6-09d1-49f1-aa29-63f63678af21_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d25ee926-b89f-47a2-a2c3-b0f5d29d2a6b_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8c644063-94f3-44a6-8c25-44c3aa05842a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_1fff95f7-9776-4989-bd15-e257aaadd605_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_def474ac-26b8-4096-9b13-039eabdba8c6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_7bc2f6bc-3a02-446e-9743-d92751519eb3_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20220401.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f2996367-3f8f-4863-8aac-5ea667d77e8c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d5ed6af9-3a5a-426b-bfbd-c6fd1c9f5042_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_499c4567-8316-4254-9374-dba73abed91e_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20220401.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_efa9584a-950b-4168-86ee-289802b69a88_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_c0d0d7ec-28e6-4ef9-b965-ef90dc936120_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_1f991261-95c1-4d29-8f5d-52b8905b291a_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20220401.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e15969d-e3e0-45c2-9edf-0e4c066a0e38_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_6306a993-d4bc-4774-81c5-d25868bd2955_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_d8d72bc9-4279-46fd-a8f5-fb8022344c5c_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_cd9c2c98-e549-49cf-a202-5cb74d8d4e38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized losses on available-for-sale debt securities, net of tax impact of $1,656 and $499</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53eb9aed-2378-401d-a9e7-1eaae28fc016_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9d84b86f-5979-4a42-ab7c-6adbce1a9fa9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_365368db-4787-40c8-98ec-086238354b40_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_14d8848b-00f2-4b82-aff6-0282d9c987d5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_a61ab69a-8621-4776-b8be-9ef36af3a9b7_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f368a983-6e27-4d0e-a11f-6eef9a6d4dc3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9efbce2a-abf8-4b24-b500-a6992838cb02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b06b0b54-7b08-4133-afc8-c2883e59d9f8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f387141f-be1e-469e-a182-2eec6543b34c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ddce2794-bcc7-4260-a21e-20bad98ddf7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28425c0f-443a-4a3b-8e8e-8baa9ff0f4bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_16aee6eb-0d53-4a5f-9e16-1b1c10b8e610_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0aaf8122-f0cd-4ab8-b0d5-551f42315528_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_14ce5d31-e7e9-48e4-a7e5-5a689877b627_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_a382f40f-e877-43ac-865d-d1ad35f1b256_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of lease property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3461e817-dca8-4283-8759-d899898bf061_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_3e068eca-1f19-4625-ae75-adf39e75744b_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20220401.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0c563e6-65cd-4283-af9b-d0d1a4d39ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_d165d635-79d3-4b4d-aaa1-cf43e952e220_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_df71ab96-ca7b-40e0-84a0-4945d620c3c7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c4d2523c-5505-4396-8639-bcc4dc02f6df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_46ad2681-1df8-49ff-ab40-ba75a66596b9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting award percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f4317a3-a827-4ad2-bf46-a8acd1cd8784_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_e29d6e18-b3c6-4340-aa41-6a16c7bea651_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment upon closing of transaction</link:label>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_label_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Payment Upon Closing Of Transaction</link:label>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Payment Upon Closing Of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:to="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e92bca5b-65e2-452d-8346-957df3c969af_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_05a3037d-b7b6-4be8-8f4d-7f7207641866_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_389e2bba-6b34-4639-a9a4-45fbab58710e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_12a7aa17-db67-4475-9487-4533d010ef67_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_f660df07-4df2-4024-bdcb-e7d5fbd08ec3_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_fb0a3db6-3bac-424e-938d-03bc2c60d63d_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_fc92430c-5714-41a4-80b5-8dbcba61091e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_80083d6f-aea4-456e-96d6-881c57463367_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_feb817ca-10c0-4f90-be00-3ce3b7fcc329_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_68c13395-1fd2-42f2-90b2-7a0963c66a4e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_ceee63fc-27b6-4954-ad4f-f4beae2d3d15_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_052aee08-affe-4cdc-958b-b9aa46693682_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b4c0a9ee-c26d-4aa0-be32-d231757299cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_946a9689-c95c-48e3-833e-9aa590c2001f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_cae05ca1-d8e2-425e-85dd-df97da9f4f13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_c7ce01b6-5941-44cd-b407-f3f544f5e4fe_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_a8003bc8-8725-4933-aaf9-ec61420cec74_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20220401.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_b9197151-3c76-4906-b806-30e99cfde86a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_4134f286-1722-44b5-a38a-133f9ea126f9_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20220401.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3500fda2-5198-45c9-902a-029395510841_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20220401.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsDomain_1d472b90-0666-4bfc-aa6b-a4c97822ba42_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_label_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain" xlink:href="exel-20220401.xsd#exel_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsDomain" xlink:to="lab_exel_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyalPharmaMember_66a4929b-9962-412a-81dd-09b2700cfe43_terseLabel_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma</link:label>
    <link:label id="lab_exel_RoyalPharmaMember_label_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma [Member]</link:label>
    <link:label id="lab_exel_RoyalPharmaMember_documentation_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember" xlink:href="exel-20220401.xsd#exel_RoyalPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyalPharmaMember" xlink:to="lab_exel_RoyalPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_c9f69b1a-740d-4a46-9c7d-b4b40a66917d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0781494b-2a55-4bdb-a4d2-13a8b27110da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00b53e73-04e4-493f-881b-bcf85fdd20cb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_740394f7-96f8-4ed9-84a2-439ad5205c16_terseLabel_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_label_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_documentation_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember" xlink:href="exel-20220401.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuiltToSuitLeaseMember" xlink:to="lab_exel_BuiltToSuitLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d497a1cd-e138-481c-b3a8-e4389a193237_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1a58e14d-3269-44dc-a144-be3baf4811bb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_429975a1-40d8-495c-a1ca-52fed1b76ede_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_66e238cc-2ec7-42b9-a49a-7ff464dce534_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3c587062-0abe-4acf-9fc7-9927caf6babb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22b88f23-feb6-472d-b58f-9ce08a669836_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f75e474c-928f-42fc-bc22-3a1761f23bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_46c75ec8-1a88-4fcf-9e3c-78e6886e8638_terseLabel_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_label_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:href="exel-20220401.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:to="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_cac42345-3026-4867-9580-9dc0fc7e7742_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_57c90984-2b2f-4ca2-846a-03e5d5097973_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_32ddafe9-dfab-4bf7-8aea-e9561d09c34d_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_1ca3f4ff-c381-4ce9-8336-ccde03e0ebc1_netLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6c6cc52f-baa6-4355-8b90-71dc5544d8e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_56d48cbb-8410-4665-aaf3-90b784cab5a5_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20220401.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2cbff024-3992-46fd-84b3-ce1447a1a128_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4975f5a8-f8cb-4091-b32c-cc992259d0d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_a7183971-b2ee-4c0c-9c1e-7a3587e0b529_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1f08d004-9b97-4647-b540-9716bbc12dfc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8d985df0-47cb-4d7b-b5b6-e7c7b0b84561_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_39a334c4-a797-4494-9775-4bff701d9a4b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e1c8bf72-bab7-411a-aa3a-47ebce08cdab_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_8c1f28c6-527a-491a-b9b5-047e2adcdc32_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20220401.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_47c45367-420d-42e7-b75c-7fa97e133a25_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_05e924fa-4fac-44a2-9fd3-aa908c91afa5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_1c9fb2ef-50d8-4f3a-894e-fb849149f29a_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e14852c-029a-40fc-a5ea-3b6d84aa8052_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6ef7d841-7aeb-4519-914f-cbb809a67adf_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e3a2f1da-e5b8-4bea-b456-b310ce391792_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_30e7f35e-47f4-4e5a-8827-705869dd3c89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_faabfe8f-c55a-4bb4-a01c-13cf99680cf5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5edac208-7d33-4657-9dd1-b2355c1c5714_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_d256091b-15be-4643-b412-c1ebe5e8ac91_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20220401.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_728d4260-6646-4438-9552-ee69d465b7e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1db90574-0c98-4e47-b7fe-c36ee3a46a74_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_968fb5f3-d3bc-4347-8cda-e67f9644a451_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_02c5eb83-0d33-45a1-bbf4-8eb26016b5af_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_6a6e2bc2-f9f6-477b-9221-81eed8b15a38_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8facf164-0464-451a-a9dc-65471255cb03_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_465651e4-524c-44e6-8d5a-97080fdc95fe_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_b3a4d008-714f-4cc2-92f3-59d3e9be5795_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_4313b43d-a8f0-4263-bda6-91721c97332c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_fd3a2bc9-aa34-4e9e-b420-99ad51d0df7a_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_84a486ef-9313-4037-8616-9ce5a261f90a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d536aeb6-c902-4889-8beb-0b37f496ffea_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 320,268 and 318,842 at March&#160;31, 2022, and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a1246719-ec94-456d-a3ec-78bdff33a964_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_3b7b6405-fc40-4d35-b123-da219b4ff46a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_76bca228-60ae-496c-9bf9-be074b8464bf_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_901164e6-611d-41cc-a752-bf795e2df1ac_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_61a60f2d-f5ab-43ab-8530-eca797afe0bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_94df963b-0612-4abc-a301-8c8650d79192_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0a65d9be-d8a8-4c04-943c-ef2cc2e3ef89_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3c81bbcd-ba3e-445f-b91a-3056e534410f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_58d4e70b-e9dd-418b-ba92-d1a2bf665a69_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_078cd897-0a65-4983-a3c8-3e4278d0e9ba_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_7b31deb6-7fb3-41ba-bfdb-f5b032673732_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_f90997e2-f6bd-46f9-97fa-46970140955e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_03be3a0f-7773-433a-9a92-60ed44eb055f_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3099731d-b858-48cb-a3a2-d829ddaf7c58_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_d76c40b8-4295-4252-99b5-79168b29ec12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_85c7c259-abc3-4692-aa2e-f33ee2451779_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c93e5cab-f17a-463a-a495-dc73d8b1aac0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e3e4c5fd-95eb-4e8f-8c77-d0580fa0af84_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af66123e-ad0c-4b38-9535-29f72292854c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c74937b-5c13-42ae-8d16-2b0a97e57c07_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2c0a449-6660-42da-af20-83e86368ffb5_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_701c3b28-1fa3-47f5-aeab-e18a2d82285f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_3f12950e-3d68-426a-9b8a-2ccb2aa1a96c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e6d79be3-9b39-446f-b413-9b8f284f8160_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_3b0cc2dd-3942-4a02-90f1-31034bc87f2f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_de4a2400-1e52-4982-b6c4-2650a5aa0fb3_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_159d88fb-6ce7-4242-abbd-7a24242905ef_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20220401.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6270c091-04b9-420d-a323-cadf65722c9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_94959415-3c18-41ca-b13b-0c42958be09f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_7524526e-b6f4-4d50-b467-ac13c0d2232c_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend the Lease</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="exel-20220401.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46ee1465-fc94-451e-b922-1b561eb3d47e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e09eb0fc-febf-49f5-abb2-37c64b7994b0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e4949c9c-dcef-4564-a0bc-1a839ba157c6_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_22354c7d-870d-4120-bdff-6a3eef8fc0c3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_055dc71e-a0f1-44c7-ab37-523228c377d0_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e96dff93-86f1-48d8-b168-7584ffec1132_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_55a6e026-8f57-432d-a6bd-801628481f34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_807f9e95-f51c-4866-9419-0ca128b9008f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b6ff2a71-0755-428a-9275-6b6c941e193a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_7e217fe5-d428-4bdb-8417-98622ddbdfef_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_75bf1023-a384-480f-bfae-e981590e0450_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fff8558c-5492-4dcc-8be7-1646c7973857_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d0cab106-0843-4585-8230-9d1d59bd336f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_4d77542b-59c6-4a85-9812-686f44df2a01_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_9678f3a4-b3b7-47fa-b65c-c464ae5a7636_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_89f38ee7-fd98-4cf1-802c-2928d55612fd_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20220401.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4ab7c8ff-fb86-4862-8c8d-d741e9bedc13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_ee064fb8-04b3-4cad-983e-3073b7291d95_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_a5031458-0efa-4696-8cfd-a59f9ea68bf4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18ff6467-5ce3-4dca-8a66-51af0518e8e4_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_f511eb90-529d-4385-a82d-213bbaf84549_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting from discovery efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20220401.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_fb846089-e4f4-42e0-9159-73d93895383c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2fe0670e-8e8f-460f-a2b4-f9bc78683177_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8219d2c-d661-4c16-a345-904d49462266_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_040dd921-e251-4fac-b9a3-f1178383ae83_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_85c552de-b365-4f1d-8297-741a29aafd0c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fa4f49f3-33d8-452d-9895-c7dc56b35cb5_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_6983c8f9-0b10-44b1-9b42-5c9a3d781d90_terseLabel_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries with drug approval, excluding the u.s.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_label_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_documentation_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:href="exel-20220401.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:to="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_eaa6985c-6b28-460a-a920-0c90a80a517d_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2b1a3d2e-23a8-4e0e-82b8-1d97d0df4835_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bc97f4b4-113c-41ca-a766-f7385d437eea_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_0bef4155-f1e3-43c9-9f5f-393518806093_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20220401.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_384388e7-01ca-4f12-8dac-0fa825304e93_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_eb71f8b9-4039-4342-b7cf-e01ecc15c3ef_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d011c4bb-6ae3-4837-9e12-fdd575787c75_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3fdf9606-9635-4ecc-ac63-4a76a81a0f89_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_facf3a4f-9e33-4646-89c9-a67fed21af19_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_256c836a-f7d6-4d01-bef4-0335b65de156_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_277a0cd1-820f-43b0-afe4-6fbe2ab223fd_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_acea50c4-750b-4f06-9ae5-b648e0796ce0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d9b304ff-63e4-4801-abbf-fce81af2830d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d3bb1286-9851-4824-8c94-3ee46d26ff78_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_22bc2eca-42d1-4bf5-ba76-b88ca10a8328_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a3207e20-7870-485f-866c-9ef0394bab48_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_796f6505-c370-4374-b485-42cffaddc168_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e2f40d73-ff84-4692-9f98-5265fd755ed9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_cf79e96a-4fc0-472f-88d3-bdcaede9bc0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CotellicMember_5dd6757c-2d7b-4161-964c-86bb502b0b5b_terseLabel_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_label_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_documentation_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember" xlink:href="exel-20220401.xsd#exel_CotellicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember" xlink:to="lab_exel_CotellicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_6d5856e3-5ff9-45b6-a2b5-120e68d0e214_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Company's common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dd174779-d52a-43c6-bda0-699de5dd6db6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_4caec439-0832-4e08-9828-6744f62f2b7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9b080a4d-2b80-4ede-86e8-1eaf8ee5c14c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_08f1db30-e590-48ba-a058-238829e479a3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_653f154a-241b-4a1a-833b-2a1a70f02613_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_49cfe04c-a371-4799-8935-1d919094a611_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b8c32a05-57ee-4eec-8a2d-6549874a4778_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20220401.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_82390481-8cba-4939-97b7-bc69ae3781be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_dd330731-f4ac-46f0-8ed4-74cb899b0f9d_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20220401.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1bce32a0-335a-4487-9401-dbca4a09fd52_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d60765d3-8169-4f2a-bdc2-49a03b2e6c63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fe5f5823-5078-4a29-8ee7-97a92b920789_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b92fb5d4-8c52-4055-aa99-4f664ee42e77_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_660d0480-dee5-4e9e-95fd-4888471bc465_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_4790eb63-147d-407a-bbec-05814cde2f2c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_f4afe3f8-b996-4b4e-8e08-6f96b1e67c4b_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_835582cb-5dc9-4a0a-8555-e0a7fef0f527_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f6899fb6-bd20-4e75-8d0f-c66f356b84b5_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_ce20c341-6d52-4a1b-a4b7-ece5071268fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_7f730e5d-95e3-4857-9500-3b492e183e63_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_d7542666-3940-42d2-8c5b-d6cdd9daa820_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_efadc1f6-c630-4534-931d-2428f81aa191_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b56c41f1-a2ae-44bc-a08b-955d2025777f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7877500e-57b1-4f59-ac60-74c748207e2b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8e8fe7c4-f597-4311-8510-f80d87812831_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_34d15b3f-9385-4b53-af40-428373153e04_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_74e9f0e5-8799-4adb-a57e-942601ce422c_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_eb2ba004-e232-43b2-8cdd-654bf1863c1a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f8bfedf-a792-435e-8787-2a943c8753fc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d5a5c3ed-f4d2-4a29-9334-4ed3a291fa86_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_531bb624-19bc-42f5-8df3-0dc993438c9d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_403fdd0f-505c-4e46-be9f-8d812bbb674d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_5c261e20-6abd-438b-9d67-c19403288b0d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_417fb0f1-d3a8-4e9a-b6ff-915e8eb11953_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_56dff390-2725-4beb-b1ff-195d828066cf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_361161e8-e4a2-4b35-a27a-e8866bb4a41a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_732c26b1-5ce0-41b9-a630-982b30e63dea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_45e8cb38-7494-4ae9-8361-278c607febce_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_00573bad-5b98-4dae-a421-b1578d15ca15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bf6e789c-15c8-4176-9f7f-2158772385d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_03aef14f-6660-474c-8999-b8540ced3c0a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_aea5261c-fae9-4de0-b618-48dbcd50e92f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b19adcbe-0225-42d8-9140-0c7157247790_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87b56fce-cb68-4193-85ed-94d6058e1816_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ee34c047-ec9e-4636-a758-f3a09fbcc283_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e76642c2-9454-4490-ac54-0bf11a8dcea4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d30d9b79-a790-4e9a-9926-0b054b46c92a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_ecb42436-6cdb-49ce-9702-b00c13312e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fd6434ce-27bf-4cdf-9cea-3f4ded9aade6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_f7bb2dd8-370f-408b-81c2-d12887102502_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_2c2536a1-cb1e-4bec-a686-ce11e8d07ac0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_f190a8f0-d1a1-437f-a478-dd1f8e8a2b08_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9b70f886-46bf-4496-aadb-f31fd1228191_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_defb9aeb-1f27-47bf-9270-ea1f7a68db84_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e03cc26a-5f57-4f92-9f48-152634798d84_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2eca07c3-f924-42d6-8272-98d53fb53501_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9af7ee83-efbe-4276-ba66-c28077e6262f_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e248cc94-efb5-42e9-9a80-cffb66079d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_3f1b8dec-21a9-4cfd-be0f-19fba9025778_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_28fc4177-0053-42dd-ae4d-5d29bbe9bfe0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4cd31006-508d-4b99-a6b5-e2ddc74b0174_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f7bc2306-9eae-4d18-bc48-56eb12d9080d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c52aeeff-eaad-47b3-907f-5c49c3fb6f68_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e2fb10ca-8e10-4ec7-b34d-4be168bfe156_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_042ef649-3034-4cd8-8b27-0e5e1e71aff6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_3a563cee-6f5d-4ff9-a30d-31bb5ad82745_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20220401.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8cc13298-4f08-4cc9-9502-ee886422ec0b_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_fa46ac8b-d0ab-451f-966b-4ed0cddb73fa_terseLabel_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_label_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_documentation_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain" xlink:href="exel-20220401.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductOrServiceAxisDomain" xlink:to="lab_exel_ProductOrServiceAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8686297d-8093-40ce-b7c4-e4f6163377ce_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_539bd9c7-c347-4040-91a5-d92f73888e81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0c64eb46-b0ff-4b6f-82e0-236031d8aa14_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5b684959-4f63-4b9e-9374-83330496b5dd_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a2f6ecd1-3c2b-48fd-b9f8-29fb24ffab25_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_780f23cc-ab5d-4f3d-ab7f-264c06f530b7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0915c3a9-69fd-4cb1-af85-1070e2e1c14a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0322c429-c991-461c-a242-abaacd2a72b0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9ac420a5-5045-4adb-9852-8aa740a403a6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d99fb42b-299c-424c-bb28-4a4667080243_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ba31e787-e365-4abe-9b6f-63795f19aa33_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_613695f2-0c55-478d-a282-e4acee078472_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20220401.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_cc98f751-6a07-4933-94cf-be6264d25212_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_7aad4f66-85f7-403b-af4d-6da6b61065ac_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_30aa40e3-ec98-45dc-9b86-2b6269eb3a28_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20220401.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_8f9c5f30-1f80-4a95-a1cd-659c5ab97a5b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_da0c83e2-cd17-4598-abc8-6b7ff9b4bfd0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease option to extend period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91060c63-dffc-4bf7-81d5-4d722f8faabe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_ea5e403a-2d70-436c-b4c9-c6a467c8197f_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8b780d08-0fb2-452f-bdd7-7d3ac647b2e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_38f9c3ef-2f5d-46dc-977d-097372a8221c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aed5c781-61de-4978-bd0e-ac54143a3690_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_fc263dcc-237e-420e-868f-d0bbad522b02_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_755a59c6-5edd-48c0-8ad4-1b8a14108dc1_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_9cab76f7-491c-44fb-90f0-6eff377bcd59_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_0d0dfb2f-eb81-4a68-bbec-93b8b5ccc0d2_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20220401.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_5e220144-d521-4ca7-b367-d189b5997d3c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_49ea145f-f105-4239-95f0-e5cf595b2a23_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20220401.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f1ee9ad-4319-45a6-8138-a168a6a31f76_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2933005d-9e99-485a-b70e-fb78c6caecae_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_aa21e64a-1df1-4d72-8104-bfa2fbd8c9d7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a688780c-3dd5-4297-b5a7-272a1dae00ac_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ccb047bd-cf2d-49f1-a712-8a6e82020ba4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_473f0b59-c06b-4e49-973a-c40752c55076_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_f17c1aee-7088-4e1b-8c51-434b87112d64_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_b0adb0a3-cae8-4db6-8d9d-f01442b47296_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_e35cf0dd-ea5c-469a-a4a7-36176716b406_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_85f2a87f-010a-4289-9913-1b5d256542c1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_24023012-77f3-4bed-ab0f-06deec577841_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8f879698-d88c-4b79-a505-109c7c154f0f_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_637ae762-85b5-4350-85df-0583bda4411f_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to terminate lease (after period)</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:href="exel-20220401.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:to="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_9aa11197-3942-470e-bbf0-24431aa82f11_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20220401.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_19921832-15bd-49d9-8a42-1c1f6abf6472_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_55bf6596-93e5-497d-b52a-3f115ad4992b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_4494f06b-231c-4e70-95b2-5a2f447ee463_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20220401.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_1969bbb1-7d1c-4b33-925f-39c8a10ad0c9_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20220401.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3ce38fbc-fa73-4f72-baa0-7afbec64ca71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_ad93ec64-e97d-42b2-ad02-3adb9f4c603a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_21c06517-3079-4abf-8b75-a246e22b6d2e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_02366e45-4372-43bc-8499-c0dc952d4a24_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2b19a735-8de1-4728-8315-e3642af87274_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3923801e-438c-452b-a53d-0293e5642caa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_b5655184-9f53-4c90-bf41-87255f53e983_terseLabel_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="exel-20220401.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_21bd9264-1d81-4df8-8147-089f22533621_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7c9e1daf-d9bb-4c5e-97ab-cd17d23bfae0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_4ca16558-6cad-43c8-bbe7-0ade61fddc88_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_21bdcf15-998e-4fa0-bd14-69a0e71f702c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_73039559-aebe-4a79-908e-ff8d5c3f7e4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_21da4f87-10f8-4fe9-911b-6a71e87ccd96_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_870d3a88-2a37-495f-b80b-5fc9237ed574_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_5a9b1609-bf3b-4d7f-998d-3731efef5ccf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4524b3e0-5ab3-466b-8b3d-5bde66497ac4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_b4f25051-3408-4081-9b31-e422bb8fb2f9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c6a7e9c5-1f83-4f61-908b-32067647bace_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_a8808e8c-f0f8-4c84-876c-7468751e4802_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_16be0de8-de66-4c98-ac59-49e9f2cc3738_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_be3ac39c-632f-416f-8736-d1d54a9a0bd3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0b85c546-b553-4540-9492-b7ff59c37cb7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2be76c55-61c6-47e3-a164-def493661079_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7c414c6b-a2f8-4b9f-ac0b-73411d15e184_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8e534ab7-16a0-4bb3-ac11-2606defd7b5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_7b369eb9-9dab-41f0-a3f6-d5d357d9c1db_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_15f07e1a-258b-493b-97be-36b9abd73269_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9578665a-8226-48be-b995-db0bda24d5c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_15d76039-ce13-4f6f-bc3e-53fce2b54a80_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_ac46bd83-5c12-4ef9-86a6-28f142e072f5_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3cc78af5-02b9-4787-ab1d-d85bae11fbee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fbedd250-2477-45c1-9807-39e0c621b2d7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_45617fbb-4c82-46eb-aaf3-ab4daec37839_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_588b687b-7ac8-4684-93d1-c84eeeb3e54c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_65311bea-1ec1-4e72-9e1b-020331624efe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_5cf3f155-67ec-40d2-8efd-4838d6191e3b_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20220401.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f255e26d-050a-4d75-80a4-3d897e78aa4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetPurchaseAgreement2021Member_0376f56e-316c-4dd8-a818-33fb6f7381c0_terseLabel_en-US" xlink:label="lab_exel_AssetPurchaseAgreement2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, 2021</link:label>
    <link:label id="lab_exel_AssetPurchaseAgreement2021Member_label_en-US" xlink:label="lab_exel_AssetPurchaseAgreement2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, 2021 [Member]</link:label>
    <link:label id="lab_exel_AssetPurchaseAgreement2021Member_documentation_en-US" xlink:label="lab_exel_AssetPurchaseAgreement2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetPurchaseAgreement2021Member" xlink:href="exel-20220401.xsd#exel_AssetPurchaseAgreement2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetPurchaseAgreement2021Member" xlink:to="lab_exel_AssetPurchaseAgreement2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_4ed45a38-085d-4573-8767-39131de8771c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019d60b1-b4ec-49ea-9236-5c3ec9fd8209_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed81ee3b-81c3-4e0a-9f25-0f7d58aa8cdb_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_0a210b04-53fc-45b1-82a4-5b52035f1cbb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4655ba09-9e71-43f3-b36d-73d29ee32107_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2ab11c4a-c5d0-4482-972e-cad054f07069_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_51e49afc-48c1-4b6c-964c-d71992ed0f8e_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_16832a72-f3e5-4364-9db2-c2bc696285d3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_1be67ffe-89c0-4f1b-855a-9d285c83c9ea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_2a963d03-9ac8-4f64-ac80-3c51260d6d03_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_785ec127-fee5-4185-881f-ff6712868af8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c461e69-906c-4015-b668-33059e96faa8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1e539099-7ea7-43ac-bb43-3c87b39d4633_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_1f5fd285-a59e-4c0b-bff6-b1872e5c94f3_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_24b6fa35-a19d-486c-8c29-ad8ffa38f99c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_e5235152-2f58-462b-8897-74088896ff9e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaAndIspenMember_4c0eff99-b010-4aa4-b5d5-75ac72f156b0_terseLabel_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda And Ispen</link:label>
    <link:label id="lab_exel_TakedaAndIspenMember_label_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda And Ispen [Member]</link:label>
    <link:label id="lab_exel_TakedaAndIspenMember_documentation_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda And Ispen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember" xlink:href="exel-20220401.xsd#exel_TakedaAndIspenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaAndIspenMember" xlink:to="lab_exel_TakedaAndIspenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6009249e-ee34-4083-9485-275d3f0c1782_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7ec02382-ba1d-4fb8-ba11-b7a8b81f69a9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_478a20d9-c064-4996-a60b-48b59879798d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_250dd33b-6762-4c95-b66b-d417d41d7d2f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_67f58ea3-590a-47a7-a987-3c163b9945d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_05d52237-d991-4a0e-9d12-730483dd3b36_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_bbf933bd-92e0-4e1b-aa82-17cd0f5a1f71_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0b7c3363-9eca-496d-92f1-9955de31d4e1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e76e765-f1fa-4c6d-b3b3-97b084ab0a1f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_49244ab6-f454-41a9-a7b8-ddd99a60207c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ad8e0b67-e945-46fb-a139-0732201a7874_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROVISION FOR (BENEFIT FROM) INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsAxis_1289045e-a6ff-4446-a579-11a2360a8573_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_label_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis" xlink:href="exel-20220401.xsd#exel_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsAxis" xlink:to="lab_exel_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e0397216-79b8-4a23-b228-4674a3d50a8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_eb034f7c-f38d-40e0-b0d4-e449fcac2c4b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e8aec90c-5a33-4e7b-b986-2c1143e62c3e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f954d523-22a8-4bba-a4c6-93b751d85d53_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3fc23379-68a3-4248-8430-40f3e7fb2213_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_90bbdf92-202f-40da-9a60-9377d048c16a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_656b9679-c846-4fa8-83aa-40b83be0b37f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_54b41e66-aa9b-47f1-ad8a-8e9c017f5d4b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_418a0b38-d9b1-4531-84a7-89cf2d8849f3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b1099b63-d6eb-4bfb-9a1f-43a6c4c88589_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_a73d0ae2-90f3-4e53-9e10-1e55c46b5ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3a37c6ab-3364-421f-8f3b-99281e690cbe_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1c589b0c-3a86-4b3b-9110-e3d3700df532_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_606bbcb6-0ae0-4658-aea9-91f230262941_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20220401.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3fa75064-36c3-4fc9-96b8-3da8a5203196_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_35d8bc90-ceac-4c69-a451-6208413b0d3b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_14409b3c-5732-4e8f-ad3c-ab0f274e002e_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3e1dfd7a-cadd-4ed6-9920-5badcd0f9634_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7daaa6c9-310e-4230-bd99-8a73369625a8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_e0b48024-ec23-439b-bf7b-087e18f53e29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position more than 12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f188f1ba-2636-406c-b8a5-09cd68a7f339_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fd4999e0-5540-4026-a37b-83924adbf137_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_60d3eb1f-a62f-4b7f-805a-a29cc8c0421d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e46b9efd-7c6a-406c-8b21-96f36fb1d11c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_77d3c880-f13a-4488-a232-e4c1f653d128_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at March&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_d741acfd-eba0-4a4e-979c-485e4d119df3_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_c075ded6-685a-4b82-8d10-e353ab23f60a_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_dcd64ab7-aaec-4647-8469-ad254e21e4d2_netLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9f5ede-e84a-4073-b914-7f5667270aa4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_dde1ea24-8544-42a7-9468-c66121b5da4d_terseLabel_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units</link:label>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember" xlink:href="exel-20220401.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TSRBasedRestrictedStockUnitsMember" xlink:to="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2c46c835-f3a9-42dd-871d-f1f028b3aeb6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4e565b00-2fd5-489a-946c-1835ab5d7cca_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_566ceb76-a2a7-45a5-870b-bccf91f44546_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f1b37ef1-0d23-4ef4-b7fb-80a968ee8659_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_0eeca2a7-a62d-447b-9065-20fbe92538ab_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a725702-68d0-4281-87d9-d96945e9fb8e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>exel-20220401_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73bfe3ae-0c1e-4ba4-a72f-9891e89b0476,g:eb76abd8-9ed1-48d1-b6dc-c6870e560f34-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20220401.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_284ebaa0-9cc8-4f27-91cb-488492ffc404" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_DocumentType_284ebaa0-9cc8-4f27-91cb-488492ffc404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_09f28a29-22d6-471f-a8bb-2560ac8800b1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_DocumentQuarterlyReport_09f28a29-22d6-471f-a8bb-2560ac8800b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0ebf0290-4d78-455a-9db5-907585019383" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_DocumentPeriodEndDate_0ebf0290-4d78-455a-9db5-907585019383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6086cff6-06af-43ae-b222-2b1d347b7651" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_DocumentTransitionReport_6086cff6-06af-43ae-b222-2b1d347b7651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_300c1363-5646-4edd-8013-dbf1743a7451" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityFileNumber_300c1363-5646-4edd-8013-dbf1743a7451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_53bf08fc-6533-418e-b889-4421047d0dff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityRegistrantName_53bf08fc-6533-418e-b889-4421047d0dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_27629e3e-9856-48cc-b2d2-cb94c1cae25e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityIncorporationStateCountryCode_27629e3e-9856-48cc-b2d2-cb94c1cae25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2dded772-7618-4cf2-9f57-59be9043cdb9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityTaxIdentificationNumber_2dded772-7618-4cf2-9f57-59be9043cdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ec5cab1a-0004-4b4a-a4d0-aa3bf436eb51" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityAddressAddressLine1_ec5cab1a-0004-4b4a-a4d0-aa3bf436eb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3cf78823-ce11-4bdf-9a4c-985ae23566bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityAddressCityOrTown_3cf78823-ce11-4bdf-9a4c-985ae23566bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e43fe25b-40c4-4f2e-885b-24d4fd622bbf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityAddressStateOrProvince_e43fe25b-40c4-4f2e-885b-24d4fd622bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_443acf31-2737-4070-9cd2-98701168dd20" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityAddressPostalZipCode_443acf31-2737-4070-9cd2-98701168dd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ff5aa683-e046-4175-89d6-330796920da9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_CityAreaCode_ff5aa683-e046-4175-89d6-330796920da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e234e90e-2454-4f55-bb2a-316ababe3756" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_LocalPhoneNumber_e234e90e-2454-4f55-bb2a-316ababe3756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0f5d4eaf-5fd9-43bb-bc53-a6072beb175a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_Security12bTitle_0f5d4eaf-5fd9-43bb-bc53-a6072beb175a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9f6c9a9b-76e9-41f3-bdaf-3edee83ffa69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_TradingSymbol_9f6c9a9b-76e9-41f3-bdaf-3edee83ffa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1d6949f3-a268-4fe2-b112-2a788e9d7218" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_SecurityExchangeName_1d6949f3-a268-4fe2-b112-2a788e9d7218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_305c5a98-c465-42d0-9712-d5f30c36bc86" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityCurrentReportingStatus_305c5a98-c465-42d0-9712-d5f30c36bc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_29166409-a1c0-4dab-a0ff-194996b5e523" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityInteractiveDataCurrent_29166409-a1c0-4dab-a0ff-194996b5e523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_671fdfcd-744d-4c8e-8fa8-87f0afc1f3f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityFilerCategory_671fdfcd-744d-4c8e-8fa8-87f0afc1f3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_88325819-be32-4c4c-b3ea-73e6a3a1510f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntitySmallBusiness_88325819-be32-4c4c-b3ea-73e6a3a1510f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b59e1c39-f5b8-4c20-99e8-343d5a5f7857" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityShellCompany_b59e1c39-f5b8-4c20-99e8-343d5a5f7857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_acf95dcd-4b77-4e8b-a3e9-e1f7802ea7eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_acf95dcd-4b77-4e8b-a3e9-e1f7802ea7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_df3f278d-c392-4e45-9211-f60f610b3742" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_AmendmentFlag_df3f278d-c392-4e45-9211-f60f610b3742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_13fdf1eb-861e-4d16-9a6a-2c51e232e686" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_DocumentFiscalYearFocus_13fdf1eb-861e-4d16-9a6a-2c51e232e686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ea02e33b-cf1b-44f5-8581-785d284b0c99" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ea02e33b-cf1b-44f5-8581-785d284b0c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3e1c8bbb-2438-4461-94d8-5fba3a45741f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityCentralIndexKey_3e1c8bbb-2438-4461-94d8-5fba3a45741f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_69247cf6-2a37-4860-81ff-cf684a54f267" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_CurrentFiscalYearEndDate_69247cf6-2a37-4860-81ff-cf684a54f267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f6bb3a93-82ed-4654-9724-a0d945367c09" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c417d4d8-0029-440a-a323-31a3cdbbd464" xlink:to="loc_dei_EntityEmergingGrowthCompany_f6bb3a93-82ed-4654-9724-a0d945367c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_61770486-a160-48b0-9d56-a6fc8a3c5384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61770486-a160-48b0-9d56-a6fc8a3c5384" xlink:to="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c0440ffb-6c9e-45c7-9a31-337137282568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c0440ffb-6c9e-45c7-9a31-337137282568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de523f16-f30a-478a-99db-bf14b846b465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c0440ffb-6c9e-45c7-9a31-337137282568" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de523f16-f30a-478a-99db-bf14b846b465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_700fa8b1-2aba-45c6-b633-6e882bf3f637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c0440ffb-6c9e-45c7-9a31-337137282568" xlink:to="loc_us-gaap_ShortTermInvestments_700fa8b1-2aba-45c6-b633-6e882bf3f637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_a5e7d289-cade-46dc-9145-5b3b8dca3f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c0440ffb-6c9e-45c7-9a31-337137282568" xlink:to="loc_us-gaap_ReceivablesNetCurrent_a5e7d289-cade-46dc-9145-5b3b8dca3f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_75f0575d-35ad-43a7-aeeb-92b8d47c2657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c0440ffb-6c9e-45c7-9a31-337137282568" xlink:to="loc_us-gaap_InventoryNet_75f0575d-35ad-43a7-aeeb-92b8d47c2657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bd0abef0-a459-466c-b57c-a5caa621d5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c0440ffb-6c9e-45c7-9a31-337137282568" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bd0abef0-a459-466c-b57c-a5caa621d5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9cceba07-2dc1-404e-927b-03c3ca1fd7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c0440ffb-6c9e-45c7-9a31-337137282568" xlink:to="loc_us-gaap_AssetsCurrent_9cceba07-2dc1-404e-927b-03c3ca1fd7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_87f917a5-493f-46df-b3e4-7f4a60000fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:to="loc_us-gaap_LongTermInvestments_87f917a5-493f-46df-b3e4-7f4a60000fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6e126ad1-2d0f-42de-b63c-1d66cdc9a92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6e126ad1-2d0f-42de-b63c-1d66cdc9a92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_156624ee-fc34-4b7b-860a-dab254ec0d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_156624ee-fc34-4b7b-860a-dab254ec0d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fe4b8b2f-feac-45ba-b012-0aeb4d0e2706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:to="loc_us-gaap_Goodwill_fe4b8b2f-feac-45ba-b012-0aeb4d0e2706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0cb48941-59ad-4188-a7c5-180e91193821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0cb48941-59ad-4188-a7c5-180e91193821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_029a825d-ecce-4d92-bda4-d739eb6bc5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_962c2aa5-7ec1-4654-a30a-77a3e360a8f0" xlink:to="loc_us-gaap_Assets_029a825d-ecce-4d92-bda4-d739eb6bc5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61770486-a160-48b0-9d56-a6fc8a3c5384" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_cdd2186f-8dd1-4dff-8df5-d41742c9f225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:to="loc_us-gaap_AccountsPayableCurrent_cdd2186f-8dd1-4dff-8df5-d41742c9f225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_fe3d0bd5-d3b8-4ab2-b7f1-02ed7bfd2085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_fe3d0bd5-d3b8-4ab2-b7f1-02ed7bfd2085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_95e28772-5735-47a8-b7e3-4954cb92e560" xlink:href="exel-20220401.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_95e28772-5735-47a8-b7e3-4954cb92e560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_8135dc9e-063a-4778-9d47-0b5c829891d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_8135dc9e-063a-4778-9d47-0b5c829891d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_b01f9d70-ccaa-4aaa-9483-6b1de09fca83" xlink:href="exel-20220401.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_b01f9d70-ccaa-4aaa-9483-6b1de09fca83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5b995b45-8108-40df-9ff9-ff3d4575685e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5b995b45-8108-40df-9ff9-ff3d4575685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d90b9c25-911c-4d6d-9633-005859951c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_abfea1b1-31fd-4b93-923d-4d8967470fc3" xlink:to="loc_us-gaap_LiabilitiesCurrent_d90b9c25-911c-4d6d-9633-005859951c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_744b1251-3ed5-4152-b361-711d156cc638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_744b1251-3ed5-4152-b361-711d156cc638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_598a20c8-f5c7-4cf2-a10b-d83230d97ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_598a20c8-f5c7-4cf2-a10b-d83230d97ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7a34b6d2-637f-4f7a-abe0-dadd9bc7b629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7a34b6d2-637f-4f7a-abe0-dadd9bc7b629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_68930850-086e-40e6-a66e-fb20a29f8cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:to="loc_us-gaap_Liabilities_68930850-086e-40e6-a66e-fb20a29f8cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d1543363-5924-467a-8fd8-38980ab8cc37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d1543363-5924-467a-8fd8-38980ab8cc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b3a97d34-1b6e-4e27-8acc-5190f630a334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b3a97d34-1b6e-4e27-8acc-5190f630a334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f3dc6b77-4543-4b84-90ff-873340b5c2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b3a97d34-1b6e-4e27-8acc-5190f630a334" xlink:to="loc_us-gaap_PreferredStockValue_f3dc6b77-4543-4b84-90ff-873340b5c2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_92aa22e4-4a3e-485d-a05e-fb1ecece3522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b3a97d34-1b6e-4e27-8acc-5190f630a334" xlink:to="loc_us-gaap_CommonStockValue_92aa22e4-4a3e-485d-a05e-fb1ecece3522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fd2d552f-988f-4c21-8655-da5cc4bc530f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b3a97d34-1b6e-4e27-8acc-5190f630a334" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fd2d552f-988f-4c21-8655-da5cc4bc530f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c24b7a78-818d-490f-9e04-f292fb3bdd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b3a97d34-1b6e-4e27-8acc-5190f630a334" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c24b7a78-818d-490f-9e04-f292fb3bdd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_345f195a-b265-40ff-8a0a-65f44879e230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b3a97d34-1b6e-4e27-8acc-5190f630a334" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_345f195a-b265-40ff-8a0a-65f44879e230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0cf493b-734f-40c7-a753-71f9972307a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b3a97d34-1b6e-4e27-8acc-5190f630a334" xlink:to="loc_us-gaap_StockholdersEquity_b0cf493b-734f-40c7-a753-71f9972307a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4132758-b7b1-4653-bb70-f46664e3c819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3de895df-b330-4e52-bb8d-a27af576fa66" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4132758-b7b1-4653-bb70-f46664e3c819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1d3f27c0-9939-4077-8857-7148fa7c6b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d64f007f-961d-4775-a8e7-3e438b2f73bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d3f27c0-9939-4077-8857-7148fa7c6b75" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d64f007f-961d-4775-a8e7-3e438b2f73bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_87d9ad63-a744-4717-9517-6166f3fe2c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d64f007f-961d-4775-a8e7-3e438b2f73bb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_87d9ad63-a744-4717-9517-6166f3fe2c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9eb1947f-470c-474b-ab31-b77bbe5f3446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87d9ad63-a744-4717-9517-6166f3fe2c0d" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9eb1947f-470c-474b-ab31-b77bbe5f3446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_079e3849-640e-4efc-9bae-f402841e7abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9eb1947f-470c-474b-ab31-b77bbe5f3446" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_079e3849-640e-4efc-9bae-f402841e7abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_91aaa26c-d77a-43c6-9a05-83b5ca60cb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9eb1947f-470c-474b-ab31-b77bbe5f3446" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_91aaa26c-d77a-43c6-9a05-83b5ca60cb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3efd813c-eb21-489b-995f-43ff0c6313e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9eb1947f-470c-474b-ab31-b77bbe5f3446" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3efd813c-eb21-489b-995f-43ff0c6313e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4c37a196-3ed5-44bc-b3eb-35ee4352a540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87d9ad63-a744-4717-9517-6166f3fe2c0d" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4c37a196-3ed5-44bc-b3eb-35ee4352a540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ebf86ee2-11db-428a-a40d-292c8b85339d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4c37a196-3ed5-44bc-b3eb-35ee4352a540" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ebf86ee2-11db-428a-a40d-292c8b85339d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a74232a5-6781-4e17-b89b-4b9e308cde3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4c37a196-3ed5-44bc-b3eb-35ee4352a540" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a74232a5-6781-4e17-b89b-4b9e308cde3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e547d1af-6f0a-42b0-a1f2-fc07be6e404a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4c37a196-3ed5-44bc-b3eb-35ee4352a540" xlink:to="loc_us-gaap_CommonStockSharesIssued_e547d1af-6f0a-42b0-a1f2-fc07be6e404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fddf1df4-a01a-4a6a-b036-f183bfbdb87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4c37a196-3ed5-44bc-b3eb-35ee4352a540" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fddf1df4-a01a-4a6a-b036-f183bfbdb87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4abd423d-1e77-4572-a177-c5d28c961707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1228955d-3031-4b8b-b9bc-ec56f306d986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4abd423d-1e77-4572-a177-c5d28c961707" xlink:to="loc_us-gaap_StatementTable_1228955d-3031-4b8b-b9bc-ec56f306d986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17956d70-07f5-4e36-ae11-00e3b6a5adc2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1228955d-3031-4b8b-b9bc-ec56f306d986" xlink:to="loc_srt_ProductOrServiceAxis_17956d70-07f5-4e36-ae11-00e3b6a5adc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_17956d70-07f5-4e36-ae11-00e3b6a5adc2" xlink:to="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c8fa394e-1e87-45c9-bf64-5c263605d2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:to="loc_us-gaap_ProductMember_c8fa394e-1e87-45c9-bf64-5c263605d2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_e079362a-e99c-46d9-ad58-4c1b569899f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:to="loc_us-gaap_LicenseMember_e079362a-e99c-46d9-ad58-4c1b569899f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_aee16e85-9201-4ac8-b260-66194a6eecfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_311c178b-80d3-4148-b5bd-9a75da7f288c" xlink:to="loc_us-gaap_ServiceMember_aee16e85-9201-4ac8-b260-66194a6eecfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1228955d-3031-4b8b-b9bc-ec56f306d986" xlink:to="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_11d51c1f-cbc9-4e20-87a3-aa0131886012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_RevenuesAbstract_11d51c1f-cbc9-4e20-87a3-aa0131886012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05da490f-23fe-417e-8cad-feb8ffbc9adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_11d51c1f-cbc9-4e20-87a3-aa0131886012" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05da490f-23fe-417e-8cad-feb8ffbc9adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_280b475e-7032-40ca-b288-0212be53fa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_280b475e-7032-40ca-b288-0212be53fa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8316bfa8-b8a1-4cdc-a330-eb8674e31411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8316bfa8-b8a1-4cdc-a330-eb8674e31411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9f21edd4-4bef-47d5-b190-eeff13f1e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9f21edd4-4bef-47d5-b190-eeff13f1e2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5d6537e3-000a-4860-bfc9-70ed722cb9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d3679e20-618f-40a8-9705-9acc8f10b249" xlink:to="loc_us-gaap_CostsAndExpenses_5d6537e3-000a-4860-bfc9-70ed722cb9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3cadd47a-6b99-4955-9678-8e0a2fdaf038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_OperatingIncomeLoss_3cadd47a-6b99-4955-9678-8e0a2fdaf038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_efdef9d6-3c22-40b9-b178-463abae85096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_InterestIncomeOther_efdef9d6-3c22-40b9-b178-463abae85096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bc637782-aecb-4365-88ff-17f343243285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bc637782-aecb-4365-88ff-17f343243285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9114331d-fc5a-4238-afad-129971f9dca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_9114331d-fc5a-4238-afad-129971f9dca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_012053aa-27a4-4e16-87be-34c1ecee1421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_012053aa-27a4-4e16-87be-34c1ecee1421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca3e9067-c1b5-490a-af29-8b8edeb927cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_NetIncomeLoss_ca3e9067-c1b5-490a-af29-8b8edeb927cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a2b86756-f5ab-4fa9-bfcd-8018101592ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a2b86756-f5ab-4fa9-bfcd-8018101592ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8b73a48b-26ca-4df2-b3bc-34e68b62aa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2b86756-f5ab-4fa9-bfcd-8018101592ea" xlink:to="loc_us-gaap_EarningsPerShareBasic_8b73a48b-26ca-4df2-b3bc-34e68b62aa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5d31bcc0-7a5a-4cfd-a8e5-a76fb00a4488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2b86756-f5ab-4fa9-bfcd-8018101592ea" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5d31bcc0-7a5a-4cfd-a8e5-a76fb00a4488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9b503232-df57-4a13-a09b-52c4cf3c0fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5330643b-43ca-4f64-b3dd-2df6b9afa253" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9b503232-df57-4a13-a09b-52c4cf3c0fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ab04ab62-7870-49c0-942b-b550d3277aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9b503232-df57-4a13-a09b-52c4cf3c0fa0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ab04ab62-7870-49c0-942b-b550d3277aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_be8a5370-7246-4e39-841e-b9b1d368cd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9b503232-df57-4a13-a09b-52c4cf3c0fa0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_be8a5370-7246-4e39-841e-b9b1d368cd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ceb4ecc-5e36-417d-8fa4-dac0b3f809c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4347b71e-df42-42f8-9086-9327f2deab8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ceb4ecc-5e36-417d-8fa4-dac0b3f809c1" xlink:to="loc_us-gaap_NetIncomeLoss_4347b71e-df42-42f8-9086-9327f2deab8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5c5c8b8a-bc20-449e-9821-4bf8c7ece999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ceb4ecc-5e36-417d-8fa4-dac0b3f809c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5c5c8b8a-bc20-449e-9821-4bf8c7ece999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_27d151e2-71d0-415b-aa31-6931347a89b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5c5c8b8a-bc20-449e-9821-4bf8c7ece999" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_27d151e2-71d0-415b-aa31-6931347a89b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7fcb2776-19b8-4f29-bd5a-03721ff5ac00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ceb4ecc-5e36-417d-8fa4-dac0b3f809c1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7fcb2776-19b8-4f29-bd5a-03721ff5ac00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1820a769-ccf6-4cba-8c0b-daadc2079afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_7a5dfb51-5f6a-4de6-8b89-eee66cfe3ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1820a769-ccf6-4cba-8c0b-daadc2079afc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_7a5dfb51-5f6a-4de6-8b89-eee66cfe3ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0d586f55-8aed-4584-8750-eda10ef42a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ba85c6a7-577b-4104-870c-ed03ed4f7767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0d586f55-8aed-4584-8750-eda10ef42a83" xlink:to="loc_us-gaap_StatementTable_ba85c6a7-577b-4104-870c-ed03ed4f7767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eef50666-8de1-47e9-8bdc-8eadd96394d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ba85c6a7-577b-4104-870c-ed03ed4f7767" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eef50666-8de1-47e9-8bdc-8eadd96394d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eef50666-8de1-47e9-8bdc-8eadd96394d6" xlink:to="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_35a7462f-d943-49e3-95e8-62beef23736e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:to="loc_us-gaap_CommonStockMember_35a7462f-d943-49e3-95e8-62beef23736e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6dec5193-7b85-4b00-96ec-a86a359894fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6dec5193-7b85-4b00-96ec-a86a359894fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b29110ca-1a04-4049-ba05-0ac1a793f150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b29110ca-1a04-4049-ba05-0ac1a793f150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cdeac8e4-6db5-4cca-bd8d-55b53d2aea53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ff21708f-00b0-4808-a562-6c5006cf52c6" xlink:to="loc_us-gaap_RetainedEarningsMember_cdeac8e4-6db5-4cca-bd8d-55b53d2aea53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f4610be0-4b40-4909-81c5-10902acc7479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ba85c6a7-577b-4104-870c-ed03ed4f7767" xlink:to="loc_us-gaap_StatementLineItems_f4610be0-4b40-4909-81c5-10902acc7479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f4610be0-4b40-4909-81c5-10902acc7479" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d2c6b199-d33e-4007-814b-ab37de4eb34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d2c6b199-d33e-4007-814b-ab37de4eb34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_921832b1-c9a4-40b6-9863-144a61ef22ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_StockholdersEquity_921832b1-c9a4-40b6-9863-144a61ef22ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_743a5fe5-e5e4-4423-8371-2bed7535314d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_NetIncomeLoss_743a5fe5-e5e4-4423-8371-2bed7535314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2247dc49-f6ee-430f-91f6-fa3b994114af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2247dc49-f6ee-430f-91f6-fa3b994114af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_baa5bca1-a35c-49c8-9a11-b4dee958216e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_baa5bca1-a35c-49c8-9a11-b4dee958216e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_43a54b38-09a0-4759-a19e-0372fd121d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_43a54b38-09a0-4759-a19e-0372fd121d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_014b8d1f-1c5a-46ef-9944-2d15f12a6a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_014b8d1f-1c5a-46ef-9944-2d15f12a6a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc44d708-4568-47a9-b235-659b8cb55cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc44d708-4568-47a9-b235-659b8cb55cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_91599882-db8d-4016-afac-a80835796b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_91599882-db8d-4016-afac-a80835796b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b1ee730-913d-449f-a277-4a71da93bfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd2863-318a-4b11-b0c6-c946efe994d7" xlink:to="loc_us-gaap_StockholdersEquity_5b1ee730-913d-449f-a277-4a71da93bfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20220401.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84f7839f-fa83-4707-8c21-5e0f4b9ff9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:to="loc_us-gaap_NetIncomeLoss_84f7839f-fa83-4707-8c21-5e0f4b9ff9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc1e4e1f-81f4-4d5c-bfc7-83acb974de98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc1e4e1f-81f4-4d5c-bfc7-83acb974de98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a3dcb2a3-b927-4eaf-ae53-de51c0884b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc1e4e1f-81f4-4d5c-bfc7-83acb974de98" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a3dcb2a3-b927-4eaf-ae53-de51c0884b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_55cf4f08-f4f1-471b-a11c-eaff23b50796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc1e4e1f-81f4-4d5c-bfc7-83acb974de98" xlink:to="loc_us-gaap_ShareBasedCompensation_55cf4f08-f4f1-471b-a11c-eaff23b50796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_39bd29d8-d113-4525-b874-db63d1f8a12f" xlink:href="exel-20220401.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc1e4e1f-81f4-4d5c-bfc7-83acb974de98" xlink:to="loc_exel_NoncashLeaseExpense_39bd29d8-d113-4525-b874-db63d1f8a12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c97a589f-dba9-452f-a798-32455f377b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc1e4e1f-81f4-4d5c-bfc7-83acb974de98" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c97a589f-dba9-452f-a798-32455f377b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_738f1be9-e287-4104-83df-bc45accdb467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc1e4e1f-81f4-4d5c-bfc7-83acb974de98" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_738f1be9-e287-4104-83df-bc45accdb467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d13a17b-4ac9-471c-b8f4-c4bad8642063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc1e4e1f-81f4-4d5c-bfc7-83acb974de98" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d13a17b-4ac9-471c-b8f4-c4bad8642063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ac58e12b-c414-401f-ae09-180d95ecd494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d13a17b-4ac9-471c-b8f4-c4bad8642063" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ac58e12b-c414-401f-ae09-180d95ecd494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_df4e19dc-f403-4d73-a468-fb07733587de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d13a17b-4ac9-471c-b8f4-c4bad8642063" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_df4e19dc-f403-4d73-a468-fb07733587de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6105470d-051a-4764-9fb6-c0fccf573579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d13a17b-4ac9-471c-b8f4-c4bad8642063" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6105470d-051a-4764-9fb6-c0fccf573579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c5417824-e0e6-4aac-914a-64ad2e349f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d13a17b-4ac9-471c-b8f4-c4bad8642063" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c5417824-e0e6-4aac-914a-64ad2e349f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_621a8222-8c2b-45c9-83df-e2a79a29a93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d13a17b-4ac9-471c-b8f4-c4bad8642063" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_621a8222-8c2b-45c9-83df-e2a79a29a93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_526e58b3-837f-4b89-b464-a13ed200ec56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d13a17b-4ac9-471c-b8f4-c4bad8642063" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_526e58b3-837f-4b89-b464-a13ed200ec56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29cc3720-415a-41a9-b3d7-1243ee2738b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29cc3720-415a-41a9-b3d7-1243ee2738b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb995cb5-3896-4379-8206-f1a5e7d97ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb995cb5-3896-4379-8206-f1a5e7d97ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b0413ed8-5489-4fcd-8906-9a89ed784ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb995cb5-3896-4379-8206-f1a5e7d97ee0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b0413ed8-5489-4fcd-8906-9a89ed784ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_7a375951-a94b-4bab-952a-e82acdeb4aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb995cb5-3896-4379-8206-f1a5e7d97ee0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_7a375951-a94b-4bab-952a-e82acdeb4aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1eb69188-c306-4a24-a9f6-4c839498ec55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb995cb5-3896-4379-8206-f1a5e7d97ee0" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1eb69188-c306-4a24-a9f6-4c839498ec55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34e7a702-477d-4b56-83b0-a03089999aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb995cb5-3896-4379-8206-f1a5e7d97ee0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34e7a702-477d-4b56-83b0-a03089999aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8134f7f3-af53-4a8f-bdec-e757874432d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8134f7f3-af53-4a8f-bdec-e757874432d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_61cbf4b2-95a8-47ba-b56a-7956c5e885dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8134f7f3-af53-4a8f-bdec-e757874432d3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_61cbf4b2-95a8-47ba-b56a-7956c5e885dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b7eb271e-c106-4d05-b2d6-15fbaeac89fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8134f7f3-af53-4a8f-bdec-e757874432d3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b7eb271e-c106-4d05-b2d6-15fbaeac89fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_443c92c0-11cd-4fe4-ab97-1229248ae939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8134f7f3-af53-4a8f-bdec-e757874432d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_443c92c0-11cd-4fe4-ab97-1229248ae939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6bd83bc6-24aa-47ce-b171-92c175f60520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6bd83bc6-24aa-47ce-b171-92c175f60520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa2aac2c-3dac-4235-a140-bc608a64964a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa2aac2c-3dac-4235-a140-bc608a64964a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d6630b7-2d33-498b-b110-be5518862736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c882ab6-beac-469f-943a-2ddd11046464" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d6630b7-2d33-498b-b110-be5518862736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20220401.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ace6c049-9a47-4c1e-9887-93315a3bb945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56910026-aa49-4d53-ba69-d2e1407731ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ace6c049-9a47-4c1e-9887-93315a3bb945" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56910026-aa49-4d53-ba69-d2e1407731ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20220401.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9f1a0ebe-3134-4d05-9a70-c5e1cc7eba27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9f1a0ebe-3134-4d05-9a70-c5e1cc7eba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_454724c9-9ffe-415f-94ce-b97ef865c548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_454724c9-9ffe-415f-94ce-b97ef865c548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_46a254c7-81d1-4592-9c18-6a9cdcab0537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:to="loc_us-gaap_FiscalPeriod_46a254c7-81d1-4592-9c18-6a9cdcab0537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5a9ab94a-9379-4345-ad03-7b12472eba81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5a9ab94a-9379-4345-ad03-7b12472eba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c3def328-a221-4f02-b992-bf82d05ef187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:to="loc_us-gaap_UseOfEstimates_c3def328-a221-4f02-b992-bf82d05ef187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f54dc255-396e-462a-b1a9-4f69233b00c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f54dc255-396e-462a-b1a9-4f69233b00c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01b73874-8e24-49aa-8ce6-1553609c6f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01b73874-8e24-49aa-8ce6-1553609c6f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_492b17a2-22fe-4aae-a3af-aca12d73dabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7108cf8-ed7c-4ad3-af43-0b31739e0843" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_492b17a2-22fe-4aae-a3af-aca12d73dabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_937cb9ea-000f-4d51-bf97-05bb0bdd5905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_73caa9fa-22a6-4b15-82d4-6d57b43c21fa" xlink:href="exel-20220401.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_937cb9ea-000f-4d51-bf97-05bb0bdd5905" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_73caa9fa-22a6-4b15-82d4-6d57b43c21fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dadbd865-c34b-4603-ac68-c08d02a3f6b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_73caa9fa-22a6-4b15-82d4-6d57b43c21fa" xlink:to="loc_srt_ProductOrServiceAxis_dadbd865-c34b-4603-ac68-c08d02a3f6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6aa7ddf0-810f-49b8-8dbb-38764369a36d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dadbd865-c34b-4603-ac68-c08d02a3f6b2" xlink:to="loc_srt_ProductsAndServicesDomain_6aa7ddf0-810f-49b8-8dbb-38764369a36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_25c63806-62d5-4ffa-b294-5830a85f9851" xlink:href="exel-20220401.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6aa7ddf0-810f-49b8-8dbb-38764369a36d" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_25c63806-62d5-4ffa-b294-5830a85f9851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_0d056562-3f9d-4bfe-8baa-628aa0c0ffd0" xlink:href="exel-20220401.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6aa7ddf0-810f-49b8-8dbb-38764369a36d" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_0d056562-3f9d-4bfe-8baa-628aa0c0ffd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:href="exel-20220401.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_73caa9fa-22a6-4b15-82d4-6d57b43c21fa" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_195b3fe8-01fe-4eaf-a9cb-04a24bdbb989" xlink:href="exel-20220401.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:to="loc_exel_NumberofProductsinCommercialMarket_195b3fe8-01fe-4eaf-a9cb-04a24bdbb989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_5f2b39ca-b24e-41b1-8345-9dc09f0ffca9" xlink:href="exel-20220401.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_5f2b39ca-b24e-41b1-8345-9dc09f0ffca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c1970705-73ee-4214-83b5-b91a8f46d620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_50b00b43-a520-4fc3-930d-c89111445a9d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c1970705-73ee-4214-83b5-b91a8f46d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20220401.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba09a0b0-1a10-41ac-a382-c2c5f3e8624f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6a92633f-c793-4642-bb3f-c41f8d556742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba09a0b0-1a10-41ac-a382-c2c5f3e8624f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6a92633f-c793-4642-bb3f-c41f8d556742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20bae3d5-09b0-4411-b79b-a3082e7d9c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_86b356dd-9259-4311-beab-6365c3b2faab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20bae3d5-09b0-4411-b79b-a3082e7d9c18" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_86b356dd-9259-4311-beab-6365c3b2faab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_db36dfa8-4de1-419f-9496-b682aa3f2a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20bae3d5-09b0-4411-b79b-a3082e7d9c18" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_db36dfa8-4de1-419f-9496-b682aa3f2a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0e0ca883-1396-40fb-92e4-2a10e2da2d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20bae3d5-09b0-4411-b79b-a3082e7d9c18" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0e0ca883-1396-40fb-92e4-2a10e2da2d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_a81157eb-4348-48fd-9b6c-1d6e838ebe31" xlink:href="exel-20220401.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20bae3d5-09b0-4411-b79b-a3082e7d9c18" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_a81157eb-4348-48fd-9b6c-1d6e838ebe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d87ca2eb-30ae-4379-8273-067ca8cf4b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20bae3d5-09b0-4411-b79b-a3082e7d9c18" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d87ca2eb-30ae-4379-8273-067ca8cf4b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b772f877-6a48-4401-b49c-66ca3635590b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_084b9842-d8e9-448b-bfa8-7fbf3a0a298e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b772f877-6a48-4401-b49c-66ca3635590b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_084b9842-d8e9-448b-bfa8-7fbf3a0a298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_58bf469e-f887-4053-9016-54330ac0cba6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084b9842-d8e9-448b-bfa8-7fbf3a0a298e" xlink:to="loc_srt_ProductOrServiceAxis_58bf469e-f887-4053-9016-54330ac0cba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_58bf469e-f887-4053-9016-54330ac0cba6" xlink:to="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_05575db3-608d-47f7-87c2-3d3f014a7e35" xlink:href="exel-20220401.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_exel_ProductGrossMember_05575db3-608d-47f7-87c2-3d3f014a7e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_fcdc76e1-3fab-4ceb-a6ae-c943fa95a273" xlink:href="exel-20220401.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_fcdc76e1-3fab-4ceb-a6ae-c943fa95a273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7f11deca-b4e0-40b1-bb8d-1d5438355420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_us-gaap_ProductMember_7f11deca-b4e0-40b1-bb8d-1d5438355420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_55c68f7c-b7e5-453f-98e2-c2e8a313b95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_us-gaap_LicenseMember_55c68f7c-b7e5-453f-98e2-c2e8a313b95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f960fc1c-63b6-4109-9045-cdb347c2a49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_us-gaap_ServiceMember_f960fc1c-63b6-4109-9045-cdb347c2a49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_545a7e72-cfd8-4983-af20-f51e7756abb7" xlink:href="exel-20220401.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_913b0baa-d668-43d4-bcf1-999baca32cc2" xlink:to="loc_exel_CollaborationMember_545a7e72-cfd8-4983-af20-f51e7756abb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6df95fc5-b02b-4ba0-bd43-18950181139e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084b9842-d8e9-448b-bfa8-7fbf3a0a298e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6df95fc5-b02b-4ba0-bd43-18950181139e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_efb4cab1-db4d-43df-ba43-d76e23e8f0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6df95fc5-b02b-4ba0-bd43-18950181139e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_efb4cab1-db4d-43df-ba43-d76e23e8f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_11b4a185-d3ce-4e3f-8f39-a64921c19d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_11b4a185-d3ce-4e3f-8f39-a64921c19d97" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_212d122e-a19f-4078-b460-3620b307230c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:to="loc_srt_MajorCustomersAxis_212d122e-a19f-4078-b460-3620b307230c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_212d122e-a19f-4078-b460-3620b307230c" xlink:to="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_2249cfbb-7a32-4ad6-b2d2-56850d772c26" xlink:href="exel-20220401.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_2249cfbb-7a32-4ad6-b2d2-56850d772c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_8edb0c96-b7b5-457e-8ffe-7d4291098937" xlink:href="exel-20220401.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_8edb0c96-b7b5-457e-8ffe-7d4291098937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_74bba8fe-1dd2-442e-8fa1-594cb7209a45" xlink:href="exel-20220401.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_74bba8fe-1dd2-442e-8fa1-594cb7209a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_1c6b256e-a091-446d-88d7-e98c1554da1b" xlink:href="exel-20220401.xsd#exel_IpsenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_IpsenMember_1c6b256e-a091-446d-88d7-e98c1554da1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_db8d322c-c947-4e77-b402-d2c9012ac63e" xlink:href="exel-20220401.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c4bcd0b-ff72-42ef-b3d2-f4283275cb2f" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_db8d322c-c947-4e77-b402-d2c9012ac63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f0b02dab-6268-46e0-8c3b-193f89c8fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f0b02dab-6268-46e0-8c3b-193f89c8fe69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_004e6ad3-74b2-41f0-a197-8a5049f8053c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f0b02dab-6268-46e0-8c3b-193f89c8fe69" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_004e6ad3-74b2-41f0-a197-8a5049f8053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1c6efaed-b107-47fc-be38-505f6e21a775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_004e6ad3-74b2-41f0-a197-8a5049f8053c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_1c6efaed-b107-47fc-be38-505f6e21a775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_551b11cc-0fa7-4572-96eb-0e65dc7103c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_004e6ad3-74b2-41f0-a197-8a5049f8053c" xlink:to="loc_us-gaap_AccountsReceivableMember_551b11cc-0fa7-4572-96eb-0e65dc7103c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d9b41785-010b-407d-a7db-17753c6ea6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d9b41785-010b-407d-a7db-17753c6ea6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_46bc756d-bb96-4e81-9df5-5e161f32f033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d9b41785-010b-407d-a7db-17753c6ea6fb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_46bc756d-bb96-4e81-9df5-5e161f32f033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2c800fff-725d-42ce-b566-274e5ef477dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_46bc756d-bb96-4e81-9df5-5e161f32f033" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2c800fff-725d-42ce-b566-274e5ef477dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_f064f222-942d-4a22-9bf1-e4ddf4eed9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6fd5fe6d-be95-4821-83d0-8cd17a522edd" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_f064f222-942d-4a22-9bf1-e4ddf4eed9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6b418615-3bbd-4ac4-ada5-0934b6bcd381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_f064f222-942d-4a22-9bf1-e4ddf4eed9da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6b418615-3bbd-4ac4-ada5-0934b6bcd381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_48beb14e-a4a2-453f-a0d6-3222644fb344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_966ca308-94cf-48ef-a5fc-95b73632490e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_48beb14e-a4a2-453f-a0d6-3222644fb344" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_966ca308-94cf-48ef-a5fc-95b73632490e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2af3ad2e-4043-49f6-beff-d464d38b8399" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_966ca308-94cf-48ef-a5fc-95b73632490e" xlink:to="loc_srt_StatementGeographicalAxis_2af3ad2e-4043-49f6-beff-d464d38b8399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2af3ad2e-4043-49f6-beff-d464d38b8399" xlink:to="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9a5ed3a6-9d0f-4824-98df-27664063a57c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:to="loc_country_US_9a5ed3a6-9d0f-4824-98df-27664063a57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_ddc8bc1c-9da2-4930-a062-45bb177a1a01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:to="loc_srt_EuropeMember_ddc8bc1c-9da2-4930-a062-45bb177a1a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_770e2e53-ca50-4daa-866d-fdf2fa6d71ad" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cc38129f-e407-4f80-9dd8-6bdf08e79f07" xlink:to="loc_country_JP_770e2e53-ca50-4daa-866d-fdf2fa6d71ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_80aa6177-a60c-49c7-be89-e43ca9b1b43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_966ca308-94cf-48ef-a5fc-95b73632490e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_80aa6177-a60c-49c7-be89-e43ca9b1b43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7dcfe12c-1263-4414-b253-1e786a7d59e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_80aa6177-a60c-49c7-be89-e43ca9b1b43e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7dcfe12c-1263-4414-b253-1e786a7d59e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c98e0863-c58e-48b7-85d7-392940ad679b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0e37c9cf-1932-47b2-8533-2e3a8fa19ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c98e0863-c58e-48b7-85d7-392940ad679b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0e37c9cf-1932-47b2-8533-2e3a8fa19ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d6678ee3-aa23-4268-be26-5a18fa2fee3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0e37c9cf-1932-47b2-8533-2e3a8fa19ecf" xlink:to="loc_srt_ProductOrServiceAxis_d6678ee3-aa23-4268-be26-5a18fa2fee3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_40a604a6-5d2d-4bae-a70f-200407bfb528" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d6678ee3-aa23-4268-be26-5a18fa2fee3d" xlink:to="loc_srt_ProductsAndServicesDomain_40a604a6-5d2d-4bae-a70f-200407bfb528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c513e9fa-94d5-42d8-817e-bd9173af9435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_40a604a6-5d2d-4bae-a70f-200407bfb528" xlink:to="loc_us-gaap_ProductMember_c513e9fa-94d5-42d8-817e-bd9173af9435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_315790ab-8946-4644-b9ec-500f3cb69b6f" xlink:href="exel-20220401.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_c513e9fa-94d5-42d8-817e-bd9173af9435" xlink:to="loc_exel_CabometyxMember_315790ab-8946-4644-b9ec-500f3cb69b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_b0443452-12a3-4846-9efc-458593de9cdf" xlink:href="exel-20220401.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_c513e9fa-94d5-42d8-817e-bd9173af9435" xlink:to="loc_exel_CometriqMember_b0443452-12a3-4846-9efc-458593de9cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d871445c-e051-493a-a40a-05b31d5f5269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0e37c9cf-1932-47b2-8533-2e3a8fa19ecf" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d871445c-e051-493a-a40a-05b31d5f5269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fe70633-a653-484d-a7ba-11505260beb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d871445c-e051-493a-a40a-05b31d5f5269" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fe70633-a653-484d-a7ba-11505260beb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_740db221-a493-4975-8b13-318e898216e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a244ef8a-4879-4396-86da-5039f0f7c8cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_740db221-a493-4975-8b13-318e898216e5" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a244ef8a-4879-4396-86da-5039f0f7c8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a244ef8a-4879-4396-86da-5039f0f7c8cc" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5e3b8ed6-f779-40a8-b1cb-66e7fbdef134" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_87727d9a-8888-46e2-aa1e-e866bc56fcb4" xlink:href="exel-20220401.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_87727d9a-8888-46e2-aa1e-e866bc56fcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_e453ecf6-fc18-447f-b8b2-50aa247f7802" xlink:href="exel-20220401.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_e453ecf6-fc18-447f-b8b2-50aa247f7802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_94f277b8-8c18-4301-9fc1-b7b90b9ac541" xlink:href="exel-20220401.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9dbfad9a-b6df-4c28-beab-9897d99ded4e" xlink:to="loc_exel_AllowanceForProductRebatesMember_94f277b8-8c18-4301-9fc1-b7b90b9ac541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_96c27987-5830-4d8c-a2f2-e51181a98766" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a244ef8a-4879-4396-86da-5039f0f7c8cc" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_96c27987-5830-4d8c-a2f2-e51181a98766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_96c27987-5830-4d8c-a2f2-e51181a98766" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e1e915b8-e31d-44b3-bef4-c24d14938e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e1e915b8-e31d-44b3-bef4-c24d14938e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2043fa46-3405-4946-b70e-835f0ff45f57" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2043fa46-3405-4946-b70e-835f0ff45f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_7ab9d817-d328-47c3-814b-1654d39bf122" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2043fa46-3405-4946-b70e-835f0ff45f57" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_7ab9d817-d328-47c3-814b-1654d39bf122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_c65f5633-b1fd-45b6-a7fa-0404f97111a8" xlink:href="exel-20220401.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2043fa46-3405-4946-b70e-835f0ff45f57" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_c65f5633-b1fd-45b6-a7fa-0404f97111a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_aa22bfc1-3d47-47ba-ac72-262eabc9497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_aa22bfc1-3d47-47ba-ac72-262eabc9497a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8a65165a-d47d-4746-9ade-5b81682b68a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0e81675-e61e-425f-9ed2-3cec55f468e6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8a65165a-d47d-4746-9ade-5b81682b68a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b9bacb92-c590-40bb-b0d5-ecd1716a6f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d3eaecce-21ef-4d36-adfa-86dce016a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b9bacb92-c590-40bb-b0d5-ecd1716a6f57" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d3eaecce-21ef-4d36-adfa-86dce016a7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_24b5dcec-374b-4cb9-9463-1f7b636bfd1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3eaecce-21ef-4d36-adfa-86dce016a7a9" xlink:to="loc_srt_CounterpartyNameAxis_24b5dcec-374b-4cb9-9463-1f7b636bfd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe59f932-423c-4403-bbc1-dec36f551496" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_24b5dcec-374b-4cb9-9463-1f7b636bfd1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe59f932-423c-4403-bbc1-dec36f551496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember_df488a25-386f-4876-85d4-87e12865a411" xlink:href="exel-20220401.xsd#exel_TakedaAndIspenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe59f932-423c-4403-bbc1-dec36f551496" xlink:to="loc_exel_TakedaAndIspenMember_df488a25-386f-4876-85d4-87e12865a411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3eaecce-21ef-4d36-adfa-86dce016a7a9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_a392191f-31c1-411b-a9e2-0756b95b2b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_a392191f-31c1-411b-a9e2-0756b95b2b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_dca0fc5c-dc21-42d1-8320-e0704dd89815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_a392191f-31c1-411b-a9e2-0756b95b2b99" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_dca0fc5c-dc21-42d1-8320-e0704dd89815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d34d50c6-b563-47cd-9d8d-84e8e3f48826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d34d50c6-b563-47cd-9d8d-84e8e3f48826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55fb39f0-05e3-4a73-a136-a3e57f78c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55fb39f0-05e3-4a73-a136-a3e57f78c06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5c922896-346b-4e31-98d9-b9c7920387a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_c78248f6-17c0-4734-9484-caa278fd5145" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5c922896-346b-4e31-98d9-b9c7920387a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_6d4d580c-c025-409f-8233-60f55a5b60c3" xlink:href="exel-20220401.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_6d4d580c-c025-409f-8233-60f55a5b60c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f15a702c-4516-41cc-8c92-b09b14cd87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f15a702c-4516-41cc-8c92-b09b14cd87c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_63211d87-b6f6-478f-a759-b61678815707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0aab0865-e623-4905-9dff-96d5b8b50770" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_63211d87-b6f6-478f-a759-b61678815707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivities"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2494153-34b9-4175-b5c4-59d260b4ec26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1ae34772-0c36-49df-a770-2b146af5247a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2494153-34b9-4175-b5c4-59d260b4ec26" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1ae34772-0c36-49df-a770-2b146af5247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_44d997d7-27ab-4734-a664-5bd2d09fc459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_d75ce5b0-d22f-4a21-9fbe-5c90557a5df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_44d997d7-27ab-4734-a664-5bd2d09fc459" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_d75ce5b0-d22f-4a21-9fbe-5c90557a5df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_026a8fb4-08fd-4742-8649-90f625b3ce27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_026a8fb4-08fd-4742-8649-90f625b3ce27" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_438c2f53-1603-46b6-becf-aa8d2d1d1a8c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:to="loc_srt_ProductOrServiceAxis_438c2f53-1603-46b6-becf-aa8d2d1d1a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea1d2495-8dea-4247-971a-b4e97969c60c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_438c2f53-1603-46b6-becf-aa8d2d1d1a8c" xlink:to="loc_srt_ProductsAndServicesDomain_ea1d2495-8dea-4247-971a-b4e97969c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_cf2cf26d-616e-4abf-83e5-f0aaa6c0cf55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea1d2495-8dea-4247-971a-b4e97969c60c" xlink:to="loc_us-gaap_LicenseMember_cf2cf26d-616e-4abf-83e5-f0aaa6c0cf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_fa32db77-5117-4131-aa96-dabc25f9b58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea1d2495-8dea-4247-971a-b4e97969c60c" xlink:to="loc_us-gaap_ServiceMember_fa32db77-5117-4131-aa96-dabc25f9b58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b52462ff-7a1f-4f81-ab76-d00d8ea09d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b52462ff-7a1f-4f81-ab76-d00d8ea09d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d9d3ca-ebf7-432d-bf19-4c4cb67890ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b52462ff-7a1f-4f81-ab76-d00d8ea09d23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d9d3ca-ebf7-432d-bf19-4c4cb67890ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_6973f3e3-2750-412d-b746-c337861dc9f8" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d9d3ca-ebf7-432d-bf19-4c4cb67890ab" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_6973f3e3-2750-412d-b746-c337861dc9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3ee5309-70b0-40d7-b258-bdf23dda5a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7cf02e7-67e2-4451-8a70-e42722c994c1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3ee5309-70b0-40d7-b258-bdf23dda5a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda9b808-e838-46c8-b2ff-fc1fe3cfd068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3ee5309-70b0-40d7-b258-bdf23dda5a46" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda9b808-e838-46c8-b2ff-fc1fe3cfd068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62e0bd3b-bd52-40c3-9156-ece0036cc905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d595a2c5-686d-4936-be10-7c7d87f9bf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62e0bd3b-bd52-40c3-9156-ece0036cc905" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d595a2c5-686d-4936-be10-7c7d87f9bf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e720aa44-9709-4aff-b71c-e1e53980e5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d595a2c5-686d-4936-be10-7c7d87f9bf7e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e720aa44-9709-4aff-b71c-e1e53980e5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_193ee7ae-8784-4fc1-b306-9f6e0a455b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e720aa44-9709-4aff-b71c-e1e53980e5e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_193ee7ae-8784-4fc1-b306-9f6e0a455b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_fcc535c0-1413-48f6-9b8f-0e31c14c601f" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_193ee7ae-8784-4fc1-b306-9f6e0a455b18" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_fcc535c0-1413-48f6-9b8f-0e31c14c601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8bd1d5-c39a-4d98-965c-9e95cb9dc217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d595a2c5-686d-4936-be10-7c7d87f9bf7e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8bd1d5-c39a-4d98-965c-9e95cb9dc217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6bca8246-934d-40c7-8289-45cd4871544a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8bd1d5-c39a-4d98-965c-9e95cb9dc217" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6bca8246-934d-40c7-8289-45cd4871544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_04e3d9a0-5ac4-4fb4-820d-54c4381108c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_04e3d9a0-5ac4-4fb4-820d-54c4381108c8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0338f753-d56e-4222-8619-71fbc1b084d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:to="loc_srt_ProductOrServiceAxis_0338f753-d56e-4222-8619-71fbc1b084d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c6f9d5e6-3165-4f43-8ef1-2b7e2d006743" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0338f753-d56e-4222-8619-71fbc1b084d9" xlink:to="loc_srt_ProductsAndServicesDomain_c6f9d5e6-3165-4f43-8ef1-2b7e2d006743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b020bcde-1347-47a0-862a-5730b2abd214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c6f9d5e6-3165-4f43-8ef1-2b7e2d006743" xlink:to="loc_us-gaap_LicenseMember_b020bcde-1347-47a0-862a-5730b2abd214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_c298d411-be34-4b68-9520-174b0830e347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c6f9d5e6-3165-4f43-8ef1-2b7e2d006743" xlink:to="loc_us-gaap_ServiceMember_c298d411-be34-4b68-9520-174b0830e347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07286376-d192-42c4-a96d-8645c144eada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f3e0fe7b-4ade-44cd-8e74-d21bb47b7d64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07286376-d192-42c4-a96d-8645c144eada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_c6a23b0c-b658-4206-8f87-bcd1b8f2db01" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07286376-d192-42c4-a96d-8645c144eada" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_c6a23b0c-b658-4206-8f87-bcd1b8f2db01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f518622-b38a-4565-bc7c-58dcb368a224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b907777b-7890-40dd-a3a9-7aa313b84a36" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f518622-b38a-4565-bc7c-58dcb368a224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5390b81c-e806-4de8-9df2-4eac8a886da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f518622-b38a-4565-bc7c-58dcb368a224" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5390b81c-e806-4de8-9df2-4eac8a886da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7438111e-0137-46f4-b16f-2646a12fa4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c6f2d47c-e1a1-42bc-9da5-d7685968b2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7438111e-0137-46f4-b16f-2646a12fa4e9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c6f2d47c-e1a1-42bc-9da5-d7685968b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1c76e65d-21e1-488b-811c-87973fe7d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c6f2d47c-e1a1-42bc-9da5-d7685968b2a7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1c76e65d-21e1-488b-811c-87973fe7d0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_875001d0-6fea-40c7-aefb-dbd7cb25023d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c76e65d-21e1-488b-811c-87973fe7d0f7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_875001d0-6fea-40c7-aefb-dbd7cb25023d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_091fb599-d3ac-41a7-ae84-85d4fc0307cf" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_875001d0-6fea-40c7-aefb-dbd7cb25023d" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_091fb599-d3ac-41a7-ae84-85d4fc0307cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e311790e-2f29-41ea-8d3c-fa9dd1bcce55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c6f2d47c-e1a1-42bc-9da5-d7685968b2a7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e311790e-2f29-41ea-8d3c-fa9dd1bcce55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d07ac075-83a8-4212-adb1-21a5a671819b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e311790e-2f29-41ea-8d3c-fa9dd1bcce55" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d07ac075-83a8-4212-adb1-21a5a671819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b2f72a5-1b3a-4668-9f49-98b60d36404d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ece827e3-d4ef-4cdf-b5a9-586dec4d7acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b2f72a5-1b3a-4668-9f49-98b60d36404d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ece827e3-d4ef-4cdf-b5a9-586dec4d7acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ece827e3-d4ef-4cdf-b5a9-586dec4d7acf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aef70535-2340-44e9-bec8-6586bf4a6284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f7b3bc7-b91a-4a1c-843b-8ec6e2abfa94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aef70535-2340-44e9-bec8-6586bf4a6284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_dbdfab34-ea89-4b0b-a6df-371778c27f5e" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aef70535-2340-44e9-bec8-6586bf4a6284" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_dbdfab34-ea89-4b0b-a6df-371778c27f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember_5b827d13-2974-4bf7-baaf-6019f9855caa" xlink:href="exel-20220401.xsd#exel_RoyalPharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aef70535-2340-44e9-bec8-6586bf4a6284" xlink:to="loc_exel_RoyalPharmaMember_5b827d13-2974-4bf7-baaf-6019f9855caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c7f35f5-e39c-4e84-9b26-59e227702a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ece827e3-d4ef-4cdf-b5a9-586dec4d7acf" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c7f35f5-e39c-4e84-9b26-59e227702a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_9e855115-8ae0-49e5-b71d-a1370734b657" xlink:href="exel-20220401.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c7f35f5-e39c-4e84-9b26-59e227702a35" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_9e855115-8ae0-49e5-b71d-a1370734b657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_f0d7dd5d-cac2-4254-8893-9542fb503240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c7f35f5-e39c-4e84-9b26-59e227702a35" xlink:to="loc_us-gaap_RoyaltyExpense_f0d7dd5d-cac2-4254-8893-9542fb503240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5402ab51-dc10-4354-9c44-30827129f66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5402ab51-dc10-4354-9c44-30827129f66c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8aa85533-99b9-486e-b0fe-d68422ca0f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8aa85533-99b9-486e-b0fe-d68422ca0f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b3521e9-a6df-49f7-ad76-bd44133be445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aa85533-99b9-486e-b0fe-d68422ca0f49" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b3521e9-a6df-49f7-ad76-bd44133be445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_408e3e20-af86-4e7c-81d4-8708d92f8295" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b3521e9-a6df-49f7-ad76-bd44133be445" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_408e3e20-af86-4e7c-81d4-8708d92f8295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis_d57233dc-9971-4fc7-92cc-bce20bb9065f" xlink:href="exel-20220401.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:to="loc_exel_ProductOrServiceAxisAxis_d57233dc-9971-4fc7-92cc-bce20bb9065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_7a98a3be-7948-460e-b151-863238bcb5a6" xlink:href="exel-20220401.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductOrServiceAxisAxis_d57233dc-9971-4fc7-92cc-bce20bb9065f" xlink:to="loc_exel_ProductOrServiceAxisDomain_7a98a3be-7948-460e-b151-863238bcb5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_092207f1-b039-44f7-846e-11a49b1cb665" xlink:href="exel-20220401.xsd#exel_CotellicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductOrServiceAxisDomain_7a98a3be-7948-460e-b151-863238bcb5a6" xlink:to="loc_exel_CotellicMember_092207f1-b039-44f7-846e-11a49b1cb665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd4a4429-8237-414f-8ac2-2bab1a0cff8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2b15339-d7b8-4e47-8400-3550106dfed9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd4a4429-8237-414f-8ac2-2bab1a0cff8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_0b1a2c16-ece5-4ab9-83b0-648d99ca71cd" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd4a4429-8237-414f-8ac2-2bab1a0cff8c" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_0b1a2c16-ece5-4ab9-83b0-648d99ca71cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b5ed416-37e3-4f04-a70b-081574576892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd4a4429-8237-414f-8ac2-2bab1a0cff8c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b5ed416-37e3-4f04-a70b-081574576892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46d9716c-a390-4834-9103-17df0b1eba27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46d9716c-a390-4834-9103-17df0b1eba27" xlink:to="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c98da7d9-ce38-434a-a04f-8acac654bdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c98da7d9-ce38-434a-a04f-8acac654bdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_fae4cfb6-9380-4423-b35c-7519e37c70ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c98da7d9-ce38-434a-a04f-8acac654bdf3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_fae4cfb6-9380-4423-b35c-7519e37c70ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetPurchaseAgreement2021Member_5251ff1f-5dc6-4a42-af23-f5ba24a9ad8d" xlink:href="exel-20220401.xsd#exel_AssetPurchaseAgreement2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_fae4cfb6-9380-4423-b35c-7519e37c70ad" xlink:to="loc_exel_AssetPurchaseAgreement2021Member_5251ff1f-5dc6-4a42-af23-f5ba24a9ad8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_501687c7-c596-4c30-a015-992c4b60686c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:to="loc_us-gaap_TypeOfArrangementAxis_501687c7-c596-4c30-a015-992c4b60686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8cf49d5-ed39-4de7-a4af-8fa17550961b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_501687c7-c596-4c30-a015-992c4b60686c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8cf49d5-ed39-4de7-a4af-8fa17550961b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_0011d0b8-0b98-4d2d-8fd8-a4e7d2095c02" xlink:href="exel-20220401.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8cf49d5-ed39-4de7-a4af-8fa17550961b" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_0011d0b8-0b98-4d2d-8fd8-a4e7d2095c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_ed0984b7-78ad-4807-8759-eb5b52265611" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_af55606e-5ac7-4027-acce-8709435d3636" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_af55606e-5ac7-4027-acce-8709435d3636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_f7db9b02-669e-448c-9d80-b9634f92955b" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_f7db9b02-669e-448c-9d80-b9634f92955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_c3636be4-04ed-40c5-9e36-625032246be9" xlink:href="exel-20220401.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_c3636be4-04ed-40c5-9e36-625032246be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_efaec324-e0c8-4ad9-bf1e-dcf1e2c1d059" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_efaec324-e0c8-4ad9-bf1e-dcf1e2c1d059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_edfc17fb-f9dc-42af-b757-b88f5e2824b7" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_edfc17fb-f9dc-42af-b757-b88f5e2824b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_ef7c6c19-eb7b-438e-baec-e3cdbbe131c9" xlink:href="exel-20220401.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8dd8a325-3d67-431c-9e28-6ed988c155df" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_ef7c6c19-eb7b-438e-baec-e3cdbbe131c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_62df11c5-d0a9-4509-9809-96e81ede37b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_faa4b558-e0b4-4115-9dd2-3dff8bcd6200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_62df11c5-d0a9-4509-9809-96e81ede37b9" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_faa4b558-e0b4-4115-9dd2-3dff8bcd6200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc8ac135-f61e-417c-926c-2abf9d770c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b50f9ddb-71b3-48af-ad31-0b7b5dedea6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc8ac135-f61e-417c-926c-2abf9d770c9e" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b50f9ddb-71b3-48af-ad31-0b7b5dedea6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bc07dc7a-cdbb-4063-90a5-0a5c13662b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc8ac135-f61e-417c-926c-2abf9d770c9e" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bc07dc7a-cdbb-4063-90a5-0a5c13662b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_f37ff980-e351-4a9d-a054-6a38eb77a04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc8ac135-f61e-417c-926c-2abf9d770c9e" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_f37ff980-e351-4a9d-a054-6a38eb77a04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_77da7143-ee1c-4455-bb81-4a41c83ce7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc8ac135-f61e-417c-926c-2abf9d770c9e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_77da7143-ee1c-4455-bb81-4a41c83ce7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_8e0163f6-fef6-4bd6-98ed-e7fc0b302f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc8ac135-f61e-417c-926c-2abf9d770c9e" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_8e0163f6-fef6-4bd6-98ed-e7fc0b302f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9b7887de-779b-460b-8809-6414ee1de89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_1e955c83-8d20-4990-931f-92a8e94e17fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9b7887de-779b-460b-8809-6414ee1de89c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_1e955c83-8d20-4990-931f-92a8e94e17fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_633fe447-170a-447f-abf0-19f38203faa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1e955c83-8d20-4990-931f-92a8e94e17fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_633fe447-170a-447f-abf0-19f38203faa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_f603304e-bce1-4a78-8ed8-159fc96ee351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1e955c83-8d20-4990-931f-92a8e94e17fe" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_f603304e-bce1-4a78-8ed8-159fc96ee351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_198b4355-665e-489c-aa86-d8fbbb1745d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1e955c83-8d20-4990-931f-92a8e94e17fe" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_198b4355-665e-489c-aa86-d8fbbb1745d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ed39e9f8-804f-483c-8461-4e02760a8c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ed39e9f8-804f-483c-8461-4e02760a8c6c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c6f76451-5202-4dba-864c-6433f9ceafe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c6f76451-5202-4dba-864c-6433f9ceafe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2ec9bd0-f720-4393-b761-894c8a516a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6f76451-5202-4dba-864c-6433f9ceafe5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2ec9bd0-f720-4393-b761-894c8a516a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_af3fb7ef-15a2-4254-8f8f-6fc03f108f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2ec9bd0-f720-4393-b761-894c8a516a92" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_af3fb7ef-15a2-4254-8f8f-6fc03f108f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5166a4c0-ac9b-4e85-8ecf-82140b91cccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7a1ac183-6afc-427d-b3dc-8aeaf138e9e5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5166a4c0-ac9b-4e85-8ecf-82140b91cccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_2d66248d-620d-4eee-97d9-b7bbd726f976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5166a4c0-ac9b-4e85-8ecf-82140b91cccb" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_2d66248d-620d-4eee-97d9-b7bbd726f976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_572e6176-f290-4b2e-9e98-d2761948eb97" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_bde3ffd6-1ba0-4b92-b17d-4600fb73aa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_bde3ffd6-1ba0-4b92-b17d-4600fb73aa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_544e0db8-974e-4637-b825-3bdb13820699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_InterestReceivable_544e0db8-974e-4637-b825-3bdb13820699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_43f621d8-e318-4126-bd46-8762e2da771d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_43f621d8-e318-4126-bd46-8762e2da771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_6c250eb1-5598-48ec-b6b6-44d457f1b622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_6c250eb1-5598-48ec-b6b6-44d457f1b622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0379b032-f4e3-442e-b81f-cbac44c3dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0379b032-f4e3-442e-b81f-cbac44c3dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_e89d6758-d22b-45e2-a438-ed23f99b4948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef84c979-572c-4366-a32c-4df29804c06a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_e89d6758-d22b-45e2-a438-ed23f99b4948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4fb3556d-91ae-4760-80db-51f5fee46a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2fee2dc4-c560-43ef-987a-a8b5351b6056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4fb3556d-91ae-4760-80db-51f5fee46a90" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2fee2dc4-c560-43ef-987a-a8b5351b6056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4ad69fc5-6930-4409-a9cc-7498ef8e81fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2fee2dc4-c560-43ef-987a-a8b5351b6056" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4ad69fc5-6930-4409-a9cc-7498ef8e81fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4ad69fc5-6930-4409-a9cc-7498ef8e81fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_683f9dff-697a-4855-a28f-3cd34cc0e02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_CommercialPaperMember_683f9dff-697a-4855-a28f-3cd34cc0e02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_af51d977-fa87-4d76-b065-680656fe0705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_af51d977-fa87-4d76-b065-680656fe0705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_5d8239cf-879f-4c46-8c0b-ee71bfd3bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_5d8239cf-879f-4c46-8c0b-ee71bfd3bd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_dd97a19c-7c72-4d03-95fd-4587e2b53672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_MunicipalBondsMember_dd97a19c-7c72-4d03-95fd-4587e2b53672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_25eeca50-c5e0-4915-9227-b9af58b305cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_CashMember_25eeca50-c5e0-4915-9227-b9af58b305cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_115a8012-4b62-4237-abdd-6cc58dfd1932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_MoneyMarketFundsMember_115a8012-4b62-4237-abdd-6cc58dfd1932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_8dedd3db-0edc-404f-bedf-5620f68a3401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78b7a1cd-181d-40d4-a5fd-d766b0d73584" xlink:to="loc_us-gaap_CertificatesOfDepositMember_8dedd3db-0edc-404f-bedf-5620f68a3401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2fee2dc4-c560-43ef-987a-a8b5351b6056" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_51f83a97-5046-4015-8260-b93c7e93940e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_51f83a97-5046-4015-8260-b93c7e93940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0da0e32-41ee-4015-b701-95c723201e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0da0e32-41ee-4015-b701-95c723201e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f07c9f3d-bc13-475d-85dd-ae51691ea0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f07c9f3d-bc13-475d-85dd-ae51691ea0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87f019eb-3c31-47eb-8b7c-7b34ffe0abee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_928a1023-172d-4fec-a487-f9ce5eeeee83" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87f019eb-3c31-47eb-8b7c-7b34ffe0abee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_2d4875e3-bdc7-4609-bc8f-b44e98e93d7c" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_2d4875e3-bdc7-4609-bc8f-b44e98e93d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_4648b361-6f6a-4514-8f4f-8b5d4befb674" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_4648b361-6f6a-4514-8f4f-8b5d4befb674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_db156ff3-e5f9-490e-9627-7664dfc56ccb" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_db156ff3-e5f9-490e-9627-7664dfc56ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a158ff37-7c4d-4556-ae60-ff49294e97f2" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0fb9bd78-29de-4549-b62f-9aaff71c4265" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a158ff37-7c4d-4556-ae60-ff49294e97f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2b047a86-aaad-4df9-bcb0-c9e4e9ddc932" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2b047a86-aaad-4df9-bcb0-c9e4e9ddc932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e6675999-58a8-487a-b551-632d5935d004" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e6675999-58a8-487a-b551-632d5935d004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_99de496f-149b-41db-8929-baae7028450a" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_99de496f-149b-41db-8929-baae7028450a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_4b91550b-b26f-4d32-a80d-966be86a2811" xlink:href="exel-20220401.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_526ca35b-b00b-4340-bbdb-193febd01b7d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_4b91550b-b26f-4d32-a80d-966be86a2811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32bf25c7-00ce-43dd-8078-54170f82f923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c583a0a-4a32-4812-ad2b-ce5c8b6f2e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32bf25c7-00ce-43dd-8078-54170f82f923" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c583a0a-4a32-4812-ad2b-ce5c8b6f2e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e5e44749-681f-4f19-931a-51dcf6c562d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c583a0a-4a32-4812-ad2b-ce5c8b6f2e9c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e5e44749-681f-4f19-931a-51dcf6c562d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e5e44749-681f-4f19-931a-51dcf6c562d3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d689c921-6bc9-4747-9c62-4155cf0ed108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d689c921-6bc9-4747-9c62-4155cf0ed108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_31ebd1e4-788b-4caa-bd3e-982b19c78985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_31ebd1e4-788b-4caa-bd3e-982b19c78985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f817deea-c7de-4c4b-b296-5138dfed4a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:to="loc_us-gaap_CommercialPaperMember_f817deea-c7de-4c4b-b296-5138dfed4a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_4d263437-6d31-47b2-8e26-f6a5b7ed92e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc18de4-14dc-40e3-8de1-387b34e35352" xlink:to="loc_us-gaap_MunicipalBondsMember_4d263437-6d31-47b2-8e26-f6a5b7ed92e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ace6744-d5a6-4aad-8c4a-4fc33815e581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c583a0a-4a32-4812-ad2b-ce5c8b6f2e9c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ace6744-d5a6-4aad-8c4a-4fc33815e581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4b89f866-cb19-4395-a3b5-2694c2122283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ace6744-d5a6-4aad-8c4a-4fc33815e581" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4b89f866-cb19-4395-a3b5-2694c2122283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fd921f43-c635-4c26-81a7-319f55512425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4b89f866-cb19-4395-a3b5-2694c2122283" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fd921f43-c635-4c26-81a7-319f55512425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8c1d7495-a11b-4eb3-a947-0bae1a490b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4b89f866-cb19-4395-a3b5-2694c2122283" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8c1d7495-a11b-4eb3-a947-0bae1a490b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2316073-ddad-4377-98ba-d96f6b2fbec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_979f9a9a-3ebc-49ae-a0e9-d7bc0c86dacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2316073-ddad-4377-98ba-d96f6b2fbec2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_979f9a9a-3ebc-49ae-a0e9-d7bc0c86dacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_59ef8e9b-1832-4392-be8b-7f3cce2af98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2316073-ddad-4377-98ba-d96f6b2fbec2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_59ef8e9b-1832-4392-be8b-7f3cce2af98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2deff6eb-93c1-4f27-bd11-cd70bc83166d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2316073-ddad-4377-98ba-d96f6b2fbec2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2deff6eb-93c1-4f27-bd11-cd70bc83166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20220401.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4534a469-169f-4674-9bf6-bdaa205e7fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_af1588e9-ba13-4322-90ea-d51ea78d6ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4534a469-169f-4674-9bf6-bdaa205e7fad" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_af1588e9-ba13-4322-90ea-d51ea78d6ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20220401.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c431a855-ed4c-4779-8f86-808056b0dc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_43b8bcbd-3a2c-41aa-b14c-26ff36470ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c431a855-ed4c-4779-8f86-808056b0dc0c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_43b8bcbd-3a2c-41aa-b14c-26ff36470ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7186622c-8328-4c71-b770-1df1cf117ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7186622c-8328-4c71-b770-1df1cf117ccf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6cfec8b4-b2ac-4aec-bc92-e0429b4d08c2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_96b52678-862c-484a-bf62-ad30371c21aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_CommercialPaperMember_96b52678-862c-484a-bf62-ad30371c21aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_c70d3ace-381d-4223-a245-7a5765c33a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_c70d3ace-381d-4223-a245-7a5765c33a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_9cff1b40-0df8-46c0-9ac3-04ac1d816c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_9cff1b40-0df8-46c0-9ac3-04ac1d816c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_3019bffd-cdbb-4c71-8201-37228516f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_MunicipalBondsMember_3019bffd-cdbb-4c71-8201-37228516f41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cb0dbf3f-f09a-4715-b86b-5d10c6b1a6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cb0dbf3f-f09a-4715-b86b-5d10c6b1a6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_82888ba7-953a-483f-b03a-b8eede8de8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4414445-7818-4dbe-a2d3-6d8254ee7581" xlink:to="loc_us-gaap_CertificatesOfDepositMember_82888ba7-953a-483f-b03a-b8eede8de8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a07a70bb-1918-416c-9f73-58d57ec5699c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a07a70bb-1918-416c-9f73-58d57ec5699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b9aacec-d1d3-442a-9cf9-34eb12e987e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a07a70bb-1918-416c-9f73-58d57ec5699c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b9aacec-d1d3-442a-9cf9-34eb12e987e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e82a4d5d-5a66-4b93-a53c-48c2cd1c3c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b9aacec-d1d3-442a-9cf9-34eb12e987e5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e82a4d5d-5a66-4b93-a53c-48c2cd1c3c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4945f25c-bfd2-4454-bfb7-80ccafebc363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b9aacec-d1d3-442a-9cf9-34eb12e987e5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4945f25c-bfd2-4454-bfb7-80ccafebc363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0d77a69-5c1a-4535-9ed2-01118db4f2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0d77a69-5c1a-4535-9ed2-01118db4f2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7c57768-c508-4278-8413-4acff7a1da09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0d77a69-5c1a-4535-9ed2-01118db4f2eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7c57768-c508-4278-8413-4acff7a1da09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_082c81e4-abd2-4a1d-b9b2-4cbfbc2be255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7c57768-c508-4278-8413-4acff7a1da09" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_082c81e4-abd2-4a1d-b9b2-4cbfbc2be255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b50465ef-a32b-4988-a8df-e860776ffc3c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_97e6c91f-be9a-4f5a-ba20-36b86faa443d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_97e6c91f-be9a-4f5a-ba20-36b86faa443d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea632ced-ee56-4e2e-b2a4-79b5cf4cbe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea632ced-ee56-4e2e-b2a4-79b5cf4cbe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8f28fedb-c4f1-4035-816f-1ea17ff5866e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30bb2282-d669-4563-8b92-c2383c2e3f81" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8f28fedb-c4f1-4035-816f-1ea17ff5866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9612702c-37f0-4dc1-8a5d-90c4552d43b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d1dac51-b37e-432c-91b5-1345c83714e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9612702c-37f0-4dc1-8a5d-90c4552d43b7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d1dac51-b37e-432c-91b5-1345c83714e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_35cd7d93-c861-4f94-ab0c-e9089e506d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d1dac51-b37e-432c-91b5-1345c83714e2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_35cd7d93-c861-4f94-ab0c-e9089e506d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b2fb86e2-42b7-46a9-a277-eb7e9a5693a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_35cd7d93-c861-4f94-ab0c-e9089e506d12" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b2fb86e2-42b7-46a9-a277-eb7e9a5693a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_a56328c6-34f8-4594-b7e1-3b7009ba57e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b2fb86e2-42b7-46a9-a277-eb7e9a5693a6" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_a56328c6-34f8-4594-b7e1-3b7009ba57e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d1dac51-b37e-432c-91b5-1345c83714e2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_e81026ec-06ee-4f7a-b362-3a4691475967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_e81026ec-06ee-4f7a-b362-3a4691475967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_d9b10624-a8c7-4db4-915c-81aeaa6d03c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_DerivativeNotionalAmount_d9b10624-a8c7-4db4-915c-81aeaa6d03c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_d22fe3eb-ba6d-44f6-be68-4e9f15a04876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_DerivativeTermOfContract_d22fe3eb-ba6d-44f6-be68-4e9f15a04876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_d9b618b1-0c0a-4f03-998c-36f46939cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17db0c65-1fce-4f61-b83d-702ab6d834ed" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_d9b618b1-0c0a-4f03-998c-36f46939cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20220401.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d5d85166-4493-483f-b030-9dcdb00c2262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_2c53a3d3-5904-48ca-bedb-b9b4363eb920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d5d85166-4493-483f-b030-9dcdb00c2262" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_2c53a3d3-5904-48ca-bedb-b9b4363eb920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20220401.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_37fe8d44-4cb8-4c9c-9deb-cadaf17a1ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_80980a0a-82fd-4c50-8ea8-4092ec9162c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37fe8d44-4cb8-4c9c-9deb-cadaf17a1ec3" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_80980a0a-82fd-4c50-8ea8-4092ec9162c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7b6c7c42-64b8-4485-9a3d-46e852868b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_23c2265e-ea8e-4a4f-a5d5-1c48895b2634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7b6c7c42-64b8-4485-9a3d-46e852868b8e" xlink:to="loc_us-gaap_InventoryCurrentTable_23c2265e-ea8e-4a4f-a5d5-1c48895b2634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9132246a-3ca2-4dd9-830e-1b3551e62e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_23c2265e-ea8e-4a4f-a5d5-1c48895b2634" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9132246a-3ca2-4dd9-830e-1b3551e62e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_082676b6-de64-441b-b545-a5c0fa10663c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9132246a-3ca2-4dd9-830e-1b3551e62e52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_082676b6-de64-441b-b545-a5c0fa10663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_654384a2-d731-40f5-99b9-ce477b80bb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_082676b6-de64-441b-b545-a5c0fa10663c" xlink:to="loc_us-gaap_InventoriesMember_654384a2-d731-40f5-99b9-ce477b80bb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_75c3f308-6a67-49a3-8061-e6c4685de970" xlink:href="exel-20220401.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_082676b6-de64-441b-b545-a5c0fa10663c" xlink:to="loc_exel_OtherLongtermAssetsMember_75c3f308-6a67-49a3-8061-e6c4685de970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_23c2265e-ea8e-4a4f-a5d5-1c48895b2634" xlink:to="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_59d0057d-f2f3-4278-b052-f1063c22e057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryRawMaterials_59d0057d-f2f3-4278-b052-f1063c22e057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_dcce8c2c-ec68-4b38-a012-ab403ceea61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryWorkInProcess_dcce8c2c-ec68-4b38-a012-ab403ceea61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_909f4866-f3f0-4e4c-af7d-2199767e6885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryFinishedGoods_909f4866-f3f0-4e4c-af7d-2199767e6885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_5efd0778-d1fc-4893-aaf8-0842a5af9d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_194e54c8-e288-477c-9251-af9307797d32" xlink:to="loc_us-gaap_InventoryGross_5efd0778-d1fc-4893-aaf8-0842a5af9d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f84d88-3873-4050-b975-2e38f2d2198c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a1d526df-7f58-49f4-b715-bbe36e152ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f84d88-3873-4050-b975-2e38f2d2198c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a1d526df-7f58-49f4-b715-bbe36e152ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fda36fb-fdd9-405c-8ca2-eea52de3590d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd2ceff6-89b0-4693-8156-a955686e238a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fda36fb-fdd9-405c-8ca2-eea52de3590d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd2ceff6-89b0-4693-8156-a955686e238a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_5134a085-6de7-4d25-8948-4863b4b7de03" xlink:href="exel-20220401.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fda36fb-fdd9-405c-8ca2-eea52de3590d" xlink:to="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_5134a085-6de7-4d25-8948-4863b4b7de03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1c14204-7b43-42b0-b0ed-3a7c0fb505ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d18ad8e6-c2a9-43d9-9357-46f118e383cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1c14204-7b43-42b0-b0ed-3a7c0fb505ff" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d18ad8e6-c2a9-43d9-9357-46f118e383cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fea397d7-1367-49bc-95cf-05ce80cd38b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d18ad8e6-c2a9-43d9-9357-46f118e383cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fea397d7-1367-49bc-95cf-05ce80cd38b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_06048ad7-81a0-495d-8ea9-2ee7f0b2a478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fea397d7-1367-49bc-95cf-05ce80cd38b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_06048ad7-81a0-495d-8ea9-2ee7f0b2a478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46bd01d2-4ba8-4af3-8a4b-a11cc8c5b731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_06048ad7-81a0-495d-8ea9-2ee7f0b2a478" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46bd01d2-4ba8-4af3-8a4b-a11cc8c5b731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_741c68c9-39a5-402f-9240-a8246238b30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_06048ad7-81a0-495d-8ea9-2ee7f0b2a478" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_741c68c9-39a5-402f-9240-a8246238b30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_af9dc396-f332-4405-a6eb-5ea874e6e472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d18ad8e6-c2a9-43d9-9357-46f118e383cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_af9dc396-f332-4405-a6eb-5ea874e6e472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1406e64f-693e-4b27-8b0a-523d6c67d1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_af9dc396-f332-4405-a6eb-5ea874e6e472" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1406e64f-693e-4b27-8b0a-523d6c67d1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87a56f99-7f67-4269-834d-5c7459efdb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508716b5-3c29-46bb-bcb1-b5d4192e6425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87a56f99-7f67-4269-834d-5c7459efdb7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508716b5-3c29-46bb-bcb1-b5d4192e6425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508716b5-3c29-46bb-bcb1-b5d4192e6425" xlink:to="loc_us-gaap_AwardTypeAxis_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ae081dd7-ee34-40dd-b1a4-6a90e0fc77bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_60817473-511c-4cbd-bfb7-76a476ddf073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_60817473-511c-4cbd-bfb7-76a476ddf073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_92830d3e-4972-45e6-86cc-d5df8306fa00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_92830d3e-4972-45e6-86cc-d5df8306fa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3a925f45-c651-4af9-94f6-65245b741991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:to="loc_us-gaap_PerformanceSharesMember_3a925f45-c651-4af9-94f6-65245b741991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2f2d6295-61c1-4516-bab5-b277cb652065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d7808e-992a-47b2-9da1-edc22d454e48" xlink:to="loc_us-gaap_EmployeeStockMember_2f2d6295-61c1-4516-bab5-b277cb652065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9a53a16-c426-4152-9697-1bb73025ed7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508716b5-3c29-46bb-bcb1-b5d4192e6425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9a53a16-c426-4152-9697-1bb73025ed7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e877f985-3db0-4f68-bbb3-a461ae351841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9a53a16-c426-4152-9697-1bb73025ed7a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e877f985-3db0-4f68-bbb3-a461ae351841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9eb999d6-58ee-405a-9186-513617617dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9eb999d6-58ee-405a-9186-513617617dfb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:to="loc_us-gaap_AwardTypeAxis_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9351dad5-2bb1-4fa6-9b1c-457dba41d8f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4927997-bfe4-44d0-9181-314a56d765fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4927997-bfe4-44d0-9181-314a56d765fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_43d3643f-7058-45cd-b434-ff0d494faf2c" xlink:href="exel-20220401.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_e4927997-bfe4-44d0-9181-314a56d765fd" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_43d3643f-7058-45cd-b434-ff0d494faf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e187d952-dbc8-4096-992e-8e3f549f337b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:to="loc_us-gaap_PerformanceSharesMember_e187d952-dbc8-4096-992e-8e3f549f337b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53712441-4831-4cfd-81f8-71f1894a4b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1f1e6a-5dfc-4992-adae-49580cc9a589" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53712441-4831-4cfd-81f8-71f1894a4b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d3598858-aac6-4a45-b570-477d725c3675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:to="loc_us-gaap_VestingAxis_d3598858-aac6-4a45-b570-477d725c3675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_afd6bf87-ce7e-4719-93a9-e5dceea0afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_d3598858-aac6-4a45-b570-477d725c3675" xlink:to="loc_us-gaap_VestingDomain_afd6bf87-ce7e-4719-93a9-e5dceea0afa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8df39a14-bcbb-41cd-a623-ed38a015dc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_afd6bf87-ce7e-4719-93a9-e5dceea0afa6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8df39a14-bcbb-41cd-a623-ed38a015dc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ed6469-d9c3-4f6d-8573-7aea7aa42596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_542534fb-3f17-4643-ab86-a10238dad1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_542534fb-3f17-4643-ab86-a10238dad1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_e2592d43-c754-4b0d-8174-0331661d137d" xlink:href="exel-20220401.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_e2592d43-c754-4b0d-8174-0331661d137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_0cec8cb8-b704-43fe-9498-6025252c2070" xlink:href="exel-20220401.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_0cec8cb8-b704-43fe-9498-6025252c2070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95b8d874-a8cc-4d33-941a-fc91d5b03679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95b8d874-a8cc-4d33-941a-fc91d5b03679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e4543ebd-9e95-4939-b764-3da90a6a571d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e4543ebd-9e95-4939-b764-3da90a6a571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_965b4bf6-1119-4062-9d2c-227b063f541a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_965b4bf6-1119-4062-9d2c-227b063f541a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90a9f449-2d68-4f25-8e81-34b3829dd61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90a9f449-2d68-4f25-8e81-34b3829dd61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60b0f452-a868-45ff-b2ea-cbc8d4a2ce1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60b0f452-a868-45ff-b2ea-cbc8d4a2ce1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c2adec4-94c2-4e24-9ebf-15b4af3df510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c2adec4-94c2-4e24-9ebf-15b4af3df510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_badd7bc2-2b8c-432d-96ad-2b80a5b6edff" xlink:href="exel-20220401.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_badd7bc2-2b8c-432d-96ad-2b80a5b6edff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2570415d-034b-4102-8c48-017c75faae25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2570415d-034b-4102-8c48-017c75faae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8c2c1479-a3be-4fb2-b4f7-3a500bb33083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8c2c1479-a3be-4fb2-b4f7-3a500bb33083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87872fdc-6321-4552-93f1-729fe64a07c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87872fdc-6321-4552-93f1-729fe64a07c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_192247d5-ba8f-4c92-a618-9ddee737e665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e67fce24-a997-4874-ad6b-a4bd583ed13b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_192247d5-ba8f-4c92-a618-9ddee737e665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca1f7fd5-6013-482c-8c6b-f693d1e88ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c12c0c95-222b-4bb1-86a6-ce7f0a9ddb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca1f7fd5-6013-482c-8c6b-f693d1e88ab6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c12c0c95-222b-4bb1-86a6-ce7f0a9ddb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c12c0c95-222b-4bb1-86a6-ce7f0a9ddb36" xlink:to="loc_us-gaap_AwardTypeAxis_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59cad1ca-7a9e-499c-9ea4-28849d6ba8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_db7f55dc-7028-4787-b6f1-8ac40c3d7d6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59cad1ca-7a9e-499c-9ea4-28849d6ba8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_b771bec0-ca37-4a2a-9e69-5c9c9b00cb24" xlink:href="exel-20220401.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59cad1ca-7a9e-499c-9ea4-28849d6ba8f7" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_b771bec0-ca37-4a2a-9e69-5c9c9b00cb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c12c0c95-222b-4bb1-86a6-ce7f0a9ddb36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59e710ac-549d-47c7-8b9e-3e66d6096ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59e710ac-549d-47c7-8b9e-3e66d6096ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_b5d648e3-4f64-4297-a369-6424e599710c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_SharePrice_b5d648e3-4f64-4297-a369-6424e599710c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b710db67-15a6-42d0-b3a5-5f7b12940fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b710db67-15a6-42d0-b3a5-5f7b12940fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c83ae5d6-5f86-49ce-87b2-40196b1d3519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c83ae5d6-5f86-49ce-87b2-40196b1d3519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f7105893-c252-4fca-89ca-3348464a3b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38985a4e-283d-4b59-8706-b87fd9f6ca1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f7105893-c252-4fca-89ca-3348464a3b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="simple" xlink:href="exel-20220401.xsd#ProvisionForBenefitFromIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a20875fd-84af-4e45-8e54-96b22db28974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6cd641b4-0caf-4fc6-9c34-4b55c80e3731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a20875fd-84af-4e45-8e54-96b22db28974" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6cd641b4-0caf-4fc6-9c34-4b55c80e3731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20220401.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9d1e3104-3e7e-4301-8cc8-84e0fb653a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f96885b4-960a-4cec-9379-7b145c14bcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9d1e3104-3e7e-4301-8cc8-84e0fb653a25" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f96885b4-960a-4cec-9379-7b145c14bcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20220401.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3d98d46a-e4e1-419b-9783-0b03d0aa7a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_78d389fe-4423-4b91-aea4-19a52082a6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d98d46a-e4e1-419b-9783-0b03d0aa7a47" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_78d389fe-4423-4b91-aea4-19a52082a6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f934f3a8-eac6-49d5-95e0-c77eb29407d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d98d46a-e4e1-419b-9783-0b03d0aa7a47" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f934f3a8-eac6-49d5-95e0-c77eb29407d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_264b13ee-ba30-4f41-be13-c0cabbc5276a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_d1dc9154-0063-421e-956e-d9d5ed9e8a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_264b13ee-ba30-4f41-be13-c0cabbc5276a" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_d1dc9154-0063-421e-956e-d9d5ed9e8a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc96a34e-a4e2-4996-a3b8-9e4befafd4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d1dc9154-0063-421e-956e-d9d5ed9e8a1d" xlink:to="loc_us-gaap_NetIncomeLoss_cc96a34e-a4e2-4996-a3b8-9e4befafd4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3caa3e4e-c29d-4e61-8061-467c0da16e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_264b13ee-ba30-4f41-be13-c0cabbc5276a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3caa3e4e-c29d-4e61-8061-467c0da16e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cc250cde-06d0-43d2-8461-b6f8b3661882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3caa3e4e-c29d-4e61-8061-467c0da16e1e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cc250cde-06d0-43d2-8461-b6f8b3661882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd3af906-6604-4357-b4a9-e5215c71d7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3caa3e4e-c29d-4e61-8061-467c0da16e1e" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd3af906-6604-4357-b4a9-e5215c71d7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b4a3d34-5c15-4040-9a3a-140e3b2051a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3caa3e4e-c29d-4e61-8061-467c0da16e1e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b4a3d34-5c15-4040-9a3a-140e3b2051a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5665c260-6e1f-4dc7-bd3c-a8bcbc44cfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_264b13ee-ba30-4f41-be13-c0cabbc5276a" xlink:to="loc_us-gaap_EarningsPerShareBasic_5665c260-6e1f-4dc7-bd3c-a8bcbc44cfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a7b8eed6-753f-43ff-808b-6e1f3bc8a059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_264b13ee-ba30-4f41-be13-c0cabbc5276a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a7b8eed6-753f-43ff-808b-6e1f3bc8a059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5443afd4-d83b-49ac-af3d-d382db265624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_65da67a1-7b40-401c-9aa3-abf328416298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5443afd4-d83b-49ac-af3d-d382db265624" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_65da67a1-7b40-401c-9aa3-abf328416298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_539fe16b-f816-456c-97ee-8f83673295cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_65da67a1-7b40-401c-9aa3-abf328416298" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_539fe16b-f816-456c-97ee-8f83673295cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82862481-5b22-40c2-bd80-c92a0fa8a6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_539fe16b-f816-456c-97ee-8f83673295cb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82862481-5b22-40c2-bd80-c92a0fa8a6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_24d8d68f-ba15-433e-8705-d66e2e5bc8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82862481-5b22-40c2-bd80-c92a0fa8a6dc" xlink:to="loc_us-gaap_StockCompensationPlanMember_24d8d68f-ba15-433e-8705-d66e2e5bc8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee745e2b-a587-43be-b25c-5cc4e850a0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_65da67a1-7b40-401c-9aa3-abf328416298" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee745e2b-a587-43be-b25c-5cc4e850a0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00ee7ebb-6fc9-40b6-b3da-5bcc228e4212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee745e2b-a587-43be-b25c-5cc4e850a0c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00ee7ebb-6fc9-40b6-b3da-5bcc228e4212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20220401.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6dd5ebde-6b65-4bfb-ae9c-56a5bdb02439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d39f4470-7db5-48ee-bfd3-ce7d046eb6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6dd5ebde-6b65-4bfb-ae9c-56a5bdb02439" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d39f4470-7db5-48ee-bfd3-ce7d046eb6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvents" xlink:type="simple" xlink:href="exel-20220401.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4599fa3a-c467-496e-b063-44faf989a6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_cab1f2e6-f93f-48e7-8000-52b914bd6440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4599fa3a-c467-496e-b063-44faf989a6a1" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_cab1f2e6-f93f-48e7-8000-52b914bd6440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="exel-20220401.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_82e3f678-756f-4689-8f1a-d43aafe4ce74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_82e3f678-756f-4689-8f1a-d43aafe4ce74" xlink:to="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_8f29e970-6409-4257-acd8-c5764aa3c6b3" xlink:href="exel-20220401.xsd#exel_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:to="loc_exel_LeaseArrangementsAxis_8f29e970-6409-4257-acd8-c5764aa3c6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_0211126d-3099-43b6-a60c-f6eba9eaea21" xlink:href="exel-20220401.xsd#exel_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsAxis_8f29e970-6409-4257-acd8-c5764aa3c6b3" xlink:to="loc_exel_LeaseArrangementsDomain_0211126d-3099-43b6-a60c-f6eba9eaea21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember_434e7a6b-5eb0-445e-be35-85cca57ad545" xlink:href="exel-20220401.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_0211126d-3099-43b6-a60c-f6eba9eaea21" xlink:to="loc_exel_BuiltToSuitLeaseMember_434e7a6b-5eb0-445e-be35-85cca57ad545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c30727fa-77ad-4377-9418-c246b7acd41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c30727fa-77ad-4377-9418-c246b7acd41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b45dc360-b9e5-45c9-a2b7-0c7c961d46c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c30727fa-77ad-4377-9418-c246b7acd41a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b45dc360-b9e5-45c9-a2b7-0c7c961d46c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bc4b59e3-6489-46e0-8891-fab1391f0b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b45dc360-b9e5-45c9-a2b7-0c7c961d46c1" xlink:to="loc_us-gaap_SubsequentEventMember_bc4b59e3-6489-46e0-8891-fab1391f0b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bdf33d99-aa31-4010-b2c1-afeb4dcd326e" xlink:to="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_ab79380a-1b0a-4770-a295-6e2d720069bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_ab79380a-1b0a-4770-a295-6e2d720069bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3bb5d40b-3c23-4548-b9d0-50ffa769bf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3bb5d40b-3c23-4548-b9d0-50ffa769bf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_4de5212a-be6e-4900-89ff-67da56d205ca" xlink:href="exel-20220401.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_4de5212a-be6e-4900-89ff-67da56d205ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3f62715c-6dce-4602-b394-451e2ab933bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3f62715c-6dce-4602-b394-451e2ab933bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_040a1963-5dfd-469f-a4d3-50f0b975a5a9" xlink:href="exel-20220401.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f1e38851-b844-4a0d-9cef-47bb48b22957" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_040a1963-5dfd-469f-a4d3-50f0b975a5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exel-20220401_g1.jpg
<TEXT>
begin 644 exel-20220401_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^%(8VAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,3,W(#<Y
M+C$U.3<V."P@,C Q-B\P."\Q,2TQ,SHR-#HT,B @(" @(" @(CX-"@D\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@
M>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O
M:6UG+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN
M<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O
M<B\Q+C O(B!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N
M,R\B/@T*"0D)/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^#0H)
M"0D\9&,Z=&ET;&4^#0H)"0D)/')D9CI!;'0^#0H)"0D)"3QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^=%\P-C(Q,3<\+W)D9CIL:3X-"@D)"0D\+W)D
M9CI!;'0^#0H)"0D\+V1C.G1I=&QE/@T*"0D)/'AM<#I-971A9&%T841A=&4^
M,C Q-RTP-RTQ-%0R,3HT,SHT-"TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X-
M"@D)"3QX;7 Z36]D:69Y1&%T93XR,#$W+3 W+3$U5# T.C0S.C0W6CPO>&UP
M.DUO9&EF>41A=&4^#0H)"0D\>&UP.D-R96%T941A=&4^,C Q-RTP-RTQ-%0R
M,3HT,SHT-"TP-SHP,#PO>&UP.D-R96%T941A=&4^#0H)"0D\>&UP.D-R96%T
M;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-#(#(P,3<@*$UA8VEN=&]S:"D\
M+WAM<#I#<F5A=&]R5&]O;#X-"@D)"3QX;7 Z5&AU;6)N86EL<SX-"@D)"0D\
M<F1F.D%L=#X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^#0H)"0D)"0D\>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^
M#0H)"0D)"0D\>&UP1TEM9SIH96EG:'0^,3$V/"]X;7!'26UG.FAE:6=H=#X-
M"@D)"0D)"3QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X-
M"@D)"0D)"3QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%
M<T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"
M3$%!04%!14$-"D%117-!04%!05%!0B\K24U716Q$43$Y455K.4=357A&04%%
M0D%!04U317AP8FTX0T5!04%B5S4P8VQ*2%%I0EE75F]G0C@T04%G04H-"D%!
M64%-44%!65=.>F-%,512;%%!04%!05-55D1)2$Y34C!)04%!04%!04%!04%!
M04%!04%!4&)704%%04%!04$P>3%)54-!9T%!04$-"D%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M4EDS0GED04%!059!04%!07H-"EI'5GI9=T%!05E104%!0G-D,U)W9$%!04%F
M04%!04%566UT=V1!04%!9U%!04%!56-L:%I79T%!06AG04%!055:,6A:5V=!
M04%I=T$-"D%!0559;&A:5V=!04%K04%!04%56D<Q=5I!04%!;%%!04%"=UI'
M,6M:04%!07-104%!0TED;E9L6D%!04$P=T%!04-'9&UL;&1W04$-"D$Y44%!
M04%K8DA6=&%104%!+V=!04%!56)75FAC=T%!0D%W04%!06MD1U9J84%!04)$
M04%!04%-8VQ24U%W04%"1'=!04%G35HQ4E,-"E%W04%"1'=!04%G35EL4E-1
M=T%!0D1W04%!9TUD1U8T9$%!04%!0D1B,T(U8VUL;F%(46=+1TUP241%-4]4
M9V=31U8S8D=6,&1#,5$-"EE73G)96$IK245.=F)80FAB;FM!04=2;&,R34%!
M04%!04%!045N3E-2,$EG4U561$YJ135.:EET36DT>$%!04%!04%!04%!04%!
M05,-"F,Q2DA1:4)*4E5-,DU4:S).:3!Y3&I%04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04$-"D%!04%!04%!
M04%!04%&:%I7:4%!04%!04%!1'I544%"04%!04%28DU71FQA24%!04%!04%!
M04%!04%!04%!04%!04)95U9O9T%!04$-"D%!04%B-DE!041J,4%!041K1FA:
M5VE!04%!04%!04)I;5%!070T54%!0FIA5T9L84E!04%!04%!04-39T%!05!H
M04%!=',Y:UI83FH-"D%!04%!04%!04):2E)536=A2%(P8T1O=DPS9#-D>35P
M6E=-=5DR9T%!04%!04%!04%!04%!0EI*4E5-9V%(4C!C1&]V3#-D,V1Y-7 -
M"EI73759,F=!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!6D=6>EEW04$-"D%!04%!04%U4U56
M1$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F1826=C,T)H
M63)59TQ30GI5:V1#04%!04%!04$-"D%!04%!04%U4U561$E$67A/5%DR3%1)
M=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F1826=C,T)H63)59TQ30GI5:V1#
M04%!04%!04$-"D%!04%!04%!04%!04%!04%!04%!04=2;&,R34%!04%!04%!
M04Q&2FQ:;59Y6E<U:EI30E=A5U8S85<U;DE%3G9B;5)P9$=L=F)I0G -"F)I
M0DI254TR351K,DYI,'E,:D5!04%!04%!04%!04%!04-X4UI76FQC;59U63)5
M9U9M;&QD,FQU6GE"1&(R-6MA6%)P8C(T9V%7-&<-"E-55D1.:D4U3FI9=$UI
M-'A!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!0C)A5U8S04%!
M04%!051P4#1!1D8X=4%"1% -"D9!040W8W=!0D)-3$%!3F-N9T%!04%&65=6
M;V=!04%!04%"34-664%504%!049C9C4R,6Q96$U!04%!04%!04%!44%!04%!
M04%!04$-"D%!04%!04%!04%!04%!2U!!04%!06Y.<%IY04%!04%!43%*54E'
M3C%C;EE!04%!04%!045!04%!04%504-G05!!0E%!1U%!94%#34$-"DM!071!
M1$E!3G=!-T%%04%244)+044X059!0EI!1C1!67=";T%',$%C9T(S04AW06=1
M0T=!27-!:T%#5D%*;T%N=T-K04MK07)G0WD-"D%,8T%V041"04U907EW1%%!
M3E5!,G=$9T%/54$V=T1W05!902MW14)!46-"1%%%5$%2:T)(=T5L05-S0DUG
M131!5#1"4E%&34%624(-"E=11F=!5V-"8F=&,4%8=T)G=T=,05I)0FUG1VA!
M86M"<U%'-4%C14)Y44A2061K0C112'!!9DE"*V=)1$%G=T-&04ED06E90TQW
M230-"D%K14-3=TI506PP0UIW2GA!;F]#:$%+3T%P9T-O9TMS07)90W=13$Q!
M=%5#-$%,<D%V541!04U,07A91$E1371!>F=$47=.4$$Q;T0-"EIG3GE!,S1$
M:6=/5T$V241R9T\V03AC1#!W4&=!*W=$*U%11T)"345)05%T0D1S15-!4E9"
M1TU%8U%2*T))=T5M9U-O0DQ917A!5%0-"D)/144X050K0E$P1DA!57)"5&]&
M4U%664)78T9D=U='0EI91G!G5S%"8U5&,5%8;$)F64="9UE70FEC1TYW6DE"
M;&M'86=:-T)O=T<-"FY1879"<T%',%%B:D)V54A"=V-:0GES2%!19%!",D5(
M9$%E1T(U:TAR064O0CE)2#519C1#07-)2'=G>4-%64E79VAU0TE)26QG:7$-
M"D-,-$DP9VIN0U!S2D5!:VQ#5&]*5'=L:T-8:TIJ=VUK0V)O2GIW;FQ#9G-+
M15%O;D-J,$M607!Q0V]%2VU!<75#<U5+,T%R>D-W<TP-"DEG<S5#,45,85%U
M04,U9TQS079)0RM%3"M1=U-$0V]-47=X8T1(54UJ9WEN1$U!33)1>GI$43!.
M2F<Q0416;TYD03)/1&%K3G=W,V4-"D1F9T]%=S1U1&MK3UI!-2]$<'-/=&<W
M4T1U-%!#43AL1#!%4%AG.39$-5E0<W<O4$0K=U%#4D%M145-45E20BM%2G-1
M=5)$6$5055(-"D5X17A%53A28E)'345A;U)Y4DAO16=C4TIH2D9%;5%3:$)+
M:D5S35,T>$U$17E-5%%X3FI%-$U4<$)01D4K555":%%N1D5K56%H4TP-"D9+
M,%5Z:%1W1E))5DY"5E=&6&=6;7A7.49E05=!>%EM1FMK5V)"85!&<DE7,6AB
M-D9X,%A14F1L1C1K6')H9E-&+V-91WAH04='55D-"FEH:79'3E59*VAK9T=5
M55IA>&U21V)C6C-2;T5':6]A55)P,T=P-&%X4G)S1WA18D]X=&I'-&]B<VAV
M84A!26-+:'A32$AS8V]X>DT-"DA0561(:#%(2%A!9&U2,T1(97=E1F@U04AM
M;V5L0C8K2'5K9D5X."M(,FMF;$(K+T@K;V=&4T)"24=W9VU#1$5)4$%H2$-&
M24E856@-"F]32$])9G-I2GE*5DEO26ER>4QD27=O:D]#3FU)-5%J=VE0=TI"
M.&M44U(X2DMS:S)I54I*5&=L84-76$IC8VPY>5EN2FQC;6AY83,-"DIU9VY'
M0V1*2C-O;G%Y9F-+03!O4'EH>$M+26\Q0VM'2U1G<&%Y;61+9$%Q06EO,4MM
M9W%M>7)02W=)<DYI='!+-3!R,%-W1DQ$:W,-"F)I>6E,3F-T1$,Q0DQ8671Q
M>3-H3&A9=51#-D-,<F-U-VDX:TPQ;W9K4R](3"\T=TY40G--2U%W,GI%4TU5
M;WAG:D<V369)>4MJ2FH-"DUP<WDQ1$U.33!9>F9Z3S1-+T4P2WI2;$Y*-# R
M1%543E4P,6AZ6$-.9C R3GI:>4YQ-#(V5&-K3C)!,VY$9EA/0E$T541I34]-
M9S4-"D)4;$-/6#@U=D1N-4]J639D1'%Y3W4X-TQ4=')/-F\W-D1W;E!'53AP
M1'IJ4%-).5E4,FA094$K240U9U!Q02LT1#AH4#)%+V]J+VD-"E%#3D%:14-M
M44]D0DM51G%187A"-VM)=U%N2D-T54PS47IP1&954$%204Y%4C!32U)--49%
M:U964EIP1C-K66E2;61'<3!B=U)Z5D@-"F4P9D%3059)4S!I4E-.9$I(56QJ
M4V%L2CA%;S-3;C%+>$5S35,Q3DQM:W9I5$-P36-K>39444I.4VLR5%1D>$]*
M535U5')D4$%%.4H-"E0U3E S5D%N54A&474Q14=55D)2;3%(;55J1E-F1DQ(
M57A.5%@Q3W%5+UI546Q34%9.=%9+1E8Q5F-*5T0Q6F-6<6Q7.3%D158U2E@-
M"C1&9W972#%9>3%K85=7;%IU1F](5VQ:87!L<C%7,%9B;%9V;%A$5F-H;'I7
M6%-D9&5&,TI8:'!E8D8V.5AW.6995BMZ64%69U8R0W$-"EE0>&A4,D=I6696
M:5-72V-9=D)J43)/6%DK=&M11U-56D]L;%!75U-:961M4%=A4UIU:&Y05V54
M6BML;U R:5=A3WAP43)M86%F1G$-"E-'<69A=F1R5#)U;F$O.7-6,GEV8E%H
M=%E',C5B:$IU83(W16)X-79E1R]28T-T=VAN1&=C5'!X;%A(=V-K='EP;DU"
M8S$Q>G5(454-"F1(0C!Z2%5O9%E6,31862MD<'0R*TAD5V0W3C1%6&AU94UX
M-4MN;4IE960V4FYQ;&5W4C=9,W9#9D-&.&=8>FAF548Y;U@T0F9M2BL-"G=N
M.&IF-%(O-5E"2&=+:4)#;T9R9V,R0TU)2U-G=E-$5C1/-FA",D5G251J:%5E
M1G$T64]H;DM',31C-V@U*TE"26AP:4TV2DTT;5H-"FEF-DM:27)+:7I#3&QO
M=CAJ1T]->6\P>&I::4XO-#5M:G,V4$YO*V5K06%18G!$5VM4*U)Q2DE2:VYQ
M4S0U3DYK-V%524I32VQ04U8-"E@U6$IL:E-7;C5C2VPS5U@T2FA-;4QI6DI*
M;5%M9GEA84IR5FTP2V)R-7=C;DEM8SDU,6MN9$ME44HV=6YX,F9I-2\V;T=M
M9S)+1D@-"F]B86E*<4M7;W=A:F1Q4&UP1F%K>#95-'!A;6U'<6%,<'8R;F)Q
M9F=Q1DMO>$MK,W%A;7%(2W%0<7=+<F1A=G!R1GES,$LQ17)B:74-"DQA-FAR
M>&%V:3=!07-(5W<V<D9G<V1A>5,W3$-S>FEZ<G)1;'1*>3%%-U=+=&=',F5B
M8G=T,FDS-$QH6G5.1S53<FY#=6IU-G1B<W4-"G4V93A)8GEB=E)7.6HW-$MV
M;U,K+S<Y-G8O6$%C341S=U=F0C0X2F9W='9$5TU057A&2$5Z<U9,>&-J1U)S
M8D1X,$A(=CAG.7E,>DH-"D]S;35Y:FI+=#AS,GDW8DU.8WDQ>E183G1C-#)Z
M<F)03C@K-#!$;E%U=$4X,&(W4U Y3$(P,%14>'122C%-=E94=%A2,6Q85S).
M9&,-"C$K1%E:3FIO,E=Z6CAD<#(R=G9B9TYW1C-)<F1%3C)7,VAZ96]T.' S
M-B]G3G5#.3155&AZ3TI4-'1V:EDK4'(U2%!K+T]7135G,VT-"FQU8V8U-FYO
M375I.#958G P3W!B-G58<F-/=C<W26)T164R8S=I:G5T3SE!-SAZ=U=01&PX
M6$QX+R]+33AX;GIP+U$P.4U,,5506&4-"CEM,S(K+V5+*T)N-'%0:S0K8V8V
M5B]R;BLS9CA"+WE9+U-N.75V-4PO='HO8F8O+R\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44$-"D)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&8-
M"DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8-"DAX.&9(>#AF2'@X
M9DAX.&9(>#AF+SA!04519T%D045!07=%4D%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!448-"D%W24=!44%(0T%K2T-W14%!9TE$05%%
M0D%114%!04%!04%!04%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$
M0D%)1T%N34(-"D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0E5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%4-"EI(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]013%/5#!:6%=&;&%7
M,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95@-"G W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;RM#:S535FQP95EM6G%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R
M839V;U)!04E#05%)1$)1544-"D)1645#04U$8E%%04%H141"0T53355%1E52
M3FA)9UIX9UI%>6]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,
M0T(S4%,-"DYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<# K
M4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<-"C%U8C)2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM$;$I75VPU:5IM<'5C
M;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V$-"D%!=T1!44%#15%-4D%$.$$Y
M531Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M;#D-"GHU:#!#,75H85A/<%<P1C!D=E)K;5)8<65L5DIQ2S563%!J:6%-9T0W
M,TIX-DQ.3U!&1T5J2'9!2UE!9VEO,T(V2$Q81V1I<5A7=74-"C)L,W)&>G!L
M<T=L97E65&1Z0VYP;S<O6FER,V5L4V9$-3542$U*5$U2,#4O<6-R2G!*47A2
M>5,R12M1-FYZ.7E9-6,T<G-69&ER<U8-"F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%895I,=39S
M+TPR<%AD<B]V5$(-"F)3>5%K8C!:54I"<#=D8W Q16I(2$EJ;4%82S!/3TTX
M.$EY*VMY05!Z9DU5:VIY3S!K:D8U2$I:,UDQ2DHS2DI/8U548C8T04%+2$H-
M"C=R*U1T+V989FQ)<F1->G)A,T1W5S=T=6940TEW6&9S<%EG9F0R>G%/>5IY
M;&DS-D=N>G(R;7=W:'%B:B]&1WHW-TM*+TU,>G%D1'0-"D5S3E O938U9F9"
M8E)Q3U)J1$AJ-FA(:EA:0C-0>7EE=C%N:$1H:CEC=516,DPR6"M9;'AZ,G=W
M-2MF;"MT3F9*,VPT849O8TYO-34-"C-K:$TY.4U457902G4U2E!7;E0V378P
M;41W;T%D95HY-V@Y<#8S.'AM36@Y23)I3S9)-4HS;5,V.3)+=7A6,DMU>%8R
M2W5X5C)+<TH-"B].=GIB<69L<GDQ2%!P:D-/.74U,6=367%'.4YE3$]Z04U#
M2R]$5&-946=V1G8X06QA+S5H9CA!5C5K+S5&=R\X,%EA4F)V*U9R+VT-"D8O
M,65:4#A!:UA$+T%-,%DP='-O+TQ0>G@U.3%Z>FI:5V1Z9GDS5FE/8C-I8TEW
M;VI61V]72W%+9D94=FE1:TUS+TYU9GHQ;SA3-C,-"F]7<%-P<&]!4SET5E-.
M=E-B;W-G2E5N:3-1*T(K97=#;$EF>7DO3B]56CE56%-F33%Y2F\W;VAB4SE:
M55%P251S:FQ1;S1T,E!9*S,-"E))548W5&=3.$TO368X-$Y53W1'>#AS,VYO
M5V1M4VMT,&=2+U=K-DYX3$)H=UAO0T]V6'!42D%)=&U(-510-3(Q3WIB5R]-
M1V]Y>3(-"FMW-#)&;WEX<GE(95IU2W%A9&PK+W=!34)5354O3E@X>2].5VTK
M8EHY2C!Q-TYL8E=34FAU0TEZ4U!*1W-P66PQ8F](<%%9449,1'8-"BM6<B]!
M2FAF.5AM5"]K6$0O=T$P63!I,V8X<E@O34PO04MV36XO275(+VUJ1VQT-T(K
M5&UT95IT6C!/-W8Y8FYE-%9P*T9N3$EQ<%8-"E98-"M014Q58W1Q*T]!<$1'
M9GIE+TU8>E!P2&U.3DHP:34K<'=1=W!*239O:D\W>59/-6-.44%D:&E!<%HW
M*U=7<F%H<3-K:E1D43$-"D=9,T8U4#8O<7I-04,S0S1K4F1L04=Y<4)I56AL
M1T)71R]M>#5R,4QY,3571C-P<%9,>35U171O-6U!8C K4T\U64LQ45133VTK
M14D-"DQ%=GE:.#9E6CEE,3(K='17=C-U-%ER6#%),%I55VIE;V]R.$MR,D]*
M54DO.#!.5C@V84)Q160U<"MO>4IP5C,X2V]%:DEI;%5B<%4-"G%44F@X42MN
M3D@R;&QZ67!C55IE:W999&=A9E-A;4)H3T$X4U!V,TAF>BM#<BM74#5H,V5R
M,T5M:F$S2W-T,#9L<E-C<7%M44%F2$<-"G=5045G8FIB<%A*9&TV.#5$=U0U
M.4=(8C-9<V-%4FQW:6\Y4C-D>%(Y-RM44&Q7-79M=55K=4QA2C(U3F)236Y!
M5C-)6&MR1E(W6EH-"E!S:D5:6'502GAS6'12<5EW-%-)>5!E8G8W,#,Q<E9D
M1#AJ*U=L5T-.55-)1T]X=$%F:6MK3RLU-CED,F(K3UI'8DQ$5%ET=F=(0S -
M"G5N>F1O86IC,V4X:C-$.&-G=V8X<V1*=F9-4&U+-3@R87543#9,;C!#=S)A
M8VHY:V9Y>$PP2&)B=WI79&TT<%IC:'EZ-F9F*W@V1'0-"C=543 R0T]M>&)7
M3B]W0W(O=T%E4#95-B]/5'IL<EAL>E,W1DY*:T5%.3E)-G9C1E%Z2W-953!5
M34-T5S5D8S9%4$5&1"]K<#5P,2\-"E@W6%9N,64X83=A,V5%46QL4F5)65!Y
M*WE&-C!X2VAK;FXO>C%:955D2U<T:U0Q-S(T2E-Y=&$P-4UO*TIM4%I6<4LT
M9TIE139N*V$-"G9N,U4W:FM.4VMT9W@O9'=79T53:7998V9J8B]!1U)/1VU.
M<4YL*UHS;C)Y;35P<D4W:TAD2C942V99:5%.:E,R.64O3$@X,')J>E0-"D\K
M;3,Y;#9D+T1'6E1C=T%M0FQ"02M)16MO,B]I469B05%K1DMR>E@O37AV:'%0
M-E%K=#1V5&UK:TIQ3&5+84Y*;5<P-$(K2EE.0T4-"DEA3W)F1E)G,T59<3E9
M:5IM:5)M6&EZ2T-Y*T))-EE%<G-695=F.$%/468O04-J3VYF.$%-8B]Z2V9#
M149I+S5$439F3'$K<4,Y4T8-"C%&=6Y!5$)32S@K,TQ#5D0R:C9L-5HO-5HW
M3"]!24-,*VU24VER2TQ466=Y,E-1;T1U-G=H4CE*-#1Q<E1W43-%16M%-DQ,
M1$MP4U<-"DYH5E=6:%%G9SEI359F32\U;651<"]+=7-K=V=V<$8R4S%L2V0K
M4&-X368U;#=E22MN2D%S4VU&>"MC3W1Z95-6,$4X=C!I9C-%=7 -"F-V:6$R
M06]"-"MO9G-L=D0S3TY*=$0O;%HK6#AN;6I69G).-&A':3)403-,9%!69G%)
M5E!V*S!2,$AZ1TI+02MK;S0T-#0Q:FI52D<-"F=#;VEI9T%'=T%!-UI&:RM:
M+WII+W=$2FHV=B]!3D<O+U5,1FMG>$PR4#A!3'$P,$(O2D=J=%!$871-8F-C
M,FM737-453EA:75!<%H-"D@Y4SAS+SA!3%!:9CA"1B]406Q-62]4.4YF4W V
M9%!G-# T,#EQ67$K9&9Z>"\U5#)8+VU(:"]58VM%1C9Z*U1V+VMU3DDO-D]0
M.$$-"G%+;'=&47I006PU;B]W035!9CA!2T<R9B]B4FDO=T-413)%24Q%=BMC
M9E K56TQ2"]M0R\U;7!H2V@W4C5G,$\P,7I33&I48F]F=34-"C%O<C!Q56-B
M<38K-$]9*V9#37-$13E83#!7<FQP.&]Y4C5J-V9*.#185G1Q96=A,CA,:W=A
M:' X=V\V.6U1,59L<C%",DDY<S0K55H-"EEP,7EL179Q94]E4%4T8D<X2F@W
M-6]V;FI3<C-Y;4YF=5I&9VIH5VPV;E5P2W5X441V>4I(2#5J3W%W-C)%<UAI
M2&%U9G9F3CE6,E0-"FMX-FYW26EY9G X>#,O<F5-835R3W(K9&9-,%-O<#54
M=4E,0S%R.$UA13DO*TI/,SA--7I.;6YQ8W9V,D%E.#!M;'AA1%1M*V=U4C<-
M"B]W061!.3@P2%)R6%)D271T3G1H*S=T,$-L=6AD:G5Z;C-:=#@V<D)H1T]!
M:4]J-79R3E9,4&QL:VQZ:V9W2&PS+T]22"LX96@O.$$-"D=3-"\T:DAL=V-5
M=2]W0V-D+SA!95!84"M-;'8O=T%2:WA+:$IV.$%N24U82"M*=$],5BMR1WE(
M<"M(4#%8-2]H>'=H4W4O2C-Z=C4-"E P0S!U3%165BMQ6#@X=DID44M&=S!:
M54)9>7EH;5AI450P<'9I46]E<E-W*U)F3CEU56(V;'%Y.6%O>5!)=BMY52MO
M;C1:1DM-.'8-"BM6=$$X=E<X:T=J,F%7:V-P-5-K1FY::4]N2C-,36%D=#A6
M5D@X=6%&2F9F6#-S65=U*U%K37!58G5V4GE/:%ED;7!81E5X>%8R2W8-"DQ0
M.$%N25 O04I2;E1V.$%M3B\U;%!H0T,X5S!B>3ER5W13>5)A5EIY6&MK2VAP
M1FI!2E9384%M=5-1;3,O2W,O4&XO049:3&XW:"\-"EA"83 Y62]*5'E8<FUG
M439J96%T06)6-WHP:V=G66=V>&HU17-W0DY+;'1H9TM1.4]W2EE&*V,R=&%&
M6F55<')(54EX8UA6.3A.:$(-"E=J3$EV*S=Q.6A(6#9E;F,T46=V;D1*2694
M2#53-C%O5V]E54Q7,S!U3F)A4WA54EAL<E=R3$MD>DE4,T5H<3%F;S=:17!$
M3DU#6'H-"DXK8U@O:W@Y6"\V3B]W1'%&:7E166Q+-TAY1C5X=C=32SAS.4IN
M;G1:,3524W%">%IF16(T,G%*:B],1'HY239O3D9N0EDP0F)I;RL-"FML9T)J
M83 K:V9+*VQZ-E8U8S S5%HR5G W4S)J:&Q:3C$U2V]"<%AT6$ES;F<S-30O
M.$%+97DO.'<X4#9J:V=G=E=F>60O.&QX<$@-"B]2>"\Q1E,T0V]:;F=3.'HO
M=T-C9U X06Q$8E O=&]X9CAM2G-)45=*9CA!3U!N+T%#:S)O+SA!348O>DY4
M0U9$,VY)<&5(+T%*>E@-"C)M6$AM84M',E%F5S=714IE>D0Y<&HX4TEF9$90
M6#-P,GIM93$U>$]7:'I!,V91=EIF1FMJ<'E:2#!Y4'!(,VXT+VIM>'!F3"]M
M0F8-"DMS;7)H6%A2,VY25U-P05IL0E9:4W94:4,S2&PT;DU0=TUN:&-F.$%"
M9C1,=%1R34(Q27AF-5AH+T$O5%-C9FQ0<65M,DAM,DPV-F<-"C582TY"8E1N
M<$A+-490.$%G=G,O5&U2,EAK:DA,-G5U=V-(,FDP*U1*<&IW9G=M>4\X9G,U
M=F9C-G X,F50.$$O3U)(*SAE:"]W1$<-"E,T+S1J2&A#0S<O;DAF.$$S:C%Z
M+VI*8B]W1$5:35-O6B\U,3AK-E@U<S!X8D\X2FEM:$IE,75K04QX<U)1-TAQ
M<"]A6'9G=$QX3%<-"G9Y5#@W864W1S%H:C%+059):W0S06%N=DA*=V%V<W1C
M;&%+661E861R3VHS4W)E5S%X65A+;7%E;VIX4%5D,4I!4#!J0V@V,RM4+S4-
M"FUA<&9A:VYL,U=P:F1'6E=.:F1U87EC:U5S63-B.7%Q9VM%-R]/=5))4T,Y
M:W=*9&ER<U9E5V8X-4(O.&]Z<#,O36(O04UY;G=H0ED-"DXK5"]!2G4P3'DQ
M<5=O5#9V33!-9'A#:5)&56%3<D(V;C=)3T5Q2'%F+TLV=GDY+S5B<% K4D4S
M+TY/0VQT1V%0*V%F:WI73E-G,#(-"G=U,VMU-VML66M-36EG:TM73S=+0C!'
M3DIT4%!-1W9A9F]/:S-'<5@W.$QE0F$P2#)N62]:4D(S6FHP=TLK661D,6Y7
M=D]0;54S3&\-"C Q-61U27)3,51C271A2D=N>7(Q*UIY5$8V>&-F:V9:1'E3
M=&Y%5E!M4E Y24XS5VEV2U)V0E4O-W(R;T0T-SEY349P<#56-58X>38-"G0U
M3SAX0S921U8T5TU.+UI05F5A03!E3F@R645B2'-C2T@P+V\R<U='<S9:8C9L
M65-E<F$S2SAK8G5/>%9H,EI4<U)K5U0U>B]/3"\-"D%-;5!Q+SA!,&(O.5%S
M5U-$17924$I(-7)E4W1+.' V6G Q-V502&17,$E36D)$2W=$5DHV:%-$9TE4
M865F.$%+-G9Y.2\U8G!0.$$-"FM23B]Z5&I3,GE$>7HU=3!,>DQ"3E!P17I4
M4C(W0DI3>4Y(4FE+:C=11T),=WHX.&8K53EL+S5H-&8Q2$I"0EID*UA(-6XK
M5'1%.&T-"F%D<&5O,V)X6&QV-C-Q;W--:F=C-35(6#1L56HW3$1!471S;"]W
M0U8Q9FPW+W=!=#!N+TEI8B]M;D=L=$M0>C5N:FXX:F%D4$5A>'D-"C,X3&]E
M;%9A,VU)>$-L:3,O3U!N+TM486HO>D)F.'I5=VQ1.6DX,F5965!,*VA83W!3
M56%20G=T-'HK,TLR>4PO12LQ8WAD5FY'3$<-"EI(.$9Z*WIT1614;6IJ2$QR
M-41R*T\Y-'0U23AP6'9M+UA*8G$Y6FI9<$E:9%%U5'-89&IY.4Y4+TTS9G=(
M,%IZ96HP<W123S5F5#$-"DPS=F$S855.1FA%66985E)(9#4O1#=8=3AU;5=%
M=6UT<')W3#E284PP1$%"4E)(5&IX04A48D]P3T]*:G<Q-F54-3%(4$U:4$5"
M.60-"C-F;2MC9DYF;#(V.'4V-U!P.'!*5D1Z='!U;D]*:CA$9E!S9F9/4#%7
M;D]'6FEF9RMP9&YA,D]Q=VE9*TDW:C$O2&,Y<B],9GIC4$T-"D]H2THS<G%6
M;E-+-TAD='9G:R\R44<O=EA/:S=0,5AI=S,K;V,O,79!.75D;2]L<S-P+W4U
M8FHY22M(,TU,+S5Y22\S:C!0+T%)>5@-"D@O15DX,D%D25AF.#0W+S=X-C4O
M>&MT+RM)>5EL46YV-6AF;35B958Y4EA3-U,P1CEF2W%V8SAN-$I'1S-69&=3
M5TLW*S(S6$5"8E<-"C9$*V58;$,O:%5A:UI.2W5F,FMK5G!9-B]W0U1*1W!0
M+T)+36%7,'0O37(X>E!),F]E5C=R5&)346%P9#-+.%E&5TYW<U16,FQ,=7$-
M"C!+.75/+S!99TM3.#DO2T14<FDY."]A8UEG949R>G5*,U@Y;$519U8Y:7I+
M=C T4V=0<&Y)<VY9<3=&5TDO;58U2G5V3C)L5W1L8E@-"DM7<E<X+W)&-4%7
M0DA";'!T+W)9459E9&8Y0S@V>B\Q9')B+T%*1G9H=$9/+W=#:&5D6B\V=3%T
M+W=!:3-X=&%:2C5$+TIK*UAT8VD-"C%I+W8Q=7!B64XY6&AI47%V2FQ+.&U:
M:G9113=5=T5R4TXO36(X=F9-;FTV.6E#86Y$8F%88D%'0S%+=5-:0U!I:V5M
M>&)S4$%F330-"F=Q,RM84#555R]L83=M,4,Y;E,Y,45J:&)/<6Q6:5%J-&E+
M+W1.,'(T9E!%;&%E9S1%=E!0>D$O2TMZ.'I8=S%/>75266%G=T,S1E4-"C52
M>3!&07I524EA;3%D.7-)2TM6=GDT.&@K62]+33 X12MP43-E;#-!-4YB2W)H
M:VQ(4C!R='5.;3AF;WA*5DIV3R\U3C9N-6DX,%@-"G5S=S9J1$)&9&5L>&ED
M2$Q$,#15:DY33G1Y;&-15G!)=BMH961:+S9U,70O>4QF1&$P-R]!2T8U,6XO
M<3<R+R]!0TQF1S%P-EHK6"\-"D%*2'0O2T=K4U=A6$)U<FDT:SE7-&Y+.$%4
M44M&5F%T44%$>"]P9TI3>&8X=U!Y:C%(>E U:69664PK1S-J84M/4# U15ET
M5D)3=%(-"FE#:6U.+SA!479/<R]W1%8R='8K4F(T8E=K4EDO=T1/4$XS.6%J
M3CEQ.&8Q545'4EE9,C5S3S1"66=#=FIV.$%,0F$P>C<X>%!*33,-"FUJ>3EA
M-E1:>G@R;C%A-%-:5V-&;#12>'9(>$90.69%1DM$+T%#,R]!0WEJ.&]08S-5
M,3,Y8W9R;%)(>5)3:4I'1'E)04I*2DQ$<FD-"E-I;4TK9%HW-WIR-7EI.'4V
M5S%B3%1Y4E!.,5)8-E-Y3E0K5#=#*R]Z>FYT6DM7<'I$2$AL2#A%=F,Y;%%H
M;TY+8RM4-C4X:#$X:#@-"F5:+UDY43!04F)$4F1-:# V>%1H0D-/<"LP-T@W
M5'-E-5DU=3A/1T]/26I(:TAK3EAQ<#4X:'E43S4O1DDO3%A'67HU-#AJ,F9M
M;3 -"FE2<&9Q,35B:VU#-4,X.6HY<$=&5G%P*V4R65=T,%%Z9V1#3W)T=7EE
M,7!A3U).8U5:8W@K;&IV;$0X<W1F.$%,;71X86A&<6-,>&8-"EEU;T%R:C%)
M;39J-6IQ4&9-4%-D;EI-37A)4TAM-U1T3'0W1'%S2F=94W9O9'1I;5@U;2M1
M3'IZ:$)P.&1T9'@R<',R:UIJ27).>3D-"E%+0E1J+W$U=6=8;$-I=GDW.&=W
M*U0Y3W5)4')2=3=Q-V18;FPT.$9!445+<7)6=6Q4=EA%;$M*.#,K45!,=FUQ
M141526I(9'AI:TX-"C=#47-Q:G=*24E:9EIH.'%9,G)Y+U50*V-E=&%342]O
M-U9B86%/=G<O5T9K:$Y09F=*<TYO<%I9+W=$3U!F;4(U44PO049/,&AI<G4-
M"C!!:VUA;GED65(K3TYR5#%8>6(U1S!4>7!:3D)P-FPU-7%'-74U2T=346IO
M3G5I:G-O>4YP6D1I<G-69&ER<U9D:7)S5F1I<G-69&D-"G)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U931'IP<F1Z<'5K*VQP-FU85CE18C9R<#!3+V%-
M:FID+VMI+T95-V5/66US>D=%2VH-"CEC=&<W3'-V4WAY-6)N=&EH-G!(>3=V
M:GE7*U-V2T9T-6(P<U$Q170O4%(W,C4V;#,X051V>%AT.2]F2%(V55E9,2]%
M95I4,G(R;$P-"E9:3#512#!J.&17435L=7-D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U8-"F1I
M<G-69&ER<U9D:7%K,7!B4&-P8W9%:EA%4VQ9-5-!5U97*S!&2C96-S!Y2FE,
M=G%Z1U-1:5EG*VLY1EA*34A9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T8-"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@-"EEQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T98+R\R43T]/"]X;7!'26UG.FEM86=E/@T*"0D)"0D\+W)D9CIL
M:3X-"@D)"0D\+W)D9CI!;'0^#0H)"0D\+WAM<#I4:'5M8FYA:6QS/@T*"0D)
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IB-3!A,C8X,BTU.60V+30R,&0M
M8C=F."TX93$X,&5F-60T8V,\+WAM<$U-.DEN<W1A;F-E240^#0H)"0D\>&UP
M34TZ1&]C=6UE;G1)1#YX;7 N9&ED.F(U,&$R-C@R+34Y9#8M-#(P9"UB-V8X
M+3AE,3@P968U9#1C8SPO>&UP34TZ1&]C=6UE;G1)1#X-"@D)"3QX;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U
M.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@T*"0D)/'AM
M<$U-.E)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^#0H)"0D\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@T*"0D)"3QS=%)E9CII;G-T86YC94E$/G5U:60Z8F1C,S)B
M,S<M-&$X82TQ-30Q+6$P-V8M.#)F9C$W9F,W-#$W/"]S=%)E9CII;G-T86YC
M94E$/@T*"0D)"3QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.3%F-S8Y9F(M
M838P."TT.#4Y+6%B-S<M.3(U960Q-CEC9CED/"]S=%)E9CID;V-U;65N=$E$
M/@T*"0D)"3QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR
M-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@T*"0D)"3QS=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP9&8\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@T*"0D)/"]X;7!-33I$97)I=F5D1G)O
M;3X-"@D)"3QX;7!-33I(:7-T;W)Y/@T*"0D)"3QR9&8Z4V5Q/@T*"0D)"0D\
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z9C1B.3AA,3<M,F8W,"TT-38W+6(U8S M968U
M,C0Q-F8R969D/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T.G=H
M96X^,C Q-RTP-2TR.%0R,CHS-3HP,BTP-SHP,#PO<W1%=G0Z=VAE;CX-"@D)
M"0D)"3QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-#
M(#(P,3<@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)
M"0D\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D
M9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M#0H)"0D)"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)
M"0D)"0D\<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F(U,&$R-C@R+34Y9#8M
M-#(P9"UB-V8X+3AE,3@P968U9#1C8SPO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)
M"0D)"3QS=$5V=#IW:&5N/C(P,3<M,#<M,314,C$Z-#,Z-#0M,#<Z,# \+W-T
M179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B!#0R R,#$W("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)/"]R9&8Z4V5Q/@T*"0D)/"]X;7!-
M33I(:7-T;W)Y/@T*"0D)/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R
M:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X-"@D)"3QP9&8Z4')O
M9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N,# \+W!D9CI0<F]D=6-E<CX-
M"@D)/"]R9&8Z1&5S8W)I<'1I;VX^#0H)/"]R9&8Z4D1&/@T*/"]X.GAM<&UE
M=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_>'!A
M8VME="!E;F0])W<G/S[_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M
M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>&_\%);V2P_8?^(3PMM9K".,_P"Z
M]Q$K#\037N5>(_\ !1[2YM8_8A^(D,*[G33EG/4_+'-'(W0?W5/^>:\/B:_]
MCXM1W]E4_P#26?3\$N*XBP#GM[>E?T]I$_%&BBBOX//]40HHHH **** "BBB
M@ HHHH **** )()VM9TEC9DDC8,K X*D<@BOZ#M(O_[5TFUNMGE_:(DEVYSM
MW '&?QK^?.RLY-1O(;>%?,FG<1HN1\S$X Y]Z_H.TRP72].M[92S+;Q+$I;J
M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
M"BBB@#A?VH/^3:?B)_V+.I?^DLM?SJ?-[5_17^U!_P FT_$3_L6=2_\ 266O
MYU/F]JVI&=0/F]J/F]J/F]J/F]JU,P^;VH^;VH^;VH^;VH /F]J/F]J/F]J/
MF]J /3?V*?\ D\CX2_\ 8Y:/_P"ET-?T,5_//^Q3_P GD?"7_L<M'_\ 2Z&O
MZ&*PJ;FM/8****S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^9?^"Q7_ "CC^(W_ '#?_3G:5]-5\R_\%BO^4<?Q&_[AO_ISM*J.Z _#3YO:
MCYO:CYO:CYO:NDYP^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O_
M "6/PE_V&;/_ -'I7,?-[5T_P5_Y+'X2_P"PS9_^CTI ?T?4445RG0%%%% !
M1110 5S'QA^%&D?'#X8ZUX3UR$S:7K=N;>7;]Z(]4D7T9&"L#ZJ*Z>BLZU&%
M:G*E55XR333V:>C3]3;#8FKAZT<10DXSBTTUNFG=->:>I^"/QV^#6K_L^_%G
M6O".MIMOM'G,?F*,)<1D;HY5_P!ET*L/3.#R#7(U^JW_  5T_9"_X7)\*1X[
MT2U\SQ)X/@8W*1KE[ZP!+./=HLM(/]DR#DD"ORIK^)^..%ZF19I/"Z^SE[T'
MWB^GJMG]^S1_I=X8<=4N*<CIX[15H^[4CVFEJTNTOB7K;=,****^//T0****
M "BBB@ K[ _X)(?M??\ "E/BO_P@^M77E^&?&4ZK TC82ROSA4?V63 C;W$9
MX -?'].1VC<,I*LIR"#R#7L9!G6(RG'T\?AOB@]NC75/R:T_X)\[Q7PUA,_R
MJME.-7NU%:_6+WC)><79^>ST9_0U17S;_P $S?VO1^U!\#8[35+GS/%_A54L
M]3W'Y[M,$17/_ P"&_VU8\ @5])5_<63YKA\RP=/'85WA-77EW3\T]'YH_S"
MXAR'%Y+F-;*\=&U2E)I]GV:\I*S7DT%%%%>D>,%%%% !1110 4444 %%%% !
M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
MV2,2JRLH96&"".M?CA_P4I_9%;]EOXZS3:7:F/P?XG+WNDE1\EJ<_O;7/_3-
MB-H_N,G)(-?LC7E?[8O[--A^U9\"]5\+W7DPZAM^U:5=.,_9+M =C9[*V2C8
M_A=N^*^#\0N$XY[E;ITU^^IWE!^?6/I):>MGT/U3PAX^EPMGD:M9_P"SU;0J
MKLKZ3]8/7ORN26Y^&]%:'BKPOJ'@GQ+J&CZK:RV6I:7<26MU;R##0R(Q5E/T
M(-9]?QC.,H2<9*S6Y_I%3J1G%3@[IZIK9I]4%%%%24%%%% !1110!Z=^R)^T
MEJ'[*OQRTGQ59^;-9QM]GU.T1L?;;1R/,3ZC 9<]&1?>OV\\(^+-/\=>%M/U
MK2;J.^TO5K>.[M+B/[LL3J&5O7D'H>17\^M?H1_P1F_:^^SW$WPEUZZ_=R&2
M\\/22-]UN6FM1]?FD7W$@[J*_;/!_C#ZGB_['Q,OW=5^XWTGV]);>J7=G\T_
M2(\/?[1P"XBP4?WU!6FEO*GW]8/7_"W?9(_12BBBOZ@/X="BBB@ HHHH ***
M* "BBB@ HHHH ***^>_^"@W[;=C^R'\,=EC)#<^--<1H])M2 P@'1KF0?W$[
M _?; Y <KY^:YIALNPD\;BY<L(*[?Z+NV]$NK/6R'(\;G&/I9;E\.:K4=DOS
M;?1):M]$FSR?_@JQ^WW_ ,*IT*X^''@^^V^)]4AVZM=PM\VE6[C_ %:MVFD4
M]1RBG/!92/R_J[XA\07WBS7;S5-2NI[[4-0F:XN;B9]TDTC'+,Q[DG-4J_BW
MB_BK$Y]CWBZVD5I"/2,?\WNWU?DDE_I1X>\"8/A3*8Y?AO>F]:D[:SEW]%M%
M=%YMME%%%?*GW04444 365E-J5Y#;V\4DUQ<.(XXT7<TC$X"@=R20,5^UW[!
MO[,,/[*O[/>EZ)+%'_;^H8U#6I5Y+W+@93/]V-=J#'!VEL L:^%?^"/7[*O_
M  M;XOR^/=7M?,T'P9(#9AURMUJ!&4Z]?*4^9V(8Q=>17ZI5_2?@OPK[*A+.
M\0O>G>,/*/VI?-JR\D^C/XQ^DEQY]8Q,.&,)+W:=IU;=9->['_MU/F:[M=8A
M1117[R?RJ%%%% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?
M\HX_B-_W#?\ TYVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 '
MS>U'S>U'S>U'S>U !\WM73_!7_DL?A+_ +#-G_Z/2N8^;VKI_@K_ ,EC\)?]
MAFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH **** .7^-/Q6TWX&_";Q%XPU=O^)?
MX=L);Z50<-+L4E8U_P!IVPH]V%?SQ_%GXG:M\:?B;KOBS7)O/U;Q!>R7MRPS
MM5G;.U1V51A5'90!VK]0/^"_7Q[;PM\&?"_P]LYMMQXKO&U&_"M_RZVV-B,/
M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\ 8S7W
M_HUJ\@^;VKJCL<X?-[4?-[4?-[4?-[4P#YO:CYO:CYO:CYO:@ ^;VH^;VH^;
MVH^;VH _H%_X)^_\F0_"K_L6+'_T2M>P5^/?P._X+A>*O@?\'O#7@^U\#>'[
MZV\-:=#IT5Q+=S+),L:A0S < G':NJ_XB%_&7_1._#/_ (&S_P"%<_(S521^
MK5%?E+_Q$+^,O^B=^&?_  -G_P */^(A?QE_T3OPS_X&S_X4N1CYD?JU17Y2
M_P#$0OXR_P"B=^&?_ V?_"C_ (B%_&7_ $3OPS_X&S_X4<C#F1^K5%?E+_Q$
M+^,O^B=^&?\ P-G_ ,*/^(A?QE_T3OPS_P"!L_\ A1R,.9'ZM45^4O\ Q$+^
M,O\ HG?AG_P-G_PH_P"(A?QE_P!$[\,_^!L_^%'(PYD?JU17Y2_\1"_C+_HG
M?AG_ ,#9_P#"C_B(7\9?]$[\,_\ @;/_ (4<C#F1^K5%?E+_ ,1"_C+_ *)W
MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
M3G:5]-5\R_\ !8K_ )1Q_$;_ +AO_ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^
M;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O\ R6/PE_V&;/\ ]'I7
M,?-[5T_P5_Y+'X2_[#-G_P"CTI ?T?4445RG0%%%% !1110 4444 %?F3_P7
M(_89D%Q_PNCPS:;D<1VOB>"-?ND82&\QZ8VQOZ8C..6(_3:JFN:)9^)M%N]-
MU"UAO;"_A>WN;>9 \<\;@JR,#P002"#ZU496=Q-7/YI?F]J/F]J^JO\ @II_
MP3BU/]C?QW+K>AV]Q??#C69S]@NLF1M,D;G[+,>V.=C'[RCJ6#5\J_-[5T)W
MV,-@^;VH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4
M?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4
M?-[4 'S>U'S>U'S>U'S>U !\WM7HGP-_:T^)'[-M\LW@OQAK&BQJVYK1)?-L
MY#U^:!]T3'W*YYKSOYO:CYO:EN!^E_[-7_!?UU:WT[XK>%U9>$.LZ$,$=!F2
MV<_B61Q[)VK[^^!_[2'@;]I#PTNJ^"?$VF:_:[09$@DVW%MGM+"V)(S[.HK^
M=+YO:M?P)X_USX8>*+76_#NK:AHFK63;H+NRG:&:/U^92#@]".A'!S6<J:Z%
MJ;/Z3J*_,']C/_@NW=64EKH/QEL_M4/$:>)-.@"R)SUN;=1AA_M1 $ ?<8DD
M?I1X&\>:+\3?"EGKGA[5+'6='U"/S+>[M)A+%*OL1W'0@\@@@@$5G*+6YHI)
MFM1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y^?^"@?_ ">Y\5?^
MQFOO_1K5Y!\WM7K_ /P4#_Y/<^*O_8S7W_HUJ\@^;VKJCL<X?-[4?-[4?-[4
M?-[4P#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO
M:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO
M:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^
M;VK]I_\ @A["T?[!FFLRLJR:Q?,I(^\-X&1Z\@C\*_%CYO:OWT_X)M_"6;X*
M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !63X\\"Z3\3?!FJ>']>L8=2
MT?6+=[6[MI1E9HV&"/4'N",$$ C! -:U>0_ML?M>Z'^QA\$;[Q1JGEW6I2YM
MM'TW?M?4;H@E5]0B_>=NRCNQ4$ _%W]O3]DR;]C3]HG4O"/VZ/4=-DC6_P!+
MG\Q3,UI(6""51]V12K*> &V[@ & KQKYO:N@^*WQ2USXU_$35O%7B2^DU+6M
M:N#<7,S^IX"J/X550%51PJJ .E<_\WM74CG#YO:CYO:CYO:CYO:F ?-[4?-[
M4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM3[6W:\N8X4V[Y6"+N8*N2<#). ![D
M@"F?-[4?-[4 ?NW_ ,$W_P!AO3/V+?@I##)]EO?&'B!$NM;U"+#*6QE;>)N\
M4>3@_P 3%FXR /HJOSK_ ."+W_!1#_A-=)M?@_XTOLZQI\6WPU>S/S>P*,FT
M8G_EI&H)0_Q("O!0;OT4KFE>^IM';0****DH**** "BBB@ HHHH **** "BB
MB@ HHHH **** "OS?_X.(?\ D3/A;_U^:C_Z!;U^D%?F_P#\'$/_ ")GPM_Z
M_-1_] MZJ.Y,MC\NOF]J/F]J/F]J/F]JZ3$/F]J/F]J/F]J/F]J #YO:CYO:
MCYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:
M@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;
MVH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#[3_P""#O\ R>Y=
M_P#8LWG_ *-MZ_9*ORS_ .#>WX4SW?Q!\?>.)(RMK8:?%H<$A'$KS2":0#W4
M019_ZZ+ZFOU,KGJ;FT-@HHHJ"@HHHH **** "BBB@#A?VH/^3:?B)_V+.I?^
MDLM?SJ?-[5_17^U!_P FT_$3_L6=2_\ 266OYU/F]JVI&=0/F]J/F]J/F]J/
MF]JU,P^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J /3?V*?\ D\CX2_\ 8Y:/
M_P"ET-?T,5_//^Q3_P GD?"7_L<M'_\ 2Z&OZ&*PJ;FM/8****S+"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^9?^"Q7_ "CC^(W_ '#?_3G:
M5]-5\R_\%BO^4<?Q&_[AO_ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^;VH^;VH
M^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O_ "6/PE_V&;/_ -'I7,?-[5T_
MP5_Y+'X2_P"PS9_^CTI ?T?4445RG0%%%% !1110 4444 %%%% !1110 444
M4 %%%% 'RK_P5<_91M_CQ\!KCQ-8I#'XD\#P2WT<C$+]IM -T\).>P7>N>ZD
M#&\FOR-K]-/^"SG[59\&^!;/X8Z/<;=2\1*+O5V1OF@LU;Y(CZ&5UR><[8R"
M"'K\RZ_D?Q@KX&IG[6$7OQBE4:V<NGS4;)OY;IW_ - OH[X7-*/"D98]_NY3
MDZ2>ZAU^3ES.*MMK=IJQ1117Y6?NP4444 %%%% !1110 4444 %%%% !1110
M 4444 ?H%_P1*_9QL]5OM;^)VH-;7%QILK:1I4(=6:VD9%::9AU5BCJB].'D
MXP0:_1JOQO\ ^":O[7K?LL_'**'5+CR_"'B@I9:J&/R6C9Q%=?\ ;,DAO]AG
MX)"U^QT<@E565@RL,@CO7]<>#^/P-;(8X?"KEG3;YUU<GJI>C6B[6MT/\_?I
M#97F>'XJEB\<^:G5BO9/HHQ23AZQ=V^_,I:<UAU%%%?JA^$A1110 4444 %%
M%% !1110 4444 %%%% !7S+_ ,%BO^4<?Q&_[AO_ *<[2OIJOF7_ (+%?\HX
M_B-_W#?_ $YVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 'S>U
M'S>U'S>U'S>U !\WM73_  5_Y+'X2_[#-G_Z/2N8^;VKI_@K_P EC\)?]AFS
M_P#1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@#)\<^!M'^)OA#4- U_3[75
MM&U:%K>[M+A-T<R'J".Q'!!'((!!! -?C[_P44_X)*^(/V7[N]\6>"8;SQ%\
M/F+2RA09+S0AG.V4#EX0.DHZ '?MP&;]F*&4.N#R#U'K51DT3*-S^9KYO:CY
MO:OU]_;=_P""*7A7XVSWGB+X;R6?@OQ-)NEET\H1I-^_7[JC-NQ]4!3C[@)+
M5^7/QU_9O\;_ +-/BQM%\;>'=0T.[R?)>5-UO=@=6BE7*2+[J3CH<'BMHR3,
MW%HXCYO:CYO:CYO:CYO:K)#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]
MJ/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]
MJ/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J]C_ &/_ -N3QS^Q
M?XR^W^&;[[1I-RX.HZ+=,6LK]?4K_!(!TD7!'?<N5/CGS>U'S>U+<#^@;]CO
M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
MQ)^'>K?"3Q]JWAO7+9K35M%N6M;F/G&Y>C*>ZL,,I[J0>]8=?I?_ ,%D?V0?
M^$Q\*Q?%+0;7=JFAQ"WUR.-.;BT'W)SCJT1.">?D8<@1U^:%?Q+QEPS5R/,Y
MX*>L=X/O%[?-;/S3Z'^FGASQK0XHR2EF5.RG\-2*^S-;KT>DH^376X4445\J
M?=!1110 4444 %?=G_!&_P#; _X0_P 5R?"W7KK;IFMR&?0Y)&XM[L\O!ST6
M4#*C^^",$R5\)U8TO5+G0]3M[VSGFM;RSE6>":)BKPR*0RLI'(((!![$5[W#
M.?U\FS&GCZ'V7JOYHO=/U6W9V?0^5XUX3PO$F3ULIQ6TU[LNL9KX9+T>_=76
MS/Z%**\4_8-_:KM_VL_@-8ZS(\2>(M-Q8ZU N!LN% _> =DD&&'8'<O.TU[7
M7]PY;F%#'86&,PSO":33\G^JV:Z,_P P\XRG%97CJN78V/+4IR<9+S7;NGNG
MU5F%%%%=IYH4444 %%%% !7S+_P6*_Y1Q_$;_N&_^G.TKZ:KYE_X+%?\HX_B
M-_W#?_3G:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0 ?-[4?-[
M4?-[4?-[4 'S>U=/\%?^2Q^$O^PS9_\ H]*YCYO:NG^"O_)8_"7_ &&;/_T>
ME(#^CZBBBN4Z HHHH **** "L3XC_$/1_A+X$U;Q)X@OHM.T71;9[J[N).D:
M*.PZECP HY)( R2!6W7Y'?\ !:3]OG_A</CA_A7X5O=WA?PW<;M8N(7^74[Y
M"1Y>1UCA.1Z-)DX.Q#51C=BE*R/FC]MK]K?6/VS/CMJ'BO4?-M=-3_1='T]F
MRNGVBDE$XX+MDLY[LQ[!0/(OF]J/F]J/F]JZ%H8!\WM1\WM1\WM1\WM3 /F]
MJ/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#7\#_ ! UWX9^(8=6\.ZSJFA:I;_Z
MN[L+I[>9/8,A!P?3O7V/\ ?^"[/Q2^&R0V?C'3])\?:?'@&64?8;_'_76-2A
M_P"!1$GUKXA^;VH^;VI<J>XTVC]H_@W_ ,%N_@I\2HXH=:N]8\$WS\,FJ6;2
MVY;_ &98=XQ[N$Z=J^F/AS\<_!?Q>MUD\*^+/#GB)6&[&G:C%<,H]U5B5/L0
M"*_G$^;VI8)WMIHY(W:.2-@RLIPRD<@@^M9^S1?M&?TR45_/'X*_;*^+/P["
M+HOQ(\;6,,?W8!K$[0#H?]6S%.WI_6O2_#O_  5Z_:&\.A57X@37D2]4N]*L
MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
M\$^H?V0_AC_PD'B*UC;XA>)X%:\+ ,=)MSAEM%/][HTA'!8 <A 3\^?\$6/^
M"> N9;/XS>-+',<9W^%K&=/O,,@WS*?3I%[Y?LC5^G-85)=#2,>H4445F:!1
M110 4444 %%%% !1110!RGQM^#&@?M!_"[6/"'B:S6\T?6H##*O&^)NJ2H?X
M9$8!E/8@=>E?@I^UY^ROK_['WQLU+PAKBM)''_I&G7P7;'J5JQ(29?R(8?PL
MK#G&3_0M7@__  4%_8ETK]MKX)S:1)Y-IXHTG?<Z#J+C_CWF(&Z-CU\J0 *P
M[$*V"4 JHRL3*-S\$OF]J/F]JT_&_@K5?AQXOU+0=<L;C3=7TBX>UN[:9=KP
MR*<$'_$<$8(R"#69\WM708A\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO
M:CYO:CYO:CYO:@#] ?\ @C-_P41_X5;XAM_A-XTOMOAO6)B-!O9W^73+IS_Q
M[L3TBE;[O99#Z.2OZR5_,TK;3D<$<@CM7[$?\$@O^"B/_#1W@I/A_P"+[X-X
MZ\.V_P#HEQ,WS:W9H -V3]Z:,8#CJRX?GYR,:D>J-(RZ'V[11161H%%%% !1
M110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\ Z!;U
M4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U
M !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\W
MM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\W
MM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!W7[+W
M_)ROP[_[&;3?_2J*OZ*Z_G4_9>_Y.5^'?_8S:;_Z515_176%0TIA11169H%%
M%% !1110!PO[4'_)M/Q$_P"Q9U+_ -)9:_G4^;VK^BO]J#_DVGXB?]BSJ7_I
M++7\ZGS>U;4C.H'S>U'S>U'S>U'S>U:F8?-[4?-[4?-[4?-[4 'S>U'S>U'S
M>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !
M\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1
M\WM1\WM0 ?-[4?-[4?-[4?-[4 ?J+_P;O?\ (F?%+_K\T[_T"XK](*_.7_@W
MBL)(_AY\3KH[?+FU&QB7GG*13$_^AC]:_1JN:I\1M'8****DH*^9?^"Q7_*.
M/XC?]PW_ -.=I7TU7S+_ ,%BO^4<?Q&_[AO_ *<[2JCN@/PT^;VH^;VH^;VH
M^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@K_R6/PE_P!A
MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
M4444 %%%% !1110 5^7'_!9#]JG_ (61\5+?X=:3<%M%\(R>9J)1OEN;\C&T
M]CY2$KGLSR#L*^ZOVW/VF+?]E;]G[5O$?F1MK$R_8M&@?!\Z[<'8<=U0 NP[
MA".I%?B1J>I7&M:E<7EY-+<W5W*TT\TC%GE=B2S,3R2222?4U^$^,_%7L,/'
M),._>J>]/RC?1?\ ;SU?DNS/ZF^C;P)]9Q<^)L7'W*5XT[]9M>]+_MU.R\V^
ML2O1117\TG]I!1110 5]0?\ !-;]A2;]J7Q[_;VO6[1^!/#\Z_:MV5_M2888
M6RG^[T+D=%('5@1YK^Q_^RGK7[7/Q=MO#VF[K738,3ZMJ)7*:?;YY/N[?=1>
M['G"AF'[3?"[X9:+\&_ 6F>&?#ME'I^CZ1"(;>%>3CJ68]69B2S,>222>M?K
MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
M4444 8/Q0\*WWCKX<ZYHNEZU=>'=1U2QFM;;4[9 \UA(Z%5E4'NI.>H/H0<$
M?S\_M+_LS^+OV5/BC>>%_%U@]O=0L6M[I 6MM1B[30N1\RG\U.0P# @?T25Y
MG^U5^R;X/_; ^&DGAOQ;8^8(]TEA?0_+=:9,1CS(F_+*G*L ,@X&*C*Q,HW/
MYYOF]J/F]J]H_;/_ &%_&G[%'CIM/\06YOM#O)&&EZW;H?LM^O4 _P#/.4#[
MT9.00<%EPQ\7^;VKH1B'S>U'S>U'S>U'S>U, ^;VH^;VH^;VH^;VH /F]J/F
M]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F
M]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:C
MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:O3OV/OV8=
M8_:[^/6B^#=*62.&Z?S]2O%3<NGV:$>;,>V0"%4' 9V1>,UP/A+PGJ?CSQ-8
MZ+HMC=:GJVIS+;VMK;QF26>1C@*H'4FOW+_X)O?L)V/[$OP<%O=?9[SQIKP2
MXUR]C&55@/EMHSU\N/)Y_B8LW (41.5D5&-SW+P!X$TOX8>"-)\.Z):I9:1H
M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
MKYE_X+%?\HX_B-_W#?\ TYVE?35?,O\ P6*_Y1Q_$;_N&_\ ISM*J.Z _#3Y
MO:CYO:CYO:CYO:NDYP^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:O:_^
M"<?PTF^*_P"W!\-=,CC:2.VUJ'5)_ERHBM3]I?=VP1%M]]P'4BO%/F]J_4O_
M ((-_LCS>%_#>K?%S6K5HY]<B;2]!61>?LP<&><#_;D144\'$;]0PJ92LBHZ
ML_1JBBBN8V"BBB@ HHHH ***^<?^"FO[57_#-'[/5S#IMRT/BCQ9OT[2RC;7
MMUP/.N!W&Q& !'1W0]C7FYOFE#+<%4QV)=H4TV_T2\V[)>;/8X?R/%9SF5'*
M\&KU*LE%>7=ORBKM^29\&_\ !4[]JK_AHC]H*;2=,N/,\+^#"]A9[&RES/D>
M?/[Y90B\D;8P1C<:^8Z**_AG.LVKYGCJF/Q+]Z;OZ=DO)*R7DC_43AO(,+DF
M64<JP:M"E%)>;ZR?G)W;\VPHHHKRSW KHOA3\+=;^-/Q!TOPSX=LVOM6U:80
MPQCA5[EV/\**,LS'@ $UAV%A/JE]#;6T,UQ=7$BQ111(7DE=CA551R220 !R
M37Z]?\$W?V%(/V4_A]_;.N012^//$$*F];AO[,A.&%JC>O0N1P6  )"J3]KP
M/P=7X@QZHJZI1LYR[+LO[SZ?-]#\U\3_ !$PW"65/$RM*O.ZIP[OJWUY8[OO
MHKIL]*_9&_99T3]DOX1VOAW2U2XOI,3ZIJ&S$FH7&,%CW"#HJ] /<L3ZE117
M]FX' T,'0AA<-%1A!))+HE_7SW/\W\SS+%9ABJF.QDW.I4;E*3W;?]:+9+1:
M!11174<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YC_\ !8W]
MD+_A!O&D?Q0T*UVZ3XBE$.LI&O%M>8^68^BR@<G^^I)Y<5\-U^_GQ3^&FD_&
M+X=ZOX7UVW^U:3K5LUM<)T8 \AE/9E8!E/8J#7X>_M&? 36OV:?B]JWA+7(W
M\ZPD+6UP4*QW]N2?+G3_ &6 ]3@AE/*D5_*WBYP?_9^._M3#1_=5GK;:,^OR
MENO._D?W=]'WQ#6;Y9_8>-E^_P .ERWWG3V7SA\+\N7=W.%HHHK\</Z*"BBB
M@ HHHH *Z#X7?$O5O@Y\0M'\4:'<?9=5T6Y6YMWZJ2."K#NK*2K#N&([US]%
M:4:TZ4U5INTHM--;IK5-&.(P].O2E1K14HR333U33T::[-'[R?L[?'/2?VD/
M@]HWB[1SMM]4A!F@+;GLYUXDA8\<JP(S@9&"."*[BOR9_P""3G[7W_"A_C!_
MPB.M77E^%?&4RQAI'Q'8WW"QR\\!7XC8_P"X20$K]9J_M7@3BJ&>Y7'$O^)'
MW9KM)=?26Z^:Z'^:OBEP)4X5SR>#BG[&?O4GW@WLWWB_=??1]4%%%%?9GYN%
M%%% !7S+_P %BO\ E''\1O\ N&_^G.TKZ:KYE_X+%?\ *./XC?\ <-_].=I5
M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
MXS1_PX<^-W_/WX%_\&DO_P 9KHYD8\K/BSYO:CYO:OM/_APY\;O^?OP+_P"#
M27_XS1_PX<^-W_/WX%_\&DO_ ,9HYD'*SXL^;VH^;VK[Z\(?\&^?Q(O;]1KW
MC;P3IEJ<9>Q^U7L@]?D>*(?^/5]5_LT?\$6?A-\"KRWU+7H[KXA:U#AE?5HU
M6QC8=UM5RI^DK2#Z4O:(.5GPU_P3>_X)9Z]^U7XAL?%'BRTN]%^&]NXF,C@Q
MS:Y@Y\J#N(ST:7IC(7)R5_9G0="LO"^B6>FZ;:P6.GZ?"EM;6\"!(X(T 545
M1P%    Z 59@@2V@6.-5CCC4*B*,*H'  'I3ZQE)LTC&P4445)04444 %%%%
M $-W=PV%I+<7$L<$$"&2261@J1J!DL2>  .237XI?MZ?M/R_M5_M"ZGK4$DA
MT#3_ /B7Z+$W&VV0G]X1_>D8LY[@,!_"*^[/^"P7[5?_  J7X.1^!=)N-FO>
M-8F6Y*-\]MIX.V0_]M3F,>JB3N!7Y55_-OC1Q5[6M'),._=A:4_.7V8_):OS
M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M'NC7W-[>SG9?KU^_-J?T]/2P7_]V_=;6UL;'QV_>O+FPL& MZ/S$9-I;T^$
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M#()$ _0+%V0O0E5]$"0:H%\8@1L! ?H!X!O0#P#?@'X ^,:_A1'B)""FIHH
+    245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
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M9J%6;5K3A8L7Z<>/'R8<,89A&(9A&(9A? F_%W;7KE^C>O7K1XDLG8#*'!!
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M]DU]%R(-+I,Y<^:T^PZL:\U;M*#P!^%VVWKQ\H6(V:O?H %ES)PI1OP=DJC
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M5!#CMVC)8N4.BLR739HV5>\CL<K'CQ\3]7@R#,,P#,,P#.,[^(VP RAGH!=
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M>@T:"*,6^.>??ZC?@/Z4.DT:FC)U*OW\UYC^2;"P0R'LY9JZ+%VZM*B?II_
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M3+T +%VV#)W7%#>3^'S\^V^:.'FRG<!.ERZ=*&B.%89-FH /#;LDBL+/7[!
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MJ]>LIDR9,ZF#4[Y"!=J[?[\2?X[@.TB6,G?^/,JI2W\;F#6K*J? ) XX]BA
M+C.Y8;)9IVY=NG#QHA#:SFXJO/;BY0N1+">C313^[Y?_4>'@(O3F;;2_^^JU
M:T1*6;R?)T\>D5S#JEA1V#'.^6O&#$KC4+S::.O;O[_E:S<9%79X5B$#&I(N
M>++A-S,'9+:/&V=A9SE8V,6?0X</B;K(\7T>XMXK7;:," >P*OXJ[-P%'F9[
M]NVE,MIU$.^:=TX:LG!V[MI%U/#V5=P2=IC8OWKU2EECT+IV[T8_;,(-@]>2
MI4M%P7'] :I:K1K-G3>73IPX(=R)0D)#1+T[6/QDD?+_V=SV2I0L2><O7$C4
MG66B^/CW1U$G,%7JZ#3=L,0V:-205JY>12=/G:3+VOFZH)T/E*Y [8] 7<'E
M7VQNEO?#HRU]UZY?$X&H\C.R#J%586''8.!=NWX=I91)B1+04J5*)196\*RU
MZBJU6\).EZ"K0Z?$K6-W_N(%:M^A@W -8V%G/5C8Q0]<.P4+&8^O<]::-&U*
MKRV::,_JPDZ"Q"=(-*;W'$QHPQRW<M4J=#'DHMF[%R_<MMC!^H;X*5F#)+TF
MXG;MWJ7>QP"&[#+9LF>W.T#)DB<7B0,*%"Q >34QAT'045TCJR)N=LX EW3
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MM"X^7C,L3"Y=NJ37PW('L3=HR&"I6JV:LO#9ER& I0Z9+^L8PG#!HH5*I)E
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31/A_].RHTP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_2.jpg
<TEXT>
begin 644 image_2.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +/" X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P 8OAMX>CC,2R/K7C#0],56G&Z%6:]O(%#3*08E)!D'*Y'(\*\0_P#!2?\
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M\*AH?+A6)_*_LVRTU/\ 2'4W$PE64+,["W$$&R%?R"HHCXD\=)JW$^:K5?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110<]NOO0 44A)QV!Y
MQGI_G'6ESW[4 %%)D?3O@XIKR(@+.P51R23P!_G].:+]>@TF]$FWV2N/HKS3
MQC\9/A5\/+&YU/QU\0O!_@_3K.%[B[O_ !+X@TW1+*V@3.Z6:ZU"X@@BC7!S
M))(J @Y88./SN^*O_!:C_@GI\*I+BUN/CKHWC2_@Z6?PXLM7\<K,=Q78FI^'
MM-O]$1P0=ZSZI$R8&X '->5CL\R?+(N689G@<(DG)^WQ5&F[*UWRN?,]^B;W
ML?=\*^%OB1QQ6IT.$>!.*^(IU9QA!Y3D68XNDY3DHQO7I8=T(IR:7-*HDKZM
M(_5RDR,<\?7K7\O/Q3_X.8/A+I_VJW^#GP"^(GBF:-IH[>\\<:QX<\&Z?.4P
M(9HAIC^,M0,$QWDB>SM+B-/++0EF>./\X_BE_P '$O[:OC07%KX%\,_"CX86
M4P=8I[;1=3\5Z];@R!HRFH:OJ5OH\DBQ@Q2-+X;9) VY(XF K\^S+QF\/\L3
M7]L?79JZ<,!1J5[M<J^)J$/)/FMH^NA_7O W[,_Z7O'$J<EX;OA?#3C"?UCB
MS,L)E24*B34G0C+$8JZ6\'14[NUC^YZ2:.%2\KJBCJS' 'U_G]/U\]\5_%[X
M7^!;:2]\9>/O"7A:SA2226[\0:]IVD6R)$CR2.T]]/!$JHD;NS,X"JK,>%-?
MYROQ)_X*7?MW_%<RCQ9^T[\4(+:7>&L?".LKX!LBC]8WA\$0>'_/0?P_:7F9
M,G:PS7QKX@\3^)?%FH3:MXJ\0ZYXFU6XE>:XU/Q!JU_K.H3S2+&CRS7FHW%S
M<2R.D,2L[R,S+%&K$A% _/LR^DAD])RAE>1XS%-74*N)K4Z%.6UFX14YKK?W
ME;4_L/@G]BGXD8Z.&Q''GBIPYD4)N+Q.!R++<7FN*I)KWHQQ.(GAL.Y)Z)JG
M*+6]C_1(^)?_  5^_P""?/PPCNGU/]H_P'XBEM50FU\!7EWX^N9B^-BPIX.L
M];#D[E_B"JK!W*QY<?!GQ#_X.0OV0- 6:W\"^ _C+X^N<'R+NUT'0_#^E%A-
M)'B>;Q#KMAJD0>*,7$9CT:8E)HHY!%+YR0_Q&Y-%? YA](KBW$<RP&!RS+T[
MV?LYXF:VMK5ERW2OM&S?0_KK@S]C1]'O)73J<6\5<<<7U(^SE*FL9A<EP\I1
MLYQY,#0=7V<VMG6<HIV4KZG]0?C[_@YC^*-X\T/PT_9Q\*Z-#B+[/>^-/&5]
MKLA'RFX633-&T/1%3_EI%!(FKOGY)W0<P#X3^(?_  7E_P""A?CI&AT[QGX#
M^'<3F0,? W@.S$S1NLR!&N/%U[XLDC9?-1Q+;?9I/,@B(*H9HY?QHHKX;,/%
MSQ S%R=3B#$T(RWIX10P\+:725.*:3MKJ?U/PA^SM^B)P;3IK">$.29M7I.+
MCB^(9XK.<0W'9R>,K3@W?6_)^&A]A^.?^"@G[;?Q&,G_  E?[47QGN(I2#):
MZ/XUU7PG8.0P8;M/\)RZ'8D!@"%^S[0>W)KY;U_Q5XH\671OO%/B37_$MZ3D
MWFOZQJ.LW1//)N-1N+F8GD\E\\GUK HKXW%<09YCI2>,S?,<1S7YO:XNM---
MW:LYVMV6Q_2F0^#_ (6<+TJ5'A[P\X.R>%%Q=/ZCP]E="47%12:G##*;E:*7
M,Y.7F%'_ -?]1BBBO*E4G+64Y2?5N3;>W?\ IGW]/"X:C&,*.'H4HQ2453I4
MX**5K)*,596TTV"BBBIL_O=OZ^\WZ:>7W7_R"BBBD'WZN_W6O_PW4****![?
M@@HH]QZGCTZ?XT4TF]DWZ)_UU(E5IQ^*I"/^*45^;"BC_#C_ #_GFG*K.RHB
MEF=@JJHRS,2 % ')))   Y/%;4\+B:NE+#UJC[0I3E^29YV,SS)<OBYX_-LN
MP<%O/%8W#T(KIK*I4BE]XVBNTT7X;_$/Q)<0VGAWP'XSUZ[N)7@@M=%\+:YJ
MES-/'%Y[PQ06-A/))*D/[YD52RQ#>0%YKU[0?V-_VM_$[VZ:%^S%\?M06Z+B
MWN8OA'X\CL)/+D,4K?VC/H45@BQ2*RR,]RJQE7WLNQ\=]+(<[KM*CE.8U+_R
M8/$2ZI=*;ZM?>?(X[Q:\+LLBYYCXB<%X&$='+%<2Y112=F[7GBUK9-VWLGIH
MSYMHK[GT;_@F;^WQKRV;6'[*WQ:1;U&>'^U-#BT+"JK2?Z2-<N]/-BQ1"%2]
M$#.Y1%&^1%/I.D?\$>?^"CVLK%)!^S/KUI%)*(O,U/QE\-=.*9W9ED@NO&4=
MTL2$*I80,27!1742-'ZV'X%XOQ-O8\.YM.__ %!UH]$[^]%?S(^!S;Z57T<\
MD3>9^,WA]ATK7?\ K)EU7=R2_@UY_P LO_ 6?F?17[$Z5_P0E_X*)ZE</!/\
M.?!NCQK$T@NM4^(6@FW=U=%$"C2VU.Y\YE9I5+VZP;(G#3*[1)+WEA_P;X_\
M% ;V 32Q_!?3F+,OV>^\?ZN9@%. Y-CX.O8-K_P@3%P!\ZKQGT8>&''L_AX8
MS/YT>7MW:[H^+Q/TZOHE857K>.G O_</,_:_A2A-_A;YGX=45^_]I_P;A_MU
M7%O!-+XU_9VM))41GMY?&GCAY(7(7?&SP_#>2-RC-MW1LRMM)7@C/<6/_!M9
M^U?+;6[ZA\9/@K9W3I&UU;VK>++Z&!B;;S5AN9=&L'N BO>%'>VMO,,%L"L8
MNY6LNR'A%XAS_P"::QL;V?O.BG9VW7M-+7V>OYGS6)_:*?0XPV_C9PW6:FX/
MV%+,JNJT;O'!6:OLTVGI9V9_.117]*FE_P#!M%^T9,LO]L_'WX5Z<Z^3Y*Z=
MH7B'5EDW1(9_-:XN=',/E3%TBVI-YT2K,_D.Y@34'_!LY\<C_P W'?#W_P (
MO6.>G_4Q=NOX5T0\&O$.<8R_L&K&_25:A&2U6Z=33>Z[JW5GBU?VEOT.*4W!
M>+.!JVY??I9=F<H/F47[LOJBO;FL]-TT?S+T5_33_P 0SGQR_P"CC_A[V_YD
MO6/;_J8NV3^73ID_XAG/CE_T<?\ #WM_S)>L>W_4Q=LG\NG3-_\ $%_$/_H1
M2_\ "C#^7_3SS_+N9?\ %3+Z'/\ T=7"]/\ F69GUY?^H7^]^!_,M17]-/\
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M7_LTGT3Z7Z/^M#Z3 _33^BQF,X4\)XX\ U)U)1C",LZH4VW.2C'^(XK66G_
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M1/"YQE68Y5B:;M/#YC@L3@JT'VE2Q-.G-?-%BBD!R2/2EK:YYH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2UP=3O+AQ#*$MK6UFGE=#'%&\AV5^5_Q=_X.'/V(/ @O+/P)'\1?BWJ5O+)
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MK,FBOM_X<_\ !-K]NKXJ+!-X2_9C^**VEP\2I?\ B?1%\#6125RGG+/XTN-
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M?VY?@]Y:>"_VE_B<;2.19!IWBO6AX]T\;$$:Q1VOC>'Q MM $"@0VAMT&U2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJUPA3;YGEO\ \)DA+&-G@&UXV_&SXW?\%8_V]/CO+?1^(?CSXD\':->R,_\
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M?!MXXF\N[^&\^J> 6A>9@QF^Q>&-0TS2;F57 9?MNGW,:\H$,;NC?F=\6_\
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MQ)IVH:A9R[%D-MJ&FQ3?;]/NEC=':VOK:VN$5U9H@",_LV3<7<-9_",\ISG
MXMR_Y=QKPA63TT=&HXU;^\OL[G^:OB3]'7QN\(L35P_B%X:\5<.QI;XVOEE>
MOEDHZVG#,L)&O@G%\KM>LG97LCZ*HIBNCC<C!AQR.>O3_/;O3BV!D_I_3UKZ
M.Y^+:K1JS%HHS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR?M%Z=%J/P>^,W@+QLT@_?:;I&OV;ZY9/L20Q:CH4QAUG3IA'(CF*^L;=PC
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MNE=3LMV^O^J7@M^V8\1^'_JF6>,_!F6\9X"')3JY[P])91G<8)1@ZE3!5'/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8G*L;1Q#AS?8KT8R]MAZJVE3K0A.+W0E%%%>4??A1110 4444 %%%% "Y/\
MGZ8KL/ GQ#\=_"[Q+I_C+X;^,?$O@7Q5I4HET_Q!X4UG4-"U6V;D.BWFG3V\
MSP3(6BN;:5GM[J!Y(+B*6&21&XZBNC#8K$8.K"OA:]7#UH2YHU:-25.<6K6Y
M90::?_ /)SG(LFXBP&(RO/<JR_.,NQ<'2Q."S'"4,7AJU.6CC4HUX3A)>31_
M1#^R5_P<,?M"_"G^S/#7[2'ANP^-_A&%X89_%>D1V/AGXE6EKO4332HBP^%/
M$<D-NI^S6KV?AJXGE!-YK3ERZ?T\_LJ?\%+_ -D7]KZU@A^%WQ0TF#Q:T1DN
M/A]XID7PYX[MO*6$W+KX=U QW&H6ML9XTEU/16U/2?,;RTOY'4X_S9:M6-]>
MZ9>6NHZ;>7>G:A8W$5W97]C<36EY9W4#B2&YM;J!XY[>>&15>*:)TDC=59&5
M@"/VOA/QWXIR/V6&S?ESW P<8OZP^7&PAHGR8A?&TE9*K&>^^B/\O_I!?LG?
M ?Q36.SGPZ5;PJXJKJI5A_9$%7X:Q.(:NEB<FJ-1H0G-MSE@:E!Z[.R1_K$I
M(DJ!HY RLH(9><@\@C'X=N0>W>0<<9_/J:_@*_9&_P""Y/[7_P"S:+'P]XZU
M2/\ :"^']NMI;+IGCZ^GC\9Z;9VR0PA-*\=QQ75]=.8(V,A\467B*>:8JRW=
ML#*7_J6_9 _X+$?L??M9BRT2R\9CX8?$2811'P#\39M/\.ZQ>74IF41:#>B[
MN-#\1EQ \ZPZ-J=W?PV[1/?6%E(_E#^G>%/%3A'BN-.GAL?#!8^22> Q\HT*
MSFTKJE-OV575Z<LN9W5H[V_PT\?_ * GTB?H_5<7C,[X3K\4\*8><_9\6<)T
MJV:8#V*?NU<9AJ<'C< W%7DJ]%TX:_O7N?K!14%O<PW42SV\J30N R21G<C*
M><ANX/8U/FOT=235T[K2SZ.Z5K?>?Q3)2BW&2<91;3C)---:--/5-=4PHIH)
MP"<#KG/'TIU,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 44C,%!). .I/IW_ $KXL_:K_P""@'[,'['>AOJ?QD^)&DZ;J\L1DTOP7I<A
MUCQMK+;UB7^S?#-@L^I26_F,JRZA-%!IEJ"9+N]MXU9QR8W'X/+L//%X_$T<
M)AJ:O4K8BI&E3BO.4FE?R5V^B;/?X:X6XDXRS?"9!PID>:<0YUCJD:6$RS*,
M%7QV+K3DU%<M&A"<E%-KFG*T(+WIR239]I,RH,G@#))[ #DD_P Z^,_VH/V^
MOV7?V1M$N-3^,?Q2\/Z/JBP^98^#["Y_M?QKJ[%TC1=+\*Z>MSK%U'OD037?
MV1;&U1O-N[J"%6D7^4/]LG_@X%_:$^-!U/PE^SAI7_"B/ D[M"GB>[^PZM\4
MM2M/]'8%9D%SX?\ "OF;;J">&P37K]8Y(YK+7K*9<#\"_$/B/Q#XNUK4?$GB
MO7=9\3^(M7G^U:MKWB'5+[6M:U2ZV)']IU'5-2GN;Z]N#&B(9KF>638BKNVJ
M /Y_XP^D#D^6NK@^&</_ &OBH\T'C:O-3P,)7M>FK*K7MT=H1?FK,_U^^CC^
MR!\1N-HX#B+QSSC_ (A]D57V5?\ U9RYTL9Q/BJ3Y9NEBZOO8/+.97C**^L5
MDGIR26G]"7[8O_!PK\=?BK+JOA3]F#P_'\%_!4QEMT\9>((-.USXF:A;NB*)
M;6T!O/#'A4\W"/&%\3WG,%Q:ZIITJF,?S\^,/&GB_P"(/B+4O%WCOQ1X@\9>
M*=8F\_5/$7B?5[_7-:U"7&U6N]2U*>YNYA&@$<2/*4AB5(HE2-%4<S17\P<2
M\<<2\65Y5LXS*O5IN3=/"4Y.EA:2?2%&%H*VFK3D^^I_NIX(_18\$?H_971P
M'AQP1E>78R-*$,5GV*HPQV?8^459U,5F>(C/$2E)ZN,)0@ME%+0/\_Y_QZ_C
M1117R)_0WY=ONM]U@HHHH&%%%% !1110 444OK0%_P -Q*/\]/\ /->I_"+X
M(_%SX]^+;;P-\&OAYXH^(WBFY,?_ !+/#6F37BV<,CF-;W5]0;R],T/30X*O
MJFLWEAI\38$ERI(!_J(_8E_X-V-+M/[*\=?MG>)5U^X9([I/A!X(O[NST.WD
M+2%8?$_B^WFM-7U5Q&8'>RT%-$M8+J.2)]3UFSD(;[SA+P[XGXQK066X&=/!
MMI5<?B4Z6$A%<O,U.2O4E;7DIJ4G:Q_)_P!(?Z9W@9]&W+ZTN-N*</C.(_92
MG@N$,DJ4L?G^+FE>G&6%I3:PE*<K1=?%RHTHWNY'\U/[//[*OQ^_:H\60^$/
M@9\-?$/C:\^TV]OJ>KVUJUKX6\.).R9N?$GB>[$6CZ1%'$QN%@N+K[?>1HR:
M=9WMQL@?^J+]C#_@W;^&O@=](\:_M;>)U^*?B:WDM+Z/X>>&GN=.^&]E/&8Y
MC;:M=2"VU_Q>D<JJ"LZZ%I5Q&9;6_P!&OH')/]$_PP^$'PV^#/A72_!7PQ\&
M>'?!/AC1K:.UT[1?#>E6NDZ?;1QJJY6VM$C1I'*AY9G!FFD+23.\C,Q]*K^K
M^#? _AGAQ4L5FD5GF9QY9<^(@OJ=&HN5_NL.[J=I)VE5YKI_!'8_Y]_I*_M2
MO'#QGECLAX$KU/"S@BM[6@L/DU=OB/,,--RBGC\XC:>&]I2:4Z. 5+EE>U>:
M.,\$?#[P5\-_#^G^%O OA;0O"7AW2;:.TTW1?#NF6NDZ996T0(2&UL;**&V@
MC&2?+BB5-Q+$<UV0YYP?QX_S_GWI:*_:J=.G1A&G2A&G3@E&$(1481BDDE&,
M4DDDE9(_S'Q6+Q6.Q%;%XW$U\7BL14G5KXG$U:E>O6JS;E.I5JU)2G4G.3;E
M*4FVW=L****LYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%(<]L9]Z %HHJC?ZE8Z7:3WVHW
M,-E:6R-)-/<2+%%&B@LS.[$*B@ DDG  W$@<TFU%-R:26K;=DO5O1%0A.I.-
M.G"52I.2A"$(N4YRD[1C&*3<I-NR23;>Q>STX/\ GUK@_B)\3O /PF\,:KXS
M^(_BW0/!GA?1+26]U77?$>J6>CZ586L()>:ZO[Z6&V@3@*#)(H+D(,LP%?B%
M^W/_ ,%YOV??V?!JW@;X"M8?'SXHV^ZV>YT'4X)/AMH%RLGES+K'BRT,\>IW
M< #[M+\.)J#I/$;34+[29<L/Y"_VHOVU?VCOVP_$[^(_CA\0M2UVSBNFNM&\
M%Z;)/I7@+PTQ1HU&A^&(KB2TCG6)GB.J7[ZAK<T3&.ZU.=< ?CO&WC/PUPJJ
MF$P=2.=9K!.*P^%J1>'I35O]YQ$;QTZPI\TGWB?Z1?1>_9H>-GCY/ \0<382
MMX:>'U:5*K+.,]PM2&<9GAI2BY?V1E%3V=9JI!R4,5B_8TD[2C"M'0_I$_;E
M_P"#A_0=&&L_#[]C+0H_%.K*;S3KKXN>+;.6'PI82Q7'D&Z\): 3;ZCXF<HD
M[6VHZF^DZ1'(;2\@@U^S=X#_ "S?&+XY?%W]H#QA=^//C+\0?$_Q#\47;S%=
M0\1ZE-=Q:?!/*9GL-$T[*:9H.E+(2T6E:-9V.G1')CME))/E/T_S_D>E%?R/
MQ=XC\3\8UI/,<=.E@^9NEE^%<J.%II[)PB[U9):.=1R;]#_H@^CO]"WP+^C;
ME]!<&<+X;'\2^QC#&\89Y2I8_/L75M'GE3Q%6#6"I2E%M4,)&E3BFU9]2BBB
MO@[_ *^I_6:36EDO3IHEM_25@HHHI#"BBB@ HHHH **** "BBK-G97FHW=K8
M:?:7-_?WUS!96-E9P2W-Y>7EU(L-K:6MM DD]Q<W$[QPP00QO+-(ZQQJSL ;
MITZE:<:5*$JE2;480A%RE*3=DDEJVWHEW.;&8W"9?AJV-QV(HX3"8:G*M7Q.
M(J0HT:-*"YIU*E2HXPA",4W*4FDD5OZ5]#_LX_LJ_'C]K#QM!X%^!OP_UCQ?
MJ'G6ZZMK"026GA7PO;7#$+?^*/$DR#3-'MMB2R1133-?W_DRPZ797UT%MV_:
M[_@G]_P0.^)OQD;0OB9^UD^J?"OX=RO;:A:_#&VQ;?$3Q-9EA*D7B"X+C_A"
M;&Z01B:S6.X\3M!-+!*GAN^B65?Z_O@E\ /A'^SOX(TKX??"#P+X?\#^%](A
M\NWT[0=/BLUED<E[B\O94#3ZAJ%Y,SW%]J-[+/?7MS))<75Q--([G^A. ? G
M,\Y=',>)W5RK+I<M2&#2MCL3"ZDN9/3#PDK:R3G9IJ/4_P >_I:_M7N!?#)Y
MGP7X&0P?'W&=/VV$Q'$<IN?"N28A+V;E3J4VI9OB:,[_ +O#R6'4H.,\0G[K
M_%_]@O\ X(/? []GO^QOB#^T#_9GQQ^+-K)!J%O::E8!OASX7NHI!<6XTCPY
M>-*-9O[.18V76M?2>07$*76G:;I#Y4_OS8V%GIMM#:6-M%:VT"+'%#"@CCC1
M %541<*H &    .!5P\^H^E%?UMD7#N3<-X.&!R; 4,%0BDI.G%>TJ-)+FJU
M7>I4D]6W*3L[VLG8_P">/Q5\9?$KQKXDQ'%7B5Q7F?$V:UIU)4EBZ\E@L!3G
M*_U?+L#!QPN"H1245"C3C=13FY2U"@9[]?:BBO;/S **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 0# Q39(TE1DD4,C AE(R"",'/KQ3Z0\^H^E'R&FTTU=-.Z:T::V:?<_)7]
MNK_@C_\ LR_MFVNI>)!HR_"WXQ/#-)9_$SP5865K>:C>>3LMU\9Z6PCL?%UB
MC)"LANS:ZW';1?9=-UW34D?=_&1^VA_P3B_:7_8@UVZ3XF^%9-:^'LE]]DT+
MXL^%HIK_ ,&:F)9-MG#J4N#=>&-6N R(-+UR.W$]QYL6E7FJQ0FX;_2A QZ_
MY]/2N;\6>#O"_CG0]0\->+M!TKQ%H.JVTMGJ.D:S86VHZ=>VLRE9;>ZLKN.6
MWN(G!PT<T;HPX*G-?E7&_A)PWQC3J8B-&.5YNTW''X2$8JI/2WUJDDHU5=:R
MTJ:M\S>C_OOZ+7[0WQK^C?BL'E%7,:_'?AY&I3AB.$\^Q56M4P6'32F\CS&H
MZE; 3C!>Y0E[3"/E453IW<S_ "C/\/Y_G_D=C17]<W_!0/\ X-\])U--<^*'
M[%,\.@ZL?M>IZC\%=<OQ%X:U&3(F:W\!ZO<!Y?#MU+^^\C2-8N)O#[3/!;6M
MYX;L(\+_ "G?$+X<>/?A-XNUCP%\2_"&O^!_&6@W,EKJOAWQ+IMSI>I6SQN\
M8F6*X1%N;*XV&6RU&T>?3[^W*75E<W%M)'*W\;<8^'O$7!6)=/,L)*IA)2:H
M9C0C*IA:T=+>];]W*S3=.I:2O9KJ_P#I1^C?],/P9^DUDM+%\$9]2PO$5.C3
MGFW!^;5*6$S_ "ZLXQY_]EE/_:L/&?-&&*PKJT9\OQ)MI<51117PUGIIOL?U
M7?\ K^NH4444@"BBB@ HHHH **** %R>G;T_GCTSWJ6WN)[2XM[NTFFM;JUF
MBN+6YMI7@N+>X@D66">":-EDAFAE1)(Y(V5D=592& -0T5<)SI3C.E.4)Q:E
M&<).,HR5G>,E9II[-'-B\)A<?AZV$QN&H8O"XB$J5;#XBE"M1JTIQY9PJ4ZB
ME"<9)M.+333L?N3^Q+_P72_:6_9L?2O"/QAEO/C]\+K<V=GNUV^"?$?P_IT"
MQP,VE>*+I91XA,4*[A9^)S-<W4BJG]O62,QK^NK]D3_@H=^S%^VAX?34_A%X
M]LW\0V]M!-K?@#7VBT?QWX>DERI34_#\LKRO;B19(X]5TR74=%N9(Y%L]3N=
MA(_S3*Z#PMXK\3^!_$&E>*_!OB#6?"OB;0[N.^T?7_#^I7FD:OIEY"P:.YLM
M0L9H+JWE4C[T<BY4E&RK,I_;>"?'#B+AQTL'F[EG>5QY8VK3:QM"$;)>QKN_
M,DE\%127:UVS_+GZ3_[+'P;\9EF'$GAS"EX7\=U_:8AU,LH)\-9IB9-R?]H9
M1#EA1E4DWS8C NC4NU*<:EFG_JZA@X5E*D8SGOSTP>WO3Z_C _86_P"#A#XC
M_#<Z-\/OVO\ 2+GXD^$8C'9Q?%;PY:VL/CK3(3)&B3>)M"C^SZ9XFMK=&9I]
M1TD:9K*6\.7T[7[^=I3_ %D_ ?\ :4^"G[2O@W3O'7P8^(7AOQUH%_%$YFT2
M_CN+JPGD0.;'6-/81:AHVIPC*W.EZI:6FH6S@I/;Q,I%?UKPIQYPUQA0C5RC
M'PEB.52K8&LU2Q=%M+F3I-^_%?STW./FKV/^>GQ^^B=XU_1OSBK@/$3A3%TL
MI=:5/ <59;3J8WAS,8)KDE2Q].'+AZDTU_L^+C0K*5THR2YG[M1117V=S^;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M16(S3@URJTUS5*N3U'>I%:-_4ZC_ (B72E/W]$HN6R_WP^A_^UJPF/\ [*X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1132VW)8@*!GWXZG\/I0 IY'<>_
M2N8\8>,_"O@'P]JOBGQGX@TGPQX=T2QN-2U;7-;O[;2]+TVQM(FFN;R^O[R6
M*VM+6"-&DFGN)8XHT!9F !-? '[='_!3[]G+]AW09HO&6OKXJ^)5Y:O)X>^%
MOA6XM;WQ7?R,DGV:ZU.)I!#X=T5I4/F:QJ[6\#JDL6GQZA?*MF_\2O[;/_!2
MO]I/]N/6[E?B#XA/A?X:17JW6A_"3PK/-;>%[ P><MK<ZQ<%8K[Q/JZQ3$27
MVJE;..8&73-*TI7>*OR[CGQ6X>X*ISH2JK,LWY7[/+L/.+E"5ERO%5%=45=W
M<6G4:7P).Z_N[Z*GT _&/Z3>-PN:T<#6X-\.E6IO&<99SAJM.&*H\R]I3R/!
MS4*F8UG"Z55<N%@VFZLFG!_N;_P4%_X.";:U?6OA9^Q1%:ZM<C[9IFK?&S7;
M%Y-(M)HY7MI&\ Z-<"$ZS(NUWM_$.KQC0WQ'/I^G:[:2QWB_RK>-_'7C/XE>
M*-6\:_$'Q3K_ (T\6Z[<&ZU?Q'XFU6]UG5[^8\*;B^OIIIVCB0+%;PAQ#;0)
M';V\<<,:1KRF:*_C#C'Q XBXTQ3K9GBY0PD9?[/EU!NGA*$>B]FG:I-=:D^:
M3ZL_Z9?HX?1!\&_HRY#2R_@;AZAB,_JTJ<<VXPS2E2Q6?YI6C%<\I8J4+X6@
MY\SAA<*J5"%](7NVN:2BBOB/P[_U^A_4H4444@"BBB@ HHHH **** "BBBG9
M_>[?U]X!117TC^R[^R?\;/VP?B3;?#+X)>%I=<U0+!<Z[K=V9K3POX0TN:4P
MKJWB?6$@N$T^U:172V@CBN-0U"5)(=.LKJ2.14[,NR['9MC*. R_#5<7B\1.
M-.E1HPE.<I2=EHD[+NWHEJSY;C+C7A;P_P"'LRXKXQSO </Y!E&'J8K'YEF.
M(IX?#T:5./-+WJDH\TVM(0C><Y-1BFW8\,\+^%_$GC;Q!I/A3P?H.K^*/$VO
M7D>GZ+H&@:?=:KJ^J7LH)2VL=/LHIKJYE*JSE8HFVQH\C[41F']<7_!,W_@@
MYHWA/_A'_C;^V=IVF^)_%'EVNJ>'/@G*L.H^%O#4S$S1S>.F+/:^*=8A1HL:
M+&DGAS3KA9Q._B"3[-/9?IU_P3L_X)1_ []AKP[:Z\]G:?$+XXZG811>)?BA
MK6GP&\MFDCC-WI/@RU?SCX7\/23!C):P33:EJ(6$ZSJ-_P#9K-+7]6P H&T#
M:!C@?0#']?85_8WAKX)8+(50SCB:-/'YM:-2C@FE/"8*3Y9)S3NJ]>+5M?W<
M'>RD[27_ #;_ $V/VH7%/BO/-/#GP.Q..X3\/^:M@LQXGA.>&X@XGI>]2J1P
MLXM5,KRRM'5<KCC*\9)R=!<T)4M-TVQTBSM]/TVUALK*TB2&WMK:-8H(HD4(
MD<<: *J(JJH50%4  # %7QVP3QGOG/U]<=J6BOZ$244E%)))))*R22LDO1*R
M\C_'N=2=6<ZE2<JE2<G.<YR<ISE)WE*4I-N4I-MMMMMZL****9 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M #AK^3_$'QXQ&+^L93P>YX?#6E2JYO-6Q%6+LI?58_\ +F#Z5'^\>ZY+V/\
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MN=1U.WL]1L?Z>K:VAM(4@MXDBBC4(D<8PJJH   [  #I@>W%3*JHH50 J@
M=@!@#\!3J_NOAGA?)^$\MI99E&&C1I04?:U6DZ^)J**3K5Y[RG*VWPQ6D4EH
M?\H_C?X[>(WT@>-<?QQXBYYB,TQ^)JU%@<"ISCEF2X*4^:G@,KPG,Z>'H4H\
ML7))U:SBIUJE2>H4445]$?C@4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5*_X)%>./V+=>U/XG_":TUOQO^S=J5S<W9OV4W^L_"MY[J&*WT7Q1,K&XO\
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M2_V2LU=2I3FJ2_12BD!R ?7IZG]:,\D'VQ[^M?JMS^!A:*** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHKZ:/[%?[8(SG]EK]H3C.?\ BSWC_C&[.?\ B0<8V-G.,;6]#0?V+/VP>?\
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M'?B!WV8/_( Z'>F#T.]<?>&3_5KB'_H29K_X08G_ .5A_P 1O\'/^CH\ _\
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M;"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*T,1@\3;EA6Y'%XC!U)*OAY.TE*#A4GN44<\^G;_ .O17UY_/ 4444 %%%%
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M&,5HKR=KRDVVVVPHHHKE/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>TJ?SS_\"?\ F0?98/\ GDOY#C_]='V6#_GDOY#C_/O4]%%EV7W![2I_//\
M\"?^9"+>!3N$2 CH0,$?C^O^14O ST'3/]*4<>I^M)M^I]<]_KZX[>E"5M$K
M+T)<F]VWZML6BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?UI<].#_ )]:_3C^&@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2],TZUGOM0U'4+Z>.VLK"QLK6.6YO+V\N98K>VM;:*6>>>1(HHGD94/]UO\
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MF&.Q4W.3G4DW&C1BWRT<-0ARTL/AZ:5.C1A"G!*,4%%%%>B?'!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57N+A+>WFN)#M2&*2
M5B<\*BEB>A[ G\O7-6*_*K_@K[^V-%^R)^R1XPU31-26S^)OQ%23P!\-8D=/
MM$6M:W:W$5_KB(W/E^&M'6_U@.RM$UY;V-I)C[8F?.S?,\-DV68[-,9-4\/@
M<-5Q%64FEI3BVHJ^\IRM&*WE)I+<^S\.^!\\\2N..%^ ^',-/%YUQ3G6!R?
MTH1<N6IBZ\*<Z]2R;C0PU-SKUYVM3HTYS>D6?R1_\%EOVPV_:R_;!\36OA_4
MYKWX7_!1]3^&_@5-P-G=ZG:W^WQUXDM1LRPUG7;./38+F.1[:^T;P[HM[;\3
MNS_DQ117^:O$V>XKB3/,QSG%R<JN-Q$ZB3;:IT[VI4XWVC3IJ,(K^5(_[;?
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M_L9_I%SH*I5XLX HUG%MX?ZUF$[2Z1]JL,HM/^;E5KZ[:_Z1RX&2"2.,D_\
MU_\ /0#-.!S_ )X_ ]Z_SP_"?_!:_P#X*-^%KE)[CXYV_BN-79C9^*/ G@>6
MV<%8P(V.BZ%H=T$38S+LN4<M*^]V C$?W9\)O^#D[]H_P_)96OQ>^#7PV\=V
M"RJMU>>#[W6/ VJ>07??(D.I/XPL9[A4,>(P;*&4QL"8O,WQ>S@/'G@/&SC3
MJXC&X*4K>]B<*_91;:^*=.52R5[WY=/5'YOQ;^R9^EKPW@ZV-P&3<,<4PHQ<
MOJ^29]36-J)*]J6'QM'#*<F_=C'VEVVKV5VO[4:*_$G]FW_@O+^Q)\=+G3M
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M2_\ 1PQ^/UY/-?-_[57[,/PP_:W^#7BSX.?%/1UU#0O$=BR6M]"L2:QX?U>
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M9])_JE150!$ "H % [ #&/\ #VJ&SM+>QMH;2UB6&""-(HHT 5$1%"JJJ
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MN_\ 3SK9_P!-DR_8M>!L(RE/Q'X^C&*<I2;RE**23;;>$V24M_F?Z2G[.?\
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M"^%K=[OQ)XLT#0K6//F7.K:G:V$";1D[YKB1(UP <Y;H"0< U_GH?&/_ (+
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M_-][[WWN^KZ7?JS_ &O244E%)**222LDEHDDM$DDK):!1112&%%%% !1110
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MK\ _"3)/ [PEX*\-,AHPAAN',FPN'Q-:,%">-S*=-5LRQ]:V];&8V=:O4?\
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M$6VH..%IPJUHQ]UXFK6GO-A1117U1^#!1110 444F?;_  _&B^MOZZ?Y@ &
M!Z49('./PJEJ.HV.E65QJ&HW<-C96D3S7%U<2K###%&A=WDD<[415!9F8@*
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MDR742/\ +M?V1?\ !NI^QW)X+^&?C#]K+QEHJ0:]\4W_ .$:^'$UW:E;VR\
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M%9[G^:UX4X4Z,)?5L'1<DJN.S#$\KIX3!8>+YZU>JTDERP4ZDH0E]H?MR_\
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M9FM!2S+'TKY=2J1_W3"32M6LUI6KJ[3^S2:M\;2_YI/VJ'TS<7X@\6XWZ/\
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M%,*N5-4:G-A\9Q1B5"6<8CW=)2P2C2RY7O*E6HXN*LIN[J***_<C_*\****
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M6!<*E6C+2GC*^*<;<S"BBBOR$_T5"BBB@ K^G7_@W._9!M?&/Q!\<_M;^+;
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M;C+-:65952<IMJ>(KR35#"T.:*G6K3Z))Z15Y2E:,4W)(_"OI"?2%\/?HW<
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M4X&E3C5JTJ<7C<RQ$8Q]KC<QQ;7ML5BJ\TYU*E63=W962211117A'ZP%%%%
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MR.[$LQ-9]?YL\6\0XCBCB#,LZQ,I-XO$3=&#U]EAX6A0I1?\L*245Z7>K/\
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M$$M]>O&B)/J&H7"RWVH7&P-<WMQ<7#Y:1J]JI , #T&!]/\ (I?3KQ_GFO\
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MY\+OC[\;O@C)J4OP?^+7Q#^&9UF(Q:LG@GQ;K?AV#4AL\M'O;;3;R"WN9X4
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MOA[0H)(UU3Q3XHU!)8="\.Z3&^2]WJ-XJ^;-M,.GV,5YJEX8[&QNIHO\W_\
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M]]XEO;=XY+JZDBGT_P -V$\6I:E'<SW&E:3JWD'[!7[$GQ#_ &Z/CMH?PO\
M"D%[IOA"PFM=5^)WCE8,V7A#PHLX$[1SRQ2VLGB/6 DMAX;TV1)FN;TR7MQ"
M-)TW5;JV_P!%3X _ /X:_LV_"[PI\)OA7X<LO#?A3PIID-A9VEI&JRW$H'F7
M>H:A< "6_P!4U&[::]U/4;EI+J_O9Y[JXD>65F/[[X/>%DN*,1#/\\HR6186
MHO84)7B\QKTW%\O1_5H:>T:^-^Y&2]YQ_P COVCWT^(>!>4U_"3PMS&E4\5,
M\P;_ +4S6A*%6/!F5XF+2K6]Z']L8J'-]3I33>&C_M-6%O8PJQ_ ']GSX6?L
MU?#7P[\+/A)X4TWPIX5\.V45K!:V$")/>3+'&MQJ.J76#<:IJU](GVC4-3OI
M)KV^N'>>YF>1B:]M]LX_S[T45_:M"A2PM&GA\/3A2H481ITJ5.*A"G"*2C",
M8I)))65D?\Q&:YKF6>9CC<WSC'8K,LSS'$U<7CL?C:U3$8K%8FO-U*M:O6JR
ME4J5)SDY2E*3;;"BBBMCSPHHHH _EB_X.:O!-C-\/?V:OB(+51J&D^-O%/@X
MW2Q<FU\3:"=9:&28<+^^\(QR1QD_O")& 81&OY!*_LR_X.8-;CM_V>?@-X>W
M1"75/C)_:B@R.)C#H_@OQ?;2-'&K 21"36(%F9PZ(SP':'9'7^,VOX1\>Z=&
MGX@8N5)^_5P6"G76UJBH0C&_K3C!W\]C_J__ &2F-S+%?1$X?HX[F^K8'B?B
MC#Y7*4F^?!O-:N(G:^RCC*V*IJ/:/31(HHHK\5/].0HHHH *]9^!/P@\3?'[
MXQ?#?X,>#X9)?$7Q&\5Z5X;LGC@>X%E!=S;]3U>>&,AFM-%TJ*]U>^;<JQV5
ME/([*BEAY-7]57_!N=^QM_:.I^,_VR/&6EMY-B;OX?\ PC-Q%F.1T=/^$X\3
M6X;<K'S1:^&+"ZB\N2%K?Q-:OE)@3]SX=\+5.+^*LMROE?U6-6.)Q]1)VAA*
M#C*K=[)S25.%]YSBNI_*_P!,GQYP/T=_ 7C+CJ=:G'/*F J9+PIA9M<V+XAS
M.$L/@(QAHZD,/*3QF(4=8X;#U9=#^HC]GWX-^$_V?_@Y\/?A#X)LULO#?@7P
MQI6@:='UEDCLK.*.6YN'R?-N[R=9;N\F8EY[F:::1B[L3[+U/0\?ES0!@  =
M.*6O]&J%"EAJ%'#T(1IT:%.%*E3BK1A3IQ481BNB44DD?\7V:9GCLYS+'YOF
M6)JXS,<SQF)Q^.Q=>3G6Q.+Q=:=?$5ZLW=RJ5*LY3E)ZMML***09QSUK4X S
M@9/ '7K_ #-?AQ_P6'_X*B:7^QS\/9/A3\*M5L=1_:)\?Z=<1:5%%)%<_P#"
MNM!N(Y[>7QMK%LT%Q"UT)2(/#.E7HC34KY9KV6.XT[2KRWF^VO\ @H/^VUX)
M_8;_ &??$7Q2\1M;ZCXHNU_L+X>>#S<I;WOB_P 7W\4ZV&G0DY>*QLUCEU36
M[Y%<V&D6-Y-#%<78M;2X_P YWXN_%KQ[\<_B1XN^+'Q,UZ[\2>-?&VLW6M:U
MJ5U+,Z+)<2$P:?I\4LLQL=(TNV\K3M'TV)_L^G:;;6UG;A8H5%?AWC%XE+A+
M+_['RJJGGN84G>4'?^S\-)<OMG;X:T[M44[.-G4:3Y+_ .IG[-SZ$53Z0W%\
M?$CC[ 58^%'!V/IR6'JPE"GQ;GF'G3JPRR#DDJN687W9YC*#M5GR81-IXA0X
M[7]?UOQ3K>K>)/$FK:AKOB#7=0N]6UK6M6NYK[4]4U.^F>XO+Z^O+AY)[FZN
M9Y'EFFE=G=V)8DUD445_#M6M5KU9UJU252K5FZE2I-N4Y3D[RE)O5MO6^Y_U
M/Y?E^"RK X7+,MPM#!9?@</2PN#PF&IQHT,/AZ,%3ITJ5.FHQA"$(J,8Q2LD
M%%%%9':%%%'TY]OQZ=/UQ3C&4Y*,4Y2DU&,4KMMNR27=LBK5IT:<ZU:<:=*E
M&4ZE2;480A%7E*4GHHQ2;;>B6K+=A87^JWUEI>EV5WJ6IZE=VVGZ=IUA;37E
M]J%_>3);VEE96ENDEQ=7=U<21P6UM!')-/-(D42.[*#_ &5?\$EO^"*^D?"2
MUT+]H3]J_P /:7K_ ,5+A;'6?!/PZOA'J>C?#=61;F&ZUNW=39:IXV1W1_-7
M[9IOA^:%!I<US>*=27D_^"(O_!*&/P7IFB_M<_M&^%U?QOJT%KJ?P?\ !&O6
M)\_P1I,\<CIXLUBRNCB+Q3KEO<0RZ3:S6L=WX:TY!+)(NJZG<VVE?U&1JJ(J
M( %4!0!T    'X5_87@]X24,NP^&XGXDPZJYA64:N7X"M&\,'3DDZ=>M"5U+
M$2OS0C)6IIIM<[M#_G _:._M#\RXQS7.? WP5SJK@>$<MK5LNXQXKRVNZ>(X
MAQ=*?)B,JRS%49*=/*Z$XRI8JO3DI8V?-2BUAXR>(9##%;Q1PPQA(HU"(BJ
MBA0%&!T P.,<5-_,?IFBBOZ42LK)*RT26EE_P/Q/\2FW)MR;;;NVVVVWNVWJ
MV%%%%,05Y%\>? .D_%'X-_$GX>Z[:I>:/XO\%^)= U"TDB\Q9K75=&O;*9"G
M&XE9V*@%26QM((S7K@]CG\<UB^))H[?0-9FE.V./3+]F)Z!1:RY)QR<#/ R2
M>/IAB*<*M"M2J+FA4I5*<T]G"<>6=UV:>OD>GDV+Q. SC*\=@YRIXO"9C@L3
MAIPTG"O1Q%.I2E%])*<8M>9_E(:G83:5J6H:9<!A<:;?7=A.&1XR)K2>2WD!
MC<*Z,'C;*. RGA@""*HUU?CJXBN_&_C&Z@;S(+GQ7XAGADPR%XIM7O)(WVR!
M73<C*V'56&<, 017*5_EUF$5#'8N,?ACB*R5NRF['_>'PC7JXKA;AS$5_P"-
M6R3+*E5_]/)8.BY:;WNW^NH4445QGT04444 %?V@?\&[?['Q^'WP:\4?M2>,
M-$6'Q5\9;@:1X%GO(,7NG?#7P]>%1<6PGMHKBR3Q;XACN]0F\N::TU32-(\*
MW\1"E2W\I/[)O[//B']JG]HCX6_ CPYY\,WCOQ-;6>L:E I9M$\+6*2:GXIU
ML.8+B%9M.T&SOYK%;B/[/=:G]BL793=+7^FG\,_ /ASX6^ ?"/P^\(Z;!I'A
MKP=X>T?PYH>EVB[;>PTS1]/MM/L[2%3SL@M[:.,%B68)N8EB2?Z9^CSPC];S
M#%\5XNE>C@.;"9?SQTGBJD5[:K&^C=&E)1O;>K=.\=/\._VQ?TB/]7^$>'?H
M_P##^.<<SXLE3X@XN5&I:I0R# UE_9V"K<K3MF684G5:>]+ 5*<XN%9'=].!
M1117]?G_ #EA1110 4444 %%%% !1110 4444 %%%% "8'IZ_KU_.OYNO^#@
M#]@VW^*OPDB_:P^'^CI_PL'X.V+KX[6TB_TGQ-\,B\D]Y-.B#]]>>"[AFUFV
ME.W;HDWB".3SG2P2+^D:N;\7^&]+\7^&=<\,ZW90:CI.N:5J&EZC87,8DMKN
MTO[2:UN;>:-N'BFBF>-QW5SGO7@<4</X3B?(\PR;&P4J>+H2C"35W1KI<U&M
M#1M3IU$FFM6KQVDT?KO@3XN\1>!GBIP?XE\-8FK0QG#V:X>MBZ%.<H0S+*JE
M2-/,\LQ"349T<9A)5:34[QA4=.LDITX2C_E%_P"?\_YYHKZ>_;-_9\O_ -EG
M]IWXQ? V[BN%LO!?BZ\3PU<7/G,][X/U98]9\)W1N)DC^USG0=0L;>^N(PT1
MU*"]B5RT3 ?,-?YJYIE]?*LQQN6XF+C7P.)K8:JGTG2FX/\ (_[;> >,<J\0
M."^%^-LCK1Q&4\49'EN=8&M#6,L/F&%I8FGU=FE42:>J::>H4445P'UP4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !4UO<W%I<P7EI/-:W5K-'<
M6US;2207%O/"ZRPS031,LL,L4BK)')&RO&ZJR,& (AHJX3G3G&I3E*$X24HS
MBVI1E&S4DUJFGJNQSXK"X?&X:M@\70IXC"XBG.C7H5H1J4JM*<7&=.I"2<90
ME%N,HM6:=C^R'_@C9_P6#;XK?\([^RU^TSKJK\38H4TWX;_$74IE2/XA6UK"
MSIH?B"YE;;'XRM[:';:W3%4\2QQGIK*NNH_TZ(ZR(DBD,K ,K#D$,,@@CL1^
MG6O\G.SO;S3KNUU#3[NYL+^QN8+RQO;*>6UN[.\M94GMKJUN8'CFM[FWGCCF
M@GA=)8I421&5E!']I?\ P1I_X*[0_'O3=+_9I_:0\26EM\;-'M5MO OB[4I$
MM5^*^CV4!,D-U<2%86\=Z5;0M+J-HOE2:[8(VL6,,TMIKBVO]A^#WBU'-J=#
MACB/$J.94TJ>7X^M))8V$5%1P]6;M_M*5^63O[5:/W^7G_YO/VCW[/&MX>XG
M-?'+P6RB=;@G%5:F-XQX5P%*4ZG#6(K3<JN;9;0IIMY/4E)RQ-"G'_8)7JP7
MU5R6'_I$HIJLKJ&4Y5@"".A!&1^E.SW[>M?TE<_Q2"BBB@ HHHH **** "BB
MB@ HHHH **** "BBHI)EA1I9#LC169F/& H))8]@ ">_'-'GVU&DVTDKMNR2
MZM[(9<W4%I;RW5Q(L4$,;222.<*JHI8DD\#@'K7\6W_!9W_@K==?&S5O$?[*
M_P"SEXC>+X2Z9<W>B?%+QSI;E/\ A8=_;3-!=^%-"O5;+^"[29);?6=0B"IX
MJN(VM+267PPDLOB#Z#_X+8?\%;Y8)/$O['O[-'B,I=@W&B_&KXD:)=RQ2Z3M
M8+=_#_PKJ%H\6=4G0RVGC#4XI'32H'E\/VV=8EU-]$_DUK^5_&;Q8]G]8X3X
M=Q'OOFI9MCZ,_A3MS8.A.+U;VKS3[TX_:;_WK_9G?L_/KLLH^D)XT9/_ ++'
MV6/\/N$<QH?Q9)JI0XDS7#U8[)J-3*\-.-DK8NHN9T8P****_E!MO5W;;;;>
MK=^_GOKU/^@J$(TX1A"*C"$5&,8I1C&,59)):))*R2T2"BBBD4%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?Z.G_  28^!G_  H+]A#X
M#>$KNQ-EKVK^%4\<>)DE0+=+KGCR9_%E[;7;85GETXZJFE*&SY4-C%$I*H*_
MSVO@EX$;XH_&3X4?#8),R^/?B/X*\(2^0%,RV_B'Q'IVEW4D8<,NZ*VNI907
M5D&S+*X!4_ZEGAK3[;2?#^BZ;:0I;V]CIEC;00QC"QQP6L,:HH.3A%4(.^T#
M//-?U1]&W*(RJ9_G=2G[U.%# 8>;7_/U^VKJ/FO94=;Z*5NK/\#OVV'B-6I8
M'PC\+L+B7['&8G-^+LUPT96=\%3HY;E4JB3NX3>-S%QBURN='F>L4;M%%%?U
M@?\ /P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4449H 9)(L:-(YPJ*SL3V51N)]\ ?3WK^$G_@O5^V0WQ^_:=3X(>%=5
M%W\.?V?7N]*NS:7'F6>K_$G4DC/B*XD\J:2WG/ABU$/AR!FCCN+'4V\3VS96
M; _K._X**_M9:3^QQ^RU\2/BW<26LOB2WTQM#\!Z3<G(UKQKKR2Z?H%D8E_>
M2VT5V_\ :&J>4"\.DV-_<8VPL:_S9M;UK5?$>LZOXAUV^GU36]>U._UG6-2N
MF#W6HZKJEU+?:A?7+@ /<7=W/-<3, -TDC$ 5_-WT@^+_J.58;A;"5>7$YFU
MB,>H2]Z&#I23I4Y6V]M53EKK:DND[G^U?['SZ.;XLX]SSQYXBR[VF2\$1GDW
M"4Z].]+$<2XVC?'8VES*TGEF7U(T8R7-'VF/E9JI1TRZ***_C@_Z30HHHH *
M*** "OZF/^#<K]D$:UXE\>_M=^+]'D^RZ#N\ ?"BXN8V\F:_E_?>.M<ME=2C
M_9H3I>@V5[%\R/)XBM-P(>OYJ?A/\,?%GQH^)?@;X4>!;+^T/%OQ \3:7X7T
M.W82^2MWJ=RD)O+MH(IY8M/T^$RZAJ5PD,AMK"UN;C8XB*G_ $SOV5_@%X5_
M9B^ WPV^"O@V#;I'@?PU8:6+DPK'/J=^8EN-6UB]"<&^U?59KS4[U@3FYNIN
M<$&OZ%\ .#WFN>U>),72YL%DRY<-SQ]VIF%1?NVKZ/ZO"]2Z;<9NGW/\=?VN
MWTCH\ ^%6 \%>'\=[/B;Q+;J9TJ%1JO@N$L%5IRQ4:G(TX+-L1[/ J,URU\*
ML<EK3/H? QCMC';_  _^L<FD&2.<@^W!IU'KUY_SQ7]IG_,B%%%% !11FLG7
M=9L?#^D:CK.IW4%G8:;9W-[=W5S(L,$%O;0O/+++*[*D<<<:,SNS!54%B0!2
ME)13E)J,4FW)Z));MM[&E*E4KU:=&C"52K5G&G2IPBY3G4FU&,(Q2;E*4FDD
MDVVT?E;_ ,%=_P!O>T_8F_9TOF\,W]H?C/\ $Y;SPM\,--=XI9;.Y-OC6_&$
M]FQ,DNG>$K2XAN6)C-O-K%YH6FW)2/4MZ_Y[=_J%_JM]>ZGJE[=ZEJ6I7=S?
MZCJ.H7,UY?W]_>3/<7=]>W=R\EQ=7EU<223W-S/))-/-(\LKL[LQ^^O^"F7[
M9.I_MK?M3^-?B':ZC=S_  U\.75QX0^$NFR[X[:U\(:9,8WUN.T<)Y5YXNU!
M+CQ!<O-%'>I:76FZ9<_+I4"I^?-?P+XP<<5.+>)*N'PU5RR?*9SPV"BG^[K3
MBTJV*:3LW5E&T7_S[C!;W/\ K@_9P_19PGT>O!7+LZSO+X4_$?Q"P^%SWB6O
M5I)8K+\)6I*KE>11DUSTX8'#5%+$4[V>-JXF7P\EBBBBOR(_T4"BBB@ J_I>
MEZEKFIZ=HNC6%YJNL:Q?6>EZ3I>G6TUYJ&I:GJ%Q':6-A8VENDD]U>7ES+%;
MVUM CS3SRQQ1(SL :%?T:?\ !OY^PQ#\8OBSJO[5/C_2(KOP1\'M0&D_#^SO
MX)#;ZO\ $:6&&>ZUM$D40W$/A#3+N'[(V)4_MS5;>YA>*[T(X^LX*X7Q7%_$
M. R7#1:C6J*>*K6;C0PD'&5:I+I[L?A3^*3C'=H_G[Z3?COD7T=/!WBKQ+SN
M5.=;+<%+#Y'E\IQA4S7/L6G1RW 4KZOVN(E&5645+V="%6JURP;/WW_X)'?\
M$^M'_8D^ .GW7B73K2;XX_$NTT[Q#\3]8\N"2:PN6A,VD^#+"Z1I2VE>$X;N
M>T5HYF@O]7GU;5XEBCOXK>#]:R3C(!SVR.:$0(BQJ-JHJJH Z!0  /P%.K_1
MK)\IP61Y;A,JRZC&AA,'1A1I0BEJHJSG)I+FG-WE.6\I-OJ?\7WB+X@<3>*7
M&O$7'O%^85LSX@XES+$9ECL16G*2C*M-NGAJ$92E[+"X6DH8?#48OEI4*<*<
M=(H****](^)"BBB@ HI,\@>O]*9+(L<<DC'"1H[L?]E%).#[8Z\^G6ANRN]$
M-)MI)7;=DEU;V1_*U_P<S?%"Q@\&?LX_!V&ZD?4-8\6>)OB%?6D,L9B@M/"V
MDGP[:27T8F$R-=3^,;E; F!HYA97Y$J26_ER?R(5^N?_  6V_: B^.O[>GQ#
MM-*O%O/#7PBL-.^%FCR0R+)#)?:2UQJOBB9651^]B\1ZOJ&D3<X/]D(5XY?\
MC*_SV\7\ZAG7'F<UJ4^:CA*D,!2L[Q7U2G"E4<?[LJL:DUWYK]3_ +$/V<WA
ME7\,/HG>&F78[#?5LTXAP6(XNS!2C:K*7$6)GF&$C65DU5HY?5PF'DGK'V?+
MKRH****_,#^YPHHHH"YW'PT^'GBCXM?$'P9\,_!5A)J?BOQUXCTKPQH5E&DC
MA[_5KN*UBEF\I)'CM+82/=7L_EE;:S@FN'^2-B/]-']DO]G_ ,-_LP?L^_##
MX)^%U5]/\#>%=-TN6^\B.WFU;5&@6YUG6;J.(;!>:QJTU[J=U@G]_=R?,:_E
M&_X-V_V/E^(GQ=\6_M7>*K RZ#\(O,\(_#Y+B ^3=^.-=T]?^$BU:*1X]I?P
M]X9OXM.A$4CJTGBF=W$4MDA;^T8#:%4 X P,=  ,?_JK^U? 'A'^R<AK<1XJ
ME;&9VU'#.2]^G@*4DHVNDXJM53DULX4Z<E=,_P"8C]KK](G_ (B%XMY=X.9!
MCG5X;\,Z?MLY5&I>CB^+<PHQE4C-1;A/^RL!.%"$OBA6Q6,I2]Z&CJ***_H,
M_P ?@HHHH ***AN)TMH)IY&"QPQO(S$] BECU] /7IR<"DVDFWHENQI.348I
MMR:22W;;LDO-L_)?_@LE^V9_PR/^R-XH/AK57T_XJ_%7S?AW\.'M9 E[I^H:
MQ:7*ZWXFC/E7!A'A?05O]3M)Y86M6UM=&T^X9?[0C)_SU:_6O_@LS^U_/^U5
M^V)XLT_1-2ENOAC\$YM0^&W@F%)EDL[W5+"\V^-_$D:K&!OU/7X#I5O*DT\%
MSHWA[2+R$QM=3*?R4K^"?&GC!\3<5UL+AZKEEN2N>"PR4KTZE5-?6:ZMHW.H
MN6,EO3A3\S_K6_9D?1QCX&^ .6Y_G."]AQMXFQPW%&=RJT^7$X/+JU%/),JF
MW[\5AL'-5ZM*7\/%XK$KT****_'C_2$**** "BBB@ HHHH **** "BBB@#['
M_P"">VN>%O#W[;/[,^H>--'T[7O#4WQ5\/:-J&FZM86VI:>S^)&F\.V%[<V=
MV&@==*U+5+/54E96DM);)+N%&F@C4_Z86F16\5A:+:Q)%#]GA*(B@*H:-2-H
M' R#VXK_ "D_#'B+4/"7B7P[XKTIPFK>&==TGQ#ILC%L+J&BW]OJ5F[%65P%
MN+:,DHRM@<$'!'^IW\+/%NG^._AUX*\8Z3*D^F^)?"^@ZW831.)8IK34]+M+
MVWECE7Y9(Y(9T9)!@,I#]#7]@?1MQU.IE.?Y?RQ57#XS#XE2LN><*]*5-Z[V
M@Z*LGMSNW4_YR_VU_"V,POB!X1\8>UKU,#FW#F<Y)*BZDGA\/B<IQN%Q49QI
M<W)&KBH9E+FE&-VL-'F>BMZ!1117],'^'84444 %%%% !1110 A./\!UK\J?
M^"P/[8DG[(7[(7C#5_#^H/8_$SXC$?#KX:R0D"XM==U^TO?MVO(3%.D9\-:%
M;:KKD#3QFTGU&ST_3YF4WT>?U49@!O/&T,>>. .<_@*_A2_X.!_VE[CXN?M?
M6OP9TO4))_"G[/\ H2:9-;QRL;67QOXP@L=<UV?:K&.=['1O^$=TU'<&2VNH
M]4@01^;,TOYUXH\3OA7@[,<;2FH8O$P6!P+O:2KXF+CSQZ\U*DJM6+MI*$?G
M_9/T#? Q>/GTD.".%\=A7B>&LEQ'^MG%,90<J,LHR2I2K+#5D[*5/'XZ>#P5
M6#U=&O5=O=9^#+,S,S,S,S$LS,269F))9B>22222>22<TVBBO\[ISE4E*<VY
M2G*4I2>K<I.[;?KJ?]E&&PU'"8>AA</3C2H8:E3H4:<$E&G2I1C"$(Q6B2C%
M)6VZ!1114FX4444 %?W/_P#!!C]AR/\ 9_\ V>1\>?&VDQP_%#X^V>GZ]!]I
MAF2_\.?#R)!<>$=%\NX"FVGU.*YF\3:EY<4,DC:GI]A>>:^C0,G\HG_!.7]E
MR?\ :]_:Z^%7PCN('?PF-57Q;\09O)\Z&/P5X7DAU#5;.<$;$77YQ9^&HY7)
M6"764F\N;RO*?_2AT;3+31M+T_2K&"*WM;&TM[6"&%%CBCCMXDB1$1 $1550
MJ*H 4  5_4OT>>#X5JF,XMQM%R]A)X++.972J2BGB,0K]80E&E!J]N>=K-'^
M"W[8WZ1^(R_!\-_1VX;S!TY9I2I<3\<_5ZC4Y8&G5<<DRNK*$OAQ&(HUL;7I
MM)VPN&33A5:-+G'/7V_^O2T=*,].#_GUK^LS_GP"C-)GC.#_ %KXL_;5_;H^
M"/[$'PRO?'GQ4UY#JEQ%<6WA+P1I4EO<>+?&>LI%N33="TR66+S$B9XFU#4K
MF2#2]*@E2;4+N!7C$G)CL=A,MPM;&X[$4L+A</3E5K5ZTE"$(15VVW]R2U;:
M23;2/?X7X7X@XTS_ "OA?A;*<;GF?9SBZ6"RW+,OH3Q&*Q6(K2480A3@G:*O
MS3J2Y:=."E4J2C",I+JOVOOVNOA+^QM\(/$/Q8^*FMQ65IIUM-#H>@V\D+Z_
MXMUZ2&5M/\/>';"5XS>ZG?31[%W/%:V<(FOM1N+33[:YNH?\[_\ ;(_;"^+'
M[;/QFU?XO_%*[C@WK)IG@_P?I\TKZ#X&\+I/+-::'I?F*C75R[R&ZUK6KB*.
M[UG47>8Q6=C%IVF:?I_MG_MM?&G]N#XI7?Q%^*NJF#2K.>\A\#^ =-GE/AGP
M+HEQ("EAIT;K&;_4YXXK<ZUX@NHDO=7N8@RQ6.GPV&EV/Q]7\0>+'BK6XPQ,
MLJRB=7#Y!AYM/5PGF%2-K5JL4]*2:?LJ;;T?-+WGI_U)?L_/H!Y7]'')Z/B#
MX@X?!YMXN9UA(._)&OAN$<'7@I2R[+JDT[XRHFEC\9%)SDO8TK4HWF4445^)
M6?W]/N_.Y_J.%%+ZU]H?L5_L)?'3]N3XB6W@WX6:)+9>&+&]MX_&_P 3-5M9
MCX2\$V4B-,S7<JM$VJZU/"F-,\.Z?*;Z\FE@DNGT[2OM6JVGHY3E&99YCJ&7
M97A*V,Q>(FH4Z5*#D]6DY2>T8QO>4I-)+5L^)\0O$7@WPLX6S3C/CO/L!P]P
M_E&'GB,7CL?7A1BU%75*C&3YJU>J[0I4::E4J3:C&+;///V6?V6OBU^U]\6]
M#^$/PBT.34=6U&2.XUK6[A)5T#PAH E2.\\0^(;Z.-EMK*V#[8(5W76I730V
M-A%-<S(E?Z$7[!?["OPM_86^#FG_  \\"VYU#Q#J/D:KX\\:WL,2ZSXO\2-:
MQ17%]=/&2;>PM]AM](TF-VM],L_W:&6YEN[JYO\ [$O["OP4_8=^&-GX$^%V
MBK-K%S'#<>+O'6K1VTWBSQEJZ@E[_6]1MX8 T4#22Q:;IMM%!IVF6Q$%K;H3
M))-]L=?4'\B,_P"?Z]:_N;PO\+L'P3A(XW&QIXK/\337M\0O>AA(32;PV';7
M3:K5T=1Z+W%K_P JOT[?IX<2_2BXBJ\,<,5,;D/A#DF,D\KRERE1Q/$6(HR<
M89QG,(2UB[<^"P,KQPT6JE5.N_W:]L?_ %OY44'GU'THK]@/\YPHHHH ***X
MKXB^._#GPS\#^*/'OB[5;/0_#7A/0M4\0:YJ]_*L%GIVEZ38SW][>7$K'"16
M]M;RRNW/RHV,G%1.I"G"52<E&G"+G.<G:,817-*3;LDDE=M[(Z,+A<1C<3A\
M'A:-2OBL57I8?#T*4)3JUJ]:<:=*E3A%.4YSG*,8QBFY2:25V?C3_P %N/\
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MMN%?"Z,HYFJ%1RH8SB_&TX_6Y3Y7R57E>$<,)"7Q4L17Q]*2NM%HHHK]^/\
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ME*3;DVW=MMZMMZM]0HHHIB"BBB@!!P.@S["OF#]M#XFP?!S]EGX[?$N=RO\
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M<V_@;P_/MNK3P[9!_LU]XT\46Z21RQZ7IP=UTNSWI+KVKK'8Q;+&WU>]T_\
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M!)X[U=(U9)GBDTV>V\,JZ$&&Y\2V]R"3 4/[KR2+#$\C$[8U9V)ZX4%B>?0
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M8UF.WDM/"OA:WN2^R^\4^))D_LS1K<I%/)!#/*VH:B()HM*L;^Z46[?V.?\
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MSK9!E$$YU\1ALGPWUK,,542_@T*,)0A[2=E*K4A"-WS6^*J***\H_0#]WO\
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M:U1\TZM:O6E.K4G)N[E.3;"BBBM3B"BBB@ HI#GMC/O2\\^G;_Z]%^G]=/\
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M@\70K4ZB3A)2E%2YX3C$HHHKC/I0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ _P ]Z^^/^">G[>GQ"_8+^-=GX[T$WVN_#KQ#+8:9\5/
M$-SLB\2:%!+((M2TZ*:6*S3Q3X>6YNKK0KBY>*&?SKK2;JXM;/4IKF#X'HKU
M<DSG,,@S+"YKEE>>'Q>$JQJ4YP=KI/WH36TH3C>,XO1Q;3/@/$[PTX1\7>"<
M^X!XXRK#YOP]Q!@JN#Q>'Q$%)TG.-J6)PTVN:ABL-44*V'KTW&I2K0A.$E**
M9_JB?!;XQ^ _CU\-?"7Q5^&NOV?B3P?XRT>UUG1M4LG)26WN$!>.:-PLUK=V
MDWF6E]8W217EA>PW%E>0PW,$L:^IYXXQ_2OX'O\ @CG_ ,%,[[]C;XFQ_"GX
MJ:]<-^SG\1M3B2[DO9'EMOAGXKNI(XH?%-FSN4LO#^J96W\6P!##$4LM>1K7
M['JO]I?WHZ5JEEK.GVFJ:;<0W=C?00W-K<6[K+#-#/&LJ/'(A*.C(ZLK*2I!
MR"<C/^A/ '&^!XWR2CF%!QIXVBH4LQP?->=#$<JO)*]W2JZSIR[7C=RC(_X\
MOI=_1;XK^BQXHX_A'-J=?'<+YC4KX_@SB-T91H9OE+J+EI3FE[..88'GCA\;
M133YU"O"*I5H&C1117W1_*84444 %%%% 'YW?\%)/V$;;]O?X(+\,V^(GB?X
M?ZIH>J#Q+X=GTJ99_#>H:];6MS!8Q^,] =H1K^DVYN'D@@CO+&ZL[HQWMK=+
M-"$?^!_]JK]C3X^_L:^.Y_!'QL\%WFCQ37-RGAKQA8I+?>"O&-I;LV+OP]KR
M1I!++Y02:YTF[%IK>G)+&=0TZV66%I/]/$\^H^E>1_&;X%?"K]H'P/K'PZ^+
MO@O0O''A+7(#!>Z3KMC'>1!N3%=6LAVSV5_:R8GL=1LI;>_L+E([JSN8+B-)
M%_)_$;PJRSCJ'UR-:6!SJC3]G0Q=Y3I5(Q7NTJ])NW+>]IPM*-V[2V/] OH9
M_3ZX\^BGB5P[6P%'BKPQS#'?6LTX><:6&S#!5JTH+$8_*<=&,6\0X1][#XMS
MHUN6*4Z-KO\ RP__ *WZ_C_^KO17]$?_  40_P""#_Q-^!<VN_$_]E6'6/BG
M\*XS<:A>_#V0OJ/Q(\(VHS-*ND"&/?XSTBU3>L42+_PD]O D,;PZ_,9[\?SQ
M7%O<6=Q/:7<$UK=6LTMO<VUQ$\%Q;W$#F*:">&15DBFAD5HY8I%5XW4HZA@1
M7\4\4<'Y[PACI8/.<'4I:_N<1%.6&Q$%M.E62Y6G'=7YHO223/\ I[\!OI)>
M$WTC.&,/Q+X<<2X3,)^RA_:61UJD*&=Y/B)1C*>&S#+IR]M2G"3M&HHRI5%:
M5.I.+3(:***^5/WL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKWG]F3]GSQO^U+\<?A_\#O %I/-K7C;6[>SN]02W-Q;^'/#\+"?Q#XHU%?,
MA06.A:4ES>O&]Q ;VX2VTRVD:^OK6*3LR_ XG,\=A<OPE.57$XNO3H4:<$W*
M4ZDE%67S/F^,.*\DX&X7S[B_B+&T<NR3AW+,7FN9XRO-4Z=#"X.A*M5G*4K*
M_)#1:MNR2;T/W _X($?L"'XP_$^X_:S^)&C/+\/_ (5:B]A\-+&^@<67B?Q]
MY4D.HZZJ282ZL/!EK.D=JQ26";Q'>)+%+'>>&YDI/^#DOPR-._:=^"7B1([A
M(]:^$6HZ*CML%F1X;\67]YY=N GFBXC'B4?:2\KQF.2S$:1,)6E_KQ_9U^!?
M@;]F[X.^!/@Y\.]+BTCPOX)T&RTBQA14\^XDC17OM1OYE4-=ZGJM^]QJ.J7L
MN9[S4+NYNIV:65C7\R?_  <X>$)%N?V5/'$<1,,;?$_PS<S".8[9;U?".J64
M3RC-NFY--OWCC?;.^R1HM\4<Q3^Q.+."L/PIX,X_*L/&,\31IX'&9A7BO>KX
MJ6*PZJN]KN$+JG"^T()V3;/^;[Z/7TG<W^D#^TOX0X_SG$UZ.29CB>)>&^$,
MLJU&J65Y!1R/-9Y=14.;DAB,6Z/UK%.-W/%8AP3<84^7^4*BBBOXO/\ IE/U
M?_X(D^)8_#?_  4E^ (D$>S7E\>:"2\ F9&G\ ^([^,Q.Q!MI#)IJ*TZ?-Y3
M2P$>7.U?Z&ZG*J?4 ^W//'MZ>U?YDO[ GCC_ (5S^VI^S%XM)VQ6GQD\%Z9<
M/NV[;3Q-JL/A>\;=T 6UUF9F)X"@EL+DC_31L9/-L[63^_;0/GUW1(W]:_M7
MZ.N*]IPCF&%NF\-F]6=NJ5?#X:U_5TI6]&?\Q'[9K()X+Z1/!^?*E*-+.?#K
M X95.5^SJ5LLS;-'4Y'LW&&.I*2Z)Q?VBW1117]!G^/P4444 %%%% !1110
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M$L/AO3(M-\,6LD82.>'1Q>&,37<Q;],/XAP>,\XXY%5-/B6+3[.%.%2UMT7
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MZT9_#ISVY]#0 M%4+[4[#3+:6\U&[@L[6%&DFGN9!%%%&H+,\CL=J*J@DL2
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ML^%>BSC[/^]N/$D ,OB9A'/))#;^%!>6<TMK-:W>N:7+L+?R-?M,?M=?'_\
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M2@:IK?P^\$ZK8Q%X!YEGH'B'5[34'"-*+AQ%+XATU=\,,D*>:%GDB>2V6?\
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M<M6/.GRU<=+^!%:6;I6E6=OAE"">DC_)C]K+](Z/A?X+T_"O(<=[+BWQ4=7
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M4I9-"5IRVDOKE1/W$^M*#YFKJ3CL_P#";Z87[6JAA7FO 'T:^3%8A>VP6/\
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M94L9F4:N39/*TO;UJ=L5B(NS2PU";C)IIO\ >32@K:<VB?\ F;]*W]IKX1>
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M8FK.W+&G2I2<FTMV?E(J,Y55!9G8*JJ"S,Q. JJ,DL20 .I)XZU]3Z]^QO\
M'+P/\#;K]H3XG^%[CX7> +B]TG2/!L7CB&XT7Q1\1-8UEY&@MO"7ABXA75)K
M&UT^WNM8O-7U.+3;!M+MY)]+DU1E>-/[:OV.?^"+_P"R'^R9'IOBK5/#G_"X
M_BCIT<=U-X[^)%K9:HFFWT4:RR3^%O#83^P?#:Q2B1K.YCMKSQ!!#(89_$%X
MJ[C_ #4?\%T/VP(_V@_VI)?A!X-U%)OA=^SNU]X6M([*3-CJGC^Z:$>,-0PC
M;)O[%:"V\+6PD0M:W6FZT\#>3?L6_5\Z\*<+P1PKB<\XKQRJ9I72PV5Y5@YV
M@L757\2O6:;G&A'FJ.-./*Y1C%SM(_S]\+_V@.=_2B\?,D\+/ +A>M@>!,IJ
M3SKCGCWB/#.6)J9!@*E-/#Y7EL9*.$GFV(G1PE*OC)O$4Z=6K6AA[T6U^(=%
M%%?A9_JR%%%% !116CI&DZGK^K:9H6B6%WJNLZUJ%EI.D:98PO<WVI:IJ-S%
M9V%A9VT0:6>ZO+N:*WMH8U+RRR)&@+'%:4J52O5IT:47.I5G&G",5=RE)J,4
MK;MMG'F./PN5X#&9ECJT,/@\#AJV+Q5>K)0ITJ&'IRJU:DY2:2C&$6VVUHC]
MW_\ @@-^Q]/\</VG9_C[XFTQ;CX>_L]JEWIWVNW,EGK7Q+URUN+71;>(36[V
M]S_PBNER7?B*Y,4T5YIFKR^$;I 4G)']TJJ(T5%!VJ J@#H!P !T&!7P7_P3
M>_9)TS]C7]E3X<?"@6]DWBXZ=_PD?Q%U>R2-O[:\=>(4AO\ 7K@W0A@DO+33
MI6BT+1I[B);@:#I&E02C= :^]\U_HMX:\*0X0X4R_+I04<;6A'&9C*WO/%UX
MQ<H-[M4(*-+>WN.2^)G_ !E_3;^D#B?I&>/_ !=QG2Q$ZO#.6XB7#?!U%R;I
M4^'\JJU:='$PB]$\RQ$L1F+;2FHXFG2DW[*-BBBBOOC^1PHHHH *K7<"W-M<
M6[#*SPRQ'/3$D;)S[<_@3FK/Z44FKJSV:M^A49.$HSCI*,E)/LXNZ?WH_P V
M/_@I[^S[=_LV?MO_ !U\!_9C!H6M^*KOXB^$)%CCA@F\->/9Y=>BAM8XW<+:
MZ/JUQJWAR,GRR[:,SB-$917P'7]@_P#P<<_LF7WB?P5\//VK/"6CS7=Y\.VF
M\&?$>:TC#R#P?KUY]HT+5KI54R/;Z#XA:6U9HL>3%XEN+FY'V>V:2W_CXK_/
M+Q7X;J<-\:9IAXTG#"8VL\=@GR\L)4L5^]<8/9JE4E.E_P!N'_8[^S^\:\+X
MV?1GX!S6IC88GB+AK+J7"7$U+VOM,33S'(X0P<<1B5)N:EC\+##XY.6\<0K-
MV84445^:G]LA1110 4444 %%%%&KT2NR7)13<FDOM2EI'9=7I_PS"BNM\%^
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MM]+\7?M9^+6^*?B" V5Z/ 'A62]T;X?V5U&T%P]MJ6H;[7Q#XKBBGC:+]Z-
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MOA?PW>"\3_$"E*="M2P6*_XQO)JT6XR_M+,Z'/&O6@T[X3!N<[V52=)/F/\
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M#*)M1GB<!3Q3]M'$8*IRPQE!3J6C4I5HOEG*,/GFBBBOQ8_TW"BBB@ HHHH
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MXO'9;+%XF;J5LPP6*J5:M*G*;E4P=51I)K#3M^?=%%%?S2?[>!1110 4444
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MBUI.K=;V@M&?\^/TJ_VI'BOXW0S'A/PWCB?#+P_Q'M,/4>#Q+_UISG"M<O\
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M45_8=_Q#,_"+_HX?XH?^"7PC_P#(5+_Q#,_"/_HX?XH<?]07PA_\A<_A1_Q
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MJ?Q+\.1-X%UB:\F>26>[O6\/RV5CJEQ<2RO+/+JUCJ#2RL97W2$L?S \>_\
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MF$:CS#&))<LDZU.E-74Z33:*=E86>G6T5I8V\5K;0($B@@01Q1JH  1%P%
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M\/@\AG@*4VOAC]9S"K0C%MJ]W'EUU>A_!4JEV5$5F9F"JJJ69F)P H4$DDG
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MAS3XFFVVL#YG\2:'!<:-)#:W.HZC;>'(V2S7\<OIS7^LA<6MO=PO;W,230R
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MK2QO!_5/I.AZ/H5I#8Z/IMGIMG;Q)##;6<"00111J%2..*,!$1% "HH"J
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MPJC4Y:GU6-59GF3Y5:4J4\%@:V'GKRWQ$5*Z?*_W!'''I1117]VG_*"%%%%
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M[_Y_^O3J* #_ #W'^?\ )ZTASVZ^_2E].O'^>:0<>I^M "^]&>O!_P ^E%%
M!1110 4444 %%%% !1110 4444 )CZCZ<>]')QG'?)'],_K2T4=_7]$ F!]?
M8]!]!1P.?\]_\:6BELON\O*_]>@#3D]/S.1_]>G=.E%%, HHHH **** "BBB
M@!#G@=N_K[8]Z%)QR,'Z8I:* $/KCZ@#K_\ JI !C.#^/7TY_P ]/J:=0>?4
M?2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H/&<<^PY
MZ\4R>9+>&6>4A4B1Y')X 5%+,3[ #/\ ]>I 3W'/Z?A_6OQ^_P""R/[=MO\
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MXD^ _AGX<AEGUSQ]XO\ #_A+3$BB:5TN=>U.VTY)VC7DQVRSM<S$'"0PR,Q
M!(_U#_@]\/- ^$_PP\"?#GPK8IIWA_P;X5T'PYH]E&I"6VG:/I5GI]I$>68E
M(+= SN[NS99Y&8EC_$K_ ,&_7[-TGQ=_;#NOB]J=G]H\,_L_>'SK"M)&6@D\
M8^,[?4O#^@1DGY':VTF/Q-J('S/#=6]C*=NY"?[M%4( HP%  4>@48QBO[3^
MCSPZ\OX;QF>UH<M7.,2H4&U=O"X6\5./93JSJ1:Z^S6R/^9#]L7XQPXO\:>&
MO"S+<2JF7>&^2RQ&9TZ<KP6?\0>QKRI5$GRN>%RVA@YP:7N_7*D;O5)U%%%?
MT*?X[!1110 ?YQ7Y/?\ !8;]C2+]KS]DGQ79^']*6]^*GPU23Q]\-98HT-[<
M:IH]O-)JOAV)VFMU\OQ3HQO-($=Q+]CCU&73=1GBDETZ$K^L-07,"7-O-;R
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M[/V^-QV(JXK%5O94XTJ?M:]:4ZE1PI0A3BY2;48Q6R"BBBM3@"BBB@ HHHH
M*/UHHH _F\_X.$_V*)/BI\%M(_:F\$:3#+XS^!L,\/C<6\(%]K?PNU2X$NHS
MNT<#R7+^"=3,>OPK/-!:6&AWOB^Z!>X:&.3^*JO]73Q=X7T7QMX:UWPGXCTZ
MTU;0_$&E:AH^JZ7?PI<V5_8:C:S6=U:W=O(&CFM[BWFDBFBD5DDC=D8$&O\
M-X_X*+?L<ZY^Q-^T[XT^%<T-W-X&U&YF\4_"_6YH+A8M2\%ZI=S-::?]JE!B
MN]3\,S"30=3>.9WF>T@U*6&U34H(5_D?Z07!3HXC#\7X&B_9XGDPN:J$=(5X
MQ2H8AI+15(+V4GHE.G&]Y3U_Z&_V/GTG(9EDV;_1RXJS'_;LF=?/N I8FK[U
M?*ZTU/-<HI2G*\IX+%S^N4*=W)T,35C"*I89V^$J***_E\_W="OU'_X)8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAJO\/#TFJF39+7<)?%6K+^T<12E:484,(VG&LT:E%%%?U>?\_84444 %%%%
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M#VE'EJ2[JBBBOMS^8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH0Y:&'I)\M*C3ITX^[%!1117H'R 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 </\1_AYX2^*O@GQ-\/O'.A:=XD\*>+='U#0M>T35;=;K3]2
MTW4K:6TNK6Y@<$/')%,ZG&'&=R,KA6'^=_\ \%+/^"??C3]@WXUWN@^1J&L?
M!OQ?>7FH?"KQK-&TJRV'F-++X3UVY11''XF\/QLL4KL(X]:T\0:Q:*COJ-AI
MG^CQT]Z^6/VOOV3?A?\ MD?!?Q/\'?B?IK3Z=K-N)])UJR\N'6_#&O6>9M*U
M_0KUE;[+J-A=!&PZRVM[;-<Z;J-O=Z;>7=I-^:^)G &$XZR:5)1A2S?!QG4R
MW%V5_:6N\/5>[HU6K/\ DE:6UT_[9^A#]+SB#Z*OB70S"K4Q.8>'?$E;#X+C
M7(83E*+PW.H4\YP5)ODCF.71E*:LE]9H<^'F[^RG3_S#J*^IOVP/V1OBK^Q?
M\9M=^#_Q1L#(]I+)=^%/%UG:W,'A_P <>&W<"TUS19;@?*ZAEMM7TPRS3:/J
M:36<DUS +6^N_EFOX S++<;E&.Q.79A0GAL7A:DJ5:C4BXRC*+MI?=/=-:-:
MIV/^O/@;C?AGQ%X5R7C+@_-L)G?#V?8&AC\NS#!U8UJ56C7IQFE)Q;Y:L&W"
MI3E:4)IQDE)-!1117 ?6!_7KU_/ZU^A_[!W_  4G^/O[!_BN*3P5J3>+?A9J
M6H)=>+/A-K]Y<'0+X2,B7>I^'I<RGPOXC>%0HU*UMYK2]9(!K&FZDD%OY'YX
M4N?\_P"?\_K7KY)GF:</8^CF64XNK@\51E%J=.32DDTW"I':I"5K2A).+6C1
M^>>)WA7P)XQ<)YCP7XA\.X#B+(<RHRIU<-C*,9U*%1Q:CB<'7M[7"XJDWS4J
M]&<*E.6L9(_TK_V+_P#@H+^SY^V[X*A\1?"SQ1%#XCL[:U;Q5\/M<DMK'QKX
M4O+A<&WU72$EE#VQF6:*UU;3Y;[1[\PR"SOYFCD5/N?(X/KW'IV)_P _A7^4
M[\/?B/X]^$_B[2/'OPT\7:_X'\8Z#<QW6E>(?#>I7.F:E;2)(DC1-+;NHN;*
MX\M8[[3KM9[#4+<O:WUM<6TDD3?U3_L#?\'">FWD>B?#/]M:PBT>_6.PTRP^
M-'ANP<Z)J<WFBV^T^.M M8Y9M N77R);K6-#CN-">:2[N9M,\.6,*"O[!X!\
M<\ISV-#+N(W3RK-+1IK$M\N!Q<]%=2VP\Y;N,WR-M\LHJR/^<#Z6_P"RM\1?
M"BMF?&/@O3QGB!P&IUL5/)*4/:\59#AU[_L_805\WPU&/-&-6A'ZUR1CST:D
MN:;_ *O**X7X?_$OP)\5/#.E>,?AWXKT'QCX9URSM]0TG7?#NJ6FKZ5J%G=(
MLD%S:7UE)+;W$4B,"KQ2,IZ9R"*[G//]?\?Z5^^TZM.M"-2E.%2G.*E"<)*<
M)1DKJ491;336S3/\DL9@\7E^)KX+'87$8/%X:I.CB,+BJ-2AB*%6FW&=*K1J
MQC4IU(23C*$XJ46FFDQ:*3/7&,_YZT<Y'3OGU_#^M6<PM%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8M%&:*8@HHHHO_7W?YH HI <YX(^HI<T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXGA_^1_\*/\ A[A_P3W_ .CGOAA[?\3P_P#R/_A7^<511_Q,CG__ $(<L_\
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M !/#_P#(_P#A7^<511_Q,CG_ /T(<L_\&XGR_O\ E^/K<_XHG^$7_1U^._\
MPCR;R_ZAO)_?Y'^CK_P]P_X)[_\ 1SWPP]O^)X?_ )'_ ,*/^'N'_!/?_HY[
MX8>W_$\/_P C_P"%?YQ5%'_$R.?_ /0ARS_P;B?+^_Y?CZW/^*)_A%_T=?CO
M_P (\F\O^H;R?W^1_HZ_\/</^">__1SWPP]O^)X?_D?_  H_X>X?\$]_^CGO
MAA[?\3P__(_^%?YQ5%'_ !,CG_\ T(<L_P#!N)\O[_E^/K<_XHG^$7_1U^._
M_"/)O+_J&\G]_D?Z.O\ P]P_X)[_ /1SWPP]O^)X?_D?_"C_ (>X?\$]_P#H
MY[X8>W_$\/\ \C_X5_G%44?\3(Y__P!"'+/_  ;B?+^_Y?CZW/\ BB?X1?\
M1U^._P#PCR;R_P"H;R?W^1_HZ_\ #W#_ ()[_P#1SWPP]O\ B>'_ .1_\*/^
M'N'_  3W_P"CGOAA[?\ $\/_ ,C_ .%?YQ5%'_$R.?\ _0ARS_P;B?+^_P"7
MX^MS_BB?X1?]'7X[_P#"/)O+_J&\G]_D?Z.O_#W#_@GO_P!'/?##V_XGA_\
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M_BB?X1?]'7X[_P#"/)O+_J&\G]_D?Z.O_#W#_@GO_P!'/?##V_XGA_\ D?\
MPH_X>X?\$]_^CGOAA[?\3P__ "/_ (5_G%44?\3(Y_\ ]"'+/_!N)\O[_E^/
MK<_XHG^$7_1U^.__  CR;R_ZAO)_?Y'^CK_P]P_X)[_]'/?##V_XGA_^1_\
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MB?X1?]'7X[_\(\F\O^H;R?W^1_HZ_P##W#_@GO\ ]'/?##V_XGA_^1_\*/\
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M<]\,/;_B>'_Y'_PH_P"'N'_!/?\ Z.>^&'M_Q/#_ /(_^%?YQ5%'_$R.?_\
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M_D?Z.O\ P]P_X)[_ /1SWPP]O^)X?_D?_"C_ (>X?\$]_P#HY[X8>W_$\/\
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M)_A%_P!'7X[_ /"/)O+_ *AO)_?Y'^CK_P /</\ @GO_ -'/?##V_P")X?\
MY'_PH_X>X?\ !/?_ *.>^&'M_P 3P_\ R/\ X5_G%44?\3(Y_P#]"'+/_!N)
M\O[_ )?CZW/^*)_A%_T=?CO_ ,(\F\O^H;R?W^1_HZ_\/</^">__ $<]\,/;
M_B>'_P"1_P#"C_A[A_P3W_Z.>^&'M_Q/#_\ (_\ A7^<511_Q,CG_P#T(<L_
M\&XGR_O^7X^MS_BB?X1?]'7X[_\ "/)O+_J&\G]_D?Z.O_#W#_@GO_T<]\,/
M;_B>'_Y'_P */^'N'_!/?_HY[X8>W_$\/_R/_A7^<511_P 3(Y__ -"'+/\
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MXGR_O^7X^MS_ (HG^$7_ $=?CO\ \(\F\O\ J&\G]_D?Z.O_  ]P_P"">_\
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M45]L?S %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !C/:OD[]J3]BG]GC]L#PE)X4^-GP_P!(\2",
M2-I'B!(C8^*O#MS(,&Z\/^(K-H-3TN5\*)X[>X6UNT40WUO=09B/UCZ=>/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBE_6FDVTNKM^(G)1UDTDDVVW9)*V[>VXE'^>G^?_ *]>D_"[X._%7XV>)(?"
M'PC^'OBWXB>))C#G2_">B7NKR6D<\GDQW6I36T3VVE6!D^1]0U*>TLHCS+<(
M 37]!'[)'_!NM\8/'DFD^*?VJ/&EI\+O#,VRXG\ ^";BRUWQY<0O KK;:EKU
MQ%/X:\/31SN!.MA!XK,L*/''/932)/%]EPWP#Q3Q55A#*<KQ$Z,I)2Q=:#HX
M2FI;.5:HHQ^2N^US^:O&OZ7/@+X!X"OB./\ CW*,/F-.G.=#A[+:]/,L^Q<H
M63ITLNPLJE:,N9I<U94Z:OK)69_.AX5\(>*_'6O:?X6\$^&=?\7^)M5F\C3/
M#WAC1]0UW6M0F_YYV>F:7;W5[<..K"*%MH^8X&2/Z)_V(O\ @WO^*WQ,;1?'
M?[6FM2_"SP9*;:^7X:>';BWO?B%JD*S,SVGB+5=L^C^%()XDCW0Z:VNZK+;7
M$L3S>'[^ -7]1'[+W[!W[,G[(?A^/1/@S\,]$T.\,:KJ/BJ\B?5O&.M2AF<R
MZMXFU*2ZU6[&]W,5L;E+*U1O)L[2VMUCB3[&50HPHP.P%?T]P7X!9/E+IXWB
M:LLXQBY9+"0YH8&E)6=I;5*]MK/DAI>S/\+/I+_M<_$GQ!AC^&?!'+JGASPW
M6<Z,^(L4Z>(XKQU!^ZY4+<^%RI32WI^VKJ,FN>$M5X!^S[^S'\$OV8/ ^F_#
M[X,> M#\%>'].B12NG6W^GZC<!0)+_6-5G>;4M9U*8Y:?4-3NKJ\F)S),> /
M?\<8_3V[=?\ .:" >HI:_H##X>AA:-.AAJ%+#T:<8QIT:,(TZ<(Q22C&,$HI
M)+2R\S_(+-\YS;/\QQ>;YYF6-S;-,?6GB,9F&8XFMC,9BJ]1WG5KXBO.=6I.
M3W<I-A1116YYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 'GU'TI,9Q[9_7M2T4 -
M(!R""0W!';'],_K7SU\;OV5/V?OVB]"G\/?&;X4^"O'MG+%+%#-KVB6MWJ&G
MF92KSZ3J>Q-2TB[&=\=YIMW;7,3A9(Y4=0U?0_KUY_SQ1[XYK#$8;#XNE.CB
M:%'$4IZ3I5J<:E.2TNI1DFI?-'IY1G><</XZAF>19KF&3YCAIJIA\=EF,Q&!
MQ=&<7=2IXC#5*=6#7>,EVV/Y??VDO^#;CX7>(YKO6OV9_BGKWPWO)6\T>$O&
M\(\8^%  KYM]-U(7-AXGTQ9&*.TU]?>(PA#I';JKHL/X1_'[_@C]^WE^SZ]W
M<:I\';SXD:!:*7?Q'\'YYO'5J4#8S_8EO9V?C!>/F9CX;\E!D&8\$_Z+N.OO
M3)(8I5*2(KJ1@JPRI![$=#7Y-Q#X)<$9ZZE6CA*F48J=W[7+Y<E/F;3<I8>5
MZ;=TW:/(M=C_ $&\'OVH?THO"N.$P&9<183Q%R/#>SA_9_&%#ZQC/84XQBJ-
M+.,.Z6,BK1TE6^L.^]S_ ">=2TS4='O;C3=6T^]TO4;21X;JPU&UGLKRVFC=
MHY(KBUN8XIH98Y$9'CD161E*, RD51_STK_4+^+O[(_[-OQVLIK/XL?!?X=>
M.?-&U+OQ%X5TK4M0MLF-BUGJ-Q;O?6;YAB.^UN(6_=H,X4 ?D9\9?^#=K]B[
MQV^H:C\/-4^)/PAU.X%Q+;6OAO7X-:\.174NQHS+I/BVUUNZ%G"ZL19Z=JVF
M*5=HTEA58C'^+YU]'//L-SU,DS3"9A#>%'$J6%K<N]FWSTG+_MY:^2N?Z:^&
M'[9_PGSJ&&POBAP)Q'P?C)12Q&89-*EGV5<[Y$W"G%T,="%Y3;YJ,K1AUE)1
M/X9Z*_I,^*G_  ;7?M%:'+=7'PD^-7PV\;V*O,T%GXRL-9\$ZFD09O(B,^E+
MXQL[N4H%$LQ33TWD[(-O(_.3XB?\$?O^"AGPXGNEO?V>];\46=L7VZEX$UKP
MYXK@N41]HDM["PU4:ZP<?.D<ND0S[/O1(WRU^89EX6\=94Y?6>'\;.$-ZN%B
ML33:TU3HN3:U[(_NS@7Z>7T4O$&&'_L;Q@X8PF*Q-E'+\\Q$LEQD)-74:E/,
M(T(QE;>TVEU9^9U%>N^-?@!\=?AO]H/Q!^#/Q3\$QVI87$_BKP!XIT&UCV-;
MHY-WJ6EV]L55[JV0N)BFZX@7.Z:,-Y(RLA*NK*RLRLK @JRG!!!Y!!R&!'!Z
MU\;7RK,\*VL3E^,H-7NJN'JPLUO\45L?TCE''O!'$$83R/B[AS-HU(QG!Y?G
M.7XOFC))Q:]A7G=---/9IW6@VBBE_P ^H_3\,?X&N)PFMX27_;K/IUB*$K<M
M:D[ZJU2#NOD_-"4444<LOY9?<_ZZK[R_:T_^?D/_  ./^?FOO"BBBCEE_++[
MG_75?>'M:?\ S\A_X''_ #\U]X4444<LOY9?<_ZZK[P]K3_Y^0_\#C_GYK[P
MHHHHY9?RR^Y_UU7WA[6G_P _(?\ @<?\_-?>%%%%'++^67W/^NJ^\/:T_P#G
MY#_P./\ GYK[PHHHHY9?RR^Y_P!=5]X>UI_\_(?^!Q_S\U]X4444<LOY9?<_
MZZK[P]K3_P"?D/\ P./^?FOO"BBBCEE_++[G_75?>'M:?_/R'_@<?\_-?>%%
M%%'++^67W/\ KJOO#VM/_GY#_P #C_GYK[PHHHHY9?RR^Y_UU7WA[6G_ ,_(
M?^!Q_P _-?>%%%%'++^67W/^NJ^\/:T_^?D/_ X_Y^:^\****.67\LON?]=5
M]X>UI_\ /R'_ (''_/S7WA1111RR_EE]S_KJOO#VM/\ Y^0_\#C_ )^:^\**
M**.67\LON?\ 75?>'M:?_/R'_@<?\_-?>%%%%'++^67W/^NJ^\/:T_\ GY#_
M ,#C_GYK[PHHHHY9?RR^Y_UU7WA[6G_S\A_X''_/S7WA1111RR_EE]S_ *ZK
M[P]K3_Y^0_\  X_Y^:^\****.67\LON?]=5]X>UI_P#/R'_@<?\ /S7WA111
M1RR_EE]S_KJOO#VM/_GY#_P./^?FOO"BBBCEE_++[G_75?>'M:?_ #\A_P"!
MQ_S\U]X4444<LOY9?<_ZZK[P]K3_ .?D/_ X_P"?FOO"BBBCEE_++[G_ %U7
MWA[6G_S\A_X''_/S7WA1111RR_EE]S_KJOO#VM/_ )^0_P# X_Y^:^\****.
M67\LON?]=5]X>UI_\_(?^!Q_S\U]X4444<LOY9?<_P"NJ^\/:T_^?D/_  ./
M^?FOO"BBBCEE_++[G_75?>'M:?\ S\A_X''_ #\U]X4444<LOY9?<_ZZK[P]
MK3_Y^0_\#C_GYK[PHHHHY9?RR^Y_UU7WA[6G_P _(?\ @<?\_-?>%%%%'++^
M67W/^NJ^\/:T_P#GY#_P./\ GYK[PHHHHY9?RR^Y_P!=5]X>UI_\_(?^!Q_S
M\U]X4444<LOY9?<_ZZK[P]K3_P"?D/\ P./^?FOO"BBBCEE_++[G_75?>'M:
M?_/R'_@<?\_-?>%%%%'++^67W/\ KJOO#VM/_GY#_P #C_GYK[PHHHHY9?RR
M^Y_UU7WA[6G_ ,_(?^!Q_P _-?>%%%%'++^67W/^NJ^\/:T_^?D/_ X_Y^:^
M\****.67\LON?]=5]X>UI_\ /R'_ (''_/S7WA1111RR_EE]S_KJOO#VM/\
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M44<LOY9?<_ZZK[P]K3_Y^0_\#C_GYK[PHHHHY9?RR^Y_UU7WA[6G_P _(?\
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M,L=B9RJ8C&8[$UL7BJU26LIU:]><ZLY-[N4FPHHHK4X@HHHH **** "BBB@
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M<DZ#X0L/#I:0IL(8Z#_9I>,K\QA;,)E+3&/SB7KQO5/^"'G_  3BU.SGL_\
MA0\%B+AE8SZ;XQ\?V5S$5EGFQ!/!XM26%=US+&5C=5,*P18$=I9K!^N=%>34
MX7X<JN3J9'E4W)MMO 8:[O:^OL[]._5GWV"\=/&?+HTX8+Q5\0,/"ER^SA#B
MS.^6'(TXI1>,:LK+3;H?B[_PX._X)O\ _1)?$7_ATOBE_P#-M1_PX._X)O\
M_1)?$7_ATOBE_P#-M7[145S_ .IG"G_1/Y5_X14?_D/ZOZ6]C_B93Q__ .CQ
M>(?_ (E&:^7_ %$>7]:6_%W_ (<'?\$W_P#HDOB+_P .E\4O_FVH_P"'!W_!
M-_\ Z)+XB_\ #I?%+_YMJ_:*BC_4SA3_ *)_*O\ PBH__(?U?TL?\3*>/_\
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M?B[_ ,.#O^";_P#T27Q%_P"'2^*7_P VU'_#@[_@F_\ ]$E\1?\ ATOBE_\
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M_P#"*C_\A_5_2Q_Q,IX__P#1XO$/_P 2C-?+_J(\OZTM^+O_  X._P"";_\
MT27Q%_X=+XI?_-M1_P .#O\ @F__ -$E\1?^'2^*7_S;5^T5%'^IG"G_ $3^
M5?\ A%1_^0_J_I8_XF4\?_\ H\7B'_XE&:^7_41Y?UI;\7?^'!W_  3?_P"B
M2^(O_#I?%+_YMJ/^'!W_  3?_P"B2^(O_#I?%+_YMJ_:*BC_ %,X4_Z)_*O_
M  BH_P#R']7]+'_$RGC_ /\ 1XO$/_Q*,U\O^HCR_K2WXN_\.#O^";__ $27
MQ%_X=+XI?_-M1_PX._X)O_\ 1)?$7_ATOBE_\VU?M%11_J9PI_T3^5?^$5'_
M .0_J_I8_P")E/'_ /Z/%XA_^)1FOE_U$>7]:6_%W_AP=_P3?_Z)+XB_\.E\
M4O\ YMJ/^'!W_!-__HDOB+_PZ7Q2_P#FVK]HJ*/]3.%/^B?RK_PBH_\ R']7
M]+'_ !,IX_\ _1XO$/\ \2C-?+_J(\OZTM^+O_#@[_@F_P#]$E\1?^'2^*7_
M ,VU'_#@[_@F_P#]$E\1?^'2^*7_ ,VU?M%11_J9PI_T3^5?^$5'_P"0_J_I
M8_XF4\?_ /H\7B'_ .)1FOE_U$>7]:6_%W_AP=_P3?\ ^B2^(O\ PZ7Q2_\
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M^";_ /T27Q%_X=+XI?\ S;5^T5%'^IG"G_1/Y5_X14?_ )#^K^EC_B93Q_\
M^CQ>(?\ XE&:^7_41Y?UI;\7?^'!W_!-_P#Z)+XB_P##I?%+_P";:C_AP=_P
M3?\ ^B2^(O\ PZ7Q2_\ FVK]HJ*/]3.%/^B?RK_PBH__ "']7]+'_$RGC_\
M]'B\0_\ Q*,U\O\ J(\OZTM^+O\ PX._X)O_ /1)?$7_ (=+XI?_ #;4?\.#
MO^";_P#T27Q%_P"'2^*7_P VU?M%11_J9PI_T3^5?^$5'_Y#^K^EC_B93Q__
M .CQ>(?_ (E&:^7_ %$>7]:6_%W_ (<'?\$W_P#HDOB+_P .E\4O_FVH_P"'
M!W_!-_\ Z)+XB_\ #I?%+_YMJ_:*BC_4SA3_ *)_*O\ PBH__(?U?TL?\3*>
M/_\ T>+Q#_\ $HS7R_ZB/+^M+?B[_P .#O\ @F__ -$E\1?^'2^*7_S;4?\
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M?$7_ (=+XI?_ #;5^T5%'^IG"G_1/Y5_X14?_D/ZOZ6/^)E/'_\ Z/%XA_\
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M]3.%/^B?RK_PBH__ "']7]+'_$RGC_\ ]'B\0_\ Q*,U\O\ J(\OZTM^+O\
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MWG=SGT[>GIFG45L>:-()QMX_,=/;_P"M_2G444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_3.jpg
<TEXT>
begin 644 image_3.jpg
MB5!.1PT*&@H    -24A$4@  #@,    '" 8   "?S]RO    "7!(67,  $SE
M  !,Y0%USO"5    [4E$051XG.W=.PJ#0!2&4?>_'1&QD,%F5C"M._%%+(,D
MA0EW$LZ!K[?\&;C8[                 ! U9KH#P
M7@L[!ISG><\YWZKKNKUM6TF2I*J:INGVSI$D2=+WZOL^?#-*DB0]EU(*WTF2
M)$FZ;AB&\+TH29)TU3B.X5M)DB3I'RNE1)W<O>7/@            /R<;=O.
MUG4]6Y9%DB1)DB3I(SW>&FKD&!                  *N<8$
M       JYQ@0                 "IW $"V'1(L86H)     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293442408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,740,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828294296904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 723,269<span></span>
</td>
<td class="nump">$ 647,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">847,060<span></span>
</td>
<td class="nump">819,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">190,614<span></span>
</td>
<td class="nump">282,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">28,467<span></span>
</td>
<td class="nump">27,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">53,333<span></span>
</td>
<td class="nump">57,530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,842,743<span></span>
</td>
<td class="nump">1,834,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">404,535<span></span>
</td>
<td class="nump">371,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">106,169<span></span>
</td>
<td class="nump">104,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">98,001<span></span>
</td>
<td class="nump">111,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">138,986<span></span>
</td>
<td class="nump">131,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,654,118<span></span>
</td>
<td class="nump">2,616,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,285<span></span>
</td>
<td class="nump">24,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">42,768<span></span>
</td>
<td class="nump">61,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">82,885<span></span>
</td>
<td class="nump">77,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">49,997<span></span>
</td>
<td class="nump">33,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">32,492<span></span>
</td>
<td class="nump">86,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">63,652<span></span>
</td>
<td class="nump">53,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">289,079<span></span>
</td>
<td class="nump">337,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenues</a></td>
<td class="nump">8,035<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">50,636<span></span>
</td>
<td class="nump">51,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">12,517<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">360,267<span></span>
</td>
<td class="nump">405,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 320,268 and 318,842 at March&#160;31, 2022, and December&#160;31, 2021, respectively</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,448,130<span></span>
</td>
<td class="nump">2,427,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,665)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(147,934)<span></span>
</td>
<td class="num">(216,507)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">2,293,851<span></span>
</td>
<td class="nump">2,210,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,654,118<span></span>
</td>
<td class="nump">$ 2,616,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293284536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">320,268,000<span></span>
</td>
<td class="nump">318,842,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">320,268,000<span></span>
</td>
<td class="nump">318,842,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297838520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 355,980<span></span>
</td>
<td class="nump">$ 270,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">13,203<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">156,671<span></span>
</td>
<td class="nump">159,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">102,863<span></span>
</td>
<td class="nump">102,351<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">272,737<span></span>
</td>
<td class="nump">274,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">83,243<span></span>
</td>
<td class="num">(4,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">1,822<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">164<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income (loss) before income taxes</a></td>
<td class="nump">85,229<span></span>
</td>
<td class="num">(2,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">16,656<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 68,573<span></span>
</td>
<td class="nump">$ 1,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">319,582<span></span>
</td>
<td class="nump">312,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">323,289<span></span>
</td>
<td class="nump">321,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 310,298<span></span>
</td>
<td class="nump">$ 227,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32,067<span></span>
</td>
<td class="nump">27,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 13,615<span></span>
</td>
<td class="nump">$ 15,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293413816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 68,573<span></span>
</td>
<td class="nump">$ 1,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized losses on available-for-sale debt securities, net of tax impact of $1,656 and $499</a></td>
<td class="num">(5,907)<span></span>
</td>
<td class="num">(1,736)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 62,666<span></span>
</td>
<td class="num">$ (135)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297022120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</a></td>
<td class="nump">$ 1,656<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828294360968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 01, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 01, 2021</a></td>
<td class="nump">$ 1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 2,321,895<span></span>
</td>
<td class="nump">$ 4,476<span></span>
</td>
<td class="num">$ (447,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(1,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">4,202<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(6,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">34,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 02, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Apr. 02, 2021</a></td>
<td class="nump">$ 1,911,187<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">2,354,103<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
<td class="num">(445,969)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">318,842<span></span>
</td>
<td class="nump">318,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 2,210,615<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">2,427,561<span></span>
</td>
<td class="num">(758)<span></span>
</td>
<td class="num">(216,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">68,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(5,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">5,513<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(4,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 20,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 01, 2022</a></td>
<td class="nump">320,268<span></span>
</td>
<td class="nump">320,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Apr. 01, 2022</a></td>
<td class="nump">$ 2,293,851<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 2,448,130<span></span>
</td>
<td class="num">$ (6,665)<span></span>
</td>
<td class="num">$ (147,934)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297119112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 68,573<span></span>
</td>
<td class="nump">$ 1,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">4,490<span></span>
</td>
<td class="nump">3,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,759<span></span>
</td>
<td class="nump">34,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">15,318<span></span>
</td>
<td class="num">(3,388)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">1,580<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="nump">91,793<span></span>
</td>
<td class="num">(17,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,520)<span></span>
</td>
<td class="num">(2,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,605)<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,169)<span></span>
</td>
<td class="nump">13,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued collaboration liabilities</a></td>
<td class="num">(54,261)<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">7,376<span></span>
</td>
<td class="num">(867)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">147,719<span></span>
</td>
<td class="nump">39,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(5,609)<span></span>
</td>
<td class="num">(13,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(336,545)<span></span>
</td>
<td class="num">(331,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">267,615<span></span>
</td>
<td class="nump">407,424<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(74,539)<span></span>
</td>
<td class="nump">62,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="nump">4,891<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(4,686)<span></span>
</td>
<td class="num">(5,441)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">205<span></span>
</td>
<td class="num">(2,650)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash equivalents</a></td>
<td class="nump">73,385<span></span>
</td>
<td class="nump">99,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">663,891<span></span>
</td>
<td class="nump">320,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">$ 737,276<span></span>
</td>
<td class="nump">$ 419,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296880648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 61 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and the European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021, included in Part II, Item 8 of our Annual Report on Form 10-K filed with the SEC on February&#160;18, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the three months ended April 1, 2022 and April 2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the three months ended March 31, 2022 and March 31, 2021, and the year ending December 31, 2022, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies during the three months ended March 31, 2022, compared to the significant accounting policies disclosed in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296828872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,692&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,392&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, and 2021, we recognized $2.4&#160;million and $2.5&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, and 2021, we recognized $31.7&#160;million and $27.8&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, $87.4&#160;million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 for information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296873944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</a></td>
<td class="text">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; to our Consolidated Financial Statements included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, or as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, $46.7&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $40.6&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royal Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $13.1&#160;million and $10.1&#160;million during the three months ended March 31, 2022, and 2021, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development milestones of up to $254.3&#160;million, regulatory milestones of up to $426.5&#160;million and commercial milestones of up to $1,911.5&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In conjunction with an asset purchase agreement entered into in 2021, we will make a $4.0&#160;million payment upon the completion of the technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $42.0&#160;million and regulatory milestones of up to $22.5&#160;million, per product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297921000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, restricted cash equivalents included $12.5 million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our January 2021 standby letter of credit will remain effective through June 30, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,459)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,459)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988,871&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $2.6 million and $2.9 million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three months ended March 31, 2022, and 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,459)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 197 and 133 investments in an unrealized loss position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for two corporate bond securities with an aggregate fair value of $6.3&#160;million and an aggregate immaterial unrealized loss as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three months ended March 31, 2022, and 2021, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296847640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,891,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had one forward contract outstanding to sell &#8364;7.5&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the three months ended March 31, 2022, and 2021, we recognized $0.2&#160;million and $0.4&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296946392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296840040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, 4,152,901 sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we granted 233,476 stock options with a weighted average exercise price of $19.02 per share and a weighted average grant&#160;date fair&#160;value of $7.51</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 12,635,435 stock options outstanding and $24.8&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we awarded to certain employees an aggregate of 1,003,482 (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to 175% of the target amount of shares. 50% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately one year later, subject to employee&#8217;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:90.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we granted 3,549,973 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $20.51 per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 11,635,329 RSUs outstanding, including the TSR-based RSUs, and $209.6&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and service-based RSUs granted to employees during the three months ended March 31, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were&#160;5,698,281 performance-based restricted stock units (PSUs) outstanding and $116.0&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296999032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR (BENEFIT FROM) INCOME TAXES</a></td>
<td class="text">PROVISION FOR (BENEFIT FROM) INCOME TAXESThe effective tax rate for the three months ended March 31, 2022 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits, partially offset by state taxes. The effective rate for the three months ended March 31, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, in relation to the generation of a small pre-tax loss during the period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296868904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297023512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the upcoming trial will address two issues: (1) infringement of claims 1 and 2 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A three-day bench trial has been scheduled to begin on May 16, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (salt and polymorphic forms), 11,091,440 (formulations) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. In the 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patents identified in the 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The 2022 MSN ANDA Complaint is a new case against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-02017 and 20-00633 described above. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. A bench trial in connection with the 2022 MSN ANDA Complaint has been scheduled for May 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Limited (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Parent), asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. On February 11, 2022, this case was administratively closed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297018904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Build-to-Suit Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is approximately 220,000 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the lease payments, we are also responsible for paying operating expenses related to the New Premises. For more information about our Build-to-Suit Lease, see &#8220;Note 11. Commitments and Contingencies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828294292344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021, included in Part II, Item 8 of our Annual Report on Form 10-K filed with the SEC on February&#160;18, 2022.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the three months ended April 1, 2022 and April 2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the three months ended March 31, 2022 and March 31, 2021, and the year ending December 31, 2022, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828298959656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,692&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,392&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text">Contract assets and liabilities were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297014344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>License revenues under the collaboration agreement with Genentech were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828290954648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,459)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,459)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988,871&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,459)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297023512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,891,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296835160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297025192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</a></td>
<td class="text">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:90.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296962520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828294375432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 01, 2022 </div>
<div>product </div>
<div>segment </div>
<div>country</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS', window );">Number of countries with drug approval, excluding the u.s. | country</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from discovery efforts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Countries With Drug Approval, Excluding The U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfCountriesWithDrugApprovalExcludingTheUS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297114184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 355,980<span></span>
</td>
<td class="nump">$ 270,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">448,237<span></span>
</td>
<td class="nump">314,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(137,939)<span></span>
</td>
<td class="num">(86,993)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">310,298<span></span>
</td>
<td class="nump">227,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32,067<span></span>
</td>
<td class="nump">27,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13,615<span></span>
</td>
<td class="nump">15,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 45,682<span></span>
</td>
<td class="nump">$ 43,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293908760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Concentration Risks (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293984472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 355,980<span></span>
</td>
<td class="nump">$ 270,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">314,065<span></span>
</td>
<td class="nump">229,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34,527<span></span>
</td>
<td class="nump">33,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,388<span></span>
</td>
<td class="nump">$ 6,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293471864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 355,980<span></span>
</td>
<td class="nump">$ 270,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">310,298<span></span>
</td>
<td class="nump">227,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">302,812<span></span>
</td>
<td class="nump">223,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 7,486<span></span>
</td>
<td class="nump">$ 3,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293933048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">$ 48,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">137,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(117,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2022</a></td>
<td class="nump">68,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">14,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">86,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(83,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2022</a></td>
<td class="nump">18,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">8,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">12,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(10,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2022</a></td>
<td class="nump">10,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">24,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">38,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(24,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2022</a></td>
<td class="nump">$ 39,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293508888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract', window );"><strong>Contract assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 3,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">7,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">8,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">15,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">$ 27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exel_TakedaAndIspenMember', window );">Takeda And Ispen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 87,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exel_TakedaAndIspenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exel_TakedaAndIspenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293885624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 355,980<span></span>
</td>
<td class="nump">$ 270,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34,527<span></span>
</td>
<td class="nump">33,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32,067<span></span>
</td>
<td class="nump">27,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">24,614<span></span>
</td>
<td class="nump">22,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13,615<span></span>
</td>
<td class="nump">15,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9,913<span></span>
</td>
<td class="nump">$ 11,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293395704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 46.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293475800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 355,980<span></span>
</td>
<td class="nump">$ 270,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,067<span></span>
</td>
<td class="nump">5,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32,067<span></span>
</td>
<td class="nump">27,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,365<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13,615<span></span>
</td>
<td class="nump">15,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,702<span></span>
</td>
<td class="nump">$ 4,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828296836760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 40.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293361128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - GSK Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember', window );">Royal Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 13.1<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293755128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 355,980<span></span>
</td>
<td class="nump">$ 270,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="nump">2,139<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 1,628<span></span>
</td>
<td class="nump">$ 951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProductOrServiceAxisAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProductOrServiceAxisAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293489240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember', window );">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Collaborative arrangement, maximum aggregate development milestone payments</a></td>
<td class="nump">$ 254.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Collaborative arrangement, maximum aggregate regulatory milestone payments</a></td>
<td class="nump">426.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments', window );">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</a></td>
<td class="nump">1,911.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=exel_AssetPurchaseAgreement2021Member', window );">Asset Purchase Agreement, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionPaymentUponClosingOfTransaction', window );">Payment upon closing of transaction</a></td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments', window );">Asset acquisition, maximum aggregate development milestone payments</a></td>
<td class="nump">42.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments', window );">Asset acquisition, maximum aggregate regulatory milestone payments</a></td>
<td class="nump">$ 22.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionPaymentUponClosingOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Payment Upon Closing Of Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionPaymentUponClosingOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=exel_AssetPurchaseAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=exel_AssetPurchaseAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293360712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 723,269<span></span>
</td>
<td class="nump">$ 647,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">14,007<span></span>
</td>
<td class="nump">16,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 737,276<span></span>
</td>
<td class="nump">$ 663,891<span></span>
</td>
<td class="nump">$ 419,921<span></span>
</td>
<td class="nump">$ 320,772<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293482728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Apr. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">$ 14,007,000<span></span>
</td>
<td class="nump">$ 16,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of investments in an unrealized loss position more than 12 months or longer | investment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</a></td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828291264360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,694,472<span></span>
</td>
<td class="nump">$ 1,534,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8,459)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,686,113<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,997,230<span></span>
</td>
<td class="nump">1,855,704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8,459)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,988,871<span></span>
</td>
<td class="nump">1,854,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">954,283<span></span>
</td>
<td class="nump">945,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">954,262<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">529,129<span></span>
</td>
<td class="nump">541,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7,123)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">522,101<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">197,605<span></span>
</td>
<td class="nump">33,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">196,464<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,455<span></span>
</td>
<td class="nump">12,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">13,286<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">97,602<span></span>
</td>
<td class="nump">135,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">97,602<span></span>
</td>
<td class="nump">135,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">87,255<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">87,255<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">117,901<span></span>
</td>
<td class="nump">119,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 117,901<span></span>
</td>
<td class="nump">$ 119,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293769624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 698,886<span></span>
</td>
<td class="nump">$ 454,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(8,459)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">456,676<span></span>
</td>
<td class="nump">385,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(7,123)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">196,464<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">32,460<span></span>
</td>
<td class="nump">43,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">13,286<span></span>
</td>
<td class="nump">7,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (169)<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828290946696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,290,576<span></span>
</td>
<td class="nump">$ 1,168,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">395,537<span></span>
</td>
<td class="nump">365,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,686,113<span></span>
</td>
<td class="nump">$ 1,533,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828290608264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,686,113<span></span>
</td>
<td class="nump">$ 1,533,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,686,113<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,891,269<span></span>
</td>
<td class="nump">1,719,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">87,255<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,686,113<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,804,014<span></span>
</td>
<td class="nump">1,652,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">954,262<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">954,262<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">954,262<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">522,101<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">522,101<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">522,101<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">196,464<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">196,464<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">196,464<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">13,286<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">13,286<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">13,286<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">87,255<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">87,255<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">117,901<span></span>
</td>
<td class="nump">119,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 117,901<span></span>
</td>
<td class="nump">$ 119,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293763912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narratives (Details) - Foreign Exchange Forward<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>EUR (&#8364;) </div>
<div>forward_contract</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of contract | forward_contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gain on derivative instruments, pretax | $</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828293772648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 10,858<span></span>
</td>
<td class="nump">$ 8,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">27,778<span></span>
</td>
<td class="nump">27,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">14,653<span></span>
</td>
<td class="nump">12,927<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">53,289<span></span>
</td>
<td class="nump">49,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">28,467<span></span>
</td>
<td class="nump">27,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 24,822<span></span>
</td>
<td class="nump">$ 22,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828295116136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,759<span></span>
</td>
<td class="nump">$ 34,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">8,899<span></span>
</td>
<td class="nump">12,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,860<span></span>
</td>
<td class="nump">$ 22,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828294376408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,759<span></span>
</td>
<td class="nump">$ 34,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,678<span></span>
</td>
<td class="nump">4,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">13,073<span></span>
</td>
<td class="nump">11,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="nump">17,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,299<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828291128296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,152,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted in the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="nump">175.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,549,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,635,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="nump">1,003,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,698,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,635,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828294056024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details) - TSR-Based Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 01, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="nump">$ 33.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of the Company's common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 20.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">46.85%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828291204584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 68,573<span></span>
</td>
<td class="nump">$ 1,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">319,582<span></span>
</td>
<td class="nump">312,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">3,707<span></span>
</td>
<td class="nump">8,814<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">323,289<span></span>
</td>
<td class="nump">321,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828384358312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">16,522<span></span>
</td>
<td class="nump">10,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139828297744232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Built-To-Suit Lease - Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2022 </div>
<div>ft&#178; </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet) | ft&#178;</a></td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">242 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the Lease | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease option to extend period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">180 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate After Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>exel-20220401_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:exel="http://www.exelixis.com/20220401"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20220401.xsd" xlink:type="simple"/>
    <context id="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="icceeeac4473d4c3e9581cd8f8a7b5119_I20220502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="i07e399f10aef4b259d2c54579c871e1a_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i07d2fa3b35a449daad65b440257d44b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idef460046aca49f3a2753fad35f32387_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i9a1f98ab028c4075b3c5959b7f157dc9_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ia7d496fb0cfe4be9ab5f4af2e1a705bd_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i3d9a170e7200455d9d99fa4118712bb7_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="icaf02010d20b45d38532755c0e8242ff_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i0f8de81af7714dbc880d1340b695ef37_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i9c02a85ca1984c97bac05b5150b1f317_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id30a451f1ae3428baafdcfb79ecdf5c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9d32bfc908c4aea8558c37289a11f4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68602b8c374e4c99bad4ffbcbe010108_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i881cc8f9bcd1476592152fb7be160129_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i6c24d1e3dc4c4181ac01f37d0cb06d20_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ib66100d961d94fc796a1669816ba4936_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ib0754265633149458c5c6423485e11cc_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ib6a0f7014d644e399cd7787b3ea5c2f1_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i667c3bfce7ba4ae99e9ae889d6f2a909_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="id5290c3943d846a0881409e0cf707dc8_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i6cce372e8cd44b4b8d65b809a8e7b49a_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i32215b9047b046b18b950af503dc8257_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2daa23ebb2ce4921b71a755a66326784_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i907cde9d0d3842e9a97643cb4ed9e659_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ib4b6a0c1e8f84451bda05b7283d51453_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6bba33a166db4495b501a3f2b8852f3c_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia9933b35b4354750bab2c5139b42078a_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i3afdd1736f3c44988bdbd68e0e8b99e2_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="idc4d5467005e45d985299ab2ab1495fc_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i61a10b6811c84b769705e56f58585a71_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="iae18b65c34724d73aab497d548fc2f19_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="if48023ef0a6d49198622a6d1d8e4809a_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ic91d1ea7f73646298e060832ddc685eb_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ic48eb912406143e587ee2129a748a248_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ib3de2311ad9f4eaa86a15e6ff586a051_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i008e83363bc848538e1a5dcbff4c3ac6_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i00814bc003494d9bb50fd207cefbb476_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="iab56d00962654960b416e521404e7025_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="if8b1dfc7877944b6bf20d7065aa99c7f_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i3a078295ea354ce7aeb0547546b5bb8f_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i39c0408a82aa46779a73c11dcfa75a56_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i551086107bad4e84b1d3ac16ad914e4d_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i8513f10a32ca4e5abd8caeb8ce075aa8_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i398655de202c44728712889a41d779af_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i74a2013f8a16433e81293adc6ea5aa4d_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ia3e90932b0d54d7da6e98d7fb3f07a50_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i35254c0fd6f2407a89472d5432f6dacb_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i7194cce6e63646fc9583d308abcef753_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ib194841422484f7ba4a2b5e11ae924ce_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ib8b84ad3f0ce4c27bd1d8097e8ef9797_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i285a461c2de24898a0698ba0e074b002_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i1cd800703a0a47a2a1821615e0313ebf_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i83adfa8283634307bba32f1f4f54be14_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="idce044eac78b4541ab6f56af1a43efe3_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ica5f788e45c34e62807c3bba9ae992de_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i961f155c52124473a01a4b5c400a76c2_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="if6ec26770cc04919bd55ec958f5914f9_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iebbff6ceb5ce44bd99cb97c1b5bf4d24_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i7546b59743254d7abf29b3243ae24052_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5ea966d46c44ecb89ce18913d688c79_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i90cb5dcefc15490d8098cf331b8ea9e1_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5766b5f0fc6649db9a9ece11f5731c2e_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="iaa84da93f4a441758b16037d47ea6de1_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="if09eb26b2a404183be3cabe74831a09a_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i2a440e479bdb4fd5bf6b77258180697f_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i1e249821f56b45859aadda9d9a17870c_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="id7134fedfc494cc3aa6a8ae4190620d4_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="if112a05a2b34404190a5729507b01b3b_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ic274dc535ec045c5a329dc95ebae978d_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="if44863bdae614924beec29fc65467290_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i3767f6dbcf4f4d6cb11379d61c886681_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i8c698e49d45749dd946feaceac85ad90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id15e0ac305444b18b2693bb09e7e1d35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib578158f471a4e36ad81dc312a12517d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35b4b3ffc9844993a92bbc43161faf68_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i47fd97f14ad845a9bc98e017beac244a_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="if4e948ebc35043fc8774b5ae38d6c32e_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="if20581f34d4d4396b415e4232596769d_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i4951c1e73e874036b22ef0fa4b27bb5d_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ib3fd33fa71724f02a5838171f02316d9_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ie18ac2c818d84341a05b5734a270a492_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exel:TakedaAndIspenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ifb9a5aa7f23e407aa788942742f46640_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i39de048fc1144bb9be6ca20c5cacab33_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ifa98a70e1323433694d00cfce4b2b09e_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i88c62f456465404387850b8211c219f4_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i4a69ed17a5c74d79b446ce43b6eaf688_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ifafb6fd490eb48bb9c8638ac3fc3247c_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ibca89d95ab5f4f82898ebc804c7d67c3_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="id880f02651a04201866bb497ae9e96c0_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ia992f174fe4c4a2c942a413095955ad3_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i1561bb88d7f84399858e3575701cc3ad_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i082deb7d649f464697d7bfcd0ecc9862_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i064bf749eb654609b6626219640cc568_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i7b8004462b3a4394be38cbda3e7571cc_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i8688f6af6d944b5d9a869f64d77e207b_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i0401aaeb66fd4321aaf94500fb43ff2d_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i72f8d2d0983748df85b871e2e1598f45_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i81b815ad748341c0a26d4fa1bcd0c7ea_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ibb9dca35b8b24f119a51c3af9f3582fc_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i538440738be741a491a5c13daa06b6ed_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i8c1bd21583b04c1198ee03ae25c583c5_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i867c322cc2874132b092bc2a3ff658c9_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:AssetPurchaseAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i65909c185a5f44b1a3af13f2646e6415_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i216f029a7d3140eda781b2bd89f45d1a_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i72e0a785551d4eb5b700653888c4db8d_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="if3a51673cab54c2c99014b6a758949cd_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="if8ce553376d14a1e9bbcaf23624a1e75_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ibb28bbb730bd440b8dd81392fd62926d_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ib35610c2f2f64e28b729777490e05b5a_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="iba307933d72242f293a72ee9fda21f66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80f302f2dfc743a7baa51a5301f9feb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieca5786fb2a340c09e8c451543dcf63d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i432f85dd8d664eee9a0730a69f1e1b48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if26e7aaf62fb4dfd93a135a62c26622d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39a97239c0614813a9bcdb47d5079585_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i5947ed8d61374685906f19d9a2843814_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i2ae72b8862524ed3bc2b8076fccf13b7_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i0f27864b6b9f4932ab380c795945d7bf_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i9a8f75092b0242e1ae826f92f356d80d_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i077a405a4ad640958488bbaf28a3f902_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ie91f2d21f92d443c8661271beebb3543_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i708e1024f4b043f5b3ca5956a7e0b0f3_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ib739bb13678f47dfafa308d8f18febb0_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i361a4fd0426d441c8c588a99db99da57_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="icb018c27cf90423abecc6191d113e300_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i9b1eef055e9241f1bb4210e3898693e9_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="iecade2a3f84649a985b16aa9c12ad66e_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="iad8a4c467cd646c8baca4f7b23ef5df5_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i65ec798216a747d2a34f9808d6def632_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i47ba248b6ca34c99b5dca94a7a314c11_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="iebc722e878a2424da9fcbea991b54c27_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i83d3eadd8ce14ffe8c19bfbb349b6627_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ibff127cda51a421eafdfdfc142c594bc_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i53790e7d78b6449e828c39355b724f3e_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ie1dcd1471658475dab1dc78d180aeb5d_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ib276f1befb584f2eb0d3d8400a5211c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1aae95b2dad1408b92e286980170dfc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf6386ba6236456c9cb250e103fddfb3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22ec7c9bfa1446a2aa2e7e77616f7444_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00701b0060ff40e3bf9e67174a926ca5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c6db7d27ba346c7a74173cedc687715_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id642b16c75c042b8b4f0872704ddeb4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9732c24ef7d4030924d2fffc47a71c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9f4cd6591c4439e807a82ca409c8519_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f55b03203d14b7199c525ee8fb9a037_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0e31300c13f4b42b4ccc7397381d5c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98e51bc0ba15407f9467b03b370593c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d9317c7dece422d8d017470956ef4c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaee8761f5b144743b68bf5786e2cb23f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41dfb8c579ab4f9bb95a37a5d8e40b2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf6962f24fdd4732b9aea4dfba7aeb43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if22e357e289d4e58b700f917e7b65f71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0be18ed8e8ba449981c62abecf9bf6ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7406990966249758acd778bc8008496_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57b1c0ac24664ff79ea2d1b0020ed617_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50204c4c28b948cb80f20f78f4be649e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e4e846c084c4559b6a9595a6687fd2f_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ic881e9f145a74a479a9c7527b88c7852_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i3f7b2f0fe2cf41038946282cc39c3653_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ia939647731704dcda59a54bb06e17828_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i6b94af5f9c714b06876549ec2d63eef9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a6ac444fe974dedb4a9b7fe83af78ce_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i3a2837ce514e4359abcc29c595fb4d0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ae08cfc122445338953c327341f7d67_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i0817dc61f16c4beb874045356c0ac962_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i6664829ae3ae483fa02b63376c5628fa_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i3b1a0fc30e914cd38e29d4ce13c7080f_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i422c757fd8504d8d9bd061c6daee9c01_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i3ac399c1a21047abb423228840492006_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i4258bed58c6048f58584c4e2f94d0ee9_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ic6c08f7404ff4eb485860a6fd51e4b73_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i14bb8ff89fac4afabb3b6fe4dc3cf4e5_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="icc7ff6b6e16e434293d751847fe852e9_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i72f50fb2bc0e46d39335240d888c8205_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="icc02918e98774e5ab327c89a0477cfcc_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ied00e348414944e896116d415bab3625_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ia195c1f38ea54879b3d52bd17362ea4e_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3c24c63c06b046a89283ea6c11d9a730_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5757437e306d438b96edc7549e66fa17_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i277d7677672b42a28307cdefe84dc555_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="if01316baae344a38a3c7cf53ddd5d7b4_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i5850614cec8549968a33dfef9671139c_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i7b2c5399d43b4b588fd04c0afca7e0f6_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i086d58fc90a14a97898df45878c69671_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ic64a47c5e8ba4d3db3fd89a64b034421_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="id6c8e9889ae843dc8773c941eac343d0_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i8602446ff3b94e92b5b78b0fb780866b_D20220402-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="country">
        <measure>exel:country</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="forward_contract">
        <measure>exel:forward_contract</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV8yLTEtMS0xLTQ4NzI5_77be437c-e305-424c-9b61-d335284044b5">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV80LTEtMS0xLTQ4NzI5_dfdd4d1c-ce8d-44f0-97d4-1210dd86199d">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV81LTEtMS0xLTQ4NzI5_8fa051e5-c51f-47e1-9ac7-2424cf2aa422">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV82LTEtMS0xLTQ4NzI5_ae5eb290-0ed4-4061-a1f7-49b1724a8d13">0000939767</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80L2ZyYWc6Y2NkYWIzNWQ4ZDZiNDAzNmFkOTMxODZlYWIzZmQxM2QvdGFibGU6MWRhM2JiZWZmNjQxNDU4YmIyZjk3YzZjOTQ3ZjU2YzUvdGFibGVyYW5nZToxZGEzYmJlZmY2NDE0NThiYjJmOTdjNmM5NDdmNTZjNV83LTEtMS0xLTQ4NzI5_4943e273-7b86-4bbe-b000-c70250a37d1f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6ZTY4NjJlZjdjMDVlNGMzZmJiZjk0NWE5NzUwMmNkNWEvdGFibGVyYW5nZTplNjg2MmVmN2MwNWU0YzNmYmJmOTQ1YTk3NTAyY2Q1YV8wLTEtMS0xLTQ4NzI5_c3af508b-c241-4a52-a7ee-f2967354dcfd">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6ZDAzZTViOGNiYmJlNGU2MWFlYWQxZDA2OWFmMmU0YjAvdGFibGVyYW5nZTpkMDNlNWI4Y2JiYmU0ZTYxYWVhZDFkMDY5YWYyZTRiMF8wLTAtMS0xLTQ4NzI5_c13927f4-b173-4023-a148-bba91b983a84">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV83Njk2NTgxMzk2NDQx_63ea5015-e743-44a2-a4c3-738a26533676">2022-04-01</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6ZmM0YmNlZmQzYTY4NDQ5MWI3MTdkYWRjNDIwMDQ0ZTEvdGFibGVyYW5nZTpmYzRiY2VmZDNhNjg0NDkxYjcxN2RhZGM0MjAwNDRlMV8wLTAtMS0xLTQ4NzI5_d9673190-a413-4e66-9d5f-6d3b19e9e6e3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODcy_5e925627-c978-4bac-a2ca-3d787bbf926e">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6YWVlZGRjMGNlMjU1NDgxNjhlMmJkYmMzZTczOGIxZmYvdGFibGVyYW5nZTphZWVkZGMwY2UyNTU0ODE2OGUyYmRiYzNlNzM4YjFmZl8xLTAtMS0xLTQ4NzI5_8581c13f-f5fa-4481-a279-3b6b9a86bc4e">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6NDJmMzE5MzBjODU1NDhkMGJhNTYxMTQ1YzU3NGJjOWUvdGFibGVyYW5nZTo0MmYzMTkzMGM4NTU0OGQwYmE1NjExNDVjNTc0YmM5ZV8wLTAtMS0xLTQ4NzI5_2ad9d8ed-9b1d-4074-a942-c35a78864826">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6NDJmMzE5MzBjODU1NDhkMGJhNTYxMTQ1YzU3NGJjOWUvdGFibGVyYW5nZTo0MmYzMTkzMGM4NTU0OGQwYmE1NjExNDVjNTc0YmM5ZV8wLTEtMS0xLTQ4NzI5_585ad83f-85aa-47fa-9cb9-ec311dc8f714">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODcz_84336e6f-9279-4d55-8576-cfe2c9d282dc">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc0_ccf6e4b5-ea7b-484e-a63d-ca638cbbba68">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc1_3b33e3c7-6000-4d9f-844e-90497c5c8641">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc4_41723fd8-76c1-4f8d-a8fd-fdbfb6900d45">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc5_645b9c98-2be4-4166-af24-3728b50378e2">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODgw_9d98fff0-b5ba-46e9-9ff7-360b88c21d8b">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6OGZjMzcxOGJmNjBkNDFmZWI2OTY4YzIwNWU0ZjNhZDIvdGFibGVyYW5nZTo4ZmMzNzE4YmY2MGQ0MWZlYjY5NjhjMjA1ZTRmM2FkMl8xLTAtMS0xLTQ4NzI5_6e33b1bd-622d-4a7a-8c42-fa6789d51d2c">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6OGZjMzcxOGJmNjBkNDFmZWI2OTY4YzIwNWU0ZjNhZDIvdGFibGVyYW5nZTo4ZmMzNzE4YmY2MGQ0MWZlYjY5NjhjMjA1ZTRmM2FkMl8xLTEtMS0xLTQ4NzI5_9c18205d-93a9-4bc8-84a0-c856b35066e9">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6OGZjMzcxOGJmNjBkNDFmZWI2OTY4YzIwNWU0ZjNhZDIvdGFibGVyYW5nZTo4ZmMzNzE4YmY2MGQ0MWZlYjY5NjhjMjA1ZTRmM2FkMl8xLTItMS0xLTQ4NzI5_7f9da0b1-4b7b-45f1-8de5-a74bbfa7c024">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODgx_ce79c767-d0bc-4c77-9988-1942c92b5a43">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc2_c48156ff-b69d-4ea9-9ad0-6ebce12b899f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6YzFkMjBlNGY4ZTNkNGI3N2IyMmE0NWUyYThhYzk1MjIvdGFibGVyYW5nZTpjMWQyMGU0ZjhlM2Q0Yjc3YjIyYTQ1ZTJhOGFjOTUyMl8wLTAtMS0xLTQ4NzI5_d25b2a08-43f4-49ed-b7c5-31afeaad4441">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6YzFkMjBlNGY4ZTNkNGI3N2IyMmE0NWUyYThhYzk1MjIvdGFibGVyYW5nZTpjMWQyMGU0ZjhlM2Q0Yjc3YjIyYTQ1ZTJhOGFjOTUyMl8xLTQtMS0xLTQ4NzI5_7207feaa-3975-422d-b582-e59c755619de">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGFibGU6YzFkMjBlNGY4ZTNkNGI3N2IyMmE0NWUyYThhYzk1MjIvdGFibGVyYW5nZTpjMWQyMGU0ZjhlM2Q0Yjc3YjIyYTQ1ZTJhOGFjOTUyMl8yLTQtMS0xLTY1NTIw_8a613469-1dfc-4546-9a39-7de49f7f4f4c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODc3_517109c0-0fee-4238-8320-165bb7861bcb">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="icceeeac4473d4c3e9581cd8f8a7b5119_I20220502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xL2ZyYWc6Yzg2OTMwNTM5OTdjNGY4MGJlODBlYjgzNTJjZDM5ZDkvdGV4dHJlZ2lvbjpjODY5MzA1Mzk5N2M0ZjgwYmU4MGViODM1MmNkMzlkOV8xODE3_96f757f2-e1c9-4cf9-9b81-c241c4ac4917"
      unitRef="shares">320740721</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNy0xLTEtMS00ODcyOQ_84d881c9-dcc2-47c5-90ea-c6fa81cf60e6"
      unitRef="usd">723269000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNy0zLTEtMS00ODcyOQ_6fe56791-5341-4dd5-85e0-508c4ce2b828"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfOC0xLTEtMS00ODcyOQ_06c100d1-33e4-48d3-8f2f-674a1727e195"
      unitRef="usd">847060000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfOC0zLTEtMS00ODcyOQ_b92f486a-6359-41f2-b04a-0e7910baa903"
      unitRef="usd">819905000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfOS0xLTEtMS00ODcyOQ_f44c770b-4fa8-483b-b95e-c4f6d76e95ad"
      unitRef="usd">190614000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfOS0zLTEtMS00ODcyOQ_51e88db1-8af7-41bf-806e-079f5207b9fd"
      unitRef="usd">282650000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTAtMS0xLTEtNDg3Mjk_5e3c62f2-91d3-4d88-bcbc-73b4205aa5cd"
      unitRef="usd">28467000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTAtMy0xLTEtNDg3Mjk_910f857b-e340-4f13-96ed-e2ca6b2a0140"
      unitRef="usd">27493000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTItMS0xLTEtNDg3Mjk_8238b078-4a8d-44b4-bde6-40f871ac7d8e"
      unitRef="usd">53333000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTItMy0xLTEtNDg3Mjk_5b1f889a-cc83-46aa-b2ee-e83e5be2e607"
      unitRef="usd">57530000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTMtMS0xLTEtNDg3Mjk_519b3fdb-4749-44d9-8a40-d4e3570f8cf6"
      unitRef="usd">1842743000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTMtMy0xLTEtNDg3Mjk_3b84710f-4cf8-41d9-ae60-d11777ce219a"
      unitRef="usd">1834747000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTQtMS0xLTEtNDg3Mjk_baaec21c-ca7e-4e0b-88ba-a625ba42899a"
      unitRef="usd">404535000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTQtMy0xLTEtNDg3Mjk_159d36b6-4fc8-4e55-8d98-25302f94a974"
      unitRef="usd">371112000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTUtMS0xLTEtNDg3Mjk_89877b0b-21d7-4c17-aa1f-76b996e6b9b4"
      unitRef="usd">106169000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTUtMy0xLTEtNDg3Mjk_48299ac3-2c80-4940-976a-809d64992090"
      unitRef="usd">104031000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTYtMS0xLTEtNDg3Mjk_810716ae-9455-4e0c-8a79-c9835607af29"
      unitRef="usd">98001000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTYtMy0xLTEtNDg3Mjk_5f989a80-5bf7-48e4-8870-81a0371830f2"
      unitRef="usd">111663000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTctMS0xLTEtNDg3Mjk_8aea7a8e-a1e8-4397-90dd-bbe34f4e3aef"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTctMy0xLTEtNDg3Mjk_b7ed051f-a95e-4d44-9d2e-a070ec676cc8"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTgtMS0xLTEtNDg3Mjk_003773d6-e728-4569-a997-32a24febcc6f"
      unitRef="usd">138986000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTgtMy0xLTEtNDg3Mjk_e9059be3-5f24-4744-9780-1771d7392436"
      unitRef="usd">131002000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTktMS0xLTEtNDg3Mjk_473b038a-9282-43d0-855d-4132c010e40f"
      unitRef="usd">2654118000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMTktMy0xLTEtNDg3Mjk_fdfca540-5aea-4473-b2d5-90a829dd1240"
      unitRef="usd">2616239000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjItMS0xLTEtNDg3Mjk_f06b7bac-c806-4b15-93d5-bf96d1f94f4e"
      unitRef="usd">17285000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjItMy0xLTEtNDg3Mjk_f76397cf-57c9-4565-9fbe-f7345da009dc"
      unitRef="usd">24258000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjMtMS0xLTEtNDg3Mjk_b5c0c6f5-891a-4d4f-9403-e81ff3a8ab88"
      unitRef="usd">42768000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjMtMy0xLTEtNDg3Mjk_f5225b49-8180-4e84-9401-1f5111e715ee"
      unitRef="usd">61969000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjQtMS0xLTEtNDg3Mjk_ee3091e5-7d4b-4d54-bff2-602d34145425"
      unitRef="usd">82885000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjQtMy0xLTEtNDg3Mjk_47a59992-c54d-49dd-aba8-e750664a13ea"
      unitRef="usd">77544000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjUtMS0xLTEtNDg3Mjk_1af33c90-e582-49e6-8e90-f4f6ea9bdaed"
      unitRef="usd">49997000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjUtMy0xLTEtNDg3Mjk_0e70d701-2290-4b13-830b-8579202db6b7"
      unitRef="usd">33700000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjYtMS0xLTEtNDg3Mjk_3cc9deb2-854a-4932-aa86-ab6205a8f419"
      unitRef="usd">32492000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjYtMy0xLTEtNDg3Mjk_e5336a7c-85ff-4af5-a88b-e930386772f5"
      unitRef="usd">86753000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjgtMS0xLTEtNDg3Mjk_ba90ff91-258a-4ee9-9932-51222050f31e"
      unitRef="usd">63652000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjgtMy0xLTEtNDg3Mjk_ca4ddf4d-2431-4f17-b1e6-207a6f7a277e"
      unitRef="usd">53366000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjktMS0xLTEtNDg3Mjk_3398d898-2050-4f18-90d5-4fefe8114e8d"
      unitRef="usd">289079000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMjktMy0xLTEtNDg3Mjk_265ae230-ec0a-4128-9ea0-77f0aaf6e157"
      unitRef="usd">337590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzAtMS0xLTEtNDg3Mjk_d664a941-68c0-4c5b-b8ef-e9a2db50a2b1"
      unitRef="usd">8035000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzAtMy0xLTEtNDg3Mjk_884d4120-b86c-41de-aefe-c47ae9121443"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzEtMS0xLTEtNDg3Mjk_77060fce-d07b-4af8-a587-d5f1e1e6d3df"
      unitRef="usd">50636000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzEtMy0xLTEtNDg3Mjk_c82e2956-6cd9-40e2-8c47-4a6c1af071e0"
      unitRef="usd">51272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzItMS0xLTEtNDg3Mjk_6dab6e25-2393-4fcd-b055-67e7feae23bd"
      unitRef="usd">12517000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzItMy0xLTEtNDg3Mjk_33953114-ce1c-47f0-83e9-4ee918bb690b"
      unitRef="usd">8023000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzMtMS0xLTEtNDg3Mjk_b00bae51-26ca-445a-9742-01fa0bc12220"
      unitRef="usd">360267000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzMtMy0xLTEtNDg3Mjk_eff60537-d53b-4f08-abc9-982bf23e0244"
      unitRef="usd">405624000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzQtMS0xLTEtNDg3Mjk_0bd42c32-6b7f-4217-9c98-9904c00b4cf6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzQtMy0xLTEtNDg3Mjk_ecb71d50-b644-4f29-adf6-3d2500b54c2a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV8yMQ_0a056031-2fc8-4ad4-9a09-f4e2e0ad4955"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV8yMQ_62f3f3d1-0d69-4641-851b-b220a848073e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV8zNQ_259cb5fd-33a2-48fc-861c-b5e4556ea78d"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV8zNQ_a5bbfc2b-9d16-48f2-ab41-b9cab70ce6bb"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV82MA_02fca04b-c0fd-4e81-ad43-acd50d0ccc34"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjpmZGVjNzA4ZWM5MGI0ZDBhYWJhMTVjZDg4MzZlOTMxNV82MA_48d6f7c1-5c0d-458e-84df-b7ada57fa95a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMS0xLTEtNDg3Mjk_72693d63-7f07-4793-a054-4475626fa8af"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzYtMy0xLTEtNDg3Mjk_4e29cd15-19b3-4b78-afdd-d1a30694c1bb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxOTAy_150d442b-62dd-4e3f-92b9-6bfccf3e60ee"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxOTAy_63396fd0-62ab-4938-a974-ec7131a5e507"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODg4_d45c5073-7e2d-44b9-bba4-bf2550cea120"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODg4_eacc4ef8-d7bb-4ee6-af48-15ebbcc45fee"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODY4_0716d809-3ae1-4c9f-b565-895f40989641"
      unitRef="shares">320268000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODY4_83e53606-9d86-4840-b5eb-e776ded39c71"
      unitRef="shares">320268000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODc4_cf6dd3db-2272-4cf7-9abe-b475d65463f6"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMC0xLTEtNDg3MjkvdGV4dHJlZ2lvbjplNDU2NjI5ZTRhMWE0NmE4ODRkNjEwMjU4NWU0NDcxYV8xNjQ5MjY3NDQxODc4_f88239d3-fcfc-4f43-ac55-529b8cf3f06c"
      unitRef="shares">318842000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMS0xLTEtNDg3Mjk_c1bb91f6-10b7-4795-aa9f-54101461582f"
      unitRef="usd">320000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzctMy0xLTEtNDg3Mjk_097303b5-f800-488b-b397-a3f2984d0064"
      unitRef="usd">319000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzgtMS0xLTEtNDg3Mjk_47ff829f-83a9-4f34-8b1d-0f0d39d817c2"
      unitRef="usd">2448130000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzgtMy0xLTEtNDg3Mjk_42af1c41-f354-4a88-9c7e-b77f39782e0c"
      unitRef="usd">2427561000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzktMS0xLTEtNDg3Mjk_036a3902-e5c8-471f-aeb3-e8bd7137420e"
      unitRef="usd">-6665000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfMzktMy0xLTEtNDg3Mjk_864698ab-1a21-4aaf-bc24-e7197e7ecde6"
      unitRef="usd">-758000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDAtMS0xLTEtNDg3Mjk_b91c6ecc-8a82-429b-8bc1-71286e12ca42"
      unitRef="usd">-147934000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDAtMy0xLTEtNDg3Mjk_81b04179-27cf-49b7-9dd3-656ac9403b4e"
      unitRef="usd">-216507000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDEtMS0xLTEtNDg3Mjk_81383fb1-05d4-48be-a50a-58bc6fc5e25b"
      unitRef="usd">2293851000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDEtMy0xLTEtNDg3Mjk_5d086165-ef79-4b8b-b14d-6081f0126ae1"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDItMS0xLTEtNDg3Mjk_46fc2f17-084d-4cf3-8fa0-8eda5a526d58"
      unitRef="usd">2654118000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xNi9mcmFnOjA5MDIzNWM5Mzk1YjQ0NDdiYjkyNGVkYTdlMTAwMTQwL3RhYmxlOmNjOTBmYjY5YjljZjQ1MDM4YTg5YzM1MTJhMTI2ZTE1L3RhYmxlcmFuZ2U6Y2M5MGZiNjliOWNmNDUwMzhhODljMzUxMmExMjZlMTVfNDItMy0xLTEtNDg3Mjk_0dd5ad0f-5ba3-4628-9c69-ded93853077a"
      unitRef="usd">2616239000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idef460046aca49f3a2753fad35f32387_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMy0xLTEtMS00ODcyOQ_fad99c1c-9bde-463b-8b2e-a5a35753679f"
      unitRef="usd">310298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a1f98ab028c4075b3c5959b7f157dc9_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMy0zLTEtMS00ODcyOQ_051c3bc3-9bcf-498b-a792-59862ae5363f"
      unitRef="usd">227212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7d496fb0cfe4be9ab5f4af2e1a705bd_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNC0xLTEtMS00ODcyOQ_85878222-8838-41d4-ba0a-75fc5801e059"
      unitRef="usd">32067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d9a170e7200455d9d99fa4118712bb7_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNC0zLTEtMS00ODcyOQ_08049445-0cf7-4fca-80e0-fdb4bd80a5ac"
      unitRef="usd">27528000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icaf02010d20b45d38532755c0e8242ff_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNS0xLTEtMS00ODcyOQ_47f29c8f-dca5-45c4-b9a4-f6233c031d5f"
      unitRef="usd">13615000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f8de81af7714dbc880d1340b695ef37_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNS0zLTEtMS00ODcyOQ_91346705-f5c9-4254-ad5a-d80ca09466ca"
      unitRef="usd">15490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNi0xLTEtMS00ODcyOQ_b751ee23-3bb9-48cd-8d70-e0030bcab6fe"
      unitRef="usd">355980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfNi0zLTEtMS00ODcyOQ_dd51d12e-8876-48c3-b7e2-a3a2d38aa8ff"
      unitRef="usd">270230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfOC0xLTEtMS00ODcyOQ_4c3cbe99-2b22-443b-b4f7-f326ff27ed58"
      unitRef="usd">13203000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfOC0zLTEtMS00ODcyOQ_1bffb3b4-6429-415d-add5-93ea9b04dc85"
      unitRef="usd">13198000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfOS0xLTEtMS00ODcyOQ_c3068cc8-fba1-4481-8d40-271d52d6b668"
      unitRef="usd">156671000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfOS0zLTEtMS00ODcyOQ_31c03312-c972-49ff-aa07-3e615921de4c"
      unitRef="usd">159288000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTAtMS0xLTEtNDg3Mjk_20375019-af1f-4264-9605-d0240ee6fa96"
      unitRef="usd">102863000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTAtMy0xLTEtNDg3Mjk_c4fff2be-e562-473e-b820-fd44191e3d20"
      unitRef="usd">102351000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTEtMS0xLTEtNDg3Mjk_b1aa5548-195f-470d-aa1e-fbfc35ceb843"
      unitRef="usd">272737000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTEtMy0xLTEtNDg3Mjk_da772141-461e-41fe-bf73-dea366571194"
      unitRef="usd">274837000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTItMS0xLTEtNDg3Mjk_e6b72206-98fe-4bfd-a62c-1dce5abd44b3"
      unitRef="usd">83243000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTItMy0xLTEtNDg3Mjk_321214cd-4f74-4d05-827d-68b3a6631820"
      unitRef="usd">-4607000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTMtMS0xLTEtNDg3Mjk_c2cba2d3-731f-4431-929d-61e8b598edef"
      unitRef="usd">1822000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTMtMy0xLTEtNDg3Mjk_2a4ffd8f-7d18-4707-aabc-88f7d34ba929"
      unitRef="usd">2682000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTQtMS0xLTEtNDg3Mjk_8f62bc68-7a4d-4d8f-9f9c-b00af633b54b"
      unitRef="usd">164000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTQtMy0xLTEtNDg3Mjk_728702a5-68e3-45f0-971c-84f77aeb1c93"
      unitRef="usd">-90000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTUtMS0xLTEtNDg3Mjk_83c821ca-8b87-40c9-ac83-fc1e2df1068e"
      unitRef="usd">85229000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTUtMy0xLTEtNDg3Mjk_1b208926-6e87-4ca9-a19d-e8d92ef1163f"
      unitRef="usd">-2015000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTYtMS0xLTEtNDg3Mjk_d63254f1-5564-4998-95dd-d17b4d62112a"
      unitRef="usd">16656000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTYtMy0xLTEtNDg3Mjk_03833372-78b3-48cd-9a6d-33d1552a0fda"
      unitRef="usd">-3616000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTctMS0xLTEtNDg3Mjk_e6f12bd3-6737-4a26-84ba-ede00144975d"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTctMy0xLTEtNDg3Mjk_bdfd9e7d-a56e-4eeb-941e-e7cf5aeddfce"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTktMS0xLTEtNDg3Mjk_824b75e3-22d1-4e4a-be41-1ba3c7788008"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMTktMy0xLTEtNDg3Mjk_cfcf81ef-1e5b-49ad-a6d4-83269d9871cc"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjAtMS0xLTEtNDg3Mjk_76b8bfa9-3cd7-4ed2-a86b-589323385452"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjAtMy0xLTEtNDg3Mjk_5e1b60f9-95e9-4bc0-9e61-217fb633c67e"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjItMS0xLTEtNDg3Mjk_adf748de-649b-493e-9e17-bee327546154"
      unitRef="shares">319582000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjItMy0xLTEtNDg3Mjk_85ef594e-7e6d-4789-ade5-824c0519b471"
      unitRef="shares">312473000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjMtMS0xLTEtNDg3Mjk_859d8612-136c-445d-a550-cc8f2c238ea1"
      unitRef="shares">323289000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjMtMS0xLTEtNDg3Mjk_c784476d-b3b8-43e6-8974-8bccf524ab2d"
      unitRef="shares">323289000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8xOS9mcmFnOjZjMGI1NDgwNjI2NTQ1NDE4OWM1M2I1Yzg5ZDhiYzcwL3RhYmxlOjhjODc5YWVlZDgzYzQwM2E5ZjJhZWM2NjJhN2FjNjMyL3RhYmxlcmFuZ2U6OGM4NzlhZWVkODNjNDAzYTlmMmFlYzY2MmE3YWM2MzJfMjMtMy0xLTEtNDg3Mjk_d78abe91-086f-4351-986f-38242cdeb39c"
      unitRef="shares">321287000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfMi0xLTEtMS00ODcyOQ_e6f12bd3-6737-4a26-84ba-ede00144975d"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfMi0zLTEtMS00ODcyOQ_bdfd9e7d-a56e-4eeb-941e-e7cf5aeddfce"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNC0wLTEtMS00ODcyOS90ZXh0cmVnaW9uOjQxNTg2YmMwNWJhMTQ2Y2M4Y2M4YTQ1MTA3ODRhYzUwXzE2NDkyNjc0NDI2Njk_99e3b20f-e909-4a3e-8cb3-bcda00e7b18f"
      unitRef="usd">1656000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNC0wLTEtMS00ODcyOS90ZXh0cmVnaW9uOjQxNTg2YmMwNWJhMTQ2Y2M4Y2M4YTQ1MTA3ODRhYzUwXzE2NDkyNjc0NDI2ODI_0efb6c43-3282-47bc-84cd-bea35c18c990"
      unitRef="usd">499000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNC0xLTEtMS00ODcyOQ_03ba9a52-10ed-4aad-a821-1d24d4e2f145"
      unitRef="usd">-5907000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNC0zLTEtMS00ODcyOQ_4428b0a4-5913-4762-adb2-146d56c134cc"
      unitRef="usd">-1736000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNi0xLTEtMS00ODcyOQ_a48b5c0a-93d8-4581-a249-1cf543ef6a78"
      unitRef="usd">62666000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yMi9mcmFnOjY3NmVkM2ZjYzdlNDRiYjM4Y2FiNzhlYTE5NTg0NWM0L3RhYmxlOmJiODhmZTY3YWE4MjQ2OGQ5NzFhMzkxZWMxYTE1MTFhL3RhYmxlcmFuZ2U6YmI4OGZlNjdhYTgyNDY4ZDk3MWEzOTFlYzFhMTUxMWFfNi0zLTEtMS00ODcyOQ_b1902ba6-2206-4019-9a33-d2261f3c2c07"
      unitRef="usd">-135000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9c02a85ca1984c97bac05b5150b1f317_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtMS0xLTEtNDg3Mjk_eddbe3eb-f3ec-429d-840e-e58095b18b46"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9c02a85ca1984c97bac05b5150b1f317_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtMy0xLTEtNDg3Mjk_e8b5b2ba-b33c-4b45-98d6-566e585cf59a"
      unitRef="usd">319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id30a451f1ae3428baafdcfb79ecdf5c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtNS0xLTEtNDg3Mjk_b4b753b8-f4c0-405d-8e01-2b2dd409b04c"
      unitRef="usd">2427561000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if9d32bfc908c4aea8558c37289a11f4d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtNy0xLTEtNDg3Mjk_283bebeb-bcf8-458b-8175-24a9612b744d"
      unitRef="usd">-758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68602b8c374e4c99bad4ffbcbe010108_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtOS0xLTEtNDg3Mjk_663de2ae-2ceb-42d9-bf86-b42cbec4cd4f"
      unitRef="usd">-216507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjMtMTEtMS0xLTQ4NzI5_5826933d-366a-4dda-8f13-8c4a194e7f4b"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i881cc8f9bcd1476592152fb7be160129_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjQtOS0xLTEtNDg3Mjk_00074c72-db14-429c-9110-4ad327d45c15"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjQtMTEtMS0xLTQ4NzI5_c7f87aea-b4c8-48b4-acfc-30e38327454d"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6c24d1e3dc4c4181ac01f37d0cb06d20_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjUtNy0xLTEtNDg3Mjk_71f71ba1-aa44-424d-bce5-12327e1fd95e"
      unitRef="usd">-5907000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjUtMTEtMS0xLTQ4NzI5_8c1aac23-2042-4826-8777-3e5b0247c1ee"
      unitRef="usd">-5907000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib66100d961d94fc796a1669816ba4936_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjYtMS0xLTEtNDg3Mjk_c5b9ecf2-dfe5-4b5f-8272-a8d8bc7bae81"
      unitRef="shares">1426000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib66100d961d94fc796a1669816ba4936_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjYtMy0xLTEtNDg3Mjk_3b94f5a6-8add-4b64-bce8-b4c6cc3d5b1a"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib0754265633149458c5c6423485e11cc_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjYtNS0xLTEtNDg3Mjk_38b21a42-38a9-4f2a-a081-690d15a2f490"
      unitRef="usd">5512000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjYtMTEtMS0xLTQ4NzI5_7ea756ab-7470-4745-a0e2-c61840b31145"
      unitRef="usd">5513000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib0754265633149458c5c6423485e11cc_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjctNS0xLTEtNDg3Mjk_8aab69bb-625d-4cc8-af3c-9c90f0e9ce45"
      unitRef="usd">4960000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjctMTEtMS0xLTQ4NzI5_b8f31ed6-0be1-4b38-b800-4945a704efdb"
      unitRef="usd">4960000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib0754265633149458c5c6423485e11cc_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjgtNS0xLTEtNDg3Mjk_79c5ff32-a3f4-4312-b491-99fc155519f6"
      unitRef="usd">20017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjgtMTEtMS0xLTQ4NzI5_07f2f316-da5c-4f9d-9e43-9ed067229177"
      unitRef="usd">20017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib6a0f7014d644e399cd7787b3ea5c2f1_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktMS0xLTEtNDg3Mjk_2edf4f06-e36b-4669-bc66-d9b5acce4f81"
      unitRef="shares">320268000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib6a0f7014d644e399cd7787b3ea5c2f1_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktMy0xLTEtNDg3Mjk_abc96399-2462-406a-b23a-25da8f5bbfa2"
      unitRef="usd">320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i667c3bfce7ba4ae99e9ae889d6f2a909_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktNS0xLTEtNDg3Mjk_5d160677-d7d5-426e-8053-ae4cc9015a44"
      unitRef="usd">2448130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5290c3943d846a0881409e0cf707dc8_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktNy0xLTEtNDg3Mjk_092571fa-357e-457c-8bc3-e796b2b9ef19"
      unitRef="usd">-6665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6cce372e8cd44b4b8d65b809a8e7b49a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktOS0xLTEtNDg3Mjk_81182240-9304-45b0-b5af-a26c770a8f36"
      unitRef="usd">-147934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjgyYzY1Y2UxNTQwMDQxY2VhODQ0MTE4OWM4ODA4ODExL3RhYmxlcmFuZ2U6ODJjNjVjZTE1NDAwNDFjZWE4NDQxMTg5Yzg4MDg4MTFfMjktMTEtMS0xLTQ4NzI5_83bc26a3-83bd-463e-a3bf-a5d63ce0cc0f"
      unitRef="usd">2293851000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i32215b9047b046b18b950af503dc8257_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtMS0xLTEtNDg3Mjk_acb8bc7c-90a3-43da-abb3-bcfb8e54df74"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i32215b9047b046b18b950af503dc8257_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtMy0xLTEtNDg3Mjk_b8e8f891-6916-4863-ba3f-e1f79b9860e4"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2daa23ebb2ce4921b71a755a66326784_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtNS0xLTEtNDg3Mjk_669c7d03-d7af-44a8-a3a9-d83f6315dab9"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i907cde9d0d3842e9a97643cb4ed9e659_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtNy0xLTEtNDg3Mjk_cdcedccc-33ba-479d-bdda-8010f8ad777f"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4b6a0c1e8f84451bda05b7283d51453_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtOS0xLTEtNDg3Mjk_7446a1f7-90f1-41ea-9fdc-d6b4acbcbfa3"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6bba33a166db4495b501a3f2b8852f3c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjMtMTEtMS0xLTQ4NzI5_f41bb4f0-550a-46d4-8566-b6fcb044a534"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia9933b35b4354750bab2c5139b42078a_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjQtOS0xLTEtNDg3Mjk_b8492745-0c1e-48dc-bf89-c2fe0351b45a"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjQtMTEtMS0xLTQ4NzI5_2330185b-eb15-4e32-a1fe-731750f6e8c3"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3afdd1736f3c44988bdbd68e0e8b99e2_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjUtNy0xLTEtNDg3Mjk_3a426d67-8998-41a9-a3bc-2ee308494a48"
      unitRef="usd">-1736000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjUtMTEtMS0xLTQ4NzI5_434fae62-a68f-4958-9da8-fe91aef3f668"
      unitRef="usd">-1736000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idc4d5467005e45d985299ab2ab1495fc_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjYtMS0xLTEtNDg3Mjk_c8f12aca-6bbf-4a14-a249-512b69aaa7a8"
      unitRef="shares">1635000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idc4d5467005e45d985299ab2ab1495fc_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjYtMy0xLTEtNDg3Mjk_a353ad4f-0d3b-499b-8bda-9fda0b654903"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i61a10b6811c84b769705e56f58585a71_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjYtNS0xLTEtNDg3Mjk_522bbcd4-4da5-4f48-8c20-b10678cadbf0"
      unitRef="usd">4201000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjYtMTEtMS0xLTQ4NzI5_d0cd07fe-e197-408c-9ee5-8969725eec0c"
      unitRef="usd">4202000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i61a10b6811c84b769705e56f58585a71_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjctNS0xLTEtNDg3Mjk_708989eb-9efe-4639-a291-fe713b971cec"
      unitRef="usd">6646000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjctMTEtMS0xLTQ4NzI5_fa58e6cf-6caa-48b1-b29a-e0bad941fe64"
      unitRef="usd">6646000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61a10b6811c84b769705e56f58585a71_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjgtNS0xLTEtNDg3Mjk_9be091ea-dc47-42ec-b3fb-3801b0783bcf"
      unitRef="usd">34653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjgtMTEtMS0xLTQ4NzI5_a0b07118-d795-44a7-9db5-bfc105a539c8"
      unitRef="usd">34653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iae18b65c34724d73aab497d548fc2f19_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktMS0xLTEtNDg3Mjk_7efc7fb9-9a1e-4b65-b830-fb91cfea9b7b"
      unitRef="shares">313262000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iae18b65c34724d73aab497d548fc2f19_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktMy0xLTEtNDg3Mjk_30ab6ec1-c79b-4234-b32f-fb4a89cd6bf0"
      unitRef="usd">313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if48023ef0a6d49198622a6d1d8e4809a_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktNS0xLTEtNDg3Mjk_caa7baca-df3f-42e4-b494-ff59bd7cbb88"
      unitRef="usd">2354103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic91d1ea7f73646298e060832ddc685eb_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktNy0xLTEtNDg3Mjk_ebef5416-8c2c-4f15-9330-f3e5c1176f45"
      unitRef="usd">2740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic48eb912406143e587ee2129a748a248_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktOS0xLTEtNDg3Mjk_b8fb118b-4d5f-41bf-be72-ef353e4afc14"
      unitRef="usd">-445969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3de2311ad9f4eaa86a15e6ff586a051_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yNS9mcmFnOjNmNGEwMWM2YmE5NTRlNDI4NmVlYTk4YTEzZjkwNmIyL3RhYmxlOjZmMTYyMWZkOGY4ZjQ5NzE5YWJiZWU4ODU3NWE3MTY1L3RhYmxlcmFuZ2U6NmYxNjIxZmQ4ZjhmNDk3MTlhYmJlZTg4NTc1YTcxNjVfMjktMTEtMS0xLTQ4NzI5_54ebef0d-01e3-41bb-8649-66dfa99e7b08"
      unitRef="usd">1911187000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMi0xLTEtMS00ODcyOQ_e6f12bd3-6737-4a26-84ba-ede00144975d"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMi0zLTEtMS00ODcyOQ_bdfd9e7d-a56e-4eeb-941e-e7cf5aeddfce"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNC0xLTEtMS00ODcyOQ_9225e05d-9121-44d2-a423-b0fe19a5c11a"
      unitRef="usd">4490000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNC0zLTEtMS00ODcyOQ_9730c840-e24e-4617-bf45-2441c08a51de"
      unitRef="usd">3227000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNS0xLTEtMS00ODcyOQ_e963cf48-7222-41c3-82b1-843e9d4467a8"
      unitRef="usd">19759000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNS0zLTEtMS00ODcyOQ_e5ad5b4f-9a19-465d-b93f-b392901558df"
      unitRef="usd">34653000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNi0xLTEtMS00ODcyOQ_0844e6cc-0a51-4449-b65c-496b435d86e7"
      unitRef="usd">1385000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNi0zLTEtMS00ODcyOQ_e6d87f0f-f147-4684-bdc6-4a5ade183b34"
      unitRef="usd">1221000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNy0xLTEtMS00ODcyOQ_202061cb-0b74-4445-9d31-d45cde45bafd"
      unitRef="usd">-15318000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfNy0zLTEtMS00ODcyOQ_c7ba68ac-6c6d-4443-8ede-52b847d98109"
      unitRef="usd">3388000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfOC0xLTEtMS00ODcyOQ_f72f941d-cb34-4c1d-a0df-a234492992fc"
      unitRef="usd">-1580000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfOC0zLTEtMS00ODcyOQ_15cb72b0-e2cc-45e2-8d64-ef758ecbcc20"
      unitRef="usd">-6578000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTAtMS0xLTEtNDg3Mjk_8dd47285-29f5-415b-9b73-220fd2e48b62"
      unitRef="usd">-91793000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTAtMy0xLTEtNDg3Mjk_d219bdac-511d-456b-bfc0-21bfd7a7b68d"
      unitRef="usd">17690000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTEtMS0xLTEtNDg3Mjk_9d5bd72f-9e17-4ec6-a218-525c6afe2a1e"
      unitRef="usd">3520000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTEtMy0xLTEtNDg3Mjk_35f8e652-beb4-494f-b277-efa70e457f57"
      unitRef="usd">2090000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTMtMS0xLTEtNDg3Mjk_f71a64da-e89d-42aa-a829-7213f79a7420"
      unitRef="usd">3605000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTMtMy0xLTEtNDg3Mjk_a674a60e-cf1c-4db0-9f88-a4b00ef1affd"
      unitRef="usd">-1872000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTUtMS0xLTEtNDg3Mjk_30903743-e21d-4139-a13a-472f84b9832e"
      unitRef="usd">-1169000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTUtMy0xLTEtNDg3Mjk_529b10df-be7f-4ddb-932d-364496576b2f"
      unitRef="usd">13422000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTYtMS0xLTEtNTkyOTU_bb5637b5-ab70-4b31-89d7-877dd19315a0"
      unitRef="usd">-54261000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTYtMy0xLTEtNTkzMDQ_c0b4ac35-b820-4c9d-9c09-7cb0e13f7e6a"
      unitRef="usd">1005000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTYtMS0xLTEtNDg3Mjk_c4f51823-ea43-468c-a2d1-267ddab09b20"
      unitRef="usd">7376000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTYtMy0xLTEtNDg3Mjk_afceabac-50bf-4cd6-9b92-147e66ed07d9"
      unitRef="usd">-867000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTctMS0xLTEtNDg3Mjk_781cea10-005a-49bc-8ebf-8a7eddb6253a"
      unitRef="usd">147719000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTctMy0xLTEtNDg3Mjk_c208ff77-0dcb-4f74-8a89-f6480121187a"
      unitRef="usd">39544000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTktMS0xLTEtNDg3Mjk_4f0dc952-e6b7-4cef-9dd9-96348cb41bef"
      unitRef="usd">5609000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMTktMy0xLTEtNDg3Mjk_39841b7d-1502-46cd-b44e-2b7340818dd2"
      unitRef="usd">13557000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjEtMS0xLTEtNDg3Mjk_decdb4fb-52c4-43ef-aa66-9f5340afdf6d"
      unitRef="usd">336545000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjEtMy0xLTEtNDg3Mjk_b2d78b40-d7ba-4961-bd93-4adb19bb075d"
      unitRef="usd">331612000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjItMS0xLTEtNDg3Mjk_42b68759-4f69-4169-bc7c-4bb65bb5bb67"
      unitRef="usd">267615000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjItMy0xLTEtNDg3Mjk_7dbe7e42-49f6-41e3-98e3-9a940e1ea7df"
      unitRef="usd">407424000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjMtMS0xLTEtNDg3Mjk_eb90d2fc-b4bf-4ab0-84f7-4cf65d9fb1c9"
      unitRef="usd">-74539000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjMtMy0xLTEtNDg3Mjk_535405a7-8d1e-46ad-ac05-7fbab6965f30"
      unitRef="usd">62255000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjUtMS0xLTEtNDg3Mjk_dc564d37-6644-43be-8d74-3b91eccac769"
      unitRef="usd">4891000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjUtMy0xLTEtNDg3Mjk_43aa0a47-6a1d-4796-97ee-4c3b3342a161"
      unitRef="usd">2791000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjYtMS0xLTEtNDg3Mjk_cbef72f6-fa31-4dbd-9ca5-4f6d5f920578"
      unitRef="usd">4686000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjYtMy0xLTEtNDg3Mjk_88977c1e-6cda-4af3-95a8-e60fc47584c4"
      unitRef="usd">5441000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjktMS0xLTEtNDg3Mjk_1a9db026-9070-49b2-9c6d-2e4d996682c8"
      unitRef="usd">205000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMjktMy0xLTEtNDg3Mjk_ae46595f-bbca-4511-a02e-14c464a6fce0"
      unitRef="usd">-2650000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzAtMS0xLTEtNDg3Mjk_e5c53f20-5c3f-49e0-ae6b-194dcc4b654a"
      unitRef="usd">73385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzAtMy0xLTEtNDg3Mjk_f39c5235-a3ec-4cec-84f9-a551e53d2f78"
      unitRef="usd">99149000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzEtMS0xLTEtNDg3Mjk_d19f90e8-162c-4eca-8da7-e897d1f1abba"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6bba33a166db4495b501a3f2b8852f3c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzEtMy0xLTEtNDg3Mjk_d362e055-dc6e-4737-b79f-58e06936181a"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzItMS0xLTEtNDg3Mjk_8f8ecf54-8a9f-40cd-9323-0897bd4ccdaf"
      unitRef="usd">737276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib3de2311ad9f4eaa86a15e6ff586a051_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8yOC9mcmFnOjY1NzdiMTc5YjZjYzRlOWY4ZTk0ZjM5NjhiNmNmNWJlL3RhYmxlOjE5OTNiY2Y3ZGY3ZjRmNjE5NGZhZWFiNDI5ZDBiMTc3L3RhYmxlcmFuZ2U6MTk5M2JjZjdkZjdmNGY2MTk0ZmFlYWI0MjlkMGIxNzdfMzItMy0xLTEtNDg3Mjk_1eb638ea-cd72-4578-9c15-b9ae7750447a"
      unitRef="usd">419921000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODY5OQ_0bd03951-4381-4ba2-81ee-094062d215f0">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 61 other countries as: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#x2019;s (BMS) OPDIVO&#xae; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and the European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#xae; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021, included in Part II, Item 8 of our Annual Report on Form 10-K filed with the SEC on February&#160;18, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the three months ended April 1, 2022 and April 2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the three months ended March 31, 2022 and March 31, 2021, and the year ending December 31, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies during the three months ended March 31, 2022, compared to the significant accounting policies disclosed in &#x201c;Note 1. Organization and Summary of Significant Accounting Policies&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i008e83363bc848538e1a5dcbff4c3ac6_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfNjI3_a38038db-97d4-42d5-baa6-02f3ca965532"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberOfCountriesWithDrugApprovalExcludingTheUS
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfMTY0OTI2NzQ1MjUzOA_210949dd-c8af-4fa3-91e9-b8aa5ab9199f"
      unitRef="country">61</exel:NumberOfCountriesWithDrugApprovalExcludingTheUS>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i00814bc003494d9bb50fd207cefbb476_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfMTYyNw_5c4bc52c-4456-477b-b626-4d70d172ef88"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODY5MA_3160969e-8d6b-4a09-87cc-aab0994e817c">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODczNQ_309480e0-b57a-4bdd-9f05-c7475a99f0e2">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021, included in Part II, Item 8 of our Annual Report on Form 10-K filed with the SEC on February&#160;18, 2022.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODY5NQ_5819be72-e269-4d7c-a3f5-c516332400bc">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the three months ended April 1, 2022 and April 2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the three months ended March 31, 2022 and March 31, 2021, and the year ending December 31, 2022, respectively.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODcwMQ_8f75dcff-b17e-4699-affc-0fac6f195a4c">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfMTY0OTI2NzQ1NTg5OQ_1ea8aaf3-ce35-4fbb-92c7-f6cefed31713"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODcyMw_a0d15c5c-651c-48bb-a01f-34a784ce15d6">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfNzY5NjU4MTQxMTg3Ng_5d101737-a26d-4c24-ac24-3d9031610e04">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNC9mcmFnOjdiNDc1YjNlNzAxZjQwYzQ5MWUxOThmYzZlZTJmZDdmL3RleHRyZWdpb246N2I0NzViM2U3MDFmNDBjNDkxZTE5OGZjNmVlMmZkN2ZfODY4Nw_80164468-1891-483d-85f7-643e93a9a70f">&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNTAwNA_535f3349-acd6-4f28-9116-95e990f34e8c">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, and 2021, we recognized $2.4&#160;million and $2.5&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, and 2021, we recognized $31.7&#160;million and $27.8&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022, $87.4&#160;million of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he combined transaction prices for our Ipsen and Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements and Business Development Activities&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 for information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNTAwNw_f0fa3403-63b4-42e6-9c9c-101e15736986">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab56d00962654960b416e521404e7025_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfMy0xLTEtMS00ODcyOQ_c379bfa4-2337-4cc0-a439-a1db49b76fea"
      unitRef="usd">448237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8b1dfc7877944b6bf20d7065aa99c7f_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfMy0zLTEtMS00ODcyOQ_d20f3fba-1f50-42e2-89a8-f04481a942c1"
      unitRef="usd">314205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a078295ea354ce7aeb0547546b5bb8f_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNC0xLTEtMS00ODcyOQ_c3a480ba-e133-4ee5-ad16-4ecb7c66fd1b"
      unitRef="usd">-137939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39c0408a82aa46779a73c11dcfa75a56_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNC0zLTEtMS00ODcyOQ_7758d72a-d000-413c-b2fa-fa390c7bb863"
      unitRef="usd">-86993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idef460046aca49f3a2753fad35f32387_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNS0xLTEtMS00ODcyOQ_fad99c1c-9bde-463b-8b2e-a5a35753679f"
      unitRef="usd">310298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a1f98ab028c4075b3c5959b7f157dc9_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNS0zLTEtMS00ODcyOQ_051c3bc3-9bcf-498b-a792-59862ae5363f"
      unitRef="usd">227212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7d496fb0cfe4be9ab5f4af2e1a705bd_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNy0xLTEtMS00ODcyOQ_85878222-8838-41d4-ba0a-75fc5801e059"
      unitRef="usd">32067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d9a170e7200455d9d99fa4118712bb7_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfNy0zLTEtMS00ODcyOQ_08049445-0cf7-4fca-80e0-fdb4bd80a5ac"
      unitRef="usd">27528000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icaf02010d20b45d38532755c0e8242ff_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfOC0xLTEtMS00ODcyOQ_47f29c8f-dca5-45c4-b9a4-f6233c031d5f"
      unitRef="usd">13615000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f8de81af7714dbc880d1340b695ef37_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfOC0zLTEtMS00ODcyOQ_91346705-f5c9-4254-ad5a-d80ca09466ca"
      unitRef="usd">15490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i551086107bad4e84b1d3ac16ad914e4d_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfOS0xLTEtMS00ODcyOQ_d008b15d-bd65-4f26-b711-0c669e80932f"
      unitRef="usd">45682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8513f10a32ca4e5abd8caeb8ce075aa8_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfOS0zLTEtMS00ODcyOQ_a9c40117-8ebe-4da1-824b-d75d54fed042"
      unitRef="usd">43018000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfMTAtMS0xLTEtNDg3Mjk_6ea1fa7a-e058-4863-a33d-70e5c066c8f7"
      unitRef="usd">355980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjI2ZjIyNjJiZWViZjQxOGVhODA0MjFjZWQzMmNmMzA4L3RhYmxlcmFuZ2U6MjZmMjI2MmJlZWJmNDE4ZWE4MDQyMWNlZDMyY2YzMDhfMTAtMy0xLTEtNDg3Mjk_79bf974b-1897-40c6-86fa-0fa57764429b"
      unitRef="usd">270230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNDk5Nw_53045bdb-82ee-4e1b-b873-c3834195dfe3">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i398655de202c44728712889a41d779af_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfMy0xLTEtMS00ODcyOQ_9dd9d317-eaf5-4189-9239-a932ef034f16"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i74a2013f8a16433e81293adc6ea5aa4d_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfMy0zLTEtMS00ODcyOQ_e8650a0c-519e-44a3-aa1f-9dd73aec733a"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia3e90932b0d54d7da6e98d7fb3f07a50_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNC0xLTEtMS00ODcyOQ_b624218e-9b37-49fb-b63d-a310f021f447"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i35254c0fd6f2407a89472d5432f6dacb_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNC0zLTEtMS00ODcyOQ_df7ee974-ec3a-44e1-af19-7a0fd66a3f7f"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7194cce6e63646fc9583d308abcef753_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNS0xLTEtMS00ODcyOQ_eaa61dfc-889b-4e14-8725-fa92af31cdb0"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib194841422484f7ba4a2b5e11ae924ce_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNS0zLTEtMS00ODcyOQ_a4dbf36b-3932-44d2-b3f9-991b422e97c3"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib8b84ad3f0ce4c27bd1d8097e8ef9797_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNi0xLTEtMS02MTk4OA_e26bd026-55b9-4f50-a476-f738209843df"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i285a461c2de24898a0698ba0e074b002_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNi0zLTEtMS02MTk4OA_8b548a93-b88e-4df1-ab2e-8fcd1caeb698"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1cd800703a0a47a2a1821615e0313ebf_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNi0xLTEtMS00ODcyOQ_32817c5f-138e-417c-ad0e-04408b107f2b"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i83adfa8283634307bba32f1f4f54be14_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjQxNDMxYTM0OWI3NTRhNTU4NzA1OWY4N2U2MTM2YTRlL3RhYmxlcmFuZ2U6NDE0MzFhMzQ5Yjc1NGE1NTg3MDU5Zjg3ZTYxMzZhNGVfNi0zLTEtMS00ODcyOQ_607d1345-dea7-4083-b92a-f7acf456c4cf"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idce044eac78b4541ab6f56af1a43efe3_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMS0xLTEtMS02MjA3NA_fec8283b-b627-4bca-a6bb-5fd57df4f0dc"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ica5f788e45c34e62807c3bba9ae992de_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMS0zLTEtMS02MjA3NA_c02a8ec4-62bb-4632-a1d3-82bfd5f00db0"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i961f155c52124473a01a4b5c400a76c2_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMS0xLTEtMS00ODcyOQ_511467bd-accb-431b-951d-3a570c749d19"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if6ec26770cc04919bd55ec958f5914f9_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMS0zLTEtMS00ODcyOQ_204a5a56-63d1-4433-b4a6-7152fe86c694"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iebbff6ceb5ce44bd99cb97c1b5bf4d24_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMy0xLTEtMS00ODcyOQ_ac395170-2592-45d3-ab4c-a6f760cc9c48"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7546b59743254d7abf29b3243ae24052_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfMy0zLTEtMS00ODcyOQ_80ce8bd2-1e63-4ab7-a51c-6381242a8e68"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia5ea966d46c44ecb89ce18913d688c79_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfNC0xLTEtMS00ODcyOQ_9b9ddbee-9769-4433-8a11-6c70ee3f80b9"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i90cb5dcefc15490d8098cf331b8ea9e1_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjMxZTE2ZjViMmJhZjRiNzI4OTJlZjI3ZGUwYmYzNDQ0L3RhYmxlcmFuZ2U6MzFlMTZmNWIyYmFmNGI3Mjg5MmVmMjdkZTBiZjM0NDRfNC0zLTEtMS00ODcyOQ_732cee55-728d-4d4c-9eec-cf5f73fa5922"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNTAwOA_4b485786-2474-4b51-abb8-f90e559ba725">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5766b5f0fc6649db9a9ece11f5731c2e_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfMi0xLTEtMS00ODcyOQ_9af1ace9-b77d-4406-83d6-85306fdb96a7"
      unitRef="usd">314065000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa84da93f4a441758b16037d47ea6de1_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfMi0zLTEtMS00ODcyOQ_45a4c0db-d5dc-441d-92ed-5a094bbd1eb7"
      unitRef="usd">229957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if09eb26b2a404183be3cabe74831a09a_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfMy0xLTEtMS00ODcyOQ_73efaf76-da7c-4699-97ab-adc311503663"
      unitRef="usd">34527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a440e479bdb4fd5bf6b77258180697f_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfMy0zLTEtMS00ODcyOQ_c3c312bf-19e9-45bd-84ad-d8739945fb1c"
      unitRef="usd">33806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e249821f56b45859aadda9d9a17870c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfNC0xLTEtMS00ODcyOQ_e0e31c5d-1835-4d70-8ae9-f8874c000841"
      unitRef="usd">7388000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7134fedfc494cc3aa6a8ae4190620d4_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfNC0zLTEtMS00ODcyOQ_1e2a7e2c-741b-457e-b22d-7d06f804c33e"
      unitRef="usd">6467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfNS0xLTEtMS00ODcyOQ_af5dec76-acfb-4296-9a7d-66cc3dd57d9b"
      unitRef="usd">355980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjIxY2I2MGE3NmIzYTQyM2RhN2U2MGYxZGE0MzVhOWI3L3RhYmxlcmFuZ2U6MjFjYjYwYTc2YjNhNDIzZGE3ZTYwZjFkYTQzNWE5YjdfNS0zLTEtMS00ODcyOQ_14754cbe-89e2-455f-bc2f-b34a05306d45"
      unitRef="usd">270230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNDk5MQ_05d5544b-8575-4f3f-8c95-6ada318841f2">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if112a05a2b34404190a5729507b01b3b_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfMi0xLTEtMS00ODcyOQ_64d0f7cc-8bae-487c-9ff5-b3b312e2a208"
      unitRef="usd">302812000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic274dc535ec045c5a329dc95ebae978d_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfMi0zLTEtMS00ODcyOQ_861d94de-4b6b-47ee-a673-2915dfc44955"
      unitRef="usd">223595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if44863bdae614924beec29fc65467290_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfMy0xLTEtMS00ODcyOQ_ceb5c5c1-688a-4c23-b526-21b3507d42d5"
      unitRef="usd">7486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3767f6dbcf4f4d6cb11379d61c886681_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfMy0zLTEtMS00ODcyOQ_245df61b-da5a-4d76-ba66-8bf7895ee5a2"
      unitRef="usd">3617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idef460046aca49f3a2753fad35f32387_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfNC0xLTEtMS00ODcyOQ_253b05a2-e8c3-4788-a84b-8ad167b5d9a3"
      unitRef="usd">310298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a1f98ab028c4075b3c5959b7f157dc9_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjgxYTUwYjFmYTNiZDQyZTliNTI4MDU4YTY3YmNmNzNiL3RhYmxlcmFuZ2U6ODFhNTBiMWZhM2JkNDJlOWI1MjgwNThhNjdiY2Y3M2JfNC0zLTEtMS00ODcyOQ_4c33fbe2-9b99-4240-8411-3bcab9e5f4d2"
      unitRef="usd">227212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNTAwOQ_0120fdb3-690a-45e5-b7a1-9bf3701b7855">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8c698e49d45749dd946feaceac85ad90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMS0xLTEtMS00ODcyOQ_075a5fd8-b5b0-48c5-aef6-a73ab0ba9016"
      unitRef="usd">14625000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id15e0ac305444b18b2693bb09e7e1d35_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMS0zLTEtMS00ODcyOQ_7425cb01-37b2-4e07-9f34-fe5e173c9363"
      unitRef="usd">8875000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib578158f471a4e36ad81dc312a12517d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMS01LTEtMS00ODcyOQ_c093a07d-dff3-436d-8fa8-d129c21f2a61"
      unitRef="usd">24825000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMS05LTEtMS00ODcyOQ_75f17a83-bec0-43da-81fc-6d3cac27c1e9"
      unitRef="usd">48325000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i35b4b3ffc9844993a92bbc43161faf68_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMy0xLTEtMS00ODcyOQ_7316e744-1fe2-4750-af6d-f8e48f514f74"
      unitRef="usd">86620000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i47fd97f14ad845a9bc98e017beac244a_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMy0zLTEtMS00ODcyOQ_df57e1ea-65b4-4226-a033-61916e0a222b"
      unitRef="usd">12087000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="if4e948ebc35043fc8774b5ae38d6c32e_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMy01LTEtMS00ODcyOQ_1695e332-06c4-42c0-9ba6-cdffbaa14bb9"
      unitRef="usd">38734000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfMy05LTEtMS00ODcyOQ_0fd1c003-09a3-47f1-ba6f-6a881db66091"
      unitRef="usd">137441000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i35b4b3ffc9844993a92bbc43161faf68_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNC0xLTEtMS00ODcyOQ_cc1fbb52-668e-4291-b266-2b208ca85127"
      unitRef="usd">154000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i47fd97f14ad845a9bc98e017beac244a_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNC0zLTEtMS00ODcyOQ_f79a84a8-9baf-4e35-991f-c3b99fc688a4"
      unitRef="usd">-43000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="if4e948ebc35043fc8774b5ae38d6c32e_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNC01LTEtMS00ODcyOQ_46b1fe31-922a-4c83-8d62-36ef1396ef69"
      unitRef="usd">387000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNC05LTEtMS00ODcyOQ_312215cf-9049-4484-b0a3-bfa7a425a916"
      unitRef="usd">498000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i35b4b3ffc9844993a92bbc43161faf68_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNS0xLTEtMS00ODcyOQ_a667b90b-ef96-4b71-b2b1-d256d71b015b"
      unitRef="usd">83004000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i47fd97f14ad845a9bc98e017beac244a_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNS0zLTEtMS00ODcyOQ_08fba883-34d5-4c5d-9502-71b66426f9f0"
      unitRef="usd">10227000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if4e948ebc35043fc8774b5ae38d6c32e_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNS01LTEtMS00ODcyOQ_11c6c884-52fc-4ffc-bbe9-7160648123d2"
      unitRef="usd">24641000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNS05LTEtMS00ODcyOQ_ebf076b2-a459-4311-9700-7d157dd86995"
      unitRef="usd">117872000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if20581f34d4d4396b415e4232596769d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNi0xLTEtMS00ODcyOQ_61d0fc8e-1dff-4bef-9405-5c1281a5f78d"
      unitRef="usd">18395000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4951c1e73e874036b22ef0fa4b27bb5d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNi0zLTEtMS00ODcyOQ_c74d967b-8ba9-45e7-b6ed-e0f9a4905a93"
      unitRef="usd">10692000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib3fd33fa71724f02a5838171f02316d9_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNi01LTEtMS00ODcyOQ_e2450a5b-d40c-428a-82aa-8fb467604379"
      unitRef="usd">39305000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOmMwYmVkMDNmODlmNDRlZWQ5OTFiODlhZDgxMjBmMGViL3RhYmxlcmFuZ2U6YzBiZWQwM2Y4OWY0NGVlZDk5MWI4OWFkODEyMGYwZWJfNi05LTEtMS00ODcyOQ_7857988a-a390-4b8a-a726-51654d87be9c"
      unitRef="usd">68392000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNDk4OQ_a64fc74f-2807-447a-a9cb-e32b453d4fca">Contract assets and liabilities were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfNC0xLTEtMS01Nzg4Mw_97d9e1bc-9d11-480f-985a-f747a3bcb8a7"
      unitRef="usd">3235000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfNC0zLTEtMS00ODcyOQ_027b37ee-7767-4d7e-b39d-eefdb2781127"
      unitRef="usd">1665000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfNy0xLTEtMS00ODcyOQ_34eaa71c-8309-435e-a260-e39b9fec2163"
      unitRef="usd">7349000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfNy0zLTEtMS00ODcyOQ_e17f141b-6eb9-453d-840f-148123f5fb53"
      unitRef="usd">7814000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfOC0xLTEtMS00ODcyOQ_e62978f8-af7b-49b8-9ebe-02771db400f7"
      unitRef="usd">8035000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfOC0zLTEtMS00ODcyOQ_163d87eb-00a9-419d-ad38-87b72a0d9898"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfOS0xLTEtMS00ODcyOQ_0f306490-b579-42e9-9a40-4d66df785f93"
      unitRef="usd">15384000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RhYmxlOjM3YTcwNDIyODgyMDQyYmJhYjU4MTI0NmRkMWQwMmUxL3RhYmxlcmFuZ2U6MzdhNzA0MjI4ODIwNDJiYmFiNTgxMjQ2ZGQxZDAyZTFfOS0zLTEtMS00ODcyOQ_3f39e5ab-dee2-466a-b204-5c04df363299"
      unitRef="usd">16553000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI1Ng_374df11a-50d7-4168-98ea-7b8780f087e0"
      unitRef="usd">2400000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI2MA_7300048e-8587-4de2-b19b-8dbb787b98c8"
      unitRef="usd">2500000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI1Nw_bcf6abdb-9ff3-400e-9744-2f81d3342f5c"
      unitRef="usd">31700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI3NA_b07e0872-1fbb-4fe5-acc7-aaa50bafadb0"
      unitRef="usd">27800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie18ac2c818d84341a05b5734a270a492_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV8zNy9mcmFnOmQ0YjdkYTQ3NTAxODQwMzZhMjkxN2U2MDhjN2YwYWIwL3RleHRyZWdpb246ZDRiN2RhNDc1MDE4NDAzNmEyOTE3ZTYwOGM3ZjBhYjBfNzY5NjU4MTQwMTI1OA_8fce6b01-ea4d-4e38-88ea-f31933656986"
      unitRef="usd">87400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfODQ0MQ_423e4933-00b0-46b1-9138-a92d8b4855ca">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 3. Collaboration Agreements and Business Development Activities&#x201d; to our Consolidated Financial Statements included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, or as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022, $46.7&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $40.6&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royal Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $13.1&#160;million and $10.1&#160;million during the three months ended March 31, 2022, and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s ZELBORAF&#xae; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#xae; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Collaborations, In-Licensing Arrangements and Other Business Development Activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development milestones of up to $254.3&#160;million, regulatory milestones of up to $426.5&#160;million and commercial milestones of up to $1,911.5&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In conjunction with an asset purchase agreement entered into in 2021, we will make a $4.0&#160;million payment upon the completion of the technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $42.0&#160;million and regulatory milestones of up to $22.5&#160;million, per product.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfODQyOA_4a94c1cf-9d2a-4dee-9e09-013c0c3ca64c">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb9a5aa7f23e407aa788942742f46640_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfMi0xLTEtMS00ODcyOQ_d261a0cf-a6ce-4ef9-9b63-486c5c4a9613"
      unitRef="usd">24614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39de048fc1144bb9be6ca20c5cacab33_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfMi0zLTEtMS00ODcyOQ_cb7980a5-bc2a-4cd1-918b-79de6855a7cb"
      unitRef="usd">22451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa98a70e1323433694d00cfce4b2b09e_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfMy0xLTEtMS00ODcyOQ_d21cfaca-4ff9-4ae6-88b2-7e48ea185679"
      unitRef="usd">9913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88c62f456465404387850b8211c219f4_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfMy0zLTEtMS00ODcyOQ_c3a5f474-9500-4594-b66c-3ea8b98cd478"
      unitRef="usd">11355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a69ed17a5c74d79b446ce43b6eaf688_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfNC0xLTEtMS00ODcyOQ_87f307ac-7c24-4643-aa2b-306c46f8ef84"
      unitRef="usd">34527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifafb6fd490eb48bb9c8638ac3fc3247c_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjc1N2IxNDRlYTI2NTRiOTI5YWQ0MjI0N2QyYzEzOGIyL3RhYmxlcmFuZ2U6NzU3YjE0NGVhMjY1NGI5MjlhZDQyMjQ3ZDJjMTM4YjJfNC0zLTEtMS00ODcyOQ_8e9be06e-4ea7-4a3a-ad75-79f9ec90e239"
      unitRef="usd">33806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ibca89d95ab5f4f82898ebc804c7d67c3_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTU4NA_cb672ed6-d02d-40cb-b719-902deb08a922"
      unitRef="usd">46700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id880f02651a04201866bb497ae9e96c0_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfMi0xLTEtMS00ODcyOQ_6c16ea4c-3891-415e-a824-58dc6ee111d9"
      unitRef="usd">2365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia992f174fe4c4a2c942a413095955ad3_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfMi0zLTEtMS00ODcyOQ_d21dd604-78c2-4d19-8fd5-ae563a88bb8f"
      unitRef="usd">1301000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1561bb88d7f84399858e3575701cc3ad_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfMy0xLTEtMS00ODcyOQ_1e9e09f8-38a5-45a6-803a-72d15131ee90"
      unitRef="usd">3702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i082deb7d649f464697d7bfcd0ecc9862_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfMy0zLTEtMS00ODcyOQ_a26cbb41-8bda-4941-909b-b8f72425a1e4"
      unitRef="usd">4135000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i064bf749eb654609b6626219640cc568_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfNC0xLTEtMS00ODcyOQ_ff7440fd-f9be-49b7-b2f0-a7c7a41fe251"
      unitRef="usd">6067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b8004462b3a4394be38cbda3e7571cc_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOjdhYWNhYmU3MGJmNjQ5ZTI4NDlhMDkzNjUzMDI4MmU0L3RhYmxlcmFuZ2U6N2FhY2FiZTcwYmY2NDllMjg0OWEwOTM2NTMwMjgyZTRfNC0zLTEtMS00ODcyOQ_540deb12-a309-4f1b-b619-df048537b526"
      unitRef="usd">5436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i8688f6af6d944b5d9a869f64d77e207b_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTU4NQ_5265d788-3e33-4168-917c-8b2caad3e56a"
      unitRef="usd">40600000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i0401aaeb66fd4321aaf94500fb43ff2d_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNDc5Mg_47f353c3-68c2-4d80-8be9-550f157a8df4"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="i72f8d2d0983748df85b871e2e1598f45_D20220101-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQxMDI5MQ_c952b955-5a7d-4c6a-a3a3-a66f74fc0dbf"
      unitRef="usd">13100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i81b815ad748341c0a26d4fa1bcd0c7ea_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTU3MA_2fe5e646-be76-42e4-bd73-22cfdac13093"
      unitRef="usd">10100000</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="ibb9dca35b8b24f119a51c3af9f3582fc_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOmM4YjUxYzk5NTZmODQxNDQ4OWQyNjU4ZDY4MWU3YWY2L3RhYmxlcmFuZ2U6YzhiNTFjOTk1NmY4NDE0NDg5ZDI2NThkNjgxZTdhZjZfMi0xLTEtMS00ODcyOQ_1b38862d-9ceb-4511-9b50-7dc75686a1d1"
      unitRef="usd">2139000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i538440738be741a491a5c13daa06b6ed_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOmM4YjUxYzk5NTZmODQxNDQ4OWQyNjU4ZDY4MWU3YWY2L3RhYmxlcmFuZ2U6YzhiNTFjOTk1NmY4NDE0NDg5ZDI2NThkNjgxZTdhZjZfMi0zLTEtMS00ODcyOQ_9fb6193a-b4e9-40ea-90b2-209fd1d66a83"
      unitRef="usd">1794000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb9dca35b8b24f119a51c3af9f3582fc_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOmM4YjUxYzk5NTZmODQxNDQ4OWQyNjU4ZDY4MWU3YWY2L3RhYmxlcmFuZ2U6YzhiNTFjOTk1NmY4NDE0NDg5ZDI2NThkNjgxZTdhZjZfMy0xLTEtMS00ODcyOQ_079445e6-7a3b-41c1-b4e4-b7d88b8af2d2"
      unitRef="usd">1628000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i538440738be741a491a5c13daa06b6ed_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RhYmxlOmM4YjUxYzk5NTZmODQxNDQ4OWQyNjU4ZDY4MWU3YWY2L3RhYmxlcmFuZ2U6YzhiNTFjOTk1NmY4NDE0NDg5ZDI2NThkNjgxZTdhZjZfMy0zLTEtMS00ODcyOQ_6b42bdad-7efd-4835-ba69-5d97904ac0ff"
      unitRef="usd">951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="i8c1bd21583b04c1198ee03ae25c583c5_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTQ2MA_f967768d-7607-47ea-907b-b71af8dbbe7c"
      unitRef="usd">254300000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="i8c1bd21583b04c1198ee03ae25c583c5_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTQ3Ng_9916a287-94d7-41fb-80b0-dc402fd88655"
      unitRef="usd">426500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments
      contextRef="i8c1bd21583b04c1198ee03ae25c583c5_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTQ5Mg_60dc2f36-4d47-4139-9150-5b31c7f39e8f"
      unitRef="usd">1911500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments>
    <exel:AssetAcquisitionPaymentUponClosingOfTransaction
      contextRef="i867c322cc2874132b092bc2a3ff658c9_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTUxMA_4503b204-c53a-4c3a-82a6-4c5060e92cd5"
      unitRef="usd">4000000</exel:AssetAcquisitionPaymentUponClosingOfTransaction>
    <exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments
      contextRef="i867c322cc2874132b092bc2a3ff658c9_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTUzOQ_5d132ca2-396b-4de5-9d5a-ad75d1da3ce1"
      unitRef="usd">42000000</exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments>
    <exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments
      contextRef="i867c322cc2874132b092bc2a3ff658c9_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80MC9mcmFnOjM5MjQ3YTJhODFlMTQ0ZmU5ZTkzY2YyOGVkNDNiOGZhL3RleHRyZWdpb246MzkyNDdhMmE4MWUxNDRmZTllOTNjZjI4ZWQ0M2I4ZmFfNzY5NjU4MTQwOTU1NA_f2bb0941-6d91-4126-b762-8305a4a709af"
      unitRef="usd">22500000</exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNzY5NjU4MTM5NzgwNA_16abe05d-9458-4515-a618-2560cd53bc5c">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, restricted cash equivalents included $12.5 million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our January 2021 standby letter of credit will remain effective through June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,988,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $2.6 million and $2.9 million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the three months ended March 31, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were 197 and 133 investments in an unrealized loss position as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for two corporate bond securities with an aggregate fair value of $6.3&#160;million and an aggregate immaterial unrealized loss as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the three months ended March 31, 2022, and 2021, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjczMQ_85e17fb6-68a6-4dde-b0f9-de470229767f">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjc1OA_4caae4b0-e85b-4afc-a7fb-e6b790035a54">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfMS0xLTEtMS00ODcyOQ_84d881c9-dcc2-47c5-90ea-c6fa81cf60e6"
      unitRef="usd">723269000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfMS0zLTEtMS00ODcyOQ_6fe56791-5341-4dd5-85e0-508c4ce2b828"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfMy0xLTEtMS00ODcyOQ_6afb4dd5-0a09-4801-806f-b2e1954cf013"
      unitRef="usd">14007000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfMy0zLTEtMS00ODcyOQ_9cfea315-2a2a-4531-b259-5865fb3ce819"
      unitRef="usd">16722000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfNC0xLTEtMS00ODcyOQ_6aca1d83-cffa-4b77-b58b-f7c8404d02c6"
      unitRef="usd">737276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjFhZDk4ODRjY2UwMTRjYTQ5ODExYzc1ODU5OGEyZTkwL3RhYmxlcmFuZ2U6MWFkOTg4NGNjZTAxNGNhNDk4MTFjNzU4NTk4YTJlOTBfNC0zLTEtMS00ODcyOQ_d19f90e8-162c-4eca-8da7-e897d1f1abba"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i65909c185a5f44b1a3af13f2646e6415_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNDM5ODA0NjUxNDUyOA_d436b1be-25a0-4f0d-8d8b-25b18b66de1d"
      unitRef="usd">12500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjcyNw_7542b1ec-9f67-4454-8e22-acbefea7097e">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,988,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMy0xLTEtMS00ODcyOQ_455fa6c7-b856-4906-9e34-146749199cde"
      unitRef="usd">954283000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMy0zLTEtMS00ODcyOQ_2bab3cbf-3a10-4094-82d1-5cd30c5a7397"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMy01LTEtMS00ODcyOQ_f70b071c-3f61-4091-8087-1ae4cb7e33ce"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMy03LTEtMS00ODcyOQ_f2e19870-df7a-4e34-b4ce-4e24343a3ff6"
      unitRef="usd">954262000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNC0xLTEtMS00ODcyOQ_c00893e1-2522-4dc4-8325-3dbb4bccf31e"
      unitRef="usd">529129000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNC0zLTEtMS00ODcyOQ_977f320e-e39c-49e9-91aa-51ac3a792a3f"
      unitRef="usd">95000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNC01LTEtMS00ODcyOQ_ee215aa9-5323-4873-b2a1-1d75236abfbb"
      unitRef="usd">7123000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNC03LTEtMS00ODcyOQ_9b0ef0b9-30dd-4734-b5d9-39fe7457ff7f"
      unitRef="usd">522101000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNS0xLTEtMS00ODcyOQ_c2ed243e-dd73-4fca-a6c8-19669e474304"
      unitRef="usd">197605000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNS0zLTEtMS00ODcyOQ_28db3bb3-1693-4117-94b1-92539ee9584c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNS01LTEtMS00ODcyOQ_cf2de0ba-124d-439c-93f6-d54c9394d340"
      unitRef="usd">1141000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNS03LTEtMS00ODcyOQ_f0c97bcf-bfe2-49f1-8ef4-57591fe58f8d"
      unitRef="usd">196464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNi0xLTEtMS00ODcyOQ_b6beb090-6775-4884-936a-058740ff3a34"
      unitRef="usd">13455000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNi0zLTEtMS00ODcyOQ_35bf5068-2c08-40a6-836b-4c1f0fb7a83b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNi01LTEtMS00ODcyOQ_f0e910da-390e-480d-9926-26cb052890fa"
      unitRef="usd">169000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNi03LTEtMS00ODcyOQ_b8d91988-2a28-45c5-b2ac-573af4681b15"
      unitRef="usd">13286000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNy0xLTEtMS00ODcyOQ_46420d25-b938-4f17-8043-927f0840faa9"
      unitRef="usd">1694472000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNy0zLTEtMS00ODcyOQ_9c5babbe-3894-4310-811e-fea88a709a17"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNy01LTEtMS00ODcyOQ_e52cecaa-a367-4b44-9732-1aabce0690b1"
      unitRef="usd">8459000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfNy03LTEtMS00ODcyOQ_72f9b708-8937-4c6d-bacc-8b5e3cbf852f"
      unitRef="usd">1686113000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ibb28bbb730bd440b8dd81392fd62926d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOC0xLTEtMS00ODcyOQ_d5f7fb3d-bc52-45b5-b180-ad2bef5a42cf"
      unitRef="usd">97602000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ibb28bbb730bd440b8dd81392fd62926d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOC0zLTEtMS00ODcyOQ_7be87e42-7eb3-406f-92fa-623054ddfdc5"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ibb28bbb730bd440b8dd81392fd62926d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOC01LTEtMS00ODcyOQ_fc6aab31-83ee-4281-934c-824d6dfb763c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ibb28bbb730bd440b8dd81392fd62926d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOC03LTEtMS00ODcyOQ_c1031373-88ce-419f-9925-085428c9d483"
      unitRef="usd">97602000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ib35610c2f2f64e28b729777490e05b5a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOS0xLTEtMS00ODcyOQ_731070a7-cbe9-44d6-807a-7b642b355526"
      unitRef="usd">87255000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ib35610c2f2f64e28b729777490e05b5a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOS0zLTEtMS00ODcyOQ_bc289b40-ac40-4724-b738-6cc1924f035a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ib35610c2f2f64e28b729777490e05b5a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOS01LTEtMS00ODcyOQ_205d80a6-a2e0-4889-be5d-09395b077674"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ib35610c2f2f64e28b729777490e05b5a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfOS03LTEtMS00ODcyOQ_37f8655c-097f-42d8-9072-2eb57874317b"
      unitRef="usd">87255000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTAtMS0xLTEtNDg3Mjk_1d7c6ba0-69d9-4c4b-b4aa-00e832fdc66a"
      unitRef="usd">117901000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTAtMy0xLTEtNDg3Mjk_103e0e44-614c-43b4-ab8c-c9c91fb1d359"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTAtNS0xLTEtNDg3Mjk_bb23d083-be0f-4651-bd66-32ee80c6dc82"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i89389d9d9b714ac6adf58d5dd25c6c6b_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTAtNy0xLTEtNDg3Mjk_4d149367-6c43-4b46-a69e-3b5e5723e962"
      unitRef="usd">117901000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTEtMS0xLTEtNDg3Mjk_311d36c7-a40a-47f6-a811-55d3c24dc346"
      unitRef="usd">1997230000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTEtMy0xLTEtNDg3Mjk_d08799c3-44af-4296-baa3-a964d5376a1d"
      unitRef="usd">100000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTEtNS0xLTEtNDg3Mjk_9f331f23-8361-43b6-a590-e6b580e904ab"
      unitRef="usd">8459000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjczN2NhODg3MDg4NjQ4MmRiYjdmMDUzOWVmNmEyNjM1L3RhYmxlcmFuZ2U6NzM3Y2E4ODcwODg2NDgyZGJiN2YwNTM5ZWY2YTI2MzVfMTEtNy0xLTEtNDg3Mjk_3b58a7b0-d7e2-48ee-8801-3d466dfee861"
      unitRef="usd">1988871000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iba307933d72242f293a72ee9fda21f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMy0xLTEtMS00ODcyOQ_48104bc4-14a3-4e42-b833-5f54ea6cd0e6"
      unitRef="usd">945801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iba307933d72242f293a72ee9fda21f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMy0zLTEtMS00ODcyOQ_ac57b6e8-b9f8-4b3b-8d6f-a312927daf4d"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iba307933d72242f293a72ee9fda21f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMy01LTEtMS00ODcyOQ_7de05d5c-c54b-43b0-a6c5-c97eb86b9a47"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba307933d72242f293a72ee9fda21f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMy03LTEtMS00ODcyOQ_89ae4858-8909-499a-8461-66cc44c09b51"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNC0xLTEtMS00ODcyOQ_cc9ddc60-eab1-4861-a8a5-27d346be39b2"
      unitRef="usd">541774000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNC0zLTEtMS00ODcyOQ_fcd904a7-955b-41f6-9413-9e83248232f2"
      unitRef="usd">876000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNC01LTEtMS00ODcyOQ_b51b9166-d0c5-4345-8a4f-26c238ced998"
      unitRef="usd">1672000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNC03LTEtMS00ODcyOQ_0b837448-8b18-447b-a41d-a43259d299cb"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNS0xLTEtMS00ODcyOQ_b6a7e0f8-a6b6-41f4-a589-f5e8fad56ecb"
      unitRef="usd">33965000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNS0zLTEtMS00ODcyOQ_c6250079-8c8c-4566-becf-8b9b38d967c0"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNS01LTEtMS00ODcyOQ_1650d70f-fd7d-4975-9ab0-e87d08aed754"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNS03LTEtMS00ODcyOQ_c04c7a6d-b9d1-4519-af33-0f4d5fe820fb"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNi0xLTEtMS00ODcyOQ_8ea59c7d-e63c-40b4-b2ea-017cd06dbda3"
      unitRef="usd">12924000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNi0zLTEtMS00ODcyOQ_9d87a5da-e1cc-4add-a28b-c00f5edfc127"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNi01LTEtMS00ODcyOQ_7413192e-3fd5-43e1-836b-337457fb4a8d"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNi03LTEtMS00ODcyOQ_3ac3e7b7-1cd1-4567-8812-28736c1df9c9"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNy0xLTEtMS00ODcyOQ_649b78e3-4cc4-4ce2-8bfa-60bf0c54f174"
      unitRef="usd">1534464000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNy0zLTEtMS00ODcyOQ_e0df490c-a0f3-408d-a6d8-9e230f2acd06"
      unitRef="usd">934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNy01LTEtMS00ODcyOQ_dfd44c31-dfa0-4588-9e2d-0cf5892d8403"
      unitRef="usd">1730000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfNy03LTEtMS00ODcyOQ_c714f4eb-1a6b-413e-b6c5-391ef57fb087"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOC0xLTEtMS00ODcyOQ_d77f52d6-120e-4722-9d48-bba01ef2f860"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOC0zLTEtMS00ODcyOQ_e3e7e1e2-7228-43dc-9005-1ecf8828e404"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOC01LTEtMS00ODcyOQ_c03be479-84e0-4fdd-b0ca-88b22c21c375"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i58ce0f0df11e4c20a38916033e6bbb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOC03LTEtMS00ODcyOQ_bdb99d56-41f9-4c68-b367-d963b7bf0ec2"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i432f85dd8d664eee9a0730a69f1e1b48_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOS0xLTEtMS00ODcyOQ_57d21a5b-a285-4c69-ac32-0cf24302f5fa"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i432f85dd8d664eee9a0730a69f1e1b48_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOS0zLTEtMS00ODcyOQ_84810118-7c43-47b4-9bd1-659feeb3541c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i432f85dd8d664eee9a0730a69f1e1b48_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOS01LTEtMS00ODcyOQ_42c05fe4-aacc-4032-88bc-182569e030f3"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i432f85dd8d664eee9a0730a69f1e1b48_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfOS03LTEtMS00ODcyOQ_7a98bac5-1b95-4ff7-a228-85ecf43e5b7d"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="if26e7aaf62fb4dfd93a135a62c26622d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTAtMS0xLTEtNDg3Mjk_82494048-c92c-433c-b2b1-631e86febd3b"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="if26e7aaf62fb4dfd93a135a62c26622d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTAtMy0xLTEtNDg3Mjk_deb815db-52fc-434b-ab69-455e5f827b9c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="if26e7aaf62fb4dfd93a135a62c26622d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTAtNS0xLTEtNDg3Mjk_d3d9908c-16fd-468c-ae61-0dae9eba4b7e"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="if26e7aaf62fb4dfd93a135a62c26622d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTAtNy0xLTEtNDg3Mjk_3876bffa-a1d8-4012-ae6e-ef18bfbb8c95"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTEtMS0xLTEtNDg3Mjk_4b9aa7bd-a635-4a88-a512-96c5a8b44fac"
      unitRef="usd">1855704000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTEtMy0xLTEtNDg3Mjk_8ee335b1-133e-4c67-867a-80022bdb35dc"
      unitRef="usd">934000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTEtNS0xLTEtNDg3Mjk_42711c23-f2dd-4ae0-add8-56595bcd3052"
      unitRef="usd">1730000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjhiODI5OWQwYzg0ODRmZGI4YTM3ODljZjE2Y2M1YzIyL3RhYmxlcmFuZ2U6OGI4Mjk5ZDBjODQ4NGZkYjhhMzc4OWNmMTZjYzVjMjJfMTEtNy0xLTEtNDg3Mjk_fdd4a0a6-3ab8-4c6a-baa3-1f6d4d40a0e2"
      unitRef="usd">1854908000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMTY0OTI2NzQ0NDQ0Mw_8e10e5c0-e878-4cfd-9b20-7108ca85c925"
      unitRef="usd">2600000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNDM5ODA0NjUxNDUwNQ_096e2ad5-aaf0-4436-9a1b-fd8b91600b9e"
      unitRef="usd">2900000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjc0MQ_04da046e-36c1-4e48-8e24-c31080d84390">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfMy05LTEtMS00ODcyOQ_bf2200e1-3dfd-434c-b15e-6fed7cd24acb"
      unitRef="usd">456676000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfMy0xMS0xLTEtNDg3Mjk_792387c0-f1ca-4636-b459-43f9b9f1d1a6"
      unitRef="usd">7123000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC05LTEtMS02MTMxMw_c25d5ad6-6483-49ba-9575-48cde989c8b8"
      unitRef="usd">196464000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if3a51673cab54c2c99014b6a758949cd_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC0xMS0xLTEtNjEzMTM_56f86c36-3c77-4503-a050-b20a2ab3aeb3"
      unitRef="usd">1141000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC05LTEtMS01Nzc1Nw_a3fd500f-ba54-4ff8-addb-254ddbc034e6"
      unitRef="usd">32460000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i216f029a7d3140eda781b2bd89f45d1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC0xMS0xLTEtNTc3NTk_40456152-25a4-4a94-bb95-2b9a8cd2d443"
      unitRef="usd">26000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC05LTEtMS00ODcyOQ_da02de75-d277-454f-88a4-53532ac722d6"
      unitRef="usd">13286000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if8ce553376d14a1e9bbcaf23624a1e75_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNC0xMS0xLTEtNDg3Mjk_96286249-de41-4f72-ba98-0782d64a9ce3"
      unitRef="usd">169000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNi05LTEtMS00ODcyOQ_c48e8de9-1c29-480b-b527-fbbe37eecffd"
      unitRef="usd">698886000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjMxODJmNjFhNmNjNDQ3MTY4NGM1MzdmMGMwODgyMmNkL3RhYmxlcmFuZ2U6MzE4MmY2MWE2Y2M0NDcxNjg0YzUzN2YwYzA4ODIyY2RfNi0xMS0xLTEtNDg3Mjk_e2248b51-bd53-4a7e-bc8b-4a37d2055df9"
      unitRef="usd">8459000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMi05LTEtMS00ODcyOQ_d58d45d8-b8b0-43a5-9d19-5ff64e29c9f7"
      unitRef="usd">385053000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia41d6e3be92a4188b3ecc0eaa44e529a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMi0xMS0xLTEtNDg3Mjk_ebba859e-1f91-48c2-9fe8-ff485a66ec8d"
      unitRef="usd">1672000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iba307933d72242f293a72ee9fda21f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMy05LTEtMS01Nzc2MQ_8d70e852-7301-44f6-b75e-ac70acc5a6b6"
      unitRef="usd">43290000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iba307933d72242f293a72ee9fda21f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMy0xMS0xLTEtNTc3NjM_ebb7dac4-4a1e-4d55-adfe-878b496f4046"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMy05LTEtMS00ODcyOQ_e5269bd4-fc04-4ac9-83d1-bb02b77a84ed"
      unitRef="usd">18962000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i80f302f2dfc743a7baa51a5301f9feb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfMy0xMS0xLTEtNDg3Mjk_b4939bf5-5170-4d4b-a3b9-68a547ea8175"
      unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfNC05LTEtMS00ODcyOQ_c718c1dc-9f9c-4514-8407-8b3da7143ff4"
      unitRef="usd">7475000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ieca5786fb2a340c09e8c451543dcf63d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfNC0xMS0xLTEtNDg3Mjk_d8552c59-102e-48ad-8331-585b990b7df8"
      unitRef="usd">35000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfNS05LTEtMS00ODcyOQ_137159aa-1a8c-487b-8494-3aad198265ab"
      unitRef="usd">454780000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOjdjMWQ4MjRhOTQ2MTRhOTViZjc3ZmVkYWM3OThiZWQxL3RhYmxlcmFuZ2U6N2MxZDgyNGE5NDYxNGE5NWJmNzdmZWRhYzc5OGJlZDFfNS0xMS0xLTEtNDg3Mjk_0b4a3005-e917-49cb-b6ae-db9c37eab085"
      unitRef="usd">1730000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMTY0OTI2NzQ0NDQ4Nw_b3aac9de-8f1a-453c-9dca-16553e15cb3a"
      unitRef="investment">197</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNDM5ODA0NjUxNDUzNg_40ab2374-e6c7-4c3e-a982-69033c57088d"
      unitRef="investment">133</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfNzE0NjgyNTU4NDkzOQ_c79eb969-4464-4e8a-853e-e9fbe8717859"
      unitRef="investment">2</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i72e0a785551d4eb5b700653888c4db8d_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfODc5NjA5MzAyNjUzNw_4207ead9-4cba-45c6-b88c-2c3310e0841d"
      unitRef="usd">6300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjEwNA_9438711e-7606-41b4-aab6-3e42a4ad73e5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ib3de2311ad9f4eaa86a15e6ff586a051_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjEwNA_b4b3233f-fa86-4de6-bdea-451655bbe3c1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RleHRyZWdpb246MzljNDljMmQ1MWVjNDkzYWI4NzY1MmYzYTg1ZWI1ZDdfMjc1NQ_3983714f-e87d-43b2-9362-1488e4c9ecc5">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMS0xLTEtMS00ODcyOQ_3d774bcb-2afb-4b9f-8db9-1500fb62e1cd"
      unitRef="usd">1290576000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMS0zLTEtMS00ODcyOQ_e5c06287-f2b2-401a-a089-677f64f9dd28"
      unitRef="usd">1168256000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMi0xLTEtMS00ODcyOQ_8cdfb80c-b815-4ae6-b837-0bc518b0310f"
      unitRef="usd">395537000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMi0zLTEtMS00ODcyOQ_0d8c4de9-a1e9-4f37-afd8-de00099fc6e6"
      unitRef="usd">365412000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMy0xLTEtMS00ODcyOQ_10ce49f6-2df3-4992-899d-09c5d18b2c54"
      unitRef="usd">1686113000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80My9mcmFnOjM5YzQ5YzJkNTFlYzQ5M2FiODc2NTJmM2E4NWViNWQ3L3RhYmxlOmQzYmMwZGFlZDcwMTRiNTdhZWJmNjM5YTQ0NTg1YTZiL3RhYmxlcmFuZ2U6ZDNiYzBkYWVkNzAxNGI1N2FlYmY2MzlhNDQ1ODVhNmJfMy0zLTEtMS00ODcyOQ_d42e07a0-280c-4be4-99f2-1873b88d42e2"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfMjQ4Nw_e2faf20b-f563-4ec7-a915-66bbef0567db">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,891,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forward Foreign Currency Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we had one forward contract outstanding to sell &#x20ac;7.5&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the three months ended March 31, 2022, and 2021, we recognized $0.2&#160;million and $0.4&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfMjQ4OA_666219fa-6741-40c8-af56-c601b4a8e06b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,891,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i39a97239c0614813a9bcdb47d5079585_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMi0xLTEtMS00ODcyOQ_1f34e742-b613-43fc-8c48-b5567ea9e9e8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5947ed8d61374685906f19d9a2843814_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMi0zLTEtMS00ODcyOQ_25d60948-daf5-4a32-a8f2-8492f28c763b"
      unitRef="usd">954262000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ae72b8862524ed3bc2b8076fccf13b7_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMi01LTEtMS00ODcyOQ_232cd6e8-e3bd-45e8-a3f1-97531df06576"
      unitRef="usd">954262000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f27864b6b9f4932ab380c795945d7bf_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMy0xLTEtMS00ODcyOQ_3c79bdb5-8a14-4d75-9bee-d145b0f34f4e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a8f75092b0242e1ae826f92f356d80d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMy0zLTEtMS00ODcyOQ_6ccfd7c3-12a8-4f3d-8b89-c053bf9e1a94"
      unitRef="usd">522101000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i077a405a4ad640958488bbaf28a3f902_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfMy01LTEtMS00ODcyOQ_33fad2fd-2537-4211-af23-4541e5f57b1d"
      unitRef="usd">522101000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie91f2d21f92d443c8661271beebb3543_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNC0xLTEtMS00ODcyOQ_facd50c5-e28b-47c5-a8d2-de9cba08060a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i708e1024f4b043f5b3ca5956a7e0b0f3_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNC0zLTEtMS00ODcyOQ_c4e7a74e-9969-4c9d-8200-c80f62b49790"
      unitRef="usd">196464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib739bb13678f47dfafa308d8f18febb0_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNC01LTEtMS00ODcyOQ_545c59bc-5cf7-4911-b36d-05978aa56155"
      unitRef="usd">196464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i361a4fd0426d441c8c588a99db99da57_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNS0xLTEtMS00ODcyOQ_eea8232e-ec53-4859-bde8-328ff36ca5b6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb018c27cf90423abecc6191d113e300_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNS0zLTEtMS00ODcyOQ_aa5c2ce7-1092-4a31-95ed-a78f56309c81"
      unitRef="usd">13286000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b1eef055e9241f1bb4210e3898693e9_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNS01LTEtMS00ODcyOQ_55e0b8df-955d-489e-977c-2b180cb57a61"
      unitRef="usd">13286000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecade2a3f84649a985b16aa9c12ad66e_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNi0xLTEtMS00ODcyOQ_0d5b6a64-e675-44f6-a2d8-cd7ffce16912"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad8a4c467cd646c8baca4f7b23ef5df5_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNi0zLTEtMS00ODcyOQ_31370249-5fa7-43e3-8143-b0ed68a3b4a8"
      unitRef="usd">1686113000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65ec798216a747d2a34f9808d6def632_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNi01LTEtMS00ODcyOQ_58a1466c-45d5-417f-a63d-8cd365fdc978"
      unitRef="usd">1686113000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i47ba248b6ca34c99b5dca94a7a314c11_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNy0xLTEtMS00ODcyOQ_f500deed-b480-4477-bada-b9d7fee67991"
      unitRef="usd">87255000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iebc722e878a2424da9fcbea991b54c27_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNy0zLTEtMS00ODcyOQ_33cdb383-29cc-4c08-a980-0279ce548a15"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i83d3eadd8ce14ffe8c19bfbb349b6627_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfNy01LTEtMS00ODcyOQ_7fe38200-4f16-43b3-8a6f-280c286ab7ea"
      unitRef="usd">87255000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibff127cda51a421eafdfdfc142c594bc_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOC0xLTEtMS00ODcyOQ_4b0ead3f-c5af-4700-92ce-6c03114506c5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i53790e7d78b6449e828c39355b724f3e_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOC0zLTEtMS00ODcyOQ_7b3ad962-6306-43c9-baaf-3295242c9435"
      unitRef="usd">117901000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie1dcd1471658475dab1dc78d180aeb5d_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOC01LTEtMS00ODcyOQ_ed606402-64af-4762-8b2e-5f5ef4bbad91"
      unitRef="usd">117901000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecade2a3f84649a985b16aa9c12ad66e_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOS0xLTEtMS00ODcyOQ_92ead3ec-315b-48ab-950e-82ea6844767d"
      unitRef="usd">87255000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iad8a4c467cd646c8baca4f7b23ef5df5_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOS0zLTEtMS00ODcyOQ_6a130e11-15c9-47f6-81ad-077288e0fb5d"
      unitRef="usd">1804014000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i65ec798216a747d2a34f9808d6def632_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmQyNjBlMmRjMjcyZTQyNjY4MDQ5MTc4MGQ0NGRjOTI1L3RhYmxlcmFuZ2U6ZDI2MGUyZGMyNzJlNDI2NjgwNDkxNzgwZDQ0ZGM5MjVfOS01LTEtMS00ODcyOQ_80aa8f01-cb77-467e-bd4a-d776e6d9921e"
      unitRef="usd">1891269000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib276f1befb584f2eb0d3d8400a5211c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMi0xLTEtMS00ODcyOQ_118ae192-3005-4ea2-a74d-85386e0f7367"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1aae95b2dad1408b92e286980170dfc9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMi0zLTEtMS00ODcyOQ_a6805990-abb7-4089-88ac-16c7ff67e5bf"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf6386ba6236456c9cb250e103fddfb3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMi01LTEtMS00ODcyOQ_b93ae13d-4d7b-47aa-be4e-eb80695487c3"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22ec7c9bfa1446a2aa2e7e77616f7444_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMy0xLTEtMS00ODcyOQ_0dcd45c6-1135-4eef-96e9-8e7958516cd2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00701b0060ff40e3bf9e67174a926ca5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMy0zLTEtMS00ODcyOQ_d9c8636d-7207-44c1-849c-4c674c35da24"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c6db7d27ba346c7a74173cedc687715_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfMy01LTEtMS00ODcyOQ_918b83b9-d755-4785-af30-b3c4616b078c"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id642b16c75c042b8b4f0872704ddeb4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNC0xLTEtMS00ODcyOQ_4dc04853-c4a5-4d31-a8d5-685564347893"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9732c24ef7d4030924d2fffc47a71c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNC0zLTEtMS00ODcyOQ_38c2e5c0-f294-48cf-b9cb-3e2db38ae6e3"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id9f4cd6591c4439e807a82ca409c8519_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNC01LTEtMS00ODcyOQ_80dff479-032b-4b6e-a24e-41b9fc45c6c5"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f55b03203d14b7199c525ee8fb9a037_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNS0xLTEtMS00ODcyOQ_a6233941-3e60-41a5-80b4-68ff2c442fde"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0e31300c13f4b42b4ccc7397381d5c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNS0zLTEtMS00ODcyOQ_de2d09e1-c2d0-4841-8a53-36b1f801cc50"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98e51bc0ba15407f9467b03b370593c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNS01LTEtMS00ODcyOQ_c83ae993-4d90-4521-af8f-f98aaadb17df"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d9317c7dece422d8d017470956ef4c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNi0xLTEtMS00ODcyOQ_d3fcb379-c348-41ac-9c02-87dd41909e37"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaee8761f5b144743b68bf5786e2cb23f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNi0zLTEtMS00ODcyOQ_ebdacb2d-51a5-4c53-97fd-39f4c30dad9c"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41dfb8c579ab4f9bb95a37a5d8e40b2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNi01LTEtMS00ODcyOQ_f3e17275-aca4-4ece-a716-ff94e5573159"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idf6962f24fdd4732b9aea4dfba7aeb43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNy0xLTEtMS00ODcyOQ_ffb2ac3d-9973-4fce-930e-0c6bb266dba1"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if22e357e289d4e58b700f917e7b65f71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNy0zLTEtMS00ODcyOQ_9dc119a1-0cf1-4c52-80e1-db1877078518"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0be18ed8e8ba449981c62abecf9bf6ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfNy01LTEtMS00ODcyOQ_40bd725f-54f5-47ae-aac8-cddafd832d56"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia7406990966249758acd778bc8008496_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOC0xLTEtMS00ODcyOQ_7803674b-9532-4313-8dc8-7e55cfe5555f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i57b1c0ac24664ff79ea2d1b0020ed617_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOC0zLTEtMS00ODcyOQ_c1d5d897-6490-4ba2-905c-ae9fb81bbc9c"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i50204c4c28b948cb80f20f78f4be649e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOC01LTEtMS00ODcyOQ_c88af359-e2f8-4f49-8c8f-c9bdbe26721b"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7d9317c7dece422d8d017470956ef4c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOS0xLTEtMS00ODcyOQ_9bd11443-5b74-4392-bd66-a2a054883556"
      unitRef="usd">66531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaee8761f5b144743b68bf5786e2cb23f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOS0zLTEtMS00ODcyOQ_8275948a-e226-47d5-92fe-57eb8484559f"
      unitRef="usd">1652724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i41dfb8c579ab4f9bb95a37a5d8e40b2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RhYmxlOmIwODJmNTNhNDYzMzQyZWE5NWIyMmQ0NmUxMDZlOGE0L3RhYmxlcmFuZ2U6YjA4MmY1M2E0NjMzNDJlYTk1YjIyZDQ2ZTEwNmU4YTRfOS01LTEtMS00ODcyOQ_3c9181aa-0569-466a-96e6-59230e4260b1"
      unitRef="usd">1719255000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i1e4e846c084c4559b6a9595a6687fd2f_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfMTg3Mw_ef06c52a-1d73-4582-8cb6-ebcc5778e716"
      unitRef="forward_contract">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1e4e846c084c4559b6a9595a6687fd2f_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfNzY5NjU4MTM5NzIyNw_6a337588-bfc1-4324-befe-3cd50adba656"
      unitRef="eur">7500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="ic881e9f145a74a479a9c7527b88c7852_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfMTk1Nw_e2174219-05ec-4506-98ca-e83f058c4820">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="ic881e9f145a74a479a9c7527b88c7852_D20220101-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfNzY5NjU4MTM5NzIyOA_b85d670f-d809-412d-ac90-835b6b67b60d"
      unitRef="usd">200000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i3f7b2f0fe2cf41038946282cc39c3653_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80Ni9mcmFnOmRkN2ZiODI1NDA2NTRiYmNiYTIwMTM0NGMwNjYzY2Y3L3RleHRyZWdpb246ZGQ3ZmI4MjU0MDY1NGJiY2JhMjAxMzQ0YzA2NjNjZjdfNzY5NjU4MTM5NzIzMQ_5e297723-80f5-4e24-a55f-7f545a0be5f0"
      unitRef="usd">400000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RleHRyZWdpb246YTc3YmIwMjk4MjFmNDhjOGFiMDljMTZiNmMwYmM2NWFfNzY_c410bcf2-7b3a-4e3f-918c-5c33ae28966f">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RleHRyZWdpb246YTc3YmIwMjk4MjFmNDhjOGFiMDljMTZiNmMwYmM2NWFfODQ_31a83ab4-5ad7-48c0-a704-2bb428ef989a">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMS0xLTEtMS00ODcyOQ_a69762a8-48df-4bcc-b93a-0beb5080fa26"
      unitRef="usd">10858000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMS0zLTEtMS00ODcyOQ_b2706a81-f1f6-4940-98fd-6429cae7cab5"
      unitRef="usd">8867000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMi0xLTEtMS00ODcyOQ_11c15e10-cba8-4148-b60f-f6d14b16b1da"
      unitRef="usd">27778000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMi0zLTEtMS00ODcyOQ_a006081a-d7e6-48a8-a318-f6397f060795"
      unitRef="usd">27717000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMy0xLTEtMS00ODcyOQ_5e7de3b3-d764-496c-972a-185f4c8d9719"
      unitRef="usd">14653000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfMy0zLTEtMS00ODcyOQ_86e084cc-d3f4-455d-baf9-60374bcc16cc"
      unitRef="usd">12927000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfNC0xLTEtMS00ODcyOQ_082412f0-b7ce-494d-bea7-fc04ea58e5bf"
      unitRef="usd">53289000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfNC0zLTEtMS00ODcyOQ_e1039833-7287-4c65-a72a-f9392ba7d2d7"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ia939647731704dcda59a54bb06e17828_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfNy0xLTEtMS00ODcyOQ_742b20f8-dde5-4856-8412-b7c0ea256eb0"
      unitRef="usd">28467000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i6b94af5f9c714b06876549ec2d63eef9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfNy0zLTEtMS00ODcyOQ_936bd88f-0336-460e-8c89-aa0cbc6281ee"
      unitRef="usd">27493000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i0a6ac444fe974dedb4a9b7fe83af78ce_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOC0xLTEtMS00ODcyOQ_e69d4dc0-6445-49f6-86bc-0fefde8e4e40"
      unitRef="usd">24822000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i3a2837ce514e4359abcc29c595fb4d0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOC0zLTEtMS00ODcyOQ_842c8b95-6ca7-4792-96c9-7761aae602e7"
      unitRef="usd">22018000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i3a2837ce514e4359abcc29c595fb4d0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOC0zLTEtMS00ODcyOQ_ba12034c-761e-4cf3-84dc-760df55080cf"
      unitRef="usd">22018000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOS0xLTEtMS00ODcyOQ_7eaaa341-e0c8-4a44-9668-be6c09691db7"
      unitRef="usd">53289000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i07d2fa3b35a449daad65b440257d44b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV80OS9mcmFnOmE3N2JiMDI5ODIxZjQ4YzhhYjA5YzE2YjZjMGJjNjVhL3RhYmxlOmE0NzE5Y2M1MzQyZTQ1ZjBiZDI5NjQ1M2U4NWExZTYyL3RhYmxlcmFuZ2U6YTQ3MTljYzUzNDJlNDVmMGJkMjk2NDUzZTg1YTFlNjJfOS0zLTEtMS00ODcyOQ_dbd8a603-84e0-46bc-8b4b-c5e6f90eeca4"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfMzg1Ng_e7e51f82-bcab-4171-bfb1-9ab6807219ad">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022, 4,152,901 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, we granted 233,476 stock options with a weighted average exercise price of $19.02 per share and a weighted average grant&#160;date fair&#160;value of $7.51&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hare. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were 12,635,435 stock options outstanding and $24.8&#160;million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, we awarded to certain employees an aggregate of 1,003,482 (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to 175% of the target amount of shares. 50% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately one year later, subject to employee&#x2019;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#x2019;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, we granted 3,549,973 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $20.51 per share. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were 11,635,329 RSUs outstanding, including the TSR-based RSUs, and $209.6&#160;million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and service-based RSUs granted to employees during the three months ended March 31, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#x201c;Note 8. Employee Benefit Plans&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were&#160;5,698,281 performance-based restricted stock units (PSUs) outstanding and $116.0&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#x201c;Note 8. Employee Benefit Plans&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfMzgxOQ_d6d8545c-9437-494c-a5f2-83498607f3fb">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1ae08cfc122445338953c327341f7d67_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfMy0xLTEtMS00ODcyOQ_c3718395-685f-4b82-b257-954b1da90266"
      unitRef="usd">8899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0817dc61f16c4beb874045356c0ac962_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfMy0zLTEtMS00ODcyOQ_4e118eba-c375-45f1-a780-f6c09ee47394"
      unitRef="usd">12396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6664829ae3ae483fa02b63376c5628fa_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfNC0xLTEtMS00ODcyOQ_faf6b385-bbd1-4cda-aa30-cec0cb272a6f"
      unitRef="usd">10860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b1a0fc30e914cd38e29d4ce13c7080f_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfNC0zLTEtMS00ODcyOQ_f1dd49fd-a933-4231-b70a-763e75657ecb"
      unitRef="usd">22257000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfNS0xLTEtMS00ODcyOQ_05e6ca8c-41b9-45bb-a44e-a107885cef5a"
      unitRef="usd">19759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmU5ZjRjMDQwYTcyODQyNGY5ZjBiNjA4YmY4ZmZjNDZiL3RhYmxlcmFuZ2U6ZTlmNGMwNDBhNzI4NDI0ZjlmMGI2MDhiZjhmZmM0NmJfNS0zLTEtMS00ODcyOQ_5cb43e31-c979-48ea-a878-953c0e3f2b81"
      unitRef="usd">34653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i422c757fd8504d8d9bd061c6daee9c01_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfMi0xLTEtMS00ODcyOQ_eaf61bcc-2f84-458a-857d-ecdfb589f37f"
      unitRef="usd">3678000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3ac399c1a21047abb423228840492006_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfMi0zLTEtMS00ODcyOQ_7a776354-ec53-42a8-8c50-e8301bae06b8"
      unitRef="usd">4694000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4258bed58c6048f58584c4e2f94d0ee9_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfMy0xLTEtMS00ODcyOQ_84068630-e5f4-4c65-89e2-d9de33b3ef19"
      unitRef="usd">13073000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic6c08f7404ff4eb485860a6fd51e4b73_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfMy0zLTEtMS00ODcyOQ_84b0614a-dc74-494e-9ee4-d01b72147939"
      unitRef="usd">11669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14bb8ff89fac4afabb3b6fe4dc3cf4e5_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNC0xLTEtMS00ODcyOQ_6c346e96-924e-4e28-bd0f-c611d57b36e1"
      unitRef="usd">1709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc7ff6b6e16e434293d751847fe852e9_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNC0zLTEtMS00ODcyOQ_a65a2aa2-9843-4af4-a666-c9d956236845"
      unitRef="usd">17947000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i72f50fb2bc0e46d39335240d888c8205_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNS0xLTEtMS00ODcyOQ_f3c62813-b054-4de4-9848-98c3a04e39b8"
      unitRef="usd">1299000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc02918e98774e5ab327c89a0477cfcc_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNS0zLTEtMS00ODcyOQ_0b5b2ebc-888b-42a6-9e02-9d5cffdef057"
      unitRef="usd">343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNi0xLTEtMS00ODcyOQ_0405065d-d79c-4a35-9c39-df4225b6333a"
      unitRef="usd">19759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOjEzODk3NDNkNTRjMDQ5Y2U4ZTlhNTk3MGEzZmRiZTVhL3RhYmxlcmFuZ2U6MTM4OTc0M2Q1NGMwNDljZThlOWE1OTcwYTNmZGJlNWFfNi0zLTEtMS00ODcyOQ_5d0ce3f3-7e30-413c-9149-c3ca6514a0b7"
      unitRef="usd">34653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDQ3MA_ccbd68bf-331e-419b-842b-64e730237d82"
      unitRef="shares">4152901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNDg3_922b4819-0f97-412a-818c-4b768939f65a"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNTQ5_379e592e-dcbf-4523-a11d-3ce54edd7142"
      unitRef="shares">1.5</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDQ4Mg_51f31b8c-6bbe-478a-8ecc-9ce6e74fbc54"
      unitRef="shares">233476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDUyMA_498cd965-0d61-4848-b0b9-6e029437a7b2"
      unitRef="usdPerShare">19.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNTQ5NzU1ODE1NTI4OQ_3cdb0210-ba09-4513-879e-32b4d23cfe2d"
      unitRef="usdPerShare">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ied00e348414944e896116d415bab3625_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDUwOA_bc5c5c3e-d799-4d0d-9bac-eeb515f63523"
      unitRef="shares">12635435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i07e399f10aef4b259d2c54579c871e1a_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDQ5Mg_3e1fc9a4-657e-4ed0-8b25-5b8e7d412c9e"
      unitRef="usd">24800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia195c1f38ea54879b3d52bd17362ea4e_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQwNzA2Mg_3669fc52-0e3a-4694-85e8-a99720e77523"
      unitRef="shares">1003482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i3c24c63c06b046a89283ea6c11d9a730_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQwNzA3NQ_51e86d78-1c8d-4ac3-b97d-834eb8dc86f4"
      unitRef="number">1.75</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i5757437e306d438b96edc7549e66fa17_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5MzI2Mw_0ead5d3e-462a-44ce-8d74-d8d4d18b34e6"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5757437e306d438b96edc7549e66fa17_D20220301-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5MzI0MA_7564368d-1613-44b3-839c-ff0944012054">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfMzgzNg_0c65eb49-40ff-4258-80ba-86273b59d867">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i277d7677672b42a28307cdefe84dc555_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzY5NjU4MTQxMDQ2MQ_3040a717-f9f1-4b3f-a445-38a1e542c3a4"
      unitRef="usdPerShare">33.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="if01316baae344a38a3c7cf53ddd5d7b4_I20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmE4MzlhNDUzMWJkMjQ1NGJhOGRlM2EyMGZjODg1Y2JhL3RhYmxlcmFuZ2U6YTgzOWE0NTMxYmQyNDU0YmE4ZGUzYTIwZmM4ODVjYmFfMC0xLTEtMS00ODcyOQ_819f2fe6-fb64-42da-9e38-ab83226a59b8"
      unitRef="usdPerShare">20.70</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i277d7677672b42a28307cdefe84dc555_D20220101-20220401"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmE4MzlhNDUzMWJkMjQ1NGJhOGRlM2EyMGZjODg1Y2JhL3RhYmxlcmFuZ2U6YTgzOWE0NTMxYmQyNDU0YmE4ZGUzYTIwZmM4ODVjYmFfMS0xLTEtMS00ODcyOQ_5243be91-cf9a-472b-a600-7ffc7d3fe8cd"
      unitRef="number">0.4685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i277d7677672b42a28307cdefe84dc555_D20220101-20220401"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmE4MzlhNDUzMWJkMjQ1NGJhOGRlM2EyMGZjODg1Y2JhL3RhYmxlcmFuZ2U6YTgzOWE0NTMxYmQyNDU0YmE4ZGUzYTIwZmM4ODVjYmFfMi0xLTEtMS00ODcyOQ_b0521528-4d4a-4343-816c-24755034123e"
      unitRef="number">0.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i277d7677672b42a28307cdefe84dc555_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RhYmxlOmE4MzlhNDUzMWJkMjQ1NGJhOGRlM2EyMGZjODg1Y2JhL3RhYmxlcmFuZ2U6YTgzOWE0NTMxYmQyNDU0YmE4ZGUzYTIwZmM4ODVjYmFfMy0xLTEtMS00ODcyOQ_2276e2c1-a999-41af-bbb1-f84db41c4e91"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4258bed58c6048f58584c4e2f94d0ee9_D20220101-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5NjgzMQ_d7b5fa0c-183d-4e9a-89f0-b1f7b20c6504"
      unitRef="shares">3549973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4258bed58c6048f58584c4e2f94d0ee9_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg0Mw_bdd20949-93c8-4ab4-b11d-f9a90c0df5bc"
      unitRef="usdPerShare">20.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5850614cec8549968a33dfef9671139c_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg1Mg_ca55d92d-6e1b-49ea-8b86-7e8842374ad4"
      unitRef="shares">11635329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5850614cec8549968a33dfef9671139c_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg2NQ_9780497c-0fec-4ed1-b759-6bd3b2f63630"
      unitRef="usd">209600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7b2c5399d43b4b588fd04c0afca7e0f6_I20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg4Mg_b480c3d1-f9ce-4b10-810f-15b2ba7a9024"
      unitRef="shares">5698281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7b2c5399d43b4b588fd04c0afca7e0f6_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81Mi9mcmFnOjk3ZDMyN2U3MWM3ODQxZDlhNzVhZmIwODgzODY3ZTBhL3RleHRyZWdpb246OTdkMzI3ZTcxYzc4NDFkOWE3NWFmYjA4ODM4NjdlMGFfNzE0NjgyNTU5Njg5NA_b5ae1cac-d343-4f5c-8222-e9357b5b591b"
      unitRef="usd">116000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81NS9mcmFnOjNlNTMyMWQyZjA0NzQ4OTA4MzQ4YjhkNGJhZTY0YzVmL3RleHRyZWdpb246M2U1MzIxZDJmMDQ3NDg5MDgzNDhiOGQ0YmFlNjRjNWZfNzg1_7bd1a272-25f4-48fb-922d-6cdf0b51b189">PROVISION FOR (BENEFIT FROM) INCOME TAXESThe effective tax rate for the three months ended March 31, 2022 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits, partially offset by state taxes. The effective rate for the three months ended March 31, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, in relation to the generation of a small pre-tax loss during the period.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RleHRyZWdpb246MDM5NTA2ZTM0M2U5NGI3YmFhN2RkMDk1MDdhMGE4MzBfNzU0_b1b5c9d7-1343-4b83-a054-23bfa3df41bc">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RleHRyZWdpb246MDM5NTA2ZTM0M2U5NGI3YmFhN2RkMDk1MDdhMGE4MzBfNzYw_227c5378-b87f-4f03-99f2-582e96310e29">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfMy0xLTEtMS00ODcyOQ_e6f12bd3-6737-4a26-84ba-ede00144975d"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfMy0zLTEtMS00ODcyOQ_bdfd9e7d-a56e-4eeb-941e-e7cf5aeddfce"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNS0xLTEtMS00ODcyOQ_adf748de-649b-493e-9e17-bee327546154"
      unitRef="shares">319582000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNS0zLTEtMS00ODcyOQ_0b9bb511-1737-424d-90ba-74bd27a0b784"
      unitRef="shares">312473000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNi0xLTEtMS00ODcyOQ_2015175b-9278-4701-b2e0-68e93057471b"
      unitRef="shares">3707000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNi0zLTEtMS00ODcyOQ_dbc7fc62-cb1a-492f-bcd9-e3b3393b247d"
      unitRef="shares">8814000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNy0xLTEtMS00ODcyOQ_548822e8-b00d-40e9-866a-373d68d2756f"
      unitRef="shares">323289000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfNy0zLTEtMS00ODcyOQ_a3e3f2e7-99d4-4b2f-b8c5-d0a99a1e18f6"
      unitRef="shares">321287000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfOS0xLTEtMS00ODcyOQ_47c83310-40fc-4cd7-88ee-c57b9426d241"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfOS0zLTEtMS00ODcyOQ_934db787-9eb4-45f7-9ac3-b4f755e6cba0"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfMTAtMS0xLTEtNDg3Mjk_2c640796-78f4-4e43-8046-13f03bfb59c5"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie9211e2290f74afabbffc22521da7d36_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOjE2YTRiNzk1NzNjYzRhNWJiYjRkY2Q4OGRhODA1ZDczL3RhYmxlcmFuZ2U6MTZhNGI3OTU3M2NjNGE1YmJiNGRjZDg4ZGE4MDVkNzNfMTAtMy0xLTEtNDg3Mjk_8132283d-36a8-4ac6-b0ec-6f8bf5a2c55c"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RleHRyZWdpb246MDM5NTA2ZTM0M2U5NGI3YmFhN2RkMDk1MDdhMGE4MzBfNzU4_4a3b5011-aa41-48fd-9e3f-011a32a16c6b">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i086d58fc90a14a97898df45878c69671_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOmRiOWFkNTA4ODhjOTRjY2M5NzJjOTU0NzgyNDdkNDVlL3RhYmxlcmFuZ2U6ZGI5YWQ1MDg4OGM5NGNjYzk3MmM5NTQ3ODI0N2Q0NWVfMi0xLTEtMS00ODcyOQ_0f0a388f-6ad7-4bc1-9f05-8274da756c5c"
      unitRef="shares">16522000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic64a47c5e8ba4d3db3fd89a64b034421_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV81OC9mcmFnOjAzOTUwNmUzNDNlOTRiN2JhYTdkZDA5NTA3YTBhODMwL3RhYmxlOmRiOWFkNTA4ODhjOTRjY2M5NzJjOTU0NzgyNDdkNDVlL3RhYmxlcmFuZ2U6ZGI5YWQ1MDg4OGM5NGNjYzk3MmM5NTQ3ODI0N2Q0NWVfMi0zLTEtMS00ODcyOQ_009d9e1e-570e-4dee-b3b3-350903fec43b"
      unitRef="shares">10007000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV82MS9mcmFnOjU5YjNkNzU1MWYzMzQzNWE4N2I1ZjVkYmM3OTcwMTY3L3RleHRyZWdpb246NTliM2Q3NTUxZjMzNDM1YTg3YjVmNWRiYzc5NzAxNjdfNjU2Mw_fff8124b-dc26-466b-b88b-f8901a01a94a">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#x2019;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the upcoming trial will address two issues: (1) infringement of claims 1 and 2 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A three-day bench trial has been scheduled to begin on May 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (salt and polymorphic forms), 11,091,440 (formulations) and 11,098,015 (methods of treatment). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the 2022 MSN ANDA Complaint) arising from MSN&#x2019;s further amendment of its ANDA filing with the FDA. In the 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN&#x2019;s ANDA would be a date no earlier than the expiration of the patents identified in the 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The 2022 MSN ANDA Complaint is a new case against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-02017 and 20-00633 described above. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are invalid and not infringed. A bench trial in connection with the 2022 MSN ANDA Complaint has been scheduled for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#x2019;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Teva Pharmaceutical Industries Limited (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Teva Parent), asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#x2019;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#x2019;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. On February 11, 2022, this case was administratively closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ib2319305255e41dea7c89963c20e9e04_D20220101-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODEzOTcyMTE_74b73096-05a9-483c-ae25-44d3331aa345">SUBSEQUENT EVENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Build-to-Suit Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is approximately 220,000 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the lease payments, we are also responsible for paying operating expenses related to the New Premises. For more information about our Build-to-Suit Lease, see &#x201c;Note 11. Commitments and Contingencies&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="id6c8e9889ae843dc8773c941eac343d0_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNDE_f250c052-bbc3-4d70-9c19-4d3214053370"
      unitRef="sqft">220000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id6c8e9889ae843dc8773c941eac343d0_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNTA_19e75030-557a-4b1e-bf5d-05425b0ddc49">P242M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i8602446ff3b94e92b5b78b0fb780866b_D20220402-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNjE_2c9a6826-cf0e-4d0b-b6a8-f7b11c180cae"
      unitRef="segment">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="id6c8e9889ae843dc8773c941eac343d0_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNjY_ff13a25e-65f0-4430-8ce5-91dcac27f068">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod
      contextRef="i8602446ff3b94e92b5b78b0fb780866b_D20220402-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkZTI0OGMzMjY1NjQ5YWM4ZDg4YjdiZmI4ZjQyZWQ5L3NlYzo4ZGUyNDhjMzI2NTY0OWFjOGQ4OGI3YmZiOGY0MmVkOV85MjQvZnJhZzowZWI2NTZlYzY0MTc0MWJkOTFmMWZjMmU0NTEwMTVkMS90ZXh0cmVnaW9uOjBlYjY1NmVjNjQxNzQxYmQ5MWYxZmMyZTQ1MTAxNWQxXzc2OTY1ODE0MDUwNTU_83ccb3cb-dd76-4bd2-9b41-55bb47736ab2">P180M</exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MU/!N8[C1<MN_'EA)#?5%?[D1'( ; 7B^EE)_OS%O'/9OF&[^ U!+ P04
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M393]BS?4IZ9I_>;@=!6Z9Z4=]6+8EC0MT7@#>E]K[?8'[Z";O]EO4$L#!!0
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MX#0&CF9@AP,&;F/@ZG<8VK37&'A5[.M@59'>4$E7RY(?4:G0X$U=5,=564.
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MYVI=<S,)ZU(]&T7P*-5M$8\(T-6^A*9/A@6H\=Y5()MX9(#721KQN#9JO%[
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M3C+A)> N6Z1AFO1ANU+3>3+ ?+CC%/P"J;QV O B]W!(E*;8R1-7+LSB*!H
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MO.,0KG580MX<X$=V#X,=!E2\() *N7+^4+SUE ED2 Z0Z ):9"54<,WBR_0
MH" E5SZ^E[7,=*FA!OM*+.5*"6U6$ "WT)+,V0:%ANQ'GMZA;&MC[$I2<2,W
M.%EK<@_Y2M:UL[73\%"Y0?$J2?W62I$IH^8ZQ).=]G?^&1VYUF5)5B'7&T7'
M9(TN"\0(,C7YJ3%M1GA:'P-""W'8"JY(7KKG3?(V.Y&=86N2D-34%>U4HJDA
M-&^<HQ4^0"WI"D^ARJ53A^+6%A).G9/;L:-H\I D6*<72$7RD=ZB3Y0RLX '
MWI)_G1)R)77)D2*[X JX/W<ZPS[2/RE\*&:RQ ZG2A:)5W3DO)0+O]2UJ"QZ
M2E,"R3D.^%.2JW0V(#Q2C60H$2!+Z18*47H'!0)75!+C@ EX%J>,>[M3)FBS
MU)F&QK2Z O9T3<ING 7@E+B#D1Z::9.734$0O)C<#L3HMS<#\<OD]2L(SU6-
M[3&H-Y-;_G^)2&5*F0B(%278AC5\>S@[%*^LC= Z)_2."G09306,8[S_ZGQT
MP&_AV.].A"6(";8S>M7_(,:CLROH\?MOWWYS\OWC9V*_[Y8#$<CA!+/V</*/
M+%:$$@!/&91/)'))448NVDJ*_9OQ^& @,IPF9&EA>=( "911H$DUAM49@!ML
M.;S8("_%[(]&9QD*-Q>,;[]Y>GKR_3,O]L\N9@?BZOI\^LM5JZ/1*ULVE<P.
M!C'W$1=M&X]$89A"M:4"(BRIUB"4??5^A'JDTJ"%*Z57="G\Q<K2YTF#]%,(
M*Q2JM&<BLS\9?_#$@7"RT#8R%:%M03'?OQE-#X;@*M12+#HSU25%A^J(SB70
MH8LVZ_;/;\<'SUB%,47E9OKSPV%!K?$-P7PG+OBX0%)X*#! =0S24[?+J5 V
M94G$X/YY%SB/0(2]RXU'-964UV00X1-N\ 3@6J5$IDV[B9/@B= J:@LZ?:'=
ME!%5;5T@"M+6:L(!Q&I0RX[<0;2"5_+=*HB2@2A$R(:UW18-6$BYA1/FSE:<
MEEW5)D$XD0L&L'UU.WF#%M?YT&;@I-&%@[]D[,7DIZT[854M7=C)Y#Y^G5HP
MO:7Z$MN+KU5.A(LB4;&_NC2I4(L8>Q386/CQ%*48IDF(+5.MZQ+C-:J[H2::
M>K"$B"I3K"9A\\:"WXO7Z":UV.\6)^1<3"\O)V<W7;(H+]\3Y)")T6H<50X$
MO@]]4 0'^IK"@0ADI<WOMF<AEH@(GL&O.B?PM'5J%WRTMM<CYF()W+B01@"$
M_1_HCY&)@8+B<2S.YU+K?*E1M<W=QK;9/Q!O=*7)2_N["X#6*^H@)46/O=\$
M]-P_520F-3$*@D8N_1)%WZ[;WHROL0R!?X3(];!9O:_;?-]!-?+5X%"@'Y6A
M!I^AA"V1[++@RDT-41M 6L96"/. .,EA;PPP%@&/XFB4*@[%KZDUR]);4:*)
M. Q-'U89FG5-/**H92P%(N2@EJ^@3M?,(KG0-B:/@DMR'ZN!K,!%8&6)-@81
M'98KM.-(52(H 1\P0)^ &_,26K2)Q0:W3(^9$O+S3'K-ZW>8-64M-5..(YT)
M)E[$<&\Y.;X\2+]C;XR4,'5D/J%C!3%:%AY('7F]M!07NS:0Z9L,?$Y+U]8/
MK*/0D9VIH8AY8]@\:EQ<__,-(ZGMJ 6E(R:3$?RKD5>N9;")@B4= ! ?_>0C
MT>,>#2VKR&4._^J(QDCT_1 =\=DNV0I'ST%-BC2)!+N"*2%7#+D=\< 9(:2F
M[K!0G+N$VYQR-N[M3*6T91-U)>;=V=K$ZX)V;JH;YQNJX< ##=/BY'CX,[\9
M444 F$Z.*1HW:H%6R]MFP]_:\C$#0-T6:)/W!#1@O]]59Q/J0B,V"1:42']L
M!<XLJE3H0$&(3U+OZSBW-F I\S[0"!=9$AOY@ \>=A9Y@Z(%OJ-Z[O!=* Y1
MC%/.HDC0D$D:R>)=TU:4?1XH/$NVIF3::$C1DHHFT,9]<;OAH)M H)5!6?6>
MNC1S+#&7FGG&SM#*7/8!W;H2C'("[N';C<2$.@ E1P*;5UW5B=UTNS\LG:+R
MP*.^HE%?7( [+<6C-*DS%Z>PM/IJV-G6PI5J(]3*98I?R0TQ=M0A])A>O]@H
M4#,<0HJ<0QSWN.X@+&)/(/?F36A<:]P#J?4E"45XN62L4+E40+5?V@934D9:
MRT15S;M4)V)^D=__CNC6TCD**=:V!D/ ?7OQ;QL?TN":V,=T"@( X>)I&_N1
M,0WDW"@B5C37M1GY$XXHL96UY<2;C/F]REQ#H#IY&MW*S8@Q(0L;TT$\.1V2
MMY\\&JZ5NMM1MJ8+HS2^;U,))O@X58(T.[@$@WZ)JNRY2O1, T0%"&9/(.F
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M:;H5X!L+18R[1AGB^= :NFODCCB!PRH&";6N2.0Z_(:OZ68(=1PXXYWJ%Y/
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M!'-MFB6U2OKF!E#\]+=N4E\"Z6++!L9K$N1NAZ"]HK#?*DTR+&1M^RS_1BE
M7D#?HIR3C>$V#<JXQ^B#0Q^&SGH?W')Z&4N?%6E*!B"QW]ZZU>[+Y=1^L-MN
MMY\]$8TH'1KM?PE2=S >'EFPV-Y4LC2?[Q:R I VE_36CRO:@.=+"7\T-W1
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M/O6W"_6-4)SCR>>0AO'D)LQBOHJJ-"4?Q1;*K16^86\<:$\VKY9V.*T^<],
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MQX7@H"M:@-]G&MZ)7TA!\U[^[9]02P,$%     @ .X&J5 !.JT(Q"0  GQD
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M4?1(8?Z_QV>:!6/8XH2EL0O0TVXQC0[C,XV"T2B%W7.*IGP$ZBP-@\EH_)P
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M@1"<=$.;LL2 ?_:U@?:8&:4Q#76N3GU/W)M:H#RQ[Q^*9@9:HP%I#_4>X\S
M!H@4S\\WI7/"HGN'12[['60U.\C:F?L'TI8.J?=W,Y=$%'_.+S\^#_5@\AB2
M[D,=\##+@7 T+72U^%DUV-?:KO8>(' 2XWGH&X-'"C+57E^(/31@=)F@E(SS
M7H$Y+"K/TC<99\"@Q..$@_8#85,(- E=D7B.+<: ^]B#_;ZJ([0,+<)WBJ9
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MJ=6+Q$(JL@T@$FP#5QAQ70>[]-KR]:]_&47A\*,AD*PL*LP<1KT.5>VX8PX
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M\.7XQ#[UM5,M6V;P1HGO/+'9(+@*(,&4E<*NU/X;UO5<.KY8">-_85_%]J(
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M]5;),K+\0$I1DE"P"301$4_YW0:5?#S6M,.P6O5@14$P9FPF/#>FH=Q[I--
M+1AN4,,PZ_\25>+RE?0%A<2]138J>(\%:KX)-ZW5# ?7S""]\%:-;A?_()Y.
M7F-":[/GV?-/:MYZ\S_A[1_NHW [24=*846IV>#UJP1<^]=H/X*MHU-O;2#?
MCT,^U^@X@-8K2^)U'US@_.N>?0=02P,$%     @ .X&J5"F6A#?("P  TR$
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M/H7;N>+\D=?@BJEL#D%K=+IX<*UDOD!+J5;$*;Q34FNHG^S# 81AZOA!@JO
M"QW?C4CO3"XJHP&% B,HK,HHT+P@<0;!X!B.TM@9#()C^ 6+SS.F@><Z_B %
MWT\<W_/1<47!)E(U=EQC^B@RK!%\@]!WW#@!)(O\] D9&4T0BNZT%SBQ%X$7
M.>' A5MI6(&FW"8*PLB)4Q_"P'&]M#VZ88,@BIQ!ZN+*3Q!ZX&[7:[+J]I9<
M<6"Z]93^7C^-AI>?KM[<_O$[@7!])T5K(0@_<*)!!"-Z=O/A5TB<,(V!U$VV
M(SOH;'[067U'-D1=-D1[9P-F'WK+M):]$?I.;\N#W0QO,;AKKH@1]@T;[H]]
M@2;.'A)[.9<@JES<BWR!4;C"/F#C$FV)+0T\]Q#PKY3*,I(+]939$R?M[97A
M="H*P0RR0,97V<]<:]1Y)%7]$%G>  XQ /'R^/#HRQC><U90@=H\GM#QZ-GQ
M(>HI-$+/^"57,UYMH0KQ\J'6^.QZSK";P7@X1N6WR_]4FT4)XYIG D&L6I)L
MU1 0Z"TN4"RG),RXN+>=Y$>]\(S?,T<\L?IK/%M.4%B[LY<+D.ZP4>N9=9#!
M(43N?S2WI?*\O7T:-1;=D6=QEV?QWGG6=86-]H.V1I>\XW*F6#T7&1Z:(81M
M^;=3T M]"&7,UC*4E?%_5;K/)^.3ML>X<63+U, 91 F\62B<4R$(L>8G$ 1.
MZL;P$ZM9A64O2%.(G1![PAXU>X<CDLX1R=Z.&-+4*8S@31]$U:@AWS16@TM6
M-$V1DF L9I68BHQ5!D;HKIE4HHF=Q[UTV/72;:[;"6V[ZRB9V6.<O,'9'L&Y
M=P,G9^@7O0$V:\"N"&K^C;;O8 D02$=3BA%F83C<,R4HLYO))>=-1C@OQLH(
M4W3&)RR[0ZYKTQ TG%C*VL U6^%[@[$0/N$HI-IK-^V-%,^%T?VWO-5W)%_5
M; 5#32,4 48736SJ-B'3.@J8V5)F#K"\.K%/\9@Z:6+C,G12NX%S48 +!'8O
MVA>9PJ:BD: 9E;62ZIRH4*^%4H0:ZZJ0.>!P%/LN>#C-I!C2J9,$(=#L%(8T
MF@E4MSF),TP4PE&(@U2 )T/LWZT!&MVZ(IPU6H/0>H$(CE(<9-P0YS#J^GZ"
M"X0=AQ[M> EJXA]O*OXD(5%KU&U 2B)]/*"=8. $+NW$]&CG])!VR93NG4R-
M%]%)O%6MV?B(8825EH)W6T;LYM^]#[ UVV+-\,5H?+$)/15PA/9%2V&QL:9S
M8BQDW9D-R1L!(97M%4<^46(]"P?V/\6N_E%6LU>&JW)]"N,@=5SD3B$SZ$;:
MYQ)(?(35,:1%[$11 ']O^5G$UU0*;+]&_:4U>]&);C6SEN&VM9=8>5=405"S
MG,9S2K%*RT+D-OH?PFI,+Z[ZQ*JV14366F 3](]("9Y((4;%,PM2&>-3CJ+S
M=:_X;K';<J"_\<)>T@Q!GR7H%0XK6?/NWNUV7SZ&S0O_^GCSV03C;R8J#06?
M(JE[DN#LK)I/$<V-D;5]_9](@V7 +N<<:XZB _A\*J5YN"$!W?>@BW\!4$L#
M!!0    ( #N!JE2!,^[U'P,  #D'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;+5536_;.!#]*P.AAQ;06I]VXL V8*<MMD"+&G&R/11[H*6Q180B
M59**D_[Z#BE9219)FA[V(G[-S'MOAAK.#DI?FPK1PFTMI)D'E;7-6129HL*:
MF9%J4-+)3NF:65KJ?60:C:ST3K6(TCB>1#7C,EC,_-Y:+V:JM8)+7&LP;5TS
M?;="H0[S( F.&Q=\7UFW$2UF#=OC!NU5L]:TBH8H):]1&JXD:-S-@V5RMLJ=
MO3?XA^/!/)B#4[)5ZMHM/I7S(':$4&!A701&PPV>HQ N$-'XT<<,!DCG^'!^
MC/[1:R<M6V;P7(EOO+35/#@-H,0=:X6]4(>_L=<S=O$*)8S_PJ&WC0,H6F-5
MW3L3@YK+;F2W?1Y>XY#V#JGGW0%YEN^998N95@?0SIJBN8F7ZKV)')>N*!NK
MZ923GUV0&L&V2C.?H^5>(U+*K8&E+&'5&C(W!M[C#96O<2>P='GDEJ.!MY=L
M*]"\FT66J+B 4='#KCK8]!G8#+XH:2L#'V2)Y6/_B"0,.M*CCE7Z8L!EHT<0
M)R&D<9J^$"\;\I+Y>-DS\;[J/9/\IT]+".=*&B5XV66)46K6&@UEH]M0._C(
M)9,%9P(VM-GG\/MR:ZRFB_?O"XSR@5'N&>7/,-K0_UBV AW:@ZK=(%Q0=61+
M];BB9&IXIJ1/%>E%1-</SDS#"IP'C9.K;S!8#&"M![,50O$(D!T!Z2;;"CXU
ME"<XH$9@!G9DJ@YT<[@D5]4:RJ5Y=P:7%3D]NA/PA>FB@JPOJ?LD\)D7U ^0
MND%/X@VD>3A)<C=)PWR<_$>](TT^YMYC&DZ3#)(DS,9CN%26*O8&LCP<IR=N
MDH6G\03^5.0EN\:2_9\JPVPRII%HQ[_7F(4G<0IYF&3W$B=A/'$*QV&>35[+
M9*W5CM-%)I2KT69$2:AKU.Z:][^&IY9D4T_M9)K#A;ICPM[=<R$;O/W+>QLF
MO)@DG*2G-$ZI7$_]&-&#=D9P>]^T#8&WTG:=;=@=WH5EUP[OS;M'A43MN30@
M<$>N\>AD'(#N&G6WL*KQS7&K++5:/ZWH;4/M#.A\IY0]+AS \%HN?@%02P,$
M%     @ .X&J5/-6,:=#!@  PA4  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL[5C;;N,V$/V5@6L4,<#$NE)2F@1(LI<NT !!DMT^%'V@9=H65A)5
MDK+7_?H.*5GV^K9)6G1?%D@L<4@.SPS/<$:\6 CY6<TXU_"ER$MUV9MI79T/
MARJ=\8*I,U'Q$GLF0A9,8U-.AZJ2G(WMI"(?>HY#AP7+RM[5A97=RZL+4>L\
M*_F]!%47!9/+&YZ+Q67/[:T$#]ETIHU@>'51L2E_Y/IC=2^Q->RTC+."ERH3
M)4@^N>Q=N^<WL1EO!WS*^$)MO(.Q9"3$9]/X,+[L.080SWFJC0:&CSF_Y7EN
M%"&,OUJ=O6Y),W'S?:7]G;4=;1DQQ6]%_GLVUK/+7MR#,9^P.M</8O$K;^T)
MC;Y4Y,K^PJ(=Z_0@K94613L9$119V3S9E]8/SYG@M1,\B[M9R*)\PS2[NI!B
M =*,1FWFQ9IJ9R.XK#2;\J@E]F8X3U_=,C4#5H[A0SGG2J.[M8*3)S;*N1I<
M##4N808.TU;=3:/..Z#.ASM1ZIF"M^68C[^>/T1H'3YOA>_&.ZKPNI)GX+@$
M/,?SCNCS.WM]J\\_H&_#3 )O^$A;X]_^56=Z"8\\K66F,Z[@C^N1TA(Y\^>1
M18-NT< N&AQ8]!%#:5SG',0$'G@JRC3+,V99B1*S!<3^6AQSEC?H#+ '!"NS
M5/.Q';!O0XXN;6+Z7%4LY9<]#%K%Y9SWKJXQG+91I!:%^06^C4*N46P/P+Y*
M2-.3E:!G',,L%47%RF563N%6( U*9="+4HD\&S,S](;EK$PY/!K:*M"BF5F(
MNM1KA8M,SUZ@]%'CH^%OZU1XAT>.@@53@'\3D=OFB=4I:H66J<$YW#&9SL!O
M*8:<2'DQXG(E<:$+D1W;^Q!Y/O%H@F\TB(B+;P]'?)65:5Z/&U\)M$M"+LKI
MJ>:R0(3*^,(-B.-$X%(2(9C;5VX*>]V^''0A&NI'Q(NH,93Z)$Y<.!(781<7
MX?>+BZ-+_XB+'W'Q_\<%[>*"/CLN-O/RJ$M12WA:5GP?[8]JWD_[0]X\ZLG2
M>' -#<-&9<H,1<S&KPVMC%._0:SK O<C^]OZ7&EX+X52\+'$"C.WTO=86:I=
M\6_8QCS]CF42/K&\YDTV5^L4SN8LRTTA<XJUZZE"X.>X1%%PF68LAXI52+0^
M)&% O-C'MQ#_3SPZ6 DI$DU(I ON/HR0&@I"+R&NEV _G""O/7^ (H^XC@L?
MSQ[/X GQJ5HNK7^F8LYE:?QSJBK#)XFXL<5E)3,#WDTB0IT0?OXI]ESO%SAQ
MB1NX Y13$M  [NHR2[,*P3:KNSX)PLWA-!D8H1=3>!(:QXV_Z0-P"4T"$D0>
MN(X#)S&J-%H(C2EQ7;^AMP7F=2NMGJT8:SR^Q"I4?L:OADEMH,48!AO05L]6
M?,MQBR=9BHZT(33&(%29!M>-2(*^VYZVDC=&'3J"7\+//EJ8('S/=\R[8WY7
MMMN^."9QY.XYYKX[/X.0Q.B+/@2>)>A@)0S<77X&+HFB /U.#9MHA*/#P"%)
M%+^&H+Y/$AJ"BZLB+4TK"'=9Z9'$"\#%D/##@6TZP4OX&/J!I7OB!P9TY#L#
M*_4)I7'#1]</"0W]7:*T\CV,I!15[%*K%1]F9$*<D.YA9"/_;QD9AR&)T%E]
M:WN_L[[I"]"1\;%\$G7Y)'IV/MD@I$%TB+=;F>?ZJWU[-/N&ISHKMV?"O?$B
MED[[4M-QD$\F:1AP\P[<U(*KUTOD+;CR.<1J &[-AJH%" LN^0OJGPV_'?+9
M=C!BQ(848]!4!ZML\:HLT62#57;8.2-\#_N=)G7M21DF.S2IHB$OEBH)'G8Q
MW3@"=X^]5]GKQR%&B=\PV1X^.V #!)0X]AA[C2]B/)"\YCC:-C7"I-:>02M#
M XRA*';6D74DF.(NF.+7!-.J,'R[%?);]1O6E?9:H49\=TS;6FY?K!S%L+^,
MVPH@>ZA],T@04KH!J6@A_>N/@\8VK/Y,25]R6'(F06!ASU5S]"$)2&A# VE-
M8RP3Z'H2F^"6K^?IF13U= :3;-Y(,#,E(9[C$?@T)('K/3_=]#=*G?Y&FMG'
MC.'&O1JR>&IO#TVMB]]CS15;)^TN**^;>[GU\.9V$QTV-75"SB<XU3F+\/-4
M-C>&34.+RM[2C836HK"O,\[&7)H!V#\10J\:9H'NVO;J'U!+ P04    "  [
M@:I4V7%%9[\#   !"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6RE
M5FUOVS80_BN$%@PKH$02+<ER9ANPG14=L !!DK8?AGV@I9-%A!(UDK*;?[^C
MWJ*B<8JU7WQW(N^YY_CPQ<N35$^Z ##D2RDJO7(*8^IKS]-I 2735[*&"D=R
MJ4IF,%0'3]<*6-8FE<*COA][)>.5LUZVW^[4>BD;(W@%=XKHIBR9>MZ"D*>5
M$SC#AWM^*(S]X*V7-3O  YB/]9W"R!M1,EY"I;FLB()\Y6R"ZVUHY[<3/G$X
MZ8E/;"=[*9]L\&>V<GQ+" 2DQB(P-$?8@1 6"&G\VV,Z8TF;./4']/=M[]C+
MGFG82?&99Z98.8E#,LA9(\R]/'V OI_(XJ52Z/:7G+JY\YE#TD8;6?;)R*#D
M56?9EWX=)@F)?R:!]@FTY=T5:EG>,,/62R5/1-G9B&:=MM4V&\GQRHKR8!2.
M<LPSZ_>,*_*)B0;(+3#=*, 5-YK\]LCV O2[I6>PBIWKI3WBMD.D9Q!GY%96
MIM#DCRJ#[.M\#]F-%.E <4O?!-S4ZHKX@4NH3^D;>+.QY5F+-_M^RS=<IT+:
MKC7Y>[/71N$N^>>-&N%8(VQKA&=J/.#AR1H!1.9D4L]&O&)5RID@&ZT!5[I?
M]HS8/4KN(6V4XM6!;)GF^K7E?[.R/<37NF8IK!P\I1K4$9SU8P$D%4QKGO.4
MV>.@<9^9@E?$X%!N&1Y;A@4'Q51:/%NNLE$D'_FRCJ\IF"$G4$#*@3FK,CR@
MJ529#<P4KVU*C4WM;5-=-M,DEP(O!=QL+0_9: 32[Z[)K65 9KWDY"\X@B!!
M;REYE ;I[&19@FJ9U:P&12[(K[\D-*"_H[>(0I?&=.+MI*JE8@;(7F*5<6Y$
MJ1OXP6@_7CU<D4?5MO;<=G:01U"5/1:7NL:5D[9EC$#5BFMX@0H6L1O&X6AO
MFXJGO$:"7Y<,9BY-XL%TW62P-T3;=>*&(R8[,B[L$;S$B_=2,]Q*8[H;)[$;
M!+.)AT<.GO%>4$]XC^>-K9;,71I%8U8?[D"9;A-@$90X@UIJ;E[ @[F[P&48
M;,?NFTV0,M3S&[$OABH72"WQ0]</PLY?!"C"@MQ "N4>M>JU#7Y(VS!RDS"8
M>&>U#7UW,4]&^Q/:SF8N5AO,664I+EHXF!]0-L("<9Q,O%>4C6,<#<:L/OR^
ML@O7C^+1_D]E^RI6S3BB[IQVRLX1S2K^VIWI39XEE//0/KY803:5Z5ZH\>OX
MOF^Z9^UE>O?G &^$ \=+2T".J?[5/'*(ZA[<+C"R;A^YO33X9+9N@?]10-D)
M.)Y+:8; %AC_]:S_ U!+ P04    "  [@:I450Y1$<T"  #5!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-2YX;6R%5,%NVS ,_17"Z*$%O-J6G<8-D@!-
MNV$#-J!HN_4P[*#83"Q,ECQ);KJ_'R4G7@:TW<62*/+QD=;C?*?-3]L@.GAN
MI;*+J'&NFR6)K1ILN3W7'2JZV6C3<D='LTUL9Y#7(:B5"4O3BZ3E0D7+>;#=
MFN5<]TX*A;<&;-^VW/Q>H=2[191%!\.=V#;.&Y+EO.-;O$?WM;LU=$I&E%JT
MJ*S0"@QN%M%5-EL5WC\X?!.XLT=[\)6LM?[I#Y_J191Z0BBQ<AZ!T_*$URBE
M!R(:O_:8T9C2!Q[O#^@?0NU4RYI;O-;R4=2N641E!#5N>"_=G=Y]Q'T]$X]7
M:6G#%W:#;\XBJ'KK=+L/)@:M4,/*G_=]. HHTU<"V#Z !=Y#HL#RACN^G!N]
M ^.]"<UO0JDAFL@)Y7_*O3-T*RC.+3^I)U1.F]]P^L#7$NW9/'&$ZV^3:H^Q
M&C#8*Q@Y?-'*-1;>JQKK?^,3XC.28@=2*_8FX%5GSB'-8F I8V_@Y6.1><#+
M_UODC;"5U+8W"-^OUM89>A4_WLA0C!F*D*%X)<,]B:7N)8+>P)CMI4Z^">,5
M.+,=KW 1D<0LFB>,CMA7FL1@'=8^C6L0-EJ2JH3:PJE09-&]Y:JV9S/XPDW5
M0+[O(=Q@A>T:S<&2P1W?T3MR: 27%DX@2^-R4M*FC,N+*3R2EH P.Z,KM!;8
M-)Y.R[!D4_@@E* W5\-6Z]I"5L07DQPR%E^R*3QHQR4!3?*8E9>T*2[C29;!
MBDNN*H3[,&PJR:T5&U%QK\X97/?&4)G0:1/D*E0E>WI.GH08.W "K(P+XG?B
MJ127.7S6:ON.RFA?C-34)0-R]*&<Z*B:(BZI*XS%:5:^2OBE=Y$<2:U%LPT#
MQ=*?Z94;5#=:QYEU-4CUK_LP\.@7;86R('%#H>GY=!*!&8;(<'"Z"\)=:T=C
M(&P;FKMHO /=;[1VAX-/,$[RY1]02P,$%     @ .X&J5,+(/MD/!   30D
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MFQ.FJXS0$N/>4'%&X"$1%7-:V1Q(U3$=\H<<3$.=VAIUX%'=,=[,AMU)N#G
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M5%K;CNL([JH(X$0$+OK(2KD6Z.\RH<E+?UMETZ0$AY3N8%3P=L-OD(/_0N
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METV7U RTJ&S?L!4:NQ#[NL?.$J0)P.\[(?3KP"S0]:K+_P%02P,$%     @
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M+8H&# J*C-?_]&=3B T \/0#2 ,@NX#@ ,!O +Y-M%9FT[JFFDY&4JR1--'
M9BYL;2P:LLFXL?%>2[B; 4Y/(/V</@A);5&G2\D8F*05FO($S2H%X4JA:[8"
MPTMS!TU-X3.=,85>H6WX'83Q"FY4/&$2Z92A _R0I4[13:D81\^OF:99KEX
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MI F ^PLA]./ /* ]P4W^ %!+ P04    "  [@:I424F-6C0"  "Y!   &0
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MB5;*7%HWW/#)2,D-438:V>R%JXU#8S:9L#8^&(5W,\29"::?\R>IN"OJ=*D
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MBE\7M-Z!S]?&T(OA;WSW7N5_ %!+ P04    "  [@:I4CDL\J;D"  !5!P
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MF.)?#2B[ =<74IKUQ#;:^C]I] M02P,$%     @ .X&J5)B,TW7; @  R <
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M\%5SE*7X;;UUSX]$Y,9 )[+@N>1"<]<K(@I!.P5</11ZC<M[+T]4\.(E!/]
M5A7X<A)P%@51T!I87UPRBP8F!AL#A^BYE%5ENA8-#&";:4\8@@,\&R^'XV:^
MXEE&1$HQ P4NB!@;3>/",'B!RFGL%X[[[Q/*";M6@X+(:X^C&Q;X:#;P:H"-
MD\/HV803]2BB;9R]00,D&T>'XY;^N<QI2@LMFJ?>8+"Q8IB\0-$T'@S'3?@)
MT<RZ-N*CSE=/3U@<Q&'_.%#CU,A[+LU4F:+K-U3[LZ<ORF_3="].$.;X]AF+
M/<TE8&2G4=XTUF6*\XGHO%"\L(>*#5?ZB&(O#_H4280)T/L[SM7CPIQ3ZG/I
M\C]02P,$%     @ .X&J5/A\AGFA @  1P8  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&ULC55-3^,P$/TKHX@#2-!\-:&@MA*TBY8#$J+ 'E9[<-M)
M8^'8Q79:^N^QG1!"-T5<$G_,>W[S)IX,MT*^J!Q1PUO!N!IYN=;K2]]7BQP+
MHGIBC=SL9$(61)NI7/EJ+9$L':A@?A0$J5\0RKWQT*W=R_%0E)I1CO<25%D4
M1.ZND8GMR N]CX4'NLJU7?#'PS59X0SUT_I>FIG?L"QI@5Q1P4%B-O*NPLM)
M8N-=P#/%K6J-P68R%^+%3FZ7(R^P@I#A0EL&8EX;G"!CELC(>*TYO>9("VR/
M/]AO7.XFESE1.!'L#UWJ?.0-/%AB1DJF'\3V-];Y.($+P91[PK:.#3Q8E$J+
MH@8;!07EU9N\U3ZT &'_ ""J =%/ 7$-B%VBE3*7UI1H,AY*L05IHPV;'3AO
M'-ID0[FMXDQ+LTL-3H\G1.5 ^!)N^0:5-O71"L[@AE )SX25""(#%_3KM:0;
MPES /F"^@XG@6IJBE(3!'=&EI'H'QU/4A#)U8BB?9E,X/CJ!(Z <'G-1*L.B
MAKXV65@M_J)6?%TIC@XHOEK+'@3A*41!%'7 )]_#I[CH05S!PZ]PWWC7&!@U
M!D:.+S[ U[+A%*8XU\X<:Y;)?X8+:P1%!7^OYLH9].^;0^/FT-@=VC]P:&4P
M7UDK!4?8(9$@)#!4G8Y6;*ECL_=Z,PZCBR Y3X?^IFU=1UR8#J+D,^Z+W'XC
MM_\SN233*#\5ZUR*<I5#9FZR6^D47W$G+5'Q19+$YWO:.\+2I!]&W=*31GKR
MK?1'H<T'O;1U59_%)!OS59,YPS/31\^4N15=PI/_W4P':1C&>\H[XI(X3M/!
MGG2_=<UMB[TC<D6Y,E7/##+HG1LB6;6M:J+%VMW\N="FC[AA;CH]2AM@]C,A
M],?$-I/FWS%^!U!+ P04    "  [@:I4QYEXBK &  #6,@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6S-6V%OFS@8_BM6;CIMTMJ C0W9M96V5M--
M6D_3NNT^G.Z#DS@-&N#,..DFW8\_0U)>$HP#K2+QI87D]<MK/_;SF(=P\2#5
M]WPIA$8_TR3++T=+K5=OQN-\MA0IS\_E2F3FFX54*=?F5-V/\Y42?%XV2I,Q
M]CPV3GF<C:XNRL\^J:L+N=9)G(E/"N7K-.7JUSN1R(?+D3]Z_.!S?+_4Q0?C
MJXL5OQ=W0G]=?5+F;%QEF<>IR/)89DB)Q>7HK?_F.BH;E!'?8O&0UXY1T96I
ME-^+DP_SRY%75"02,=-%"F[^;<2U2)(BDZGCQR[IJ+IFT;!^_)C]?=EYTYDI
MS\6U3/Z.YWIY.8I&:"X6?)WHS_+A3['K$"WRS622EW_1PR[6&Z'9.M<RW34V
M%:1QMOW/?^X&HM; #UH:X%T#W+4!V34@94>WE97=NN&:7UTH^8!4$6VR%0?E
MV)2M36_BK(#Q3BOS;6S:Z:OW/%;H&T_6 MT*GJ^5,!CI'+V\$9K'2?X*G:&O
M=S?HY8M7Z 6*,_1E*=<YS^;YQ5B;ZQ=9QK/=M=YMKX5;KO5VI<Z1Y[]&V,/8
MTOS:W?Q&S,X1V3;W]YN/3:^KKN.JZ[C,1XYV_35ZF^?"]-KT"WV,^31.8AV+
M_'%(YLA,N,]BME8JSN[+J+]DIJH/WO$\SM$_'\T%T <MTOQ?1WFD*H^4Y04M
MY7V1FB=F1DXURHLK;2OB&X,*GR;BS"SALYPGPH;#-C,K,Q<+>7/ELXCY/KD8
M;^H#;HFCA# 657%[I0=5Z8&S]&JH',- JUQTB"BQJCQV,I2VF>E1E"QQ+I3"
MJO2P0^F+../9+#9'?#NZ,VZ&RPPFUVA1C/VF&'M;^6&SK&CB8S8Y*-\2%_H3
M3*F]_*@J/W*6_U%L1()\]!_J,MTF5=;)$*>;[P%?>R>;<+O4=2B\ ["<(?LE
MUR3&/^E$VZ6OUQ2%]?FS*[T9QA@E?DOY(!,^/C[1?O_-9]X?N.-L\X'D?3+(
M^094[KNY_%GS+>C(<+9 %\7YH!X^/>W<HQ:6\P+/#PZ[8 ED%(<X:.D"*(SO
MEIAKF:9"E=6O^$HH%ZS _7XXR'D'[.Z[Z?U9\RYJ8#&A 6;X$#-+7$"CH(TR
M0$3\22_(.M(&!A7 WA#AP\#YN OG/PT^W"1R*WRV. =\N'9CX&9\"WS]=AL8
M^!\/DO\Q\#\^'?_C)JT?[C><(?LE ^=C-^>WP==/PS$0-&:#Q!#('G?9Z3\1
MP^;VW;X8+7&NQ0A"@-U"<"W52BJN!9K*ANVPGQ/X&0]RET^ W\GI=OFDN86G
M&/N>?WCS;XD+O$G8LN<BP/W$S?T'B'5<;P3HF0S3N*DY-R>T;DA']"QQ+O2
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M, =VH ;4K09-[/H)(P42IX,T@!AP.CN= <2./^9UANR7#"S/W"S?@EX_U6-
MS&R0+A #EF>G<X%8T]VQ+41;6/M"9,#_S,W_MS(3OU#*U7>AT6+=G4<9\#0;
MI/G#:C_L.?+8E>?+\F*SXD#\6,<; U:FK3]\8TTKQ_83!4N8XR<*##B?N3G?
MBE<_[F3 TFR0G@\#<F='GK[V0JYIWEB1:X8YD N!YT,WS[<CUX\W0Z#I<)#N
M3@C$'AYY^MH'OK!ITQQJG3-DOT;@]M#-[=="Z7@1S[@VPR47AN57,H]U5["
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M@FPUNU1E74R28F/5PO?6L;+4J?UR3L,7M7.@[U.E[&;C#JC&^> /4$L#!!0
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M%IEM+CF+N30OP.]S =\3Y8,9H+HQG?P'4$L#!!0    ( #N!JE1 )6Z7Z@(
M %4'   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;(V5;6_:,!#'O\HI
MVK1-*B0$:-D$2-"'K=(J571K7TQ[8<A!K#IV9A]0OOW.#LV8!M'>@.W<_>]W
M#W&&6V.?78Y(\%(H[4913E1^BF.WR+$0KFU*U/QD:6PAB+=V%;O2HLB"4Z'B
M-$G.XT)('8V'X>S>CH=F34IJO+?@UD4A[&Z*RFQ'42=Z/9C)54[^(!X/2['"
M!Z3OY;WE75RK9+) [:318'$YBB:=3].!MP\&CQ*W[F -/I.Y,<]^<YN-HL0#
MH<(%>07!?QN\1*6\$&/\VFM&=4CO>+A^5;\)N7,N<^'PTJ@GF5$^B@819+@4
M:T4SL_V"^WSZ7F]AE N_L-W;)A$LUHY,L7=F@D+JZE^\[.MPX)#V3CBD>X<T
M<%>! N65(#$>6K,%ZZU9S2]"JL&;X:3V37D@RT\E^]'X@<SBN37EO#*X- 7W
MVHE0KA9<.Y*<-L)G*S2UKOSR1D@+CT*M$=Y?(0FIW <V_?8PVVO,T)&5"^)E
MD(;O6I(;QL2L/F*\V'--*Z[T!%<7[HRFW,&USC#[VS_F'.M$T]=$IVFCX*2T
M;4@Z9Y F:?H&8G"YL.@:E+MU";M!N7NJA%ZH-?^WA!/+A5LACS#!? >'=O=B
M%XXG6V$S^/&5)>&6L' _&X!Z-5 O /5. #V%4>0H8H.6WRQ8^09"YANX] W<
M^ :>@?#!V>R]U) 9I81U4**M*O/A6,^JN(,0U[_NFW&WV^Y<#./-$=Q^C=MO
MQ+VID< L@7(,511Z]\[!PA0%5]*%4>+%02;_3]W_ASI-VB>@SVOH\T;HZY<2
MPY1OC.)N*TF[8Z&;17KG[4'_;4/'+VJ:BT:AF73/K:5%!*D)>:P)+-?H&%&S
M4*?=_]@$-*B!!HTZ5W(C,]09["2J[!A'LW_23I*C'/'!55>@784+W<_)6E-U
MZ]6G]3=C4EV5?\RK#\Z=L"NI'2A<LBM/!,^)K2[Q:D.F#!?GW!!?PV&9\W</
MK3?@YTMCZ'7C ]1?TO%O4$L#!!0    ( #N!JE2 E\O<(P,  &X)   9
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;*U676_:,!3]*U;4AU;JR!>04 %2
M@4WK0R=4UO79)(983>S,=J#[][MV0@@0H)KVDOCCGN-[KJ^O/=QR\2X30A3Z
MR%(F1U:B5/Y@VS)*2(9EA^>$P<R*BPPKZ(JU+7-!<&Q 66I[CM.W,TR9-1Z:
ML;D8#WFA4LK(7"!99!D6?R8DY=N1Y5J[@1>Z3I0>L,?#'*_)@JC7?"Z@9]<L
M,<T(DY0S),AJ9#VZ#U/7T0!C\8N2K6RTD9:RY/Q==Y[BD>5HCTA*(J4I,/PV
M9$K25#.!'[\K4JM>4P.;[1W[-R,>Q"RQ)%.>OM%8)2,KM%!,5KA(U0O??B>5
MH)[FBW@JS1=M*UO'0E$A%<\J,'B045;^\4<5B 8 >-H!7@7PC@'=,P"_ OA&
M:.F9D37#"H^'@F^1T-; IALF-@8-:BC3V[A0 F8IX-3X!V3*$XMX1M"<"+1(
ML"#H"YKR+"\4-I'F*S3!DD8(LQC-:%HH$J-6W.V,*$Q3>0<,KXL9NKVY0S?(
M1E+/2D09>F54R?O&P,^$%Q*(8?#FH#^T%<C33MI1)6522O'.2/'1,V<JD>@K
MBTE\B+<A+'5LO%UL)MY%PL=<=)#CWB//\;P6?Z:?@7L&[EYPQZ^WRC=\_KFM
M*C(BL.+BX0)9MR;K&K+NA7VG9O_: EUB^P:K"\%FW ][@3^T-TWYIU9NWW%K
MHP._>K5?O8LB9X1Q2/-K,OLU7?^BS#=SC$G\!6\@=FN"0'$&.5TE(-0UJ2#;
M*%M#RBY-EM_2W?1=6VC*]7H-T;X[Z(7>46S:S+QN(X0'<H):3G!1CCE]4/:0
M)%$AJ**@X8J_P:DC@1,<>7MJ%(9NM]W7L/8U_'^ACZNR<D5,>"K&\[UP<"2G
MS<SUPJ!=T* 6-/CDD4$YE#Q9E<I]UL0\3;&0^]E6#>4B8<,YI^.Y1PK:C,X=
M+=?9UWKG7Q0T@_\Y#=4Z5T145LT"X1Q)L!LW%U2WM;G0):1*P519J.O1^M'P
M:*[*H_&)?DR8&W%/4[Y$GK%84R912E9 Z70"R M17NYE1_'<W(]+KN"V-<T$
M'D1$: .87W&N=AV]0/W$&O\%4$L#!!0    ( #N!JE1[<&@DL (  $4&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;(U5VV[;, S]%<%/+;#6CI.T
M0Y$82-(.*[ 50;/+P[ 'Q:9CH;IX$MVT?S]*=MRL2(*]Q!+%<WA(2LQD:^R3
MJP"0O2BIW32J$.N;.'9Y!8J[2U.#II/26,61MG83N]H"+P)(R3A-DJM8<:&C
M;!)L2YM-3(-2:%A:YAJEN'V=@S3;:32(=H9'L:G0&^)L4O,-K "_UTM+N[AG
M*80"[831S$(YC6:#F\78^P>''P*V;F_-?"9K8Y[\YKZ81HD7!!)R] R</L^P
M "D]$<GXTW%&?4@/W%_OV#^%W"F7-7>P,/*G*+":1A\C5D#)&XF/9OL9NGR"
MP-Q(%W[9MO--(I8W#HWJP*1 "=U^^4M7AST \1P&I!T@?0\8'0$,.\ P)-HJ
M"VG=<N39Q)HML]Z;V/PBU":@*1NA?1=7:.E4$ ZS![HH]SHW"M@2+%M5W *[
M8$N#H%%PV5H<,R5;&*6H\"LT^1-[, $GFP(*)C3#"KQ#W2 /[2'_6R$;I-.#
M(<YN ;F0[IR"N39$]R&R;Y5I'->%F\1(.7JE<=[E,V_S28_D,V1?C<;*L3M-
MRO[%QU2;OD#IKD#S]"3AK+:7+!E\8&F2I@?T+/X'G@;XX(2<8=^O8> ;'>$+
MU;OP%[=@2_Y*[PG9S%JN-^#7)R*,^@BC$&%X3#'UO?"MH^?%5I W5J"@OMR]
M=-TNK5'O>WW'K19ZX_8Z_.L+$;-[!.5^GY U[F6-3R;N95WTNMR;+KHG+*>>
M4W@J@'QEPKF&KR7L+A3LA)_1U6IMYX<N5AM_'.+[X?><#:[&ON?/^^T^X)4D
MR77OU287[[U(!783!I4CG8W&]N[UUGX6SL((>&>?TXQL1]H;33M@OW*[$=HQ
M"251)I?7I,FV0ZO=H*G#NU\;I"D2EA7->;#>@<Y+0X^\V_@ _3]']A=02P,$
M%     @ .X&J5#8AQ>.T @  _P8  !D   !X;"]W;W)K<VAE971S+W-H965T
M-38N>&ULC95M3]LP$,>_RBF3)I &2=/'L;82!:8AP8;H'EY,>^$VE\8BMH-]
M:4'BP\]VTJR,DNU-8CN^__WN+CZ/-TK?F0R1X$'DTDR"C*@X"4.SS% P<ZP*
ME/9+JK1@9*=Z%9I"(TN\D<C#.(H&H6!<!M.Q7[O1T[$J*><2;S284@BF'V>8
MJ\TDZ 3;A5N^RL@MA--QP58X1_I6W&@["QN5A N4ABL)&M-)<-HYF8W<?K_A
M.\>-V1F#BV2AU)V;7":3(') F..2G *SKS6>89X[(8MQ7VL&C4MGN#O>JG_T
ML=M8%LS@F<I_\(2R23 *(,&4E3G=JLTGK./I.[VERHU_PJ;:.W@?P+(TI$1M
M; D$E]6;/=1YV#&(>Z\8Q+5![+DK1Y[RG!&;CK7:@':[K9H;^%"]M87CTA5E
M3MI^Y=:.IO-R8?"^1$EPL;9/ P?G2(SGYA".8%;RG(Z^JJ-YR0FNT(9O5_^V
M&8=D29Q>N*R]SBJO\2M>.W"M)&4&+F2"R7/[T$;0A!%OPYC%K8*GA3Z&;O0.
MXBB.4WK[IC,<?3"X$B_PGLEWFRQUO7SW/[,$/Z_L#K@D%.97BWZOT>]Y_=YK
M^/8\@4HA]QDNM#USFA[A@$O[FY9,(Z2VP(?P!-O8]N6\\M'W/MQA7$]C>S:C
M:!RN][#U&[9^*]L7R\*(RU5-1ZC%/N_M*G$O!N%KWI*N08,T:!7[7(H%:I<P
M5;BS;8 4X .A3( RK'_4)]C[ U2T@Y>YVI^F8<,T;&6J?%8\.S@V>5PE^PC:
MY?KPB$RW)6O4@(W^4;\MDJL<EXRPKN0!2^U2C7BXC[%=N3.*6FH:[C0E@7KE
M6Z^!I2HE5?VI66VZ^VG5U/YLKZZ&:Z97W%8YQ]2:1L=#6S==M=MJ0JKP+6ZA
MR#9,/\SL#87:;;#?4Z5H.W$.FCMO^AM02P,$%     @ .X&J5,Z='0TX P
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M2A(_ IA?011A"#R-.((I  T8$D75/KBS'X7K?2IL_UT;_0)02P,$%     @
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MVK[J/XTL^N>$^F></OX+4$L#!!0    ( #N!JE0,/Y#\Y0$  '\A   :
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M46\GT-M'+[L)]';4VPGT=M3;"?1VU-L)]';4VPGT=M3;"?2.J'<DT#NBWI%
M[XAZ1P*](^H="?2.J'<DT#N./E82Z!U1[_B?>N=RVJ5\[?E>X_7_D^IR/C==
M+W]9?N\<W>,7G /\;_'X!5!+ P04    "  [@:I4C^&W:=,!   V(0  $P
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M(FN&(FN&(FN&(FN&(FOVG[*^&[/\ZS?Y[36M==D<\EGWN<3D$U!+ 0(4 Q0
M   ( #N!JE0'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ .X&J5-3JGRSO    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ .X&J5)E<
MG",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    "  [@:I4#KQK0D(%  !K%0  &               @($.
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ .X&J5+#V
M:'N@!@  ;1H  !@              ("!A@T  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( #N!JE22Z,D4JP(  -X(   8
M  " @5P4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  [
M@:I4DI<YPP<%  !K$P  &               @($]%P  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ .X&J5"1J@J'9 @  )@<  !@
M         ("!>AP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( #N!JE2B%MY&@@(  (L%   8              " @8D?  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  [@:I4)Z"F0S<%   #%@
M&               @(%!(@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ .X&J5&B&>CK^!0  QQ8  !@              ("!KB<  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #N!JE1SC"YKF@T
M /,B   8              " @>(M  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    "  [@:I4XZ$]'L<*  #;'0  &0              @(&R
M.P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #N!JE2_
M9]: 1 L  *,?   9              " @;!&  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ .X&J5 !.JT(Q"0  GQD  !D
M     ("!*U(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #N!JE2K#W>FV ,  !<)   9              "
M@8%Q  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ .X&J
M5-HP_<-3#   RR<  !D              ("!D'4  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    "  [@:I41TK4"K4#  #&!P  &0
M        @($:@@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( #N!JE0IEH0WR L  -,A   9              " @0:&  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ .X&J5*LSO.""!@  &Q(
M !D              ("!!9(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    "  [@:I4@3/N]1\#   Y!P  &0              @(&^F
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( #N!JE3S5C&G
M0P8  ,(5   9              " @12<  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ .X&J5-EQ16>_ P   0D  !D
M ("!CJ(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  [
M@:I450Y1$<T"  #5!0  &0              @(&$I@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #N!JE3"R#[9#P0  $T)   9
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M970S,"YX;6Q02P$"% ,4    "  [@:I45+LR8M<"   I"0  &0
M    @(%QO   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M #N!JE0O?;[OW (  %L)   9              " @7^_  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ .X&J5#-/G]2.!   5A,  !D
M             ("!DL(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    "  [@:I4LTBOBV\#  "W"@  &0              @(%7QP  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( #N!JE06[Z3R9P,
M ,T-   9              " @?W*  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ .X&J5$E)C5HT @  N00  !D              ("!
MF\X  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  [@:I4
M4 @09&4#  #,#0  &0              @($&T0  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( #N!JE0$4XX -0(  +L$   9
M      " @:+4  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ .X&J5(Y+/*FY @  50<  !D              ("!#M<  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  [@:I4$O;LW_ "   :"
M&0              @('^V0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( #N!JE2JVU^:! ,  #,)   9              " @27=  !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ .X&J5)B,TW7;
M @  R <  !D              ("!8.   'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    "  [@:I4;"T.EE\#   <"P  &0
M@(%RXP  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #N!
MJE10+R^P$ 8  .P@   9              " @0CG  !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ .X&J5!9>,_NH P  HPX  !D
M         ("!3^T  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M    "  [@:I4^'R&>:$"  !'!@  &0              @($N\0  >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( #N!JE3'F7B*L 8  -8R
M   9              " @0;T  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
M4$L! A0#%     @ .X&J5'(?$V($ P  V@<  !D              ("![?H
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  [@:I4/JU_
M?M@"  #>"   &0              @($H_@  >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;%!+ 0(4 Q0    ( #N!JE3-C>5,_0(  !()   9
M  " @3<! 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M.X&J5"]<S4,V P  !0P  !D              ("!:P0! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    "  [@:I4J<5<%_L$   ]%0  &0
M            @('8!P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( #N!JE1 )6Z7Z@(  %4'   9              " @0H- 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ .X&J5("7R]PC P
M;@D  !D              ("!*Q ! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    "  [@:I4>W!H)+ "  !%!@  &0              @(&%
M$P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( #N!JE0V
M(<7CM (  /\&   9              " @6P6 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ .X&J5,Z='0TX P  :A,   T
M     ( !5QD! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  [@:I4EXJ[',
M   3 @  "P              @ &Z' $ 7W)E;',O+G)E;'-02P$"% ,4
M"  [@:I4VVRU3W8$  !G)0  #P              @ &C'0$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ .X&J5 P_D/SE 0  ?R$  !H
M ( !1B(! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M.X&J5(_AMVG3 0  -B$  !,              ( !8R0! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     $  0 !W$0  9R8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>192</ContextCount>
  <ElementCount>228</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Collaboration Agreements And Business Development Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</Role>
      <ShortName>Collaboration Agreements And Business Development Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121104 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132106 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2141108 - Disclosure - Provision For (Benefit From) Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes</Role>
      <ShortName>Provision For (Benefit From) Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2146110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables</Role>
      <ShortName>Collaboration Agreements And Business Development Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2333305 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2343307 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Concentration Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2424416 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2430420 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2431421 - Disclosure - Fair Value Measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails</Role>
      <ShortName>Fair Value Measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2434422 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20220401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/SubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel-20220401.htm">exel-20220401.htm</File>
    <File>exel-20220401.xsd</File>
    <File>exel-20220401_cal.xml</File>
    <File>exel-20220401_def.xml</File>
    <File>exel-20220401_lab.xml</File>
    <File>exel-20220401_pre.xml</File>
    <File>exel20210331exhibit10110q.htm</File>
    <File>exel20210331exhibit10210q.htm</File>
    <File>exel20210331exhibit31210q.htm</File>
    <File>exel20220331exhibit31110q.htm</File>
    <File>exel20220331exhibit32110q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20220401_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="533">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20220401.htm": {
   "axisCustom": 2,
   "axisStandard": 21,
   "contextCount": 192,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20220401_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20220401_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20220401.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20220401_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20220401_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20220401.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 405,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 31,
   "keyStandard": 197,
   "memberCustom": 27,
   "memberStandard": 35,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20220401",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Collaboration Agreements And Business Development Activities",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities",
     "shortName": "Collaboration Agreements And Business Development Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121104 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128105 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132106 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135107 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141108 - Disclosure - Provision For (Benefit From) Income Taxes",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes",
     "shortName": "Provision For (Benefit From) Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Subsequent Events",
     "role": "http://www.exelixis.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables",
     "shortName": "Collaboration Agreements And Business Development Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333305 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343307 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "iab56d00962654960b416e521404e7025_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i398655de202c44728712889a41d779af_D20220101-20220401",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails",
     "shortName": "Revenues - Revenues Disaggregated by Concentration Risks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i398655de202c44728712889a41d779af_D20220101-20220401",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i5766b5f0fc6649db9a9ece11f5731c2e_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "if112a05a2b34404190a5729507b01b3b_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07d2fa3b35a449daad65b440257d44b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07d2fa3b35a449daad65b440257d44b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i4a69ed17a5c74d79b446ce43b6eaf688_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ibca89d95ab5f4f82898ebc804c7d67c3_I20220401",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ibca89d95ab5f4f82898ebc804c7d67c3_I20220401",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i064bf749eb654609b6626219640cc568_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i8688f6af6d944b5d9a869f64d77e207b_I20220401",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i8688f6af6d944b5d9a869f64d77e207b_I20220401",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i0401aaeb66fd4321aaf94500fb43ff2d_D20220101-20220401",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - GSK Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i0401aaeb66fd4321aaf94500fb43ff2d_D20220101-20220401",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
     "shortName": "Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ibb9dca35b8b24f119a51c3af9f3582fc_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i8c1bd21583b04c1198ee03ae25c583c5_I20220401",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i8c1bd21583b04c1198ee03ae25c583c5_I20220401",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424416 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430420 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i65ec798216a747d2a34f9808d6def632_I20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i1e4e846c084c4559b6a9595a6687fd2f_I20220401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forward_contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431421 - Disclosure - Fair Value Measurements - Narratives (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails",
     "shortName": "Fair Value Measurements - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i1e4e846c084c4559b6a9595a6687fd2f_I20220401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forward_contract",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434422 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i1ae08cfc122445338953c327341f7d67_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i422c757fd8504d8d9bd061c6daee9c01_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i07e399f10aef4b259d2c54579c871e1a_I20220401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i277d7677672b42a28307cdefe84dc555_D20220101-20220401",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
     "shortName": "Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "if01316baae344a38a3c7cf53ddd5d7b4_I20220401",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i086d58fc90a14a97898df45878c69671_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i086d58fc90a14a97898df45878c69671_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "id6c8e9889ae843dc8773c941eac343d0_I20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.exelixis.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "id6c8e9889ae843dc8773c941eac343d0_I20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i32215b9047b046b18b950af503dc8257_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "i32215b9047b046b18b950af503dc8257_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220401.htm",
      "contextRef": "ib2319305255e41dea7c89963c20e9e04_D20220101-20220401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of Optum Specialty Pharmacy [Member]",
        "label": "Affiliates of Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Aggregate Development Milestone Payments",
        "label": "Asset Acquisition, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Asset acquisition, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Asset acquisition, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetAcquisitionPaymentUponClosingOfTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Payment Upon Closing Of Transaction",
        "label": "Asset Acquisition, Payment Upon Closing Of Transaction",
        "terseLabel": "Payment upon closing of transaction"
       }
      }
     },
     "localname": "AssetAcquisitionPaymentUponClosingOfTransaction",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetPurchaseAgreement2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, 2021",
        "label": "Asset Purchase Agreement, 2021 [Member]",
        "terseLabel": "Asset Purchase Agreement, 2021"
       }
      }
     },
     "localname": "AssetPurchaseAgreement2021Member",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_BuiltToSuitLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Built-To-Suit Lease [Member]",
        "label": "Built-To-Suit Lease [Member]",
        "terseLabel": "Built-To-Suit Lease"
       }
      }
     },
     "localname": "BuiltToSuitLeaseMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Domain]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend the Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Terminate After Period",
        "label": "Lessee, Operating Lease, Option To Terminate After Period",
        "terseLabel": "Option to terminate lease (after period)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminateAfterPeriod",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberOfCountriesWithDrugApprovalExcludingTheUS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "label": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "terseLabel": "Number of countries with drug approval, excluding the u.s."
       }
      }
     },
     "localname": "NumberOfCountriesWithDrugApprovalExcludingTheUS",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductOrServiceAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Or Service Axis",
        "label": "Product Or Service Axis [Axis]",
        "terseLabel": "Product Or Service Axis [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxisAxis",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ProductOrServiceAxisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Or Service Axis [Domain]",
        "label": "Product Or Service Axis [Domain]",
        "terseLabel": "Product Or Service Axis [Domain]"
       }
      }
     },
     "localname": "ProductOrServiceAxisDomain",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities",
        "label": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]",
        "terseLabel": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities"
       }
      }
     },
     "localname": "ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from discovery efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RoyalPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royal Pharma",
        "label": "Royal Pharma [Member]",
        "terseLabel": "Royal Pharma"
       }
      }
     },
     "localname": "RoyalPharmaMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_TSRBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR-Based Restricted Stock Units",
        "label": "TSR-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaAndIspenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda And Ispen",
        "label": "Takeda And Ispen [Member]",
        "terseLabel": "Takeda And Ispen"
       }
      }
     },
     "localname": "TakedaAndIspenMember",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20220401",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r94",
      "r95",
      "r231",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r168",
      "r263",
      "r268",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r168",
      "r263",
      "r268",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r263",
      "r266",
      "r415",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r263",
      "r266",
      "r415",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r94",
      "r95",
      "r231",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r263",
      "r267",
      "r447",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r263",
      "r267",
      "r447",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r38"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r55",
      "r57",
      "r58",
      "r435",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r58",
      "r65",
      "r66",
      "r67",
      "r102",
      "r103",
      "r104",
      "r339",
      "r449",
      "r450",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r306",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r303",
      "r304",
      "r305",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r283",
      "r285",
      "r308",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r285",
      "r299",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "netLabel": "Total stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of lease property (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r147",
      "r156",
      "r162",
      "r190",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r335",
      "r340",
      "r366",
      "r377",
      "r379",
      "r418",
      "r433"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r48",
      "r91",
      "r190",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r335",
      "r340",
      "r366",
      "r377",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r171",
      "r197"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r429"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r176",
      "r177",
      "r428"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r170",
      "r172",
      "r197",
      "r422"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r287",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r33",
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r217",
      "r423",
      "r440"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r218",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 320,268 and 318,842 at March\u00a031, 2022, and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r64",
      "r69",
      "r425",
      "r442"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r363",
      "r364",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r363",
      "r364",
      "r456",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r363",
      "r364",
      "r456",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r363",
      "r364",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r241",
      "r243",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]",
        "terseLabel": "Contract assets:"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r241",
      "r242",
      "r264"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r241",
      "r242",
      "r264"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r241",
      "r242",
      "r264"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenues",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r72",
      "r415"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r134",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r173",
      "r197",
      "r204",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r185",
      "r202",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position more than 12 months or longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r182",
      "r198",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r183",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r181",
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r184",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r145"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r51",
      "r346",
      "r347",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of contract"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r117",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r353",
      "r354",
      "r426",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r353",
      "r354",
      "r426",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r65",
      "r66",
      "r67",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r128",
      "r191",
      "r239",
      "r240",
      "r303",
      "r304",
      "r305",
      "r318",
      "r319",
      "r352",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r449",
      "r450",
      "r451",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r356",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r355",
      "r356",
      "r358",
      "r359",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r232",
      "r275",
      "r276",
      "r281",
      "r282",
      "r356",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r275",
      "r276",
      "r281",
      "r282",
      "r356",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r201",
      "r203",
      "r206",
      "r207",
      "r233",
      "r238",
      "r351",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainOnDerivativeInstrumentsPretax": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on Derivative Instruments, Pretax",
        "terseLabel": "Gain on derivative instruments, pretax"
       }
      }
     },
     "localname": "GainOnDerivativeInstrumentsPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r209",
      "r210",
      "r379",
      "r417"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r67",
      "r73"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r315",
      "r316",
      "r317",
      "r320",
      "r322",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "PROVISION FOR (BENEFIT FROM) INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r93",
      "r113",
      "r114",
      "r146",
      "r314",
      "r321",
      "r323",
      "r444"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r84",
      "r413"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r46",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease option to extend period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r91",
      "r157",
      "r190",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r336",
      "r340",
      "r341",
      "r366",
      "r377",
      "r378"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r91",
      "r190",
      "r366",
      "r379",
      "r419",
      "r437"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r91",
      "r190",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r336",
      "r340",
      "r341",
      "r366",
      "r377",
      "r378",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "netLabel": "License revenues",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r59",
      "r62",
      "r67",
      "r68",
      "r86",
      "r91",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r118",
      "r147",
      "r155",
      "r158",
      "r161",
      "r163",
      "r190",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r354",
      "r366",
      "r424",
      "r441"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r101",
      "r141",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r38"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r60",
      "r63",
      "r333",
      "r334",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r55"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized losses on available-for-sale debt securities, net of tax impact of $1,656 and $499"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r53",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r80",
      "r302"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Net product revenues",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r211",
      "r379",
      "r430",
      "r439"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r20",
      "r27",
      "r379",
      "r438",
      "r457"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r311",
      "r414",
      "r475"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r8",
      "r16",
      "r88",
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r240",
      "r306",
      "r379",
      "r436",
      "r452",
      "r454"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r191",
      "r303",
      "r304",
      "r305",
      "r318",
      "r319",
      "r352",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r143",
      "r144",
      "r154",
      "r159",
      "r160",
      "r164",
      "r165",
      "r168",
      "r262",
      "r263",
      "r415"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r135",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r265",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r285",
      "r298",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r285",
      "r298",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r13",
      "r88",
      "r416",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r287",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r137",
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "netLabel": "Collaboration services revenues",
        "terseLabel": "Collaboration services revenues",
        "verboseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted in the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r290",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r284",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted in the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of the Company's common stock on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting award percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r420",
      "r421",
      "r432"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r65",
      "r66",
      "r67",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r128",
      "r191",
      "r239",
      "r240",
      "r303",
      "r304",
      "r305",
      "r318",
      "r319",
      "r352",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r449",
      "r450",
      "r451",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r128",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r240",
      "r286",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r91",
      "r169",
      "r190",
      "r366",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r374",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r374",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r374",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r374",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r187",
      "r188",
      "r189",
      "r233",
      "r238",
      "r351",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r275",
      "r427",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r96",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at March\u00a031, 2022",
        "periodStartLabel": "Balance at December\u00a031, 2021"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5291-111683"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r476": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r477": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r478": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r479": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r481": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r482": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r483": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r484": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r485": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r486": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r487": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r488": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0000939767-22-000058-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-22-000058-xbrl.zip
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MBSSUBB%D>%$W<!YVB,WNEHL2\H3G*>[XMC:F;.::6^(- !Y25I- E- *88F
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M0*G5[0W26N\5VQWT+[/=;C=[)Q72E%+@])GQRA(@#:N09L843PVG2OHYR*%
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M4:NDKF,VJOOSCOXH@]_UQO^$E=&%:Q>][!O51LN%[MW]]>07$@OW""_5[LQ
M@"G!]NO>H V6?_Z",%GJ-+VK6XVU]<;.^EH-/NULO=M<6]F%+V]6WH$:KM=V
M_KV^OKLSLZW_K=FI]8^Z [B'[RW6PID+I_U4^V688[UFVJF:2^_WV7V!P;5=
MD ^T<9ZR#@NV)"0=>WY@S)<D?EHVX^\?HWK\.9*+QLIQ9C-^I#?1;GK?"C]P
MW9]7!N/^U,(WJX4\Q\^]/UWRU8N]S#L5EELWN3NJ43PLZ?%B94!GIP/6@@MM
M"U [Z@/\X^31WR]J-MTSJP;/<V]8XTX.<R #/AN91:JD Z[+4R'TA4C"L&[V
MSLYU$O:=//0/O>6($A2^\(/9Z1^3Z/Y'W?B<>_Q\(W]:Z+'X,V-"OS^$OSK(
M<\#ZFNGU0K_W^DG2O_6Z3Q+.I.\Q)L.M%?^2(I/+;,HS93A*RR!=^A#^&32_
MF-8-7_@F&7S4BZ/:5&KX/O*5_^M9K_;'[>F*F7BG!\NU#7K^5JTV) /5.F)D
M0F26<.V)XXQ+[93$ 9M1K;:B0..W6FT9O2S5-NAEA\:<ODZ:L]+QZ9_U;VJS
MTE\U>9[*FGXTK4%X7,4V.N6*;8VF;KOVV\[6\0JOKVU>-#[5>?WB!.\??T"-
M-=_</SXY;VQ\/-G?]:WZ[LK7^NZ'K^_H]M%^^ZRUU6X<;^V^:>\?[_/]X]8Q
MM /7U^IL?_>0[U_4<7WW[Z/Z[B8YV%W'E]? LP8'9$_L$WC.QD&S<=QJ;GUJ
MM!MK>U_K%T='6VLM:/?>6;V]?E8_/H!G?HR-\U3<=ST5^45;:^Y\Z\-GQ;Q2
MJ=R;=XYD3#J>:11,YD0T\'L4*(B%94GH(A'Z3KVW6][/$VSA$M]^PB;&.8A7
MB#0WB.1)--12;AC3WA@ON&4,$2X]8U86B(0QH14BS1@B7=Q")!$#%U+CC%.&
M,^8]SQ0/*.-(.>8"L:I(Q,?D(IXI1!H38Y]YMK=SU,W[63_D[5JS\R7T^NW[
MJ-Y5#Y"?ZX%[0;:DB#0>CE3T]RYT]^:WWJX :%P M+5ZAQ(AX4#8'F>4!I8Q
MY6FF(HF9D,Q@263 FB\L*P @)-!S >@[(# I2O18M_<7MMSQ<(G*<B=LN;>I
M@]4D,B5,)BC7&<.19!8QDZ$ ? )98W1:&JNP7M2(SY#E_BJ!HMW<^%05W 4@
MUK85>HNU3N@_B3H\UC\K*0"-ASIL?^OI1NB/PJX5 HT-@7;N<(?(F),2V8Q%
MHX [4)M9S4/F6!1>BJ"Y\0O+6*-%@=D,.2_CGA/YA4UW/-RA,MU)F^YM\L!Q
M4,I;G"D3)9 '&S.%1,B0U)$3)*V.8+I$D47!GTW[J[C#SV_\ 1+=Z7?S\RK4
M,"F^<-7% #D5UHP+:^"Y"6<*JM!8.Z3UXY///% G"/@G&GN:I3F8S#KK,DDM
M(X@;PUT!-HM,R!ER5*H0PXS1A,IB)V:QYS<M5F,4%9<V"Y0AH/>89EH$GP7B
MC+#$(,P06*Q<9)K.D,7^JJO=9I[.O,_#J6GZ6C@[376%AGG$NL7V>W=C?505
M'ID4W1F)8'TH@96.+[(?K!2]7GE<8\?4S3LL2!&J+)(J8T;Y#,8]EED?1,8
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M*7YG5VO.1?ZTA'XQFRQ9Z.]9Z&<("?>E$EAP%"*P$F93D 9F'HE2X5AB(DS
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MBW"%/<,<$I90K&G)">>!81^,=$IK01TI@PXER\QLJ8"[,\?,K.0X!$(1M1:
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M S;-D4C/O&5> ,^\95X S[QE7@#/O&5> ,^\95X S[QE7@#/O&5> ,^\95X
MS[QE7@#/O&5> ,^\95X S[QE7@#/O&5> ,^\95X S[QE7@#/O&5> ,^\95X
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M:5*NV7N4]B7,TG2[EUXR:)M/P[0H7+MX(J4^CY(!Z[: =3H#6,IR2ZQ!EE(
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M;@Z'X^IL:3\F&SE5[AJFJ(>B*M%:A"KJ(>WQ@EPDR_FX"P][)IN]MSM.:H6
MKWDML-<L.JF%P4)HA84U3%-Q:[]=%7V2YB?X]?$ QNP-O$;?UV=,JY]_F&'P
M">< Y*K"NAFY%H=<>W/'31VW.KA(D(] ()GE$2DB"3+**^ND-4'A%Z]PBQ'1
M(-]>=LPORC'_0 +^C^F.PW7RG47X=B(\8PU2"U/'#3 .6*(@PH(E:U E=[UP
MCGINL0$1SN+[!,6WE)REZO*48J895XX[P0AEB@>,G7L0\<WJ>7&R/7LDD2I+
ML &3@BJC$8O$(%,JC(0N/>:&1*;+9%=P?.=<$%F^&^WNR=.3IR=/S^-&G63M
M^,C,=];M)F%.N3 6229+Q"3CH!X#04Y@Q4I+,6:\5H\Y,N5AQ+,2D6(T@%O4
MXSPLS'#8=YVJH/9)9W10C,S7,*P^'H2N+T"&)QXY<V(&/L>PY$V?/#UY>A:X
M)[=H(WG5'XZ'HZ/0&PW?A6X"MMW^KOGZ(2%:OYN&\'5_D/G ??,!-V<M*V.L
MT-8B0;A'S#F%3*0.::?+")S/A40'6$N+LAF[<%G(,P;GZ<G3\^@J<M&6<E:1
M#5&1<R:S59'BX 4J;<"(6:J05248S\",C"Q9B-XV2D<^Y4B5REI&-HE =9IC
M*@-//QB%9%=KGIX\/7>9GH:8P+O]51BRU /3?6,Z?K.W9HX[(].MU+N=5>_O
MDK-OV!F%G3#XTG&A=J&_"ZZ_WZON4GG3,PE8' G8G[.3I78\1DJ0H9$A1C%!
MEFF,M(X.<\ZQCN+%*U*V2CP?KIKAH)EPD-$Z3T^>GF7<5L[*=)F4Z9Q%7<I(
MP*86R!ON$(O:(QT8A1^^%)(0C:5LH#9]-N7%MLS '5RJ+4865ENL'M*7%.;
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MH[3SH@K!IXM.W9SQ,./A\\7#R%1):(BE$9YIK)4@!#YBKP)<T>8N>)@)Y.+
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M;8*F),<3>Z.(XUXEOLFNJ<P#=UHAY=3 ]DDI#E:*5<"/%- PF/I9)X["21\
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MNOJ!6?N-[X'U :N-KU0;7V-_.V]ZA5[<W#EDT*9O,EJ2K+(H8J$1UY(ARUA
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M>,:CI!HKSYRSQD9C:%@,&B645<CR9,ARMH L'E.KH^=(4L 3+AE%E@2&-'6
M+0GC<5#YBI-IO@9D>0$JXOVB/Y]E1JKHSUL@LY$D$2&\H(1RKIC%H.TYX>'9
M5DE/*YVO!#K?]%A/$,*E<@%9[P&9&7'("!(0LT)AK[@)Q(#.1ZKHKBKZ<T7X
MD&3T5"I87AYS0XP+0L1,"DS"$)Y,I;F50'.;X@/ LQ562"19((ASQI#C5B)%
M!$U12R\-W]@2573X"U7.UM9_5]&T[XK+,5>RD#Z"JA8Y=\$8[XSRQ F7>* W
M%0^J</GQ<'DY':3U#/0TA1$5AJ)<IQY9QSVR,BD).ZOQ7*]";WN1\5A5N.:]
MTC@(+ITPBC.:4WI9EZAQC')F(^58++)V*KWM*?%A46_3V$?M D4D2H:X=0I9
M03RH<1JL\NR-DYFU4^'#"]7;UHA27>58O&^.11&MD3)PZ3F/WFGC(]&&L""U
M]LI4"MMS ?(E.1:-,R&X&)%1THP-:6T)0=(K'"-+&CM3Y5"K'&VK=,1C[T3P
M,7DBN,$Y!8/VB3'B- !'))7"]HSXL*BP*49!E1("*:H#X@%L.1.C1SZ)I%BR
M8.;1%?!K7B0\K)V^5KX&K\N5U< ^'6WA:4M@SI7!??MK&/M=VYZ6P!W\<?H^
M]@[[]N2HY;?[T0[V<SM?;2G,_>V?>]O?N.-:*"T1Y8HC[D1.S.$T2@;#/F*<
M552L3RG,CW,E+P]GDUWKQ\.LZ"R01FK_:'5KPZ/>"-X8!K]5]2M?$86DJE_Y
M^+24JGYE10&JZE<^S8"M)Q&H%$[N-0I.^+SY:?/1PI@O]5J5INO_Y_'ZO69>
MNM$@++CHA)+2B823EY*;X(PUT4="DE",>!IO<.$C=HT5]::7?75^^*4U/)I:
M4F]_^?8HC]_V8!#AO[!O?VUD[G;'#J$YOX:_=T<=%'I#-'G)S*_'UM/(FKCU
M=G\=T%W:>/^6-3N[9W#O:2,;6_GZ]P>_OK[/J7'^/LHI=9;<>L?OC@^.X7G[
MGAX<-\% VSV#ZPNC[.OQN]R.L^:7MP+:E!K+:;5,YKKY:)!3*B#.L42:!?@A
M&)8))EQ:M;'%"*]C^6#?_TKH#]?+T2JC*BK\>_7X9ZWFP1J6N.6<**$=+'BF
M E?1RK!T1+&8 JS"O[+AW^*Q!A>6>QP<"B)XP#\2D*$Q(&&QX<X%$IW*G%)3
M-V)5-46>"?_*IU"70DE?(WK7VU&_=Q)?>ZS),DHG;**CTE'+,2>:N<B\=5%Q
MS0C(L:VTU+5"Z>5H8L5BLDE)%*P"E);&(*.L0S9X1HC 3$H&6BJO"_ID14!7
MJ(=6P2(W"#@(-L>1*^."XRD(ER38*U1HHK$T*E5JV)H)^*(:YAD(,G4)$0.V
M*!<NH%RA!06MF#%<)$<\"#BKPWR77L#+IQ250M%:(V_HGQ9>]MI)6,LP3"+E
M1E.2A'1<:&$L=-.:8"Q16F%?Z5GK!,.7! %''!GQ(B!0H@7B06&D+0!RTEJ!
MF8RQYF1C2]69UD]%S'@Z=U\EWT$1QE,,R?-<$9=9*RW,/R<&2XK#30GO*_DN
MFWPOJED X%9%ZI'BQ(&:I2)RE :D I9)8^X9@_U=UKE\LOJYE9;U%.ZL,431
M32I*JG'M]X:V7>M/@NSNJLM//*J30#<&_0V]40Z;FS;XU1W5K'Y@UGYWNU<,
M<+6[E75W6\X599. D50269]@=Z-&(F-50%*"+A-RCE#C-K:8$'6C5Y409G4"
M]LQ.Q@IB*XA],,1&0PGHF-3@I+A--F=L\90*2@(((I.5 ;%F$+MD0' EN'<1
M:1-S6A>1D/,4?C!N<0X9"EQL;%&%ZY2]=(@MG['P3+RKTG)VGHX1=ADX_07K
MT)^^6A+8SG?1^/ -BR $YPYIH03BB26DO1%(VF 9T9J31,>;2 N&,FQGV(9=
MPP:N08M+CEN/'::16)@:@R7\+RR2QB[:CK56-V\*L=:-P]I)OQ=&?GC^I1T.
M^RTWRA6!AKUE(M>@YBQL([5>IF_%VN"H=0*+N0;S5Y#*:[8;:C"KL3N(Q>>"
M?^4F24!JL$Q_P)>#^[YN]II)<:*+3S^Q_6$W]@?_][\T)>I?M:-HP_\;P1_A
M;YM+0GF!<9:_G(QQ\:Q[R.S6OUW_GUM7$MDF<B<X/.&D-VCEM_S>CVUXW8]X
MSBW[[XL4OPFFX_-;K /XAO&Z\I9;,.:>$F+,PD#/_3SJGW-L#B-R_6B_(YN@
MC;_;]D][.MCXY\6>0;?FA_$6(T#$=9B:TETZK&_1W_%P@RXU69._PVX=^_DJ
M:(5][B;4COH9VO^KI4.D7'M&I9#<6*^#UDZYY'3B- ;S30%H%+1*$+1__].N
M6]OS;@.+?5 T_9+UMR#MXXW'$B4B"<3KJ+C"U'%B4^2<$2&M2&P1A3E --72
M<&4]QSQH!A#N@XI><YJ,O2M9]])&W0SU%QL58X !"BD2*3CCR:9@@B).4 S;
M-S=/+/W-2[>8N3WB_(_]HLI<UE0#[%!%8;I^L%T?:S]!9ZAM?WI3V^^=P,X@
ML:S/:LZMN#/%DWYOP7;9\K?G/-<2:#BUJ8HS&#=XQGU_I*9>V[#:/V9C]=MF
M[3^+@SW5 /*>F@?]L-N:;JOY3R>]_O17:%.$?G3AC_:TDV6J9MO%-CS>L?/E
MT.ON(,5^OKX%@M=N1S\<@<9QDJ,Q^\/3Z6P/BB*#/V%[/ZJUAK4C&VH.WMZ)
M^4I7X$UKO-'[4;\/+\NU#5L]>-&1'19_/V_.S]ZHG6^'A7+4@GZ%8ED!3,%.
MUTI@J73'*ZX_@(9 PV9]']_8[0UK/0^OJ6=6^D]H<_ZWWSNU;6COA:6:%8W!
MD1V71(2&IA8,0@%,E^@@]K ?8QZG\2)X'[MYT_5'F[ \KM>$"H;\]1+PN0;Z
MMD9$EV7]S_7I1ZQM]V$A',;Q*IDL0(WU;[_7WK0MO/$4S,QB%G>S'C)QEK@X
M_!ECMS:[O!CSV>I]%N')+7"G\(]M]PY/\S*?M>?F>;Q&MD($*>G#[,XNSO*P
M('&C$T 36#^Y$3=)7UY__3B(!5<ZWQ#@P>W>2;$ 9TT#(2H\/GDE]1RH@D73
M!_4+5_O>( M,J^-&_<%D#N&Y77C1C6L='C4%^<'HY*1]+D#UPL@8R\W\]_EM
M\&5N<C%.A=RU"BF KK8*A1\$=YQ1<'+OH-CJ;*N;EY&'9IS9O/.U7)ZKJZV!
M<];FDHY_C3+ % Z)$"P2S_E2F:9:<$QS%![!5LLR9^*X=-.%,9K^K<K%4>7B
MJ')Q5+DXJEP<I9Z(*A='E8NC]-'GSY)P^LWV'WN-M_L'_]_S)^1XEOX_)R']
M63I\%ZHC(=1B8:EC/),=#;9"42.P<I@XYJH@IM6<L!_^.MC__//@^%WG8+_9
M^KH#[=AOMYK[N[RQ\YD?[!_ ^YJ=YEFSM7C"OK?S[JBY_T>K\07>0?_\WMSY
ML[WW99<TC@]_-O>/CIK0MP,*(T'_O"PAA^0!)^4]TLY&Q+7RR*0D$,PM(S12
M2['>V&*8UC4I1Z7CZ^5HO1-R5/A7,OSS5/'@!1/18RZ\L(R:X(V(("U&Z5!%
M&*T9_BT5AI$D&!X ^IQTB*L8D96*(6J(R,04;D2.,**L+DR)$Q+=!O_*IU67
M0E-?H](P;[*>_G'WP].GY"@[3B?.M60NV"@)-Y2[&#TUR4O!)>BKN-)3UPJG
MEU-R%'48A2=(:FT1]Y0A)ZA$%*P0L$8"IT%DJB@L@V<E[-]/$7WVC!QEEV^F
MI$HR.)]XXD%Z1PA3)DCBM9925XG1UDV^EPHK<U"W)'$H6&$S%5PB9Z4$LS0I
M#?IV%):"'5J7Y'DS[E2*UHI=HG>ABCX+2EUV_GM/C?\IV4QKY4IX$C93V?>X
M$!.7&'-IO>4F,4N58,D&)E(.F5"5#KM.>]PEZ4ZH8"[[TE'4GB&NM$969ZZ"
M#40J)X*Q.:T<P75J5I7PY#G83,_IC*T@MH+8JR'66)*,M@Y3[3E6PC$OC#!.
M)2)4\*8R(]8,8I?R*WO&DHL4&6<,XI1CI#DAB#EOG8D"C$>:W;FJ3E=]G%4Z
MB"V?R?"$A-%;TL\>#:HNCZGY:V)'?"J"<7=: P_K:3@.C-_.X:,YJGAP,63T
M<4BE\5=L WK!XWQ1;1R&:2\5S9JV:KL;SIOT,>;XY_B';1>_5O4&/WS#,*4I
M.(:DP19Q$05RRA) GL04)DYIL4;U!O>/,O=CV/K1*@+'\X*,W0Q,140\3'W-
M3>:^B+*/UA]=((?D(/K#7O^T",R_L*[M;!'5)V056'2#86LX&L;:#]MO%4'.
M^6]@ 8VCS>LO)ZC:F$V0SOO$5'.RR>BMXXEO'Z9,-S5GCQ)3;:K&/G=C'V,C
MOML R%LU=761R??-[SL'&H]&ZKXQT'9\JGL$L!*S>@D(>:X39)@%?:$#.N%?
M8[I2 :=[PZ/87V#AWCPZKV(@BZ&9,45K;_HQM(:#?[Z+DPWM30^=V-,:V&*M
MP3#O2-4P7C:,'V$M#A>UT-4,SF,8!>L_X$5"D4N&^XF"SD%9&@_'T[IM)K9$
MS0YK.]''CHO]L?W-2+UV@7QP80$^?5!FR?/"O;XJ:=I+HR,W@0L%/X/A,H%!
M O]I88/!WW;S\B%@'%_OO/O;ML<.@G,[%XS>B:D[F*S/5^"NZS1^'L!S&CO-
MSMY.N]/<^=C.[=C;?]>"WX^@C;\:QW]T&N__7G+7'9S]T8)K?S;H =_[<H";
M[_]N?\VIF+[LPN_OON_MO#UMO#_X^?7+GZFQG$(3*V%%"AHYX3#BV@MD8Y+(
M*F8==M9@(C>V"*]+6N+@RZH:9(5SCW(@3$3$UC,L..>.:$>E8<YA$U4D@8D*
MY\J*<XO'$HI3X1TFB"E'$8]8(9,81RF*2!3SAN6"8KJN505S%<R],IAS0FDB
M=.**6!Z9M$&37&B/6D(%4:&"N;+"'%D,TL:&6:P""BDQQ)D,2">K42#4>$H2
MM9)L;%%>UZ].G7M$QVR%G:\7.T'8:++,,6$YF,+6!BD<YY@*%4!G5!5VEA4[
MQ:***!)15C/DH@=3F 6+-$D>R<"\]51Y$LW&%M=UMC[8^5JJ"?W5[_UH#;*H
M%BF(Q]GDQ@G7.C;D-(R_WR;US+UI0=4S'O,9CW%H<;=VK9)J0<6F*JL<O;F0
MI[0JB+K$@H.]W;&4O-&PVX.N;:ASGC,B2;))ZELS!(KHK^OW_&T8P"*QY;M>
MOX@+V^U.IN>O8G8J96!ERL!E!>B)C(IS1%*N>Z($1C"_ 24=N4Z"\*3XQI:6
M=4D?7/:DJHQ:/D'G*@6C$N$V:"ZL<2#Q$1/E(JB"G-M*T-=4T!<=PR$)%4FT
M*)MMB%,JD<6,(4D,( "VE%*WL45H'>ORETBM!/T>>2NBX3HZSP3F+'FM%'?"
M1J:#](S&2M#75- 77:-$&A$9HPA+GP4=;'SCK$0^I.2L)=PY,.^9KBO&7["@
M/X95]6K!8V459BOP*!=X+/H&<0K$8\P0-C83AQ/)R3$2DE9K$IR4V!#0$IBJ
M<TY*A!ZK]/^5V6_Q%TA ?^*U6,H-<2N<>E#RGK+CU#.[+8K9F:)4!42W!J)+
M,AAX3Y)S@B(I=<PEKP&(J)2(.HJUMUH0J@"(Q(-5F ?EZ'F4@M4O5(S_\;1>
MB4P9A$^50#^30"_Z'Y(R5G.KLS&2$(],(&-(0IXYD],G:FWYQA9G2_+\6R7*
M91/E]7$[5 )\;P%>]"MPZ4B*C"!#:<Z+J1F".:2(R9@(,_!3%GZ%Y\V:][AB
M_-1.A1<-#<_L5*B@X=[0L.@U8(12(GQ"!G.#.-<<.6P9<LDJRRDH<)E<PQ^>
M:FR%T/ ,226?QV,P*T"9J[I/&<M^S%BNM0:#47PM\0]WL4!6YDFX7=SC3LS9
M>C) 5>[-E0'5,@O02JF<P0[%9"3B3F6O@B,H4"%SM6U,A-O8TJR.\;)CX?:&
M2(F/15ZO1*\LTJ&2Z&>4Z$6W M;)60VV".-!@%4B C("4P3"+"6G,IF$-[9R
MHE.Z;)A4$KW6$KTRWT(ET<\HT4OQ"\1+K\&$$#1YQ$$%0\Y% Q(ML>2:4%8D
MUN1U><D)Y(N0Z"IT894HL3(W0X42SX@2BRZ'Z!)6TE%DN3 ([#*"C,(8J9#S
M*P<MC1&P[Q-5UVHY_>ZSP,03U0M[_B1+1=GQ"QF6Z!TS+$UZ?O]\QR^2=+KB
M42DGM-]%_Z-8:)) \X?_,R,=)P#QE%%AI))F3.=_,*!7E-15H_DEM8%)P*"_
M1T1"2HB[F)#A6"#A"=7$BJ1T #37=?;PTIBKE:)G/IFJ$+1"T(>P?XP@GD3%
MHE8<,]"G:$PX6>ZH<DY4"%I:!%WT@WG% ^QZ+E=7-SE'O$).QH B3L9R@X4U
MK/"#2?/@:A05@E8(6B'HQ+O 4F L6444Y0E3*S331!'XR(@,ID+0LB+HHM\Q
M4BZP%0X%CCWB5%NDJ84?R7$P)S!G*L<WF3K#E0[Z; FG'CQR%3"_HI15D1F3
M"+8Q@48K3*!><*&,UXI$8BML+BLV+Z6LTC!KN1R[908C[O(G12421 H>M'+1
M^(TMF?T#SZ_=K@J>KZ@W=EZBJY"%^?)CX[458] AAA3SX#">; HF![<(BKTV
MW&R4O3C45,J*PB1^OF9)N%"SY&1<L^1DKF9)KRC,8?NQUH\^3U#(M9TL_#8Y
ME<E5HX;]G"H++HBM'WETX<'=.+X?;H<O.K;5G2M(-5AZ8']<N**X)>6B'V$4
M<R:N:7S=H%94D<J%KCRTT79/\^/>]/*X#F*N#](MUDN1P6OJ.?]T%.-PL%F[
M9<FI1YN9RPO*38M.YJ(F<1).^)^6=:WVN([7G0IE/=\"^S*=^#A=-["68!W5
M>J-^UD_:%N1Z+$PGMC_LYKET-L\9_ 4ZV\X3.?!'L)YRTK4XR/+9&L#O><J+
M8F5^,E*;M>W.I#C9XGKTDU5\O@9K/X]BMVA$@0S%8IHO5%9K#6"K@S^-XYAM
M>[,&7>G84Q"70:]X^F$7QF%:.#RWQH8?Q<+*2_XHSMHULNVEGA33.1A!Z^U5
M;9[=#[_!"A@W>/;>,&N/R_?]OU&K/TY.%V("B9Q<-Y7 :2.S%(].8/PGX@L3
M#2,*JN#YY$!C6NW:SYA)KWF'+<:H!V-^6(Q+O@#&*'=P +WH]VWW,!9WUF_N
M4]&VW,YI>T8G168]F!3 %6A;T4>0[<W:NUY^1V]P/HP#^-T.:T<6EE)GU!ZV
M3MJS1HZ'_;R1]=E=X\W(GLM0>TZ&QNT[Z?6'X_5FQU<#.(T_P$)L#29/&.8N
MCS]??'8;^M(^1Y%YX;IRLWMLJ7MS8>F,.WK2!\VH#^^83V6X>S* $?\+,+]C
M:Y^V/]7^4?SEMW'T\O0IBV-VZ:,6)W<BY_OV>PQV\@H?1\7^"X!<H#0@6J>5
M[__'^++?-A<.+I?J?5Y; 70R!H+#()WT!L7R_[UH(N#/I&S?1*N=NVNB<N#S
M6ZR#W6(TO/J66Q0C?$J0)7AAV.9^'O6GK3BQAQ&Y?K3?D4W0R-]M^Z<]'6S\
M\V+7H%_SXWB+(2#BNFTEI;OT6-^BP^/Q#AE8BC7P>P%)^2IHA7WN)M2.^MD:
M^J\6*(64:\^H%)(;ZW70VBF7G$Z<QF"^*="_BKT($/K?_[3KUO8,,AGXBZ9?
MLOXN59:YM(%J:;BRGF.P)1B8&CZHZ#6GR=@R*\NU1ZK8.[5[+ZLS7FA_8/U.
M5;_3UUV@=^<[+V@%/'G%$Z(:*\1A+2%KO$.14<<%"_"M'?LF8/'%L)V=!,JJ
MD QS$DQ6CB/5,2:JN-0N2F*T62SHN[2%+N@.-]:Q73 =)P)RJ5#<W+:+??$"
M^RAEPE(3[HQSCF$<=/1>D5Q,!N3BR6OA:D'N4PM7\DVE[E<^]=J"I6)3\:N_
M?DC%UMN50;UC8X6Y77G9)ZFN.M9A'M?[>&/]Q )QB\BVVE)0VV.7\RS/ $SK
M)]:62B?>8C4\1GKKAUU9-?B9&[RJRJ+SM5:?.)/XPKY\F=U][S;(37&+1EQB
M6V8-%;'-2S;+[,P:FR;_(+_=,2SWIFH.+_)@[6Z=K@[-;C(>FG'X"L[*CAOL
M8-__;.[LGN[M')XV=CZ<'G3^!*/A,V] FYN=C]\;^3RL\_G7XEE9XRP<-<^V
M<>-XE^_M[,(S_FP==-ZUFOOY?.T#_?K^PZ^O.]NG7_??S6=.(\VS0][X^<VH
M8")Q'IE ".(:)V2TL"@IL$N8\TY;,)99G;)'K^Y2)G95!6JO&M164[RJ K4G
M K4EFC=5CJD8D5)2(1Y41(Z9@& 5!T>5)N-TD'4IUP/4)FKQPD'!Q'']#$6*
MYGJ[$.I0FCI*=VWB4UL>SV)TS'D [U?XZ^Z<Y*=_QA,1)^=MR 6G#,K7/VK0
MQ0UEJGK]#&7K8UO6_D'O:ES>-M==:83PSK&9+TVG>CQ#<7:Z-!& 2K=:F6ZU
M7 *,\6BM(AYIAC.57D1DJ<0(IM>9%#TEN62\JC-N2I2_[XGH/Q4<K0T</9Z)
M5\'1(\+1HJD724[21AR2T64F(PM(<YP0*7+_))&<*.!(DS+E_G^&<XZ2Z*C_
MZ<&[A['?F6JIZW0$PJ[04E]HWJ2RJ7?-7M=7D+I:2-U;+J82)35*)XUL4@YQ
MXS0RT46$J5(D.%@K26ULZ3I>V9% B1S_E2@_B6I4B?*CB/*B=@2V6- J.H1Q
MSO- 3$ V,(VT<HI:'(PV.HNR8@\VUM8O]=FS".)^;VC;EW(35DHY?&4'E*L<
MDA< X$^@BU6PO3+87DX\CQ/#DAN,',P:XC0:9"S'B <I0U):I"(]CZ@SO2JK
M=A6B4W+G7 68%6 ^G\9; >8* 7-1SV6)F2BL@_&,%'$I+7*PPR'A,0^)24:-
M <"4=2&62P:N'V!>S/6PS#*]FL!V"^[-5;["3%F[P&%#1*_.?;A(*+B<P_;M
MDO]=F4K@"5LO-O6-?D=ZG=^1W!1[/5ZDRS]7ZCV]W23\E1-==(?C' ;C%!KM
MF5=W$M?^& DM7M!\TI+/Y\0W<X$R>/\I?0TSRDH[HWG2VDNG+KUT2<J#>T_Q
M37D/2DN*WAGU<R=SKX='_1AK';CE:%"+W9STXR*!;YPB)*N"]9QAY#R92>W_
M/&&!"7&ACN6U*N=NU[='6<":\>?TPH_CN?XX:_SM]%*YGGKI_:G:9P>B6>BM
M\/S]7=(\_,84J)*$6"1P4(@3J9'1T2+EM-(X8:TBWMBBFU=9Y)V<1">G:>G>
M;<%$ [9'I-3@I+A-UKF4/*6"DF!58+)8,+!<,$7%![!;J@7SW N&-K:_*5"M
M,=<1::%S%#I8)HX8AW1P3FGEC/8Z+YBK3M$F"Z:>$XN=1)\WH_9I/8/T#+"+
MG$(%E[]53-TYXKL(*%ND)5N&>3?![C3+4G12%+:]9J>N4'M%J'V=K^"O\W10
M>[-L4)_@YR"U8L@UB../5F\TF)8AKN3P%L#]\YOS25H7'#(I,00K*B*C.$<T
M:1(8XS0)O['%R.95M<B?';FK1?.DBX8UM[\Y#-NY5A21Y!SB*0H$:K%"UEJ!
M'4QF<'FW5YM75:F^!7H762DO3P%7&TQG,-]Q,IG#&4[7/N5$=;,'%3O I6G-
M^KU3VQZ>GB?(R^DR_?3;PC1H^:S>7]F0W,BE;(?P2EB"X_QK]4F2M'IMQ[9:
M_JA5^V2[WT][A;B\C]ULB/BC==E:M@?C?%8E2H=W28&L^MUPB&CKJ==$!\T9
M)Q8+)Q3CEBILN:%7' @NP<],%9QD/+T4>BJ$N<VVM+?]32<?I0.%(5H>$(\Y
M+"/;$REK&DP*:;3<V-+J1H,B)^Q<J9/AENNR2!+:<?#WD)/D=@>3E0A Y.,Y
M<(R3-&8PF"137$22(A75/"P5>4WC(!9Z7+XQY"25O9,B;V_.L5L\_RK FN39
M#+5N;U@[C4-0A>'],SP%[ 2%\?_^EX85_Z]F;QAK;+/VYD(JU^U#T"DG< EO
M_V,T@#X.!K6=N69L9T0O'&/%H\B_IGE3YYX\R)VYX#5YU^I">UNV7?LTA#\4
M[YC>/Z_!_V7[P]KN;KVV"Q?5='YV'I3M;C>G8_U8)/W,*3_?Y12G!*/_G>CR
MH-.WLH1!OVU_H@Y/D_!<0!!2W-#JCF6U4&Y<;U1D":W%7WF_RE/1ZA1J=F\R
M>J>3O*E7C/R-V2_O#/I;_W;]?VXM[QP%=-R8Y(_CC;*E16X"-N3U]NBI^&;+
M^4?</L]RNP.+H]T;C/IE2<&'&V\F.'S<$(WC#^Q@_\^CO9UW;<!)_+7S67S=
M_WYV0 ].]][__;VYTX1[OQXMXG#C[#N\+QPU.F]YX\OG7\V=CYVO^^WVWG[S
M^.LQM._+!]R@\&_G70)\QXT/WSAED0/*(HP=1EPZ@@P! +:&!NVX%F(Y!1]7
M2@7)I4X"7FJCACLD+#D<F#/&AZ44?'O_^<_V'WL?M_=W]YJU[?<?W[YMO&WN
M?ZIM-W=J?WS^M-M\^^E3;>?MWV__L_=7_J:V_69_]^_=_=VWGZ[*OW==:LH;
MF[>0A<_FHJ?6&:HD#]8:IK46"I0$PYT@I<[[_B6.$RG/Y].>)56^3%%M1YO=
M6K63BWE\QV[NUF2S&F>][L"(9X1NG4UP,2=M'_6+8Y'Y?6@"R1Y>=6;SP+9<
M+8&D@0(\B)NU[3!-O9VU_I_3!N?,; 7$9U"%I_6A%;.M[F)"\?QB&/*Q?IX;
M/Y^N.H/RM%6Q>S2&8F@./*A]BF!8#@&F6R?%Z43Q) #U(N,]7#-Q]A59CW.&
M?&A%?=JU2>;D\T&(L(W"-WEP^O:D2!V9!S2/U6$/&@_#<-+O_6@5P]N-/T$3
MB'8X'J&3<PO"YQ:"M0-=F^VK\(P6_.GH=-""=\'^4?N?%MBT_3PUDT$KLI5?
M&+3)^=1]YOADU!^,8*IRQW\>@:62WP";WF2(8Y@]O'.2U?QQ*Z%WAWW;*0Y'
M\NCEK3?!AMZ[=>K]YY:61])W)HK:C?K-$RLV]9R)/6<VG<GLP/=;#JYWT)F?
M]>*!=B:=%W0@^ ]6Z="VNC/QOBB2%P?J2NF\K;'[U$49YK'JPA(8E&<I%T_Z
MO36$R_TM^C2V+BZNY_)TYOJ$S+NPSJ/KCVS_%)8ND07D74 [>]4"G/._W&_O
MFM^W-FN?IU41:OF0>'!> ^+2E]>+"@^=0@KKDT9,RF3DC0:D?9 K9BRWIPAM
MFFP(DPB# F)[.1-W1HTT&H)R>G%3A0D"(!\#/:!U+G(Q;=_GS4^;Q1/^M#!O
M14V)8ILMMHVBN6%<&F/:C3@_;KWQ2<DU W-S2^<:MUG+Y6AR&9 )2!+UKUI,
M\(A)"8/#O-,6QO)1OS<Z!-.V=MQK99-V&&-QH)%'K#6$WXJ7V1/8>\"8SLT>
MC-SLRXMU1*!_AZ,\)L7V#F\8Q+@\>9/VP B>Q#G]8C#,@W(()DAH]6-AOO]K
MLI_GJ3WJ_8R%=C Y9X)9+L QM3)R9I_. .Y '?N]0,#1\ AV;] LBD&>^#V+
M"9@;T_.6= ][X_.IV?@O;JE5N83+RB60A4&JRB6L2<F!5U<NX48;<\$F!;6,
M>9F$M9)QSHB+22M#5,)1&:[B+*K[L1PGGR8%CO;252Z47,LODQ>O^'K_W \Z
M*%.M@^=PM)SN;7_CUG!/?$(F4)MC("*"J3 ($^:Q9[! N%]<!<PE39(**0K%
MI<-.,:F<DV!U&&)<6G2TE%?#^S@]H)M5G;J-/G=C;88[:+<+^]33UE6 ?603
MC_>2>Q16 "OS40HK$/$HA17N]]2;"BM(?=O'KD5^]V?(&7\CT=^L5TV%_2+@
MJ3$.>'I[,>#I%CD=GW>LY]A]=ZB'6LZ)N&5-CUMU]+4,&'GT%;HN5[[D?+/_
MF8043>.35I9,>8EZ^D+8N'?N]]I3;I,S%LP\E?)!+%;P28--2!6GB4O)\4WQ
MM$O<VXFJ_:[?ZUP6)?GVUR2R/>=?A__"OOVU%HS<^QIN$T:N)TVZFPVU]L%^
M?M?'UM[^+K3O0V;:XB;]<'IP]O8,WGNZR,AMGGUF!\=O<^WUHZ)?[W?A_;EN
M^X?3W(ZO.W\>-_8;T,<_4Z.UE,(@4$DL!L//2A\1C\D@XR1#7$LO/)B%DC#8
M$GA=/CPQWUW%9UUK2U3P]U+@CYD0,=?)$\*Y<\9%Z2W%(!G66\?839'A%?R5
M#/X6$Q)XIXS&5B#GL]_+AQQ@I!U2,/%2"V&5=P!_M,X%66_X*Y]J70IU?8U2
MDET\/)_%UUZEO=\J0^)M\V&O)7HG:[15.!)&&6=,&AXPJ#H^<D<=-K%27M<*
MO9=SW =*?(*=&/$$>BNW42*M'44J<ATMT4(JL[%EZH:L*IM,B=)H5?*MM9=@
MAPK)I>"8,ZVTP$Y30CPE)O%*.ULS^5[2SI@5B2N.C, 8<6$X<E)ZQ*+5F98=
MN-(YT*+.Q(-3'#^Z@)=/62J% G9-/EI"-ZDHJ3)6Y(>]I^I_>2XR?%TZLM?A
M4EC%P*S]KL:M-#$09857/"CC.)>@LC(GHTU2ZTIK7:==K;F<MU^KQ+"R'BE/
M.>*2,V0M=8AAZ;E,.B;--[88KPMZ5::#YY.O]?#)5@A;(>QU?H'D9 K<X.BX
M=LYX+9FVGB7/*%>^LAO6#&$7[08=C8M8YO,LJQ"WS"(;E$#*)!,]3#ME!A"6
MU366+QQARV<A/)K5,4NT.^,DS#-S2QM\^A(SF3AOM0DYI!SL]Z2I-CHZKS'W
M*DCEV>O+9/+D@=WSF4SV]C_SYO8W[Z2B,4@4, V(8^^04\0@ []&A[4UE&YL
M<7EC@JT)K6LIF4CMIQT\0HJ0'_&J'"'E81#>D0XY2;%RX4BG/)VY%AQVN[4_
M;7=*AE2W($/"M$^S5RT$TD^&807,R+_F2./#H];@-FVXR(^<M.4(_O:HW,A6
M=TR#K$_)]5,NXH03>2D=<L*!]# =!5O^.C+D] 5CHN.-1,*I-"\P(B^.'PSH
ME;3(^"OZT7 Z6K?@16[>(DW&S>22BV04Z8.FU">2G.4L82T](R1)JP/E5I4Z
M3<9=Z2>3E5KQ3RK^2<4_J?@G%?^DU!-1\4\J_LFSGZ>6THE=\4^J .P;'$E!
MYY(-5 IB,0=S4TOI'#?*1A.-]!7_9$6N^G!T\*4)GS^SQOL_.[EMT%;>W&D?
M-7:^GS6//Y\U=G9YH_,9+[GJZ;NC _JN]77?_SSH'%"XI]TX/H2VOOVYM]^
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MU&KN0[OVOY-FYX W=][BYLZA^+J3VWSTO7E\^.OK?CCZ>OSULI0PQ($Y)VE
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M<ADE)S>2K%?CZ7EV#M)3TR=V&K"1;./F<>8J?3[=V_X6.)..N(BHL!CQA .
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M:)"(4!P15Y0B$[A&SED,L$63ECDHFHF6%*Q&CMGFE.79*/LEWHJ+*I^Z/V)
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M6Y-&WUQYT\/])HV^2:._/-LST 2F+!.6<Q.L#5(XSC$5*G#N5,-N5V)+_+3
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M+W_6+P:3X3D#XAQ56"]^MR, GLG1]*K_3.P08+UW<OY)P_B]&X\K$(KPZ2$
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MUEF9%],D0DI<&809=8@[&1&8_A%QX@S L_!E*:#:*?-S/E)H^C1>5ZDX">%
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M!V7GE#<7.Z?<(+3U:>?ZTL:GUQ+Y>B[$#2N;WNA%7\J$D0>7T%6Y\AI-JM^
M7_*5S[E(RL<XBN7^D=EIR"V^!D?9]&Y*]S8E+N<;3MJ(M4^>4,K!O&?:".89
M58R3I()4UW536W#FOIZ95Y>;VV\JLVHEG+QW-;FG3M[/8O?@XT%[\\/QSK8_
M@7M..N]V1';T=L#4WCG<X;N'NP>=S=WNO)-W=[MW6/;DVOP=ON,]F.GO\>Y!
M[[#][CUM;^YW=P_V#W</V[AS>&DA&<\4T2R'M6B1B_IF7Q,5"AG!<[$Y@ZF4
M9?%+L^1SL>=R[-4 WO,%/*R)"EZ21*3G+CJM. ;@$])CZXVDU_4*; #OZ0%O
M_E2+1T)T=!8!\@G$12+(*HU1RH$ ,7+%#"_+[S C5QOQZL>C:\'-ZY79_$NH
M^A1[\,>]5K$7^W%H>R5'M^$PU^H:#\O.CTTZQ$*:EI1<4V,CLY%KEBRF3C*F
MI!>2ZF0;EEIST+ZDF$^R23JF!7(N$,1]L,A:AI&/'GM'%;4R5:TG)*Y1G&V3
M+[&L? E'+$Z>X6@(K#[3D9K ?23,J]QYI"%B]=?I>2*62 C<I("L80QQR@AR
M"END)(M*2*&B=V4P/9BCM=?I^O&B6G"M%:TP4J8.7'O<W^06-'&R2]_I[A34
MU.QT-=KI%I,/L(C26^T1)\X@+IQ#EO.(+,%*:^%C$A;8JVDIT20?-,D'#:@N
M&U2CH81$2@U.BMMDG4O)4RHH"58%)AOSH?Z@.F\^".\XBV T>*, 5'6TR&JE
M43Z3Q)$EZC19VV#+[(!05U"MGZ'P8,;'Q<R,VH8.?[K*=,@1PM'Z_6)\<A1S
MTWM[;(<!L ODYKK0X1P87!S'86R"@YO@X&<8'/R$@;R@%DT4;Q/%>X<7;4)X
MGP.VK'0$9Y5%-#C*!&.A/%X3Q?3BHY@XI5X)E8(6F <=C M8$B^#C=%X3!J7
MXEVMWX,W\+=OK+/9^=;9+JU@L4,_<[!L]SO;WUC[W9O3W<./W=WMLWS^F?7;
MWF[SK6V/V_0#J:S@WL'N]GYOZ\L; G\':[ISN/ONSU[GR]O+&@5'FR1QWB.:
M=&XBIBW20@44?4A.:).82F#]MN3]^P0W89L-X-7@A6]56<\S8SRQV96GK'.<
M,DJUYI@;BG'C[EL!P)MW]RFKE&2" \*)'"U@-=)>8!0UP\39B*73:QN\)0U?
M;<![!MQYA2(L/\;1>-CU.<._/.XO8:6I,7T)AQ3:Q2"TEYCK)+30W/-(D^$!
M XUL.&3=(74Q]0?V0ZDE PP5N1%M;BBF3:0HF! 9<RRFLH<T:V%U[Q.4)JBR
M?CKMI<<ZY926E'AT''1:8BM3$"1RIUA#D^JOTXM5JAW8]MRBX%7N"\\CRDDM
M* !)4I1P95C6:=*2<EE=3QLJ]#S<B'_%8:F8N7'>?;G035L;K21N$NZ<3DF;
M9'T53<*<3)$'SSP J6BX4,UQ\Y($$^D9E]%(9"A )A!;C5S "7E)2!#*,1D)
MX&9+X65%Z-7(9=:HM/<J)>E@D67DC%/#@A)$\]Q%1]"I>=-0H5JK]#P5LE)8
M:BU%1G.& *@YLE)*Y$TP0E(F-1>@TJIE>/V[#CX#*K1"7J$<:=7X@.9!4M$D
M<'+4>1RY#,PP)BC'06OM-<4-[ZD]2"ZF)B16=D%DR&$!]F( 4Q'@4L,_GEG,
M(S/9K4Y:]/[E7QH74/U4VGM,#='1:*7 <K&.T9QO!"NOE$_>/QCO:;3V-EH[
M3VVP$X[&7(]?:Y</P\!NB;!&)@B?4H@)"Y5CW^OOMGT&O*;)<;UIBL351ZHO
M(/#B?E.R\CM-D]>ZZMO08A :+)+ 4@04E/%@83.!C&<&A<0I%;GH#GO4O-8;
M*M-J!*@U$-I :)/%^MP@="&+-6 ?66)(1881)\PC0[A!GGDK!>$6._686:Q/
M J$U-0)^W06LMKFGKT<YKW0F%>>_^4K[[J&'5*:V5=+*2*O(!*]57(E\HXQ&
MHZ7T7'W?>;O0\NGRSD[#H>WOQ5SX_/>3A39DKW.2+JR\B\.M5'XZ>OW==GM9
M/MX.AN_@WO'-8!*O)DS>N3%4YW1'= X^\_;VAQ\ JZS]^JOW+DCM$F(L-]$F
MQB'-J4.21\4P92IHFB-YB: M@Q<["Q:C_<N$^Z%E."_Z-/MZMO1E-O=>7OQI
M G=N$O7F1^QU?W1'K>)]WZ^#K!-5O*F2NM__3.JN.CW940&B629_YOQN^()Q
MWHU;Y7/*&_-U_UHOMG/SJ2QV^9HXA =T1_!CF'BXU9W<4I7N:8J=TZD([WIW
MA?J87R!?^[Y?7O"Q>K?-2=P>E#EM6V5*V]:P_.7UT=$0QE ]/-_^<G5J<X]]
M-90ZKHE!.!D%6D0MTB27&')*:L-,DF5-H<NT)\O1SSH$U:_=T6@"HG0T&8XF
M69S'@\).@X"JO,)20)^?F&V!I@W+JT8O5YRV/XBO3)DH#(TH>$!F+BA#EI"
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MKV #.A[ _,3^RY9+W'[]50G)F00X(Y(PD$O' ,Z,1REAP\':HSA[]0?]6)R
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MNN%Y*VCYJ7=#$PJC*<Q;P,I@[<D@0/#7*2.2PS=DQXR8VEG@8B6$^&,C8^>
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M>DZGV>W[<"J-9KF:Y_S#F_/#WS\<GEP8AW]@3<\=*GAN?>?S<E8:Z14HBJ/
M6X'RWZ3!R(?IU<[1['B'0G1+I,21RJ7)%;EH,$!SRL4UH0*X@Z4Y[V,!AI?
M\%F21![7[)#IBJ(]*U]H6'W^(FX&V6 CP2YQL,+(FMZ9LU>[I*%I?!G5,[1B
M0:IS]IJASX'<[6A_?"7I#0\OKKS^9S MU5W[':\G^KU>WQ&]5M/W>MUNT^NW
M+.%X3?B]\?<1\YUF0R^W/CIY.U-O#<K2Z> ,[+[#!"LQWL>HM$QO5BNA?F98
MY.=D5HWC@P_7)P>'?P_L=L,#45!S7:]9:_G=1JWO6<"V_*9MM1KM9K/;^.%G
M. RS,0?EV$C^25&T#X1@4Y]RA(V]$9R2#Q8ZW@\XB3! YYC_V?%$F#DUQ=>
MW:U>%$\BRGB\%(Z/ Z(_D&EN#J4:J&;BBY:)N'4HK$A2[T '$N*4==]P2*^\
M@#>>#C"O A=>("ZX]-XK/XW'B$7UO=/3Q=[?5E]TVXUFH]9N=YU:R[5$S1VT
M?9"%+;OM-GS?:_6!GEIV66 9M(,92*E(EG 407ZB$E/I=1IVJ]49#)INOR7Z
MMMMVNSVW,8!_&[U.QY5:38O!')9Q%_%5C.;2@6I">P:6W[4S.F68U5EZ (9S
M#2IV(L**URC:^'SXM^WUG4[/[M2\ 6$O--R:B\#J@ZYK69[5:W@.J#;3ZVB6
MSSS=79=GBU=^[D7/#O8[/\Y/?P\&5M.QVZ+6:0\:H-W"I>]YHEWK6[[G>'9W
MT.CT?OAY$%R)VHUPXID++U&*.8]I*B1.+7%WZ0R0B@LZ=(T(03C1;.:OD15-
M_@84'-K#F$&YE%SNQ"=N80S,"2ZB"S6C/9S&>\+,K<3%0G'QX6\PCCRWZ;DU
MW^]V0%SX=JWOMBR0'J[;@GO<<5P;4>8;"\0%I\O+ *"*OC E3)R;L= +$V3)
M,V56D >+@WI8#Z5\7?"3^#H1(6JX&NCRM*3]UHVW\-5Q1/$7/EWRG[D8#4'=
M9H[:0I5OU'O+;KP^B8!HT4S7T#%DN9:&CT$/6Z_5;="^2Y=F7T]'>9OY\Z@D
MF494W\\"SZ":O0?MRC@Z,HTC>,CHJ9+(O1!,PY%Q1GC/Y.&%51E6H_:_K)AY
M$* H,_ J&YP1>2 \CHHT90G5TWEHOO/$<KNQ.+%\#52:W']59:-O<D;W2\Y&
MOPNQ/(KKE!BB73>.G=#AM(,LH(I 12D7:B*3W@N=T4T24) DY[O[A3C*61Y'
M.<WC*)OCD5KH75L4^X+E_LZF^>AFCISXG90LC)NCP+AV8K\VBJ(OW)-""22R
MZ1.A_84$,S>B@,%4?B;G?&7;OY/__1KD*,HK#'$DNX:7QK&,J@EOFF&;)$DZ
M5BTP5(")Y>LDCCYSPEZBB6L5^^"4B13!9"@YAA/-5'CC2QA=AS) P3_'0?*%
MNFR4(Q@<M<$ZV"B6$1 ,E'"7"%4WZ80WV1*Q/E9[;_9W&8XS0:>Y$B,B)S2)
MKH+IC8DY#*1\(+@+#.!XEP$\Q?O*R19:#+"4X8I!-0[4W/T=L.M8W,81IV \
M&7'2+^9OL,J-23 <4&:WYC+*.$UQ]"EJ(2H&J5I73 ,JJ\/R6PHVT%[R>DKA
MTRQ JH;P^>;FZ6O+IO"V<%Y(_?+$DA0#:-D6>B*##.%$X<);I)IV!K2A1LP5
ML:+^Q7B"UEY64;CTAA6RO<LOAH,3E+'#"PT2V;M#73F.U6%:3($T.0;MR%XD
M< 22)O+P,)%SIAW+?:5D%A((4^<+99A$+FA#6:9!.J',$R*R11N.SX$<P1Q.
M=:YLO.$Q^5E(.%_)=C-/ORA#'"5#DDN5;@\ZER^3BCDC266#,L/ !>%)%[+0
M\W/2>2J.[TD6@WL>1E.]85"10O0.,7<;F#(.<AP=>L&=C8KGR+=1A@S?1V7-
MF(\TE36I1V;S9#F*YT4H\<.OWB5E2I IR02V<WZXOZOGZ4A&TYM;NKLIL>MM
M@]V3^7R8LA?BNX8WM4$$=QP%7@ 7P[L,Z:]*V+-<P52J*S;@X2J)D8B5 PLY
M1 1[<(,P+5F*O$PR50 ;P;<L:P^+7;"*R$/=164H!W11B5A07"%&U10=$93:
M#>(,515@WQ\H*U8REB0 1LZ9%H@FM]8\0"# *)["M7<FCAN,B#K)[Z(R1@0E
MEN$C;ARE*%GSW/H@#*,KLMB)DSB30*BL$8PP3N* (XRN,R(U1*X2:S'$()!L
MB52QU_A*JKM7T772@] 9@[>!F!Z!<TA_#8I3>2#XH,H\YUTJ[2;N=I8?G_LN
MJ6!T3"! C)"B5%)J$P:"C_0I#PAE@^37<FD5^<X-8O\!<4P4L""M,XJ#(7DW
MB<-GQ50C4*0)L8E8$MZ(*R<8$3VQ%HI:HJR!PEV6VUHWSBF!3?.SD0(R<H;)
M93 QQA&H!ND($XG@!=\HC3=P31) F"*F1,@(=@\UW<\P <9!T'/GZL:^]FT*
M6R.TS&7@!E,"I3'&<$.""4[V)H[0#C! 3W&23&!2)=[AA6GL_?G.-/XX_.4M
MU;Q,2'\B4^_P@OZ;%?B40:$H6^\MIL+A8XRPJ:5"(L-^BQB;;&P8'4LJ:;1.
MWM7D59[E!\R\VWIM[.C;LIO5!F<OQ_UQ_"ND94SKP_((#Y5'H$7@&-'8,7;.
M]O=W3<.%MU'I@E S@&ONXD%G&L@;N%[3:%0[OL%*C?-_TL!UJ;1)MV%VWAR?
M[QJG[P^._CA5<PP#L)W2L>/N,IJDAF%'EPFF=BF (B*<&L+IZ=/[%::'4S+5
MI4(FD.%LL?1+,>(/1ZI+O\/]A6\SC=CQ@\CAC.H@\O&\=\[VCG9KH(O&I!5K
MMA+G6$PO@3("7_&%G8.+_5U&X-C'$SD[^GW^D0 W!&U9E,X$?ARBV003,(%_
M3QU4L (/67DZ&F%27OE]Q_ ^=CE/+D%G!/:+G <7E"<'3V\F0K(:_%+QTDC2
M5#F7@?Q%5D9)T"6X4DJ:2&,I /-*C&1]&UI?62IZQJ>WAJEA4@V#G1&2HF1K
M;,YD!2+(.#+I)R%XB*7![3N].'SW[F@_.^G(#>#PZ*#-&9YR?/@_,S]U)Z$4
MSP*ST:]8+(8P%D?"6$YCS11:M5Q*3Q:YNLEC8)=T/=BB0PDJ?+;%J*!I)-EQ
M=G=_$5CF -H(>U409&_,;GL95SB+//CW%Y#+$V,G>UI2^/'1R<GAF[/L0HO$
M^8I7 [C%KBQ70#0P^!WT6H%DB[]*L@%*<3$I,'\7Y@?#%R(/VTIZ2.2*EYK%
M6T)V?RYN!\;E#6;VP"XQ-ICQFS-QV)0"-9HM(]B^ R<(O,L 1$OXY28R%8\R
M\QJGXA.[VT+ Z!Z9C)#.B$S2*6A9W]B7E%OGGI-<@@#%'HJLC<&OTH,EDFGF
M&!)?)YG-IW,)X'\A; UP$U?+N!YQA1U:>X@6%?H*UP)/P<%L=3R>-(3;P P$
M48$%)HU]E,H8!=[0N40](A=.&6:6J6U,[DI'A5,1F*:<C+%Z02D&K$X&T33'
M.TZ8NSJ4%?UU D>"0V27;@RJS2@WG<8"3:<@&6<^+_9>*!9 "U:Z/>G&E!UM
M#"3J:U)6F*6+47AP?K0/TH^6H70QOV']B10L]21<'MEL=H+Z*8C[/]\U^K9)
M->U >%1K(#7_&"M3B[J*QGUV+OYW!'?WSS>-AFVJMK-NY/,"V+DP1)-C9^\
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M$>FQ,R)/X+@6QJ7C&S_:]8;A!J,1'C40@N<DER;]:PC8@BMGA,"#"#&:3./
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MA<T-/]4"A,41XBVH(]M-&#&MMN&&FO]$C=$3TS:A;#)VG7?ZZ'\XX#ZLFQN
M_QT8DP 7&J#)^6VD/>AS**:Q=O%>KU8 OA-":6_K7S: ^Z-K;:3;SF)W[1/N
MGAT:WS;H!Y)H"UL>D'./DW+?&Y#3UU^=?OWLR9>-&\)BG_T)@4.]1YS0YPDE
MM;>A[;.!BOZLQ-!?)C#L3T&1>^04_@,XA8^XJIV3")TP=V!8R%P<Z!$^B"/B
MZ@N!K'SU+'MV]OS/#5@Y"N^?4WB?/,^>?G6_L()'J,Q!T_2@:Y'+>I@8*<XM
M?:21.B(6[L [/7CV5?;TR?/[/-[\*&!W6<"^?IP]?OKTKN%ACL'(C8*1J/T7
M@=KAX\.2/^.%''NUNWDA'S^ZZ6V\[I#?NQ,['"7LL_H4C[.OGSZZ\;R,.ZWM
M=Z*'OEAVOL>]G/"1G>^>,-Q]D>Q\G[NJ?"WJ5,91W(Q =93<]3;H35.ZUTXH
M/7B=>-!(@EIYA(=8 A#-9H?Y@W>A"D;);H<8AD!C>P,FW&P/Y>W'8!:>/?ZD
M="P[Y"V<SOG03[_;5^7E=4HA=$N\!O$V%A_)Y[]VG(CJ@4!)*+PQ/X&HQ <5
M&[=J)VU'6$EZT,(UP#_1>(1L@FD )\RJ1M@H5[4YD__-W;IQLT+^*SR869J
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MMY2MT&$T]P#A//ZZ1]S@Q^ &[T:+%;T5317=R"S.,%2\IM2&XYJ2]"3U-$,
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MQW-8"?B2+TGHSIDF]_&CLT?<QK'B',*#MV_/7YX_S.3'%L$GT@IYC,*RR0S
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M?:=VD"DXG7SK."]X):-0I:=<W$F[8.3W4;B>4'E6]F'TL9GMFD$J+-76,7C
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M>.T;0P#V1MZ[]28Z]'P4(8#I5XY[!PH/+D1RJK4E6.6]0,:P7$OI-.K" /G
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M!\AM\X])MRX>B??]5^!MK_0?12CX-& 8JCV\X-Z UDUD35H7#:>T*YZ(0.=
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M@ KIY=MW1(4DY0-Y1M@T)D4$#=4'M]6( 0SP?_=VB_"/3._RQ*M[Z?,9'X
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MH67$0NFG8'LP=,#V].P8:HH&31H_=Q2AVYQZONXVME4];R@#-G6;*PKYN_8
M!<-$9M@K])U50LE41",SHZZK+E#R3&#S7.":S N0"2RC$!M2=90^-?<C?%^M
MAA5DIS8E%T8&L<6H*4W>C/ ,_@Y0ON<B,/SFS;20N1!'J?RLBLU,!8BUO=#%
M'ELD$6LBI;;B-/6B*Q>:<8/S9'ML(G#/0/6.!_WI?-_$B=%NS1W4YKV9EF:V
MRW%P\J<\LQW11^DN BGU^'3:T+$NOF5"O9[%LE1*>"0S'71X.JV//VFP@V$
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MR-[PUENG<WIUP&[H.9%<2:OC(S43DKBN]'8\.5X82)E:.Z2N.QLJFM3(#6Z
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M+P91S>FW>#9[VED&MW@;R*!!>5HJ/VNL>3,YX1PUEMF.58D"3?) (J0 R4P
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M X@3'L3>"TL3$G%?:N8G9L?40,FI%)&"?0>/3<Q )X>@$.H &T+>A7]SHK8
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M<"Y3'U=+C2_]37UARAN,PM;K\T_7>Q?)/_8&>'-?CJQ8=-2M=<IIIS<A<R3
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M\_C@<\G+LZ(''/#9:#+V4[A;W19XDS2D !+/J\;D%<)6C&I6N:U.3<94_8>
MFE3O&<.);()'(4C.BIT6(C4K,7!MG$255ZC.,(E(FH1R^JFL.,1Q=IP7KJ)M
M9\*7Z@,B)7 AS\X *VJ1"+_"F1/1M+ID(^'1MR2H*A-1NT)H]IE1RIIU$++)
M5,1]T.V7X,FU8("5O5@=K[(1"^_&1(9ZB#M<\_/5.6HDYQL^UV&N%^-9:2,E
ME=XP4Z?(46AUQ5*8H<Z56"HY.N/_0+;8>T=U/RZBB$I]1BC#!@6]&R#8L.0
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MB&[;*J5OV<(@U!)7!!VM[:GDQ"1)]B +LOV0;NV*&AL%IF2-=SV2Q^YEU'#
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M0&@RR<*":TV89[HO;3L_8HU@I&;*\B@'\DA?>/249<@ X&%QZ1&! 'X6A6K
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M<7UNKC=*@GOUGVD^G_WR_U!+ P04    "  [@:I4*G\C:+$1   OO0  $0
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M'06VGN=FDK[DL!,7WRQGZ<_#V82F<U$YN3P9N6*E=Z82S@FFLTDL:@KRM8Q
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MI[%@&M?!C9P/2(:1L^R!WAUT8%%AY:Z%J"1'G3H=MEF]OVTU7X*,.2G/4)3
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M>K#G9'5%\62":55A_K)<!NH#AY1L9,'4;4\>8NT/1O;%HE'HZ;].;9*V /L
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M$65)0O3)3=^$:%"V=F],6]-9:W=Y-3W466.6JP-\0C'4?'Y"X=+IE;C9D%_
M52"M+FK?8E>/XD3ZFY+<0P$R(9U:#VX";U#F]]YXU5Z2>[;/E_X:3\YZGYR\
M)0Q-C?!7W]+'TMYM<#N:TU4![4Y,/*O KU76B^6H0)0Y<LZ2KA>/0KUS-/+
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MY[?ONLRM7GA6FCLK%ZGDXVDUZG">QK1]A_D?N!QQKZ,L9,0Q7KOM8R@0?(K
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M==^UET/_JN\BW1Y5OEKPWN"""%5S\6CDM8G5[!/.O[PH939?7@20A$Y&.F;
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M9YYAM*DP@1:,1=KTE>;@@F505T8ADO<J;7670V>R]C^6H2(T1\/@ ]/A&&)
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MDJ4+N@@G;2IZ=.N3]PSU7#SZV6*!JYK37\<ACB?GMLSJ=?G5]$VU;^;$5_K
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M-=;-UH2Y0(WM_69[/V*-H\@LJV66U0IN9YG-L^%?P.Z"HLS+8NNG"+"XV3J
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MN1F;&*A %9<C!G)+Q%,O$7%GS(]#EH KZ48+-A7+PEC6#BR><@6@8C0FZ_Y
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MA=X>!U>3[(%J(]9L8;E23<[;-%_+WBBT4E"LX??4L)RYRB!D#8Y$[2AF4RW
MYAK-=,T!B[ZH+9')(# I9..H#KQO;T\R&\ 8G[F \RD&4^O5__KWAE_\6E%1
M$"T7X32N01;29$S-8#$BE4Q!9@]M2]K-+5H.-"IMP$(Y(T&*PY.F@[Y=?YD!
M,OV?^YGG?_0W([L'5)3_<\B [_T?1 9R\O]!9/^V%&"0G,R9\^.Y@YWG"[X_
M(?$OCI_\VC&+V0,GA691I6J-+7$"Y9X+'LR497Y6#C.S(,-"^S$';^NWHF:^
M/V<7\7Y<0'"S(&*\E>,&</YT^JY8W66NWCGW]!U6_C_$NLOT7;&&=5F22ZRZ
MR^MZ':#&W*@9=Z!6A\7I<3L1Q(%8"1QSF-T6!#/C+OQ[M+\R?U?T4:'$RYWS
M72Z5K5;G:GJY+'8.&WT__6?O?T*OH,L-@??HY>*_.J8R>^#,U2SY1\8-T)#C
M.0N:L]C[K2S.]B.8%>D'"8#8CZ.BB-A%SF[MG#+ZQ=R?X.1_R74'(MIM#C'7
MS]K,>+\5<*6?S=GM_0X4$WC$YN!$!_\]6OYG;/D>;?F_9OL_G/\3_/H_Y/NO
MOO]1IW_*^)\(Q"=7:V6]M>N)HIA0^<]/% V<<9O%<IWEYU99L%1G5[L\^QFD
M_$MS$JTY!\XB]GY4M)O[K9C-WI_#.',_T'G4BMA$5!!_0/H+R?Z V,@+I>_.
M:F']*!Y'T5D6;)89_?ZLUBY0/YM9+8LU@]4%0@*\_W>/:_W:U)_AY?)L21+X
MN?#WT-\_^'6G]+_+]'_/V_P'3/_5 W+_GV?ZSML?-/][J_F)=<S>Y9SEK%B-
M!?FJ%M'+HJP*<R,ZV-QL^)] [$0!K'46>,+7.4'_CMJ(V].GRCF=U5M]"#:S
MPZZ?0 T<K(5_=K)VX,@N_-V9W<YQ8?B'\\+@KN]_H>U>9/<BNQ?9O<CN178O
MLGN1W8OL7F3W(KL7^1]H/_[!(%#.SYEN3)\W=\<[H]*4RS4_$@U[J !IZNHR
MF4;Y G*I/&A/DZE8JNE1K[,OG<GV#7O.-,@TPC34A)A,+%?5@C%/O/-WBRC2
MU5<%0*:?M*]>-G5U/E?U^R)]?:;_K(WA-+UF,G5%P-C"@]($C$\%8]6H:9WG
M&\!X7$[IC <-[HQUL$$PGM 92SO'APW [!P?T1GSQ1(/QIT]:WR1[XP?!>/?
M-NH"&'<'P/CTABP88+P:C ]2ZT49C#=WYA8%MFHR#1[5>5X3N#P8F\%XE!Z/
MNL!XMLDT?)2TRSBWR[@F-&L=HEQEK:5W_JI)WPSND#[$X<#[?(*A"K5:?P0(
MA=7Y/E>YJ+&EELFTD^:!ME>'MWV R3;$8;/UHS.171CU3U_^FZTCVYVC+Y@!
MF76-?^;'9[\&5[[*9,*_!+SYW8_/<A>;3'>>9C)->.W'9P?]T60:#>1VQ_.[
MT#.^HR^[_/DG6>!F=ACZ0_N7 /]&VV6]F1UT/["GS[WSSP;U=?C&E=5R7>^K
M IL0^OI_KL3_]<1?W\=A44$4=*$$9B2!ELDE"8C[NR_5^N32/Q+B?SGM9VVG
M7H,V]IKMIG'S9YKV?'Z<J?O39TR#QXXT=1]U.7C3]8/< B.2IH[EI:9\L%/O
M!UK7+[$.6MRY5&5I8)XK&N_CZGICY[N.69J&F'I,HTWC3/N:)IL.-,TP]9M0
MD]UTN.D($VFB36%3W)0Q'6/B3'E3T:2;#-/QII--IYL6F7YG^KWI$M,5IFM,
MUYMN-MUFNM-TG^DATU],3YO^:GK)]+IIC>D]T\>F#::O3%NZNKJ&=?5VC>W:
MMVM*U[0NJ OMPKOF=I%=@:YH5Z;KV"ZIJ]15[SJ^ZS==B[J6=%W2=677]5VW
M=MW=]5#7DUTO=+W:M;;KHZ[/N[X=U#UHU*!Q@R8-.G@0/ @?1 SR#XH/.GJ0
M-*@RJ#WHU$'G#+IHT%6#;AQTQZ"'!CT]Z*5!:P9]/.C+;E/WR.[QW0=T]W?C
MW:[N<'>V6^S6NT_L7MA]0?=5W3=WW]/]>/>J[C7=GW1_,WCHX+&#^P;W#SY\
ML&]P8C WN#+XQ,%G#;YD\)\'WS'XT<&K!J\=O&'P]B&]0R8.@8;,&D(-20^1
MAAA#3A]RP9!KAZP8\MB0EX:\-^2KH4.'CA\Z?:A]J&]H9FAAZ'%#SQKZAZ'+
MACXX](6AZX9^.6S8L'V'0</F# L/8X?5AIT^[.)A-PY;.>S%8>\-VSQ\Y/ I
MP]'AGN'9X:7AIPR_8/@-PQ\8_N+P#X9O&;'GB&DC9HT(C^!'M$8L'G'-B'M&
M/#_BO1%;>L;T3.^9TQ/O*?2<W'-1S\T]C_6\T?/%R)$CIXYTC&1&RB-/&GG1
MR%M&/C%R[<AO1NTUZM!1KE%'C:J/.F?4=:,>'/7JJ"]Z>WL/[CVB-]M;ZSVG
M]_K>1WK?ZMV\Q]@]9NY![<'OL6"/2_>X8X\7]_AL](C1TT83HX\9W1Y]P>CE
MHY\?_<F>(_8\>$_7GNR>)^YYZ9YW[_G*GE^.&3L&&1,>4QQSUI@;QCPYYL.]
MANUU\%[D7OQ>I^YU]5Z/[+5N;/?8 \>ZQG)C?S/VFK&/C7UOW-!QT\=1XPKC
M%HV[:=QSXS;LO=?>UKV3>S?WOG3O^_=>,[Y[_,'CJ?'J^,7C;QO_\OAO]YFT
M#[&/L,^9^]R\SXO[?#UA_PE'3! F+)RP;,)+$[[=MV]?<E]EWW/WO7/?-_<;
MO-^A^S'[&?M=OM]C^WVR_[C]#]^?VW_A_K?M_]K$01,/G1B=>-S$JR<^,_'+
M29,G>2=IDRZ>],BD3R:/GWS$Y,+D\R<_,/FC*6.GS)TB3SE_RLHIZ_OV[B/Z
MU+Z+^A[MVW# Q -\!]0/N/* YP[8,G7ZU,344Z8NF_KF@3T'X@>*!YY_X,,'
M;CAHRD'!@XX_:.E!KTT;,0V?EI]VX;3'IWU]\/2#4P>?<?"=!W\X?<)T:GI[
M^M+I;\SHG3%O1F7&53-6'S+T$/P0Y9 _'/+70P<=BAV:/_320Y^'!D$V2(;^
M +UPV)##'(>5#KOJL%?Z1_43_8W^I?UK9XZ?&9AYRLP[9WX&'P1GX7/AQ^'M
M9LRLFJ\QOX[LA=#(*<@]R.?HH2B'7HJNMO1:/)8%EKLL&ZV05;!>;OT;-A8+
M8F=@#V/;;':;;KO9]I'](/NQ]LOLK^#C\ A^%OZ$8XC#Z5C@N,_QS2S;K-JL
MVV;]_?#^PY7#;SC\P]G39PNSKYF];L[4.>R<*^>LF=LW]]BY?YR[9MX!\]AY
M5\U[YX@#C^"/N/:(#XA#B )Q(_&9T^S4G2N<7[MFN4YP/>CN=GO="]W/D7N1
M"?(2\BW/5(_D6>K9X,6\QWD?] WQ^7WG^EZA)E$<=3VU@;;3)]"/^D?Y8_Y+
M_.\$#@WH@7N"@X)T\+S@&Z%IH5+HSK I3(7/"[\9F1ZI1.YEAC(1YE+F_2@2
M/3[Z>&QL;'[LAMA7<6=\<?SUQ(Q$/?%P<G3RJ.3UR:]3[M22U)HTG#XA_71F
MOXR<N2L[+)O,7IO]\DCRR-\?^=Y1V%&G'_7RT=./;A[]Y#'[':,><__\T?/9
M^<N/'7)LZM@;CMW*AMFKV"]S5.ZRW ;.Q5W(?<P?P9_/?R3,$98('XASQ"7B
MA](<Z3SIH_R\_ 7Y3V27?(F\L> K7%'X6@DKURD[U)2ZK#B\>&SQ[M)>):7T
M:'ERN5E^08.TT[4UE5F5WU<VZ'[]VFI7]>CJ7;5Q()EZICZC?EI];6-NX]+&
M9B-I+&^.:9::S[0.;9W9^J#M:?_IN,''<<<]?/P!QY]\_-H3B!.N/+'KQ-R)
M#R\X<,&I"]X[R7O2GT_N.5DY^=E3S*<L.673;U*_N>?42:>>=.JZT[RG+3U]
MC]/UTU\YX_ SKOCMX-_*OWWN3,N9%Y^Y?2&_\*E%YD47+-IZ%G?64V<C9U]T
M]HYSQ'.>6VQ;?/GOAOZN]+N7SYUW[I^7C%G27K+NO.!Y=YS?=_["\S?]?O[O
MG[S >L$5%_9<6+]PS46!B^ZZ^*"+?W?QUDORE[QTJ?/299=-O.S,R[[^ _^'
M%R\_XO*;KYATQ:(KOOVC_,>_7>F]\HZK#K[J@JN'7MVX^OUKDM<\_B?\3]=?
MN]^UBZ[==EWINC5_CO[YT>OMUU]_P\0;%B\=M+2^]*,;C[KQKS>Y;[KKYOZ;
MKUPV?MFB6TRWU&]9?^NQM[Y\F_^VAY?CRV^^?=KMEZT8NV+A'5UWM.[8<&?^
MSC5W9>YZX6[Z[H?O.?R>%??.O/>Z^PZX[]+[][Y_\0,]#YSZP(Z5[95?/J@]
M^,E#TD/K'I[_\.N/I!]9_2CSZ'./^1][XB^>OSSR./'XRB?F/''?D[.>O/LI
M_*D[G[8]?<<SV#,KGL6>7?&<[;D[GK<_?]=?'7^]YX79+SSPXKP7'UKE7O67
MU=3JIU\*O?3"RXF7__;*4:^L^1O_MP]?55_=^%KCM2VOG_3&D#<6OKGGFQ>\
M-?&MJ]X^Y.UE:VQK[E_K7OO,.[%W7E_'K?OXW>J[6]\[]?W>]R_X8,H'UW^(
M?GC?1YZ/_KK^R/7O?:Q]O.63TS\=\^EEG\WX[/:_'_'W9S:D-[RW4=^XX_.S
MOMCWB^LV63<]_&7DR[>^*GZUY>N%F_?=_.=O\&\>_S;U[0=;C*W#MEZT[9!M
M]VSW;W]C1W''CAVOFURF05U=G?_?M>XAW9TV=/#@[B'#AH)P!?KP$2-'#!_>
M,WS8L)[>GIZ1HT ;-F*/T;VC]NB,.T@ZTSNSP/]1PX<-'_4?MQT/FL8,'[1I
M^!W=75--@\9T=8_IVO&H:0K(:89T#;3O$YJN0=V#APP%6^H9"0!6[ FVW]T]
M"&QVR&"0SW2= -Z;!H\9LM<!"#%T+,,.FUH9AYY\[I7##W3>^M#>T1<V'&3)
MZ:>,Z!F_SX1]]YMV\/09AQS:^:D1=\QRN4F/UT?1L7@BF0*)%L<+HI27"]5:
MO6$T6^W?G'K:Z6?\]LR%2\X[__<77'C1Q9=<=?4U?[KVNC]??\-MRV]?<<>=
M=]U]S\.///K87QY_XLFG7ERU^J677_G;JZ^M?6?=N^^]_\&''ZW?^/D7F[[\
MZNO-WWS;H:O+U-WU??M5NL8 N@8!&0P>UJ&K:Y#1 1@S>,@!R-"]"&886QD[
M%3UY^#CGN5?>^M"( RW1#7OG]!=ZQA]D73MM8X>T <K^/<).^:\H^X&P'^EZ
MS32JNPL(KWN,:9YIV]:K%LXP[>Z[^^Z^N^_NN_ONOKOO[KO[[KZ[[^Z[^_]_
M^NGOKX>@UL&7N$^?L'KYO;<DR$G4]).&]+Z>[/GTU;',48M/W7[X9NCQMPZY
MT/77XS-KWU22IX^=?<<%^YV:0A^;<(#?[,$?ZJNNGT/67SI[(GGH"^__:=JT
M%:O"G\]")F0WMS[/];WSZ7'65<M??753SXRK[G \O'#&'P?M[KO[/^S0>9M?
MVG@>L;E[PZKXQM1O/WO@Z6OERF?'WH6&/CAMH=GWQB>:Z>MW3QHQX95EH;,=
MR1M7<^->+[N7O+G\ZI&GW73F31/G3IX9NY0^!+KC]=LH0WUW@;+#]-H'C[Q]
MV^A'DB^O6+SIV>@7M6SRXOT_O6#[L997-G-'G?*<UW02^EA\NW?["SM,=\"+
M%Q3FZ$<N'JNDIKSZEOBA]5(126?/>9U[;L+BO]O>__K3^,H"_%KLF&TWG-@_
MOWG=4=Q^3QQ_Z?[3]!?DEQ_\P[G35QVT_-A2[O%N?-('6\<:7Z7FK1C]Z6BI
M=]N]U-H%O9^NKC>@S^D_;E__QA69B=R4-S+#/YK_U'W,8Z^>,5X\]ZG/7U[G
MB;YW5OVH-]^;-_..-MF_K+&@N<%^QMU>T[NQYZL779]C)[>>?/7SQFF'?WG_
MU?4;K_EZQ;E?E[?N5?XJ/J5K>_?T,^M'QJ:<>5_I3*.O\L5KKWYY"IQ[\.()
MFKY^]"'S4]$A/7=-[/+/7Y69''9!#[[X(+M] M1^X*9O[FQL"[\3FO'.8<GC
M+DD^6UG\]M*#/WVA_^J]W]N;O^]W#+GWQY.',^0XT^[^?T,_H+CTO ?'F58\
MN36S^;VU4T[.[O/5A8ON(Z_-VVX<$;[]Z2U/;ESMG?#T$Q[O\!'+?K?#5-QA
MV@S==,4C3R]Z?N36F4M6I5Z^LG_OY^Y:XY?$1TXY8$I#FO*6XZP%=SXQY;++
M9V\^[>;C(QOG_&7%._W9':;L2Z7%?R_=_#[ZQ(.U?>>,:W2;]KAHV>/->Q_[
M9/R1]M.>SBU-9.T+*O,2-UZQY+;M7VZ:=]5]<[^=\W[K67S=\HMGS]FW<'7Y
M+<I8_N*(3?J]VS^]\?D7WEZT8,-1\X9_.)8JKWF[9_U;4^M/[)-:-7*X9?T-
MW?>._OJ4*1\<L\\[RS;WG_'8V6)RO\:E:[9-GKCU\J//7^X;-BGSWJ'';6)>
MV;AL<7[98Y;18^]:O ]TG^N43P=?=>&S,\OW+__VR!D;O+_1]F32&+/#A'G>
M?_O)!^;?,^/;)?#FP^Q_>?3N)>%/C^Y].="U[XNYUR?/09Z?^^[VO?_6M&\?
M>?+&*=3O/7>N?7[$Q^9S'@A4LX$%:XY\<\'&IS;?O/"+#RM?CXE>:*V<]\T#
MPM>'7_WR8TWFH2_7/CG[GB7SWUP,;5DG;;YBZ;RA*]?</J]W]G&5WF5GWEA?
M,.1HZN3WGUE97#YXXV(4N>^$P+%[O)MZ:?M>&R\X;]VVH;U'NEZR;N,"]^R[
M</U3]<L/F7O6-8LW+/O@K7N7G;S@]L5GSY-&C[WY^K63](_]Y_[6\OH')]ST
MMTT7'/CYRM5GG?/H9&53:/+&Y?O3A<O+P?CB+TC]R=;K:T]<=.'JK6<L>N"L
M;\2IERW5ODQY3CC ]MZP]Y[=^/A+=W\[Y;YXZIF5M_Q]Z[BK'UFPHNVZ<OVM
M#ZU]>^*A_-\NW&'RKM;09]5G=-]#!UN^Z/KK+8,77[OTV_UG/&=N7;X??M^H
MU6N^O7GQ\B.OO=?RS;#?X@;R)'+;TU_0H3_X-AV'O7#M[?*FPH<SKEJXZ?EQ
MX&KZ1_WZFY3QET]\X;,5([=<I'ZBLL<M6G3F90=I?_GC<LO8!TV#J&6/+]X\
M8\&G]QM;CCK>O\5VZ;3'5IY2.V1?Z[WBM!-7;]MO/;G]"WW<E'NNF[C7JU\N
MVPP-^W3C#M/(Z:E[-G-K]W]F\X+@I:45QXW<>L_Y'S9/]GT\3D7#&_%)YX_?
M7%IYT=;DNK_?O+IEFP^_26[Y?'[!?]7V3^:_M77)RJ\^..F!<0O$%Q:/>?^O
MV[:^\MD[VQ^=_]H)UTV[\_/'G[W]BE']E4,?W^_V)3[G#7]^(WWY2:-C\V]?
MN2&\[-7* F'QJQ^$5\V\,K%Q\JUG>S/:T/<N/C\W\5OW7?.#KS^QY:4-R[;N
MM<]7B7D3MMOL9]>/7&!YY*WAYPJGSGJOM.QY!-ZV?(<I?<+PQ<M3Z[\\8=@I
M6Z%//O+/?K1?:*[:M"7ZS?W[+#EAW\_G43-G?_72VD<F4,?=<OOZUV^\_)8S
MMMUSA>4C8_*M("];>?R\\YW_KT?^W?U_K:]T+%AS_=L;&/^B-[W1S?/7'/GW
M0U_L??FMOM5K%EQB?/C5N;=\>/4UI^JAV$G[&R],V1!;_-K+X5?/6'/XD1_9
M)X<7S4X?\WA0F#?GAJXM'Y_\V<*GQGUEN)X8NG+2FZ]Y#WMT.?+D09\'3QS]
MS@<35S^\[)/ J)L<T.HE;TZ_/75I=B4T\\;M?_YV[N;Y_DGPEY=:S\#P>Z.+
MLC3UL>V>/]]_X+9WWW[5E;]JX79EWNV[[G;$IFV>==[5!]R[_'+ER*7R^+1X
MVC.Z>[V^;UH?CO>=0YYXRX*'T!VF\I?;_K35.GO:.Y>>.G]2?D-IK&V<$H$G
M%\ZYO'"*?=F"!_ W]OD\=\<#DYL[3,G-J75GPX^V)[W^M_6OS7GXS2,#*Q]^
MJCWF3=\3?1N(OG?WVS)YY#M;/<0YB;5&*!N:\\J"C?VKOE%?_>;M,X^9O&;S
M<NB"\3<P-^U_3_7C?1L+WKS@Q?G8#=Y-0TAMWO)YCY]]^%>_WWS(E<U'@LQ>
MZ[7<^V\WULG:=>JM4[Y.3QQ[ULVK3K[D[TNWA$<N_-.95T\DAST[XJ!5GUUR
MC_3-TG,>?.6A=PHL@E2N#X70<&W5\OD'CV/(VL0KR7&1KI_W^7OO,#V4F%>^
M8G/L\BEW;3;60L\TER5_L]\?WH"_D,=_9KE]S(ORN(UO1CY;_Y3R$F#-\Z]G
M'__JB,W9%X_$[G_[+.Q/^=L737<,;^]_YK#Y_7/FG7G+ ]><:&^>]ZBQW;QQ
MR&<WW7#T\R=<7XC=_^Q+SSR3I=[5,Q<OUBEL\[*%EYWP94]XQH/^KU<=LV5^
M#KYJ^Z8+WUCQYK4K_W3?L U7;\G>USS#=L:6.?8M=ZW\IH6]]/6I\Y^*KN)7
M79T]9LR&:Z]<MW+<1]_./$^9]OYU2X^:]J<;QYQU^VV'#XG,VVON[R^=?\*"
MA\;O, GS/[WIQ"WO7'MK\=*C#WO@BBN7GC-91ZSKMCUV>->'_I7U91]LWWOM
MMW<_)_F[_/+A3WZU\,UMKQN-H\,?AV:]\]1$^Y+DLTO7OW/3WEM7M3WS3KSY
M==+^URW'?979=L6F':97SUO3.&/MR"DSJ<.F?@'?O.>"Q]];]<5A#]S5__ '
MO[O26]A$SUCVV6&3QU\P_E3SZKVO'+SDZ"5)[S>_N8C[>%T%0RZZOAJ_?OHA
M]I?N;&S?<-5"Z(_K@,\\:7?_OZ'?G%JW8/&\M8FM^VV<?Z;GS=?V.+=^XDF;
MI',.%J8L,LW;[ZG[\\QUAZZP+2Q^VY]Y8)_1L3'9"6WZ\_.H]IW"YBO.O6)#
M].W%^O&M;3<>3QP4N]AZ1>\3M> <XAOGPX_ZUMWZ-GS1JY_=>\*0YA!J]N='
MAS[W/7O0$D1J''[QF>\N.>[]JY>M.>MU9.GBOR3^\O+F&Z@GM[[UUB+AW05+
M6WN$78<\G1?N$CZ+GI6[[Y.;%B2_/%$%&=$7SZ=_GB-M6;Y]^)D;UP='OF/_
M[=Q);X6WG['LB'IPSH0-%R*F@Q*3EXV?L.6(>5-6]6R%MBU^X( ['U[YVN('
MVQ^>]]0YSV?O])\^Z8_G/AK=87K7WMZV>MGZYX=\T<K=EF$//?P>]+8=IE$K
MYB^V/[&]]UM*VVJ>38UZ>,EMCQ+V[?AQRW:8IKU7?NX3L/ZVD[:W?L'2-2OE
MT:_M0VR[Z,2QZR=#&P>OO&O%Y*-7W'97IOS9\,,/6+SMVH<<V_<>]?A)RO4;
M+SSK]I5G/#!N-?9LX?-)\Z@7URB7+OT_[+P'5%/KMC:\%!4%%:6*"E&Z5)6J
ME-@0$!$! 0$A*B "0D1!6D@4!*0+2+$1 1&0$NF=T)L@G=!)Z)V$$@)I_W+O
M;^^[S][GG'ON]XW[W?O__QUCO0S>$7C76^9\YO/,-5>";O"*&$3YT)]/1@'-
M*I@&V% JN;$7^@@2<A;&V.ZN/:KCH6"Q!SJ?+/[VCNN:395,^'/)R:5F"L<A
ME<'8B[[TD8^>(Q>?K8A/8OF^X!PW(O8AY#'U;]$K\.,R8A]UW)?V8J?C3,DF
M90,:'!,SC7K>Y'!*2KH'ILY4T);\J5_[-5JRZ^3FR5#!5Y_H.B(?HG0F'B9A
MP\\<"2X.SLTROV$8[514!G_6OF[-ZI?\,G&_TE')T[X&P>8BL4%R5]S0+)4<
M\VB(AO2LU>'...7!D:XJD:$2IPEJU[5::MJ+>.HIS# 3\$<?<,7XH0^ZPMEG
MO]'1NAU+AGV[H9[/YUN]\\Y(ZS^IPS6BB5=A T:,0VC DG:]=XD\GR!VM:#+
M&!<O'1,P=^XXOR48Y.XK"@<J;HJB;GEHUF '!N#D,#?J(-FQ!6*+&AKC6IU:
M1.VCGU19H<+.,1IK6M9/9Z4ZI1C90ZGN!$NT\E4P]B#+4>K^W 87=O]/^_]'
M\X#3N&/)NAS]J'&NFB&S3.%0)E"Z>5B*HX[+:LI*F GL%NR:[H/>A[QZ75/V
M46'JPP94^JF6L"MDQ(CAB>$(PM C0@S&!FXQ@2ZS=1KG>'$(,%-4E(+2M^<B
M70V6P.#7Z 9_#V5%?)\5?!0->RL2YB?%XOOYR5[,K*HVEM';Y>1<Z(EZ&"0Z
M]&%I>$<#ZB@#L9@YV0,_6>2/:$YU.2JKU5J'/^BSL'VP6YI/MSMKZ4V>3+DN
M9^S\I>?G,+/P'5N8L"4J%CL&C43&W(G]SC=(WQRA)M5S&\ Z&E?_)JUER#M8
MHK9#%\8"TBHSD"^A*%<?P35X*!I$U$/+QBE*P#8?$XBXW8]J3(JD/=H[ZBWW
MO?<]_$5=N:9_\VG.QOL)(5=*6RR%*E"[W3NV?[#C:>Z<T_FKY6Q]YBV6)WG*
MT5&SI66B&6IP!EL8U9L)U%Z@9.OOHABNN?OF@[?KDA6"QYF7&&VNC7(+3RXV
MRC4-1$3,)F&#\Q;7>-Y/V(4WJ+; GEAR+L;1^#+LMHUKRL^\(-!R$TSC&CI\
MQS+19CH;3BNKUYI%>.91.8V+8YY4(QJBLUR*XZU@@L62U^<Y)B#;%_G:!IYA
M(\0$\A>&%*=BMI>8P*[/]!@L <W8D5WQU<+32HR4ICOT?&%M</#Y]4/4XV>>
MS3[!0XJE9A'J!/>$!QW)BM0T[^YUF!UCU,N]8.SR).+.1$HM_^[K>N+4[80I
M1?IT0=QGW@J,S:;&^TX%"_W]LX5>SF@X3THX>J>%Q<5#-9<Y)8PU!9[?!+:-
M2R4P2T?J-9]D1:P],'SS>4K\64VPQ%>1?R;W_Z?]?ZM)?:3DX6\SQ&DR)/&
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M8X'BRZ"\&A#+6HY0&5>XH/W7"Z^_L_5;3=#?WML)I<Z+B>.RD"'(IC&B@5P
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MH<OID?2G\+X?+:*^>ZV/&4IT[#9F^08 &C'45#\UJ272V1\Y[".IG]6F>IG
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M$4*3^,L(WK<$V]#MN%^D(ZQ#CJ9*Q4?0.;$[0:68)$=,9@C0B5J,(-@+%-&
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MHR[4(W'(:FS>?F@N9G$S93:J'D)F)(9=-H_QE'N"MY6G]^,<]C]^%ELE[4@
M]1!N,8,)L%N,TRK5>Y<0;:S542P/!)X4F;_@OU&!2-&PNW^D'A<)^VI,%\=C
MV:B2G#]([*,?)S@DZ.F(P=Q5_61H*#+JCN=&Z'45ZWURSSZFFHS8X,H@5#>-
M!V4%?2<UN4U7Q%?3_N:MUE8L\39F2PM2!Z?^/^R]=UA3:_8O'D5%44 %!*1$
M!4%$X$A56D2DB1B1CD)41)HTZ1H2%1&D"@@(")$FG4CO1+J B/0F)!2I 1)*
M"*3=S3EWYNN94V?NS/SFWM\\C_N/S?.8O??[KK4^G[7>59X#1N)S=VT\.@Z)
M*X"MA$$"L1NL#%!/8KJAUP7$T>\/)[I_=JSWB[S:?RC':OLZCPR%<!5CGV#V
M56M,LEI@)F#C(_N<TZ^Y=..O&\LQ0'8C+"J#)JLM1)L)SSQBQH13U43' V>(
M,7$W/K;LC$R)V8B2H:<1CY' JQW#F&L0' 8F.%*/W0.7(I ^.Y8)BE<[:E+%
MD>UYI?)"[%IQ?0'5>S"B -8/OW&O>#56^K. ^+$_\J^ ?Q04?=\ZP%\<^Q@@
M6PN1EF;8(9%J M9OZ6FGU>V]^S/MB>ML#]BC]K.%J'GR/WZ;\^K;[72W">0!
M;P,C8FD)6T+*7.7SO,RO_!H.UDX;')>10Y=VA^/$9\.?0PC:SN%(CCO/;^-*
MOTB(-(OTHT\4B:&6+^F\1F*Y*'($$Y(7 8)?&.]*)XLW*$(#\CS]7XZH4Q9"
MW*7;W(1#E_!ZGM%168,8FZ_4EP0LE6^1*+UR;#@CI)H](U*F=#0___(:;EI8
ML*(.$N9@0C\^2XRE<4(/ +@&H,,D+,?0D*)I<@)R<CV<K- P<88%641UQ>6\
M&WDI>62:/:'G6RAY@R;N3_2B'FR?+'O>%9J(]H=?,#EWY&CY12RT6-C"EP@K
M-C0@A9P_1-Y!W$_?-TK$C+^,*'%^;GGZ;+.VSQE'9+'0%8^3>9^"F&M=+2&9
M=F5'5=9BRF)6S4<O>K9R?K2*8$\V^(B>0U2@ [%[J">)R*L4J:!JF;?D,*R=
MD=[E>O%$/UKB_.6D39YC/49*4?A.@,K]"#/H(10  NHH/Q2'50R2-;\ IZ)6
M:)0KR=J1;#6:_+J@I5"1A8PB 8#[5)1J298NXZX%/^^<V!/!9JH:_7HY6LNS
M%/D:1;ICQRYGGW*WO!CN^R,-,4ITN%1-&,MQO9UI;F&WT1]FE30V+1)D>M/#
MV!CT5&5OA_%F37;K[Q)%S'4D+@A#@#X9SSL],@D..8.<N(WD98">W?GL/CU\
M!#?V$AG:? D1J.M6<YGL3#W<0]_GZTO1\8YL;[&4+XSO'%]*D&YW=I3F0A[2
MSCC."=[T8E[&$!_D4*^@"HQ)Q*$Z_A^:(]0//[ND,9R9^A@D  +(<(ILR,/"
MRW\Y\%05W\9N>ETLN+BEX92RX[B#2 4QPP]WBT24M.Z[_\ L17],N]7FPOG[
ME2$Q^C ^@+X!_P.7'HGX.';<>0^Y9KJ<[)M[<WG5Q5)OC^<'Z>QUVX30V?,\
M7ZN73&AOT$^1N%0(04L7%E;Y+GD2$&*K;O@-=W-?=>WH9_(/J]:E-4>/QU7-
M3#UX<%G@T["F[KTKJ7E=/<@Z-> 9* 4(07_4I*[V#"$\% YQ2!N<*]3@_!3J
MQC6A/=ZO/2;S5#&\866C<S"#Y%5!>X6Y!SW@O6?5(,"TXHM&9YS7 9%3WV0L
M]%SK([5'IA>G5LN4;9B(Z'&;15%B WU?PZ1#'MN8'JS!J7"Y\HM'@L')Z#KF
MW8W.S7S@A1.G37>L'@K:&AF?H?++Y]R*(!>-9SFDZU=.ZO2=Y0\8%CL8S0!A
M0@=&(IJ-"T_J6,[,12/<Z;U8PL4%5#!,8'V9TUNAR5PJ0#;4$UF&M+EIKHVU
M3MR,O:T>ZK_RX9;C:+'+;H4F,,$%^WP1GZ8HU>#X8&42?*RF=Z+TRF36J4A!
M=J?)[EHS6BH&E\L \4+LW1WW?)Y3EDB=/W#KJ$U ]Z4D@L).A5@1D\\N1BPY
M-M&RFM+JKR+68A=' <9UII:\CW"T$[<1 +_M/,$ !1),6:4:DTZ_-^ W?J+9
M8JB4H'"E6BD''EI.1:]D) +;"7AFMQ;009!#>0AQ[YAF;>K9\;B-V:S3M^R]
M/GI'N/6?@Y[GY]WY^&H+)P!:! WD8?BUOC-P7:)Y_T*#*D]HOV$7[*R]^6O^
MQ9<>92%KYQN?W07%L<-R!;D(^0DX).O@[)9*:'Y"NMW[O)J\O.H[Y_(F]?V-
M]#^ ],6$<Y]%.>$!AB N<^'O:9:YN0G(+$"X6Y?@1@!EC:<P0)HE/@#&6&*
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M&KR@$M_C&CX5S48!G]Y[_' NW5O/;-/3H4/%)%XE2;"SP$?26DNV3LDP77C
M9A0B)OZN\EWG3'17ZH/<=+.K>X5>VI60F*E<#20UP+*($6]Y3VJ4K%!E)L6&
M,@QOG@S=W)VH$G/A0/"2, ^(A4S'!+CA8P^]FIR_=1;"*4@[.CL098Z:6V9Q
ME>> M&5.#RHL]9J4F;;;:6PVC?HL%=\&O)$PWX-__:3Y@.T!W@!^^%<0FFK!
M"[&6-H'50B *Q\>A1^V@B^B^E)/7&*!"JX4.A,F "4%W@EY X)A("I[H8(-)
MZ7<M[6I+&Q=5;VC$XBN/&. =%LA"0:?OFJ6==2 [C\8O<V,ZG&HDBFQF:D4(
M<I*G/\[?$H@VI?1^&W:PGI/RWU1:BJ!,:CQ [:)+V8$%:X_,UDI\^;8J2[/_
M>B5;6X)IS3L!W!C""RV7ZQL@U;"L+1B$VE\E1NK)%4$-Z3:;J4'U?0W&28+5
M-VWV3 IOZ"G)4K?SRTO/_T6\]NB<:.!3*LS.;#][#O0PG@IHP=.WB+%0B@:Y
MB2HP_@C8L&?@BV\VHS2QDD4NU3[/-EZP760+B)WY-H*'$(R1(\L4P?[5<:B?
M,[)[Q@ <N)SLO+X7^:V#?>,U,E?HK=+YD_7T!R:K <'\OHO6VTWG*HNS3O8!
MIL W=GAI;7:9%H%C]Q>L_V$B9$R0&CW;E!?% ,6&>B&M"C?*[+>'_3T!]_^U
MG,V: H$?Z66 ;)$AYNQ^:Q&E"V85AZK+VT8NJ=I9.]^]T+$<XB%'221@QTFQ
MA(P/YEK/UVYXE':OZ1H6EZD-V(?<W2KBCWP4"7VXR4[?.[J=BEU?1K9Q(_*9
ME@[E>E="1/785!T>@3XLD59O[F& / Z&5SLL!@&[&>Z/+'J 10_ :M VT\DD
MD\X)I&0+ =+-' XI=4/C<\^@U5F&>^P,*5#Z*-DD/LH<X"WBZT6;U%_8Q_\H
ME^#38M^GV++K>N*\)^."JP1S&Z>BKFS69 T<63&_J<,9U-7*Q^EQ^VF:B]H[
MZEA?_^\'*O[G!HS!$*YV( 8:,>\'ZD>"97B?0]AOF)?%7%7^:-(:53$#=T3!
MUV954C!22%P K$PU8=Q6A*PT$3R([U^9RZ?*N2DMAJ:_#)?N%/4_@U5DG[CW
MTL;U O):3OSE3\.2LW^;B/&OO/Y569[T)T@<"K-R%\*"P9L6;.?36-990@ F
M0P,PZ#@9(*YWFL+I+\Q)+%,*8=M%$W\O#?[KA6Y?)DLH4#G*Y[A-D+S*W%8)
M-P)&)X)Y.&BZ2;OG,^E'E'5F&R''*F"]1]'9=IY;TPFNUC[.K'V)4WJ["%>>
M3,;+[S8S@^[^L8JQ3]/XCOW,JL9/R3V]2((A=)!M@21#+J$EIS;(CH&(LFB1
M:,B9,R>_Q7=TWLS\MH_2.F]$7)GI6+38][7AUN_5\W\7FANC=X"+30*1ULB0
M>&BHLH)\^Z@<J</I$SR!XMD2M\NO\AS8Z+CI[5>'UD2IG MT%B_1Q3C!B'',
M_A;?-&^1ME-HJ6.H_?+)#Z\=%FZA%CV+S%:4V>.&BG)NP?[([R6-'H4M]?^L
MSXC?'Y><Y@>/B]8G>DW&-H:"ZQ%'"Z*N]9>T/W%V9%EKG:H"CVM<,WM-R$Y+
MVGU,A8_$00OU0(^83/JB ^[#%_38VAW[*[)V;]YW+/HBF.2 RY9RB]HP"J2-
MDYT)"YID+9R*:(.JX':/'_<;'B7%9>%IMK4967<>Z IN3RC6 [@HWH0B9 LK
M0-6)@_?/B0LT)XM(ROEJW1/N=0K<\69CK^J\%"%S29=C(;I3[.;P6<#UX#KY
MJQ-B_QL&_O]G&/C'$D-L.')W<?@PW[A(R;B '?)+2> !A]/YEOWZJUK2R.(0
M)K86'N7#XH29B8WZ&BM<>&.-57WE&MBF3_;&\[+7[%7'Y@O%EL+2S: N'P:6
MF^"Z +SXTUXBQ^_"56$OS 7R%YWK"?B^Z[*;Z#-NB3-,,<\BW6CU0Y2W)I-T
M"4(X*8R9HGL \TC#8>S:*-J4JMNVX!D^ZPR0X4#8X!":)"EMW#!A7D(*U8M:
M2XI P-&7XC8? 9*R$D>;^KYYC"\@4[O\:>\AX_K4*\X!PXMCG6SDRMLD[HC:
M[5(X_=8/9IH'&:!BH;D8N:UD6*>LC%QUCO#]KE;> [D9N[6G#CZZ@[D+^!%O
MP"7=]#[DSF1Z5[D)T>OY4S,'%F@'A+FMHB7MR=6'\'GJCB#Z2X)S,"U=(>).
M^K+F4H*O\1)$8B!Z2QC)YRM4K4*2,^'$62U][LJ-U7'D98!&L >J-RU7;+[T
MZFL@R,A3/RH<?#OF<(I6=9P6H[Q[>^";$'G9\AGMY0$%TEW18U_+YY+V:JB8
M<GR\SIZ.& 27. 53A.#"%<0]Z:4+U\NW'<X]PQL;/+A')P@656QQ)]6H9N14
MHI(YN75RT:!Q[$0-8(7D[$(&.!28OIP."PKZ(3OU,>>.;LQQHGJXL8$Z18E)
MBO0BSYQRR!?92.^T1CLP0&ID\+AN)]'AW*=Q>JO.+(I:'3\WLY>6OSPZ,%8J
ML8@?CIX:X.;0=75U610N_-B4I"EZ\J<AH%-1U[HTD&+R(U60FNLZ9G^ME:CQ
M(@G1XO(A]NAA)AW"="ND8-RY=(%#1"O*]ADWKP!OZ]Z,HG,J.] GT(/LY).H
M[22I PL4U89L>^,Q6)#R78YK-6.JCVS/4@)5WN=:/)F2#6$?Y=I($B 4?5ZU
M[<[$>$#'4"G#$-)J3_=R\J9-,-6]W.I8XD/)OGG**\J[_D(&J.Q(346%P=<M
M@RL]CFL6BF.?NWD6\QQ/;)?NLT2<>,QER/88!!)\FJNO@;1I%A,7HHZ\>I,X
M-J[!:7#P/UQW(6]0PWSU>3A8^-BY+EYX:1=5#7G7T'-E21AJ,#>//#H%_-"6
M%9UEG=!*/XH8HTNKPF(=)ICVE-QW#9VPC?T$V=BT%B2CX^@_DA.EGV'>;].W
M_9QYN[)G/X6%\)I=Y=6>55M'?UD>=*#O]\_T9FOK; !SIU0/R'XL;6 .S&N)
M\W6J81X68H!BVLYM#FR\9CYQT6'U)ZZ:?BJCO*> )@@_21X9!X?1>2VLZL9.
M=,,U,OCWQ+2Y'G\6\;)0:BRT@"K)Q'YYWF&SB,#>&'X0?IK(K]CRW"//0*WO
M."76F%O*^10O,]^KIX:XNX+L+@YXJ2=@@D5X$);MR'X8MYDM7;EGLKXX2G30
M.2CLAY.!]Y6];%]'8?-=W;'J&G*]M*"46ADRX!OO;B/+$ ]9!32RYI,%UQ^S
MDBCJ;@[E)+-;8ZY+LT]KWY(=B"-U,-X\Y>5]Y**&VA-Z58$]ZWOS!9@IEW/-
MH 6@WG,E%5Y:9AJ<U__E(T;_W0',2>R'9;(D=U M,U60,."W"&<=IRPXL]I]
MF>NZJ>LEW2K=G*S^ _].U^%*-#D0U@Q;NTJ5 9SX(L ;=EN1,1)&Y.G#7F&(
M!S$AF-E$L@T#Q&2SG1<^<1S)B^Q2(G32]W32.2MX-B.V2C00UQF@QHMT:08H
MQ6L<165%;2>$!_I3K1F@2\L-$#(?A*S_L2$.G&-H\DV*>DEJ4FI+% $8UP]#
M@*<6_K>/YP\Y_W_[CXHO+0\RD3)Z(?>=A\9&FN-CHFQ2+?1\76T=\]+LA';*
M@_C+SI]/;GI['6HU\D>.#YO"Y,8'-#N]&[FO)'P/.7Y@4=$2?:2^O3&FF^VZ
M;2>A4GZOZN#Y77YD48HQ_5/2,5H$778^B95XP#J]1-4C>CA_L(3/6+0]425A
MUZ&HDNA7*^\PR?.;&W06<0J;';:TL\[NC-6-1S >V]M+LGP;..%GK%_.;_<3
M=00Q0.[^3IZXKR>WFY$0W'Z:#T,_0WB7CH-QS!^5+[!V?3=?:=$P/#K\N>KN
M4\.39J8/G[)>VZS)>=OX)U(U_XX;TQ2[;X8:-EZWLK.E39,>LYO3DK=KB  B
MJF)"TB>[,4#[8$%G>N%J1+GRU>L:NXL=#)X?:>C6'$_;8,'4ZVPNT/=6 0QC
MF0%Z%J5?1&Z9U 638X=:,0U'##*H\"L98,=;2/^])Y37;V/(AJC>H.:T2B'M
MEDR <4>\_4U"^"O13]HQ= <#1#X70+_4Z8]9W\QD@&:/K.M_C;N/L/@9LMSY
MW>K>OZ78FW$ $_^">6]#Y90RH_DAQT_3/Q*68M'(>B,25&'1K1JA-42E57FN
M=R8-=6YH7(GN"PJ;6=[-M0G0N4/[R>WT%]CG2((\DI!*/\%-C*5Q8+;S2@&
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M+2%O)DK;!0\&R XTJ^>CP37PI,6X;N)X4$-[C(M=QC0F[]$;WG=FSS^Y>/S
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MN<@@Z@ZRVG9R +F+H))JP3S!'7BT7WEW<:_(4?_WL*7 &39.9)7?,LR(RL,
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M_*.T&V+*[4J1Y3=&;*;/:_6Z7)AM:RCQ640>ND,H<2G)"$ +FC45]\SVAS!
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M4#MJU1Y A-FVG3X+P!DL @AAJN,"Z3+F#+!T8UA_F5&J&G$C3#@D+^\YZDC
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M#4Y]LU=_1 W^S(6$0 C7()LJG4$8D@P,.=N//@:LS !@[=\B5QZAN)#X>[6
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MZ/L D=\%2/=S&@/TK(4N+D6^M)WI1.&FUB.P)'2Q;RH]0:/(.8+>[T5J@<@
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M.$DK*+:&K])Q/>RG4EXA<N><P/ARWT+^J0\M7Q/TL[=+>;=TQY%C.O-3G7
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M*VG8 =0(8=ET0.$7;3*-]KFAWVX=5S[-M/-QY;*BU@W*'C7MBW^$FO9?2_0
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M3 ?&N]D\27S5?$?-_8&SRH6C:?L8SG"1X.0J&"9\C)\H)##[HH93S7\2?;C
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M_YOK-V+KE<Z\C_,'7[<HB;'<C+F<<>&PHD'&.GG"J"G335:ED*C[(^,\AV@
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M'*%=G_Y)Q9NV0SOV2*=^UD4( PPSUC)1'07C]5.6-,[=1_!AS>ASH0),9SI
MJYWI'33@\)X*.*;$X16(%8H4]9.?\#^W9=)7PKZ&*2F)=D-F"Z5D+1B&ZN[U
M^O<O TFG-"F'OV;20BS&Q/N]0_WWB<\*KI^DK%UZNW1NHJ;ML.)]B8-P0/G^
MS_D^5,#2ZNYYK_T$?1S6IH8>MYP14P2XZ!AE45G%5Q5[Q;1\ZN@R)^;(AFWK
MO9K@5Y$T>)!U_O?8["-AM<K0_7;PXO&E\,G5_42'//.^$E0A.0DA<$E9(7=
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MZ>^B/_$D;")"@)^ 3='A8DP$\7H(ZU?6)H7RE:7VR,K $4VEAN::)9WJIVO
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MW?GFGOKJ-;+H_)^<[ON?\3\W]K\B3N,#-8GTN'@3O,>G\3DY@<+W&<OYSE2
MQ]775(#W2 Z3!RO1'']O4B\;'SUYI6@RTM:IV#9ANGM4NWXE6Y%5S4*W[MG
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M]@:EJ78'&N7_K=81;"@)?M-J_G__\M/:JIYP3@<!:3HR?.9L2Y>I=@WFY5L
MYLP(@/7G5BG=:^LEJ6BM?GN_@B(*?Q+31;7\#=2_@4'8^@[_V"GHIYW!/2^7
M%I"2'1F!]HJ?V%QY1,\+N#48VH,T-W4Q-W\O&FB5\._ O.2B5+[N'D-6;VE5
M+B;7:HQOY&?R7_/RXJ5:S)]$^7'^1(K9)*&4IB1G,,*<0!1*#'$J!<SS.$LS
MEB01X29??:>4L7WV2^W ;XU^AM][-Y+='[PS?#Q_\>;0&'_J1J9W?>OJ 1O?
MN?KI[3?>+6&0C]S(R.57;G:QW6>^9(ZKV5>UIIV7KWI]>C6[+>=,5-4DSC*1
M2QK"*(W5[!YB FD>9% Y#%F(XS0+0J/OO%O,V#YTK1PH9N"Y4<]N6C^ I-G$
M?CH^GC_TE8)G8(E2J^09^*6<=X!E/<=W8^%TEC\@:M!YOMO<MS/]D:OM2$!\
M4Z_FQ7RJ_CXOR:+X*L[+4HVZT/M<5S.F6.:3&MJ?E<[G#Z6H?SW!*9(<"P9#
M2C!$!,>0HCR"*>)9&O(LP"(WH88^PL=&& I^62PJH#S=7W^\^Q$HI14QLX),
MB_^N-[G,**37.'03BV]T??L5FYJ##=7/0*,\^%ZK_P/0!H"5!1[AYNWV;SVL
M[P;[EA8C@%^:P6\\!YR"7S,SZ"=HNH\"%#1DW^N9@TP!IUB[G!A.>D8_G_%G
M4I1_(=,7\5F0ZJ6L'UFM?OGG0I3JD8^O[4*'APC'+ \@SRB"2" $:9JJ=2-)
MPBP2:L9 B8TK:25];!.&UA/4BH*5IH#,.+@^_XOE\K+?:)BYH]XP]CQMG :O
MM:?:"R:G#JR=!H/ZM;W >>ON]GM(/UJ[%AM\.0FDB%(D4AB%N80H0K%B+!9!
M3,,$YUE"$<:3Q6J#_N@GM?5T*UHZ<-;@\KM1RJD5G=;.CGNV(1-4)CP*,I@1
M02&2 8.8BUSC)H*41"(6J0W3]X=L "9W UFH)L&0JM433W(U.6:20Y*DF7K+
MD(PCQGFD;OTJ2CKW#MJFE+'#EJ9Q0,(0PUC)@RB, DCR2$"D%J YBS(1AFRR
M/+3V %GG@?OXX#*;]'N_.9XG=8W!]JKC?+$H"_JR('0JP&(.;DGI9/71B833
M>7M;PJ#S\E[CWLZ[^R_J-Z_^HJ;FF]E'419?Z_7)U:Q:E/4JMKHMQ8)\F[ @
MI 0A!@E1TP4B:0[S(%7KA(R+"&&"$LYL)HZC$L<VF6B%]2827ZD,BK7.9^"Y
MUMJ. H[#;D8+3L'T3!5+'-?:@JM-'&^[<;0F"F-LG)+'<:F#$HHQ"&])QOS&
M?L1SSMC\13^,O.J9XGS&U6_*%\$_%806TV)1B.KBI=1SA_JW:V5M^P-5>A"V
MF+!,(I$AY69D>:!#-!FD$<MAPJ1,190%<6@7XW*B0F.CK8OYK-8+3-?Z_\DR
M&.;4,3(CL2&1]\QQ2U- :TN]O]%: S;, ;\ME7<9?^,(1[>Q.J<J-6Q<CR,(
M=V* 7#VW;R"!=A?O%F11;](LH[SKX#:>H93%(8(\""A$0:1<NSQ49$ICAD5(
M,"+2+IK@H*RQ462[<%GI"I;*]@H=[ +9C @=0>>9XWJCUB/8X"@>CB,.#LL;
M..S@J.&[L0?';^E''G?B03_QBWB>EXMB]G [GQ;LM?GS7GQ;?%":_VTB1!A0
MDC(H2*QI1*T0"<UT*DS(E9NF_IX'-C1B)'5LA-(JK=8U<EX^6009V&%MQB;.
M$?3,*TOP5@JK)6&M+/BM_:_6&M1J.R09*YB<THV9Y$&)QPJ,MQ1D=[,=&7%1
MJ.<KKZA8O%Y^8X_Z$%V'74YB1N.48P)%+'.(XIQ#(FD.,8L%YVD68$E->.>0
M@/%13*,C6"H)M)9F+',0Q&Y"<0&-=^ZP0L68)(Z9OH</*L%^?)A__4G=6E/!
MWY'^*VS^6G__!Q\ZR*=^S*3E5WWTNA[AC+?EG+^P155O*PFNXUYN%H^BO)@_
M/:OU$:\^BR<JRDE&<Y;G.84\9P%$DC.8I[GR*(*8QTE"8[54,0YC-!0ZM@]]
MJ7:S[RQX$\XUUYKK4,9&=8N8.E/LN[G %Z*>^6$%9JMR$YI8*PU66H/?&KT-
MUWU6J%I$*'I =Z#(1$<HVP4D6L+5&8AH^JSA A MK=L*/+2]U]XCNYPMU.R@
MEY[E<QW@.)_5*] +O=E5OE[,N9A@EC(4!@+R#(5MMHI, B@1ET0D@0@"HX6A
MH;RQT7BC,MC2^:S9/%$P@U9SH%4W=^),<#_NTSE&TS.%NP#2RN^S@*>W&V@B
M8S"OT,+@32?1YK8>/N/5<R5F[2R:LPQ%3'F#7)$*1$C$D C&H, IE5PD/#;+
M?'O[X+&11JT:N'TDY1,!=^=W%@[))EP&KEQ/$'QO,=?V]W#'-JVW<+EZHC"0
M6V6(AIW;M,?D3M=H\_KAW)\]6FZY./O^O=\N]Q?Q5<Q>A':2EB?G?RT6C\M\
MWG78 >48!8J"!$4Q1 G.((UP"+%$2<A$*)+4:&EJ*7=L#-6JW2Q*5Z$&==6M
M==KY\3/NDX;";!O< \">V<\1MM8[X99(.=T+-Y4]Z&ZX)2!O]\-M;^]'7'L?
M79<<F:VB"U[O==3!^@ I1C*+XBR#<2H5B0F10!RR!$9I%,:A"#,NB V)]=!A
M;(2FB^+QEZE:2\AVQZ(VH*HC>)I?;,1JV!%:GR$R(S?/P'LFNOW<=K;FO-J4
MC9]7)IW5P_)%,%%\K>.L?JN-]'-"> +(3CFRCQZ#\N4)0+WESE,>U8]'+TDY
M*V8/U:TH[]3"2ZB72UFMY#1Q%$NG@X9!DLE8PDCD!*(H#F >L!P22:((LQA%
MN54XO)G8L;'EM5KWE/JSL8PH-039C/S<0^=["ZM5&"B-0:TRV-;9BUMG!Y-3
MQC(4/2A)V<'QEI<L[^Y_1GI3WHGR:\&$CN"J8PCS(,@X302,F4@AXI2J12>.
M8,R3@$6!B"(F; ]%=Z2,C6A:/<&-^F :38%6TRI LQM6\_/.D\ :YH#3(T[V
M)Y@GX37LD>5;W-R>31X$PN0P<O?FP4\?#^J_[[CQ\,7]_+)Z[=6LQ=9Q\1.2
M9CSD60I%P"A$(1.*#)-(K66S/)8Y07$:V.5F[Y5C\\8.DZ/=+$6G\]D#5/S[
M!$BML9T7MA]2,Z?K9)@\$^'FVOT,K%5TYT]U(N#4?=HO:5!OJ=/8M\Y1]\4]
MH\_;?9D;6?M;'T@EN Y@$+.J<;G6!96J#Z_K:V[)J_[=^>^DY/4Z<<*D("3(
M)!0DRR#"20IQPF-(4!(%(8\I1U8[]\XT&YO/M;D55JL-=2,'#C:-VZP[5@'Z
MNG5A:R&H36RW9BS/ -P-NQFMO<M@>J;"@<?1/O+>->9NH_.=:3=L!+]K4'>B
M_)T+Z#DQ')-^2/BJ0I6:J5Z>GO5=U>6W9\$6@G\LOA9<S/@7LA"3.$U0@H1:
M9N=2>99,,HA#*NLN"BR+<QI%5AGFWC4>VT2RU V\%F+*+2< [\-K.#&,:=!\
M3Q@&DT3G''$&-HK\;=A]!I:6@]4[H6UW.)<,-4QNYQCO6@\[]PPU"#MSTF""
M!YZKKE]T:%,[U5;G7TDQU5/GS_/R%W7O8I+%2 H9<<@"K*:H($D@Q@+!. @P
MYD$81H'1GK!O1<<V,S7J:L>XJA4&9*DQD/,2/&B=P??%K/WG'P::NXX-M^<I
MR^$@CG^F6K\"C;G@?.L5J"T>P?QD.";CF):.*?O'F(T,(7<V"9G*<]@_XHON
M?5J=S_@-G18/M:+59_*M>'IY.G]X*.L.=Q_%5S&=/^O+/Q=342WF,]&J74U0
M&H9)B C,<IQ E*N7*(\C74X6AS'G 0OBTQM-G*KEV&:=[<K]9+-R_U-C%B!+
MNP!?&P:>EI:!Y]8T!\T43GX'#$Y.QS"RGJ>BCG8,C97@7$<0KNT\ ZVE8&4J
MV+ 5K(Q=SEBC&&P'+3:&'/3W[\7A??#=].UP-2B]&GR<+/S].X&XPL^H98@S
M83U#S4GUJ/]W^?>7XBN9ZB=^40+*0B^7]3\HS;9_L7%ETX_X:L9*H1R@CZ+Y
MK_IY^J+;NB]+3.C5]J64:@4^42O;),K2&'*:(5T%(H)$G]IE+,[S6+UAF>0V
M5?Z'5=_*^1BNC4"MMNX0QY1]9_6?0*S-; *KRQ4*.Q=81KX/^\:8K8_'^Q[X
M=E7J(==_@LO-(5\;V_QC$UN__;NM&QH0P!(%\/T2AQ_J'E0-%.M:/!H,T*#A
M,"K_74;1;4#_L"8,FPOP+L.SDT;P/EJ<UNZU$,NJ,0RE-)(Y@X@P"1%*,T@H
MC6#$1)8G<1QGPJH]UXZ$T:V0FY@A4%>0F\_TA*7 5AQ4Z+^WW37[M7Y=HVHV
M2YR$E6<BW]#-85[X4<N]M'==2WF7SJX[1AYJZKI[8=]Z.3\KM[S9\YO$7&11
M2C"D6 >ORD0'&] 8RI!SE 11CL/8KCC.^N%C^[8;_8!6L-U\MRUXLP%<]S=\
M*AR>/U\+)'I4K-DU^<3R-!L/'+@6S:XINX5G]ES3-Y'ZZ4F7KIFSOVWOR-^2
M]HQ8K;MUA.O'HF+3N>YX5ZW3 E% .!4)3"F/(<)40L)B"5.),0]9QFB,[#*J
M^RLSM@^_L054VAC;Q.D3AL1P,3@0T-YWH6N,:SMVSS;/=!>N-BQGG<^^89&7
MQ$,7T#I.H#Y!H8$SJ4^';C>EVL$S>S;[X?_U4BWJ+<C[^3GGA7;NR?26%&IY
M=4&>BP69UKK0M\>G7_364U4L1)M4U*S)=-;EPZQ^2JWY)!>1Y DB,&:Y\J,R
MEL*<B QBHARL,*)Y**RRLGTK/#:*KM^*-DZ";5ACV2_(]S";4?J8!L\S[9_?
M7EV<[8]R>=,7OMFHDW6EQ&H!-FQRV(!H(.#=-BCRK?2P#8P&&H*=!D=#R>WI
MVXMR4<A"O<"BNI$?Q?-<25S6":1Y+@-*82AEJ%QWQ*":+BB,>2@3%F1Y9A;*
M8B!K;+2_J:KV%GFCK*63WH%MCB1B,4]A1@,!49YQ2%)$81:Q*"&<1$1A:Y6F
MZPC=89)UO>-KN,9Q@YGO)<P;L%H]/6QP&N#A=MW1(6_89<5QPW=6#0:W]#WN
M4!0GJK:7<;WR4'Y\B!.AO/< <\W%BI )B3!,8YG&:983&85V!QX[,L;&P4L5
M>[42WX>AZ?'&2<AX/^!H06G4.VMV+%P><1RTWO$AQZZ<@8\Y#AJZ>]!Q^%*[
M+[PJ%Q/MM34!T#/^'R]D6LC78O:P[(.YWF+X5,S$U4(\51,>)4+@*(4TQU*M
MX4D$2<1B2 .9\ CSB)A5UNTE?6RL<'=Y 9:9MF<@C!0AGH&55?4FWMHNL&H[
MN[8,_*9M [5QAKGW_8:MFVZ\#X9G(AIH'(P)["0\NZA-/7B#UM1/;RFMG^1!
MR.XD4)8T>-I#>N8%OM!*+7_5JOE2'S+?JZ=\G#^18C;)68I0D,80(UVA%Y$4
MYFK)I/[&8D*")$>1587>@Y)&1WPK14&M*="J@M\:96V+B!R$U\Q'<@*:;X+J
MAY=] MLQ+-QFH!V4-FP*V3&C=W+ CM[0/S2LW5Z[FGT45)?!U9%JNN]*M2CK
M5(>JC6=[$\7VZZP4BLG^6_ ZUJWYZR]*I>K3O*I$M2XY'4HI<2(SB+,L58NO
M'$/*PP2**,D((9RG@76TF6^EQT9?%^=W?P;GUQ_!U?5?+N_N/U]>WQMV;QET
MJ$W7B.,:0.^+SI6Y.MY0&UP[>(W)8,/FLW6<]&YP]-KT-I"Z_:&V'GS?V/\#
M^,U+K?(AA\QY.*!WQ0>/,!QJ*/8%+0XFNV==S_*!S(K_KMWMB_FLFD\+OO2]
M;]5GO4S>NY$_%S,R8P69KKK;KX-\N) H0X3!**4Y1 %.(:9A#(,8"T(Y)<J1
MMIFSG&@UMDEITZBZF\+:K)JB-@W3.^\KT\#:MM[=?-R,L]F$-?CH>9Z1AAHX
M^QJH+H%V6S/5B6;#UEAU">9.35:G#^]1@J+>2/XTGSWH<L5-<=A5EV\6R90R
M&),@TMDM0JT\4 PYCK(D3$(LJ%'P>[>8L9'QIU7IYGU)+O,3RCL?@;N;0MV!
MZ)L3FUY,*X3:-DT]FD4>ALJBV($3R :J5M 7.KM* T<1Z2P5</CNX7+]CUJP
ME:Q__.J>0;.S1<&+Z8NN 7 GV$M9=QZ[_-:01=-5[NGY94G?;SN3G#_I3>N)
MC##61^<PEKF$*$]CF!/E+R>"I&G&LTS8]2MRHM78.%D;!9=6@6IE5NUDJ3=F
MH4Q0G^?T%115]5+7"&OKQHG6\/[%XMP,LYE_//C@>9X+-NT!:X/ TJ)E"\V5
M3=I)WNW"= 8:RQQ&PKH$VFVXJQ/-AHUI=0GF3N"JTX>?VN-@F6SZVB9"OVD*
MR1/!4R*Q\I@3W7PNI9!*RB%+)0\9EDF HGXM#+H%CXVO-RO;7_5+"S?&W/"H
MT .2OD\.]X%X!I8I^#X[:MJBY:FP_Q'A[U2WWPR2PV7Y#>_OL90_9ZQ\T='[
MJ^I4\]FJ&6<K;8(P9BA1#F<>AZGBJ 1!'&<(<DJR6#V3X]"\39V)Q+&14ZNS
M\ALWE 93V^;!YH@;+.Q=X^C;KVLAW-)WL_OOQ9&F3CV1M%CWNT9TH"V DY&U
MVPNP0:ES6\#H0</M$-C8M;598'5C/V_RBZB$NDD?[6W4 M15[6>5:#>XA"0X
MR1&!. ET^[PTAWDJ!(QRG <133')K7*>#&2.C::7*M=K_(UBNW9NI G89AZD
M8P@],_06>IL%3%N%/63M6 #DU%\TD3NHJV@!Q%LOT>96)R&MZQ-<%O" 9X(I
MCM'MBX7418_2!*J_!)SA. VCX(2(UM$>OK\-T.Q_DGX06L,EJ@/ ?"])^V!U
M:BBKW_/H@\+>,Y#UZ*GQT>O[K!ZGT_GO1*G[\[QL>P5_$53G%;;S9"@Q#J,T
M5$X)"R'B$8:Y3#A,(IKC(*$1#HUBWHVDC8TF6N5L5C3'\#19%SI$R?>:<*DJ
M4+J"9=_N5ML^Q[]'\;-9#3K$<:B5X&EX6JX##?'I7@,>>\B ZS]#>[;7?J8W
M#=QD;"<PM#[1OG\DLYNF(UK=AJ:ZFC6E.?XJ=!5ZP<^_BI(\B/H?/RHK5KW4
M)HD($YQB#D4L H@2%D$LN(2!0"Q(4Q((VZH/H['-YD,>IL;$4F5 &IW;YF5<
MU]R6NAOC5ZWW&2 :CO:@FNOMA[("SZ)L#JV':G#F_%4S='W'HN^(YE,'+=1V
M$R/:RH(+!1"X6?;^;##2T6T-2F=@]<ZV0#67  W51@?1$71?\S7^XVC7YMRZ
M/T9_-U^#ZJPAG#<%^SD6GU]F!2N>R?3#?,:7SG$:!RG!.(8<4091EB&8ARR!
M/$KR-*=J\998)0ON$S*V-=I*1T"UDG9SYEX4><ZSB#(,492I/U+)(5%K7BAI
MKMS?&"&6,#M/Z50<AW%:W"-IY@B<BH[G.7D-2ZV?ATWT+@"<3DI[!0TZ/W29
M^I:J.Z_MF=^F.5L3?RD>%?<77T536&>=7_?G^53W$=&Y=3JU[F:VCC\[+XM*
M_=-']>/LH6'Y:[&XD??DVX1QS"*&<R@2I#@#,PF)&@28,)HA12A(V-4K]*7H
MV-A;-\!Z6>?F3NML1J SJ98=5Z&<E[ B4]U\DRXVXH#/P$S=/)=@0;Z!XDD)
MJ'_ZI_ L3=+Z".R?$,:6>7&^W@\S)AS#J'MFTYN+J[,FB_MN8R3/MT;[CNBZ
M/ALIVZW5=;9VDZS]PQF@0ETKP+K(J5I.2_7. F6PPZ0ZST/B-L_.E[+#IMYY
MAGPG&\^W/$];A]6AI4K]ARYSHM,)U==WK;['ML9.$@N*B> PBC.=FATJWQ:+
M#(:"$!'ED@6A56JV#R7'-D?5FIY4\LC'2#K:9/,\/K[/GRR&QOT&U0G8#;O7
MU$?1<6T;G0"U]0[0*;+LVX]]4N_A]/9Q/EMVT<(\1S1/)4RPWGX@*(*$9@RF
MA%,F0H(EP:;MQ]X^?&S46NL':@6MVX_M -?-B*?"X9G)+)"P:C]VR.3>[<=V
M'CA8^[%#IFRV'SMX3<]TWSIS>!73%:=)G.:<0I3EF?*>6 YQ+A@,\C2*\SA!
M%%F%RVT_?FP?Y_G=W:5MH;0W@)DY*?UA\.U>M+GX'N+=]MOL-JMT6\2PZ:%[
MS=O)\]Q_5=\0^Z]B]J+6;FI=1J;GS\]372!?3>W-JNSBY>EE2G1&:=,7^%[-
M]U7=RZ3.Q9J$B.<YRBD, AE!-0.K:5?*% 91'G',<)YQJ[.3T]09&Q>TUNBN
M1;4]8,.@9>?QM4EM7W&P-JK-7+1<.)TXI&;L,]Q >68K[V/4(SO !;2.$P=.
M4FG@G (7\.VF&SAY:H]@XXT$JZ]B8\'U11^55[K3(9T6#[4NU6?RK7AZ>3I_
M>"B%^I7X(AZT6O/R]7,Q%=5">7CMTJR:D#0D.CT**C<LU,?>NET!%1 +&:=$
MQ@33S#A&V9.28R/T+3,!V6Q,]]18!<C2+%"N[ )/2\/ <VN9172OKQ>@F^C'
M,JR>Z7][1+=:#39&@G/=979MYAEH#04K2\':5+"R=1EA-H:1M@C_'L&(#Q0U
M_HXC;Q=Q[GE(.@/5?<D>+K[=,WI;8?&^99U<<?]B2JJJD(7@'UXOYK-Z ?E"
MII_)0A_,O>I0NS<U8Y0OD!.<QS 54081#P0D82C5CT)BDG+$F5%E2Q?*C,T;
MV"P[LX[UU3^]+:5>!U9L%F6GKV##9+"TN7=]??N!-5OF#35<GF?Y3>C7=AP:
MA29ZVV?5(!>P^JI9;Z_0>]6B[PU=1XWY_L\<=ZK31"WK*!,1@83*'"(:(4B3
M(( DQ3C*XYS1P*[@VD"*CXWTFQ,23?)U&E+5)"F=4C9SL%? 4?##.PRLY^GA
M_1*(_GB)0>\3B^%*^7'%9S@>DO?*VCEQ"KS0:.J95C_Z2U']33U5_X(\B'!"
M@Y0&-$&Z[;J:ML(XAD2R'+(HSV.18(ZE74O[#F%CFVI:U>IH[?E".:AELPEM
MF632B:_9G. *->^;>1MJ JWG&5AKZK#KN@$<;MNN=PD<MN^Z@>D[C==-[NG'
M';<*95&6@M\ME"_>)%++.,]"%$I(12@@2K'>LL@C& G!T@3%-$96=>+WR!@=
M4RQ5!)76\0S\4_!C$(3@F:R2YL/@+ B"9;%W\K)XG)>KSFZS^?(?=%5X<=@M
M,1X$,UXY$5K/=+)&]:Y!]2\-E%?=&%G320<*3EEDGYQ!R:/#T+><T75I7ZJ8
M,R%XI0NAZQ'4Y4MN9.T 5;_.U'.N:I;2.[<SOM]UTN&KRNO1!=6+V4.M6>L0
M33A7B^L,JT4U8YFN9ZY6UI&BGRB@A..<<YD9M7P?1-OQT5=C;-/DH&C-U7X/
MFS\]J:F\9C7PHNT&HEEI%4O[P;.VTY:Q?+X+IMPWDA'VSJ*-G0UO+@>VL?-L
M_Y)Z\RQN95Z[B :7WY3W4%1N"7B H7!,Y3XU'GA2& #\W>EE"*$#;PFWXF]>
M%M5">75*JS;&/\I1E+! 0H1B A&)*<Q%+F!."<%2!A)1/LC>[R$-QS8AM7J"
M^5K1=]C?/3B>GC=R78S2^'=L5WNR&W:>.<LB\3X(X]A_/:CE'V.C]1C(SG94
MCPKJ&[V_(,5,\&4OIV7YV90(D0H* Y[$BN\3";$(4QC2D(4!S44:6F7<[!<S
M-M(^9ZR)PA6ZCKLL6&%= 7\OFF9L>SI&GBESJ>"Z:YR/PO9=(#@.2=\K:N!0
M\RYS=T/(.Z_N&]S%2J'8YJ-H_GLUNRW%,RGXQW;_I*V(KX//]"%.DSPT"0B1
M>1A%4 :,*X:@.:2*+&"2A!)%<9@D43Z9U8%IW#2PJX\B1M\';KZ/376\;OII
MK8%HU&U"MYI>QC8=C$\<']/H+&^8#Q67U2@.OE^:\$-]-MZ.P;(#AQZ"YC3]
MO'L(>@1BG8*@XQ"L7JH,''QU"ER[85<G/:UG<O*R:-+/\U*73-HH2K/,OPT1
M$PF/0R@R@2'*!8(D$XH<29KC/,MH&AEEQIB+')LK]7&[:-B>NF)_LLQP/HZZ
M&>6YQ=(SO1VIV%779_.2)FT,DMO4Z>-BATVG-H9A)\7:_,Z>+*0([T9^$61Z
MJ1:$"W%;SI]%N7B=D#B/) HD%(IH((H)@WF:<,A#PN-$AC1*K$I-'1(T-L;1
M>NIS@6GM#CRW6C:;;G]_44MJ((58V#8D/X2R(=<XP,XSPRQATTJ"1DNP5-,A
MGQP!PBV+'!(V+'<<,7F',8Y=WS<V[NFI:"+3E1>D ]+5RE',F&*BCT7%IO/J
MI=Q(ZHA1&HH\S"!G)(<HRF.89PF&/%<O$LZI#-+0+EK.1OS8..7BYO/GJ_O/
ME]?W=^#\^B.XN+F^O[K^Y?+ZXNK2LD*+Y3B8\8L_=#VSSH;B]=IL2W6PUAW\
MYB5[IA]NC@/RK%08.$2O#SR[07N]GG):@8/YK-USC460YH(1&,I05Y./$DA$
MIO[@,L;J+QE"U*R:_"$1-I_3,)7D[^L8W^U>VW81OP?A[.8C%Q!Y9YQ-5'JT
M2-N'2K^T^#[H#)_2;H)2[S3TMQ"8II"O[GN7].^W6A]*W=ZYKF<81YL=?"//
M%7?R8OJBPTG6*\G+;SIT1' =@J)/$U^:M^-&+L\';D59'R8V99E8P)(T%BE,
M$[UCKUT[(C&%/%!+0\05*S*K $.WZHW-]=M,S=ZT;V,W!BPM;*(.-VS4-ZT.
MR929311!OV)<CM\",\?R_<;6\S3P'L-J'_+A!7VW\1YN51PVV,,+O#N1'GZD
M])M*]#[RQA;DF\W)=<5]76;_=M[4'5NUS'I3]X&':<+3.($9YC%$%'%(" DA
MDR@6.(E$9->\W*%N8YY$-NI[Z!7O+Z4R9[/9QJ>V!XO<*O.QVZ%#'V^2V=L[
MP1(9N\G%Y7MA-K.\TVB__SG-V<$A.]M\-WP6#?& O=-)Q:5^@\XH'H!].YWX
M$-&_&M1,EYFZ>"E+];?&K^0R"PG%*60DHQ %(H Y(@%$&*G9(@I8S*R.O/=*
M&1N_KY0\ ZV:_7S\_9":$>K)0'FFQAX8]:J&=! #YV6.=B4-7K_HH+'["A,=
MOMA5Q. Y8_,7Y:Y\$4P47YO=!L2C)(H93)(@@2A6S)"G,=;9C8BS()(IE\OX
MP'L;6C@NNT=(X/T 9'%?$JYKNB[5;#KIG1H,N =Z4]YPA.2[!OHM=09KI7W&
M]AV&R',DWQ[![QRW=QB*XU%Z'?>>D/%&CZ=5T+V]A?ZBEEMJQ=T4V5R7EIB@
ME/ HS4,8<EWQ#$L)"44!I"1+2)HF.*5&+8&\:CDVGZA5LREN!IZ/%T\9<$ -
M-S_?>YA\[X&>GOK6-(!;#G5CJY]*.5X'PWT*G'--AT^#\P7VWE0X;\(\1DNM
M HX#B>(P(S$DN2YMK"8+2"5*U8^$\9#Q/,N1\V"IL49\FX?T'(]7=C V9E3O
M#7'/%.X2;#_14U[CQ.TT&%_LU+'H\7X/Z1$Y52?$G+._OQ3-CF%+L[\^SV<7
M2HJ2>B/K3C1*3AWB$F&>BC"'-&:I6M4K9Y@0%,*4A"G+J"!I8A0>VD?XV AO
MZ1*]*'T!:Q2N*RVN5;8(+[(=B6Y^\XVO9WJK-0<;JI^M'%"M/6C5!S<2W ^"
MMD6@ET?4!PH"<XR^79!83_@Z \ALGSE<<%E/:[<"S_H^HY^'W%2=N)$W:F5/
M]+1T)QZ:'D$"1Y21A,(T$1%$2<1A'BMO&"<9ES'#*2;2QAL^*&EL$\&ZH#M]
M47"+J@)5JZJ=AWL86S-OU@EBGJE]#=9*2W!W#"UK%_4H$D[=T</2!G4]CQK]
MULT\?D,_CKA\>I[.7X6X$^77@HD#-6^F]3#6(4]?!)L_S/3Q==L,<5XMJD_J
M4[I:B*=J$B0D#N*,0YI1Y752D<-<(@XSF45!EJ(P3ZU2&AWK-S8^6IH'6OO
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MT*J5]+%- 4<JM]2E>.RWJOH-C)DCZ0UNSS.#,Z3MLQK[(.8VJ]%*@V&S&ON
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M_?VEJ(JZ!@#Y5CR]/)TO>X9]$0]Z@I^7KY^+J:@6\YEHJSE4DR!).,M"H99
M,H1(39F0T#B#211'4<[B+.-&.V.G*C*V^:XV!9"U+6?@J;$&K'JQ@7)E#WA:
M&@2>6XLL3CM/&4"#X^6!AL7S--2,R/GFB+2&@)4E8&T*6-FR+%TRU(A8'$@/
M-#(#G5!['"&[$VL'L'8>89_R_.'.M!V@L'7([>)Y?6.5]Z?GK.?9M3LO<*K6
M>3B&>:HGM)SGD(9I#K,D1U(*%H:Q5=,:"]ECF\,N;CY].O]P\Z5=M/WRY?+R
M\^7U_5V]?OOPZ]W5]>7='?AX^9?+3S>W^E_4ZNW^ZB]7]]:+-IL!,EMO>8+=
M\QQU.,MO8_WC9VW3 S#'D=?F\@>.R;8&9C=:V_X1_9CN:L9TPU#Q433_O6IB
MQ!_G4_6,ZE)Q[^+UB]+FYWGY.RGY)$E(*H(HA;E,,HCBB$.BFRKG09A&.<I#
M&2,;MK.4/S;&6ZH/OE\:\ ,HVIR&UH;_"1HKP&_:#M :8AGM8SM,9ISG$7S/
MO.<!=VL"[(F>4Q*TU6%0(NP)T%LR[/N8_@5Q?E8T2Z;Z)/EG]9MJD@>9Q (G
M4"8A4RY>FD*,0@P#1L(HIS@(<NN".&]DC(W85A5?&CV;,(U:4_N*.&_A["8G
M1R#Y/BFUQZ=729P#")Q<$N?M<P<OB7/ L'TE<0Y=VC.B6=>8_:!+S.KF=F)6
M-=LF-)4R(IDBV2S1O4=S G&4)3"E*5,?NPAQ3*Q"E_>*&=MG7C-I6W"7;>AI
M&8N\'U(S)^1TH#Q_ZD>+$E^KMYY4C^Z;HG=#XS:,>+^H8>.%.\W="0SNOMIQ
MO:RKYTJLJI>+*,RD2"!7- $1Y13F*,P@SM,HXIQR:5$@Q5#HV(CC2'FA6G-'
M)9PVH3<X?/  Z+MMXJRQ=%T7:Q-41S6Q>H([CGI8AB"[JX6U!ZW>=; VGS6.
M&EA[K#.N?[7OWI[ANYS7!P=D>DL*?C6[(,_%@DR7-)Y0&091#$F<([6J"R2D
MD@@H<!XF.! !2NQR-+JDC8V_U\H"K2TL9J#5US+:MA-B,P_0&7">>?HP9A[*
MEQB!XC:,M5/BL.&I)L;OA)T:W=3S0%#Y]^<SKO^C-YR^DJD^93Q?7)"R?"UF
M#TVJD)0R3Y*<P03A""+.&,RIR&"8HI1E.(OS)+,Z"C21.C9FT=K6(7?UFDBL
M];8\X3-"G >,T#!(89"C&*(D3V >Q0'$/.0)ICR.4VG72\TYYL-T3QL4=3-:
M=XZD;S=\"6']EPV5SP!9@*763:Z;PV-4&Y3<'J :21[VZ-0&C)U#4ZN;^^P/
MJ">_>?H742W*@BT$;Z5O_V)3CZ=YN=!9#A?S:C%!/,L2%%&88)9"1!1O*:\S
M@FF>2H2XC$@0FI3*<JR7U5PR0'FME7) :V>S]'4W5"9;#N\R  /0X=D>+EP;
MTORC+@'Z]G=;-XQA$&VV.-YE,(?:!1EX4"WW2YQ#W[VEXD[<@+LNSC':WIAQ
M_WBG*ZYE0SJ<9KF,"8(TIIGN($H@31,&&4H1$0G)TCAUL-0::^._0ZZJ21.Z
M/G"?Y/&/L.7?*?BY<O&]]NWK%CD&I_Y8=SZSNWH=\ST)Q5]_;_<H<RSC7(@,
M2HYSB)@,81Y$#$8XRGF2I&$DN<5IWN:S1T<;-Y\O[[]<_8?5&=(66$;G;WTA
M\'[,UBC6[RAM"P:K$[.^< QV,&8*B^WAUS[#CYQQ;=TRY%'6/EW?G%CMO<15
MU/5'(459"M[4Z[TGWT0U081F+)<22IJG.NPP@CG+.>09"@6F@K,P7M:-N3\E
MY'J/<*,7=;LXS/T088FMIF"AE3PUAGH?Z&:>CCL,WS5>>@5G6YK[OA-5!Q'2
M'2AYCHO>)_F=HZ$[P#@> ]UU\]![FWOJN$R$"%*DB$LW]XB56T4XQ'DL8!QD
M:L46X9#CQ(*\O"@Y4I([J0R6G]'TO0G:=W#^8%NA>T?V/<=UJ'W1$\?WC[8[
M:C?. VZ2=HR#OZW2?4+_(!NF'7BYVS;M$N)J?7'.6/FBGET06DSK.FP3D@1Q
MB!(U0PM)($IQJI87DD.28(D%27,J3TSEW!4ZMAV15D/ UO&(\QF8KA4^=8FQ
M!_>^*XS3T'R?!<82WT\&B#I87AR&R//J8H_@=UY<'(;B^-JBX]Z>@;CK"-]*
M,>'U?$;6O[E7?ZL(J[M5M/MK82YEJKL&)4S$.I".P)RD*4Q"(H,DS$4NK*C)
M4O[86.IP[+H^P]C\^6;Q*'3Q=#(#VS?]]G'^1(J9Y:F0[;B949O'T?"^A>Q_
M(.PCA?O!Z39VV%*'8:.)^P&T$U_<\S$]=F.4J_@RU67[?E;&Z*(?\Z^B?+V4
M<EXNEM^:3,)04!S ),(<HCA/(,DC#J,PII3('"4(&Y];&0@<&RFN5&[:+O*E
MTD T6ELLJTW@-M@!<0RB9RY;XZ?5!2M]0:MPGV,R$R MMAP< SK0+L+IP-IM
M"%B@U+G&-WG.<,MV"ZNV5N(V]_5S9C^*4JW<]61^/6_R3<Z?=)75B:0Y2H,<
M0X%TZ\M(!!"'"899S'&<XR3.8ZM^UH<$C8V)UWJ"6:LH(+6F=M[F06#-W$H7
M<'GFW+6*NFI "]5Y-U36_N Q')PZ?@>%#>KA'3/YK2MW]/J>30>TTZ_\POEV
M]]VV+L0DDB)(LT! M7Z54%&%A"2B"$I,69:G>1QF5NEAW>+&QA+-BJAH>T"+
M1LD?SL!,6-+$$93-R,(==IXIHX%M4]-5'^U669>MM(U0<5M=OEODL+7@C<S?
MJ=QN=E<_2ED6M+V?UX5P2W%;:CF+U]NIKN\^X_H<X5E?,J%Y%&(>,<C3-(2(
MA2DD,4H@#A!'&*51E%JVF3(7WN,DW3/=W*H'/9)*5+I#Q'.K]UF=&?F\VK&9
MZZ&S8Q^+ 3%C(L<@#\-*2Z5U5_-6;7"[ KG6_*Q&>*6\.Y*R!\PI85F('Y2\
M[&%Y2V0]GM!S!;4J8WLC-XLW?1%U6RB=/5+5Y9WJHEM+M5;)"&K9RCE6@R.B
M1!&=) Q23&(HPS#+U2*+B-RJU=)IZHS-SSI2KJQWALB)@V:XAAML*#P3I(-1
ML%_X.0'/[?+P-)6&740Z@6]GJ>GFJ3UK7:Z:9Q\JN-2>9+ #_[QYK'&O6_JM
MR^KG"4N2B*N7/$X3Q<(AAWF$,YBAD$28$,D#J]TNC[J.CJ);4[5KNGTZ^$5\
M%;,7H6/'U"AO_N-\!LX?2B$Z?:G!7P(S5A_)T/X!#H=KXX"7?@T##(+;BJ0>
M]1VVK*E_X'=JHPX@LM^,M!D()PF2",L8QC'/(5*3"<0Y3B#+.$M2&B>,)B9%
M4/8\VXKQ!RAD<J]E](\KM \?'&>4H)<P0-_1?N\6U&<0NW=ZB%Y]:'K]HL]%
M-5N\S!:E>MA?B\7CQ_+EX?SYN9Q_)=/+;VSZPHO9P_VC^/5NDN(\9KG$,*!A
M !&B(<0413!A:AW.LSSDV+R)HZ7PL3ESC?K:E6-+ YJ2LER9 $AKPQD02RO4
MQ"_ RX_5CQ:!%;8#U$T2OF'WS"(MXC?:>5XBKI4'6GMPOD)\90!0%H!??[SS
MB;A%6(M'Y <*<?$P G8Q+STA[(Q_L7WF<+$P/:W=BHOI^PR[V:2AP-?)O]].
M!"%JFD@83*FNDI\&!!(<!3!@."!Y0)(P,ZJKL7[DV)C_W\DS,2QROX%+-S7W
ML]8SX?[[^>WY]>E?[JYM'6ULVHL;-ZW]H?;0Z@]VXU&#?(:[JB\_KCW_TC-'
M0C>ONE?WGG\KJDE$0^5)10)&,5%?C]!1(_^7NW=MCAO'V@3_"B,V8J<J0GB'
M!$ 2>/>3?.MQC,ORVJ[N>;<^9. JYU0J4YV94EG]ZQ?@)>_)!)@ Q9Z(;I=L
MD< Y#X@'!\"Y0$Z L:Q*F4J-"<J](B!V6Q_;1*J$2ZQTR1]6/M\HA3WDW/9'
MO?&(/-7<H?"/$SBE<M@H@+T>AO7Q/Z7<D0?_R8="EI':/6%Y\[)]ICG7KP2X
M>ZR.5?YFGERO/LZ_J.5T(?^AIO<_UDK>/JLENU?O?ZJEF*[4E^54J D7M-28
M8Y!E2 "<";.4ED4!M,TH+C$JE6)^6:X'E-YG<@V3*[M1(;FW.BAIXQ3MENRQ
M4B7YQ?Q5VF.QY<K^4[*R,)SWL7KUC\/Q"'Z< QZ937=O87?UWCV-7R7\)3EY
M76NUOTD:_6U0OT7 ?BTU!C=)BT+2P)"T."05$+$+@44=O0&JB\61?P0ERZ(.
MC%L=M+@B]#AB_+)<R">QKG(=-)% *5<:9WD.=&:C?)&@@.I< T11GA&2%BEU
M\N,YT_[8K-PZ*<AC+6>R;&YZ/8ZD3D#H<,YW'3"1";H1KLV8TB/D[ 0H'D=Q
MUX$ST&F;+TA^1VGG(>@\+3OQVG '8N=EWCOSZGBLG]'_6:UM[A;3[O-4*OGF
MY?>5S<#V83IG<S&=W]^*]?2YNHW9^+TA@A$AJC2KHC';L<X@()()D&I&8(Y2
MK-Q(KK\(8^/!*EV2GBW^6M61N[H5/6$;V?_3S][N,2YN9G-<M&/?DZAUG9NJ
M%=]:NK]8#8P1^VNR42+9:A'%+[$_B$&-T!YB#&I+]H?IT"2\HJ6>AR&VC/2/
MQ<R\L;).XNN7B>)EI@FG *?(_($P!+P4&J@T4T)DN4"V2*Z[<\=Q%^/T\5CM
MR/G?JG"3]8OGX<$QF#+-,H$Y!P6SEC)!):#*K"1:RKS,2U**,I_4YQ??UFRY
M'@+2P^[B ?M&W4_G<TM4G)E?=&RL7?%$6FI:I 6@!<H!-A\D8*(PR+*R8"1C
MJ2:TP?/]W#%8*@2:;6?QL#0]A 32\?#I*FABGQ'M3=A:O.1VO5Y.^=.Z<L=<
M+Y(O9O\<,H;I/")ASUV.NQGV>.2LFD>G&.>?[%D_9O'PL)A7S5:G'ZN/J]63
MDA/-A*T;HPV!(C/A"UP 0@4%K"BUDC!C.J.>%2-/]S2^<^]:NF1:B5>=<U=G
MVRO/P^USR+IQ00"T(A-"+6%2B7A3GPRO;I):S(!%8;IQ"%L-YDQ?PY:!Z5;X
MJ/[+A<=?.<?YW]AT/H%Y(0@J&-"E+  V5AJP1YH@12CG12Y5ECL5H8HBW=BV
M_4<YD:V0KY7\NAH^A\/3UQR4V#07+=FU5?0UQ_65DIK[CN^_?5+SSG%^O:3F
MN^,P6%+SJM-_SZ3FNWA%2VJ^UTG/5"C+IN3)L>D)RY*E0F: P%0#C'@*F%88
M%)HKR#B$9L/O9]2?[^S_6+N^ U\WTSX,9M%O'-N:1WL&?G#[_C(88;.2G.]N
MV"PD%]4^RCIR^0T_OI!J.GD[7;_<&NYYNY!J8CX$EJ<"@S)/.<#:GOLQE0->
M8*+2DA9".44K'38\-@O[;75R981+K'1ND_\(K.ZI?@T$L>U9-^V=)_(Y53M\
MULTKU8S])[8_@OK':IH>-3;(I#RG0CL%S_X^Q +=!IS4,_H+6_Z=S9Z4,1FJ
MZ/=M6HSME:RD'*58:U @LW9C8EB.<:Z!%HID3$."4J>(D4#RC&UZ;U>NZH[I
MFL7=?VSZ6 !1$1_:3-B&>;8G@D:AI-*HRN]0YW3842K*57H@@".:'OXRO:)]
MTAO ;B.F?[/^EL[[^=HRN)2FN94E\[OE]\5?\XE$G&>0&%.'V"1I!&) !,4
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M*02J/?9-'B@%WD&Y]#SP7LH#C.-=E<_+?>,M/TQG:OG6]'2_6+Y,,!5:I5@
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M\UQ1M8UWX^UJ]?105UC[.EW]^<$(_'%NV-ILGK^:]6Q"(*(I)AD@@C. *:*
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MM@A!;NRD-,\!8]3:3D6!E<)0E:6?B]Q^!V,C@<8A;"MD8J7T=9([ +%[XH>
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M<S9;_&4=\U;U[:-:/IL?I9Q6ERD?%DL;7K#Z.'];)TEOBB<1E.<$"@YR*2C
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MV$RHO:+=BX?'I_6F;'JE1Q7WTFB2?%;KY.-<&&LV^<7>A_SJ4/TVZ""Z<=
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MF?="+>@YNI\$@QZN]P+G\,2]7R/]%I_W;#DW3:V^J&75_KOI[,ET/6$,9JK
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MTVTOHMGS57\7@>96X\-T)=CLOQ1;OI_+=Z:_"=*LS&VU&U0(LYG6PO!UP0E
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MJ5Z0$.M-*M+7BYQMO>G;DL52KJ"M:88V^9M3S![=>9TFHPICEOQ(PU.M0-2
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M K%3A R:V497#AV1D&QF);L#X@!*&Q%ZU8.?_$I")(F]K%'<Q4TYTH<D?')
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MZV)H(8]]TO*LE$V18%XMRB_Q7\D9K5/!EI^NQ^9"*!]+"& IJ*_C%$V]XUF
M-DZS9*V(PCSFKNW^N/'@,9!.%TT%W!-DGO_;V_^1<4;;_2V6'+G!+-:2?!MJ
MQM=FVN]+!IN4\)QYYV]>X+ #9NY_WG@'<XU!,Y"(^T'-J_*,1#1=+<Z6,?^0
ME^_S'0O"JA#0$2\\D< 4R8Y80P[:JQBL8!YO7C[X*'IV>>YXIW1-432XR,=&
MTXM/I)@MW3R:(+2A#9QY3G23M^=<LI"]BUQKE9"'G:!RY4/'.XQK@(-#A36V
MDJ]:P5>?UF<?WW[*=1S-^LOK#[C\B/'+EJD47))"Q%J/8"FTM)9<."8@B>@9
M%QB-?#2;M-<3QSN(:[S9#";F#M+GMU)P/WSY(<_CAX^X_&WC^1<6F$BULU74
MXRN3:UPH W OB_.13*&Y,?-GN,:/!RGKHN7SE"%W$Y5U"<$+;K:+EC&539U.
M3YLO+5I>6 U#+3C43/GBF)9M+OU]C+)QLS[#XN!1D!VAE Y ]D@"]NO&GPMF
M6I:<V5K^&6F!2@>:Z6*RX&AMF\GP.Y'7&]R.0<1^1X$'J*<#S&WO1EB]R3%/
M/U>[?UGGQ0/G,0(K:&M(*L";'(!EHU.TG,G=ROCWAME]%(V[ES9%UB!*Z !,
M=UC[=_2GYY.^?5#<.DT:)]=6,9L ;2)#3^M!TII!4]K4,SQ 5!?##3IQSPY2
M5(^8JXQLUZ0R(5I=113J>(;L./A4-.C,#2]2%";;3(=Y@*C>-L@#%?\8H [4
M0@^ VN[GMUBZR/!'QU@I!:S0B<+S>@VS-@:$55GGHJQM5%OP"&&= >M0 -P$
MUH#:Z !<!]O\EY?5;(49580@3T )XACK=Z%PR"JEHG)./F%+__\(VKL8U3+&
M?GMBM7< ]%OKE3BM+^#[S">&-AIGN 890N4E*L"$=<J(5(&,19*-[NI^B*HG
M6AYS($(>V[\/5=<3K6?].N;K37Y/CVI7S7K?DTY1R[H3ER>N9%4NY,!5!B3$
MGO>3(4L&)"'9*%6"5*KE=C;JM!:_F2W"'"W96&A/R<2\+A&\#E8:*91G?TYK
M.1XW>TUKV4<G(Y<'7E[G^'5AT]ZQJ87#(C&)3&&<DJ!\,>2VD)><E%%DKH.3
M?J<3L9W* ^\EH\N^D .TO!A:Y&/CYOSJA*LL;$.U&&DO%[Z0TU"SU\4Q"M62
M Q-282Y;7]A.?06[X>8^,L:K&QQ(O8NA93TB8#:IZ>67R=_?3CSJG"0:HK->
MJ^:$ N]2H6#;&,6,1&T?.N1<Y?C7]XO/WV\_\1P@VQ\V^-@@X^OS1H3!,$I;
M'"7!D8W$3V?+Q:>+@XB4H@NUI9MB"-IMO62TVYJZ[X; K46.NXTNWLDN7'WR
M>-6@PV+@*(EVL/K_Y^N)M2R+K"5$U Q40@1G3(*2BBAHDN7X4.)SO]7_/U^/
M5\'99O7O*<$.<CB/-M8ZAF@(K("&1<)PM+0G.D_2D1%]X$'=+-?[LR_^$,>S
MB4(Z -@AS=4VQ9*YB,"%D74DL8(@:$GQ;)U!F[3/H]R(] 3[XO="RP!]\?NH
MKO<\XJ]YO1VG<D^N;?O; 1*)^SYJT$SB47R>.)48O<O,$;2B=A2GN6#!Z61!
M>N$5PV2L_X8'/V=IHZ<MA?O:>&:#(.:E!)$EUNX/GV.;*_.>?BIQ']SL-_AY
M#YWT,<_W^M3:9(QU.4M %&2P:X5NR,* 1D[DBT*_VJG4X9L<_+R/;A\;_+R/
MH/L RAU#Q&BI&*:0J$[U_#%@!K2LD*YI2[.A!"UVNAKOFQK\O)=F=QK\O(^8
M._#QKX\7C9K+[ M2]),TB8-B9\=MAI \MQ*+5S?'/H\VPO7$$Z+W4NN#(USW
MD?'^ /'G )GG]0"C%S'01KS^\L>6<LFU]0P#.*],O4&5 @2RHZ 9*S(&XX,I
MCWG-=WWPN-O($=I9#"2LL1M GU?*E]/_V)(>F%)2:4&!())1=$2_SX5"4.VT
MERG[F';4\[7/'3?K,Y2:#Q=5!];^T9Q#<K9>]!XA,\UKVAL!R?0!TT'RI(L6
MC5HUGW#*\!!7LXE".@#8(7DG5K)EA@2&1F_64"UL#PB<:T;LL9!#&\Q]>RG#
MO= R0,IP']4-Y,LT2A@^B^OIY^EZFE<X3S_-*Z,W+FPLB^7;Z?OYM$PCSM?;
M&]6FM9G_\DH'O'JEPP"IQ79$#9J$/)'L3IRNM(JE(,AP(*TC6DM6@PM<DA%Q
MV7DGN,FC-/(>FZZL<<Z_X>SLW&K-T_\ZP]FT?*DK>]OG6'4R6ZS.EML-#H52
MN3BD!6[K1>7>@#,)R965OK!BHXO##4;<B[2GD<#<!TE7DPSMM-2!I_"5N<M5
M3VQN[<;JLNM-9QE<3@:*K5PQ=!!X#&!,MB6D7+AL4W^\&WWCI2H:@F/17%/=
MX^_BXH44"B:/$$PJH**HZ4&*Z;WS-GE/FY%J4T&Q"W7C&K\6J-@+> >H:/0\
MRP=<OL\!XV^5D4O7Y^?%\C7)]]/Z-7ZIE4T74P>M%;9RYNB?.GM% "+/D)TQ
M(6I38E"/>9+[/[9G5!VB\L5)Y#\VLB[%]?/7>67/B88I<9<W?OGS!7%'L=MT
MM:[OV_*8E98Y%EJ>D==+=6V!X(*@?0%IR[#%.B9VPMB!!(R;UFF+ME/HI"?<
M71:BA#KC;LN,5T58&QRX#3.2MCI/?-5)JIX%CU$KOC? [GK2N,-"3H>DHZ4\
M\@'UKG[KUZ26-U%8[RQH)VM9KHN H@C(FG/'D7YCAKO?>F_RQJN ;Q\!M-=7
M!X' +XO/FY:B%_.'%_&;Q6Q&Z^]W7*8)LNRXH3@^&W((E- %?$X"9,Q1ZZ*,
MRSM!<N^XX !B^P]1#X3.XK1Z[ "J#S.V3;9.,L^>:]H,LN2)_(<@:RN<@BA4
MXLI+EV_Z="<)6K?DC1M?- ?)7B'L(1H[&(:?-I,JWJYQ.4!IR,-\/4MI,_QB
M]6Y![LKGZ:J^\2(;2GZ=+*@,2,4TJ%H=$2S+X*2F?:@H7?1N]Q4<3L.X4<>I
M,'A*18T=A^S()HES<PG[B_GSLV75U?GXEHG%X)/C%I(DIUS9*,%Q%8 ;K9*L
M8UK$;F'P<72,8QM/BI,#L#F$TIX</E\3B\LMH]&0".LI>^ EU0Y4 V@+ D%/
M%6\YY^C:H/,*%>/8S*>#S4,5UKU;^6.N^8;*[ 11B%#S"C+5BPEJI0=&*T 8
MD3%$K[QM,]MN5PK'30+UY5P>J+<CRG0V+6?O3ASM.#2:+#X"L49KS=8*3$P9
MR)WFQHE@'+:Y:G6X:*?92,6^ 'F(QHZ,=GZ:I_:E8Q>U'[4P;E/']'**83K;
M%$0-4 2VR\</6LZU-S\G+LP*/F ,7D#4GH%B(4!@B0!;)WUR@^96 /DT"K-V
M*C9.,F..,8/@N0#YN>1:I%('5:28&7%O\:0%VD^H#&L?W.S51[J/3D8^?7E>
M4Z]Y28)=?ZE77)W/SE)!$Z41I*7P29&,@!QE";S88*0))?&=JEQV.F"YBX(N
MJZH/T.UB0$&/#)0W^=/9,G[ 57Y&HMEX$3=9VIYJEJQ]V70^"!E!*49A3R!?
M,^4H:4EIKOQPQW,[DS7>J<?QFE^T5L/8V9!W^%M.2*[AB]6GRQL34U'.H= @
MG:F3=ZRI;?X*G,U<./(7%=^M4N"N3Q\/#HTTN!A2G!WD(!YM;6&(@1'=%)?4
M3FW/=+VE@((3DRAP")I9RT[I^(Q< -!L\VJBD X =J=K6".<7_-ZFU>^]!11
M>L$]+P0%6G^T4 *@SP*8U29X'438;3SO(0/P=R6R2Y_I0'3<GG;?1%6=HW"2
M(K(2=804"1U*I'J%A6"0F64J)><=;]-Q]!!5H]];TP8*>T!N+[UT@+&+ IO7
M^*7N N07T"O+LWPUCW,ANWGZ=3&/-P09K1/*%0/<1@J4K53DK#H%$5%85Q)Y
M(FUP>"SE76[%P]C$DRJU Q#?M2 O6/VR993\&Y4TBZ;>*27K"7 B@;H$3F67
M976 19LRO%VH&]=PGA8O.UC3HY37.R"_RF^B=0FUHA:8SL066@G(J^,MLZZU
M^Y&9-BUC.Q(XKHWL%Y8'JO!@9'[.R[ X!38G.GHAG*\U$": RI+7H?8>@H_6
M"R:=Q=.YE9=DC7M4WR\.]U+7X79QL<;9$(.C'N#DQ7P[,>37_/O%&[<^T9L<
M%^_GT__,:6(2;0..18A,:%#,%W!"2C"L:(TZ&!9O7 )[[["I8VD9%Y)-W,<Q
MM-3I9OTZ+\MB^;&6(+P*L^FYF-_2UU69YE0+N/+GZ>)LM:WA*ERC9:*.\N*&
MHLD8P='*A,!\X"HF9^-.XS('L9K[T3YNT<G)4T,-%=L!E"_78CTCH&5Z)[<3
M(P7G1#H$0WN2HAT(T&K:- PWUCFN[6X70QU:$_$P>3L!4C])0 ZOGEY'ZS]?
MS B>B_,[2"_/LFJ!UP]G*Y+E:O4CR6*V^%1?_CH2ZI#2IT,?-4@9U"!\#E02
M]6KY'FD#WI!"IF^UF$W314?=ZRL<OBH_3^>$N2G.+J](6WU-C KE%=>2/,K@
MR>)933%W5*!]JC/:5(Z-TB2#D'^\+W"IS\_YV7*)\_>;!UQID"5M_4!_\MN$
M8Y;*6@'DSM Z)2M Z]0R$+0S&"Q:J$8%SGL0.6Y>Z?2(O.T"M-'G-V9W-R?
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M?[BZ4PK.=7",DSY$4U]D2 LAY@PF)>URR=S+1M9K*SW3EC:Z@=D(PNH <O_
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MQ!UD+':]!#"I8')1012!C'G !#%Y <B4\%%EYAKEU[M\YC,1//9\##1$5AU
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M7IK)+&&'CR9@[[P_$E.8Z_<BNQ.KZIL_"9K\<XBM'2W01.82%32,??M42PP
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MN:@:ZIF_% I>^T5^B_@74H+IP<I'UN%QKB2Z1N/HRN6ZQ"$/@>MA\ 7FCVG
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M%#7F9*4S*4F<41(%G*N(8/A@P>2X6=@R+>I?(CS6]6J)7V2^Q)U(U(,CN9@
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MWI*GY/BD6@<6!VV\_:Z"MM25_RNXF31H;@$0NQ0\JF7'E=QB5T(U#I+N=+,
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M!;3A$.0KC9D<:?*S+_7Y\<E8"'\KFE2Y6C0+SSL<O9$E88CS9(#XFKU8U'7
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M^+/;J6?F^RW.VKJCIE6LC7GW&Q&16R3AQSK?#:,B9MOLCH%^48'.-T%]*LM
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M?<Y)K:U)<C>@<'52T].'<G?+9JE-PW7+163R<>N%MZQ9+AH"V^F2O#5H"9T
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MJ:Q F^=V/3[>M/5$KU:WI[?CA6/D=3"1UV=CY'6,O.XT\MHOQ;?D3NO2=8-
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MXX9B)*F89%BMBP2JA3'4'HK!U-?9MM;Z&!)]Z)#HZ1@2'4.BPPK\/1Z,J*?
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M"QID=> :.\DY>\/=A;IZD[;\JHTZ@.GD17_HQ%X@OFT5T[:8/[W.50'<N50
M/PF"1*R9Z-[B<<A*;ML'2K=R\BV0:O/,)2V#FL "[\0$I&B!D'SIXFI*C]!#
M>0[06F0>X1L4>:Q)2"D &H/V\E ZXFFQZ>#V2Z7".O1GN/$W#/O07S,USC49
M#/A%+07:8A7YDZUMGM $K%>PHVS"E?7A"#7N]4;28Y(9=F[D-GE^<G2\IU2J
M3XYZ4V\72'&P!ME]H7% 0KF\IS.<PUV.N\/QY,$7HB7T:_J.=.S5)L>V/U!S
M@:A;=63E%3Q:&&PB $/BV#V[>$I/=1*_1Z+:7\.=:CC&HK<:R*"+L?1W<K?8
MPF;!.)=59H7INE]%T&+M"BI%1Z GR3_X0XNC<CIB YC&<A:FP-S2&K%47^L?
MZ(HJ.] ])$QZDS Y'A(F0\)DAPD3S(S AY3P!B^U*=O(%=>F6VN)B<$54E%6
MG"VK5;<D6_4%(#-W.*(ZK*3N8TH]JWU$$7JEJ2UF&";5^+8GU7K SM:'4OV5
M#J4V>LDYD)Q1;GLH.3\*'DPA:5QC77\#B53OO9^V\)-^V<+M7FPH$Z?2;?/L
MQK Y[AK]LX^ S!X62JUIOK=C#^BW$!MCTL&_Q!I%* &H)1^S'$AXY+P )9EH
M>DQ?_0?B2>L4NXVT5 J^(3)P5%_1HKV'-,]!G36J4:.HLMNRFJ6W&&]I_PYT
M^#A+D>]2UQ5U]3A7XUD3'*ICQ<KF-,L5U$'L]M15K2OY&SP7^"<8#!03K\KK
M3X@S!UN,WNT G]6#X'%/15I%D15FUQ(*%9-,YIBH]HE)_82 VT.(!)Z!&RBW
MK?X)'-)$_F.:"IV[I+QB.**IJ.HM\=-#;/.<L'ADC'&TAXUL0<L9&#JS.)I1
M8Q2'I#G8^,@F861KR^<5V4>]WT,@_B]<XF@I@A%HS;X \-'MS&JD_^5 CS%,
MT3#.BR7EG['^CBB#T?:78JK84>12R"FZ*Y6WM$USW4&"5&/X>DZCE!&!;50?
M4GU6*$'U@.H*^MYND*6[2MAO3.D8VT^PDDOP-6^N4F7M\1VMI8O1E38EK"#Q
MPAL8FRYH':^66]Q>F :-9ME4Z7>S0:UM*0"4;<]'>B]2=82TPP-G#"?UHLP+
MP=P@?4^98F^8Z101:4WF-C:K8V^6$M)4"H0GE[A@8TQ331EDD$K7U#HPKC]P
M%)0$TE ^(?CS[M[J%$D_5T@&Z<I+9;;BJS(LA*%SG(33*,  4Y2C"DV9\<9"
MC/.)K@11/ZS]9*%^AV#0D@ NSLOZPW6J39 L2GJ<T,#UPB2UD\_T.9O@;\')
MJU\(6*<+'R^X'GBX>017T8 3KZ!PAXX?R^/?R_-AW)_SX=$1<7]\^"?(2]WL
M.@MRBM''YA8#D-;F;<4ZMBVT!26QK*3>7-\"K]9G3:@1[[J30:4\[10ITR:O
MUVF1X8=FMOHQH519;V.Q!J62=::<N;.I99N7\.V-T?W/G39WV.6K[WRC:-9&
M[?,Z'H-U8K-<T@&%_<H9MTY- TDYNX[&$BRMF?O9-CNOU8!<Z9+V*7KW>S!R
M&78&Q@%V/YI]/&S2_APVRAF!^?P%:PN*'K1%O&*"%!7840<#F!\J H+1>0'X
M:?2P:XR;0CL[I&),,0-"LHMZN05"QT.TI(,))D!)I*<L _0"RT6JZ'F[3BW5
M28GPY)==SU4>%UVKV0D\,(P=2C)^O!]1@XOOPVK 8;WP+@5E![L,*RF&Y'A?
MCL*31T-R?$B.[S Y[A_=./U&*_UKR;U<*'Z*%G[M1[W9U7=UFJYK<V/I2O5+
MMJ'$Z(M4[_GW1%5IPICW4X1:;J2^3]QCT=O@K"^EQ@X?1M5/Y$W[I3[;$\IT
MOK@J J(73TR_>/&RMDD 2V%5'/AY;$Y:?5[!UVW,IV$ XTZ$9-7BWC2%=M]@
MW==/&C>Q4*6)H"'*6[A_%=MEH_3^ICX'GH,='%OY>9H6'7;S>8(TZYBMOW2W
M$-TX:;TMX;9NE-Y!7GK!PU6WX_,T.=T9%R622C&ZP(TV\,'@-[R!<(VO%8?<
MRW3_T_[8WC@+[\KH5SEO3GL >]WP\,GD6]I-.^WDAL7.NOJ#%(*$B%K%&?!Y
M\DF*#:@V-^6RH.03UZDF%E3&-M6-*8ZW'9/Q84681IE3CB%\/L9J$6V9SQ?8
M/\LJY[3X(+&UH:[]]7+ID[RJFVY6%:JSMDI@B"9-=U.:(R9()_,)(&2XETP3
MGG9>7K5>=,N5J40=S'D5YD>7"IS/_=0HS_JF4:B7L(Z$7EU3X3V>WZQA=IUB
MW+)F*]@+5-(-]IF;-RJE7EM\"GA58]Z<LEQLLO'VC"U46]PNI1JM.@NI%'J
MVMIQS91UU&,H>X+3/UYAB7@^U_ASW2-+-W2E-&KJUA*&TI7N#9 \=T%TN/#2
M"],1UIJ3$$!&HQ$E@\3ZB<Q(GG6"[DCY%^DK4 TWF?2#76)+0 R#CY%6EHQH
MC4U@,Y!5HI-RHLG=SSW]O%][^H),5O(C5%VL&\_175YVW.'9VMP8)!X)O8"N
MFW6H';0O B]6V2_6Q0:P'2.-%=,+U+>;(TY"C3YW  7PZLSV%9SQ2=EBP/<1
MNNW8T,/&K516!T&LX^!8K?]<WH2-+8[@E4#]XQ?8\50GXZV6>B&VA&N%J.A8
MC2!C#A:&4\<FY:RIM+3&.X3(V,YA;Z,B1EWW&[< G:U"'H^3K/-P2;HN,?0R
MBV15MT1-5^%R'URONE-5]#T_>K2W%7TO>J:P,DRG[CIY?6[WP^5\+\H+<0:B
MI*55<IO,Y/BO%&/[@8MD 0NVSN9YH<_B*IME-UR*;:CZ_%.>6([6D+38Q.M)
MN&";N&(P,(FC_V-9Y76:&WLE;Y$SV;12@D1!["%R(L _'>(3M1W< ;K]4/U0
M0(I<Y_EHB2>[RG>_RI(J>E6.A2X4>VPQ.54DG"\X$%!QG'M1MMFRSD).2N=\
MZ?=M+9Z_= 0M]FK2G6E/44\*4019,2TJ15(^V+D./9<JX_EN\;K499?96I01
MAJV$T\JU7O$ETQN[JQW,'_B:%&["0&GNH:0W"JOIV8J!R:;%=H;T%K51?TFA
MO%-R2$/"<_2WOQX_??A3=&I0/>TQF '0>%I;Q+;/A6MLD\0<VME?4X MK0J(
M6[L'( O6:SV &H!V^^"2(H\RW%LDE;E01T07LG9W8V_1G</1B!B'6A"K$OHQ
MM=VP.-5U-,,A"O#9 ;6,47)300$D_!PDW%>OLEZOFLQDDGLLJ79.>,A6]B9;
M>3)D*X=LY0ZSE4X'<LGS"&[14TI>-FHKJU#IN5;("TR#=$9TC;-ES>M(FKB:
M)H6*^E!)K6K_8VP"<HW)N%[?6&2C)\C6XY@SE<Z[S2W"!\5./5MY;JJ#X/29
M4K0BGA*HR!34P/CFBLI4N G] BJ%2[;RM9<\ "^E!3_Y'TDK[CGC_/'#OGAO
MW/_\<ED@$#<SA:94^=.?P'&[O8MOR(A%4INV7),LQ89T,:5),BF(BIE/2Y5$
MX9_I$OT<T;SR[0QL^MLZ5LD6#D)4RYDD_+&V*\,QM]1$1SH<+?-DQ24&),O"
M.D1[ ?REI<6N2T9P,D.6>40KP^>3C.S[9(9GBO65K3XDG\M38NDFV!%YNL3V
M6EPSU@B+WKAOW=A[*(.F?I"0)SI;OYX*T2O7-VXP&:=:##"<V)8"UST%^\%M
MD]>BW3:1-#*4$6,\P\T UG1EPPFZJ_VHL"DX]W?2K?UM\OJT9TU>6_F>/3S"
MGO:MP:O??70WV1"O*62W\6.Q"SX-UHEI\!:%IM@P%=O1+4A?A1%=BC0PH9RG
M-KF"N<;MP5:64_VWOSYY_E-TD!Q&*:<SU:$G?9KP+ZYVH,?!>;HL*""58N7.
M _D3PU5Q=# "'PC,5 J%:8)R8PXR4IW,XEFKB1EK0U"K2-QBE"V7".5"IU%E
M^7RTK&JI_M:X"?O5.;1V,#ZT^SK2<,MY:6)O!^DA>&XE'?)UHBP"'2Q5EKPP
M3ZK8GS(30+1N8%#J8=DANP;TK.\59PIOZ9V"<2PQI=K8'W8B#*H5]]I-F8]U
M5E%9;(QEP!2'ZI'**3'<*DJN)H=62><8#-P2]J'J.F2'QK3TS;.4Z#G^M82!
M*W2@19^J#4L2XPGL7FF!@<^CF,7TD"(G%MVJU*?*%K&X#4 _^JP)-A$4[UW9
M=;&UR_3&C*4L.VYO/F]7[Z.#^+1O+<G:Q\8'4-P[/FS?=2=>UI9>RQ%46\TZ
M_O'R)5+4M-X2CR>[ _#VQR/E<G1P/,V:)$=VZ#2KQU6^T*<$YF<*Q:";LOF.
M=OB$<$&!WGPV,W1[O(&FHP[(H.DB/,_X5:G&7OK=Q(($RHM\OIS'6[R0[#QK
M$!@PS1  +GF!2\4M]_3H,:*URN7T&O[]K#<UM6%![X,/&L;X2^$9B1(RV708
M>?@2ND*:<%T'7E<[0\^AM@:YFGS_VCR ?5=KVTRH;%J3.0C\DWO!_F8'6XU1
M)NU2C"E\J7*;&#P%Y1=KV9"G!/>S@VN3 X;<<C5HF\K \L)5$W6*P] !5<M^
M"]C&VVW\=C_XP%NZT4SRVO/$Z7@07KAN_V"R%'J6JN3H56+(WP.D5&FR>M"4
M#^!_MO #PM'H[E'NYSG;L[XAK\"CFV:[KLC=QQ+K'O+\24ABQT'T5TN-Z0=U
M-0\J$TQ)FET]PS21IH@Y,^TA[(V?M8T+#GRFNHD#A>E)3VD&-$7C(Q\$P9&B
M^O'<6,_$8S.Q<GL-/FV&;']OLOV/AVS_D.W?8;;?RO*+\6+EP]N*,+;[!L%>
M5T7-LUEYBTJ44%5O3T^ULCJH#V,5V;13Y3I58_0AQRJYP0X5P>B\S@<=I;QP
MHI3J(3X#2TB!-SGIY$U*7(Q8U>I+XD%W(V,]ZE:P/;8/>L@'^98]:VO1H@\F
M:-P+"W GX=?=5H4:JT*Y35IE"/O@3+K-S;F*/; =8<\B;^0U59FKS<7EF'7^
M.3IX>LBNVTL$2J=)%?V>)55M*1J\_C5=;PG'93++?$S.AOYR/8FJK)=T_'=>
MIGT(LM#YK&->D31DQOAS= /VWCPS13 4Z;*HYF8<<X,COS8*=2.SA/<D'?06
MRT#?=IRY-)6;'D ,>WA:.2+6*H2A)"7#XC,0O>B WE\-SH6([(4L]4&(I,QL
M@]"K%>1M_KJE#@RD+LTPCYP+J,Z+<Y.4^$LZ\52'$Z>QC8DH-=[A5ILTWN92
M<O%&*@Z7^D.F6O )2I;/I$WBF,_;#=FU*:2!@)W:,7&,,-H#0C";VM;8>L4)
M^^0V8Z0[PB+A]IA8K_),M6>PC'0[MT\U]8LJPS[C\!;=D107@_?BZ#F;1KP7
MM=>)F= 'N N319W]7?WC)[#_%[-D]?>\("&D'_WDVEY@8/QT@WU"QLE,W%"R
MQ/AK,>U?',-SGZ)UWX!)WZ3JP6+X'Y'A_U]-&OCNQ='QX\>=7S\\.N[^Z9K;
M/GYX]/CDR5>_[<FSH^-'W3^U;_M?-!,\&S#?]2(I_L]?3O[B+0FMVL,CF&2$
M9^1II)2+?-^4B^#7LNI_?[3X'!TKX]@.$K36K%SLR&!N*R0MRS*'/_3T7-+!
M_$^V"40=?KT)HK+</_D,?K!,'>6>AB;R!]R18?/B^ ?=@%W&EF53##OOZTS=
ML-=DBAX->VW8:\->^RY3=#+LM6&O#7OMNTS1XV&O#7MMV&O?98J>#'MMV&M]
MV&L*O=0]23^ _#W=7N:&^;K_?OWRN1MV-/P',SJ;LD86;CJ R>HC&HOQ_>W_
M8JNL\2QAKEV5%_63AM<JR2Z)>*<R$Q-TS&,K"?7./'<RPE:3*D-9E# ON= $
M8R;54'UB/0P1> K?IQ2;3I#O+6,68%4_[Q%RO@Z_09@O1=,"-@8Q(LQ]K5=6
M8 %%1-IZ^]I4ZV 3'P0:(NKP:XRI>S %=30*%BM-DGQ&W57-?;;(BF-2V 5L
M>CB9NR:MHP.JG=9EP5[IBWYO+"C)84F1+] @-!$ZB:0+?A5''$V9AK3*Z\RN
M-=%]-E'T"41$Z7O5(,J4@8!DU<N$J] 4)>GQXZ-'6%1-_'?!VN]YEK*$AFI;
MEL13W1JYO3IV;SJKC8=5AQ,]/3HY&!WV@A6D"Q[1 Z!'-,\2SOFK)G]6<S]!
M" U8]-Y@T9^TUF+ H@]8].\G_?](BB7"O;\-<<JSH^=;C"*@9]"<?@!:J T8
M0J@CWN O_UTW.ZWT=G&Q5/ J,-BO@)%E5JQ4=/:K;)S-1V!\G0S+=-=E4@S/
MSCD-U@:9&]GG!(M)8U0>6Z]<.1Z#B80+>+J<+N'Z1P\?'<?K89.C#+9[C6NI
M-UR,OWND5KKVUIF_W<NBQ_XU,;<6]"-78>^X_+&[9EX5L&-ICN=OP)9RS&KD
M,EE+MA"JMMZZ<IQH#JUJ>^.0$*4;&@%XSU'&#'2:6I-(*W39?KV<8V_6?V=!
M5RSV^L#)Y]*#SR)^5\[+UCP3]W_UV!J]V#=(.3'+$$'?ZK2GFOG-D&T*%053
M4/@4U+G?:QZ)[!6 .NRE^I7X.%.I*L1V"/-,3(%9RE4G7T4XP.\B_!D=_!W,
M9:/G+[;)IJQ/<6K>"B4/+%L"ZHZZ.?'W^UEL_[@WVDI(;:3+LI0'ML7<3'@O
MJK'VZ6CJ;SW^;-6#=N>J55>5C4M0M%1.SZ2V>45U-ZPX4 B9V+;()N"ZZ58[
M8T]VQ^) 6HHY+W1]YSKR/UM7DUNXP5;&K[5RM8^Q4^XI%.NSB;6A<,,$E6%[
M0$+.$B PVE3JQDTGP ,VT=PY%MA.A4K-(OW%TP9.TKI&1:L^?(!A56[>_H#/
M&.H9@O<>E6 'U-BL@\GI; K8O%@LF= EK:08!-LHP-&Q4KPN91V:^LUOVIYE
MBU*!*EJH?R.6$8-7+F$]'4<_D/8@IGH167VXH97NA"M!SZ;"MG1);8AZ@LM%
M 4U%&ZMBA2='3ZQZ-CUFYQERAG)$&9MF=1W$!3$/!=I!4.N4&D/X>7VM.'3^
M]M?'SW["3C%MTG3L98(G;6Q3QL&EBN4ND2/5,-1U3OI>JM\>ECN_R;$;J:YU
MQW]1]S!F7AHI9:;T4?_\AD]9MK#L2F9:9A/5E(0::E'J#,LDA_1B3"/'+]U=
M[$]"J@)R%I$5=FJ$Q]+FW.(NV]/4%2N+L\OT7@DTF7(M?;2 FS*.;O)$:7Q_
MVHA"RG$[6NZ&I2=J*KBS.FKYE8ZP6Q,^S+QO2BIL;7]83B:@J#RJNU+380I#
MC3+7=>%@S$<G%@XJ(NU$-<3"9I=(D%UB.D?"G^6RD(Z@\ :4,20A]V(9SC!L
M9:U:M\8P%Q1W=>805"T>*]QG/ )KH2CG^;AM$-2J_+$0/ESN#YXM*52$QX7I
M1 S2JTLBV;%<UAQ9'EL;4>M=/2WN*^RC6NQ?P.02UDGJ7>V**-W>LW=J,$PW
M+=R:L2*#CD7B,MZ(*)*WF"95!"B@!A1GB9S35C8[YM[73<XTN-8)?IN-ZAQ[
M.61P;]W"01HJ<+]-I3SKWK ?]&Y=-=L!6F/B(FP,<6V*8ME>C42DKI%MM::X
M;]TIX';WQ;-BBO8=]T68B5;,)VY:&Y17E=&)H4PV^=4L*:;+9)H=MCNQ@X!8
M/5:W(T*GFY1%IE0JNCC"# +CUZ.Q#U-E76KI%#>$/W7Z-=O,#C[30UN68XU8
MF2=X5&%].<%9 EUVE]PK6G/_2&.V;GT]I**_=RKZZ9"*'E+1O3*,TOX81LI?
M;&MHD+>V>[YC ^E.'3\,=,R+D^AN'Q;02Z''.EDWU\2)+!,-.]O9C>UB.=@J
MS9=Y=9U7*1\>!W!Z[V4_[*='3_HCP,3D2]DIY:5KRV?((_0TCQ"&803S"('0
MD-Z_>M=FQ10.&'MO,5$W6-1BZX''Q$SK9&35W/9MMC!^M_:([@9H4=MZ4>6X
MR2L\= M.%DMT*+9ZS7$$A$#-U#2=WX=468G==HHEP204MF/#.X#ZRGS")S5Z
MOE_X=WH\[:3%EB@>YI*:YA@4=Q]OH84ORE4R@Y5 (N0MY@E)AEWL;)3-J$W-
MO1:8TC/CLDIMTG<'=?L$Q!TS]3J1S+E_R:?DCEDOZ6^9);-,FZ5L9'H-HD\#
M#[K#2_!KDXG7M0]4#I]!Z+9PP0TIZ%8H//\\H\;S.6S=I#*I?4.V%4?C9)%0
MHRN=%M?N45*'\PAHM)5H889?P4NW[*5:_%[Q_2W4HK'76N* )CVN@UYLQ\LM
M1<.1#(@XVSN>&AI$-0:6$!7CAS#=78X0_VRAU<0XJ7V<?V WIUF=2SNB[S/,
M8,6%L-)EK&%Y3$[O"GR":S#&JOTO50B@XU-E'%<P6)?;ZXS+2$J$I\]SP<]L
M?#>=!+9?T.H[N?C";;-3*_%IOZS$;H3/8"C^*0U%.!A3[1[2YH(/NZ7@CB"(
MH(61M9/>G,%2ML,OKSX8BS".KLM;.(>KF#58Z[<4;1$\7$=TTPX;:RRCU9A9
MUSJ='#U&_*-2;13CI#,#$09-\BDCHV[-]-S%$G8@,[IGD,(<>$52L39WZ5L<
ME&3*"@MPB'<!FQW-J'W<,CTT(JY*"8,T5"#'Z RT=SLZNC$(QY(@6%9ERL.B
M$=A 04I=@P'W2GJCVG.BG&DDD ?_620%_#G/* <ES_B4K2)L>8JRA'LZ:_4>
M?<6),$K+=S67NA-,^'RB0ODNPO4.,Y/HN6&T\ J3+RI_<JB=//6J^WG$/^O7
M$?\*?(ZJ[DOH9Q=+LEM"?T+7LVN+D)41>KC@C":%]#A37=W)7&]"F!7MR\3R
MK859KY@>&LX"A7&+#BBYO5U'I:Q@0]R)K2#=M$&='[*=;V-F^#2*!12"SZ[(
MB>"_5"H]4YGSV/1'Q?J;.;> 1; *)>?)9P<_(K7!-W964R%\S@E#F34,4<+8
M X(A8TZPKIP@0EFI3V%#(-(2/]&_AV<TY1A;UIDO\0&S_)/.SUH93>W7-Y8V
M?"=%\OP\7A".3<0P/Y5R>0+P(V<J=2"'/"H>L(8>X+@<1GYC>-C=:FW,DLHR
M\V)D2%&08UD&+)*#/%*@B&BT7,G?\+.JUCI8W7!6C@DX*:,CL%%%$_S'LLIK
ML(QL.O/0K UYW][D?9\->=\A[[O#$N3&($#14BQA_O*&U7C-4$+4,:#R"#F#
M6<C%LAK#0H)2^7)%U+C&;&+."D]+4_,L2TE+M\":'LP(?.():6E=?H4M7N"+
MAB^^H7WRY'-T@QD26F43[DG=F&H!*WS&/S.5;RC^V,M\P1D,OI)6)'S*W?%X
MPXC@#$U0.F0S@NX?H#=,6Y%]6KF"^S/R-5EZ&#S7MEK>N[@-+4HCQY%XL$-/
MXMD.C6;/D2"DZ-ND6$[0/)06YI?+Q6)V_^J$G<[LMRFNOW\8=OW4[L10L?Q[
MU0P;P8AH>Y=51]YQ;MZC4IA!%0E 74/OE6=IU[:V8Q8X#YN#%AT46*>AA]7J
M Z\\-TQ"1<WG&4F?_0M=(KC2P]"W6MMZJ)HMG3 ?F7_N%1@P'1A"6\=+3%.V
M7HQJQ750$).78ZEU"N;#%SAC.(A&19Y2+!$#%PU<D>:Z]1J2!G:F"=V2!3E[
M5M-U#O(XU\'"3LLR128NBO]8"62L]&(7D[C.N"T30K8[</Z["1WL.'B@5N+@
M?GO0(A?3R"XR$>H%U@ER=U%A>B.=@Q+1DB]_C_#6#&V:CH=HS+[&@)GN8T5>
M7\.S;!6HR57D.Y4HC\+ CM9X536)KU)NR^J3UAB4=["I#J@*)_B[EPK"1HAR
MS7^@T.:!K(?*,#P^>F(G& 277BYUS"6LI)A?C3P4]1 QQ,3"A)E"2,(*$7:>
M0BOU156V6#8<NT8%ED]R3*]0T@$C#/BG(T+P3:Q>G_$29$2Z^[EN"8]DDE0Q
MUTN08DJ77#;+%$<>8ID#EQ\'^OCHI*5MU'G!R6*>#5\ =7O;UL,Z,E"PU%(A
M+,UU+7UI!?DC;DI'H$:B6$0+_E6"82N!DN ;\MQP4D=@ES *\E?-)@H*9N@]
MY/CSY31V1$S%EW!T>2%E$_"@1)UY)E,W]VR)KS.D8 ;!BD<=(--?3$0F.Z]W
M8>O)V -]*'6)!:;Q/[@1&VMPR.G12!TJ<X5:$(]_R=5)72\KDNBDJK!;(2^Y
M4)".X=2L)%?K<T#.7;7:6OZ^U"BUYJ4/B]92W3$7MX2+TUL5+S':O*5+/<!4
MI%@R[\!K="4Y4JCJ)2.QT)H^O(&I+E7*?$G5*SU@<6M6IIK6/[I#P]?PM629
M4C7^W3IN]]>C?MXSCQH,'-C4Q!F+AQXFZ>H]=*>?]\V=_K@ "P@&\B%9B3^X
M2VT2L)3G!"U!6_X!EO''Q -=91.P37D3X]]C,#5S)HU>R@LM^(4<<![L[TD^
M 04!0Y_AJ?SQZ/((/#IX: 7G\G\\>1C#^^'_<UTBG# 3-&L.GAQ&/X.M7J N
M>I6LZD[C9Q]#/,^/'O5+)J7.FA2]PYE *^A[&WRV?_@G_]&+S/T^ 8MZ2/[T
M>DDV6&NA=UP^]JZ,9@EO^\0O7##Z@#@M"Z$)<-NZ@^%668V\;Z]SXJU@CY(#
M@,R'SLZA898"Y?(;^N.*ZZ)U1]MOU##!5N:C7HXP$1&H0TZ("R5D9(?\>W0=
MQ\NJRE(;>M"5:^#2\@/P/#$DI[(ZW4$ PC9ALA',PGQ./V@/0%EN#3;QIK'
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M)=GH$X*FRA:PR73QS&U2(8B33Y%X#0 +DQ*^(8!G1[<Q8-D"UM8PI@ ^9;D
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MP)H"';PT0 IK%VILK_=</3^</\'-7)@(N=S2GBBUG35%'QAJ4NFBJGBY",,
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M8KU+#%A^?_6N8.":YV/\+1A;[QS)>M@/@X,$'M,1O](9F/"#6TUE-@VE30U
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MK@FPB?'T4!')*#-)68P9RDS84(7:&X1D!6G]::P6R68MMFL^7V#MD42&I.Q
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MLZ04_(:IJM*'^HHKKAR!9 O7D$%>9\8TH)PN]4$ONI@9]I<BM'^TXM:&8VL
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MZYV 5A3,%IFXO69=Z:G.BI!0M@&!PXT[!#A?P+9JM>BHHM!GE6)IMI1/.7N
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MU9(.XCN/[>,2BL_[)11/+5#I!UPZK/;8<)=BQMUYC<J$D<5:FWA0;&:C-,+
MQI*P81&0LDA EB[L(1>?U3$--(:9C^'&^UVS<![QAI<88H3R6PC6,3JHXH6I
M.6VQ>K!U9GY.V#9UK$*&80TIGT4$+?"!JC56&XN#0E:HS<71)@_IC#3 O1L"
M@JQ1":GKAW40:S8-DD>:SGG1K\-W1;A?4;KA$W=^#^/#!L]!72=**K%T5$CO
M5J/,R.(@*P,<H((TG\%%Y>#ZLF=[#7660'6DD*0'+E5IJ6ZY5#MKF?>T71L:
M5>)FNL!+1FSC2=;(]S,IG1.@$=ON8[=UV&?XM[8/X-1A998V*VSLBKH\2@%W
M-"(HV'F)T5#&5]QETT5_^2+8N61":'!A/[ U%0:G-8CZYJ7#@V#G N9@EAD
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ML\'8/=A;'B>Z&Q?6ABUK6)&,>_>$"$0WA&F?5U>;X1.*BFFD*WE9S+3EA#6
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M\-:@5*B40T[<-K'7F\3>P3:QMTWL;3!L[ZND&%Z[0WV@( 97(E59# (&+S+
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MHD-=)(A $,V)5@T% !SEHP"/YUV=##UZZS7DZU8%NBKP9*L"MRKP$1WE/JC
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M2GT4WT0T<06I@3&J@;$1\SL?SLY@(^&C6+?X]RZ%H,11-!DMTA6CO'9H'/"
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M]EF$5.4PP#8F@U,C*UUVJ.>9B(+LH<A'V0]*13=W8.::<MG7GJ9X[CNA#CL
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MMSV5;OA[.M\<G>]I?$G9:T@<3W]ZC- G#/_MR73ML&]R)HA-&KX+"S1;M+8
MZLMZ=)L 3FX<. L]X3TMK@C<^7%PF_!]#9KJ4RA&A^D7?T&TUV#BO2#\CR\'
MJNTV]_C8*:9547*2P8N$8-_P7YA4N#LT$& Y@$[1FZXG43(O_/#CL<=F$3(*
M\GRP#2H>9_<9Z'==7$B%Y[4D P1.\4J\7R?>T\+]28YI,@'68B &>Z$_-[5"
MHO)^#Y"?3 '^:SZH]RRYI\ ]!29*@0O@LH?(RB'R ]O8BR&VMYE7;3/GQFQF
M] ;]IS%C^;I:W5O&W\'R=C;>6;N7@ B.HSTX]M2QMUGW-NM64N#>9MT03_[
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MIO2Q>\\#*O)TZ4X@Q- ,9]X;X4A_A8)+&,>4C-%)M8<C(X\9->@'H#^C+/Q
M-]BQ#;/D^BDTTJCPL&Z/<I%"==GO!![3UWR]")/V1D]3)\$9SE-#74]53Q2^
MZ+B>AD,WJD: Y0.TFI^!!-9+&*KIB:9+Z6]M$QBF"\ 5T0)F!.4.=<U+.O:5
M.:&* OQ!J'2'".A45]U<#'A<_,[S:F%K>+46A.@8(E2C5/5UK!@I I"O"/9+
MZDB.;WS( T"0JE D^.YI@F>C,J!#6HJ2V_MAMP6Z0#/E:&G (!18<5BF:9C'
M'_/H1Y2:(BT@1;P^;*:")Z-:3'LL"*6X@L?IY/L<OHDP8IMOS YYQ&4>:$K,
MY\&&,-8E.S#3_X"TAZ#&QKK8@I8?4;>!^<8FT#/J(V/T %.9I;FH,TUY5*QQ
MASPF:9>]PJJC,8:L.IIS)*Y,L2Q=W'2GK/5$BFF2CQ_L7/YDR#H MR=&+N.J
M7W:NN/AEYGXGR'XGR)IV@B"Q</>7 W[$G*-BJ]TN%6FE4,F6J9//5W)NR2D7
M:=ZESI^%@_?O'L&HT[IWCFR8KQ>!O.&3+USY6)==U\T,VDGHRLEB@SB/6 =H
M3G -&R4AO!\8QIA^FFI/B<8 46%/6R!:!VI1BC<Q-L X5@#"\F AF.("QM?[
M;\#*@[9:STBT%")/>E%X;S65@G:^/$BA;!67+ _RIF$K5OYM54>^56%DAX^2
M?9OU2@7]@M%4_4J1AN]8RV_D6G(7S[K5S@Q+ZT6=#R;+_&SNV6;M+HAO4Z#P
M6)=%-JE4/WXHE$ZD_B37X#51YI%KBUP'0G IV2!%[CK6Q9J=A?D ^Q-^?@"\
MWX#;9C"_#(!W>*%-KKQXI7>@@[1'8*KP=3AK8RT_4&:H=6ZQ]C(32^\-^'DD
M7Y0*^PY]%NJP4"\+C\_V,#QRQ<$M8HMKTK^?5MZP:W:K:3$6MELL;9LR= ,.
M,F$0R Y/2L"._?P :!^3M?/!N\-K&Q>OGQG5A3Y_HR 7R*V/SWX:D/-0<NV_
M/OI<S9&N;]^Q,Q7/LFW;.EI7/"ONLKZXWW2D:V%(9C;L%P50C0\\YDI%UT?;
MK#'LA3IOYM7N@HCA9M?VMB*3.^2]O;VXXY+&!L'?>:M46M;NV =E5QB4?6<1
MS4PK< ?PJZ.ZWMG_ 5!+ P04    "  [@:I45)?!($,(  #-)   '0   &5X
M96PR,#(Q,#,S,65X:&EB:70S,3(Q,'$N:'1M[5IM;]LV$/Z^7\&Y6)<"?G])
M$R<-X#K.ZB%+LL1=MT\#+9XL(K*HD90=[]?OCI1?$MNM@W5I6JQ '4DDC_?R
M\+DCI>/O3R^[@S^N>BRRXYA=O7][WN^R0JE2^=#H5BJG@U/V;O#+.6N6JS4V
MT#PQTDJ5\+A2Z5T46"&R-FU7*M/IM#QME)4>50;7%1+5K,1*&2@+*PHGQ_0$
M?X&+D^^.OR^5V*D*LC$DE@4:N 7!,B.3$?L@P-RR4BGOU57I3,M19%F]6J^S
M#TK?R@GW[5;:&$[F<HXK_OZXXB8Y'BHQ.SD6<L*D>%.0?%^(@U:SP0^AU=P/
MX: %M:!1/W@-O%D?AM4_:ZAD!;O[,<;.8GA3&,ND% '-WVXU4WLTE<)&[5JU
M^D/!]3LY#E5B<3*-@_VEE[$FR<*=+?%8CI*VLZ?@A\Z; Q4KW7Y1=?^.J*44
M\K&,9^T?NSAJJ.6/18.^+QG0,O0=C/P;4!=4R]U.O9ZO<7PL$YCK7:N3LKV[
M2 ZE98U:N7Y?TU5KN1ZAP5:E[4.4NJ)R@ X&_<0Z=WO7@_Y9O]L9]"\OV.49
MN[KN7W3[5YUS=M:_Z. E7EV>88_>]5:;OK015^^O;]YW+@9L</EL=>S]WGW7
MN?BIQSK= ;M^?]Z[8;4&+]6:>_P5XXE@M9;P=\5G:T/GAG5.+Z\&O5/V-;C\
MIM=UJ&Y4ZX3LP;L>N^E<O^U<]&Y*E[^?]_YPL<"6>K6ZZX+]STQH;C2A7V3=
M2$N#LT>@V<]E=@-) KK( M!6AC-F(VY?OF@='.W*."D7 I- *8;0MI&J6G,6
MDHG *+5+]3H]>V)#:^67+VK[U:/UWSZ+^ 28AHF$*:8P&TG#SI0>LUJU]"M3
M(>O=02SOI"FR?A*@G-;A5^Z,^E9GO.4&7: 2-IZQVT1-8Q C*'J?:$B5MDPH
M,"Q1F/-Q'BX3))<9RQ*K,T#]L0IP!0&ZC;,QWFG)8Q;R !]IIL:8OJSR_=8Z
M)!" ,5S/J,N8WP+.NR+3X#.!RN"4L:LF< [J$$B-U0-V2W X:B(0R--(!A$S
M&?TLQT]!0RZ$#!A+$V.9017+5-H(#30I!$Y!DINB:DJ@F1,<)MAPMNJ&;P %
MC<>C %@H$_0SA6SIUZ+++\H2@RS;91+B(N)49^)U$&<"96+L5IQ8Q+A+'<]8
MBJXGU!":XG@)BSPBYL'4B#SA"M@B]<AB[(!84!@P-YUQ^@3<1"R,U=3,@:)A
MA$R'U:]EG!YZO5'+XDJ\S5R9-6V_@9 WMX9\<,\_+U\<U&NOCTP>U#P7T$)1
M82CQ=L_XHJ+/N 87)G2[',9 [F2 V!C&TD0T@KJ-D2>(*^A>2!/$RF0XCAA$
MJ]C'*]4J (&/#=O#\ C >/L8].Z"B"<C8!U<G-=9C#U<:=/:@Y72AN[\K:1:
M(/$X(?F,5O *?'PX29>=)PKO313B1&3G0U!A#\HE.Z?+UD.@[#<>PL1#YXEA
M@D7B7/VGF_:^)^K5\KXS_!0,%G@8'T?FGP9/D?),P#.S^Q B_"$@$/*9? I1
MF48!2 H3:1S58"](G!RJB98DM4IT&F+ND)7GD"4ZBCD)4J-$PD)=C(JE<-MF
MDPV-%))K209(G^D<]28D*3.4?=Q:-"Y5.6+"?3DJA!MF-RCE".D@BSGQ*9KE
ME%AF,1SA<^)J*L>K(5!'I#P<#V)GBGNVR!T^!^36#M>1NS,IK0%X=SK;&<>(
M_8D4!$]N5,*)M[E!:%,)19CE6LSQ@XB6?"AC:6>41S=-2ZO)0<VAR"^$>UU7
M2C"7'NYR@]),IXABX_)^$"@MG *N&!L!;D.P&)A1"Z2T2J@+%IH>L+B:9(H,
M_?5#-OCRD*V5ZW4RO#?A<>88B>()88C%EYQ@),R&(FI1).S L/YV<UWE$(H#
MD1V-K]Z&*K/;-=@E!_!%;Z#2-/QT0<^&\Z+7+3KPGD!]',!H@J\:9.++@VS!
MBSY^ZSB@C61>@+F6C6![!!M2EE9!D&F*]DI*W"!UK(S%YW2,A+),@(+^RC"C
MHNB]+4-"A"WRU(/>N>*X^0"W!Z;M<9(M]'KEM8JX6=0/Q' .YB <]3M_Y+0\
MPYWN+<3YAOA!_^*_=M&CH/U\=S6MS[^K<4="8@[4XI(<B*M6P;+D"0KW(Y+\
M6H&XT(YCD6B5-HN\ZAZ@R/%86@OP$28>*LS<U"XDZN>$["&DD/@,$2O^I5)U
MO@[@KTRB^@[S61*XK?.K_S<OGW'STHFQ^,%B3"*\:(=(>\U  H(ASXF+3<04
M^"TE.5\,N33GRCAW:C8_V'@4Q/)ZW^_/-_ )%SC0P().ML(Q+_YP"&(*:[2B
MS[0&TZS)QH@(])(S)J?QC4= WT86?4:[BPXFRU C-10QT. (#:'BCC5S3!5]
MKI')1,43H(23\%%^.JMS#H1Q&JL98.LT4I[U^#W$(L(^2S8NK\7],_GP<*?(
M^72P*_8VO.>U;I.4=Q_B*@!=0IUCGAIHSR^.,&.D,9^U9>)4<(..<N%#9:T:
M._D3RCQ8->1SN.E\<_YRNMDH[U=K]'[::OPOYA/GKZ[+[M5UQ8KUML.#\F%U
M>S.B9]%6<;*]?+3 I#QY4V@4Y@-RV+7KZ1VK;7J3_- ,;\'3+<FJ#VSS]=&-
M^]W\)FL1\QU,SN-*,$"+F3N?87/=O[ _#C[U2M*YXU^[X"-6$O\\BYCW[B#(
M:%?(?L.JC5WACD]25G!)J!M)"-G9@H$N?6E'7W?L7?E3 WRZUOYJW4D5MWP_
MSA;-)\]!I\CNKD9CO_"9I[5:M>B_K-G*;ZN?OZ3*?_S3]F>5$UC[(&:Y'!QC
M59=#^!#71&:W#]GV2G[KUS7YK__0QWUR=/(/4$L#!!0    ( #N!JE2 3 (Z
M1P@  .DD   =    97AE;#(P,C(P,S,Q97AH:6)I=#,Q,3$P<2YH=&WM6FMO
MVS@6_;Z_@N-B.RG@E_Q($R<-X#KNU$!>FSC;SJ<%)=(V$5G4D)0=[Z_?0U)^
M)+93!]M-TV(+5+%$\O(^#L^]%'7\V^EEI__G59>,S#@F5[<?SWH=4BA5*E_J
MG4KEM']*/O?/STBC7 U(7]%$"R-D0N-*I7M1((61,6FK4IE.I^5IO2S5L-*_
MKEA1C4HLI>9E9ECAY-@^P953=O*WX]]*)7(JHVS,$T,BQ:GAC&1:)$/RA7%]
M1TJEO%='IC,EAB-#:M5:C7R1ZDY,J&\WPL3\9"[GN.+OCRMNDN-0LMG),1,3
M(MB'@JB%8?VP&31IU."-)JT?1 %N&M7W(:L=4L;^%4#)"KK[,=K,8OZA,!9)
M:<3M_*UF(S5'4\',J!54JW\ON'XGQP.9&$RF,-C_]#+6)!E^;THT%L.DY>PI
M^*'SYDC&4K7>5-V_(]M2&M"QB&>MWSL8%2KQ>U'#]R7-E1CX#EK\FT,7J.5N
MIU[/]Q@?BX3/]0YJ5MGN_4B$PI!Z4 X>:KIJ+55#&&QDVCJ$U!65(SB8JQ?6
MN=.][O<^]3KM?N_R@EQ^(E?7O8M.[ZI]1KI?NYW;?N^?73Q&C^[U5IM^M!%7
MM]<WM^V+/NE?OEH=NU\[G]L7?W1)N],GU[=GW1L2U&DI:.S1=X0FC 1-YN^*
MK]:&]@UIGUY>];NGY&=P^4VWXU!=K]8LLON?N^2F??VQ?=&]*5U^/>O^Z6*!
MEEJU6MMQP?[/3&AL-*%7).<B&E$>D_,R.9=*":WYK$BN1N73<I%$7!DQF!$S
MHN;MF^;!T:Z\DX*.D0I*,1^8%@BK.><BD3#$JE6JU>RS%S8W*+]]$^Q7C]:O
M/3*B$TX4GP@^12(S(Z'))ZG&)*B6_D'D@'3O>2SNA2Z27A)!3O/P)W=&;:LS
M/E(-%\B$C&?D+I'3F+,A+WJ?*)Y*90B37)-$(O-C'BH24,R,9(E1&8?^J 5<
M60"W43+&G1(T)@,:X9$B<HPD9J3OM]8AX1'7FJJ9[3*F=QSSKLC4>,:@#*:,
M74V!.6R'2"C4$.B68#@T85R1Z0C8)CJSE^7X*5<\%V(-& L=H]BP=<M4F!$,
MU"F/G()6;@K5)(.9$PQC))RMNN$70$']^2C@9" 2^-F&;.G7HLLR$LUJI5TD
M RPB:JM-_([BC$$F8K?BQ"+B+E0\(RE<;U%CT13'2UCD$=&/I@;RF"MCB[9'
M%J,#L" 1,#>==OI$5(_(()93/0>*XD.A#6I@0ZA]Z/6&EL65>.NY,FO:_@(A
M;VP->?^!?]Z^.:@%[X]T'M0\%]B%(@<#@=L][4N+'J&*NS#![2*,N74GX<!&
M& L]LB-LMS%XPG*%O6="1['4&<99!E$R]O%*E8PXPV--]A >QA%O'X/N/?)4
M,N2DC<5YG<7HX0J<YAY?*7#LG;\5MB)(/$ZL?&)7\ I\?#BM+CM/-'@PT0 3
M63L?@PH];"[9.5TV'P-EO_X8)AXZ+PP3E(IS]5]NVH>>J%7+^\[P4ZY1YB$^
MCLR_#9ZBS3,1S?3N0RSAAQQ R&?R*41F"@) "A.A'=6@%T^<'%L3+4EJE>@4
MCZE#5IY#EN@HYB1H&P4("[IH&0OF-L\Z"[5@@BIA#1 ^TSGJ3:RD3-OLX]:B
M=JG*$1-VYU (VV8W**6 =)3%U/(IS')*++,81OB<N)K*\2ODMB,H#^,YVYGB
M7BURP]> W.!P';D[D](:@'>GLYUQ#.Q/!+/PI%HFU/(VU8"V+:$L9JEB<_P
MT8*&(A9F9O/HIFGM:G)0<RCR"^%!UY42S*6'^]R@-%,I4*Q=WH\BJ9A3P!5C
M0YX@G<< ,UIX:E>)[8)"TP,6JTFD8.B?'[+1CX=L4*[5K.'="8TSQT@VGGPP
M0/$E)HB$WE!$+8J$'1C6WVZNJQQ",1#LJ'WU%LK,;-=@EQQ %[VY+4T'WR[H
M23@O>MVBX]X3T,<!S$[P4X.,_7B0+7C1QV\=!W8CF1=@KF4CV)[!AC9+RRC*
ME(WV2DK<('4LM<%S^S()LG0$07]ER*@0O;=ER "P!4\]ZITKCLT'=WM@NSU.
MLH5>[[Q6(ZH7]8-E. =SSASU.W_DM#S#3O>.Q_F&^%'_XG_MHF=!^_7N:IK?
M?U?C7@FQ.5"+2W*P7+4*EB5/V' _(\FO%8@+[2B*1".57N15]P BQV-A#.=/
M,'$HD;EM.Q/0SPG9 Z1 ?-H2*_[:4G6^#OA?F8#Z#O-9$KFM\[O_;UZ^X^:E
M':/X03$F "^[0[1[S4AP@"'/B8M-Q)33.YOD?#'DTIPKX]Q;L_F+C6=!+*_W
M_?Y\ Y]0AH&:+^AD*QSSX@]#@"G4:$6?:372K,[&0 2\Y(S):7SC*Z!?(XN^
MHMU%&\ERH$ -102:.T(#5-QKS1Q319]K1#*1\83;A)/08?YV5N4<R,=I+&<<
MK=.1]*Q''R 6"/LNV;C\]%E.'M;Z_O>+Z>%.(?5Y8E=0;C@&-F[WE'</L3RX
M*D'GF*::M^8_CI!*TIC.6B)Q*KA!1[GP4!HCQT[^Q*8DE!/Y'&XZWYR?73?J
MY?UJ8(^OC<)_-I\X/]DNNY/MBF'K;8<'Y</J]F; :M%6<;*]?%B@4YI\*-0+
M\P$Y'ENU])X$FPZ:'YOA+7BYM5KU@6V\/[IQUZ<.NA:1W\'P/+H6#+";N-<W
M9&[!#_;*P;?.+9U3OI,CGK#5DM2KB/\5]H'"DHI+39V1X.X@+\KL=I)<^H+/
M?OFQ=^7?)8"MUMK?K7NEXM;NTU31>/',= K.=Y4;.:<SSVE!M>B_NME*;JN?
MQJ32?QC4\F\P)WSM8YGE*G!T55T.H2&60F:V#]EV7+_URYO\ZC\"<I\CG?P'
M4$L#!!0    ( #N!JE3^&^"JCP4  !D;   =    97AE;#(P,C(P,S,Q97AH
M:6)I=#,R,3$P<2YH=&WM66U3VS@0_GZ_8AOF6IB)7Q,@;V4F-6&:&TA2$DK[
MZ4:Q9:RI8[F20LC]^EO)#N^TE!O>IL>'8'NUJV=WGUU)=N?-[C"8?!WU(%&S
M%$9''_;[ 50LQSFN!8ZS.]F%CY.#?:C;K@<303+)%.,921VG-ZA )5$J;SG.
M8K&P%S6;BQ-G<NAH4W4GY5Q2.U)19:>CG^ O)='.'YTWE@6[/)S/:*8@%)0H
M&L%<LNP$CB,JOX%EE:,"GB\%.TD4^*[OPS$7W]@I*>2*J93NK.QTG.*^XYA)
M.E,>+7<Z$3L%%KVO,!J2AK\=A;&WU:PWFW6RZ7LN;7@>(<V:NT7^]A"D@\,+
M':F6*7U?F;',2JB>OU5OVINY:B]8I)*6Y[I_5LS(G4[,,X73"50O+@LK-VPI
M>J8LDK*3K&4\JA2J*W'(4RY::Z[Y:VN)%9,92Y>M=P%J305[5Y48?4M2P>)B
M@&3_4,2"L,SMHD"ZC?HIR^@*N>=KL+VSA$V9@IIO>U>17O:7B!-T6?&\U42K
MER"'&&(JGAAST#N<]/?Z07?2'P[&,-R#T6%_$/1'W7WH?>D%1Y/^YQX^QB&]
M0^@.=B_)]_J#+E[B52F_T^GG]G)T=#@^Z@XF,!F^6(Q> X[LL1W8,.X%.AO@
MU3;=ZHO%VQU#=W<XFO20$J\@O*N@-MTMS?+)QQZ,NX<?NH/>V!I^V>]]A6XP
MT1+?=?U?JEZ61>A0J[:5/U[#J=].Z[F0<X+S*0Z7Z$-#O7P4] $B@40\U^T_
MOS1\-4B'@\>@$@IC(J8DH](:GJ5T"=U0:8D.1Q4.6)@0FL*!#0=<""8E759A
ME-B[=M4HCP253,<!2!9!D# :0^^,AG/%3BD,XYB%5&A[^#!E9TQ6H9^%-JQK
MY;=K#=]WVP&?Y21;FCNOO5$M3>%L&.\$U?_2SF49%<6<%_8_H_5;(>RQC&0A
M(^EE"%JWG*L*E(0)H'$Z70+*%8L9E3B$J*J.DQX[I=*$(F$2OF5\D=+HA+Y=
MVVRT[\,3O:3E)(IPZ;52&JO69OT:<RROIA>^)R:/9Z_0/]VLUP)A-WWM]N0B
M'SKWWG9;PJ<Y$=@DTB4<TIP+C'\&>US,P'.M3Q!S83*3(P@> <4X1M#-!4O?
MKGE;;MNKFLV,R> B0>[B:$Q>4.0W)(;Z^( HA>E'7:R2RZOW%5H6 "Y8&<]3
MA!4BX%139<%48L (^GW.!-4[):GI4I98B:BV3C8 85]]NKD>;9S7'[)9X,Z/
M:BQ8;MD)716AUZS5BU*>&5^1?,VVIOEK)J#_H@C(,B35K&!&B%8(:D;XU*2F
MY&!,F&9DCHU&)[FJQ21- =40##89%.287UGTI_B\^:#!R.SI36O"4?.TX A'
M!ILYY;7&9+^2):B?P3%3N&I(.-9=E,>%[W-$)"2N]AC$A&"+EE1I 1-XFT72
MM%RL3G+NN.=B'45DJ>\/\)\NX+NC\%AN-^_E=5&]]RP^A*;(-*4KZ90+C(V%
M$%.22]I:7;0C)O.4+%LL,S,:I79I:\J5XC-3RZ>ZBX4D+7=3)A*%^.+H9+O%
M\4GAF4E%JYE+L6U$CHINRNHUN^[=+79M[T$RW][R&@_2_"%8VZ\_#,\S8-6!
MK=W+K&.25B0.N2&Q';ROU"HKA;*#M?S\#+S;3I#7"5)PX^GZ@EM42'V[/3:_
M/]H\GI=0&91?\U<W\<?UMG%/9Z^T@Y_[XFI/*K^=VZ^'LK>>.JYX^I,J+9N\
M7@+08Y \91&LL#]S/*YG]\:!V83C_ZK]S:OV]5/X/U?QLZ;SGFWK7F]>],OS
M]9%@>!S)\3QR0[[Q.&7P.$-?<C8>\D[J6G)NR#=N4M8QAX-;CAXE&'/$SWGQ
M(:DE:$HTIAN?5BY*W9PNW L5,L5ZGZN[5>YZGWOG=YKRM_AH9#Y?[?P+4$L!
M A0#%     @ .X&J5*#H)3*<,P( #2P6 !$              ( !     &5X
M96PM,C R,C T,#$N:'1M4$L! A0#%     @ .X&J5"I_(VBQ$0  +[T  !$
M             ( !RS," &5X96PM,C R,C T,#$N>'-D4$L! A0#%     @
M.X&J5$/+28CY&0  W 4! !4              ( !JT4" &5X96PM,C R,C T
M,#%?8V%L+GAM;%!+ 0(4 Q0    ( #N!JE2=(X^<?4X  .F5 P 5
M      "  ==? @!E>&5L+3(P,C(P-# Q7V1E9BYX;6Q02P$"% ,4    "  [
M@:I48=$JD5D1 0#"Q@$ %               @ &'K@( 97AE;"TR,#(R,#0P
M,5]G,2YJ<&=02P$"% ,4    "  [@:I4%C1T-]6_  #D# @ %0
M    @ $2P , 97AE;"TR,#(R,#0P,5]L86(N>&UL4$L! A0#%     @ .X&J
M5$,0J&]L=0  F(H% !4              ( !&H $ &5X96PM,C R,C T,#%?
M<')E+GAM;%!+ 0(4 Q0    ( #N!JE19JS^I>D4! 'TY"@ =
M  "  ;GU! !E>&5L,C R,3 S,S%E>&AI8FET,3 Q,3!Q+FAT;5!+ 0(4 Q0
M   ( #N!JE1J$#*M+Q$  #V<   =              "  6X[!@!E>&5L,C R
M,3 S,S%E>&AI8FET,3 R,3!Q+FAT;5!+ 0(4 Q0    ( #N!JE14E\$@0P@
M ,TD   =              "  =A,!@!E>&5L,C R,3 S,S%E>&AI8FET,S$R
M,3!Q+FAT;5!+ 0(4 Q0    ( #N!JE2 3 (Z1P@  .DD   =
M  "  595!@!E>&5L,C R,C S,S%E>&AI8FET,S$Q,3!Q+FAT;5!+ 0(4 Q0
M   ( #N!JE3^&^"JCP4  !D;   =              "  =A=!@!E>&5L,C R
L,C S,S%E>&AI8FET,S(Q,3!Q+FAT;5!+!08     #  , $,#  "B8P8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
